A	O
common	O
human	O
skin	DiseaseClass
tumour	DiseaseClass
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs.	O
In	O
response	O
to	O
this	O
stimulus,	O
cytoplasmic	O
beta-catenin	O
(encoded	O
by	O
CTNNB1)	O
is	O
stabilized,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF/TCF	O
family.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin/TCF	O
encodes	O
c-MYC,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	DiseaseClass
,	O
particularly	O
in	O
the	O
colon.	O
Most	O
colon	DiseaseClass
cancers	DiseaseClass
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
APC	SpecificDisease
),	O
a	O
protein	O
required	O
for	O
ubiquitin-mediated	O
degradation	O
of	O
beta-catenin,	O
but	O
a	O
small	O
percentage	O
of	O
colon	CompositeMention
and	CompositeMention
some	CompositeMention
other	CompositeMention
cancers	CompositeMention
harbour	O
beta-catenin-stabilizing	O
mutations.	O
Recently,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	DiseaseClass
tumours	DiseaseClass
resembling	O
pilomatricomas	SpecificDisease
.	O
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair-follicle	O
morphogenesis,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	SpecificDisease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin-stabilizing	O
mutations.	O
Here,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	DiseaseClass
tumour	DiseaseClass
.	O
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	Modifier
cells,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	SpecificDisease
are	O
derived	O
from	O
hair	O
matrix	O
cells.	O
At	O
least	O
75%	O
of	O
these	O
tumours	DiseaseClass
possess	O
mutations	O
affecting	O
the	O
amino-terminal	O
segment,	O
normally	O
involved	O
in	O
phosphorylation-dependent,	O
ubiquitin-mediated	O
degradation	O
of	O
the	O
protein.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	DiseaseClass


HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	Modifier
probands:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis	SpecificDisease
.	O
Hereditary	SpecificDisease
hemochromatosis	SpecificDisease
(	O
HH	SpecificDisease
)	O
is	O
a	O
common	O
autosomal	DiseaseClass
recessive	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
of	O
iron	O
metabolism.	O
The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I-like	O
protein	O
involved	O
in	O
HH	SpecificDisease
was	O
identified	O
in	O
1996.	O
Two	O
missense	O
mutations	O
have	O
been	O
described	O
	O
C282Y,	O
accounting	O
for	O
80%	O
to	O
90%	O
of	O
HH	Modifier
chromosomes,	O
and	O
H63D,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40%	O
to	O
70%	O
of	O
non-C282Y	O
HH	Modifier
chromosomes.	O
We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y,	O
H63D,	O
and	O
the	O
193A--	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	O
substitution	O
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls.	O
The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	SpecificDisease
,	O
accounting	O
for	O
85%	O
of	O
carrier	O
chromosomes,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39%	O
of	O
the	O
HH	Modifier
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation.	O
In	O
addition,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	O
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	O
an	O
assigned	O
mutation.	O
This	O
substitution	O
accounted	O
for	O
7.	O
8%	O
of	O
HH	Modifier
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D.	O
This	O
enrichment	O
of	O
S65C	O
among	O
HH	Modifier
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	SpecificDisease

Germline	O
BRCA1	O
alterations	O
in	O
a	O
population-based	O
series	O
of	O
ovarian	Modifier
cancer	Modifier
cases.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	Modifier
cancer	Modifier
susceptibility	O
gene	O
1	O
(BRCA1)	O
germline	O
alterations	O
in	O
the	O
ovarian	Modifier
cancer	Modifier
population.	O
To	O
achieve	O
this,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population-based	O
series	O
of	O
consecutive	O
ovarian	Modifier
cancer	Modifier
cases.	O
This	O
is	O
the	O
first	O
population-based	O
ovarian	Modifier
cancer	Modifier
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region.	O
One	O
hundred	O
and	O
seven	O
ovarian	Modifier
cancer	Modifier
cases	O
were	O
analyzed	O
for	O
BRCA1	O
alterations	O
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing.	O
Two	O
truncating	O
mutations,	O
962del4	O
and	O
3600del11,	O
were	O
identified.	O
Both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	DiseaseClass
.	O
The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	Modifier
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele-specific	O
amplification.	O
The	O
rare	O
form	O
of	O
the	O
Q356R	O
polymorphism	O
was	O
significantly	O
(P	O
=	O
0.	O
03)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	Modifier
cancer	Modifier
risk.	O
In	O
summary,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
some	O
uncharacterized	O
variants	O
and	O
rare	O
forms	O
of	O
polymorphisms	O
in	O
determining	O
ovarian	Modifier
cancer	Modifier

Identification	O
of	O
APC2,	O
a	O
homologue	O
of	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
tumour	Modifier
suppressor.	O
The	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(APC)	Modifier
tumour	Modifier
-suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(GSK-3beta),	O
axin/conductin	O
and	O
betacatenin.	O
Complex	O
formation	O
induces	O
the	O
rapid	O
degradation	O
of	O
betacatenin.	O
In	O
colon	Modifier
carcinoma	Modifier
cells,	O
loss	O
of	O
APC	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf-4	O
transcription	O
factor	O
(reviewed	O
in	O
[1]	O
[2]).	O
Here,	O
we	O
report	O
the	O
identification	O
and	O
genomic	O
structure	O
of	O
APC	O
homologues.	O
Mammalian	O
APC2,	O
which	O
closely	O
resembles	O
APC	O
in	O
overall	O
domain	O
structure,	O
was	O
functionally	O
analyzed	O
and	O
shown	O
to	O
contain	O
two	O
SAMP	O
domains,	O
both	O
of	O
which	O
are	O
required	O
for	O
binding	O
to	O
conductin.	O
Like	O
APC,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin-Tcf	O
complexes,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-/-	O
colon	Modifier
carcinoma	Modifier
cells.	O
Human	O
APC2	O
maps	O
to	O
chromosome	O
19p13.	O
3.	O
APC	O
and	O
APC2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	O
and	O
cancer	SpecificDisease

Familial	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
associated	O
with	O
recurrent	O
bacteremic	DiseaseClass
infections	DiseaseClass
due	DiseaseClass
to	DiseaseClass
Neisseria	DiseaseClass
.	O
The	O
serum	O
of	O
a	O
29-year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	SpecificDisease
gonococcal	SpecificDisease
infection	SpecificDisease
and	O
a	O
history	O
of	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
and	O
arthritis	DiseaseClass
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity.	O
The	O
seventh	O
component	O
of	O
complement	O
(C7)	O
was	O
not	O
detected	O
by	O
functional	O
or	O
immunochemical	O
assays,	O
whereas	O
other	O
components	O
were	O
normal	O
by	O
hemolytic	O
and	O
immunochemical	O
assessment.	O
Her	O
fresh	O
serum	O
lacked	O
complement-mediated	O
bactericidal	O
activity	O
against	O
Neisseria	O
gonorrhoeae,	O
but	O
the	O
addition	O
of	O
fresh	O
normal	O
serum	O
or	O
purified	O
C7	O
restored	O
bactericidal	O
activity	O
as	O
well	O
as	O
hemolytic	O
activity.	O
The	O
absence	Modifier
of	Modifier
functional	Modifier
C7	Modifier
activity	O
could	O
not	O
be	O
accounted	O
for	O
on	O
the	O
basis	O
of	O
an	O
inhibitor.	O
Opsonization	O
and	O
generation	O
of	O
chemotactic	O
activity	O
functioned	O
normally.	O
Complete	SpecificDisease
absence	SpecificDisease
of	SpecificDisease
C7	SpecificDisease
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
and	O
arthritis	DiseaseClass
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight-year-old	O
son.	O
HLA	O
histocompatibility	O
typing	O
of	O
the	O
family	O
members	O
did	O
not	O
demonstrate	O
evidence	O
for	O
genetic	O
linkage	O
of	O
C7	SpecificDisease
deficiency	SpecificDisease
with	O
the	O
major	O
histocompatibility	O
loci.	O
This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	SpecificDisease
deficiency	SpecificDisease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	SpecificDisease
neisseria	SpecificDisease
infections	SpecificDisease

GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult-onset	O
oromandibular	SpecificDisease
dystonia	SpecificDisease
.	O
The	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
GCH1	O
in	O
a	O
patient	O
with	O
adult-onset	O
oromandibular	SpecificDisease
dystonia	SpecificDisease
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	DiseaseClass
.	O
The	O
patient	O
responded	O
positively	O
to	O
treatment	O
with	O
L-dopa.	O
These	O
findings	O
demonstrate	O
that	O
GCH1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	Modifier
symptoms	O
not	O
typical	O
of	O
dopa-responsive	SpecificDisease
dystonia	SpecificDisease

The	O
hereditary	Modifier
hemochromatosis	Modifier
protein,	O
HFE,	O
specifically	O
regulates	O
transferrin-mediated	O
iron	O
uptake	O
in	O
HeLa	O
cells.	O
HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
(Feder,	O
J.	O
N.,	O
Gnirke,	O
A.,	O
Thomas,	O
W.,	O
Tsuchihashi,	O
Z.,	O
Ruddy,	O
D.	O
A.,	O
Basava,	O
A.,	O
Dormishian,	O
F.,	O
Domingo,	O
R.	O
J.,	O
Ellis,	O
M.	O
C.,	O
Fullan,	O
A.,	O
Hinton,	O
L.	O
M.,	O
Jones,	O
N.	O
L.,	O
Kimmel,	O
B.	O
E.,	O
Kronmal,	O
G.	O
S.,	O
Lauer,	O
P.,	O
Lee,	O
V.	O
K.,	O
Loeb,	O
D.	O
B.,	O
Mapa,	O
F.	O
A.,	O
McClelland,	O
E.,	O
Meyer,	O
N.	O
C.,	O
Mintier,	O
G.	O
A.,	O
Moeller,	O
N.,	O
Moore,	O
T.,	O
Morikang,	O
E.,	O
Prasss,	O
C.	O
E	O
.,	O
Quintana,	O
L.,	O
Starnes,	O
S.	O
M	O
.,	O
Schatzman,	O
R.	O
C	O
.,	O
Brunke,	O
K.	O
J	O
.,	O
Drayna,	O
D.	O
T.,	O
Risch,	O
N.	O
J	O
.,	O
Bacon,	O
B.	O
R	O
.,	O
and	O
Wolff,	O
R.	O
R	O
.	O
(1996)	O
Nat.	O
Genet.	O
13,	O
399-408).	O
At	O
the	O
cell	O
surface,	O
HFE	O
complexes	O
with	O
transferrin	O
receptor	O
(TfR),	O
increasing	O
the	O
dissociation	O
constant	O
of	O
transferrin	O
(Tf)	O
for	O
its	O
receptor	O
10-fold	O
(Gross,	O
C.	O
N	O
.,	O
Irrinki,	O
A.,	O
Feder,	O
J.	O
N	O
.,	O
and	O
Enns,	O
C.	O
A	O
.	O
(1998)	O
J.	O
Biol.	O
Chem.	O
273,	O
22068-22074;	O
Feder,	O
J.	O
N.,	O
Penny,	O
D.	O
M.,	O
Irrinki,	O
A.,	O
Lee,	O
V.	O
K.,	O
Lebron,	O
J.	O
A.,	O
Watson,	O
N.,	O
Tsuchihashi,	O
Z.,	O
Sigal,	O
E.,	O
Bjorkman,	O
P.	O
J.,	O
and	O
Schatzman,	O
R.	O
C.	O
(1998)	O
Proc.	O
Natl	O
.	O
Acad.	O
Sci.	O
U	O
S	O
A	O
95,	O
1472-1477).	O
HFE	O
does	O
not	O
remain	O
at	O
the	O
cell	O
surface,	O
but	O
traffics	O
with	O
TfR	O
to	O
Tf-positive	O
internal	O
compartments	O
(Gross	O
et	O
al.,	O
1998).	O
Using	O
a	O
HeLa	O
cell	O
line	O
in	O
which	O
the	O
expression	O
of	O
HFE	O
is	O
controlled	O
by	O
tetracycline,	O
we	O
show	O
that	O
the	O
expression	O
of	O
HFE	O
reduces	O
55Fe	O
uptake	O
from	O
Tf	O
by	O
33%	O
but	O
does	O
not	O
affect	O
the	O
endocytic	O
or	O
exocytic	O
rates	O
of	O
TfR	O
cycling.	O
Therefore,	O
HFE	O
appears	O
to	O
reduce	O
cellular	O
acquisition	O
of	O
iron	O
from	O
Tf	O
within	O
endocytic	O
compartments.	O
HFE	O
specifically	O
reduces	O
iron	O
uptake	O
from	O
Tf,	O
as	O
non-Tf-mediated	O
iron	O
uptake	O
from	O
Fe-nitrilotriacetic	O
acid	O
is	O
not	O
altered.	O
These	O
results	O
explain	O
the	O
decreased	O
ferritin	O
levels	O
seen	O
in	O
our	O
HeLa	O
cell	O
system	O
and	O
demonstrate	O
the	O
specific	O
control	O
of	O
HFE	O
over	O
the	O
Tf-mediated	O
pathway	O
of	O
iron	O
uptake.	O
These	O
results	O
also	O
have	O
implications	O
for	O
the	O
understanding	O
of	O
cellular	O
iron	O
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver,	O
pancreas,	O
heart,	O
and	O
spleen	O
that	O
are	O
iron	O
loaded	O
in	O
hereditary	Modifier
hemochromatotic	Modifier

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population.	O
Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
is	O
a	O
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	DiseaseClass
or	O
synovitis	DiseaseClass
.	O
The	O
FMF	Modifier
gene	O
(MEFV)	O
was	O
cloned	O
recently,	O
and	O
four	O
missense	O
mutations	O
were	O
identified.	O
Here	O
we	O
present	O
data	O
from	O
non-Ashkenazi	O
Jewish	O
and	O
Arab	O
patients	O
in	O
whom	O
we	O
had	O
not	O
originally	O
found	O
mutations	O
and	O
from	O
a	O
new,	O
more	O
ethnically	O
diverse	O
panel.	O
Among	O
90	O
symptomatic	O
mutation-positive	O
individuals,	O
11	O
mutations	O
accounted	O
for	O
79%	O
of	O
carrier	O
chromosomes.	O
Of	O
the	O
two	O
mutations	O
that	O
are	O
novel,	O
one	O
alters	O
the	O
same	O
residue	O
(680)	O
as	O
a	O
previously	O
known	O
mutation,	O
and	O
the	O
other	O
(P369S)	O
is	O
located	O
in	O
exon	O
3.	O
Consistent	O
with	O
another	O
recent	O
report,	O
the	O
E148Q	O
mutation	O
was	O
observed	O
in	O
patients	O
of	O
several	O
ethnicities	O
and	O
on	O
multiple	O
microsatellite	O
haplotypes,	O
but	O
haplotype	O
data	O
indicate	O
an	O
ancestral	O
relationships	O
between	O
non-Jewish	O
Italian	O
and	O
Ashkenazi	O
Jewish	O
patients	O
with	O
FMF	SpecificDisease
and	O
other	O
affected	O
populations.	O
Among	O
approximately	O
200	O
anonymous	O
Ashkenazi	O
Jewish	O
DNA	O
samples,	O
the	O
MEFV	O
carrier	O
frequency	O
was	O
21%,	O
with	O
E148Q	O
the	O
most	O
common	O
mutation.	O
Several	O
lines	O
of	O
evidence	O
indicate	O
reduced	O
penetrance	O
among	O
Ashkenazi	O
Jews,	O
especially	O
for	O
E148Q,	O
P369S,	O
and	O
K695R.	O
Nevertheless,	O
E148Q	O
helps	O
account	O
for	O
recessive	O
inheritance	O
in	O
an	O
Ashkenazi	O
family	O
previously	O
reported	O
as	O
an	O
unusual	O
case	O
of	O
dominantly	O
inherited	O
FMF	SpecificDisease

Autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
with	O
defective	O
Fas:	O
genotype	O
influences	O
penetrance.	O
Autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
(	O
ALPS	SpecificDisease
)	O
is	O
a	O
disorder	CompositeMention
of	CompositeMention
lymphocyte	CompositeMention
homeostasis	CompositeMention
and	CompositeMention
immunological	CompositeMention
tolerance	CompositeMention
.	O
Most	O
patients	O
have	O
a	O
heterozygous	O
mutation	O
in	O
the	O
APT1	O
gene,	O
which	O
encodes	O
Fas	O
(CD95,	O
APO-1),	O
mediator	O
of	O
an	O
apoptotic	O
pathway	O
crucial	O
to	O
lymphocyte	O
homeostasis.	O
Of	O
17	O
unique	O
APT1	O
mutations	O
in	O
unrelated	O
ALPS	Modifier
probands,	O
12	O
(71%)	O
occurred	O
in	O
exons	O
7-9,	O
which	O
encode	O
the	O
intracellular	O
portion	O
of	O
Fas.	O
In	O
vitro,	O
activated	O
lymphocytes	O
from	O
all	O
17	O
patients	O
showed	O
apoptotic	O
defects	O
when	O
exposed	O
to	O
an	O
anti-Fas	O
agonist	O
monoclonal	O
antibody.	O
Similar	O
defects	O
were	O
found	O
in	O
a	O
Fas-negative	O
cell	O
line	O
transfected	O
with	O
cDNAs	O
bearing	O
each	O
of	O
the	O
mutations.	O
In	O
cotransfection	O
experiments,	O
Fas	O
constructs	O
with	O
either	O
intra-	O
or	O
extracellular	O
mutations	O
caused	O
dominant	O
inhibition	O
of	O
apoptosis	O
mediated	O
by	O
wild-type	O
Fas.	O
Two	O
missense	O
Fas	O
variants,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	SpecificDisease
,	O
were	O
identified.	O
Variant	O
A	O
(-1)	O
T	O
at	O
the	O
Fas	O
signal-sequence	O
cleavage	O
site,	O
which	O
mediates	O
apoptosis	O
less	O
well	O
than	O
wild-type	O
Fas	O
and	O
is	O
partially	O
inhibitory,	O
was	O
present	O
in	O
13%	O
of	O
African	O
American	O
alleles.	O
Among	O
the	O
ALPS	Modifier
-associated	O
Fas	O
mutants,	O
dominant	O
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular,	O
versus	O
extracellular,	O
portion	O
of	O
the	O
Fas	O
receptor.	O
Mutations	O
causing	O
disruption	O
of	O
the	O
intracellular	O
Fas	O
death	O
domain	O
also	O
showed	O
a	O
higher	O
penetrance	O
of	O
ALPS	Modifier
phenotype	O
features	O
in	O
mutation-bearing	O
relatives.	O
Significant	O
ALPS	Modifier
-related	O
morbidity	O
occurred	O
in	O
44%	O
of	O
relatives	O
with	O
intracellular	O
mutations,	O
versus	O
0%	O
of	O
relatives	O
with	O
extracellular	O
mutations.	O
Thus,	O
the	O
location	O
of	O
mutations	O
within	O
APT1	O
strongly	O
influences	O
the	O
development	O
and	O
the	O
severity	O
of	O
ALPS	SpecificDisease

Mutational	O
analysis	O
and	O
genotype-phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
.	O
BACKGROUND	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
is	O
an	O
inherited	DiseaseClass
disease	DiseaseClass
characterized	O
by	O
progressive	O
neurologic	SpecificDisease
dysfunction	SpecificDisease
,	O
occasionally	O
associated	O
with	O
adrenal	DiseaseClass
insufficiency	DiseaseClass
.	O
The	O
classic	O
form	O
of	O
ALD	SpecificDisease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	SpecificDisease
cerebral	SpecificDisease
ALD	SpecificDisease
),	O
with	O
rapid	O
neurologic	DiseaseClass
deterioration	DiseaseClass
leading	O
to	O
a	O
vegetative	O
state.	O
Adult-onset	O
cerebral	SpecificDisease
ALD	SpecificDisease
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	DiseaseClass
dysfunction	DiseaseClass
.	O
Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	SpecificDisease
and	O
Addison	SpecificDisease
disease	SpecificDisease
only	O
also	O
have	O
been	O
recognized.	O
Despite	O
discovery	O
of	O
the	O
causative	O
gene,	O
a	O
molecular	O
basis	O
for	O
the	O
diverse	O
clinical	O
presentations	O
remains	O
to	O
be	O
elucidated.	O
OBJECTIVES	O
	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	O
patients	O
with	O
ALD	SpecificDisease
from	O
29	O
unrelated	O
families,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene,	O
and	O
to	O
study	O
genotype-phenotype	O
correlations	O
in	O
Japanese	O
patients.	O
METHODS	O
	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	SpecificDisease
cerebral	SpecificDisease
ALD	SpecificDisease
,	O
11	O
patients	O
with	O
adult-onset	O
cerebral	SpecificDisease
ALD	SpecificDisease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	SpecificDisease
.	O
We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	SpecificDisease
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts,	O
lymphoblastoid	O
cells,	O
or	O
peripheral	O
blood	O
leukocytes.	O
RESULTS	O
	O
Three	O
patients	O
with	O
adult-onset	O
cerebral	SpecificDisease
ALD	SpecificDisease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements.	O
The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	Modifier
gene.	O
Eighteen	O
(69%)	O
of	O
26	O
mutations	O
were	O
missense	O
mutations.	O
Most	O
missense	O
mutations	O
involved	O
amino	O
acids	O
conserved	O
in	O
homologous	O
gene	O
products,	O
including	O
PMP70,	O
mALDRP,	O
and	O
Pxa1p.	O
The	O
AG	O
dinucleotide	O
deletion	O
at	O
position	O
1081-1082,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
be	O
the	O
most	O
common	O
mutation	O
in	O
white	O
patients	O
(12%	O
-17%),	O
was	O
also	O
identified	O
as	O
the	O
most	O
common	O
mutation	O
in	O
Japanese	O
patients	O
(12%).	O
All	O
phenotypes	O
were	O
associated	O
with	O
mutations	O
resulting	O
in	O
protein	O
truncation	O
or	O
subtle	O
amino	O
acid	O
changes.	O
There	O
were	O
no	O
differences	O
in	O
phenotypic	O
expressions	O
between	O
missense	O
mutations	O
involving	O
conserved	O
amino	O
acids	O
and	O
those	O
involving	O
nonconserved	O
amino	O
acids.	O
CONCLUSIONS	O
	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	SpecificDisease
and	O
their	O
genotypes,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	SpecificDisease

Absence	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
a	O
patient	O
with	O
chronic	SpecificDisease
meningococcemia	SpecificDisease
presenting	O
as	O
vasculitis	SpecificDisease
.	O
A	O
previously	O
healthy	O
40-year-old	O
man	O
presenting	O
with	O
fever	SpecificDisease
,	O
arthritis	SpecificDisease
,	O
and	O
cutaneous	SpecificDisease
vasculitis	SpecificDisease
was	O
found	O
to	O
have	O
chronic	SpecificDisease
meningococcemia	SpecificDisease
.	O
Evaluation	O
of	O
his	O
complement	O
system	O
showed	O
an	O
absence	O
of	O
functional	O
and	O
antigenic	O
C7,	O
compatible	O
with	O
a	O
complete	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
.	O
Study	O
of	O
the	O
patients	O
family	O
spanning	O
four	O
generations	O
showed	O
heterozygous	O
deficiency	SpecificDisease
of	SpecificDisease
C7	SpecificDisease
in	O
five	O
members.	O
Chronic	SpecificDisease
neisserial	SpecificDisease
infection	SpecificDisease
can	O
be	O
associated	O
with	O
C7	SpecificDisease
deficiency	SpecificDisease
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	SpecificDisease
vasculitis	SpecificDisease

Genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
.	O
Dihydropyrimidine	SpecificDisease
dehydrogenase	SpecificDisease
(DPD)	SpecificDisease
deficiency	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
characterised	O
by	O
thymine-uraciluria	O
in	O
homozygous	O
deficient	O
patients	O
and	O
has	O
been	O
associated	O
with	O
a	O
variable	O
clinical	O
phenotype.	O
In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	SpecificDisease
deficiency	SpecificDisease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	SpecificDisease
of	SpecificDisease
DPD	SpecificDisease
.	O
In	O
this	O
group	O
of	O
patients,	O
7	O
different	O
mutations	O
have	O
been	O
identified,	O
including	O
2	O
deletions	O
[295-298delTCAT,	O
1897delC],	O
1	O
splice-site	O
mutation	O
[IVS14	O
+	O
1G	O
>	O
A)]	O
and	O
4	O
missense	O
mutations	O
(85T	O
>	O
C,	O
703C	O
>	O
T,	O
2658G	O
>	O
A,	O
2983G	O
>	O
T).	O
Analysis	O
of	O
the	O
prevalence	O
of	O
the	O
various	O
mutations	O
among	O
DPD	Modifier
patients	O
has	O
shown	O
that	O
the	O
G--	O
>	O
A	O
point	O
mutation	O
in	O
the	O
invariant	O
splice	O
donor	O
site	O
is	O
by	O
far	O
the	O
most	O
common	O
(52%),	O
whereas	O
the	O
other	O
six	O
mutations	O
are	O
less	O
frequently	O
observed.	O
A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed,	O
with	O
convulsive	DiseaseClass
disorders	DiseaseClass
,	O
motor	DiseaseClass
retardation	DiseaseClass
and	O
mental	DiseaseClass
retardation	DiseaseClass
being	O
the	O
most	O
abundant	O
manifestations.	O
A	O
clear	O
correlation	O
between	O
the	O
genotype	O
and	O
phenotype	O
has	O
not	O
been	O
established.	O
An	O
altered	O
beta-alanine,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	DiseaseClass
abnormalities	DiseaseClass
encountered	O
in	O
patients	O
with	O
DPD	SpecificDisease
deficiency	SpecificDisease

Molecular	O
characterization	O
of	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
by	O
natural	O
and	O
amplification	O
created	O
restriction	O
sites:	O
five	O
mutations	O
account	O
for	O
most	O
G6PD	SpecificDisease
deficiency	SpecificDisease
cases	O
in	O
Taiwan.	O
We	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
to	O
diagnose	O
the	O
molecular	O
defects	O
of	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
Chinese	O
in	O
Taiwan.	O
This	O
method	O
involves	O
the	O
selective	O
amplification	O
of	O
a	O
DNA	O
fragment	O
from	O
human	O
G6PD	O
gene	O
with	O
specific	O
oligonucleotide	O
primers	O
followed	O
by	O
digestion	O
with	O
restriction	O
enzymes	O
that	O
recognize	O
artificially	O
created	O
or	O
naturally	O
occurring	O
restriction	O
sites.	O
Ninety-four	O
Chinese	O
males	O
with	O
G6PD	SpecificDisease
deficiency	SpecificDisease
were	O
studied.	O
The	O
results	O
show	O
that	O
50%	O
(47	O
of	O
94)	O
were	O
G	O
to	O
T	O
mutation	O
at	O
nucleotide	O
(nt)	O
1376,	O
21.	O
3%	O
(20	O
of	O
94)	O
were	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
1388,	O
7.	O
4%	O
(7	O
of	O
94)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
493,	O
7.	O
4%	O
(7	O
of	O
94)	O
were	O
A	O
to	O
G	O
mutation	O
at	O
nt	O
95,	O
4.	O
2%	O
(4	O
of	O
94)	O
were	O
C	O
to	O
T	O
mutation	O
at	O
nt	O
1024,	O
1.	O
1%	O
(1	O
of	O
94)	O
was	O
G	O
to	O
T	O
mutation	O
at	O
nt	O
392,	O
and	O
1.	O
1%	O
(1	O
of	O
94)	O
was	O
G	O
to	O
A	O
mutation	O
at	O
nt	O
487.	O
These	O
results	O
show	O
that	O
the	O
former	O
five	O
mutations	O
account	O
for	O
more	O
than	O
90%	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Homozygous	SpecificDisease
hypobetalipoproteinemia	SpecificDisease
:	O
a	O
disease	O
distinct	O
from	O
abetalipoproproteinemia	SpecificDisease
at	O
the	O
molecular	O
level.	O
apoB	O
DNA,	O
RNA,	O
and	O
protein	O
from	O
two	O
patients	O
with	O
homozygous	SpecificDisease
hypobetalipoproteinemia	SpecificDisease
(	O
HBL	SpecificDisease
)	O
were	O
evaluated	O
and	O
compared	O
with	O
normal	O
individuals.	O
Southern	O
blot	O
analysis	O
with	O
10	O
different	O
cDNA	O
probes	O
revealed	O
a	O
normal	O
gene	O
without	O
major	O
insertions,	O
deletions,	O
or	O
rearrangements.	O
Northern	O
and	O
slot	O
blot	O
analyses	O
of	O
total	O
liver	O
mRNA	O
from	O
HBL	Modifier
patients	O
documented	O
a	O
normal	O
size	O
apoB	O
mRNA	O
that	O
was	O
present	O
in	O
greatly	O
reduced	O
quantities.	O
ApoB	O
protein	O
was	O
detected	O
within	O
HBL	Modifier
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques;	O
however,	O
it	O
was	O
markedly	O
reduced	O
in	O
quantity	O
when	O
compared	O
with	O
control	O
samples.	O
No	O
apoB	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
HBL	Modifier
individuals	O
with	O
an	O
ELISA	O
assay.	O
These	O
data	O
are	O
most	O
consistent	O
with	O
a	O
mutation	O
in	O
the	O
coding	O
portion	O
of	O
the	O
apoB	O
gene	O
in	O
HBL	Modifier
patients,	O
leading	O
to	O
an	O
abnormal	O
apoB	O
protein	O
and	O
apoB	O
mRNA	O
instability.	O
These	O
results	O
are	O
distinct	O
from	O
those	O
previously	O
noted	O
in	O
abetalipoproteinemia	SpecificDisease

A	O
population-based	O
study	O
of	O
the	O
clinical	O
expression	O
of	O
the	O
hemochromatosis	Modifier
gene.	O
BACKGROUND	O
AND	O
METHODS	O
Hereditary	SpecificDisease
hemochromatosis	SpecificDisease
is	O
associated	O
with	O
homozygosity	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
hemochromatosis	Modifier
(HFE)	O
gene	O
on	O
chromosome	O
6,	O
elevated	O
serum	O
transferrin	O
saturation,	O
and	O
excess	DiseaseClass
iron	DiseaseClass
deposits	DiseaseClass
throughout	O
the	O
body.	O
To	O
assess	O
the	O
prevalence	O
and	O
clinical	O
expression	O
of	O
the	O
HFE	O
gene,	O
we	O
conducted	O
a	O
population-based	O
study	O
in	O
Busselton,	O
Australia.	O
In	O
1994,	O
we	O
obtained	O
blood	O
samples	O
for	O
the	O
determination	O
of	O
serum	O
transferrin	O
saturation	O
and	O
ferritin	O
levels	O
and	O
the	O
presence	O
or	O
absence	O
of	O
the	O
C282Y	O
mutation	O
and	O
the	O
H63D	O
mutation	O
(which	O
may	O
contribute	O
to	O
increased	O
hepatic	O
iron	O
levels)	O
in	O
3011	O
unrelated	O
white	O
adults.	O
We	O
evaluated	O
all	O
subjects	O
who	O
had	O
persistently	O
elevated	O
transferrin-saturation	O
values	O
(45	O
percent	O
or	O
higher)	O
or	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation.	O
We	O
recommended	O
liver	O
biopsy	O
for	O
subjects	O
with	O
serum	O
ferritin	O
levels	O
of	O
300	O
ng	O
per	O
milliliter	O
or	O
higher.	O
The	O
subjects	O
were	O
followed	O
for	O
up	O
to	O
four	O
years.	O
RESULTS	O
	O
Sixteen	O
of	O
the	O
subjects	O
(0.	O
5	O
percent)	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation,	O
and	O
424	O
(14.	O
1	O
percent)	O
were	O
heterozygous.	O
The	O
serum	O
transferrin	O
saturation	O
was	O
45	O
percent	O
or	O
higher	O
in	O
15	O
of	O
the	O
16	O
who	O
were	O
homozygous;	O
in	O
1	O
subject	O
it	O
was	O
43	O
percent.	O
Four	O
of	O
the	O
homozygous	O
subjects	O
had	O
previously	O
been	O
given	O
a	O
diagnosis	O
of	O
hemochromatosis	SpecificDisease
,	O
and	O
12	O
had	O
not.	O
Seven	O
of	O
these	O
12	O
patients	O
had	O
elevated	O
serum	O
ferritin	O
levels	O
in	O
1994;	O
6	O
of	O
the	O
7	O
had	O
further	O
increases	O
in	O
1998,	O
and	O
1	O
had	O
a	O
decrease,	O
although	O
the	O
value	O
remained	O
elevated.	O
The	O
serum	O
ferritin	O
levels	O
in	O
the	O
four	O
other	O
homozygous	O
patients	O
remained	O
in	O
the	O
normal	O
range.	O
Eleven	O
of	O
the	O
16	O
homozygous	O
subjects	O
underwent	O
liver	O
biopsy;	O
3	O
had	O
hepatic	DiseaseClass
fibrosis	DiseaseClass
,	O
and	O
1,	O
who	O
had	O
a	O
history	O
of	O
excessive	SpecificDisease
alcohol	SpecificDisease
consumption	SpecificDisease
,	O
had	O
cirrhosis	DiseaseClass
and	O
mild	O
microvesicular	SpecificDisease
steatosis	SpecificDisease
.	O
Eight	O
of	O
the	O
16	O
homozygous	O
subjects	O
had	O
clinical	O
findings	O
that	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
,	O
such	O
as	O
hepatomegaly	DiseaseClass
,	O
skin	DiseaseClass
pigmentation	DiseaseClass
,	O
and	O
arthritis	DiseaseClass
.	O
CONCLUSIONS	O
	O
In	O
a	O
population	O
of	O
white	O
adults	O
of	O
northern	O
European	O
ancestry,	O
0.	O
5	O
percent	O
were	O
homozygous	O
for	O
the	O
C282Y	O
mutation	O
in	O
the	O
HFE	O
gene.	O
However,	O
only	O
half	O
of	O
those	O
who	O
were	O
homozygous	O
had	O
clinical	O
features	O
of	O
hemochromatosis	SpecificDisease

Overexpression	O
of	O
DM20	O
messenger	O
RNA	O
in	O
two	O
brothers	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
.	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
is	O
a	O
rare,	DiseaseClass
sex-linked	DiseaseClass
recessive,	DiseaseClass
dysmyelinating	DiseaseClass
disease	DiseaseClass
of	DiseaseClass
the	DiseaseClass
central	DiseaseClass
nervous	DiseaseClass
system	DiseaseClass
that	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
myelin	O
proteolipid	O
protein	O
(PLP)	O
gene.	O
Only	O
25%	O
of	O
patients	O
studied	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
have	O
exonic	O
mutations	O
in	O
this	O
gene,	O
the	O
underlying	O
cause	O
of	O
the	O
disease	O
in	O
the	O
remaining	O
patients	O
is	O
unknown.	O
The	O
PLP	O
gene	O
encodes	O
two	O
major	O
alternatively	O
spliced	O
transcripts	O
called	O
PLP	O
and	O
DM20.	O
PLP	O
messenger	O
RNA	O
is	O
specifically	O
expressed	O
in	O
central	O
nervous	O
system	O
tissue,	O
whereas	O
DM20	O
messenger	O
RNA	O
is	O
found	O
in	O
central	O
nervous	O
system,	O
cardiac,	O
and	O
other	O
tissues.	O
We	O
studied	O
cultured	O
skin	O
fibroblasts	O
from	O
2	O
brothers	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
who	O
exhibited	O
no	O
detectable	O
exonic	O
mutation	O
of	O
the	O
PLP	O
gene.	O
Examination	O
of	O
RNA	O
from	O
these	O
cells	O
showed	O
that	O
the	O
level	O
of	O
DM20	O
messenger	O
RNA	O
is	O
elevated	O
sixfold	O
relative	O
to	O
male	O
control	O
skin	O
fibroblasts.	O
An	O
unrelated	O
female	O
carrier,	O
also	O
with	O
no	O
detectable	O
exonic	O
mutation,	O
showed	O
a	O
threefold	O
increase	O
in	O
DM20	O
messenger	O
RNA	O
in	O
cultured	O
skin	O
fibroblasts.	O
Our	O
findings	O
suggest	O
that	O
in	O
some	O
patients,	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease

Homozygosity	O
for	O
a	O
novel	O
DTDST	O
mutation	O
in	O
a	O
child	O
with	O
a	O
'broad	O
bone-platyspondylic'	O
variant	O
of	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
.	O
Atypical	O
or	O
variant	O
forms	O
of	O
well-known	O
chondrodysplasias	DiseaseClass
may	O
pose	O
diagnostic	O
problems.	O
We	O
report	O
on	O
a	O
girl	O
with	O
clinical	O
features	O
suggesting	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
but	O
with	O
unusual	O
radiographic	O
features	O
including	O
severe	O
platyspondyly	DiseaseClass
,	O
wide	O
metaphyses,	O
and	O
fibular	O
overgrowth,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	SpecificDisease
dysplasia	SpecificDisease

Carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
using	O
a	O
combination	O
of	O
anonymous	O
DNA	O
polymorphisms	O
and	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
cDNA.	O
We	O
report	O
carrier	O
identification	O
and	O
a	O
prenatal	O
diagnosis	O
using	O
DNA	O
polymorphisms	O
in	O
2	O
families	O
with	O
X-linked	SpecificDisease
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
(	O
PMD	SpecificDisease
).	O
In	O
both	O
families,	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
in	O
the	O
single	O
affected	O
male	O
could	O
be	O
traced	O
back	O
to	O
his	O
unaffected	O
maternal	O
grandfather.	O
Therefore,	O
each	O
family	O
contains	O
a	O
new	O
mutation.	O
In	O
the	O
case	O
of	O
the	O
prenatal	O
diagnosis,	O
the	O
fetus	O
was	O
shown	O
by	O
cytogenetic	O
analysis	O
to	O
be	O
a	O
female,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
PMD	SpecificDisease

Gardner	SpecificDisease
syndrome	SpecificDisease
in	O
a	O
boy	O
with	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5.	O
We	O
described	O
a	O
15-year-old	O
boy	O
with	O
Gardner	SpecificDisease
syndrome	SpecificDisease
(	O
GS	SpecificDisease
),	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
craniofacial	DiseaseClass
abnormalities	DiseaseClass
.	O
High-resolution	O
banding	O
analysis	O
showed	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(q22.	O
1----q31	O
1----q31.	O
1).	O
The	O
breakpoints	O
in	O
the	O
present	O
case	O
and	O
in	O
3	O
previously	O
reported	O
5q-	O
patients	O
with	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
suggest	O
that	O
the	O
gene	O
responsible	O
for	O
GS	SpecificDisease
/or	O
familial	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
FPC	SpecificDisease

Type	SpecificDisease
I	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
.	O
A	O
28-base	O
pair	O
gene	O
deletion	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing.	O
Two	O
variants	O
of	O
a	O
genetic	O
deficiency	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
protein	SpecificDisease
C2	SpecificDisease
(C2D)	O
have	O
been	O
previously	O
identified.	O
No	O
C2	O
protein	O
translation	O
is	O
detected	O
in	O
type	O
I	O
deficiency,	O
while	O
type	O
II	O
deficiency	O
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion.	O
Type	SpecificDisease
I	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
was	O
described	O
in	O
a	O
family	O
in	O
which	O
the	O
C2	O
null	O
allele	O
(C2Q0)	O
is	O
associated	O
with	O
the	O
major	O
histocompatibility	O
haplotype/complotype	O
HLA-A25,	O
B18,	O
C2Q0,	O
BfS,	O
C4A4,	O
C4B2,	O
Drw2;	O
this	O
extended	O
haplotype	O
occurs	O
in	O
over	O
90%	O
of	O
C2-deficient	Modifier
individuals	O
(common	O
complotype/haplotype).	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
type	SpecificDisease
I	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
,	O
the	O
C2	O
gene	O
and	O
cDNA	O
were	O
characterized	O
from	O
a	O
homozygous	O
type	Modifier
I	Modifier
C2-deficient	Modifier
individual	O
with	O
the	O
common	O
associated	O
haplotype/complotype.	O
We	O
found	O
a	O
28-base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene,	O
beginning	O
9	O
base	O
pairs	O
upstream	O
of	O
the	O
3-end	O
of	O
exon	O
6,	O
that	O
generates	O
a	O
C2	O
transcript	O
with	O
a	O
complete	O
deletion	O
of	O
exon	O
6	O
(134	O
base	O
pair)	O
and	O
a	O
premature	O
termination	O
codon.	O
In	O
studies	O
of	O
eight	O
kindred,	O
the	O
28-base	O
pair	O
deletion	O
was	O
observed	O
in	O
all	O
C2Q0	O
alleles	O
associated	O
with	O
the	O
common	O
type	O
I	O
deficient	O
complotype/haplotype;	O
this	O
deletion	O
was	O
not	O
present	O
in	O
normal	O
C2	O
nor	O
in	O
type	Modifier
II	Modifier
C2-deficient	Modifier
genes.	O
These	O
data	O
demonstrate	O
that	O
	O
1)	O
type	SpecificDisease
I	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
is	O
caused	O
by	O
a	O
28-base	O
pair	O
genomic	O
deletion	O
that	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing,	O
resulting	O
in	O
generation	O
of	O
a	O
premature	O
termination	O
codon,	O
2)	O
the	O
28-base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	O
haplotype/complotype	O
A25,	O
B18,	O
C2Q0,	O
BfS,	O
C4A4,	O
C4B2,	O
Drw2,	O
suggesting	O
that	O
all	O
C2-deficient	Modifier
individuals	O
with	O
this	O
haplotype/complotype	O
will	O
harbor	O
the	O
28-base	O
pair	O
C2	O
gene	O
deletion,	O
and	O
3)	O
type	SpecificDisease
II	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
is	O
caused	O
by	O
a	O
different,	O
as	O
yet	O
uncharacterized,	O
molecular	O
genetic	DiseaseClass
defect	DiseaseClass

(Over)correction	O
of	O
FMR1	SpecificDisease
deficiency	SpecificDisease
with	O
YAC	O
transgenics:	O
behavioral	O
and	O
physical	O
features.	O
Fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
common	O
cause	O
of	O
mental	DiseaseClass
retardation	DiseaseClass
involving	O
loss	O
of	O
expression	O
of	O
the	O
FMR1	O
gene.	O
The	O
role	O
of	O
FMR1	O
remains	O
undetermined	O
but	O
the	O
protein	O
appears	O
to	O
be	O
involved	O
in	O
RNA	O
metabolism.	O
Fmr1	O
knockout	O
mice	O
exhibit	O
a	O
phenotype	O
with	O
some	O
similarities	O
to	O
humans,	O
such	O
as	O
macroorchidism	SpecificDisease
and	O
behavioral	O
abnormalities.	O
As	O
a	O
step	O
toward	O
understanding	O
the	O
function	O
of	O
FMR1	O
and	O
the	O
determination	O
of	O
the	O
potential	O
for	O
therapeutic	O
approaches	O
to	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
yeast	O
artificial	O
chromosome	O
(YAC)	O
transgenic	O
mice	O
were	O
generated	O
in	O
order	O
to	O
determine	O
whether	O
the	O
Fmr1	O
knockout	O
mouse	O
phenotype	O
could	O
be	O
rescued.	O
Several	O
transgenic	O
lines	O
were	O
generated	O
that	O
carried	O
the	O
entire	O
FMR1	O
locus	O
with	O
extensive	O
amounts	O
of	O
flanking	O
sequence.	O
We	O
observed	O
that	O
the	O
YAC	O
transgene	O
supported	O
production	O
of	O
the	O
human	O
protein	O
(FMRP)	O
which	O
was	O
present	O
at	O
levels	O
10	O
to	O
15	O
times	O
that	O
of	O
endogenous	O
protein	O
and	O
was	O
expressed	O
in	O
a	O
cell-	O
and	O
tissue-specific	O
manner.	O
Macro-orchidism	O
was	O
absent	O
in	O
knockout	O
mice	O
carrying	O
the	O
YAC	O
transgene	O
indicating	O
functional	O
rescue	O
by	O
the	O
human	O
protein.	O
Given	O
the	O
complex	O
behavioral	O
phenotype	O
in	O
fragile	Modifier
X	Modifier
patients	O
and	O
the	O
mild	O
phenotype	O
previously	O
reported	O
for	O
the	O
Fmr1	O
knockout	O
mouse,	O
we	O
performed	O
a	O
more	O
thorough	O
evaluation	O
of	O
the	O
Fmr1	O
knockout	O
phenotype	O
using	O
additional	O
behavioral	O
assays	O
that	O
had	O
not	O
previously	O
been	O
reported	O
for	O
this	O
animal	O
model.	O
The	O
mouse	O
displayed	O
reduced	O
anxiety	Modifier
-related	O
responses	O
with	O
increased	O
exploratory	O
behavior.	O
FMR1	O
YAC	O
transgenic	O
mice	O
overexpressing	O
the	O
human	O
protein	O
did	O
produce	O
opposing	O
behavioral	O
responses	O
and	O
additional	O
abnormal	O
behaviors	O
were	O
also	O
observed.	O
These	O
findings	O
have	O
significant	O
implications	O
for	O
gene	O
therapy	O
for	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease

Fabry	SpecificDisease
disease	SpecificDisease
:	O
identification	O
of	O
novel	O
alpha-galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches.	O
Fabry	SpecificDisease
disease	SpecificDisease
(	O
FD	SpecificDisease
)	O
(	O
angiokeratoma	SpecificDisease
corporis	SpecificDisease
diffusum	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
inborn	DiseaseClass
error	DiseaseClass
of	DiseaseClass
glycosphingolipid	DiseaseClass
metabolism	DiseaseClass
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha-galactosidase	O
A	O
gene	O
(GLA).	O
The	O
enzymatic	O
defect	O
leads	O
to	O
the	O
systemic	O
accumulation	O
of	O
neutral	O
glycosphingolipids	O
with	O
terminal	O
alpha-galactosyl	O
moieties.	O
Clinically,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	SpecificDisease
,	O
severe	SpecificDisease
acroparesthesia	SpecificDisease
,	O
renal	SpecificDisease
failure	SpecificDisease
,	O
and	O
vasculopathy	CompositeMention
of	CompositeMention
the	CompositeMention
heart	CompositeMention
and	CompositeMention
brain	CompositeMention
.	O
While	O
demonstration	O
of	O
alpha-galactosidase	SpecificDisease
deficiency	SpecificDisease
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive,	O
due	O
to	O
random	O
X-chromosomal	O
inactivation,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling.	O
By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence-based	O
detection	O
systems,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha-Gal	SpecificDisease
A	SpecificDisease
deficiency	SpecificDisease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	SpecificDisease

Evidence	O
for	O
linkage	O
of	O
bipolar	SpecificDisease
disorder	SpecificDisease
to	O
chromosome	O
18	O
with	O
a	O
parent-of-origin	O
effect.	O
A	O
susceptibility	O
gene	O
on	O
chromosome	O
18	O
and	O
a	O
parent-of-origin	O
effect	O
have	O
been	O
suggested	O
for	O
bipolar	SpecificDisease
affective	SpecificDisease
disorder	SpecificDisease
(	O
BPAD	SpecificDisease
).	O
We	O
have	O
studied	O
28	O
nuclear	O
families	O
selected	O
for	O
apparent	O
unilineal	O
transmission	O
of	O
the	O
BPAD	Modifier
phenotype,	O
by	O
using	O
31	O
polymorphic	O
markers	O
spanning	O
chromosome	O
18.	O
Evidence	O
for	O
linkage	O
was	O
tested	O
with	O
affected-sib-pair	O
and	O
LOD	O
score	O
methods	O
under	O
two	O
definitions	O
of	O
the	O
affected	O
phenotype.	O
The	O
affected-sibpair	O
analyses	O
indicated	O
excess	O
allele	O
sharing	O
for	O
markers	O
on	O
18p	O
within	O
the	O
region	O
reported	O
previously.	O
The	O
greatest	O
sharing	O
was	O
at	O
D18S37	O
	O
64%	O
in	O
bipolar	O
and	O
recurrent	O
unipolar	O
(RUP)	O
sib	O
pairs	O
(P	O
=.	O
0006).	O
In	O
addition,	O
excess	O
sharing	O
of	O
the	O
paternally,	O
but	O
not	O
maternally,	O
transmitted	O
alleles	O
was	O
observed	O
at	O
three	O
markers	O
on	O
18q	O
	O
at	O
D18S41,	O
51	O
bipolar	O
and	O
RUP	O
sib	O
pairs	O
were	O
concordant	O
for	O
paternally	O
transmitted	O
alleles,	O
and	O
21	O
pairs	O
were	O
discordant	O
(P	O
=	O
0004).	O
The	O
evidence	O
for	O
linkage	O
to	O
loci	O
on	O
both	O
18p	O
and	O
18q	O
was	O
strongest	O
in	O
the	O
11	O
paternal	O
pedigrees,	O
i.	O
e	O
e.,	O
those	O
in	O
which	O
the	O
father	O
or	O
one	O
of	O
the	O
fathers	O
sibs	O
is	O
affected.	O
In	O
these	O
pedigrees,	O
the	O
greatest	O
allele	O
sharing	O
(81%;	O
P	O
=.	O
00002)	O
and	O
the	O
highest	O
LOD	O
score	O
(3.	O
51;	O
phi	O
=	O
0.	O
0)	O
were	O
observed	O
at	O
D18S41.	O
Our	O
results	O
provide	O
further	O
support	O
for	O
linkage	O
of	O
BPAD	SpecificDisease

BRCA1	O
mutations	O
in	O
a	O
population-based	O
sample	O
of	O
young	O
women	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
BACKGROUND.	O
Inherited	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
are	O
associated	O
with	O
a	O
high	O
risk	O
of	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
in	O
some	O
families.	O
However,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
BRCA1	O
mutations	O
to	O
breast	SpecificDisease
cancer	SpecificDisease
in	O
the	O
general	O
population.	O
We	O
analyzed	O
DNA	O
samples	O
from	O
women	O
enrolled	O
in	O
a	O
population-based	O
study	O
of	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
to	O
assess	O
the	O
spectrum	O
and	O
frequency	O
of	O
germ-line	O
BRCA1	O
mutations	O
in	O
young	O
women	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
METHODS.	O
We	O
studied	O
80	O
women	O
in	O
whom	O
breast	SpecificDisease
cancer	SpecificDisease
was	O
diagnosed	O
before	O
the	O
age	O
of	O
35,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
family	O
history.	O
Genomic	O
DNA	O
was	O
studied	O
for	O
BRCA1	O
mutations	O
by	O
analysis	O
involving	O
single-strand	O
conformation	O
polymorphisms	O
and	O
with	O
allele-specific	O
assays.	O
Alterations	O
were	O
defined	O
by	O
DNA	O
sequencing.	O
RESULTS.	O
Germ-line	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
the	O
80	O
women.	O
Four	O
additional	O
rare	O
sequence	O
variants	O
of	O
unknown	O
functional	O
importance	O
were	O
also	O
identified.	O
Two	O
of	O
the	O
mutations	O
and	O
three	O
of	O
the	O
rare	O
sequence	O
variants	O
were	O
found	O
among	O
the	O
39	O
women	O
who	O
reported	O
no	O
family	O
history	O
of	O
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
None	O
of	O
the	O
mutations	O
and	O
only	O
one	O
of	O
the	O
rare	O
variants	O
was	O
identified	O
in	O
a	O
reference	O
population	O
of	O
73	O
unrelated	O
subjects.	O
CONCLUSIONS.	O
Alterations	O
in	O
BRCA1	O
were	O
identified	O
in	O
approximately	O
10	O
percent	O
of	O
this	O
cohort	O
of	O
young	O
women	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
The	O
risk	O
of	O
harboring	O
a	O
mutation	O
was	O
not	O
limited	O
to	O
women	O
with	O
family	O
histories	O
of	O
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

Retinoschisin,	O
the	O
X-linked	Modifier
retinoschisis	Modifier
protein,	O
is	O
a	O
secreted	O
photoreceptor	O
protein,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
Weri-Rb1	O
cells.	O
X-linked	SpecificDisease
retinoschisis	SpecificDisease
is	O
characterized	O
by	O
microcystic-like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers,	O
leading	O
to	O
visual	DiseaseClass
deterioration	DiseaseClass
in	O
males.	O
Many	O
missense	O
and	O
protein-truncating	O
mutations	O
of	O
the	O
causative	O
gene	O
RS1	O
have	O
now	O
been	O
identified	O
and	O
are	O
thought	O
to	O
be	O
inactivating.	O
RS1	O
encodes	O
a	O
224	O
amino	O
acid	O
protein,	O
retinoschisin,	O
which	O
contains	O
a	O
discoidin	O
domain	O
but	O
is	O
of	O
unknown	O
function.	O
We	O
have	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
a	O
peptide	O
from	O
a	O
unique	O
region	O
within	O
retinoschisin,	O
which	O
detects	O
a	O
protein	O
of	O
approximately	O
28	O
kDa	O
in	O
retinal	O
samples	O
reduced	O
with	O
dithiothreitol,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non-reducing	O
conditions.	O
A	O
screen	O
of	O
human	O
tissues	O
with	O
this	O
antibody	O
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	O
and	O
the	O
antibody	O
detects	O
a	O
protein	O
of	O
similar	O
size	O
in	O
bovine	O
and	O
murine	O
retinae.	O
We	O
investigated	O
the	O
expression	O
pattern	O
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(using	O
in	O
situ	O
hybridization	O
with	O
riboprobes)	O
and	O
retinoschisin	O
(using	O
immunohistochemistry).	O
The	O
antisense	O
riboprobe	O
detected	O
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	O
layer	O
but	O
the	O
protein	O
product	O
of	O
the	O
gene	O
was	O
present	O
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina.	O
Furthermore,	O
differentiated	O
retinoblastoma	Modifier
cells	O
(Weri-Rb1	O
cells)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin.	O
These	O
results	O
suggest	O
that	O
retinoschisin	O
is	O
released	O
by	O
photo-receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	O
layers.	O
Thus,	O
X-linked	SpecificDisease
retinoschisis	SpecificDisease
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo-receptor	O
protein	O
associated	O
with	O
a	O
retinal	DiseaseClass
dystrophy	DiseaseClass

Aberrant	O
splicing	O
of	O
the	O
CHM	Modifier
gene	O
is	O
a	O
significant	O
cause	O
of	O
choroideremia	SpecificDisease
.	O
Choroideremia	SpecificDisease
(	O
CHM	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
progressive	DiseaseClass
degeneration	DiseaseClass
of	DiseaseClass
the	DiseaseClass
choroid	DiseaseClass
and	DiseaseClass
retina	DiseaseClass
.	O
12%	O
of	O
unrelated	O
male	O
patients	O
carry	O
deletions	O
of	O
the	O
partially	O
cloned	O
CHM	Modifier
gene.	O
In	O
Finland,	O
there	O
are	O
more	O
than	O
120	O
living	O
CHM	Modifier
patients	O
belonging	O
to	O
eight	O
apparently	O
unrelated	O
pedigrees.	O
Molecular	O
deletions	O
involving	O
the	O
CHM	Modifier
gene	O
have	O
been	O
detected	O
in	O
three	O
families.	O
We	O
have	O
screened	O
the	O
remaining	O
five	O
families	O
for	O
point	O
mutations.	O
In	O
one	O
large	O
family	O
a	O
single	O
nucleotide	O
(T)	O
insertion	O
into	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
C	O
leads	O
to	O
two	O
aberrantly	O
spliced	O
mRNAs	O
both	O
producing	O
a	O
premature	O
stop	O
codon.	O
The	O
mutation	O
can	O
be	O
assayed	O
easily	O
by	O
amplification	O
and	O
digestion	O
with	O
Msel.	O
Our	O
findings	O
provide	O
additional	O
evidence	O
for	O
the	O
pathogenetic	O
role	O
of	O
CHM	Modifier
mutations	O
and	O
provide	O
a	O
diagnostic	O
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
CHM	Modifier

X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
):	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	Modifier
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes.	O
Fragments	O
of	O
the	O
adrenoleukodystrophy	Modifier
(	O
ALD	Modifier
)	O
cDNA	O
from	O
a	O
patient	O
with	O
adolescent	SpecificDisease
ALD	SpecificDisease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned.	O
Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	Modifier
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five,	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine.	O
Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient,	O
comprising	O
two	O
cerebral	SpecificDisease
ALD	SpecificDisease
,	O
one	O
adrenomyeloneuropathy	SpecificDisease
,	O
one	O
Addison	SpecificDisease
only	SpecificDisease
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids)	O
carried	O
this	O
mutation,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons,	O
in	O
five	O
unrelated	O
ALD	Modifier

Statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	SpecificDisease
Hippel-Lindau	SpecificDisease
disease	SpecificDisease
,	O
and	O
in	O
sporadic	SpecificDisease
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
and	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
.	O
Analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	CompositeMention
and	CompositeMention
bilateral	CompositeMention
retinoblastoma	CompositeMention
led	O
Knudson	O
to	O
propose	O
that	O
hereditary	DiseaseClass
tumours	DiseaseClass
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	DiseaseClass
tumours	DiseaseClass
by	O
a	O
two	O
stage	O
mutation	O
process.	O
It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process.	O
We	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
(n	O
=	O
26)	O
and	O
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
(n	O
=	O
68)	O
in	O
109	O
patients	O
with	O
von	SpecificDisease
Hippel-Lindau	SpecificDisease
(VHL)	SpecificDisease
disease	SpecificDisease
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
and	O
43	O
patients	O
with	O
sporadic	SpecificDisease
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
.	O
The	O
age	O
incidence	O
curves	O
for	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
and	O
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
in	O
VHL	SpecificDisease
disease	SpecificDisease
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
and	O
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
suggested	O
a	O
two	O
stage	O
mutation	O
process.	O
These	O
data	O
are	O
compatible	O
with	O
the	O
VHL	Modifier
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	Modifier
suppressor	O
gene.	O
Sporadic	SpecificDisease
cerebellar	SpecificDisease
haemangioblastoma	SpecificDisease
and	O
some	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
VHL	Modifier

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	SpecificDisease
syndrome	SpecificDisease
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene.	O
The	O
oculocerebrorenal	SpecificDisease
syndrome	SpecificDisease
of	SpecificDisease
Lowe	SpecificDisease
(	O
OCRL	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
major	O
abnormalities	CompositeMention
of	CompositeMention
eyes,	CompositeMention
nervous	CompositeMention
system,	CompositeMention
and	CompositeMention
kidneys	CompositeMention
.	O
Mutations	O
in	O
the	O
OCRL1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
disease.	O
OCRL1	O
encodes	O
a	O
phosphatidylinositol	O
4,	O
5-biphosphate	O
(PtdIns	O
[4,	O
5]	O
P2)	O
5-phosphatase.	O
We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	SpecificDisease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in-frame	O
deletion.	O
Among	O
the	O
new	O
mutations,	O
two	O
nonsense	O
mutations	O
(R317X	O
and	O
E558X)	O
and	O
three	O
other	O
frameshift	O
mutations	O
caused	O
premature	O
termination	O
of	O
the	O
protein.	O
A	O
missense	O
mutation,	O
R483G,	O
was	O
located	O
in	O
the	O
highly	O
conserved	O
PtdIns	O
(4,	O
5)	O
P2	O
5-phosphatase	O
domain.	O
Finally,	O
one	O
frameshift	O
mutation,	O
2799delC,	O
modifies	O
the	O
C-terminal	O
part	O
of	O
OCRL1,	O
with	O
an	O
extension	O
of	O
six	O
amino	O
acids.	O
Altogether,	O
70%	O
of	O
missense	O
mutations	O
are	O
located	O
in	O
exon	O
15,	O
and	O
52%	O
of	O
all	O
mutations	O
cluster	O
in	O
exons	O
11-15.	O
We	O
also	O
identified	O
two	O
new	O
microsatellite	O
markers	O
for	O
the	O
OCRL1	O
locus,	O
and	O
we	O
detected	O
a	O
germline	O
mosaicism	O
in	O
one	O
family.	O
This	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
Lowe	Modifier
syndrome	Modifier

Aminoglycoside	O
antibiotics	O
restore	O
dystrophin	O
function	O
to	O
skeletal	O
muscles	O
of	O
mdx	O
mice.	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene,	O
leading	O
to	O
the	O
absence	O
of	O
the	O
dystrophin	O
protein	O
in	O
striated	O
muscle.	O
A	O
significant	O
number	O
of	O
these	O
mutations	O
are	O
premature	O
stop	O
codons.	O
On	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
DMD	SpecificDisease
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene.	O
Exposure	O
of	O
mdx	O
myotubes	O
to	O
gentamicin	O
led	O
to	O
the	O
expression	O
and	O
localization	O
of	O
dystrophin	O
to	O
the	O
cell	O
membrane.	O
We	O
then	O
evaluated	O
the	O
effects	O
of	O
differing	O
dosages	O
of	O
gentamicin	O
on	O
expression	O
and	O
functional	O
protection	O
of	O
the	O
muscles	O
of	O
mdx	O
mice.	O
We	O
identified	O
a	O
treatment	O
regimen	O
that	O
resulted	O
in	O
the	O
presence	O
of	O
dystrophin	O
in	O
the	O
cell	O
membrane	O
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	DiseaseClass
injury	DiseaseClass
.	O
To	O
our	O
knowledge,	O
our	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
aminoglycosides	O
can	O
suppress	O
stop	O
codons	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo.	O
Furthermore,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	SpecificDisease
dystrophy	SpecificDisease
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations.	O
This	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15%	O
of	O
patients	O
with	O
DMD	SpecificDisease

Molecular	O
and	O
metabolic	O
basis	O
for	O
the	O
metabolic	DiseaseClass
disorder	DiseaseClass
	O
normotriglyceridemic	SpecificDisease
abetalipoproteinemia	SpecificDisease
.	O
We	O
have	O
previously	O
described	O
a	O
disorder,	O
normotriglyceridemic	SpecificDisease
abetalipoproteinemia	SpecificDisease
,	O
that	O
is	O
characterized	O
by	O
the	O
virtual	O
absence	O
of	O
plasma	O
low	O
density	O
lipoproteins	O
and	O
complete	O
absence	O
of	O
apoB-100,	O
but	O
with	O
apparently	O
normal	O
secretion	O
of	O
triglyceride-rich	O
lipoproteins	O
containing	O
apoB-48.	O
The	O
patients	O
plasma	O
lipoproteins	O
were	O
shown	O
on	O
polyacrylamide	O
gels	O
and	O
by	O
antibody	O
mapping	O
to	O
have	O
a	O
new	O
truncated	O
apoB	O
variant,	O
apoB-50,	O
circulating	O
along	O
with	O
her	O
apoB-48.	O
We	O
have	O
found	O
this	O
individual	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
C-to-T	O
nucleotide	O
substitution	O
at	O
apoB	O
codon	O
2252,	O
which	O
produces	O
a	O
premature	O
in-frame	O
stop	O
codon.	O
Thus,	O
this	O
is	O
a	O
rare	O
example	O
of	O
homozygous	SpecificDisease
hypobetalipoproteinemia	SpecificDisease

von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
type	SpecificDisease
B	SpecificDisease
:	O
a	O
missense	O
mutation	O
selectively	O
abolishes	O
ristocetin-induced	O
von	Modifier
Willebrand	Modifier
factor	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib.	O
von	Modifier
Willebrand	Modifier
factor	O
(vWF)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib.	O
For	O
human	O
vWF,	O
this	O
interaction	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
the	O
antibiotic	O
ristocetin	O
or	O
the	O
snake	O
venom	O
protein	O
botrocetin.	O
A	O
missense	O
mutation,	O
Gly-561--	O
>	O
Ser,	O
was	O
identified	O
within	O
the	O
proposed	O
glycoprotein	O
Ib	O
binding	O
domain	O
of	O
vWF	O
in	O
the	O
proband	O
with	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
type	SpecificDisease
B	SpecificDisease
,	O
a	O
unique	O
variant	O
characterized	O
by	O
no	O
ristocetin-induced,	O
but	O
normal	O
botrocetin-induced,	O
binding	O
to	O
glycoprotein	O
Ib.	O
The	O
corresponding	O
mutant	O
recombinant	O
protein,	O
rvWF	O
(G561S),	O
formed	O
normal	O
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	O
as	O
the	O
patients	O
plasma	O
vWF,	O
confirming	O
that	O
this	O
mutation	O
causes	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
type	SpecificDisease
B	SpecificDisease
.	O
These	O
data	O
show	O
that	O
botrocetin	O
and	O
ristocetin	O
cofactor	O
activities	O
of	O
vWF	O
can	O
be	O
dissociated	O
by	O
a	O
point	O
mutation	O
and	O
confirm	O
that	O
these	O
mediators	O
promote	O
vWF	O
binding	O
to	O
platelets	O
by	O
different	O
mechanisms.	O
The	O
normal	O
botrocetin-induced	O
binding	O
and	O
the	O
defective	O
ristocetin-induced	O
binding	O
of	O
rvWF	O
(G561S)	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
type	SpecificDisease
B	SpecificDisease

A	O
high	O
incidence	O
of	O
BRCA1	O
mutations	O
in	O
20	O
breast-ovarian	Modifier
cancer	Modifier
families.	O
We	O
have	O
analyzed	O
20	O
breast-ovarian	Modifier
cancer	Modifier
families,	O
the	O
majority	O
of	O
which	O
show	O
positive	O
evidence	O
of	O
linkage	O
to	O
chromosome	O
17q12	O
for	O
germ-line	O
mutations	O
in	O
the	O
BRCA1	O
gene.	O
BRCA1	O
mutations	O
cosegregating	O
with	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
were	O
identified	O
in	O
16	O
families,	O
including	O
1	O
family	O
with	O
a	O
case	O
of	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
.	O
Nine	O
of	O
these	O
mutations	O
have	O
not	O
been	O
reported	O
previously.	O
The	O
majority	O
of	O
mutations	O
were	O
found	O
to	O
generate	O
a	O
premature	O
stop	O
codon	O
leading	O
to	O
the	O
formation	O
of	O
a	O
truncated	O
BRCA1	O
protein	O
of	O
2%	O
-88%	O
of	O
the	O
expected	O
normal	O
length.	O
Two	O
mutations	O
altered	O
the	O
RING	O
finger	O
domain.	O
Sequencing	O
of	O
genomic	O
DNA	O
led	O
to	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
BRCA1	O
in	O
12	O
families,	O
and	O
cDNA	O
analysis	O
revealed	O
an	O
abnormal	O
or	O
missing	O
BRCA1	O
transcript	O
in	O
4	O
of	O
the	O
8	O
remaining	O
families.	O
A	O
total	O
of	O
eight	O
mutations	O
were	O
associated	O
with	O
a	O
reduced	O
quantity	O
of	O
BRCA1	O
transcript.	O
We	O
were	O
unable	O
to	O
detect	O
BRCA1	O
mutations	O
in	O
4	O
of	O
the	O
20	O
families,	O
but	O
only	O
1	O
of	O
these	O
was	O
clearly	O
linked	O
to	O
BRCA1.	O
It	O
is	O
expected	O
that	O
the	O
majority	O
of	O
clear	O
examples	O
of	O
the	O
breast-ovarian	SpecificDisease
syndrome	SpecificDisease

Assignment	O
of	O
the	O
human	O
Na+/glucose	O
cotransporter	O
gene	O
SGLT1	O
to	O
chromosome	O
22q13.1.	O
The	O
Na	O
+/glucose	O
cotransporter	O
gene	O
SGLT1	O
encodes	O
the	O
primary	O
carrier	O
protein	O
responsible	O
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	O
and	O
galactose	O
from	O
the	O
intestinal	O
lumen.	O
SGLT1	O
transport	O
activity	O
is	O
currently	O
exploited	O
in	O
oral	O
rehydration	O
therapy.	O
The	O
75-kDa	O
glycoprotein	O
is	O
localized	O
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	O
to	O
comprise	O
12	O
membrane	O
spans.	O
In	O
two	O
patients	O
with	O
the	O
autosomal	SpecificDisease
recessive	SpecificDisease
disease	SpecificDisease
glucose/galactose	SpecificDisease
malabsorption	SpecificDisease
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
SGLT1,	O
and	O
the	O
Asp28--	O
>	O
Asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	O
transport	O
activity.	O
The	O
SGLT1	O
gene	O
was	O
previously	O
shown	O
to	O
reside	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
(11.	O
2--	O
>	O
qter).	O
We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	O
in	O
situ	O
hybridization,	O
which	O
refines	O
the	O
localization	O
to	O
22q13.	O
1,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	DiseaseClass
diseases	DiseaseClass

A	O
pseudodeficiency	O
allele	O
common	O
in	O
non-Jewish	O
Tay-Sachs	Modifier
carriers:	O
implications	O
for	O
carrier	O
screening.	O
Deficiency	SpecificDisease
of	SpecificDisease
beta-hexosaminidase	SpecificDisease
A	SpecificDisease
(Hex	O
A)	O
activity	O
typically	O
results	O
in	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
.	O
However,	O
healthy	O
subjects	O
found	O
to	O
be	O
deficient	SpecificDisease
in	SpecificDisease
Hex	SpecificDisease
A	SpecificDisease
activity	O
(i.	O
e.,	O
pseudodeficient)	O
by	O
means	O
of	O
in	O
vitro	O
biochemical	O
tests	O
have	O
been	O
described.	O
We	O
analyzed	O
the	O
HEXA	O
gene	O
of	O
one	O
pseudodeficient	O
subject	O
and	O
identified	O
both	O
a	O
C739-to-T	O
substitution	O
that	O
changes	O
Arg247----Trp	O
on	O
one	O
allele	O
and	O
a	O
previously	O
identified	O
Tay-Sachs	Modifier
disease	Modifier
mutation	O
on	O
the	O
second	O
allele.	O
Six	O
additional	O
pseudodeficient	O
subjects	O
were	O
found	O
to	O
have	O
the	O
C739-to-T	O
mutation.	O
This	O
allele	O
accounted	O
for	O
32%	O
(20/62)	O
of	O
non-Jewish	O
enzyme-defined	O
Tay-Sachs	Modifier
disease	Modifier
carriers	O
but	O
for	O
none	O
of	O
36	O
Jewish	O
enzyme-defined	O
carriers	O
who	O
did	O
not	O
have	O
one	O
of	O
three	O
known	O
mutations	O
common	O
to	O
this	O
group.	O
The	O
C739-to-T	O
allele,	O
together	O
with	O
a	O
"	O
true	O
"	O
Tay-Sachs	Modifier
disease	Modifier
allele,	O
causes	O
Hex	O
A	O
pseudodeficiency.	O
Given	O
both	O
the	O
large	O
proportion	O
of	O
non-Jewish	O
carriers	O
with	O
this	O
allele	O
and	O
that	O
standard	O
biochemical	O
screening	O
cannot	O
differentiate	O
between	O
heterozygotes	O
for	O
the	O
C739-to-T	O
mutations	O
and	O
Tay-Sachs	Modifier
disease	Modifier

The	O
presence	O
of	O
two	O
different	O
infantile	O
Tay-Sachs	Modifier
disease	Modifier
mutations	O
in	O
a	O
Cajun	O
population.	O
A	O
study	O
was	O
undertaken	O
to	O
characterize	O
the	O
mutation	O
(s)	O
responsible	O
for	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
in	O
a	O
Cajun	O
population	O
in	O
southwest	O
Louisiana	O
and	O
to	O
identify	O
the	O
origins	O
of	O
these	O
mutations.	O
Eleven	O
of	O
12	O
infantile	O
TSD	Modifier
alleles	O
examined	O
in	O
six	O
families	O
had	O
the	O
beta-hexosaminidase	O
A	O
(Hex	O
A)	O
alpha-subunit	O
exon	O
11	O
insertion	O
mutation	O
that	O
is	O
present	O
in	O
approximately	O
70%	O
of	O
Ashkenazi	O
Jewish	O
TSD	Modifier
heterozygotes.	O
The	O
mutation	O
in	O
the	O
remaining	O
allele	O
was	O
a	O
single-base	O
transition	O
in	O
the	O
donor	O
splice	O
site	O
of	O
the	O
alpha-subunit	O
intron	O
9.	O
To	O
determine	O
the	O
origins	O
of	O
these	O
two	O
mutations	O
in	O
the	O
Cajun	O
population,	O
the	O
TSD	Modifier

Canavan	SpecificDisease
disease	SpecificDisease
:	O
genomic	O
organization	O
and	O
localization	O
of	O
human	O
ASPA	O
to	O
17p13-ter	O
and	O
conservation	O
of	O
the	O
ASPA	O
gene	O
during	O
evolution.	O
Canavan	SpecificDisease
disease	SpecificDisease
,	O
or	O
spongy	SpecificDisease
degeneration	SpecificDisease
of	SpecificDisease
the	SpecificDisease
brain	SpecificDisease
,	O
is	O
a	O
severe	O
leukodystrophy	SpecificDisease
caused	O
by	O
the	O
deficiency	SpecificDisease
of	SpecificDisease
aspartoacylase	SpecificDisease
(ASPA).	O
Recently,	O
a	O
missense	O
mutation	O
was	O
identified	O
in	O
human	O
ASPA	O
coding	O
sequence	O
from	O
patients	O
with	O
Canavan	SpecificDisease
disease	SpecificDisease
.	O
The	O
human	O
ASPA	O
gene	O
has	O
been	O
cloned	O
and	O
found	O
to	O
span	O
29	O
kb	O
of	O
the	O
genome.	O
Human	O
aspartoacylase	O
is	O
coded	O
by	O
six	O
exons	O
intervened	O
by	O
five	O
introns.	O
The	O
exons	O
vary	O
from	O
94	O
(exon	O
III)	O
to	O
514	O
(exon	O
VI)	O
bases.	O
The	O
exon/intron	O
splice	O
junction	O
sites	O
follow	O
the	O
gt/ag	O
consensus	O
sequence	O
rule.	O
Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
human/mouse	O
somatic	O
cell	O
hybrid	O
cell	O
lines	O
localized	O
ASPA	O
to	O
human	O
chromosome	O
17.	O
The	O
human	O
ASPA	O
locus	O
was	O
further	O
mapped	O
in	O
the	O
17p13-ter	O
region	O
by	O
fluorescence	O
in	O
situ	O
hybridization.	O
The	O
bovine	O
aspa	O
gene	O
has	O
also	O
been	O
cloned,	O
and	O
its	O
exon/intron	O
organization	O
is	O
identical	O
to	O
that	O
of	O
the	O
human	O
gene.	O
The	O
500-base	O
sequence	O
upstream	O
of	O
the	O
initiator	O
ATG	O
codon	O
in	O
the	O
human	O
gene	O
and	O
that	O
in	O
the	O
bovine	O
gene	O
are	O
77%	O
identical.	O
Human	O
ASPA	O
coding	O
sequences	O
cross-hybridize	O
with	O
genomic	O
DNA	O
from	O
yeast,	O
chicken,	O
rabbit,	O
cow,	O
dog,	O
mouse,	O
rat,	O
and	O
monkey.	O
The	O
specificity	O
of	O
cross-species	O
hybridization	O
of	O
coding	O
sequences	O
suggests	O
that	O
aspartoacylase	O
has	O
been	O
conserved	O
during	O
evolution.	O
It	O
should	O
now	O
be	O
possible	O
to	O
identify	O
mutations	O
in	O
the	O
noncoding	O
genomic	O
sequences	O
that	O
lead	O
to	O
Canavan	SpecificDisease
disease	SpecificDisease

Adrenoleukodystrophy	SpecificDisease
:	O
survey	O
of	O
303	O
cases:	O
biochemistry,	O
diagnosis,	O
and	O
therapy.	O
Adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
is	O
a	O
genetically	O
determined	O
disorder	O
associated	O
with	O
progressive	DiseaseClass
central	DiseaseClass
demyelination	DiseaseClass
and	O
adrenal	DiseaseClass
cortical	DiseaseClass
insufficiency	DiseaseClass
.	O
All	O
affected	O
persons	O
show	O
increased	O
levels	O
of	O
saturated	O
unbranched	O
very-long-chain	O
fatty	O
acids,	O
particularly	O
hexacosanoate	O
(C26	O
	O
0),	O
because	O
of	O
impaired	O
capacity	O
to	O
degrade	O
these	O
acids.	O
This	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome,	O
and	O
ALD	SpecificDisease
,	O
together	O
with	O
Zellwegers	SpecificDisease
cerebrohepatorenal	SpecificDisease
syndrome	SpecificDisease
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	DiseaseClass
disorders	DiseaseClass
.	O
Biochemical	O
assays	O
permit	O
prenatal	O
diagnosis,	O
as	O
well	O
as	O
identification	O
of	O
most	O
heterozygotes.	O
We	O
have	O
identified	O
303	O
patients	O
with	O
ALD	SpecificDisease
in	O
217	O
kindreds.	O
These	O
patients	O
show	O
a	O
wide	O
phenotypic	O
variation.	O
Sixty	O
percent	O
of	O
patients	O
had	O
childhood	O
ALD	SpecificDisease
and	O
17%	O
adrenomyeloneuropathy	SpecificDisease
,	O
both	O
of	O
which	O
are	O
X-linked,	O
with	O
the	O
gene	O
mapped	O
to	O
Xq28.	O
Neonatal	SpecificDisease
ALD	SpecificDisease
,	O
a	O
distinct	O
entity	O
with	O
autosomal	O
recessive	O
inheritance	O
and	O
points	O
of	O
resemblance	O
to	O
Zellwegers	SpecificDisease
syndrome	SpecificDisease
,	O
accounted	O
for	O
7%	O
of	O
the	O
cases.	O
Although	O
excess	O
C26	O
	O
0	O
in	O
the	O
brain	O
of	O
patients	O
with	O
ALD	SpecificDisease

French	O
Machado-Joseph	Modifier
disease	Modifier
patients	O
do	O
not	O
exhibit	O
gametic	O
segregation	O
distortion:	O
a	O
sperm	O
typing	O
analysis.	O
Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	DiseaseClass
repeat	DiseaseClass
disorders	DiseaseClass
.	O
On	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
Japanese	O
descent	O
with	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
),	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis.	O
We	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
MJD	Modifier
patients	O
of	O
French	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
	O
436	O
(46.	O
5	O
	O
53.	O
5%),	O
which	O
does	O
not	O
support	O
meiotic	O
segregation	O
distortion.	O
To	O
confirm	O
these	O
results,	O
sperm	O
typing	O
analysis	O
was	O
also	O
performed	O
using	O
a	O
polymorphic	O
marker,	O
D14S1050,	O
closely	O
linked	O
to	O
the	O
MJD1	O
gene.	O
Among	O
910	O
sperm	O
analyzed,	O
the	O
allele	O
linked	O
to	O
the	O
disease	O
chromosome	O
was	O
detected	O
in	O
50.	O
3%	O
of	O
the	O
samples	O
and	O
the	O
allele	O
linked	O
to	O
the	O
normal	O
chromosome	O
was	O
found	O
in	O
49.	O
6%	O
of	O
the	O
sperm.	O
The	O
difference	O
in	O
frequency	O
of	O
these	O
two	O
alleles	O
is	O
not	O
significant	O
(P	O
=	O
0.	O
8423).	O
Likelihood-based	O
analysis	O
of	O
segregation	O
distortion	O
in	O
the	O
single	O
sperm	O
data	O
using	O
the	O
SPERMSEG	O
program	O
also	O
showed	O
no	O
support	O
for	O
segregation	O
distortion	O
at	O
the	O
gamete	O
level	O
in	O
this	O
patient	O
population.	O
The	O
previous	O
report	O
on	O
the	O
Japanese	O
patients	O
also	O
suggested	O
that	O
disease	O
allele	O
stability	O
may	O
be	O
influenced	O
by	O
a	O
trans	O
effect	O
of	O
an	O
intragenic	O
polymorphism	O
(987	O
G/C)	O
in	O
the	O
wild-type	O
allele.	O
All	O
of	O
the	O
French	O
patients	O
were	O
heterozygous	O
for	O
this	O
polymorphism.	O
However,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
French	O
MJD	Modifier

Nebulin	O
seen	O
in	O
DMD	Modifier
males	O
including	O
one	O
patient	O
with	O
a	O
large	O
DNA	O
deletion	O
encompassing	O
the	O
DMD	Modifier
gene.	O
The	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	O
specimen	O
from	O
a	O
patient	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
due	O
to	O
a	O
large	O
deletion	O
precludes	O
the	O
possibility	O
that	O
this	O
protein	O
is	O
the	O
DMD	Modifier

The	O
human	O
gene	O
for	O
alkaptonuria	SpecificDisease
(	O
AKU	SpecificDisease
)	O
maps	O
to	O
chromosome	O
3q.	O
Alkaptonuria	SpecificDisease
(	O
AKU	SpecificDisease
;	O
McKusick	O
no.	O
203500)	O
is	O
a	O
rare	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
the	O
lack	O
of	O
homogentisic	O
acid	O
oxidase	O
activity.	O
Patients	O
excrete	O
large	O
amounts	O
of	O
homogentisic	O
acid	O
in	O
their	O
urine	O
and	O
a	O
black	O
ochronotic	O
pigment	O
is	O
deposited	O
in	O
their	O
cartilage	O
and	O
collagenous	O
tissues.	O
Ochronosis	SpecificDisease
is	O
the	O
predominant	O
clinical	O
complication	O
of	O
the	O
disease	O
leading	O
to	O
ochronotic	SpecificDisease
arthropathy	SpecificDisease
,	O
dark	O
urine,	O
pigment	O
changes	O
of	O
the	O
skin,	O
and	O
other	O
clinical	O
features.	O
A	O
mutation	O
causing	O
alkaptonuria	SpecificDisease
in	O
the	O
mouse	O
has	O
mapped	O
to	O
chromosome	O
16.	O
Considering	O
conserved	O
synteny,	O
we	O
were	O
able	O
to	O
map	O
the	O
human	O
gene	O
to	O
chromosome	O
3q	O
in	O
six	O
alkaptonuria	Modifier

The	O
APC	Modifier
gene,	O
responsible	O
for	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
,	O
is	O
mutated	O
in	O
human	O
gastric	SpecificDisease
cancer	SpecificDisease
.	O
Although	O
gastric	SpecificDisease
cancer	SpecificDisease
is	O
the	O
most	O
common	O
cancer	DiseaseClass
in	O
the	O
world,	O
genetic	O
changes	O
during	O
its	O
carcinogenesis	O
are	O
not	O
well	O
understood.	O
Since	O
some	O
gastric	SpecificDisease
cancers	SpecificDisease
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene,	O
the	O
mutation	O
of	O
which	O
causes	O
adenomatous	SpecificDisease
polyps	SpecificDisease
in	SpecificDisease
the	SpecificDisease
colon	SpecificDisease
,	O
is	O
associated	O
with	O
carcinogenesis	O
of	O
gastric	SpecificDisease
cancer	SpecificDisease
.	O
Based	O
on	O
this	O
idea,	O
DNAs	O
isolated	O
from	O
gastric	SpecificDisease
cancers	SpecificDisease
were	O
examined	O
by	O
means	O
of	O
a	O
RNase	O
protection	O
analysis	O
coupled	O
with	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products.	O
By	O
screening	O
nearly	O
one-half	O
of	O
the	O
coding	O
region	O
of	O
the	O
APC	Modifier
gene	O
in	O
44	O
tumors	DiseaseClass
,	O
somatic	O
mutations	O
were	O
detected	O
in	O
three	O
tumors	DiseaseClass
a	O
missense	O
mutation,	O
a	O
nonsense	O
mutation,	O
and	O
a	O
5-base	O
pair	O
deletion	O
resulting	O
in	O
a	O
frame	O
shift	O
which	O
causes	O
truncation	O
of	O
the	O
gene	O
product.	O
These	O
results	O
suggest	O
that	O
the	O
mutation	O
of	O
the	O
APC	Modifier
gene	O
also	O
plays	O
an	O
important	O
role	O
during	O
the	O
carcinogenesis	O
of	O
at	O
least	O
some	O
gastric	SpecificDisease
cancers	SpecificDisease

Molecular	O
epidemiology	O
of	O
C9	Modifier
deficiency	Modifier
heterozygotes	O
with	O
an	O
Arg95Stop	O
mutation	O
of	O
the	O
C9	O
gene	O
in	O
Japan.	O
Deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
ninth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
(C9)	O
is	O
the	O
most	O
common	O
complement	DiseaseClass
deficiency	DiseaseClass
in	O
Japan,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries.	O
Genetic	O
analyses	O
of	O
Japanese	O
C9	SpecificDisease
deficiency	SpecificDisease
have	O
shown	O
that	O
a	O
C-to-T	O
transition	O
leading	O
to	O
TGA	O
stop	O
codon	O
for	O
Arg95	O
in	O
exon	O
4	O
of	O
the	O
C9	O
gene	O
(Arg95Stop)	O
is	O
common	O
in	O
Japanese	O
C9	SpecificDisease
deficiency	SpecificDisease
.	O
To	O
determine	O
the	O
prevalence	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
in	O
a	O
Japanese	O
population,	O
we	O
collected	O
DNA	O
samples	O
from	O
300	O
individuals	O
in	O
two	O
of	O
the	O
four	O
main	O
islands	O
of	O
Japan.	O
Heterozygote	O
detection	O
was	O
performed	O
with	O
an	O
allele-specific	O
polymerase	O
chain	O
reaction	O
(PCR)	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles,	O
followed	O
by	O
confirmation	O
with	O
PCR/single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
and	O
direct	O
sequencing.	O
Twenty	O
individuals	O
were	O
heterozygous	O
for	O
the	O
Arg95Stop	O
mutation.	O
None	O
was	O
homozygous.	O
The	O
prevalence	O
of	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
was	O
6.	O
7%	O
(20/300).	O
An	O
estimated	O
frequency	O
(0.	O
12%)	O
of	O
complete	O
C9	SpecificDisease
deficiency	SpecificDisease

Molecular	O
analysis	O
of	O
a	O
female	O
Lesch-Nyhan	Modifier
patient.	O
We	O
report	O
the	O
identification	O
of	O
a	O
female	O
patient	O
with	O
the	O
X-linked	O
recessive	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
(	O
hypoxanthine	SpecificDisease
phosphoribosyltransferase	SpecificDisease
[HPRT]	SpecificDisease
deficiency	SpecificDisease

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein-protein	O
interactions	O
resulting	O
in	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
recessive	DiseaseClass
muscular	DiseaseClass
dystrophy	DiseaseClass
characterized	O
by	O
early	O
contractures	CompositeMention
of	CompositeMention
the	CompositeMention
elbows,	CompositeMention
Achilles	CompositeMention
tendons	CompositeMention
and	CompositeMention
spine	CompositeMention
,	O
slowly	O
progressive	O
muscle	DiseaseClass
wasting	DiseaseClass
and	O
weakness	DiseaseClass
,	O
and	O
cardiomyopathy	SpecificDisease
associated	O
with	O
cardiac	SpecificDisease
conduction	SpecificDisease
defects	SpecificDisease
.	O
The	O
emerin	O
gene	O
has	O
been	O
mapped	O
to	O
Xq28	O
and	O
encodes	O
a	O
34-kDa	O
serine-rich	O
protein,	O
emerin,	O
which	O
has	O
been	O
localized	O
to	O
the	O
nuclear	O
envelope	O
in	O
a	O
wide	O
variety	O
of	O
tissues,	O
including	O
skeletal	O
and	O
cardiac	O
muscle.	O
Mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	SpecificDisease
.	O
We	O
present	O
here	O
the	O
effect,	O
on	O
emerin	O
protein	O
expression,	O
of	O
two	O
missense	O
mutations	O
identified	O
in	O
unrelated	O
EDMD	Modifier
patients.	O
These	O
alterations	O
predict	O
the	O
replacement	O
of	O
a	O
proline	O
residue	O
at	O
position	O
183	O
with	O
either	O
a	O
histidine	O
or	O
a	O
threonine.	O
Biochemical	O
analysis	O
has	O
demonstrated	O
that	O
the	O
mobility	O
and	O
expression	O
levels	O
of	O
the	O
mutant	O
forms	O
of	O
emerin	O
are	O
indistinguishable	O
from	O
that	O
of	O
wild-type	O
emerin,	O
but	O
that	O
they	O
have	O
weakened	O
interactions	O
with	O
nuclear	O
lamina	O
components.	O
In	O
comparison	O
with	O
the	O
usual	O
EDMD	Modifier
phenotype,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms,	O
elbow	SpecificDisease
contractures	SpecificDisease
,	O
ankle	SpecificDisease
contractures	SpecificDisease
,	O
upper	SpecificDisease
limb	SpecificDisease
weakness	SpecificDisease
and	O
lower	SpecificDisease
limb	SpecificDisease
weakness	SpecificDisease
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	DiseaseClass
involvement	DiseaseClass
.	O
This	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
EDMD	SpecificDisease

Decreased	O
expression	O
of	O
BRCA1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	Modifier
breast	Modifier
cancer	Modifier
progression.	O
We	O
have	O
characterized	O
expression	O
of	O
the	O
familial	Modifier
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
gene,	O
BRCA1,	O
in	O
cases	O
of	O
non-hereditary	SpecificDisease
(sporadic)	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
BRCA1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells.	O
BRCA1	O
mRNA	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	DiseaseClass
in	DiseaseClass
situ	DiseaseClass
to	O
invasive	DiseaseClass
cancer	DiseaseClass
.	O
Experimental	O
inhibition	O
of	O
BRCA1	O
expression	O
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	O
of	O
normal	O
and	O
malignant	O
mammary	O
cells,	O
but	O
had	O
no	O
effect	O
on	O
non-mammary	O
epithelial	O
cells.	O
These	O
studies	O
suggest	O
that	O
BRCA1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	SpecificDisease
cancer	SpecificDisease

Additional	O
copies	O
of	O
the	O
proteolipid	O
protein	O
gene	O
causing	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
arise	O
by	O
separate	O
integration	O
into	O
the	O
X	O
chromosome.	O
The	O
proteolipid	O
protein	O
gene	O
(PLP)	O
is	O
normally	O
present	O
at	O
chromosome	O
Xq22.	O
Mutations	O
and	O
duplications	O
of	O
this	O
gene	O
are	O
associated	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
(	O
PMD	SpecificDisease
).	O
Here	O
we	O
describe	O
two	O
new	O
families	O
in	O
which	O
males	O
affected	O
with	O
PMD	SpecificDisease
were	O
found	O
to	O
have	O
a	O
copy	O
of	O
PLP	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome,	O
in	O
addition	O
to	O
a	O
normal	O
copy	O
on	O
Xq22.	O
In	O
the	O
first	O
family,	O
the	O
extra	O
copy	O
was	O
first	O
detected	O
by	O
the	O
presence	O
of	O
heterozygosity	O
of	O
the	O
AhaII	O
dimorphism	O
within	O
the	O
PLP	O
gene.	O
The	O
results	O
of	O
FISH	O
analysis	O
showed	O
an	O
additional	O
copy	O
of	O
PLP	O
in	O
Xp22.	O
1,	O
although	O
no	O
chromosomal	O
rearrangements	O
could	O
be	O
detected	O
by	O
standard	O
karyotype	O
analysis.	O
Another	O
three	O
affected	O
males	O
from	O
the	O
family	O
had	O
similar	O
findings.	O
In	O
a	O
second	O
unrelated	O
family	O
with	O
signs	O
of	O
PMD	SpecificDisease
,	O
cytogenetic	O
analysis	O
showed	O
a	O
pericentric	O
inversion	O
of	O
the	O
X	O
chromosome.	O
In	O
the	O
inv	O
(X)	O
carried	O
by	O
several	O
affected	O
family	O
members,	O
FISH	O
showed	O
PLP	O
signals	O
at	O
Xp11.	O
4	O
and	O
Xq22.	O
A	O
third	O
family	O
has	O
previously	O
been	O
reported,	O
in	O
which	O
affected	O
members	O
had	O
an	O
extra	O
copy	O
of	O
the	O
PLP	O
gene	O
detected	O
at	O
Xq26	O
in	O
a	O
chromosome	O
with	O
an	O
otherwise	O
normal	O
banding	O
pattern.	O
The	O
identification	O
of	O
three	O
separate	O
families	O
in	O
which	O
PLP	O
is	O
duplicated	O
at	O
a	O
noncontiguous	O
site	O
suggests	O
that	O
such	O
duplications	O
could	O
be	O
a	O
relatively	O
common	O
but	O
previously	O
undetected	O
cause	O
of	O
genetic	DiseaseClass
disorders	DiseaseClass

Linkage	O
relationships	O
of	O
the	O
apolipoprotein	O
C1	O
gene	O
and	O
a	O
cytochrome	O
P450	O
gene	O
(CYP2A)	O
to	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
We	O
have	O
studied	O
the	O
genetic	O
linkage	O
of	O
two	O
markers,	O
the	O
apolipoprotein	O
C1	O
(APOC1)	O
gene	O
and	O
a	O
cytochrome	O
P450	O
(CYP2A)	O
gene,	O
in	O
relation	O
to	O
the	O
gene	O
for	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease

beta-galactosidase	O
gene	O
mutations	O
affecting	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
elastin-binding	O
protein	O
in	O
GM1-gangliosidosis	Modifier
patients	O
with	O
cardiac	SpecificDisease
involvement	SpecificDisease
.	O
GM1-gangliosidosis	SpecificDisease
is	O
a	O
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
deficiency	SpecificDisease
of	SpecificDisease
acid	SpecificDisease
beta-galactosidase	SpecificDisease
(GLB1).	O
We	O
report	O
five	O
new	O
beta-galactosidase	O
gene	O
mutations	O
in	O
nine	O
Italian	O
patients	O
and	O
one	O
fetus,	O
segregating	O
in	O
seven	O
unrelated	O
families.	O
Six	O
of	O
the	O
eight	O
patients	O
with	O
the	O
infantile,	O
severe	O
form	O
of	O
the	O
disease	O
presented	O
cardiac	DiseaseClass
involvement	DiseaseClass
,	O
a	O
feature	O
rarely	O
associated	O
with	O
GM1-gangliosidosis	SpecificDisease
.	O
Molecular	O
analysis	O
of	O
the	O
patients	O
RNA	O
and	O
DNA	O
identified	O
two	O
new	O
RNA	O
splicing	O
defects,	O
three	O
new	O
and	O
three	O
previously	O
described	O
amino	O
acid	O
substitutions.	O
Interestingly,	O
all	O
patients	O
with	O
cardiac	DiseaseClass
involvement	DiseaseClass
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
	O
R59H,	O
Y591C,	O
Y591N,	O
or	O
IVS14-2A	O
>	O
G.	O
In	O
contrast,	O
all	O
other	O
patients	O
were	O
compound	O
heterozygous	O
for	O
one	O
of	O
the	O
following	O
mutations	O
	O
R201H,	O
R482H,	O
G579D,	O
IVS8	O
+	O
2T	O
>	O
C.	O
Although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	DiseaseClass
abnormalities	DiseaseClass
with	O
specific	O
genetic	DiseaseClass
lesions	DiseaseClass
,	O
the	O
mutations	O
identified	O
in	O
patients	O
with	O
cardiomyopathy	DiseaseClass

Exclusion	O
of	O
linkage	O
between	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
and	O
the	O
human	O
serum	O
amyloid	O
A	O
(SAA)	O
gene	O
cluster.	O
We	O
studied	O
the	O
relationship	O
between	O
the	O
autosomal	O
recessive	O
trait	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
and	O
the	O
serum	O
amyloid	O
A	O
(SAA)	O
genes	O
by	O
comparing	O
alleles	O
of	O
a	O
highly	O
polymorphic	O
dinucleotide	O
repeat	O
and	O
a	O
conventional	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
in	O
the	O
SAA	O
gene	O
cluster	O
in	O
Israeli	O
FMF	Modifier
kindreds.	O
By	O
haplotype	O
analysis,	O
our	O
data	O
indicate	O
a	O
minimum	O
crossover	O
frequency	O
of	O
22%	O
between	O
the	O
SAA	O
gene	O
marker	O
and	O
FMF	SpecificDisease
.	O
By	O
conventional	O
linkage	O
analysis	O
this	O
eliminates	O
a	O
minimum	O
of	O
10.	O
4	O
cM	O
including	O
and	O
surrounding	O
the	O
SAA	O
gene	O
cluster	O
as	O
the	O
site	O
of	O
the	O
FMF	Modifier

Mice	O
deficient	SpecificDisease
in	SpecificDisease
Six5	SpecificDisease
develop	O
cataracts	SpecificDisease
:	O
implications	O
for	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
Expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
UTR	O
of	O
the	O
gene	O
DMPK	O
at	O
the	O
DM1	O
locus	O
on	O
chromosome	O
19	O
causes	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
a	O
dominantly	DiseaseClass
inherited	DiseaseClass
disease	DiseaseClass
characterized	O
by	O
skeletal	O
muscle	SpecificDisease
dystrophy	SpecificDisease
and	O
myotonia	DiseaseClass
,	O
cataracts	SpecificDisease
and	O
cardiac	DiseaseClass
conduction	DiseaseClass
defects	DiseaseClass
.	O
Targeted	O
deletion	O
of	O
Dm15,	O
the	O
mouse	O
orthologue	O
of	O
human	O
DMPK,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	DiseaseClass
and	O
cardiac	DiseaseClass
conduction	DiseaseClass
abnormalities	DiseaseClass
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
such	O
as	O
myotonia	DiseaseClass
and	O
cataracts	SpecificDisease
.	O
We,	O
and	O
others,	O
have	O
demonstrated	O
that	O
repeat	O
expansion	O
decreases	O
expression	O
of	O
the	O
adjacent	O
gene	O
SIX5	O
(refs	O
7,	O
8),	O
which	O
encodes	O
a	O
homeodomain	O
transcription	O
factor.	O
To	O
determine	O
whether	O
SIX5	SpecificDisease
deficiency	SpecificDisease
contributes	O
to	O
the	O
myotonic	Modifier
dystrophy	Modifier
phenotype,	O
we	O
disrupted	O
mouse	O
Six5	O
by	O
replacing	O
the	O
first	O
exon	O
with	O
a	O
beta-galactosidase	O
reporter.	O
Six5-mutant	O
mice	O
showed	O
reporter	O
expression	O
in	O
multiple	O
tissues,	O
including	O
the	O
developing	O
lens.	O
Homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	DiseaseClass
of	DiseaseClass
skeletal	DiseaseClass
muscle	DiseaseClass
function	DiseaseClass
,	O
but	O
developed	O
lenticular	SpecificDisease
opacities	SpecificDisease
at	O
a	O
higher	O
rate	O
than	O
controls.	O
Our	O
results	O
suggest	O
that	O
SIX5	SpecificDisease
deficiency	SpecificDisease
contributes	O
to	O
the	O
cataract	Modifier
phenotype	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
and	O
that	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
represents	O
a	O
multigenic	DiseaseClass
disorder	DiseaseClass

Screening	O
for	O
germ-line	O
mutations	O
in	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
patients:	O
61	O
new	O
patients	O
and	O
a	O
summary	O
of	O
150	O
unrelated	O
patients.	O
We	O
report	O
here	O
the	O
result	O
of	O
a	O
screening	O
for	O
germ-line	O
mutations	O
in	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
in	O
61	O
new	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
(	O
FAP	Modifier
)	O
patients	O
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	O
of	O
150	O
patients.	O
Examination	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	Modifier
gene,	O
based	O
on	O
a	O
ribonuclease	O
protection	O
assay	O
coupled	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(PCR),	O
disclosed	O
mutations	O
that	O
were	O
considered	O
to	O
cause	O
significant	O
defects	O
in	O
the	O
APC	Modifier
product	O
in	O
97	O
of	O
150	O
unrelated	O
FAP	Modifier
patients.	O
Our	O
findings	O
revealed	O
the	O
following	O
characteristics	O
of	O
the	O
germ-line	O
mutations	O
of	O
APC	O
	O
1)	O
the	O
great	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
to	O
truncate	O
the	O
APC	Modifier
product;	O
2)	O
almost	O
all	O
of	O
the	O
mutations	O
were	O
located	O
within	O
the	O
first	O
half	O
of	O
the	O
coding	O
region;	O
3)	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
locations	O
of	O
germ-line	O
mutations	O
and	O
extracolonic	O
manifestations	O
in	O
FAP	Modifier
patients;	O
4)	O
more	O
than	O
80%	O
of	O
base	O
substitutions	O
in	O
the	O
APC	Modifier
gene	O
were	O
from	O
cytosine	O
to	O
other	O
nucleotides,	O
nearly	O
one-third	O
of	O
which	O
occurred	O
at	O
the	O
GpG	O
site.	O
Our	O
results	O
provide	O
information	O
helpful	O
to	O
an	O
understanding	O
of	O
the	O
APC	Modifier
gene	O
and	O
will	O
also	O
contribute	O
to	O
presymptomatic	O
diagnosis	O
of	O
members	O
in	O
FAP	Modifier

Hereditary	O
deficiency	SpecificDisease
of	SpecificDisease
C5	SpecificDisease
in	O
association	O
with	O
discoid	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
.	O
A	O
29-year-old	O
woman	O
with	O
discoid	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
had	O
undetectable	O
classic	O
pathway	O
complement	O
activity.	O
Hypocomplementemia	DiseaseClass
was	O
due	O
to	O
selective	O
deficiency	SpecificDisease
of	SpecificDisease
C5	SpecificDisease
.	O
One	O
of	O
her	O
children	O
was	O
also	O
deficient.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
an	O
association	O
between	O
discoid	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
and	O
C5	SpecificDisease
deficiency	SpecificDisease

Isolation,	O
genomic	O
organization,	O
and	O
expression	O
analysis	O
of	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV,	O
the	O
gene	O
for	O
familial	SpecificDisease
mediterranean	SpecificDisease
fever	SpecificDisease
.	O
Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
is	O
a	O
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
episodes	O
of	O
fever	DiseaseClass
with	O
serositis	SpecificDisease
or	O
synovitis	SpecificDisease
.	O
Recently	O
the	O
FMF	Modifier
gene	O
(MEFV)	O
was	O
cloned;	O
the	O
protein	O
product,	O
pyrin/marenostrin,	O
is	O
thought	O
to	O
regulate	O
inflammation	O
in	O
myeloid	O
cells.	O
In	O
this	O
manuscript	O
we	O
report	O
the	O
mouse	O
and	O
rat	O
homologs	O
of	O
MEFV.	O
The	O
murine	O
gene	O
contains	O
ten	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2304	O
bp,	O
while	O
the	O
rat	O
homolog	O
has	O
nine	O
exons	O
with	O
a	O
coding	O
sequence	O
of	O
2253	O
bp.	O
A	O
considerable	O
amino	O
acid	O
sequence	O
homology	O
was	O
observed	O
between	O
the	O
mouse	O
and	O
human	O
(47.	O
6%	O
identity	O
and	O
65.	O
5%	O
similarity)	O
and	O
between	O
the	O
mouse	O
and	O
rat	O
genes	O
(73.	O
5%	O
identity	O
and	O
82.	O
1%	O
similarity).	O
The	O
predicted	O
rodent	O
proteins	O
have	O
several	O
important	O
domains	O
and	O
signals	O
found	O
in	O
human	O
pyrin,	O
including	O
a	O
B-box	O
zinc	O
finger	O
domain,	O
Robbins-Dingwall	O
nuclear	O
localization	O
signal,	O
and	O
coiled-coil	O
domain.	O
However,	O
perhaps	O
because	O
of	O
an	O
ancient	O
frame-shift	O
mutation,	O
neither	O
the	O
mouse	O
nor	O
the	O
rat	O
protein	O
has	O
an	O
intact	O
C-terminal	O
B30.	O
2	O
domain,	O
in	O
which	O
most	O
FMF	Modifier

Analysis	O
of	O
X-chromosome	O
inactivation	O
and	O
presumptive	O
expression	O
of	O
the	O
Wiskott-Aldrich	Modifier
syndrome	Modifier
(	O
WAS	Modifier
)	O
gene	O
in	O
hematopoietic	O
cell	O
lineages	O
of	O
a	O
thrombocytopenic	O
carrier	O
female	O
of	O
WAS	SpecificDisease
.	O
We	O
report	O
on	O
a	O
thrombocytopenic	Modifier
female	O
belonging	O
to	O
a	O
pedigree	O
with	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
).	O
Restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
with	O
probe	O
M27	O
beta,	O
closely	O
linked	O
to	O
the	O
WAS	Modifier
gene,	O
demonstrated	O
that	O
she	O
is	O
a	O
carrier	O
of	O
WAS	SpecificDisease
.	O
Both	O
small-sized	O
and	O
normal-sized	O
platelets	O
were	O
present,	O
suggesting	O
that,	O
unlike	O
the	O
vast	O
majority	O
of	O
WAS	Modifier
carriers,	O
she	O
does	O
not	O
manifest	O
nonrandom	O
X-chromosome	O
inactivation	O
in	O
the	O
thrombopoietic	O
cell	O
lineage.	O
Study	O
of	O
X-chromosome	O
inactivation	O
by	O
means	O
of	O
RFLP	O
and	O
methylation	O
analysis	O
demonstrated	O
that	O
the	O
pattern	O
of	O
X-chromosome	O
inactivation	O
was	O
nonrandom	O
in	O
T	O
lymphocytes,	O
but	O
random	O
in	O
granulocytes.	O
While	O
this	O
is	O
the	O
first	O
complete	O
report	O
on	O
the	O
occurrence	O
of	O
thrombocytopenia	SpecificDisease
in	O
a	O
carrier	O
female	O
of	O
WAS	SpecificDisease
as	O
the	O
result	O
of	O
atypical	O
lyonization,	O
it	O
also	O
suggests	O
that	O
expression	O
of	O
the	O
WAS	Modifier

hCds1-mediated	O
phosphorylation	O
of	O
BRCA1	O
regulates	O
the	O
DNA	O
damage	O
response.	O
Mutations	O
in	O
the	O
BRCA1	O
(ref.	O
1)	O
tumour	Modifier
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	SpecificDisease
cancer	SpecificDisease

Ataxin-3	O
with	O
an	O
altered	O
conformation	O
that	O
exposes	O
the	O
polyglutamine	O
domain	O
is	O
associated	O
with	O
the	O
nuclear	O
matrix.	O
Spinocerebellar	SpecificDisease
ataxia	SpecificDisease
type-3	SpecificDisease
or	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
SCA3	SpecificDisease
/	O
MJD	SpecificDisease
)	O
is	O
a	O
member	O
of	O
the	O
CAG/polyglutamine	DiseaseClass
repeat	DiseaseClass
disease	DiseaseClass
family.	O
In	O
this	O
family	O
of	O
disorders,	O
a	O
normally	O
polymorphic	O
CAG	O
repeat	O
becomes	O
expanded,	O
resulting	O
in	O
expression	O
of	O
an	O
expanded	O
polyglutamine	O
domain	O
in	O
the	O
disease	O
gene	O
product.	O
Experimental	O
models	O
of	O
polyglutamine	DiseaseClass
disease	DiseaseClass
implicate	O
the	O
nucleus	O
in	O
pathogenesis;	O
however,	O
the	O
link	O
between	O
intranuclear	O
expression	O
of	O
expanded	O
polyglutamine	O
and	O
neuronal	DiseaseClass
dysfunction	DiseaseClass
remains	O
unclear.	O
Here	O
we	O
demonstrate	O
that	O
ataxin-3,	O
the	O
disease	O
protein	O
in	O
SCA3	SpecificDisease
/	O
MJD	SpecificDisease
,	O
adopts	O
a	O
unique	O
conformation	O
when	O
expressed	O
within	O
the	O
nucleus	O
of	O
transfected	O
cells.	O
The	O
monoclonal	O
antibody	O
1C2	O
is	O
known	O
preferentially	O
to	O
bind	O
expanded	O
polyglutamine,	O
but	O
we	O
find	O
that	O
it	O
also	O
binds	O
a	O
fragment	O
of	O
ataxin-3	O
containing	O
a	O
normal	O
glutamine	O
repeat.	O
In	O
addition,	O
expression	O
of	O
ataxin-3	O
within	O
the	O
nucleus	O
exposes	O
the	O
glutamine	O
domain	O
of	O
the	O
full-length	O
non-pathological	O
protein,	O
allowing	O
it	O
to	O
bind	O
the	O
monoclonal	O
antibody	O
1C2.	O
Fractionation	O
and	O
immunochemical	O
experiments	O
indicate	O
that	O
this	O
novel	O
conformation	O
of	O
intranuclear	O
ataxin-3	O
is	O
not	O
due	O
to	O
proteolysis,	O
suggesting	O
instead	O
that	O
association	O
with	O
nuclear	O
protein	O
(s)	O
alters	O
the	O
structure	O
of	O
full-length	O
ataxin-3	O
which	O
exposes	O
the	O
polyglutamine	O
domain.	O
This	O
conformationally	O
altered	O
ataxin-3	O
is	O
bound	O
to	O
the	O
nuclear	O
matrix.	O
The	O
pathological	O
form	O
of	O
ataxin-3	O
with	O
an	O
expanded	O
polyglutamine	O
domain	O
also	O
associates	O
with	O
the	O
nuclear	O
matrix.	O
These	O
data	O
suggest	O
that	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
SCA3	SpecificDisease
/	O
MJD	SpecificDisease

A	O
zinc	O
finger	O
truncation	O
of	O
murine	O
WT1	O
results	O
in	O
the	O
characteristic	O
urogenital	DiseaseClass
abnormalities	DiseaseClass
of	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
Wilms	Modifier
tumor	Modifier
-suppressor	O
gene,	O
WT1,	O
plays	O
a	O
key	O
role	O
in	O
urogenital	O
development,	O
and	O
WT1	SpecificDisease
dysfunction	SpecificDisease
is	O
implicated	O
in	O
both	O
neoplastic	Modifier
(	O
Wilms	SpecificDisease
tumor	SpecificDisease
,	O
mesothelioma	SpecificDisease
,	O
leukemias	SpecificDisease
,	O
and	O
breast	SpecificDisease
cancer	SpecificDisease
)	O
and	O
nonneoplastic	Modifier
(	O
glomerulosclerosis	SpecificDisease
)	O
disease.	O
The	O
analysis	O
of	O
diseases	O
linked	O
specifically	O
with	O
WT1	O
mutations,	O
such	O
as	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
(	O
DDS	SpecificDisease
),	O
can	O
provide	O
valuable	O
insight	O
concerning	O
the	O
role	O
of	O
WT1	O
in	O
development	O
and	O
disease.	O
DDS	SpecificDisease
is	O
a	O
rare	O
childhood	O
disease	O
characterized	O
by	O
a	O
nephropathy	SpecificDisease
involving	O
mesangial	SpecificDisease
sclerosis	SpecificDisease
,	O
XY	O
pseudohermaphroditism	SpecificDisease
,	O
and/or	O
Wilms	SpecificDisease
tumor	SpecificDisease
(	O
WT	SpecificDisease
).	O
DDS	Modifier
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
WT1,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
C-terminal	O
zinc	O
finger	O
(ZF)	O
region.	O
We	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
Wt1	O
allele,	O
Wt1	O
(tmT396),	O
which	O
truncates	O
ZF3	O
at	O
codon	O
396,	O
induces	O
mesangial	SpecificDisease
sclerosis	SpecificDisease
characteristic	O
of	O
DDS	SpecificDisease
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice.	O
Male	DiseaseClass
genital	DiseaseClass
defects	DiseaseClass
also	O
were	O
evident	O
and	O
there	O
was	O
a	O
single	O
case	O
of	O
Wilms	SpecificDisease
tumor	SpecificDisease
in	O
which	O
the	O
transcript	O
of	O
the	O
nontargeted	O
allele	O
showed	O
an	O
exon	O
9	O
skipping	O
event,	O
implying	O
a	O
causal	O
link	O
between	O
Wt1	SpecificDisease
dysfunction	SpecificDisease
and	O
Wilms	SpecificDisease
tumorigenesis	SpecificDisease
in	O
mice.	O
However,	O
the	O
mutant	O
WT1	O
(tmT396)	O
protein	O
accounted	O
for	O
only	O
5%	O
of	O
WT1	O
in	O
both	O
heterozygous	O
embryonic	O
stem	O
cells	O
and	O
the	O
WT	SpecificDisease

Heterogeneity	O
of	O
"Mediterranean	O
type"	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
Spain	O
and	O
description	O
of	O
two	O
new	O
variants	O
associated	O
with	O
favism	SpecificDisease
.	O
Glucose-6-phosphate	O
dehydrogenase	O
(G6PD);	O
EC	O
1.	O
1.	O
1.	O
49	O
from	O
thirty-six	O
unrelated	O
Spanish	O
males	O
was	O
partially	O
purified	O
from	O
blood,	O
and	O
the	O
variants	O
were	O
characterized	O
biochemically	O
and	O
electrophoretically	O
according	O
to	O
the	O
methods	O
recommended	O
by	O
the	O
world	O
Health	O
Organization.	O
Subjects	O
were	O
from	O
multiple	O
geographic	O
regions	O
within	O
Spain,	O
and	O
all	O
suffered	O
from	O
hemolytic	SpecificDisease
anemia	SpecificDisease
,	O
either	O
acute	O
(34	O
cases)	O
or	O
chronic	O
nonspherocytic	O
(2	O
cases).	O
Almost	O
all	O
the	O
variants	O
studied	O
presented	O
residual	O
erythrocyte	O
G6PD	O
activity	O
ranging	O
from	O
0	O
to	O
10%	O
of	O
normal,	O
and	O
five	O
different	O
mutants	O
were	O
responsible	O
for	O
the	O
deficient	O
phenotype.	O
Three	O
variants	O
were	O
similar	O
to	O
others	O
previously	O
described	O
	O
G6PD	O
Mediterranean	O
(11	O
cases),	O
G6PD	O
Athens-like	O
(3	O
cases),	O
and	O
G6PD	O
Union	O
(2	O
cases).	O
The	O
remaining	O
variants	O
were	O
different	O
from	O
the	O
numerous	O
variants	O
already	O
reported	O
and	O
have	O
been	O
considered	O
as	O
new	O
mutants.	O
Provisionally	O
they	O
are	O
called	O
G6PD	O
Betica	O
(19	O
cases)	O
and	O
G6PD	O
Menorca	O
(1	O
case).	O
The	O
present	O
study	O
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	Modifier
G6PD	Modifier
variants	O
found	O
in	O
Spain	O
and	O
supplies	O
new	O
data	O
on	O
the	O
relationship	O
between	O
molecular	O
characteristics	O
of	O
deficient	O
variants	O
and	O
their	O
clinical	O
manifestations.	O
The	O
most	O
important	O
findings	O
can	O
be	O
summarized	O
as	O
follows	O
	O
(1)	O
The	O
Spanish	O
population	O
is	O
characterized	O
by	O
an	O
important	O
heterogeneity	O
in	O
G6PD	SpecificDisease
deficiency	SpecificDisease
.	O
(2)	O
Although	O
G6PD	O
Mediterranean	O
is	O
very	O
frequent,	O
it	O
presents	O
a	O
relatively	O
high	O
degree	O
of	O
polymorphism.	O
(3)	O
Favism	SpecificDisease
has	O
been	O
observed	O
associated	O
with	O
all	O
kinds	O
of	O
variants	O
described	O
here.	O
(4)	O
G6PD	O
Betica,	O
which	O
is	O
the	O
most	O
frequent	O
variant	O
found	O
in	O
subjects	O
of	O
Southern	O
Spanish	O
origin,	O
has	O
been	O
observed	O
associated	O
with	O
favism	SpecificDisease

Early	O
onset	O
of	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
in	O
a	O
boy	O
with	O
emerin	O
gene	O
deletion.	O
A	O
boy	O
developed	O
contractures	DiseaseClass
of	DiseaseClass
the	DiseaseClass
Achilles	DiseaseClass
tendons	DiseaseClass
at	O
3	O
years	O
and	O
of	O
the	O
postcervical	O
muscles	O
at	O
7	O
years,	O
although	O
neither	O
contractures	DiseaseClass
of	DiseaseClass
the	DiseaseClass
elbows	DiseaseClass
nor	O
cardiac	DiseaseClass
abnormality	DiseaseClass
were	O
recognized	O
by	O
the	O
age	O
of	O
9	O
years.	O
Muscle	O
computed	O
tomography	O
scanning	O
revealed	O
changes	O
characteristic	O
of	O
muscle	O
involvement.	O
Emerin	O
was	O
not	O
detected	O
in	O
the	O
biopsied	O
muscle,	O
and	O
RT-PCR	O
and	O
PCR-based	O
genomic	O
DNA	O
analyses	O
of	O
the	O
emerin	O
gene	O
demonstrated	O
no	O
amplification	O
product	O
in	O
the	O
patient.	O
These	O
results	O
confirmed	O
the	O
diagnosis	O
of	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
),	O
and	O
reinforce	O
the	O
necessity	O
of	O
molecular	O
genetic	O
diagnosis	O
of	O
the	O
membrane	O
protein	O
emerin	O
in	O
younger	O
patients	O
with	O
possible	O
EDMD	SpecificDisease
before	O
appearance	O
of	O
the	O
typical	O
symptoms,	O
to	O
avoid	O
sudden	SpecificDisease
cardiac	SpecificDisease
death	SpecificDisease

PRAD1,	O
a	O
candidate	O
BCL1	O
oncogene:	O
mapping	O
and	O
expression	O
in	O
centrocytic	DiseaseClass
lymphoma	DiseaseClass
.	O
Rearrangement	O
of	O
the	O
BCL1	O
(B-cell	O
lymphoma	O
1)	O
region	O
on	O
chromosome	O
11q13	O
appears	O
to	O
be	O
highly	O
characteristic	O
of	O
centrocytic	DiseaseClass
lymphoma	DiseaseClass
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
B-cell	SpecificDisease
neoplasms	SpecificDisease
.	O
Rearrangement	O
is	O
thought	O
to	O
deregulate	O
a	O
nearby	O
protooncogene,	O
but	O
transcribed	O
sequences	O
in	O
the	O
immediate	O
vicinity	O
of	O
BCL1	O
breakpoints	O
had	O
not	O
been	O
identified.	O
PRAD1,	O
previously	O
designated	O
D11S287E,	O
was	O
identified	O
on	O
11q13	O
as	O
a	O
chromosomal	O
breakpoint	O
region	O
rearranged	O
with	O
the	O
parathyroid	O
hormone	O
gene	O
in	O
a	O
subset	O
of	O
parathyroid	DiseaseClass
adenomas	DiseaseClass
;	O
this	O
highly	O
conserved	O
putative	O
oncogene,	O
which	O
encodes	O
a	O
novel	O
cyclin,	O
has	O
been	O
linked	O
to	O
BCL1	O
and	O
implicated	O
also	O
in	O
subsets	O
of	O
breast	CompositeMention
and	CompositeMention
squamous	CompositeMention
cell	CompositeMention
neoplasms	CompositeMention
with	O
11q13	O
amplification.	O
We	O
report	O
pulsed-field	O
gel	O
electrophoresis	O
data	O
showing	O
BCL1	O
and	O
PRAD1	O
to	O
be	O
no	O
more	O
than	O
130	O
kilobases	O
apart.	O
PRAD1	O
mRNA	O
is	O
abundantly	O
expressed	O
in	O
seven	O
of	O
seven	O
centrocytic	DiseaseClass
lymphomas	DiseaseClass
(Kiel	O
classification),	O
in	O
contrast	O
to	O
13	O
closely	O
related	O
but	O
noncentrocytic	DiseaseClass
lymphomas	DiseaseClass
.	O
Three	O
of	O
the	O
seven	O
centrocytic	DiseaseClass
lymphomas	DiseaseClass
had	O
detectable	O
BCL1	O
DNA	O
rearrangement.	O
Also,	O
two	O
unusual	O
cases	O
of	O
CLL	O
with	O
BCL1	O
rearrangement	O
overexpressed	O
PRAD1,	O
in	O
contrast	O
to	O
five	O
CLL	O
controls.	O
Thus,	O
PRAD1	O
is	O
an	O
excellent	O
candidate	O
"	O
BCL1	O
oncogene.	O
"	O
Its	O
overexpression	O
may	O
be	O
a	O
key	O
consequence	O
of	O
rearrangement	O
of	O
the	O
BCL1	O
vicinity	O
in	O
B-cell	SpecificDisease
neoplasms	SpecificDisease
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	DiseaseClass
lymphoma	DiseaseClass

Adrenoleukodystrophy	SpecificDisease
:	O
increased	O
plasma	O
content	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids.	O
With	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	Modifier
(	O
ALD	Modifier
)	O
hemizygotes,	O
ALD	Modifier
heterozygotes,	O
and	O
controls.	O
ALD	Modifier
hemizygotes	O
showed	O
increased	O
levels	O
of	O
hexacosanoate	O
(C26	O
fatty	O
acid)	O
which	O
represented	O
0.	O
081	O
+/-	O
0.	O
0066%	O
(SEM)	O
of	O
total	O
fatty	O
acids,	O
compared	O
to	O
0.	O
015	O
+/-	O
0.	O
0032%	O
in	O
the	O
controls.	O
C25,	O
C24,	O
and	O
C23	O
fatty	O
acids	O
were	O
also	O
increased,	O
but	O
the	O
C22	O
and	O
C20	O
fatty	O
acids	O
were	O
normal.	O
C26	O
levels	O
were	O
also	O
increased	O
in	O
most	O
ALD	Modifier

Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
inhibits	O
in	O
vitro	O
growth	O
of	O
Plasmodium	O
falciparum.	O
Glucose-6-phosphate	Modifier
dehydrogenase	Modifier
(G6PD;	Modifier
EC	Modifier
1.	Modifier
1.	Modifier
1.	Modifier
49)	Modifier
-deficient	Modifier
red	O
blood	O
cells	O
from	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
from	O
the	O
island	O
of	O
Sardinia	O
were	O
studied	O
for	O
their	O
ability	O
to	O
support	O
growth	O
in	O
vitro	O
of	O
the	O
malaria	Modifier
-causing	O
organism	O
Plasmodium	O
falciparum.	O
Parasite	O
growth	O
was	O
approximately	O
one-third	O
of	O
normal	O
in	O
both	O
hemi-	O
and	O
heterozygotes	O
for	O
G6PD	SpecificDisease
deficiency	SpecificDisease
.	O
In	O
Sardinians	O
with	O
the	O
beta	O
0-thalassemia	O
trait,	O
parasite	O
growth	O
was	O
normal	O
except	O
when	O
G6PD	SpecificDisease
deficiency	SpecificDisease
occurred	O
together	O
with	O
the	O
thalassemia	Modifier
trait.	O
The	O
data	O
support	O
the	O
hypothesis	O
that	O
G6PD	SpecificDisease
deficiency	SpecificDisease
may	O
confer	O
a	O
selective	O
advantage	O
in	O
a	O
malarious	Modifier
area;	O
the	O
female	O
heterozygote	O
may	O
be	O
at	O
a	O
particular	O
advantage	O
because	O
resistance	O
to	O
malaria	SpecificDisease
equals	O
that	O
of	O
male	O
hemizygotes,	O
but	O
the	O
risk	O
of	O
fatal	SpecificDisease
hemolysis	SpecificDisease

Heterozygous	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
associated	O
with	O
angioedema	SpecificDisease
,	O
myasthenia	SpecificDisease
gravis	SpecificDisease
,	O
and	O
systemic	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
.	O
We	O
describe	O
a	O
patient	O
with	O
myasthenia	SpecificDisease
gravis	SpecificDisease
,	O
systemic	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
,	O
and	O
angioedema	SpecificDisease
associated	O
with	O
heterozygous	O
complement	SpecificDisease
factor	SpecificDisease
2	SpecificDisease
(C2)	SpecificDisease
deficiency	SpecificDisease
.	O
The	O
significance	O
of	O
this	O
association	O
is	O
controversial,	O
though	O
the	O
association	O
of	O
C2	SpecificDisease
deficiency	SpecificDisease
with	O
certain	O
histocompatibility	O
antigens	O
suggests	O
possible	O
linkage	O
to	O
immune	O
response	O
genes.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
heterozygous	O
C2	SpecificDisease
deficiency	SpecificDisease
in	O
association	O
with	O
this	O
combination	O
of	O
autoimmune	DiseaseClass
disorders	DiseaseClass

Inherited	O
C3	SpecificDisease
deficiency	SpecificDisease
with	O
recurrent	O
infections	O
and	O
glomerulonephritis	SpecificDisease
.	O
A	O
10-year-old	O
Laotian	O
boy	O
had	O
homozygous	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
third	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
and	O
recurrent	O
bacterial	DiseaseClass
infections	DiseaseClass
beginning	O
at	O
age	O
5	O
months.	O
Cellular	O
and	O
humoral	O
immunity	O
were	O
normal,	O
as	O
were	O
polymorphonuclear	O
leukocyte	O
chemotaxis	O
and	O
bactericidal	O
activities.	O
Serum	O
complement-mediated	O
hemolytic,	O
chemotactic,	O
and	O
opsonic	O
activities	O
were	O
deficient.	O
In	O
vitro	O
addition	O
of	O
purified	O
C3	O
to	O
patient	O
serum	O
restored	O
hemolytic	O
complement	O
to	O
normal	O
levels,	O
and	O
plasma	O
infusion	O
during	O
each	O
of	O
four	O
episodes	O
of	O
pneumonia	SpecificDisease
significantly	O
enhanced	O
serum	O
opsonic	O
activity	O
for	O
as	O
long	O
as	O
36	O
hours.	O
A	O
renal	O
biopsy	O
specimen	O
revealed	O
mesangiopathic	SpecificDisease
glomerulonephritis	SpecificDisease
,	O
although	O
significant	O
levels	O
of	O
circulating	O
IgG	O
immune	O
complexes	O
were	O
not	O
detected.	O
These	O
findings	O
further	O
support	O
the	O
association	O
of	O
C3	SpecificDisease
deficiency	SpecificDisease
with	O
immune-complex	DiseaseClass
disease	DiseaseClass
and	O
suggest	O
that	O
plasma	O
infusion	O
may	O
be	O
an	O
adjunct	O
to	O
antibiotic	O
therapy	O
in	O
the	O
management	O
of	O
severe	O
pyogenic	DiseaseClass
infections	DiseaseClass
in	O
patients	O
with	O
C3	SpecificDisease
deficiency	SpecificDisease

Southern	O
analysis	O
reveals	O
a	O
large	O
deletion	O
at	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
locus	O
in	O
a	O
patient	O
with	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
Whole	O
genomic	O
hprt	O
clones	O
were	O
used	O
in	O
Southern	O
analysis	O
to	O
screen	O
the	O
integrity	O
of	O
the	O
hprt	O
gene	O
in	O
a	O
family	O
that	O
includes	O
a	O
patient	O
with	O
HPRT	SpecificDisease
enzyme	SpecificDisease
deficiency	SpecificDisease
causal	O
to	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

Association	O
of	O
BRCA1	O
with	O
the	O
hRad50-hMre11-p95	O
complex	O
and	O
the	O
DNA	O
damage	O
response.	O
BRCA1	O
encodes	O
a	O
tumor	Modifier
suppressor	O
that	O
is	O
mutated	O
in	O
familial	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
.	O
Here,	O
it	O
is	O
shown	O
that	O
BRCA1	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
hRad50,	O
which	O
forms	O
a	O
complex	O
with	O
hMre11	O
and	O
p95/nibrin.	O
Upon	O
irradiation,	O
BRCA1	O
was	O
detected	O
in	O
discrete	O
foci	O
in	O
the	O
nucleus,	O
which	O
colocalize	O
with	O
hRad50.	O
Formation	O
of	O
irradiation-induced	O
foci	O
positive	O
for	O
BRCA1,	O
hRad50,	O
hMre11,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC/1937	O
breast	Modifier
cancer	Modifier

Nebulin	O
and	O
titin	O
expression	O
in	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
appears	O
normal.	O
Monoclonal	O
antibodies	O
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	O
staining	O
patterns	O
on	O
frozen	O
sections	O
of	O
three	O
muscle	O
biopsies	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
Gel	O
electrophoresis	O
and	O
immunoblotting	O
performed	O
on	O
two	O
of	O
these	O
muscle	O
biopsies	O
show	O
the	O
normal	O
pattern	O
of	O
titin	O
and	O
nebulin	O
polypeptides.	O
Since	O
the	O
donor	O
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	O
deletion	O
of	O
the	O
5-region	O
of	O
the	O
DMD	Modifier
gene,	O
our	O
results	O
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	O
mutated	O
in	O
DMD	SpecificDisease

Myotonic	Modifier
dystrophy	Modifier
kinase	O
is	O
a	O
component	O
of	O
neuromuscular	O
junctions.	O
The	O
clinical	O
manifestation	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
correlated	O
to	O
the	O
extent	O
of	O
expansion	O
of	O
an	O
unstable	O
[CTG]	O
n	O
DNA	O
motif.	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
this	O
trinucleotide	O
motif	O
forms	O
part	O
of	O
the	O
last,	O
3	O
untranslated	O
exon	O
of	O
a	O
gene	O
which	O
potentially	O
encodes	O
multiple	O
protein	O
isoforms	O
of	O
a	O
serine/threonine	O
protein	O
kinase	O
(	O
myotonic	Modifier
dystrophy	Modifier
protein	O
kinase,	O
DM-PK).	O
We	O
report	O
here	O
on	O
the	O
development	O
of	O
antisera	O
against	O
synthetic	O
DM-PK	O
peptide	O
antigens	O
and	O
their	O
use	O
in	O
biochemical	O
and	O
histochemical	O
studies.	O
Immunoreactive	O
DM-kinase	O
protein	O
of	O
53	O
kD	O
is	O
present	O
at	O
low	O
levels	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
extracts	O
of	O
DM	Modifier
patients	O
and	O
normal	O
controls.	O
Immunohistochemical	O
staining	O
revealed	O
that	O
DM-PK	O
is	O
localised	O
prominently	O
at	O
sites	O
of	O
neuromuscular	O
and	O
myotendinous	O
junctions	O
(NMJs	O
and	O
MTJs)	O
of	O
human	O
and	O
rodent	O
skeletal	O
muscles.	O
Furthermore,	O
very	O
low	O
levels	O
of	O
immunoreactive	O
DM-PK	O
protein	O
are	O
present	O
in	O
the	O
sarcoplasm	O
of	O
predominantly	O
type	O
I	O
fibres	O
in	O
various	O
muscles.	O
Strikingly,	O
presence	O
of	O
the	O
protein	O
can	O
also	O
be	O
demonstrated	O
for	O
NMJs	O
of	O
muscular	O
tissues	O
of	O
adult	O
and	O
congenital	O
cases	O
of	O
DM	SpecificDisease
,	O
with	O
no	O
gross	O
changes	O
in	O
structural	O
organisation.	O
Our	O
findings	O
provide	O
a	O
basis	O
for	O
further	O
characterisation	O
of	O
the	O
role	O
of	O
the	O
kinase	O
in	O
protein	O
assembly	O
processes	O
or	O
signal	O
mediation	O
at	O
synaptic	O
sites	O
and	O
ultimately	O
for	O
the	O
understanding	O
of	O
the	O
complex	O
pathophysiology	O
of	O
DM	SpecificDisease

New	O
genetic	O
variants	O
of	O
glucose	O
6-phosphate	O
dehydrogenase	O
(G6PD)	O
in	O
Italy.	O
Six	O
new	O
variants	O
of	O
human	O
erythrocyte	O
G6PD	O
have	O
been	O
characterized.	O
All	O
of	O
them	O
were	O
found	O
in	O
Italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	DiseaseClass
deficiency	DiseaseClass
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	SpecificDisease
.	O
These	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
Italy	O
where	O
common	O
types	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

ATM-heterozygous	O
germline	O
mutations	O
contribute	O
to	O
breast	Modifier
cancer	Modifier
-susceptibility.	O
Approximately	O
0.	O
5%	O
-1%	O
of	O
the	O
general	O
population	O
has	O
been	O
estimated	O
to	O
be	O
heterozygous	O
for	O
a	O
germline	O
mutation	O
in	O
the	O
ATM	O
gene.	O
Mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
)	O
(MIM	O
208900).	O
The	O
finding	O
that	O
ATM-heterozygotes	O
have	O
an	O
increased	O
relative	O
risk	O
for	O
breast	SpecificDisease
cancer	SpecificDisease
was	O
supported	O
by	O
some	O
studies	O
but	O
not	O
confirmed	O
by	O
others.	O
In	O
view	O
of	O
this	O
discrepancy,	O
we	O
examined	O
the	O
frequency	O
of	O
ATM	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
Dutch	O
patients	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
We	O
have	O
analyzed	O
ATM	O
germline	O
mutations	O
in	O
normal	O
blood	O
lymphocytes,	O
using	O
the	O
protein-truncation	O
test	O
followed	O
by	O
genomic-sequence	O
analysis.	O
A	O
high	O
percentage	O
of	O
ATM	O
germline	O
mutations	O
was	O
demonstrated	O
among	O
patients	O
with	O
sporadic	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
.	O
The	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	SpecificDisease
cancer	SpecificDisease

Autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
(	O
ALPS	SpecificDisease
)	O
in	O
a	O
child	O
from	O
consanguineous	O
parents:	O
a	O
dominant	O
or	O
recessive	O
disease?	O
Autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
(	O
ALPS	SpecificDisease
)	O
is	O
characterized	O
by	O
autoimmune	O
features	O
and	O
lymphoproliferations	O
and	O
is	O
generally	O
caused	O
by	O
defective	O
Fas-mediated	O
apoptosis.	O
This	O
report	O
describes	O
a	O
child	O
with	O
clinical	O
features	O
of	O
ALPS	SpecificDisease
without	O
detectable	O
Fas	O
expression	O
on	O
freshly	O
isolated	O
blood	O
leukocytes.	O
Detection	O
of	O
FAS	O
transcripts	O
via	O
real-time	O
quantitative	O
PCR	O
made	O
a	O
severe	O
transcriptional	O
defect	O
unlikely.	O
Sequencing	O
of	O
the	O
FAS	O
gene	O
revealed	O
a	O
20-nucleotide	O
duplication	O
in	O
the	O
last	O
exon	O
affecting	O
the	O
cytoplasmic	O
signaling	O
domain.	O
The	O
patient	O
was	O
homozygous	O
for	O
this	O
mutation,	O
whereas	O
the	O
consanguineous	O
parents	O
and	O
the	O
siblings	O
were	O
heterozygous.	O
The	O
patient	O
reported	O
here	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Fas-null	O
mouse,	O
inasmuch	O
as	O
she	O
carries	O
an	O
autosomal	O
homozygous	O
mutation	O
in	O
the	O
FAS	O
gene	O
and	O
she	O
shows	O
the	O
severe	O
and	O
accelerated	O
ALPS	Modifier
phenotype.	O
The	O
heterozygous	O
family	O
members	O
did	O
not	O
have	O
the	O
ALPS	Modifier

A	O
prevalent	O
mutation	O
for	O
galactosemia	SpecificDisease
among	O
black	O
Americans.	O
OBJECTIVE	O
	O
To	O
define	O
the	O
mutation	O
causing	O
galactosemia	SpecificDisease
in	O
patients	O
of	O
black	O
American	O
origin	O
who	O
have	O
no	O
galactose-1-phosphate	O
uridyltransferase	O
(GALT)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome.	O
METHODS	O
	O
We	O
discovered	O
a	O
mutation	O
caused	O
by	O
a	O
C--	O
>	O
T	O
transition	O
at	O
base-pair	O
1158	O
of	O
the	O
GALT	O
gene	O
that	O
results	O
in	O
a	O
serine-to-leucine	O
substitution	O
at	O
codon	O
135	O
(S135L).	O
We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	O
populations	O
for	O
its	O
prevalence.	O
We	O
compared	O
galactose-1-phosphate	O
uridyltransferase	O
among	O
erythrocytes,	O
leukocytes,	O
and	O
transformed	O
lymphoblasts,	O
as	O
well	O
as	O
total	O
body	O
oxidation	O
of	O
D-	O
(13C)	O
-galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	O
(S135L/S135L,	O
Q188R/Q188R,	O
and	O
Normal/Normal).	O
RESULTS	O
	O
We	O
found	O
a	O
48%	O
prevalence	O
of	O
the	O
S135L	O
mutation	O
among	O
17	O
black	O
American	O
patients	O
with	O
classic	SpecificDisease
galactosemia	SpecificDisease
and	O
a	O
1%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
Americans	O
without	O
galactosemia	SpecificDisease
.	O
The	O
S135L	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
G/G	O
galactosemia	SpecificDisease
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	SpecificDisease
.	O
We	O
found	O
normal	O
whole	O
body	O
oxidation	O
of	O
D-	O
(13C)	O
-galactose	O
by	O
the	O
patient	O
homozygous	O
for	O
S135L	O
and	O
various	O
degrees	O
of	O
enzyme	O
impairment	O
among	O
different	O
tissues.	O
CONCLUSIONS	O
	O
The	O
S135L	O
mutation	O
in	O
the	O
GALT	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	SpecificDisease

Constitutive	O
and	O
regulated	O
modes	O
of	O
splicing	O
produce	O
six	O
major	O
myotonic	Modifier
dystrophy	Modifier
protein	O
kinase	O
(DMPK)	O
isoforms	O
with	O
distinct	O
properties.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
the	O
most	O
prevalent	O
inherited	DiseaseClass
neuromuscular	DiseaseClass
disease	DiseaseClass
in	O
adults.	O
The	O
genetic	DiseaseClass
defect	DiseaseClass
is	O
a	O
CTG	O
triplet	O
repeat	O
expansion	O
in	O
the	O
3-untranslated	O
region	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
protein	O
kinase	O
(DMPK)	O
gene,	O
consisting	O
of	O
15	O
exons.	O
Using	O
a	O
transgenic	O
DMPK-overexpressor	O
mouse	O
model,	O
we	O
demonstrate	O
here	O
that	O
the	O
endogenous	O
mouse	O
DMPK	O
gene	O
and	O
the	O
human	O
DMPK	O
transgene	O
produce	O
six	O
major	O
alternatively	O
spliced	O
mRNAs	O
which	O
have	O
almost	O
identical	O
cell	O
type-dependent	O
distribution	O
frequencies	O
and	O
expression	O
patterns.	O
Use	O
of	O
a	O
cryptic	O
5	O
splice	O
site	O
in	O
exon	O
8,	O
which	O
results	O
in	O
absence	O
or	O
presence	O
of	O
15	O
nucleotides	O
specifying	O
a	O
VSGGG	O
peptide	O
motif,	O
and/or	O
use	O
of	O
a	O
cryptic	O
3	O
splice	O
site	O
in	O
exon	O
14,	O
which	O
leads	O
to	O
a	O
frameshift	O
in	O
the	O
mRNA	O
reading	O
frame,	O
occur	O
as	O
independent	O
stochastic	O
events	O
in	O
all	O
tissues	O
examined.	O
In	O
contrast,	O
the	O
excision	O
of	O
exons	O
13/14	O
that	O
causes	O
a	O
frameshift	O
and	O
creates	O
a	O
C-terminally	O
truncated	O
protein	O
is	O
clearly	O
cell	O
type	O
dependent	O
and	O
occurs	O
predominantly	O
in	O
smooth	O
muscle.	O
We	O
generated	O
all	O
six	O
full-length	O
mouse	O
cDNAs	O
that	O
result	O
from	O
combinations	O
of	O
these	O
three	O
major	O
splicing	O
events	O
and	O
show	O
that	O
their	O
transfection	O
into	O
cells	O
in	O
culture	O
leads	O
to	O
production	O
of	O
four	O
different	O
approximately	O
74	O
kDa	O
full-length	O
(heart-,	O
skeletal	O
muscle-	O
or	O
brain-specific)	O
and	O
two	O
C-terminally	O
truncated	O
approximately	O
68	O
kDa	O
(smooth	O
muscle-specific)	O
isoforms.	O
Information	O
on	O
DMPK	O
mRNA	O
and	O
protein	O
isoform	O
expression	O
patterns	O
will	O
be	O
useful	O
for	O
recognizing	O
differential	O
effects	O
of	O
(CTG)	O
(n)	O
expansion	O
in	O
DM	Modifier

Linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
family	O
with	O
van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
suggests	O
the	O
existence	O
of	O
a	O
susceptibility	O
locus	O
for	O
cleft	SpecificDisease
palate	SpecificDisease
at	O
17p11.2-11.1.	O
van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
(	O
VWS	SpecificDisease
),	O
which	O
has	O
been	O
mapped	O
to	O
1q32-41,	O
is	O
characterized	O
by	O
pits	CompositeMention
and/or	CompositeMention
sinuses	CompositeMention
of	CompositeMention
the	CompositeMention
lower	CompositeMention
lip	CompositeMention
,	O
cleft	SpecificDisease
lip/palate	SpecificDisease
(	O
CL/P	SpecificDisease
),	O
cleft	SpecificDisease
palate	SpecificDisease
(	O
CP	SpecificDisease
),	O
bifid	SpecificDisease
uvula	SpecificDisease
,	O
and	O
hypodontia	SpecificDisease
(	O
H	SpecificDisease
).	O
The	O
expression	O
of	O
VWS	SpecificDisease
,	O
which	O
has	O
incomplete	O
penetrance,	O
is	O
highly	O
variable.	O
Both	O
the	O
occurrence	O
of	O
CL/P	SpecificDisease
and	O
CP	SpecificDisease
within	O
the	O
same	O
genealogy	O
and	O
a	O
recurrence	O
risk	O
<	O
40%	O
for	O
CP	SpecificDisease
among	O
descendants	O
with	O
VWS	SpecificDisease
have	O
suggested	O
that	O
the	O
development	O
of	O
clefts	DiseaseClass
in	O
this	O
syndrome	O
is	O
influenced	O
by	O
modifying	O
genes	O
at	O
other	O
loci.	O
To	O
test	O
this	O
hypothesis,	O
we	O
have	O
conducted	O
linkage	O
analysis	O
in	O
a	O
large	O
Brazilian	O
kindred	O
with	O
VWS	SpecificDisease
,	O
considering	O
as	O
affected	O
the	O
individuals	O
with	O
CP	SpecificDisease
,	O
regardless	O
of	O
whether	O
it	O
is	O
associated	O
with	O
other	O
clinical	O
signs	O
of	O
VWS	SpecificDisease
.	O
Our	O
results	O
suggest	O
that	O
a	O
gene	O
at	O
17p11.	O
2-11	O
2-11.	O
1,	O
together	O
with	O
the	O
VWS	Modifier
gene	O
at	O
1p32-41,	O
enhances	O
the	O
probability	O
of	O
CP	SpecificDisease
in	O
an	O
individual	O
carrying	O
the	O
two	O
at-risk	O
genes.	O
If	O
this	O
hypothesis	O
is	O
confirmed	O
in	O
other	O
VWS	Modifier

Diverse	O
point	O
mutations	O
in	O
the	O
human	O
glucose-6-phosphate	O
dehydrogenase	O
gene	O
cause	O
enzyme	DiseaseClass
deficiency	DiseaseClass
and	O
mild	O
or	O
severe	O
hemolytic	SpecificDisease
anemia	SpecificDisease
.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD;	SpecificDisease
EC	SpecificDisease
1.	SpecificDisease
1.	SpecificDisease
1.	SpecificDisease
49)	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
common	O
genetic	DiseaseClass
abnormality	DiseaseClass
affecting	O
an	O
estimated	O
400	O
million	O
people	O
worldwide.	O
Clinical	O
and	O
biochemical	O
analyses	O
have	O
identified	O
many	O
variants	O
exhibiting	O
a	O
range	O
of	O
phenotypes,	O
which	O
have	O
been	O
well	O
characterized	O
from	O
the	O
hematological	O
point	O
of	O
view.	O
However,	O
until	O
now,	O
their	O
precise	O
molecular	O
basis	O
has	O
remained	O
unknown.	O
We	O
have	O
cloned	O
and	O
sequenced	O
seven	O
mutant	O
G6PD	O
alleles.	O
In	O
the	O
nondeficient	O
polymorphic	O
African	O
variant	O
G6PD	O
A	O
we	O
have	O
found	O
a	O
single	O
point	O
mutation.	O
The	O
other	O
six	O
mutants	O
investigated	O
were	O
all	O
associated	O
with	O
enzyme	DiseaseClass
deficiency	DiseaseClass
.	O
In	O
one	O
of	O
the	O
commonest,	O
G6PD	O
Mediterranean,	O
which	O
is	O
associated	O
with	O
favism	DiseaseClass
among	O
other	O
clinical	O
manifestations,	O
a	O
single	O
amino	O
acid	O
replacement	O
was	O
found	O
(serine----phenylalanine)	O
	O
it	O
must	O
be	O
responsible	O
for	O
the	O
decreased	O
stability	O
and	O
the	O
reduced	O
catalytic	O
efficiency	O
of	O
this	O
enzyme.	O
Single	O
point	O
mutations	O
were	O
also	O
found	O
in	O
G6PD	O
Metaponto	O
(Southern	O
Italy)	O
and	O
in	O
G6PD	O
Ilesha	O
(Nigeria),	O
which	O
are	O
asymptomatic,	O
and	O
in	O
G6PD	O
Chatham,	O
which	O
was	O
observed	O
in	O
an	O
Indian	O
boy	O
with	O
neonatal	DiseaseClass
jaundice	DiseaseClass
.	O
In	O
G6PD	O
"	O
Matera,	O
"	O
which	O
is	O
now	O
known	O
to	O
be	O
the	O
same	O
as	O
G6PD	O
A-,	O
two	O
separate	O
point	O
mutations	O
were	O
found,	O
one	O
of	O
which	O
is	O
the	O
same	O
as	O
in	O
G6PD	O
A.	O
In	O
G6PD	O
Santiago,	O
a	O
de	O
novo	O
mutation	O
(glycine----arginine)	O
is	O
associated	O
with	O
severe	O
chronic	O
hemolytic	SpecificDisease
anemia	SpecificDisease
.	O
The	O
mutations	O
observed	O
show	O
a	O
striking	O
predominance	O
of	O
C----T	O
transitions,	O
with	O
CG	O
doublets	O
involved	O
in	O
four	O
of	O
seven	O
cases.	O
Thus,	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Increased	O
high-density	O
lipoprotein	O
levels	O
caused	O
by	O
a	O
common	O
cholesteryl-ester	O
transfer	O
protein	O
gene	O
mutation.	O
BACKGROUND	O
AND	O
METHODS.	O
The	O
plasma	O
cholesteryl-ester	O
transfer	O
protein	O
(CETP)	O
catalyzes	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
high-density	O
lipoprotein	O
(HDL)	O
to	O
other	O
lipoproteins.	O
We	O
recently	O
described	O
a	O
Japanese	O
family	O
with	O
increased	O
HDL	O
levels	O
and	O
CETP	SpecificDisease
deficiency	SpecificDisease
due	O
to	O
a	O
splicing	O
defect	O
of	O
the	O
CETP	O
gene.	O
To	O
assess	O
the	O
frequency	O
and	O
phenotype	O
of	O
this	O
condition,	O
we	O
screened	O
11	O
additional	O
families	O
with	O
high	O
HDL	O
levels	O
by	O
means	O
of	O
a	O
radioimmunoassay	O
for	O
CETP	O
and	O
DNA	O
analysis.	O
RESULTS.	O
We	O
found	O
the	O
same	O
CETP	O
gene	O
mutation	O
in	O
four	O
families	O
from	O
three	O
different	O
regions	O
of	O
Japan.	O
Analysis	O
of	O
restriction-fragment-length	O
polymorphisms	O
of	O
the	O
mutant	O
CETP	O
allele	O
showed	O
that	O
all	O
probands	O
were	O
homozygous	O
for	O
the	O
identical	O
haplotype.	O
Family	O
members	O
homozygous	O
for	O
CETP	SpecificDisease
deficiency	SpecificDisease
(n	O
=	O
10)	O
had	O
moderate	O
hypercholesterolemia	SpecificDisease
(mean	O
total	O
cholesterol	O
level	O
[+/-	O
SD],	O
7.	O
01	O
+/-	O
0.	O
83	O
mmol	O
per	O
liter),	O
markedly	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
(4.	O
24	O
+/-	O
1.	O
01	O
mmol	O
per	O
liter)	O
and	O
apolipoprotein	O
A-I,	O
and	O
decreased	O
levels	O
of	O
low-density	O
lipoprotein	O
cholesterol	O
(1.	O
99	O
+/-	O
0.	O
80	O
mmol	O
per	O
liter)	O
and	O
apolipoprotein	O
B.	O
Members	O
heterozygous	O
for	O
the	O
deficiency	O
(n	O
=	O
20),	O
whose	O
CETP	O
levels	O
were	O
in	O
the	O
lower	O
part	O
of	O
the	O
normal	O
range,	O
had	O
moderately	O
increased	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
apolipoprotein	O
A-I	O
and	O
an	O
increased	O
ratio	O
of	O
HDL	O
subclass	O
2	O
to	O
HDL	O
subclass	O
3,	O
as	O
compared	O
with	O
unaffected	O
family	O
members	O
(1.	O
5	O
+/-	O
0.	O
8	O
vs.	O
0.	O
7	O
+/-	O
0.	O
4).	O
CETP	SpecificDisease
deficiency	SpecificDisease
was	O
not	O
found	O
in	O
six	O
unrelated	O
subjects	O
with	O
elevated	O
HDL	O
cholesterol	O
levels	O
who	O
were	O
from	O
different	O
parts	O
of	O
the	O
United	O
States.	O
CONCLUSIONS.	O
CETP	SpecificDisease
deficiency	SpecificDisease
appears	O
to	O
be	O
a	O
frequent	O
cause	O
of	O
increased	O
HDL	O
levels	O
in	O
the	O
population	O
of	O
Japan,	O
possibly	O
because	O
of	O
a	O
founder	O
effect.	O
The	O
results	O
that	O
we	O
observed	O
in	O
heterozygotes	O
suggest	O
that	O
CETP	O
normally	O
plays	O
a	O
part	O
in	O
the	O
regulation	O
of	O
levels	O
of	O
HDL	O
subclass	O
2.	O
There	O
was	O
no	O
evidence	O
of	O
premature	SpecificDisease
atherosclerosis	SpecificDisease
in	O
the	O
families	O
with	O
CETP	SpecificDisease
deficiency	SpecificDisease
.	O
In	O
fact,	O
the	O
lipoprotein	O
profile	O
of	O
persons	O
with	O
CETP	SpecificDisease
deficiency	SpecificDisease

Hereditary	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
and	O
recurrent	O
meningococcal	SpecificDisease
infection	SpecificDisease
:	O
investigations	O
of	O
an	O
Irish	O
family	O
using	O
a	O
novel	O
haemolytic	O
screening	O
assay	O
for	O
complement	O
activity	O
and	O
C7	O
M/N	O
allotyping.	O
Terminal	SpecificDisease
complement	SpecificDisease
component	SpecificDisease
deficiency	SpecificDisease
predisposes	O
to	O
meningococcal	SpecificDisease
infection	SpecificDisease
and	O
is	O
inherited	O
in	O
an	O
autosomal	O
co-dominant	O
manner.	O
An	O
Irish	O
family	O
is	O
described,	O
in	O
which	O
2	O
of	O
3	O
brothers	O
had	O
recurrent	O
meningococcal	SpecificDisease
infection	SpecificDisease
.	O
A	O
novel	O
screening	O
assay	O
was	O
used	O
to	O
investigate	O
for	O
terminal	SpecificDisease
complement	SpecificDisease
deficiency	SpecificDisease
and	O
the	O
2	O
affected	O
brothers	O
were	O
found	O
to	O
be	O
completely	SpecificDisease
deficient	SpecificDisease
in	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C7).	O
Enzyme-linked	O
immunosorbent	O
assay	O
for	O
C7	O
revealed	O
lower	O
than	O
normal	O
levels	O
in	O
the	O
remaining	O
brother	O
and	O
parents.	O
C7	O
M/N	O
protein	O
polymorphism	O
allotyping,	O
used	O
to	O
investigate	O
the	O
segregation	O
of	O
the	O
C7	Modifier
deficiency	Modifier
genes,	O
showed	O
that	O
the	O
apparently	O
complement	O
sufficient	O
brother	O
was	O
heterozygous	O
C7	SpecificDisease
deficient	SpecificDisease
and	O
a	O
carrier	O
of	O
one	O
of	O
the	O
deficiency	O
genes.	O
Complement	O
screening	O
should	O
be	O
carried	O
out	O
in	O
any	O
individual	O
suffering	O
recurrent	O
meningococcal	SpecificDisease
infection	SpecificDisease
or	O
infection	O
with	O
an	O
uncommon	O
meningococcal	Modifier
serogroup.	O
Identification	O
of	O
complement	Modifier
deficient	Modifier

Mild	O
and	O
severe	O
muscular	DiseaseClass
dystrophy	DiseaseClass
associated	O
with	O
deletions	O
in	O
Xp21	O
of	O
the	O
human	O
X	O
chromosome.	O
We	O
have	O
analysed	O
over	O
300	O
patients	O
suffering	O
from	O
Duchenne	CompositeMention
or	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
(	O
DMD	SpecificDisease
or	O
BMD	SpecificDisease
).	O
Deletions	O
have	O
been	O
characterised	O
which	O
encompass	O
either	O
the	O
pERT87	O
(DXS164)	O
locus	O
only,	O
the	O
XJ1.	O
1	O
(DXS206)	O
and	O
HIP25	O
loci	O
only,	O
or	O
all	O
three	O
loci.	O
These	O
loci	O
have	O
been	O
shown	O
to	O
lie	O
within	O
the	O
DMD	Modifier
region	O
covering	O
several	O
hundred	O
kilobases	O
(kb)	O
of	O
DNA.	O
One	O
mildly	O
affected	O
BMD	Modifier
patient	O
possesses	O
a	O
deletion	O
of	O
at	O
least	O
110	O
kb	O
including	O
exons	O
of	O
the	O
DMD	Modifier
gene.	O
Other	O
patients	O
with	O
similar	O
exon	O
deletions,	O
or	O
smaller	O
deletions,	O
show	O
the	O
more	O
severe	O
phenotype	O
typical	O
of	O
DMD	SpecificDisease

Meiotic	O
segregation	O
analysis	O
of	O
RB1	O
alleles	O
in	O
retinoblastoma	Modifier
pedigrees	O
by	O
use	O
of	O
single-sperm	O
typing.	O
In	O
hereditary	SpecificDisease
retinoblastoma	SpecificDisease
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	Modifier
alleles	O
to	O
offspring,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive.	O
To	O
investigate	O
this	O
mechanism,	O
we	O
analyzed	O
sperm	O
samples	O
from	O
six	O
individuals	O
from	O
five	O
unrelated	O
families	O
affected	O
with	O
hereditary	SpecificDisease
retinoblastoma	SpecificDisease
.	O
Single-sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	Modifier

Functional	O
differences	O
of	O
the	O
PDS	Modifier
gene	O
product	O
are	O
associated	O
with	O
phenotypic	O
variation	O
in	O
patients	O
with	O
Pendred	SpecificDisease
syndrome	SpecificDisease
and	O
non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
(	O
DFNB4	SpecificDisease
).	O
The	O
PDS	Modifier
gene	O
encodes	O
a	O
transmembrane	O
protein,	O
known	O
as	O
pendrin,	O
which	O
functions	O
as	O
a	O
transporter	O
of	O
iodide	O
and	O
chloride.	O
Mutations	O
in	O
this	O
gene	O
are	O
responsible	O
for	O
Pendred	SpecificDisease
syndrome	SpecificDisease
and	O
autosomal	SpecificDisease
recessive	SpecificDisease
non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
at	O
the	O
DFNB4	Modifier
locus	O
on	O
chromosome	O
7q31.	O
A	O
screen	O
of	O
20	O
individuals	O
from	O
the	O
midwestern	O
USA	O
with	O
non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
and	O
dilated	O
vestibular	O
aqueducts	O
identified	O
three	O
people	O
(15%)	O
with	O
PDS	Modifier
mutations.	O
To	O
determine	O
whether	O
PDS	Modifier
mutations	O
in	O
individuals	O
with	O
Pendred	SpecificDisease
syndrome	SpecificDisease
differ	O
functionally	O
from	O
PDS	Modifier
mutations	O
in	O
individuals	O
with	O
non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
,	O
we	O
compared	O
three	O
common	O
Pendred	Modifier
syndrome	Modifier
allele	O
variants	O
(L236P,	O
T416P	O
and	O
E384G),	O
with	O
three	O
PDS	Modifier
mutations	O
reported	O
only	O
in	O
individuals	O
with	O
non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
(V480D,	O
V653A	O
and	O
I490L/G497S).	O
The	O
mutations	O
associated	O
with	O
Pendred	SpecificDisease
syndrome	SpecificDisease
have	O
complete	O
loss	O
of	O
pendrin-induced	O
chloride	O
and	O
iodide	O
transport,	O
while	O
alleles	O
unique	O
to	O
people	O
with	O
DFNB4	SpecificDisease
are	O
able	O
to	O
transport	O
both	O
iodide	O
and	O
chloride,	O
albeit	O
at	O
a	O
much	O
lower	O
level	O
than	O
wild-type	O
pendrin.	O
We	O
hypothesize	O
that	O
this	O
residual	O
level	O
of	O
anion	O
transport	O
is	O
sufficient	O
to	O
eliminate	O
or	O
postpone	O
the	O
onset	O
of	O
goiter	DiseaseClass
in	O
individuals	O
with	O
DFNB4	SpecificDisease

Late-onset	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
:	O
molecular	O
pathology	O
in	O
two	O
siblings.	O
We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(ARSA)	O
locus	O
causing	O
late-onset	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
).	O
In	O
that	O
allele	O
arginine84,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family,	O
is	O
replaced	O
by	O
glutamine.	O
In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early-onset	O
MLD	SpecificDisease
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity.	O
A	O
comparison	O
of	O
genotypes,	O
ARSA	O
activities,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	Modifier
examined,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	SpecificDisease

Defective	O
CD95/APO-1/Fas	O
signal	O
complex	O
formation	O
in	O
the	O
human	O
autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome,	SpecificDisease
type	SpecificDisease
Ia	SpecificDisease
.	O
Heterozygous	O
mutations	O
in	O
the	O
CD95	O
(APO-1/Fas)	O
receptor	O
occur	O
in	O
most	O
individuals	O
with	O
autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
(	O
ALPS	SpecificDisease
)	O
and	O
dominantly	O
interfere	O
with	O
apoptosis	O
by	O
an	O
unknown	O
mechanism.	O
We	O
show	O
that	O
local	O
or	O
global	O
alterations	O
in	O
the	O
structure	O
of	O
the	O
cytoplasmic	O
death	O
domain	O
from	O
nine	O
independent	O
ALPS	Modifier
CD95	O
death-domain	O
mutations	O
result	O
in	O
a	O
failure	O
to	O
bind	O
the	O
FADD/MORT1	O
signaling	O
protein.	O
Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele,	O
lymphocytes	O
from	O
ALPS	Modifier
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking.	O
These	O
data	O
suggest	O
that	O
intracytoplasmic	O
CD95	O
mutations	O
in	O
ALPS	SpecificDisease

Classical	SpecificDisease
galactosemia	SpecificDisease
and	O
mutations	O
at	O
the	O
galactose-1-phosphate	O
uridyl	O
transferase	O
(GALT)	O
gene.	O
Classical	SpecificDisease
galactosemia	SpecificDisease
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose-1-phosphate	O
uridyl	O
transferase	O
(GALT),	O
which,	O
in	O
turn,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
GALT	O
gene.	O
The	O
disorder	O
exhibits	O
considerable	O
allelic	O
heterogeneity	O
and,	O
at	O
the	O
end	O
of	O
1998,	O
more	O
than	O
150	O
different	O
base	O
changes	O
were	O
recorded	O
in	O
24	O
different	O
populations	O
and	O
ethnic	O
groups	O
in	O
15	O
countries	O
worldwide.	O
The	O
mutations	O
most	O
frequently	O
cited	O
are	O
Q188R,	O
K285N,	O
S135L,	O
and	O
N314D.	O
Q188R	O
is	O
the	O
most	O
common	O
mutation	O
in	O
European	O
populations	O
or	O
in	O
those	O
predominantly	O
of	O
European	O
descent.	O
Overall,	O
it	O
accounts	O
for	O
60-70%	O
of	O
mutant	O
chromosomes,	O
but	O
there	O
are	O
significant	O
differences	O
in	O
its	O
relative	O
frequency	O
in	O
individual	O
populations.	O
Individuals	O
homoallelic	O
for	O
Q188R	O
tend	O
to	O
have	O
a	O
severe	O
phenotype	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
virtually	O
complete	O
loss	O
of	O
enzyme	O
activity	O
observed	O
in	O
in	O
vitro	O
expression	O
systems.	O
Globally,	O
K285N	O
is	O
rarer,	O
but	O
in	O
many	O
European	O
populations	O
it	O
can	O
be	O
found	O
on	O
25-40%	O
of	O
mutant	O
chromosomes.	O
It	O
is	O
invariably	O
associated	O
with	O
a	O
severe	O
phenotype.	O
S135L	O
is	O
found	O
almost	O
exclusively	O
in	O
African	O
Americans.	O
In	O
vitro	O
expression	O
results	O
are	O
discrepant,	O
but	O
some	O
individuals	O
carrying	O
S135L	O
appear	O
to	O
exhibit	O
GALT	O
activity	O
in	O
some	O
tissues.	O
Duarte	O
1	O
(or	O
Los	O
Angeles)	O
and	O
Duarte	O
2	O
(or	O
Duarte)	O
variants	O
carry	O
the	O
same	O
amino	O
acid	O
substitution,	O
N314D,	O
even	O
though	O
D1	O
is	O
associated	O
with	O
increased	O
erythrocyte	O
GALT	O
activity	O
and	O
D2	O
with	O
reduced	O
activity.	O
N314D	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
other	O
base	O
changes	O
that	O
differ	O
on	O
the	O
D1	O
and	O
D2	O
alleles.	O
N314D	O
does	O
not	O
impair	O
GALT	O
activity	O
in	O
in	O
vitro	O
expression	O
systems.	O
However,	O
there	O
are	O
differences	O
in	O
the	O
abundance	O
of	O
GALT	O
protein	O
in	O
lymphoblastoid	O
cells	O
lines	O
from	O
D2	O
and	O
D1	O
individuals.	O
It	O
is	O
unclear	O
whether	O
the	O
specific	O
molecular	O
changes	O
that	O
distinguish	O
the	O
D1	O
and	O
D2	O
alleles	O
account	O
for	O
the	O
different	O
activities.	O
The	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	SpecificDisease

X-linked	SpecificDisease
retinoschisis	SpecificDisease
with	O
point	O
mutations	O
in	O
the	O
XLRS1	O
gene.	O
BACKGROUND	O
X-linked	SpecificDisease
retinoschisis	SpecificDisease
(	O
XLRS	SpecificDisease
)	O
is	O
a	O
relatively	O
rare	O
vitreoretinal	DiseaseClass
dystrophy	DiseaseClass
that	O
causes	O
visual	SpecificDisease
loss	SpecificDisease
in	O
young	O
men.	O
Recently,	O
a	O
gene	O
responsible	O
for	O
this	O
disease,	O
designated	O
XLRS1,	O
was	O
identified,	O
and	O
several	O
deleterious	O
gene	O
mutations	O
were	O
reported.	O
OBJECTIVE	O
	O
To	O
analyze	O
Japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
XLRS	Modifier
formutational	O
changes	O
in	O
the	O
XLRS1	O
gene.	O
METHODS	O
	O
Ten	O
patients	O
with	O
XLRS	SpecificDisease
underwent	O
full	O
ophthalmologic	O
examination,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy.	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes,	O
and	O
all	O
exons	O
of	O
the	O
XLRS1	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
using	O
a	O
direct	O
sequencing	O
method.	O
RESULTS	O
	O
Point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
were	O
identified	O
in	O
all	O
10	O
patients.	O
The	O
mutations	O
were	O
identical	O
in	O
each	O
of	O
2	O
pairs	O
of	O
brothers.	O
Six	O
of	O
the	O
point	O
mutations	O
represented	O
missense	O
mutations,	O
1	O
was	O
a	O
nonsense	O
mutation,	O
and	O
1	O
was	O
a	O
frameshift	O
mutation.	O
Five	O
of	O
the	O
mutations	O
are	O
newly	O
reported	O
herein.	O
CONCLUSIONS	O
	O
The	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	DiseaseClass
abnormalities	DiseaseClass
and	O
clinical	O
manifestations	O
of	O
XLRS	SpecificDisease
.	O
However,	O
the	O
limited	O
data	O
failed	O
to	O
reveal	O
a	O
correlation	O
between	O
mutation	O
and	O
disease	O
phenotype.	O
CLINICAL	O
RELEVANCE	O
	O
Identification	O
of	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
and	O
expanded	O
information	O
on	O
clinical	O
manifestations	O
will	O
facilitate	O
early	O
diagnosis,	O
appropriate	O
early	O
therapy,	O
and	O
genetic	O
counseling	O
regarding	O
the	O
prognosis	O
of	O
XLRS	SpecificDisease

Relationship	O
among	O
genotype,	O
biochemical	O
phenotype,	O
and	O
cognitive	O
performance	O
in	O
females	O
with	O
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
deficiency	SpecificDisease
:	O
report	O
from	O
the	O
Maternal	Modifier
Phenylketonuria	Modifier
Collaborative	O
Study.	O
OBJECTIVE	O
	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(PAH)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	SpecificDisease
phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
).	O
METHODOLOGY	O
	O
PAH	O
gene	O
mutations	O
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	Modifier
females	O
enrolled	O
in	O
the	O
Maternal	Modifier
PKU	Modifier
Collaborative	O
Study	O
(MPKUCS).	O
A	O
total	O
of	O
84	O
different	O
mutations	O
were	O
detected,	O
and	O
complete	O
genotype	O
was	O
obtained	O
in	O
199	O
individuals.	O
Based	O
on	O
previous	O
knowledge	O
about	O
mutation-phenotype	O
associations,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(severe	O
PKU	SpecificDisease
,	O
moderate	O
PKU	SpecificDisease
,	O
mild	O
PKU	SpecificDisease
,	O
and	O
mild	SpecificDisease
hyperphenylalaninemia	SpecificDisease
[	O
MHP	SpecificDisease
]).	O
Then,	O
189	O
MPKUCS	O
subjects	O
were	O
grouped	O
according	O
to	O
the	O
various	O
combinations	O
of	O
mutation	O
classifications.	O
The	O
sample	O
sizes	O
were	O
large	O
enough	O
for	O
statistical	O
testing	O
in	O
four	O
groups	O
with	O
at	O
least	O
one	O
mutation	O
that	O
completely	O
abolishes	O
enzyme	O
activity.	O
These	O
patients	O
are	O
considered	O
functionally	O
hemizygous.	O
RESULTS	O
	O
The	O
biochemical	O
phenotype	O
predicted	O
from	O
the	O
genotype	O
in	O
functionally	O
hemizygous	O
patients	O
was	O
related	O
significantly	O
to	O
the	O
assigned	O
phenylalanine	O
level.	O
Cognitive	O
performance	O
(IQ)	O
was	O
also	O
significantly	O
related	O
to	O
genotype.	O
The	O
IQ	O
of	O
PAH-deficient	Modifier
mothers	O
with	O
a	O
severe	O
PKU	Modifier
mutation	O
in	O
combination	O
with	O
a	O
MHP	Modifier
mutation	O
or	O
a	O
mild	O
PKU	Modifier
mutation	O
was	O
99	O
and	O
96,	O
respectively,	O
whereas	O
the	O
IQ	O
of	O
PKU	Modifier
mothers	O
with	O
two	O
severe	O
PKU	Modifier
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
PKU	Modifier
mutation	O
was	O
83	O
and	O
84,	O
respectively.	O
Of	O
the	O
patients	O
with	O
PKU	SpecificDisease
,	O
92%	O
had	O
been	O
treated	O
during	O
childhood.	O
Those	O
who	O
were	O
untreated	O
or	O
treated	O
late	O
had	O
lower	O
than	O
average	O
IQ	O
scores	O
for	O
their	O
group	O
of	O
mutation	O
combinations.	O
Females	O
with	O
moderate	O
or	O
mild	O
PKU	SpecificDisease
who	O
were	O
treated	O
early	O
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
IQ	O
scores	O
10	O
points	O
above	O
average	O
for	O
their	O
group.	O
CONCLUSIONS	O
	O
The	O
reproductive	O
outcome	O
in	O
maternal	SpecificDisease
phenylketonuria	SpecificDisease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances.	O
Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	SpecificDisease
.	O
The	O
significant	O
relationship	O
among	O
genotype,	O
biochemical	O
phenotype,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	SpecificDisease

Uncoupling	O
of	O
hypomyelination	SpecificDisease
and	O
glial	SpecificDisease
cell	SpecificDisease
death	SpecificDisease
by	O
a	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
gene.	O
Proteolipid	O
protein	O
(PLP;	O
M	O
(r)	O
30,	O
000)	O
is	O
a	O
highly	O
conserved	O
major	O
polytopic	O
membrane	O
protein	O
in	O
myelin	O
but	O
its	O
cellular	O
function	O
remains	O
obscure.	O
Neurological	O
mutant	O
mice	O
can	O
often	O
provide	O
model	O
systems	O
for	O
human	O
genetic	DiseaseClass
disorders	DiseaseClass
.	O
Mutations	O
of	O
the	O
X-chromosome-linked	O
PLP	O
gene	O
are	O
lethal,	O
identified	O
first	O
in	O
the	O
jimpy	O
mouse	O
and	O
subsequently	O
in	O
patients	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
.	O
The	O
unexplained	O
phenotype	O
of	O
these	O
mutations	O
includes	O
degeneration	CompositeMention
and	CompositeMention
premature	CompositeMention
cell	CompositeMention
death	CompositeMention
of	CompositeMention
oligodendrocytes	CompositeMention
with	O
associated	O
hypomyelination	SpecificDisease
.	O
Here	O
we	O
show	O
that	O
a	O
new	O
mouse	O
mutant	O
rumpshaker	O
is	O
defined	O
by	O
the	O
amino-acid	O
substitution	O
Ile-to-Thr	O
at	O
residue	O
186	O
in	O
a	O
membrane-embedded	O
domain	O
of	O
PLP.	O
Surprisingly,	O
rumpshaker	O
mice,	O
although	O
myelin-deficient	SpecificDisease
,	O
have	O
normal	O
longevity	O
and	O
a	O
full	O
complement	O
of	O
morphologically	O
normal	O
oligodendrocytes.	O
Hypomyelination	SpecificDisease
can	O
thus	O
be	O
genetically	O
separated	O
from	O
the	O
PLP-dependent	O
oligodendrocyte	SpecificDisease
degeneration	SpecificDisease
.	O
We	O
suggest	O
that	O
PLP	O
has	O
a	O
vital	O
function	O
in	O
glial	O
cell	O
development,	O
distinct	O
from	O
its	O
later	O
role	O
in	O
myelin	O
assembly,	O
and	O
that	O
this	O
dichotomy	O
of	O
action	O
may	O
explain	O
the	O
clinical	O
spectrum	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	Modifier
patients.	O
Alkaptonuria	SpecificDisease
(	O
AKU	SpecificDisease
),	O
the	O
prototypic	O
inborn	DiseaseClass
error	DiseaseClass
of	DiseaseClass
metabolism	DiseaseClass
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate-1,	O
2-dioxygenase	O
gene	O
(HGO).	O
So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	Modifier
patients	O
of	O
different	O
ethnic	O
origin.	O
We	O
describe	O
three	O
novel	O
mutations	O
(R58fs,	O
R330S,	O
and	O
H371R)	O
and	O
one	O
common	O
AKU	Modifier
mutation	O
(M368V),	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
five	O
Finnish	O
AKU	Modifier
pedigrees.	O
The	O
three	O
novel	O
AKU	Modifier

Putative	O
X-linked	Modifier
adrenoleukodystrophy	Modifier
gene	O
shares	O
unexpected	O
homology	O
with	O
ABC	O
transporters.	O
Adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
disease	DiseaseClass
affecting	O
1/20,	O
000	O
males	O
either	O
as	O
cerebral	SpecificDisease
ALD	SpecificDisease
in	O
childhood	O
or	O
as	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
)	O
in	O
adults.	O
Childhood	O
ALD	SpecificDisease
is	O
the	O
more	O
severe	O
form,	O
with	O
onset	O
of	O
neurological	O
symptoms	O
between	O
5-12	O
years	O
of	O
age.	O
Central	DiseaseClass
nervous	DiseaseClass
system	DiseaseClass
demyelination	DiseaseClass
progresses	O
rapidly	O
and	O
death	O
occurs	O
within	O
a	O
few	O
years.	O
AMN	SpecificDisease
is	O
a	O
milder	O
form	O
of	O
the	O
disease	O
with	O
onset	O
at	O
15-30	O
years	O
of	O
age	O
and	O
a	O
more	O
progressive	O
course.	O
Adrenal	DiseaseClass
insufficiency	DiseaseClass
(	O
Addisons	SpecificDisease
disease	SpecificDisease
)	O
may	O
remain	O
the	O
only	O
clinical	O
manifestation	O
of	O
ALD	SpecificDisease
.	O
The	O
principal	O
biochemical	O
abnormality	O
of	O
ALD	SpecificDisease
is	O
the	O
accumulation	O
of	O
very-long-chain	O
fatty	O
acids	O
(VLCFA)	O
because	O
of	O
impaired	O
beta-oxidation	O
in	O
peroxisomes.	O
The	O
normal	O
oxidation	O
of	O
VLCFA-CoA	O
in	O
patients	O
fibroblasts	O
suggested	O
that	O
the	O
gene	O
coding	O
for	O
the	O
VLCFA-CoA	O
synthetase	O
could	O
be	O
a	O
candidate	O
gene	O
for	O
ALD	SpecificDisease
.	O
Here	O
we	O
use	O
positional	O
cloning	O
to	O
identify	O
a	O
gene	O
partially	O
deleted	O
in	O
6	O
of	O
85	O
independent	O
patients	O
with	O
ALD	SpecificDisease
.	O
In	O
familial	O
cases,	O
the	O
deletions	O
segregated	O
with	O
the	O
disease.	O
An	O
identical	O
deletion	O
was	O
detected	O
in	O
two	O
brothers	O
presenting	O
with	O
different	O
clinical	O
ALD	Modifier

Cardiac	O
Na(+)	O
channel	O
dysfunction	O
in	O
Brugada	SpecificDisease
syndrome	SpecificDisease
is	O
aggravated	O
by	O
beta(1)-subunit.	O
BACKGROUND	O
	O
Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	O
cardiac	O
Na	O
(+)	O
channel	O
alpha-subunit	O
(hH1)	O
are	O
responsible	O
for	O
chromosome	O
3-linked	O
congenital	SpecificDisease
long-QT	SpecificDisease
syndrome	SpecificDisease
(	O
LQT3	SpecificDisease
)	O
and	O
idiopathic	SpecificDisease
ventricular	SpecificDisease
fibrillation	SpecificDisease
(	O
IVF	SpecificDisease
).	O
An	O
auxiliary	O
beta	O
(1)	O
-subunit,	O
widely	O
expressed	O
in	O
excitable	O
tissues,	O
shifts	O
the	O
voltage	O
dependence	O
of	O
steady-state	O
inactivation	O
toward	O
more	O
negative	O
potentials	O
and	O
restores	O
normal	O
gating	O
kinetics	O
of	O
brain	O
and	O
skeletal	O
muscle	O
Na	O
(+)	O
channels	O
expressed	O
in	O
Xenopus	O
oocytes	O
but	O
has	O
little	O
if	O
any	O
functional	O
effect	O
on	O
the	O
cardiac	O
isoform.	O
Here,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(1)	O
-subunit	O
(hbeta	O
(1))	O
on	O
the	O
heterologously	O
expressed	O
hH1	O
mutation	O
(T1620M)	O
previously	O
associated	O
with	O
IVF	SpecificDisease
.	O
METHODS	O
AND	O
RESULTS	O
	O
When	O
expressed	O
alone	O
in	O
Xenopus	O
oocytes,	O
T1620M	O
exhibited	O
no	O
persistent	O
currents,	O
in	O
contrast	O
to	O
the	O
LQT3	Modifier
mutant	O
channels,	O
but	O
the	O
midpoint	O
of	O
steady-state	O
inactivation	O
(V	O
(1/2))	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild-type	O
hH1.	O
Coexpression	O
of	O
hbeta	O
(1)	O
did	O
not	O
significantly	O
alter	O
current	O
decay	O
or	O
recovery	O
from	O
inactivation	O
of	O
wild-type	O
hH1;	O
however,	O
it	O
further	O
shifted	O
the	O
V	O
(1/2)	O
and	O
accelerated	O
the	O
recovery	O
from	O
inactivation	O
of	O
T1620M.	O
Oocyte	O
macropatch	O
analysis	O
revealed	O
that	O
the	O
activation	O
kinetics	O
of	O
T1620M	O
were	O
normal.	O
CONCLUSIONS	O
	O
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(1)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(window	O
current)	O
in	O
T1620M,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
IVF	SpecificDisease

Autosomal	SpecificDisease
recessive	SpecificDisease
familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin.	O
Familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
post-natal	O
development	O
of	O
arginine	SpecificDisease
vasopressin	SpecificDisease
(AVP)	SpecificDisease
deficiency	SpecificDisease
due	O
to	O
mutations	O
in	O
the	O
AVP	O
gene.	O
All	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin-II	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone,	O
leading	O
to	O
neuronal	DiseaseClass
damage	DiseaseClass
.	O
We	O
studied	O
an	O
unusual	O
Palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
,	O
suggesting	O
autosomal	O
recessive	O
inheritance.	O
All	O
three	O
affected	O
children	O
were	O
homozygous	O
and	O
the	O
parents	O
heterozygous	O
for	O
a	O
single	O
novel	O
mutation	O
(C301-	O
>	O
T)	O
in	O
exon	O
1,	O
replacing	O
Pro7	O
of	O
mature	O
AVP	O
with	O
Leu	O
(Leu-AVP).	O
Leu-AVP	O
was	O
a	O
weak	O
agonist	O
with	O
approximately	O
30-fold	O
reduced	O
binding	O
to	O
the	O
human	O
V2	O
receptor.	O
Measured	O
by	O
radioimmunoassay	O
with	O
a	O
synthetic	O
Leu-AVP	O
standard,	O
serum	O
Leu-AVP	O
levels	O
were	O
elevated	O
in	O
all	O
three	O
children	O
and	O
further	O
increased	O
during	O
water	O
deprivation	O
to	O
as	O
high	O
as	O
30	O
times	O
normal.	O
The	O
youngest	O
child	O
(2	O
years	O
old)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
Leu-AVP	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8-year-old	O
brother,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	DiseaseClass
of	DiseaseClass
active	DiseaseClass
AVP	DiseaseClass

Autosomal	O
dominant	O
aniridia	SpecificDisease
linked	O
to	O
the	O
chromosome	O
11p13	O
markers	O
catalase	O
and	O
D11S151	O
in	O
a	O
large	O
Dutch	O
family.	O
In	O
a	O
large	O
pedigree	O
with	O
autosomal	O
dominant	O
aniridia	SpecificDisease
,	O
we	O
found	O
close	O
linkage	O
between	O
the	O
aniridia	Modifier
locus	O
AN2	O
and	O
the	O
markers	O
catalase	O
(CAT)	O
(zeta	O
=	O
7.	O
27	O
at	O
theta	O
=	O
0.	O
00)	O
and	O
D11S151	O
(zeta	O
=	O
3.	O
86	O
at	O
theta	O
=	O
0.	O
10)	O
flanking	O
the	O
AN2	O
locus	O
on	O
11p13.	O
Positive	O
lod	O
scores	O
were	O
also	O
obtained	O
for	O
the	O
11p13----11p14	O
markers	O
D11S16	O
and	O
FSHB	O
with	O
the	O
linkage	O
group	O
CAT/AN2/D11S151.	O
We	O
conclude	O
that	O
the	O
autosomal	O
dominant	O
aniridia	SpecificDisease
in	O
this	O
family	O
is	O
due	O
to	O
a	O
mutation	O
at	O
the	O
AN2	O
locus	O
on	O
11p13.	O
We	O
have	O
excluded	O
linkage	O
(zeta	O
less	O
than	O
-2	O
at	O
theta	O
less	O
than	O
0.	O
18)	O
between	O
the	O
aniridia	SpecificDisease

Knobloch	SpecificDisease
syndrome	SpecificDisease
involving	O
midline	DiseaseClass
scalp	DiseaseClass
defect	DiseaseClass
of	DiseaseClass
the	DiseaseClass
frontal	DiseaseClass
region	DiseaseClass
.	O
We	O
report	O
on	O
a	O
4-year-old	O
boy	O
with	O
Knobloch	SpecificDisease
syndrome	SpecificDisease
.	O
He	O
has	O
vitreoretinal	SpecificDisease
degeneration	SpecificDisease
,	O
high	SpecificDisease
myopia	SpecificDisease
,	O
cataract	SpecificDisease
,	O
telecanthus	SpecificDisease
,	O
hypertelorism	SpecificDisease
,	O
and	O
a	O
high-arched	SpecificDisease
palate	SpecificDisease
.	O
He	O
also	O
has	O
a	O
defect	DiseaseClass
of	DiseaseClass
the	DiseaseClass
anterior	DiseaseClass
midline	DiseaseClass
scalp	DiseaseClass
with	O
involvement	O
of	O
the	O
frontal	O
bone	O
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(CT)	O
scan.	O
The	O
brain	O
was	O
normal	O
on	O
CT	O
scan	O
and	O
magnetic	O
resonance	O
imaging.	O
We	O
present	O
a	O
review	O
of	O
the	O
23	O
published	O
cases	O
with	O
this	O
syndrome.	O
Our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	DiseaseClass
scalp	DiseaseClass
defects	DiseaseClass

Pendred	SpecificDisease
syndrome	SpecificDisease
:	O
phenotypic	O
variability	O
in	O
two	O
families	O
carrying	O
the	O
same	O
PDS	Modifier
missense	O
mutation.	O
Pendred	SpecificDisease
syndrome	SpecificDisease
comprises	O
congenital	SpecificDisease
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
,	O
thyroid	SpecificDisease
goiter	SpecificDisease
,	O
and	O
positive	O
perchlorate	O
discharge	O
test.	O
Recently,	O
this	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
was	O
shown	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
PDS	Modifier
gene,	O
which	O
encodes	O
an	O
anion	O
transporter	O
called	O
pendrin.	O
Molecular	O
analysis	O
of	O
the	O
PDS	Modifier
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
Southern	O
Tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	SpecificDisease
deafness	SpecificDisease
;	O
the	O
same	O
missense	O
mutation,	O
L445W,	O
was	O
identified	O
in	O
all	O
affected	O
individuals.	O
A	O
widened	SpecificDisease
vestibular	SpecificDisease
aqueduct	SpecificDisease
was	O
found	O
in	O
all	O
patients	O
who	O
underwent	O
computed	O
tomography	O
(CT)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear.	O
In	O
contrast,	O
goiter	SpecificDisease
was	O
present	O
in	O
only	O
11	O
affected	O
individuals,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed.	O
The	O
present	O
results	O
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	O
for	O
the	O
diagnosis	O
of	O
Pendred	SpecificDisease
syndrome	SpecificDisease
and	O
support	O
the	O
use	O
of	O
a	O
molecular	O
analysis	O
of	O
the	O
PDS	Modifier
gene	O
in	O
the	O
assessment	O
of	O
individuals	O
with	O
severe	O
to	O
profound	O
congenital	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
associated	O
with	O
inner	SpecificDisease
ear	SpecificDisease
morphological	SpecificDisease
anomaly	SpecificDisease
even	O
in	O
the	O
absence	O
of	O
a	O
thyroid	SpecificDisease
goiter	SpecificDisease

The	O
type	O
of	O
somatic	O
mutation	O
at	O
APC	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation:	O
a	O
new	O
facet	O
to	O
Knudson's	O
'two-hit'	O
hypothesis.	O
APC	O
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	Modifier
suppressor	O
gene.	O
Truncating	O
germline	O
and	O
somatic	O
mutations	O
(or,	O
infrequently,	O
allelic	O
loss)	O
occur	O
in	O
tumors	DiseaseClass
in	O
FAP	SpecificDisease
(	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
).	O
Most	O
sporadic	SpecificDisease
colorectal	SpecificDisease
cancers	SpecificDisease
also	O
have	O
two	O
APC	Modifier
mutations.	O
Clues	O
from	O
attenuated	Modifier
polyposis	Modifier
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(codons	O
1,	O
250-1,	O
450)	O
indicate,	O
however,	O
that	O
APC	Modifier
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function.	O
We	O
have	O
found	O
that	O
FAP	Modifier
patients	O
with	O
germline	O
APC	Modifier
mutations	O
within	O
a	O
small	O
region	O
(codons	O
1,	O
194-1,	O
392	O
at	O
most)	O
mainly	O
show	O
allelic	O
loss	O
in	O
their	O
colorectal	SpecificDisease
adenomas	SpecificDisease
,	O
in	O
contrast	O
to	O
other	O
FAP	Modifier
patients,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	O
by	O
truncating	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region.	O
Our	O
results	O
indicate	O
that	O
different	O
APC	Modifier
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages,	O
with	O
mutations	O
close	O
to	O
codon	O
1,	O
300	O
providing	O
the	O
greatest	O
advantage.	O
Allelic	O
loss	O
is	O
selected	O
strongly	O
in	O
cells	O
with	O
one	O
mutation	O
near	O
codon	O
1,	O
300.	O
A	O
different	O
germline-somatic	O
APC	Modifier
mutation	O
association	O
exists	O
in	O
FAP	SpecificDisease
desmoids	SpecificDisease
.	O
APC	O
is	O
not,	O
therefore,	O
a	O
classical	O
tumor	Modifier
suppressor.	O
Our	O
findings	O
also	O
indicate	O
a	O
new	O
mechanism	O
for	O
disease	O
severity	O
	O
if	O
a	O
broader	O
spectrum	O
of	O
mutations	O
is	O
selected	O
in	O
tumors	DiseaseClass
,	O
the	O
somatic	O
mutation	O
rate	O
is	O
effectively	O
higher	O
and	O
more	O
tumors	DiseaseClass

Purification	O
of	O
human	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
and	O
characterization	O
of	O
its	O
deficiency	O
in	O
seven	O
patients.	O
Mitochondrial	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
(VLCAD)	O
was	O
purified	O
from	O
human	O
liver.	O
The	O
molecular	O
masses	O
of	O
the	O
native	O
enzyme	O
and	O
the	O
subunit	O
were	O
estimated	O
to	O
be	O
154	O
and	O
70	O
kD,	O
respectively.	O
The	O
enzyme	O
was	O
found	O
to	O
catalyze	O
the	O
major	O
part	O
of	O
mitochondrial	O
palmitoylcoenzyme	O
A	O
dehydrogenation	O
in	O
liver,	O
heart,	O
skeletal	O
muscle,	O
and	O
skin	O
fibroblasts	O
(89-97,	O
86-99,	O
96-99,	O
and	O
78-87%,	O
respectively).	O
Skin	O
fibroblasts	O
from	O
26	O
patients	O
suspected	O
of	O
having	O
a	O
disorder	O
of	O
mitochondrial	O
beta-oxidation	O
were	O
analyzed	O
for	O
VLCAD	O
protein	O
using	O
immunoblotting,	O
and	O
7	O
of	O
them	O
contained	O
undetectable	O
or	O
trace	O
levels	O
of	O
the	O
enzyme.	O
The	O
seven	O
deficient	O
fibroblast	O
lines	O
were	O
characterized	O
by	O
measuring	O
acyl-coenzyme	O
A	O
dehydrogenation	O
activities,	O
overall	O
palmitic	O
acid	O
oxidation,	O
and	O
VLCAD	O
protein	O
synthesis	O
using	O
pulse-chase,	O
further	O
confirming	O
the	O
diagnosis	O
of	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
.	O
These	O
results	O
suggested	O
the	O
heterogenous	O
nature	O
of	O
the	O
mutations	O
causing	O
the	O
deficiency	O
in	O
the	O
seven	O
patients.	O
Clinically,	O
all	O
patients	O
with	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
exhibited	O
cardiac	DiseaseClass
disease	DiseaseClass
.	O
At	O
least	O
four	O
of	O
them	O
presented	O
with	O
hypertrophic	SpecificDisease
cardiomyopathy	SpecificDisease
.	O
This	O
frequency	O
(>	O
57%)	O
was	O
much	O
higher	O
than	O
that	O
observed	O
in	O
patients	O
with	O
other	O
disorders	O
of	O
mitochondrial	O
long-chain	O
fatty	O
acid	O
oxidation	O
that	O
may	O
be	O
accompanied	O
by	O
cardiac	DiseaseClass
disease	DiseaseClass

A	O
germ	O
line	O
mutation	O
within	O
the	O
coding	O
sequence	O
for	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
binding	O
site	O
of	O
hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT)	O
in	O
a	O
Lesch-Nyhan	Modifier
patient:	O
missense	O
mutations	O
within	O
a	O
functionally	O
important	O
region	O
probably	O
cause	O
disease.	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
caused	O
by	O
a	O
complete	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
hypoxanthine	SpecificDisease
guanine	SpecificDisease
phosphoribosyltransferase	SpecificDisease
(HPRT)	O
is	O
the	O
result	O
of	O
a	O
heterogeneous	O
group	O
of	O
germ	O
line	O
mutations.	O
Identification	O
of	O
each	O
mutant	O
gene	O
provides	O
valuable	O
information	O
as	O
to	O
the	O
type	O
of	O
mutation	O
that	O
occurs	O
spontaneously.	O
We	O
report	O
here	O
a	O
newly	O
identified	O
HPRT	O
mutation	O
in	O
a	O
Japanese	O
patient	O
with	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
This	O
gene,	O
designated	O
HPRT	O
Tokyo,	O
had	O
a	O
single	O
nucleotide	O
change	O
from	O
G	O
to	O
A,	O
as	O
identified	O
by	O
sequencing	O
cDNA	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction.	O
Allele	O
specific	O
oligonucleotide	O
hybridization	O
analysis	O
using	O
amplified	O
genomic	O
DNA	O
showed	O
that	O
the	O
mutant	O
gene	O
was	O
transmitted	O
from	O
the	O
maternal	O
germ	O
line.	O
This	O
mutation	O
would	O
lead	O
to	O
an	O
amino	O
acid	O
substitution	O
of	O
Asp	O
for	O
Gly	O
at	O
the	O
amino	O
acid	O
position	O
140	O
located	O
within	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
(PRPP)	O
binding	O
region.	O
Missense	O
mutations	O
in	O
human	O
HPRT	Modifier
deficient	Modifier

In	O
vitro	O
and	O
in	O
vivo	O
correlations	O
for	O
I65T	O
and	O
M1V	O
mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
locus.	O
Mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
(PAH)	O
locus	O
are	O
the	O
major	O
cause	O
of	O
hyperphenylalaninemia	DiseaseClass
.	O
We	O
have	O
previously	O
described	O
four	O
mutations	O
(M1V,	O
IVS12nt1,	O
R408W,	O
and	O
S349P)	O
at	O
the	O
PAH	O
locus	O
in	O
French	O
Canadians	O
with	O
ancestry	O
in	O
eastern	O
Quebec.	O
Here	O
we	O
report	O
(1)	O
identification	O
of	O
another	O
mutation,	O
on	O
a	O
haplotype	O
9	O
chromosome,	O
which	O
converts	O
codon	O
65	O
from	O
isoleucine	O
(ATT)	O
to	O
threonine	O
(ACT),	O
(2)	O
expression	O
analysis	O
of	O
the	O
I65T	O
mutation	O
in	O
COS	O
cells	O
demonstrating	O
75%	O
loss	O
of	O
both	O
immunoreactive	O
protein	O
and	O
enzyme	O
activity,	O
and	O
(3)	O
expression	O
analysis	O
of	O
the	O
most	O
prevalent	O
PKU	Modifier
allele	O
(M1V)	O
in	O
eastern	O
Quebec,	O
showing	O
nondetectable	O
levels	O
of	O
PAH	O
protein	O
and	O
activity,	O
a	O
finding	O
compatible	O
with	O
a	O
mutation	O
in	O
the	O
translation	O
initiation	O
codon.	O
Homozygosity	O
for	O
M1V	O
and	O
codominant	O
inheritance	O
of	O
I65T/R408W	O
were	O
both	O
associated	O
with	O
classical	SpecificDisease
phenylketonuria	SpecificDisease

Experimental	O
hemochromatosis	SpecificDisease
due	O
to	O
MHC	O
class	O
I	O
HFE	SpecificDisease
deficiency	SpecificDisease
:	O
immune	O
status	O
and	O
iron	O
metabolism.	O
The	O
puzzling	O
linkage	O
between	O
genetic	O
hemochromatosis	SpecificDisease
and	O
histocompatibility	O
loci	O
became	O
even	O
more	O
so	O
when	O
the	O
gene	O
involved,	O
HFE,	O
was	O
identified.	O
Indeed,	O
within	O
the	O
well	O
defined,	O
mainly	O
peptide-binding,	O
MHC	O
class	O
I	O
family	O
of	O
molecules,	O
HFE	O
seems	O
to	O
perform	O
an	O
unusual	O
yet	O
essential	O
function.	O
As	O
yet,	O
our	O
understanding	O
of	O
HFE	O
function	O
in	O
iron	O
homeostasis	O
is	O
only	O
partial;	O
an	O
even	O
more	O
open	O
question	O
is	O
its	O
possible	O
role	O
in	O
the	O
immune	O
system.	O
To	O
advance	O
on	O
both	O
of	O
these	O
avenues,	O
we	O
report	O
the	O
deletion	O
of	O
HFE	O
alpha1	O
and	O
alpha2	O
putative	O
ligand	O
binding	O
domains	O
in	O
vivo.	O
HFE-deficient	Modifier
animals	O
were	O
analyzed	O
for	O
a	O
comprehensive	O
set	O
of	O
metabolic	O
and	O
immune	O
parameters.	O
Faithfully	O
mimicking	O
human	O
hemochromatosis	SpecificDisease

[Genetic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
:	O
mutant	O
alleles	O
of	O
G6PD	O
in	O
the	O
Shekii	O
district	O
of	O
Azerbaijan]	O
Examination	O
on	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
349	O
patients	O
of	O
Shekii	O
district	O
hospital	O
(Azerbaijan)	O
revealed	O
16	O
hemi-,	O
4	O
homo-	O
and	O
9	O
heterozygotic	O
carriers	O
of	O
the	O
defect.	O
Gd-	O
frequency,	O
calculated	O
from	O
the	O
data	O
obtained	O
(7.	O
7%),	O
may	O
be	O
compared	O
to	O
neighbouring	O
regions	O
frequencies	O
(6-30%).	O
Carriers	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
are	O
residents	O
of	O
11	O
villages	O
located	O
in	O
Alasani-Aphtalan	O
valley,	O
highly	O
endemic	O
with	O
malaria	SpecificDisease

[Gd-	O
allele	O
distribution	O
patterns	O
in	O
Azerbaijan.	O
III.	O
The	O
identification	O
of	O
mutant	O
forms	O
of	O
glucose-6-phosphate	O
dehydrogenase]	O
In	O
28	O
families	O
with	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Determination	O
of	O
carrier	O
status	O
for	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
by	O
flow	O
cytometric	O
analysis	O
of	O
Wiskott-Aldrich	Modifier
syndrome	Modifier
protein	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells.	O
The	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
is	O
caused	O
by	O
defects	O
in	O
the	O
WAS	Modifier
protein	O
(WASP)	O
gene	O
on	O
the	O
X	O
chromosome.	O
Previous	O
study	O
disclosed	O
that	O
flow	O
cytometric	O
analysis	O
of	O
intracellular	O
WASP	O
expression	O
(FCM-WASP	O
analysis)	O
in	O
lymphocytes	O
was	O
useful	O
for	O
the	O
diagnosis	O
of	O
WAS	Modifier
patients.	O
Lymphocytes	O
from	O
all	O
WAS	Modifier
patients	O
showed	O
WASPdim	O
instead	O
of	O
WASPbright.	O
Here	O
we	O
report	O
that	O
FCM-WASP	O
analysis	O
in	O
monocytes	O
could	O
be	O
a	O
useful	O
tool	O
for	O
the	O
WAS	Modifier
carrier	O
diagnosis.	O
Monocytes	O
from	O
all	O
nine	O
WAS	Modifier
carriers	O
showed	O
varied	O
population	O
of	O
WASPdim	O
together	O
with	O
WASPbright.	O
None	O
of	O
control	O
individuals	O
possessed	O
the	O
WASPdim	O
population.	O
In	O
contrast,	O
lymphocytes	O
from	O
all	O
the	O
carriers	O
except	O
two	O
lacked	O
the	O
WASPdim	O
population.	O
The	O
difference	O
of	O
the	O
WASPdim	O
population	O
in	O
monocytes	O
and	O
lymphocytes	O
observed	O
in	O
WAS	Modifier
carriers	O
suggests	O
that	O
WASP	O
plays	O
a	O
more	O
critical	O
role	O
in	O
the	O
development	O
of	O
lymphocytes	O
than	O
in	O
that	O
of	O
monocytes.	O
The	O
present	O
studies	O
suggest	O
that	O
a	O
skewed	O
X-chromosomal	O
inactivation	O
pattern	O
observed	O
in	O
WAS	Modifier

Linkage	O
of	O
DNA	O
markers	O
at	O
Xq28	O
to	O
adrenoleukodystrophy	SpecificDisease
and	O
adrenomyeloneuropathy	SpecificDisease
present	O
within	O
the	O
same	O
family.	O
We	O
present	O
a	O
large	O
kindred	O
that	O
contained	O
patients	O
with	O
either	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
or	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
).	O
The	O
pedigree	O
clearly	O
supported	O
the	O
X-linked	O
mode	O
of	O
inheritance	O
of	O
the	O
nonneonatal	O
form	O
of	O
ALD	SpecificDisease
/	O
AMN	SpecificDisease
.	O
Analysis	O
with	O
DNA	O
markers	O
at	O
Xq28	O
suggested	O
segregation	O
of	O
both	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
with	O
an	O
identical	O
haplotype.	O
This	O
indicated	O
that	O
nonneonatal	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
same	O
gene	O
at	O
Xq28.	O
It	O
showed,	O
furthermore,	O
that	O
phenotypic	O
differences	O
between	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
are	O
not	O
necessarily	O
the	O
consequence	O
of	O
allelic	O
heterogeneity	O
due	O
to	O
different	O
mutations	O
within	O
the	O
same	O
gene.	O
The	O
maximal	O
lod	O
score	O
for	O
linkage	O
of	O
the	O
ALD	Modifier
/	O
AMN	Modifier

Further	O
investigation	O
of	O
the	O
HEXA	O
gene	O
intron	O
9	O
donor	O
splice	O
site	O
mutation	O
frequently	O
found	O
in	O
non-Jewish	O
Tay-Sachs	Modifier
disease	Modifier
patients	O
from	O
the	O
British	O
Isles.	O
In	O
a	O
previous	O
study	O
we	O
found	O
that	O
a	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
causing	O
mutation	O
in	O
the	O
intron	O
9	O
donor	O
splice	O
site	O
of	O
the	O
HEXA	O
gene	O
occurs	O
at	O
high	O
frequency	O
in	O
non-Jewish	O
patients	O
and	O
carriers	O
from	O
the	O
British	O
Isles.	O
It	O
was	O
found	O
more	O
frequently	O
in	O
subjects	O
of	O
Irish,	O
Scottish,	O
and	O
Welsh	O
origin	O
compared	O
with	O
English	O
origin	O
(63%	O
and	O
31%	O
respectively).	O
We	O
have	O
now	O
tested,	O
in	O
a	O
blind	O
study,	O
26	O
American	O
TSD	Modifier
carriers	O
and	O
28	O
non-carriers	O
who	O
have	O
British	O
ancestry	O
for	O
the	O
intron	O
9	O
splice	O
site	O
mutation.	O
Six	O
of	O
the	O
carriers	O
and	O
none	O
of	O
the	O
controls	O
were	O
positive	O
for	O
the	O
mutation.	O
All	O
six	O
had	O
Irish	O
ancestry,	O
compared	O
with	O
nine	O
of	O
the	O
20	O
other	O
(intron	O
9	O
mutation	O
negative)	O
TSD	Modifier
carriers	O
(p	O
<	O
0.	O
05).	O
These	O
results	O
confirm	O
the	O
previously	O
found	O
high	O
frequency	O
of	O
the	O
intron	O
9	O
mutation	O
in	O
non-Jewish	O
TSD	Modifier

The	O
murine	O
homologues	O
of	O
the	O
Huntington	Modifier
disease	Modifier
gene	O
(Hdh)	O
and	O
the	O
alpha-adducin	O
gene	O
(Add1)	O
map	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16.3.	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
is	O
a	O
severe	O
autosomal	DiseaseClass
dominant	DiseaseClass
neurodegenerative	DiseaseClass
disorder	DiseaseClass

Linkage	O
analysis	O
of	O
the	O
apolipoprotein	O
C2	O
gene	O
and	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
on	O
human	O
chromosome	O
19	O
reveals	O
linkage	O
disequilibrium	O
in	O
a	O
French-Canadian	O
population.	O
The	O
gene	O
for	O
human	O
apolipoprotein	O
C2	O
(APOC2),	O
situated	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
19,	O
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	DiseaseClass
dystrophy	DiseaseClass
,	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
).	O
Six	O
APOC2	O
RFLPs	O
(TaqI,	O
BglI,	O
BanI,	O
BamHI,	O
NcoI,	O
and	O
AvaII)	O
have	O
been	O
identified	O
to	O
date.	O
We	O
have	O
conducted	O
a	O
comprehensive	O
DM	Modifier
linkage	O
study	O
utilizing	O
all	O
six	O
RFLPs	O
and	O
involving	O
50	O
families	O
and	O
372	O
individuals.	O
The	O
most	O
informative	O
RFLPs	O
are,	O
in	O
descending	O
order,	O
NcoI	O
(lod	O
=	O
6.	O
64,	O
theta	O
=	O
0.	O
05),	O
BglI	O
(lod	O
=	O
6.	O
12,	O
theta	O
=	O
0.	O
05),	O
AvaII	O
(lod	O
=	O
6.	O
02,	O
theta	O
=	O
0.	O
03),	O
BanI	O
(lod	O
=	O
5.	O
76,	O
theta	O
=	O
0.	O
04),	O
TaqI	O
(lod	O
=	O
4.	O
29,	O
theta	O
=	O
0.	O
06),	O
and	O
BamHI	O
(lod	O
=	O
1.	O
75,	O
theta	O
=	O
0.	O
01).	O
A	O
substantial	O
increase	O
in	O
the	O
lod	O
scores	O
over	O
those	O
seen	O
with	O
the	O
individual	O
RFLPs	O
was	O
obtained	O
when	O
the	O
linkage	O
of	O
the	O
entire	O
APOC2	O
haplotype	O
(composed	O
of	O
the	O
six	O
RFLPs)	O
was	O
studied	O
(lod	O
=	O
17.	O
87,	O
theta	O
=	O
0.	O
04).	O
We	O
have	O
observed	O
significant	O
inter-APOC2	O
RFLP	O
linkage	O
disequilibrium.	O
Consequently,	O
the	O
three	O
most	O
informative	O
RFLPs	O
have	O
been	O
found	O
to	O
be	O
BanI,	O
TaqI,	O
and	O
either	O
BglI,	O
AvaII,	O
or	O
NcoI	O
polymorphisms.	O
We	O
also	O
demonstrate	O
linkage	O
disequilibrium	O
between	O
DM	O
and	O
APOC2	O
in	O
our	O
French-Canadian	O
population	O
(standardized	O
disequilibrium	O
constant	O
phi	O
=.	O
22,	O
chi	O
2	O
=	O
5.	O
12,	O
df	O
=	O
1,	O
P	O
less	O
than	O
0.	O
04).	O
This	O
represents	O
the	O
first	O
evidence	O
of	O
linkage	O
disequilibrium	O
between	O
APOC2	O
and	O
the	O
DM	Modifier

A	O
retrospective	O
anonymous	O
pilot	O
study	O
in	O
screening	O
newborns	O
for	O
HFE	O
mutations	O
in	O
Scandinavian	O
populations.	O
We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(DBS)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	SpecificDisease

Hereditary	O
TP53	O
codon	O
292	O
and	O
somatic	O
P16INK4A	O
codon	O
94	O
mutations	O
in	O
a	O
Li-Fraumeni	Modifier
syndrome	Modifier
family.	O
Li-Fraumeni	SpecificDisease
syndrome	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorder	DiseaseClass
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	DiseaseClass
in	O
childhood	O
and	O
adult	O
cases.	O
Although	O
hereditary	O
TP53	O
mutation	O
is	O
very	O
rare	O
in	O
different	O
human	O
cancers	DiseaseClass
,	O
it	O
has	O
been	O
frequently	O
reported	O
in	O
Li-Fraumeni	SpecificDisease
syndrome	SpecificDisease
.	O
On	O
the	O
other	O
hand,	O
hereditary	O
mutations	O
of	O
TP57KIP2,	O
P15INK4B,	O
and	O
P16INK4A,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
TP53,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	DiseaseClass
.	O
In	O
a	O
Turkish	O
family	O
with	O
the	O
diagnosis	O
of	O
Li-Fraumeni	SpecificDisease
syndrome	SpecificDisease
,	O
we	O
analyzed	O
the	O
mutation	O
pattern	O
of	O
TP53,	O
P57KIP2,	O
P15INK4B,	O
and	O
P16INK4A	O
in	O
the	O
peripheral	O
blood,	O
and	O
loss	O
of	O
heterozygosity	O
(homo/hemizygous	O
deletion)	O
pattern	O
of	O
TP53	O
and	O
P15INK4B/P16INK4A	O
in	O
two	O
tumor	Modifier
tissues.	O
The	O
propositus	O
had	O
a	O
seminoma	SpecificDisease
,	O
his	O
daughter	O
a	O
medulloblastoma	SpecificDisease
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins,	O
a	O
TP53	O
codon	O
292	O
missense	O
point	O
mutation	O
(AAA--	O
>	O
ATA;	O
Lys--	O
>	O
Ile)	O
in	O
the	O
peripheral	O
blood	O
cells.	O
Tumor	O
tissue	O
obtained	O
from	O
the	O
propositus	O
with	O
the	O
seminoma	SpecificDisease
revealed	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene.	O
In	O
the	O
analyses	O
of	O
tumor	Modifier
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter,	O
a	O
P16INK4A	O
codon	O
94	O
missense	O
point	O
mutation	O
(GCG--	O
>	O
GAG;	O
Ala--	O
>	O
Glu)	O
was	O
observed	O
with	O
the	O
hereditary	O
TP53	O
mutation.	O
P16INK4A	O
codon	O
94	O
mutation	O
observed	O
in	O
our	O
family	O
is	O
a	O
novel	O
mutation	O
in	O
Li-Fraumeni	SpecificDisease
syndrome	SpecificDisease
.	O
No	O
other	O
gene	O
alteration	O
in	O
TP53,	O
P57KIP2,	O
P15INK4B,	O
and	O
P16INK4A	O
was	O
observed.	O
Existence	O
of	O
the	O
P16INK4A	O
mutation	O
and	O
the	O
hereditary	O
TP53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
(	O
seminoma	SpecificDisease
/	O
medulloblastoma	SpecificDisease
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	DiseaseClass
.	O
The	O
gene	O
alterations	O
in	O
TP53	O
and	O
P16INK4A	O
genes	O
may	O
be	O
used	O
as	O
tumor	Modifier

An	O
amino-acid	O
substitution	O
involved	O
in	O
phenylketonuria	SpecificDisease
is	O
in	O
linkage	O
disequilibrium	O
with	O
DNA	O
haplotype	O
2.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
human	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
hepatic	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH,	O
phenylalanine	O
4-monooxygenase,	O
EC	O
1.	O
14.	O
16.	O
1).	O
PKU	SpecificDisease
is	O
a	O
common	O
inborn	DiseaseClass
error	DiseaseClass
of	DiseaseClass
amino-acid	DiseaseClass
metabolism	DiseaseClass
in	O
caucasian	O
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	O
are	O
carriers	O
of	O
a	O
PKU	Modifier
allele.	O
To	O
define	O
the	O
molecular	O
basis	O
of	O
PKU	SpecificDisease
,	O
we	O
characterized	O
twelve	O
restriction	O
fragment-length	O
polymorphism	O
(RFLP)	O
haplotypes	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
northern	O
European	O
population	O
and	O
observed	O
that	O
90%	O
of	O
the	O
PKU	Modifier
alleles	O
in	O
this	O
population	O
are	O
confined	O
to	O
four	O
common	O
RFLP	O
haplotypes.	O
We	O
have	O
recently	O
reported	O
a	O
splicing	O
mutation	O
in	O
the	O
PAH	O
gene	O
that	O
is	O
associated	O
with	O
RFLP	O
haplotype	O
3	O
which	O
is	O
present	O
at	O
about	O
40%	O
of	O
mutant	O
alleles.	O
We	O
now	O
report	O
the	O
molecular	DiseaseClass
lesion	DiseaseClass

The	O
effects	O
of	O
dystrophin	O
gene	O
mutations	O
on	O
the	O
ERG	O
in	O
mice	O
and	O
humans.	O
PURPOSE.	O
The	O
authors	O
earlier	O
findings	O
of	O
a	O
negative	O
electroretinogram	O
(ERG)	O
in	O
a	O
boy	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
led	O
them	O
to	O
investigate	O
dystrophin	O
gene	O
deletions	O
and	O
ERGs	O
in	O
five	O
boys	O
with	O
DMD	SpecificDisease
.	O
The	O
authors	O
wanted	O
to	O
determined	O
whether	O
there	O
were	O
similar	O
ERG	O
findings	O
in	O
an	O
animal	O
model	O
for	O
DMD	SpecificDisease
,	O
the	O
mdx	O
mouse.	O
METHODS.	O
Ganzfeld	O
ERGs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
DMD	SpecificDisease
after	O
a	O
complete	O
ophthalmic	O
examination.	O
The	O
dystrophin	O
gene	O
was	O
analyzed	O
by	O
Southern	O
blot	O
hybridization.	O
ERGs	O
were	O
recorded	O
in	O
anesthetized	O
mdx	O
and	O
control	O
mice	O
with	O
a	O
modified	O
Grass	O
photostimulator	O
(Grass	O
Instrument	O
Company,	O
Quincy,	O
MA).	O
RESULTS.	O
Ophthalmic	O
examinations	O
in	O
all	O
five	O
boys	O
had	O
normal	O
findings,	O
yet	O
an	O
abnormal	O
negative	O
ERG	O
was	O
recorded	O
for	O
each	O
subject.	O
The	O
subjects	O
gene	O
deletions	O
were	O
variable,	O
ranging	O
from	O
large	O
deletions	O
to	O
no	O
detectable	O
deletions.	O
The	O
ERGs	O
of	O
the	O
mdx	O
mice	O
were	O
normal	O
and	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
the	O
control	O
mice.	O
CONCLUSIONS.	O
The	O
authors	O
believe	O
the	O
unique	O
ERG	O
recorded	O
for	O
the	O
human	O
subjects	O
is	O
a	O
manifestation	O
of	O
DMD	SpecificDisease
associated	O
with	O
defects	O
at	O
the	O
dystrophin	O
gene	O
locus	O
and	O
represents	O
a	O
new	O
clinical	O
entity.	O
The	O
ERG	O
of	O
the	O
mdx	O
mouse	O
may	O
be	O
spared	O
for	O
several	O
reasons,	O
including	O
milder	O
effects	O
of	O
the	O
mouse	O
gene	O
defect,	O
differences	O
in	O
muscle	O
and	O
retinal	O
gene	O
product,	O
or	O
species	O
differences	O
in	O
the	O
biochemical	O
role	O
of	O
dystrophin.	O
The	O
ERG	O
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	O
tool	O
for	O
DMD	SpecificDisease

Eight	O
novel	O
inactivating	O
germ	O
line	O
mutations	O
at	O
the	O
APC	Modifier
gene	O
identified	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis.	O
Familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
)	O
is	O
a	O
dominantly	O
inherited	O
condition	O
predisposing	O
to	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
The	O
recent	O
isolation	O
of	O
the	O
responsible	O
gene	O
(	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
or	O
APC	SpecificDisease
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	O
line	O
mutations	O
in	O
affected	O
individuals.	O
Previous	O
authors	O
have	O
used	O
the	O
RNase	O
protection	O
assay	O
and	O
the	O
single-strand	O
conformation	O
polymorphisms	O
procedure	O
to	O
screen	O
for	O
mutations.	O
In	O
this	O
study	O
we	O
used	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE).	O
DGGE	O
analysis	O
of	O
10	O
APC	Modifier
exons	O
(4,	O
5,	O
7,	O
8,	O
9,	O
10,	O
12,	O
13,	O
14,	O
and	O
part	O
of	O
15)	O
in	O
33	O
unrelated	O
Dutch	O
FAP	Modifier
patients	O
has	O
led	O
to	O
the	O
identification	O
of	O
eight	O
novel	O
germ	O
line	O
mutations	O
resulting	O
in	O
stop	O
codons	O
or	O
frameshifts.	O
The	O
results	O
reported	O
here	O
indicate	O
that	O
(1)	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
is	O
caused	O
by	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
point	O
mutations;	O
(2)	O
all	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
chain	O
terminating;	O
and	O
(3)	O
DGGE	O
represents	O
a	O
rapid	O
and	O
sensitive	O
technique	O
for	O
the	O
detection	O
of	O
mutations	O
in	O
the	O
unusually	O
large	O
APC	Modifier
gene.	O
An	O
extension	O
of	O
the	O
DGGE	O
analysis	O
to	O
the	O
entire	O
coding	O
region	O
in	O
a	O
sufficient	O
number	O
of	O
clinically	O
well-characterized,	O
unrelated	O
patients	O
will	O
facilitate	O
the	O
establishment	O
of	O
genotype-phenotype	O
correlations.	O
On	O
the	O
other	O
hand,	O
the	O
occurrence	O
of	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
mutations	O
spread	O
throughout	O
the	O
entire	O
length	O
of	O
the	O
large	O
APC	Modifier
gene	O
among	O
the	O
FAP	Modifier
patients	O
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	O
procedure	O
in	O
a	O
routine	O
laboratory.	O
Nevertheless,	O
the	O
above	O
DGGE	O
approach	O
has	O
incidentally	O
led	O
to	O
the	O
identification	O
of	O
a	O
common	O
polymorphism	O
in	O
exon	O
13.	O
Such	O
intragenic	O
polymorphisms	O
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	SpecificDisease

Novel	O
mutations	O
in	O
XLRS1	O
causing	O
retinoschisis	SpecificDisease
,	O
including	O
first	O
evidence	O
of	O
putative	O
leader	O
sequence	O
change.	O
Juvenile	SpecificDisease
retinoschisis	SpecificDisease
is	O
an	O
X-linked	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
XLRS1	O
gene.	O
We	O
screened	O
31	O
new	O
unrelated	O
patients	O
and	O
families	O
for	O
XLRS1	O
mutations	O
in	O
addition	O
to	O
previously	O
reported	O
mutations	O
for	O
60	O
of	O
our	O
families	O
(	O
Retinoschisis	Modifier

Clinical	O
use	O
of	O
DNA	O
markers	O
linked	O
to	O
the	O
gene	O
for	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
Seventy	O
families	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
known	O
to	O
the	O
Institute	O
of	O
Child	O
Health	O
fall	O
into	O
three	O
categories	O
with	O
respect	O
to	O
potential	O
linkage	O
analysis	O
with	O
the	O
X	O
chromosome	O
DNA	O
markers	O
RC8	O
and	O
L1.	O
28	O
that	O
bridge	O
the	O
DMD	Modifier
gene.	O
Families	O
in	O
which	O
there	O
is	O
at	O
least	O
one	O
obligatory	O
female	O
heterozygote	O
(n	O
=	O
13).	O
Here	O
prediction	O
and	O
exclusion	O
of	O
DMD	Modifier
gene	O
transmission	O
may	O
be	O
possible,	O
the	O
accuracy	O
being	O
dependent	O
on	O
the	O
closeness	O
of	O
the	O
linkage	O
of	O
the	O
DNA	O
marker	O
(s)	O
to	O
the	O
DMD	Modifier
gene;	O
an	O
illustrative	O
case	O
is	O
reported.	O
Families	O
in	O
which	O
there	O
is	O
a	O
single	O
affected	O
boy,	O
who	O
also	O
has	O
one	O
or	O
more	O
healthy	O
brothers	O
(n	O
=	O
26).	O
Given	O
an	O
informative	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP),	O
the	O
probability	O
that	O
the	O
boy	O
represents	O
a	O
new	O
mutation	O
can	O
be	O
reassessed;	O
it	O
is	O
also	O
possible	O
to	O
exclude	O
the	O
DMD	Modifier
gene	O
in	O
a	O
sister.	O
Families	O
with	O
a	O
single	O
affected	O
boy	O
with	O
no	O
brother	O
(n	O
=	O
30).	O
Here	O
exclusion	O
of	O
the	O
DMD	Modifier
gene	O
in	O
a	O
sister	O
may	O
be	O
possible.	O
Only	O
in	O
one	O
family	O
was	O
there	O
no	O
possibility	O
of	O
useful	O
linkage	O
analysis.	O
The	O
linkage	O
analysis	O
required	O
is	O
described,	O
and	O
the	O
need	O
to	O
check	O
DMD	Modifier

Molecular	O
characterization	O
of	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
patients	O
of	O
Chinese	O
descent	O
and	O
identification	O
of	O
new	O
base	O
substitutions	O
in	O
the	O
human	O
G6PD	O
gene.	O
The	O
underlying	O
DNA	O
changes	O
associated	O
with	O
glucose-6-phosphate	Modifier
dehydrogenase	Modifier
(G6PD)	Modifier
-deficient	Modifier
Asians	O
have	O
not	O
been	O
extensively	O
investigated.	O
To	O
fill	O
this	O
gap,	O
we	O
sequenced	O
the	O
G6PD	O
gene	O
of	O
43	O
G6PD-deficient	Modifier
Chinese	O
whose	O
G6PD	O
was	O
well	O
characterized	O
biochemically.	O
DNA	O
samples	O
were	O
obtained	O
from	O
peripheral	O
blood	O
of	O
these	O
individuals	O
for	O
sequencing	O
using	O
a	O
direct	O
polymerase	O
chain	O
reaction	O
(PCR)	O
sequencing	O
procedure.	O
From	O
these	O
43	O
samples,	O
we	O
have	O
identified	O
five	O
different	O
types	O
of	O
nucleotide	O
substitutions	O
in	O
the	O
G6PD	O
gene	O
	O
at	O
cDNA	O
1388	O
from	O
G	O
to	O
A	O
(Arg	O
to	O
His);	O
at	O
cDNA	O
1376	O
from	O
G	O
to	O
T	O
(Arg	O
to	O
Leu);	O
at	O
cDNA	O
1024	O
from	O
C	O
to	O
T	O
(Leu	O
to	O
Phe);	O
at	O
cDNA	O
392	O
from	O
G	O
to	O
T	O
(Gly	O
to	O
Val);	O
at	O
cDNA	O
95	O
from	O
A	O
to	O
G	O
(His	O
to	O
Arg).	O
These	O
five	O
nucleotide	O
substitutions	O
account	O
for	O
over	O
83%	O
of	O
our	O
43	O
G6PD-deficient	Modifier
samples	O
and	O
these	O
substitutions	O
have	O
not	O
been	O
reported	O
in	O
non-Asians.	O
The	O
substitutions	O
found	O
at	O
cDNA	O
392	O
and	O
cDNA	O
1024	O
are	O
new	O
findings.	O
The	O
substitutions	O
at	O
cDNA	O
1376	O
and	O
1388	O
account	O
for	O
over	O
50%	O
of	O
the	O
43	O
samples	O
examined	O
indicating	O
a	O
high	O
prevalence	O
of	O
these	O
two	O
alleles	O
among	O
G6PD-deficient	Modifier
Chinese.	O
Our	O
findings	O
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
much	O
of	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Norrie	Modifier
disease	Modifier
gene:	O
characterization	O
of	O
deletions	O
and	O
possible	O
function.	O
Positional	O
cloning	O
experiments	O
have	O
resulted	O
recently	O
in	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Norrie	SpecificDisease
disease	SpecificDisease
(	O
pseudoglioma	SpecificDisease
;	O
NDP	SpecificDisease
),	O
a	O
severe	O
X-linked	DiseaseClass
neurodevelopmental	DiseaseClass
disorder	DiseaseClass
.	O
Here	O
we	O
report	O
the	O
isolation	O
and	O
analysis	O
of	O
human	O
genomic	O
DNA	O
clones	O
encompassing	O
the	O
NDP	Modifier
gene.	O
The	O
gene	O
spans	O
28	O
kb	O
and	O
consists	O
of	O
3	O
exons,	O
the	O
first	O
of	O
which	O
is	O
entirely	O
contained	O
within	O
the	O
5	O
untranslated	O
region.	O
Detailed	O
analysis	O
of	O
genomic	O
deletions	O
in	O
Norrie	Modifier
patients	O
shows	O
that	O
they	O
are	O
heterogeneous,	O
both	O
in	O
size	O
and	O
in	O
position.	O
By	O
PCR	O
analysis,	O
we	O
found	O
that	O
expression	O
of	O
the	O
NDP	Modifier
gene	O
was	O
not	O
confined	O
to	O
the	O
eye	O
or	O
to	O
the	O
brain.	O
An	O
extensive	O
DNA	O
and	O
protein	O
sequence	O
comparison	O
between	O
the	O
human	O
NDP	Modifier

Prenatal	O
diagnosis	O
of	O
Wolman	SpecificDisease
disease	SpecificDisease
.	O
Two	O
pregnancies	O
at	O
risk	O
for	O
Wolman	SpecificDisease
disease	SpecificDisease
were	O
monitored	O
by	O
assay	O
and	O
electrophoresis	O
of	O
acid	O
lipase	O
in	O
cultured	O
amniotic-fluid	O
cells.	O
Cells	O
from	O
patient	O
1	O
had	O
5%	O
of	O
control	O
levels	O
of	O
acid	O
lipase,	O
using	O
14C-triolein	O
as	O
substrate;	O
however,	O
when	O
artificial	O
substrates	O
(esters	O
of	O
4-methylumbelliferone	O
and	O
p-nitrophenol)	O
were	O
used	O
to	O
measure	O
acid	O
lipase,	O
these	O
cells	O
had	O
30%	O
of	O
control	O
levels.	O
Electrophoresis	O
of	O
cell	O
extracts	O
revealed	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Wolman	SpecificDisease
disease	SpecificDisease
.	O
Analysis	O
of	O
fetal	O
tissues	O
following	O
prostaglandin	O
termination	O
of	O
this	O
pregnancy	O
confirmed	O
the	O
diagnosis.	O
Assay	O
of	O
fetal-skin	O
fibroblasts	O
with	O
14C-triolein,	O
as	O
well	O
as	O
with	O
artificial	O
substrates,	O
showed	O
marked	O
deficiency	O
of	O
acid	O
lipase	O
activity.	O
Electrophoresis	O
of	O
fetal-tissue	O
extracts	O
also	O
demonstrated	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase.	O
Amniotic-fluid	O
cells	O
from	O
patient	O
2	O
showed	O
normal	O
levels	O
of	O
acid	O
lipase	O
with	O
all	O
substrates	O
tested;	O
the	O
electrophoretic	O
pattern	O
of	O
acid	O
lipase	O
was	O
normal.	O
The	O
results	O
suggest	O
that	O
the	O
prenatal	O
diagnosis	O
of	O
Wolman	SpecificDisease
disease	SpecificDisease

Somatic	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
sporadic	SpecificDisease
ovarian	SpecificDisease
tumours	SpecificDisease
.	O
The	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
syndrome	DiseaseClass
of	O
increased	O
susceptibility	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
but	O
no	O
somatic	O
mutations	O
in	O
tumours	DiseaseClass
have	O
yet	O
been	O
described.	O
To	O
study	O
the	O
potential	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
carcinogenesis,	O
we	O
analysed	O
the	O
genomic	O
DNA	O
of	O
tumour	DiseaseClass
and	O
normal	O
fractions	O
of	O
47	O
ovarian	SpecificDisease
cancers	SpecificDisease
for	O
mutations	O
in	O
BRCA1	O
using	O
the	O
single-strand	O
conformation	O
polymorphism	O
technique.	O
We	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
DNA	O
of	O
four	O
tumours	DiseaseClass
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(LOH)	O
at	O
a	O
BRCA1	O
intragenic	O
marker.	O
Our	O
data	O
support	O
a	O
tumour	Modifier
suppressor	O
mechanism	O
for	O
BRCA1;	O
somatic	O
mutations	O
and	O
LOH	O
may	O
result	O
in	O
inactivation	O
of	O
BRCA1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	SpecificDisease
cancers	SpecificDisease

Skewed	O
X	O
inactivation	O
in	O
a	O
female	O
MZ	O
twin	O
results	O
in	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
One	O
of	O
female	O
MZ	O
twins	O
presented	O
with	O
muscular	DiseaseClass
dystrophy	DiseaseClass
.	O
Physical	O
examination,	O
creatine	O
phosphokinase	O
levels,	O
and	O
muscle	O
biopsy	O
were	O
consistent	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
However,	O
because	O
of	O
her	O
sex	O
she	O
was	O
diagnosed	O
as	O
having	O
limb-girdle	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
With	O
cDNA	O
probes	O
to	O
the	O
DMD	Modifier
gene,	O
a	O
gene	O
deletion	O
was	O
detected	O
in	O
the	O
twins	O
and	O
their	O
mother.	O
The	O
de	O
novo	O
mutation	O
which	O
arose	O
in	O
the	O
mother	O
was	O
shown	O
by	O
novel	O
junction	O
fragments	O
generated	O
by	O
HindIII,	O
PstI,	O
or	O
TaqI	O
when	O
probed	O
with	O
cDNA8.	O
Additional	O
evidence	O
of	O
a	O
large	O
gene	O
deletion	O
was	O
given	O
by	O
novel	O
SfiI	O
junction	O
fragments	O
detected	O
by	O
probes	O
p20,	O
J-Bir,	O
and	O
J-66	O
on	O
pulsed-field	O
gel	O
electrophoresis	O
(PFGE).	O
Immunoblot	O
analysis	O
of	O
muscle	O
from	O
the	O
affected	O
twin	O
showed	O
dystrophin	O
of	O
normal	O
size	O
but	O
of	O
reduced	O
amount.	O
Immunofluorescent	O
visualization	O
of	O
dystrophin	O
revealed	O
foci	O
of	O
dystrophin-positive	O
fibers	O
adjacent	O
to	O
foci	O
of	O
dystrophin-negative	O
fibers.	O
These	O
data	O
indicate	O
that	O
the	O
affected	O
twin	O
is	O
a	O
manifesting	O
carrier	O
of	O
an	O
abnormal	O
DMD	Modifier
gene,	O
her	O
myopathy	DiseaseClass
being	O
a	O
direct	O
result	O
of	O
underexpression	O
of	O
dystrophin.	O
Cytogenetic	O
analysis	O
revealed	O
normal	O
karyotypes,	O
eliminating	O
the	O
possibility	O
of	O
a	O
translocation	O
affecting	O
DMD	Modifier
gene	O
function.	O
Both	O
linkage	O
analysis	O
and	O
DNA	O
fingerprint	O
analysis	O
revealed	O
that	O
each	O
twin	O
has	O
two	O
different	O
X	O
chromosomes,	O
eliminating	O
the	O
possibility	O
of	O
uniparental	SpecificDisease
disomy	SpecificDisease
as	O
a	O
mechanism	O
for	O
DMD	Modifier

Coincident	O
Kaposi	SpecificDisease
sarcoma	SpecificDisease
and	O
T-cell	SpecificDisease
lymphoma	SpecificDisease
in	O
a	O
patient	O
with	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
.	O
A	O
24	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
eczema	DiseaseClass
,	O
recurrent	O
mild	O
infections,	O
and	O
thrombocytopenia	SpecificDisease
consistent	O
with	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
presented	O
with	O
a	O
mediastinal	O
mass,	O
generalized	O
lymphadenopathy	SpecificDisease
,	O
splenomegaly	SpecificDisease
,	O
and	O
severe	O
thrombocytopenia	SpecificDisease
.	O
Studies	O
of	O
immune	O
function	O
including	O
immunoglobulin	O
levels	O
and	O
T-cell	O
subsets	O
were	O
normal.	O
Furthermore,	O
his	O
T	O
lymphocytes	O
proliferated	O
normally	O
in	O
response	O
to	O
phytohemagglutinin,	O
concanavalin	O
A,	O
and	O
the	O
combination	O
of	O
neuraminidase/galactose	O
oxidase.	O
However,	O
their	O
proliferative	O
responses	O
to	O
anti-CD43	O
antibody	O
and	O
periodate	O
were	O
diminished,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
WAS	SpecificDisease
.	O
An	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	O
surprisingly	O
revealed	O
Kaposi	SpecificDisease
sarcoma	SpecificDisease
.	O
However,	O
following	O
splenectomy	O
to	O
increase	O
the	O
platelet	O
count,	O
biopsy	O
of	O
the	O
mediastinal	O
mass	O
revealed	O
T-cell	SpecificDisease
large	SpecificDisease
cell	SpecificDisease
lymphoma	SpecificDisease
.	O
Studies	O
of	O
biopsied	O
tissue	O
for	O
the	O
presence	O
of	O
Epstein-Barr	SpecificDisease
virus	SpecificDisease
and	O
cytomegalovirus	SpecificDisease
were	O
negative,	O
as	O
were	O
studies	O
of	O
blood,	O
including	O
the	O
polymerase	O
chain	O
reaction,	O
for	O
the	O
presence	O
of	O
the	O
human	SpecificDisease
immunodeficiency	SpecificDisease
virus	SpecificDisease
(	O
HIV	SpecificDisease
).	O
This	O
is	O
the	O
first	O
report	O
of	O
Kaposi	SpecificDisease
sarcoma	SpecificDisease
arising	O
in	O
a	O
patient	O
with	O
a	O
congenital	DiseaseClass
immunodeficiency	DiseaseClass
syndrome	DiseaseClass
.	O
Although	O
Kaposi	SpecificDisease
sarcoma	SpecificDisease
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	O
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	O
infected	O
with	O
HIV	SpecificDisease
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	O
factor	O
in	O
the	O
development	O
of	O
Kaposi	SpecificDisease
sarcoma	SpecificDisease

Treatment	O
of	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
:	O
effects	O
of	O
chenodeoxycholic	O
acid,	O
pravastatin,	O
and	O
combined	O
use.	O
Treatments	O
by	O
oral	O
administration	O
of	O
chenodeoxycholic	O
acid	O
(CDCA)	O
alone,	O
3-hydroxy-3-methylglutaryl	O
(HMG)	O
CoA	O
reductase	O
inhibitor	O
(pravastatin)	O
alone,	O
and	O
combination	O
of	O
the	O
two	O
drugs	O
were	O
attempted	O
for	O
7	O
patients	O
with	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
).	O
CDCA	O
treatment	O
at	O
a	O
dose	O
of	O
300	O
mg/day	O
reduced	O
serum	O
cholestanol	O
(67.	O
3%	O
reduction),	O
lathosterol	O
(50.	O
8%),	O
campesterol	O
(61.	O
7%)	O
and	O
sitosterol	O
(12.	O
7%).	O
However,	O
the	O
sera	O
of	O
the	O
patients	O
changed	O
to	O
be	O
"	O
atherogenic	O
";	O
total	O
cholesterol,	O
triglyceride	O
and	O
low-density	O
lipoprotein	O
(LDL)	O
-cholesterol	O
were	O
increased,	O
while	O
high-density	O
lipoprotein	O
(HDL)	O
-cholesterol	O
was	O
decreased.	O
Contrarily,	O
pravastatin	O
at	O
a	O
dose	O
of	O
10	O
mg/day	O
improved	O
the	O
sera	O
of	O
the	O
patients	O
to	O
be	O
markedly	O
"	O
anti-atherogenic	O
",	O
but	O
the	O
reductions	O
of	O
cholestanol	O
(30.	O
4%),	O
lathosterol	O
(44.	O
0%),	O
campesterol	O
(22.	O
9%)	O
and	O
sitosterol	O
(9.	O
6%)	O
were	O
inadequate.	O
Combined	O
treatment	O
with	O
CDCA	O
and	O
pravastatin	O
showed	O
good	O
overlapping	O
of	O
the	O
effects	O
of	O
each	O
drug	O
alone.	O
The	O
sera	O
of	O
the	O
patients	O
were	O
apparently	O
more	O
"	O
anti-atherogenic	O
"	O
than	O
those	O
after	O
CDCA	O
treatment.	O
Serum	O
cholestanol	O
concentration	O
was	O
still	O
2.	O
7	O
times	O
higher	O
than	O
in	O
controls,	O
but	O
the	O
serum	O
lathosterol	O
level	O
was	O
within	O
the	O
normal	O
range,	O
indicating	O
that	O
the	O
enhancement	O
of	O
overall	O
cholesterol	O
synthesis	O
in	O
the	O
patients	O
was	O
sufficiently	O
suppressed.	O
Plant	O
sterol	O
levels	O
were	O
also	O
within	O
the	O
normal	O
range.	O
The	O
combination	O
of	O
CDCA	O
and	O
pravastatin	O
was	O
a	O
good	O
treatment	O
for	O
CTX	SpecificDisease
,	O
based	O
on	O
the	O
improvement	O
of	O
serum	O
lipoprotein	O
metabolism,	O
the	O
suppression	O
of	O
cholesterol	O
synthesis,	O
and	O
reductions	O
of	O
cholestanol	O
and	O
plant	O
sterol	O
levels.	O
In	O
all	O
of	O
7	O
patients,	O
the	O
progression	O
of	O
disease	O
was	O
arrested,	O
but	O
dramatic	O
effects	O
on	O
clinical	O
manifestations,	O
xanthoma	DiseaseClass

Combined	CompositeMention
genetic	CompositeMention
deficiency	CompositeMention
of	CompositeMention
C6	CompositeMention
and	CompositeMention
C7	CompositeMention
in	O
man.	O
By	O
routine	O
screening	O
of	O
sera,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub-total	CompositeMention
deficiency	CompositeMention
of	CompositeMention
C6	CompositeMention
and	CompositeMention
C7	CompositeMention
.	O
No	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic,	O
the	O
C6	SpecificDisease
deficiency	SpecificDisease

Partial	O
deletion	O
8q	O
without	O
Langer-Giedion	SpecificDisease
syndrome	SpecificDisease
:	O
a	O
recognisable	O
syndrome.	O
We	O
report	O
two	O
de	O
novo	O
cases	O
of	O
del	O
(8)	O
(pter----q24.	O
1	O
)	O
with	O
breakpoints	O
involving	O
the	O
distal	O
part	O
of	O
band	O
8q24.	O
1	O
1.	O
The	O
clinical	O
features	O
were	O
similar	O
and	O
there	O
were	O
no	O
obvious	O
stigmata	O
of	O
Langer-Giedion	SpecificDisease
syndrome	SpecificDisease
(	O
LGS	SpecificDisease
).	O
There	O
are	O
three	O
other	O
cases	O
reported	O
with	O
a	O
deletion	O
of	O
chromosome	O
8	O
at	O
approximately	O
the	O
same	O
breakpoint,	O
one	O
without	O
LGS	SpecificDisease
and	O
some	O
similarities	O
to	O
our	O
cases,	O
the	O
other	O
two	O
with	O
LGS	SpecificDisease
.	O
Our	O
findings	O
would	O
support	O
the	O
observation	O
that	O
the	O
critical	O
segment	O
for	O
the	O
assignment	O
of	O
LGS	SpecificDisease
is	O
proximal	O
to	O
or	O
involves	O
the	O
proximal	O
part	O
of	O
8q24.	O
1,	O
but	O
a	O
review	O
of	O
published	O
reports	O
suggests	O
that	O
the	O
aetiology	O
of	O
LGS	SpecificDisease

Iron-dependent	O
self-assembly	O
of	O
recombinant	O
yeast	O
frataxin:	O
implications	O
for	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
.	O
Frataxin	SpecificDisease
deficiency	SpecificDisease
is	O
the	O
primary	O
cause	O
of	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
),	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
cardiodegenerative	DiseaseClass
and	DiseaseClass
neurodegenerative	DiseaseClass
disease	DiseaseClass
.	O
Frataxin	O
is	O
a	O
nuclear-encoded	O
mitochondrial	O
protein	O
that	O
is	O
widely	O
conserved	O
among	O
eukaryotes.	O
Genetic	O
inactivation	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
(Yfh1p)	O
results	O
in	O
mitochondrial	SpecificDisease
iron	SpecificDisease
accumulation	SpecificDisease
and	O
hypersensitivity	SpecificDisease
to	SpecificDisease
oxidative	SpecificDisease
stress	SpecificDisease
.	O
Increased	O
iron	O
deposition	O
and	O
evidence	O
of	O
oxidative	O
damage	O
have	O
also	O
been	O
observed	O
in	O
cardiac	O
tissue	O
and	O
cultured	O
fibroblasts	O
from	O
patients	O
with	O
FRDA	SpecificDisease

Human	O
mutations	O
in	O
glucose	O
6-phosphate	O
dehydrogenase	O
reflect	O
evolutionary	O
history.	O
Glucose	O
6-phosphate	O
dehydrogenase	O
(G6PD)	O
is	O
a	O
cytosolic	O
enzyme	O
encoded	O
by	O
a	O
housekeeping	O
X-linked	O
gene	O
whose	O
main	O
function	O
is	O
to	O
produce	O
NADPH,	O
a	O
key	O
electron	O
donor	O
in	O
the	O
defense	O
against	O
oxidizing	O
agents	O
and	O
in	O
reductive	O
biosynthetic	O
reactions.	O
Inherited	O
G6PD	SpecificDisease
deficiency	SpecificDisease
is	O
associated	O
with	O
either	O
episodic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
(triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents)	O
or	O
life-long	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
.	O
We	O
show	O
here	O
that	O
an	O
evolutionary	O
analysis	O
is	O
a	O
key	O
to	O
understanding	O
the	O
biology	O
of	O
a	O
housekeeping	O
gene.	O
From	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(aa)	O
sequence	O
of	O
52	O
glucose	O
6-phosphate	O
dehydrogenase	O
(G6PD)	O
species	O
from	O
42	O
different	O
organisms,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
G6PD	O
	O
two-thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(50-99%)	O
aa;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(where	O
they	O
might	O
be	O
lethal)	O
or	O
in	O
poorly	O
conserved	O
aa,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Regionally	O
clustered	O
APC	Modifier
mutations	O
are	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
occur	O
at	O
a	O
high	O
frequency	O
in	O
new	O
mutation	O
cases	O
of	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
.	O
Germline	O
mutation	O
in	O
APC	O
at	O
5q21-22	O
results	O
in	O
the	O
dominantly	O
inherited	O
syndrome	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
APC	SpecificDisease
).	O
Somatic	O
mutation	O
in	O
this	O
gene	O
is	O
an	O
early	O
event	O
in	O
colorectal	O
tumourigenesis.	O
Both	O
types	O
of	O
mutation	O
are	O
concentrated	O
in	O
the	O
5	O
half	O
of	O
exon	O
15.	O
We	O
have	O
used	O
single	O
strand	O
conformational	O
polymorphism	O
(SSCP)	O
and	O
heteroduplex	O
analysis	O
to	O
screen	O
for	O
variants	O
in	O
this	O
region	O
of	O
the	O
gene	O
in	O
a	O
total	O
of	O
45	O
affected	O
but	O
unrelated	O
individuals.	O
Eighteen	O
patients	O
had	O
no	O
family	O
history	O
of	O
the	O
disease;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	O
phenotype,	O
based	O
on	O
an	O
early	O
age	O
at	O
presentation	O
or	O
cancer	Modifier
development.	O
This	O
compared	O
with	O
6	O
of	O
27	O
familial	O
cases.	O
A	O
5	O
bp	O
deletion	O
at	O
codon	O
1309	O
reported	O
to	O
occur	O
in	O
10-15%	O
of	O
unselected	O
APC	Modifier
patients	O
worldwide,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	O
cases	O
and	O
4	O
of	O
the	O
27	O
familial	O
cases	O
	O
all	O
nine	O
were	O
classed	O
as	O
severe.	O
A	O
further	O
3	O
new	O
mutations	O
and	O
1	O
familial	O
mutation	O
were	O
located	O
downstream	O
from	O
codon	O
1309,	O
these	O
individuals	O
similarly	O
being	O
classed	O
as	O
phenotypically	O
severe.	O
In	O
contrast	O
all	O
of	O
the	O
APC	Modifier

Analysis	O
of	O
alkaptonuria	Modifier
(	O
AKU	Modifier
)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1,2	O
dioxygenase	O
gene	O
(HGO).	O
We	O
recently	O
showed	O
that	O
alkaptonuria	SpecificDisease
(	O
AKU	SpecificDisease
)	O
is	O
caused	O
by	O
loss-of-function	O
mutations	O
in	O
the	O
homogentisate	O
1,	O
2	O
dioxygenase	O
gene	O
(HGO).	O
Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	Modifier
pedigrees.	O
These	O
analyses	O
identified	O
two	O
novel	O
single-nucleotide	O
polymorphisms	O
(INV4	O
+	O
31A--	O
>	O
G	O
and	O
INV11	O
+	O
18A--	O
>	O
G)	O
and	O
six	O
novel	O
AKU	Modifier
mutations	O
(INV1-1G--	O
>	O
A,	O
W60G,	O
Y62C,	O
A122D,	O
P230T,	O
and	O
D291E),	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
AKU	SpecificDisease

Further	O
evidence	O
for	O
heterogeneity	O
of	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
in	O
Papua	O
New	O
Guinea.	O
Four	O
new	O
G6PD	O
variants	O
have	O
been	O
characterized	O
in	O
individuals	O
from	O
Papua	O
New	O
Guinea.	O
This	O
study	O
demonstrates	O
that	O
the	O
previously	O
reported	O
Markham	O
variant	O
and	O
the	O
newly	O
characterized	O
Salata	O
variant	O
may	O
be	O
widely	O
distributed	O
in	O
Papua	O
New	O
Guinea.	O
Th	O
data	O
presented	O
here	O
together	O
with	O
those	O
of	O
previously	O
published	O
studies	O
demonstrate	O
a	O
degree	O
of	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	O
of	O
the	O
world	O
where	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Overgrowth	CompositeMention
of	CompositeMention
oral	CompositeMention
mucosa	CompositeMention
and	CompositeMention
facial	CompositeMention
skin	CompositeMention
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	SpecificDisease
.	O
Aspartylglucosaminuria	SpecificDisease
(	O
AGU	SpecificDisease
)	O
is	O
a	O
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
deficiency	SpecificDisease
of	SpecificDisease
aspartylglucosaminidase	SpecificDisease
(AGA).	O
The	O
main	O
symptom	O
is	O
progressive	O
mental	DiseaseClass
retardation	DiseaseClass
.	O
A	O
spectrum	O
of	O
different	O
mutations	O
has	O
been	O
reported	O
in	O
this	O
disease,	O
one	O
missense	O
mutation	O
(Cys163Ser)	O
being	O
responsible	O
for	O
the	O
majority	O
of	O
Finnish	O
cases.	O
We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	Modifier
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin.	O
Biopsy	O
specimens	O
of	O
16	O
oral	O
lesions,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth,	O
plus	O
two	O
facial	DiseaseClass
lesions	DiseaseClass
were	O
studied	O
histologically.	O
Immunohistochemical	O
staining	O
for	O
AGA	O
was	O
performed	O
on	O
15	O
oral	O
specimens.	O
Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients,	O
with	O
erythema	SpecificDisease
of	SpecificDisease
the	SpecificDisease
facial	SpecificDisease
skin	SpecificDisease
already	O
common	O
in	O
childhood.	O
Of	O
44	O
patients,	O
nine	O
(20%)	O
had	O
facial	SpecificDisease
angiofibromas	SpecificDisease
,	O
tumours	DiseaseClass
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	SpecificDisease
sclerosis	SpecificDisease
.	O
Oedemic	SpecificDisease
buccal	SpecificDisease
mucosa	SpecificDisease
(	O
leucoedema	SpecificDisease
)	O
and	O
gingival	SpecificDisease
overgrowths	SpecificDisease
were	O
more	O
frequent	O
in	O
AGU	Modifier
patients	O
than	O
in	O
controls	O
(p	O
<	O
0.	O
001).	O
Of	O
16	O
oral	SpecificDisease
mucosal	SpecificDisease
lesions	SpecificDisease
studied	O
histologically,	O
15	O
represented	O
fibroepithelial	CompositeMention
or	CompositeMention
epithelial	CompositeMention
hyperplasias	CompositeMention
and	O
were	O
reactive	O
in	O
nature.	O
Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four.	O
Immunohistochemically,	O
expression	O
of	O
AGA	O
in	O
AGU	Modifier
patients	O
mucosal	SpecificDisease
lesions	SpecificDisease
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects.	O
Thus,	O
the	O
high	O
frequency	O
of	O
mucosal	SpecificDisease
overgrowth	SpecificDisease
in	O
AGU	Modifier

Molecular	O
characterization	O
of	O
galactosemia	Modifier
(type	O
1)	O
mutations	O
in	O
Japanese.	O
We	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(GALT)	O
gene	O
in	O
two	O
Japanese	O
patients	O
with	O
GALT	SpecificDisease
deficiency	SpecificDisease
and	O
identified	O
N314D	O
and	O
R333W	O
mutations,	O
previously	O
found	O
in	O
Caucasians.	O
One	O
novel	O
missense	O
mutation	O
was	O
an	O
G-to-A	O
transition	O
in	O
exon	O
8,	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	O
231	O
(R231H).	O
GALT	O
activity	O
of	O
the	O
R231H	O
mutant	O
construct	O
was	O
reduced	O
to	O
15%	O
of	O
normal	O
controls	O
in	O
a	O
COS	O
cell	O
expression	O
system.	O
The	O
other	O
was	O
a	O
splicing	O
mutation,	O
an	O
A-to-G	O
transition	O
at	O
the	O
38th	O
nucleotide	O
in	O
exon	O
3	O
(318A--	O
>	O
G),	O
resulting	O
in	O
a	O
38-bp	O
deletion	O
in	O
the	O
GALT	O
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	O
acceptor	O
site.	O
In	O
seven	O
Japanese	O
families	O
(14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
Duarte	O
variant)	O
with	O
GALT	SpecificDisease
deficiency	SpecificDisease
,	O
the	O
R231H	O
and	O
318A--	O
>	O
G	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband.	O
The	O
N314D	O
and	O
R333W	O
mutations	O
were	O
found	O
on	O
one	O
allele	O
each.	O
The	O
Q188R	O
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	O
patients.	O
The	O
N314D	O
mutation	O
was	O
associated	O
with	O
the	O
Duarte	O
variant	O
in	O
Japanese	O
persons,	O
as	O
well	O
as	O
in	O
the	O
United	O
States.	O
We	O
speculate	O
that	O
classic	Modifier
galactosemia	Modifier
mutations	O
appear	O
to	O
differ	O
between	O
Japanese	O
and	O
Caucasian	O
patients.	O
Our	O
limited	O
data	O
set	O
on	O
galactosemia	Modifier
mutations	O
in	O
Japanese	O
suggests	O
that	O
the	O
N314D	O
GALT	O
mutation	O
encoding	O
the	O
Duarte	O
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	O
people	O
diverged	O
and	O
that	O
classic	Modifier
galactosemia	Modifier

Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
founder	O
populations:	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
in	O
Finland.	O
Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
populations	O
provides	O
a	O
powerful	O
tool	O
for	O
fine	O
structure	O
localization	O
of	O
disease	O
genes.	O
Here,	O
Luria	O
and	O
Delbrucks	O
classical	O
methods	O
for	O
analysing	O
bacterial	O
cultures	O
are	O
adapted	O
to	O
the	O
study	O
of	O
human	O
isolated	O
founder	O
populations	O
in	O
order	O
to	O
estimate	O
(i)	O
the	O
recombination	O
fraction	O
between	O
a	O
disease	O
locus	O
and	O
a	O
marker;	O
(ii)	O
the	O
expected	O
degree	O
of	O
allelic	O
homogeneity	O
in	O
a	O
population;	O
and	O
(iii)	O
the	O
mutation	O
rate	O
of	O
marker	O
loci.	O
Using	O
these	O
methods,	O
we	O
report	O
striking	O
linkage	O
disequilibrium	O
for	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
(	O
DTD	SpecificDisease
)	O
in	O
Finland	O
indicating	O
that	O
the	O
DTD	Modifier

Mutations	O
in	O
TNFRSF11A,	O
affecting	O
the	O
signal	O
peptide	O
of	O
RANK,	O
cause	O
familial	SpecificDisease
expansile	SpecificDisease
osteolysis	SpecificDisease
.	O
Familial	SpecificDisease
expansile	SpecificDisease
osteolysis	SpecificDisease
(	O
FEO	SpecificDisease
,	O
MIM	O
174810)	O
is	O
a	O
rare,	O
autosomal	DiseaseClass
dominant	DiseaseClass
bone	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
focal	O
areas	O
of	O
increased	SpecificDisease
bone	SpecificDisease
remodelling	SpecificDisease
.	O
The	O
osteolytic	SpecificDisease
lesions	SpecificDisease
,	O
which	O
develop	O
usually	O
in	O
the	O
long	O
bones	O
during	O
early	O
adulthood,	O
show	O
increased	O
osteoblast	O
and	O
osteoclast	O
activity.	O
Our	O
previous	O
linkage	O
studies	O
mapped	O
the	O
gene	O
responsible	O
for	O
FEO	SpecificDisease
to	O
an	O
interval	O
of	O
less	O
than	O
5	O
cM	O
between	O
D18S64	O
and	O
D18S51	O
on	O
chromosome	O
18q21.	O
2-21	O
2-21.	O
3	O
in	O
a	O
large	O
Northern	O
Irish	O
family.	O
The	O
gene	O
encoding	O
receptor	O
activator	O
of	O
nuclear	O
factor-kappa	O
B	O
(RANK;	O
ref.	O
5),	O
TNFRSF11A,	O
maps	O
to	O
this	O
region.	O
RANK	O
is	O
essential	O
in	O
osteoclast	O
formation.	O
We	O
identified	O
two	O
heterozygous	O
insertion	O
mutations	O
in	O
exon	O
1	O
of	O
TNFRSF11A	O
in	O
affected	O
members	O
of	O
four	O
families	O
with	O
FEO	SpecificDisease
or	O
familial	SpecificDisease
Paget	SpecificDisease
disease	SpecificDisease
of	SpecificDisease
bone	SpecificDisease
(	O
PDB	SpecificDisease

Adrenoleukodystrophy-related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	SpecificDisease
protein	SpecificDisease
deficiency	SpecificDisease
(	O
X-ALD	SpecificDisease
):	O
implications	O
for	O
therapy.	O
Inherited	DiseaseClass
defects	DiseaseClass
in	O
the	O
peroxisomal	O
ATP-binding	O
cassette	O
(ABC)	O
transporter	O
adrenoleukodystrophy	Modifier
protein	O
(ALDP)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	DiseaseClass
disorder	DiseaseClass
	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
X-ALD	SpecificDisease
),	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far.	O
Three	O
other	O
peroxisomal	O
ABC	O
transporters	O
currently	O
are	O
known	O
	O
adrenoleukodystrophy-related	O
protein	O
(ALDRP),	O
70	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(PMP70)	O
and	O
PMP70-	O
related	O
protein.	O
By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta-oxidation	O
in	O
fibroblasts	O
of	O
X-ALD	Modifier
patients.	O
The	O
pathognomonic	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
could	O
also	O
be	O
prevented	O
by	O
overexpression	O
of	O
ALDRP	O
in	O
immortalized	O
X-ALD	O
cells.	O
Immunofluorescence	O
analysis	O
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	O
ALDP	O
itself.	O
Moreover,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	O
beta-oxidation	O
defect	O
in	O
the	O
liver	O
of	O
ALDP-deficient	O
mice	O
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	O
expression	O
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate.	O
These	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
X-ALD	SpecificDisease

The	O
normal	O
Huntington	Modifier
disease	Modifier
(	O
HD	Modifier
)	O
allele,	O
or	O
a	O
closely	O
linked	O
gene,	O
influences	O
age	O
at	O
onset	O
of	O
HD	SpecificDisease
.	O
We	O
evaluated	O
the	O
hypothesis	O
that	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
is	O
influenced	O
by	O
the	O
normal	O
HD	Modifier
allele	O
by	O
comparing	O
transmission	O
patterns	O
of	O
genetically	O
linked	O
markers	O
at	O
the	O
D4S10	O
locus	O
in	O
the	O
normal	O
parent	O
against	O
age	O
at	O
onset	O
in	O
the	O
affected	O
offspring.	O
Analysis	O
of	O
information	O
from	O
21	O
sibships	O
in	O
14	O
kindreds	O
showed	O
a	O
significant	O
tendency	O
for	O
sibs	O
who	O
have	O
similar	O
onset	O
ages	O
to	O
share	O
the	O
same	O
D4S10	O
allele	O
from	O
the	O
normal	O
parent.	O
Affected	O
sibs	O
who	O
inherited	O
different	O
D4S10	O
alleles	O
from	O
the	O
normal	O
parent	O
tended	O
to	O
have	O
more	O
variable	O
ages	O
at	O
onset.	O
These	O
findings	O
suggest	O
that	O
the	O
expression	O
of	O
HD	SpecificDisease
is	O
modulated	O
by	O
the	O
normal	O
HD	Modifier

Synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
the	O
FMR1	O
gene.	O
Most	O
fragile	Modifier
X	Modifier
syndrome	Modifier

Genetic	O
heterogeneity	O
in	O
X-linked	SpecificDisease
amelogenesis	SpecificDisease
imperfecta	SpecificDisease
.	O
The	O
AMELX	O
gene	O
located	O
at	O
Xp22.	O
1-p22.	O
3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	DiseaseClass
dental	DiseaseClass
abnormality	DiseaseClass
	O
X-linked	SpecificDisease
amelogenesis	SpecificDisease
imperfecta	SpecificDisease
(	O
XAI	SpecificDisease
).	O
Three	O
families	O
with	O
XAI	SpecificDisease
have	O
been	O
investigated	O
using	O
polymorphic	O
DNA	O
markers	O
flanking	O
the	O
position	O
of	O
AMELX.	O
Using	O
two-point	O
linkage	O
analysis,	O
linkage	O
was	O
established	O
between	O
XAI	SpecificDisease
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6.	O
05	O
for	O
DXS16	O
at	O
theta	O
=	O
0.	O
04	O
04.	O
This	O
supports	O
the	O
involvement	O
of	O
AMELX,	O
located	O
close	O
to	O
DXS16,	O
in	O
the	O
XAI	SpecificDisease
disease	SpecificDisease
process	O
(AIH1)	O
in	O
those	O
families.	O
Using	O
multipoint	O
linkage	O
analysis,	O
the	O
combined	O
maximum	O
lod	O
score	O
for	O
these	O
two	O
families	O
was	O
7.	O
30	O
for	O
a	O
location	O
of	O
AIH1	O
at	O
2	O
cM	O
distal	O
to	O
DXS16.	O
The	O
support	O
interval	O
around	O
this	O
location	O
extended	O
about	O
8	O
cM	O
proximal	O
to	O
DXS92,	O
and	O
the	O
AIH1	O
location	O
could	O
not	O
be	O
precisely	O
defined	O
by	O
multipoint	O
mapping.	O
Study	O
of	O
recombination	O
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	O
between	O
DXS143	O
and	O
DXS85.	O
There	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family,	O
indicating	O
locus	O
heterogeneity	O
in	O
XAI	SpecificDisease

Anonymous	O
marker	O
loci	O
within	O
400	O
kb	O
of	O
HLA-A	O
generate	O
haplotypes	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
hemochromatosis	Modifier
gene	O
(HFE)	O
The	O
hemochromatosis	Modifier
gene	O
(HFE)	O
maps	O
to	O
6p21.	O
3	O
and	O
is	O
less	O
than	O
1	O
cM	O
from	O
the	O
HLA	O
class	O
I	O
genes;	O
however,	O
the	O
precise	O
physical	O
location	O
of	O
the	O
gene	O
has	O
remained	O
elusive	O
and	O
controversial.	O
The	O
unambiguous	O
identification	O
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	Modifier
families	O
is	O
very	O
difficult;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	O
of	O
the	O
phenotypic	O
expression	O
as	O
well	O
as	O
by	O
the	O
sex-	O
and	O
age-related	O
penetrance	O
of	O
the	O
disease.	O
For	O
these	O
practical	O
considerations,	O
traditional	O
linkage	O
analysis	O
could	O
prove	O
of	O
limited	O
value	O
in	O
further	O
refining	O
the	O
extrapolated	O
physical	O
position	O
of	O
HFE.	O
We	O
therefore	O
embarked	O
upon	O
a	O
linkage-disequilibrium	O
analysis	O
of	O
HFE	O
and	O
normal	O
chromosomes	O
from	O
the	O
Brittany	O
population.	O
In	O
the	O
present	O
report,	O
66	O
hemochromatosis	Modifier
families	O
yielding	O
151	O
hemochromatosis	Modifier
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
RFLP-typed	O
with	O
a	O
battery	O
of	O
probes,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6.	O
7	O
and	O
HLA-F	O
loci	O
located	O
150	O
and	O
250	O
kb	O
telomeric	O
to	O
HLA-A,	O
respectively.	O
The	O
results	O
suggest	O
a	O
strong	O
peak	O
of	O
existing	O
linkage	O
disequilibrium	O
focused	O
within	O
the	O
i82-to-6.	O
7	O
interval	O
(approximately	O
250	O
kb).	O
The	O
zone	O
of	O
linkage	O
disequilibrium	O
is	O
flanked	O
by	O
the	O
i97	O
locus,	O
positioned	O
30	O
kb	O
proximal	O
to	O
i82,	O
and	O
the	O
HLA-F	O
gene,	O
found	O
250	O
kb	O
distal	O
to	O
HLA-A,	O
markers	O
of	O
which	O
display	O
no	O
significant	O
association	O
with	O
HFE.	O
These	O
data	O
support	O
the	O
possibility	O
that	O
HFE	O
resides	O
within	O
the	O
400-kb	O
expanse	O
of	O
DNA	O
between	O
i97	O
and	O
HLA-F.	O
Alternatively,	O
the	O
very	O
tight	O
association	O
of	O
HLA-A3	O
and	O
allele	O
1	O
of	O
the	O
6.	O
7	O
locus,	O
both	O
of	O
which	O
are	O
comprised	O
by	O
the	O
major	O
ancestral	O
or	O
founder	O
HFE	O
haplotype	O
in	O
Brittany,	O
supports	O
the	O
possibility	O
that	O
the	O
disease	O
gene	O
may	O
reside	O
immediately	O
telomeric	O
to	O
the	O
6.	O
7	O
locus	O
within	O
the	O
linkage-disequilibrium	O
zone.	O
Additionally,	O
hemochromatosis	Modifier
haplotypes	O
possessing	O
HLA-A11	O
and	O
the	O
low-frequency	O
HLA-F	O
polymorphism	O
(allele	O
2)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	O
chromosome	O
containing	O
a	O
second,	O
independently	O
arising	O
mutant	O
allele.	O
Overall,	O
the	O
establishment	O
of	O
a	O
likely	O
"	O
hemochromatosis	Modifier
critical	O
region	O
"	O
centromeric	O
boundary	O
and	O
the	O
identification	O
of	O
a	O
linkage-disequilibrium	O
zone	O
both	O
significantly	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
DNA	O
required	O
to	O
be	O
searched	O
for	O
novel	O
coding	O
sequences	O
constituting	O
the	O
HFE	SpecificDisease
defect	SpecificDisease

Natural	O
selection	O
of	O
hemi-	O
and	O
heterozygotes	O
for	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
Africa	O
by	O
resistance	O
to	O
severe	O
malaria	SpecificDisease
.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
,	O
the	O
most	O
common	O
enzymopathy	DiseaseClass
of	O
humans,	O
affects	O
over	O
400	O
million	O
people.	O
The	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	SpecificDisease
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	SpecificDisease
.	O
However,	O
attempts	O
to	O
confirm	O
that	O
G6PD	SpecificDisease
deficiency	SpecificDisease
is	O
protective	O
in	O
case-control	O
studies	O
of	O
malaria	SpecificDisease
have	O
yielded	O
conflicting	O
results.	O
Hence,	O
for	O
this	O
X-linked	DiseaseClass
disorder	DiseaseClass
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or,	O
as	O
frequently	O
suggested,	O
only	O
females.	O
Furthermore,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown.	O
Here	O
we	O
report	O
that,	O
in	O
two	O
large	O
case-control	O
studies	O
of	O
over	O
2,	O
000	O
African	O
children,	O
the	O
common	O
African	O
form	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
(	O
G6PD	SpecificDisease
A-	SpecificDisease
)	O
is	O
associated	O
with	O
a	O
46-58%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	SpecificDisease
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes.	O
A	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	SpecificDisease
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage,	O
associated	O
with	O
this	O
enzyme	DiseaseClass
deficiency	DiseaseClass
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria	Modifier
-endemic	O
regions.	O
Although	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Prader-Willi	SpecificDisease
syndrome	SpecificDisease
and	O
chromosome	O
15.	O
A	O
clinical	O
discussion	O
of	O
20	O
cases.	O
A	O
chromosome	SpecificDisease
15	SpecificDisease
anomaly	SpecificDisease
was	O
observed	O
in	O
12	O
of	O
20	O
patients,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
The	O
clinical	O
features	O
of	O
eight	O
cases	O
with	O
15q11-12	O
deletion	O
were	O
very	O
similar	O
to	O
those	O
originally	O
described	O
in	O
PWS	SpecificDisease
.	O
On	O
the	O
other	O
hand,	O
the	O
group	O
of	O
normal	O
karyotype	O
patients	O
is	O
heterogeneous,	O
and	O
their	O
features	O
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	O
definition	O
of	O
PWS	SpecificDisease
.	O
However,	O
the	O
hypothesis	O
that	O
PWS	SpecificDisease

Molecular	O
basis	O
of	O
phenylketonuria	SpecificDisease
and	O
related	O
hyperphenylalaninemias	DiseaseClass
:	O
mutations	O
and	O
polymorphisms	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene.	O
Mutations	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
gene	O
producing	O
phenylketonuria	SpecificDisease
or	O
hyperphenylalaninemia	DiseaseClass

The	O
intron	O
7	O
donor	O
splice	O
site	O
transition:	O
a	O
second	O
Tay-Sachs	Modifier
disease	Modifier
mutation	O
in	O
French	O
Canada.	O
Mutations	O
at	O
the	O
hexosaminidase	O
A	O
(HEXA)	O
gene	O
which	O
cause	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
have	O
elevated	O
frequency	O
in	O
the	O
Ashkenazi	O
Jewish	O
and	O
French-Canadian	O
populations.	O
We	O
report	O
a	O
novel	O
TSD	Modifier
allele	O
in	O
the	O
French-Canadian	O
population	O
associated	O
with	O
the	O
infantile	O
form	O
of	O
the	O
disease.	O
The	O
mutation,	O
a	O
G--	O
>	O
A	O
transition	O
at	O
the	O
+	O
1	O
position	O
of	O
intron	O
7,	O
abolishes	O
the	O
donor	O
splice	O
site.	O
Cultured	O
human	O
fibroblasts	O
from	O
a	O
compound	O
heterozygote	O
for	O
this	O
transition	O
(and	O
for	O
a	O
deletion	O
mutation)	O
produce	O
no	O
detectable	O
HEXA	O
mRNA.	O
The	O
intron	O
7	O
+	O
1	O
mutation	O
occurs	O
in	O
the	O
base	O
adjacent	O
to	O
the	O
site	O
of	O
the	O
adult-onset	O
TSD	Modifier
mutation	O
(G805A).	O
In	O
both	O
mutations	O
a	O
restriction	O
site	O
for	O
the	O
endonuclease	O
EcoRII	O
is	O
abolished.	O
Unambiguous	O
diagnosis,	O
therefore,	O
requires	O
allele-specific	O
oligonucleotide	O
hybridization	O
to	O
distinguish	O
between	O
these	O
two	O
mutant	O
alleles.	O
The	O
intron	O
7	O
+	O
1	O
mutation	O
has	O
been	O
detected	O
in	O
three	O
unrelated	O
families.	O
Obligate	O
heterozygotes	O
for	O
the	O
intron	O
7	O
+	O
1	O
mutation	O
were	O
born	O
in	O
the	O
Saguenay-Lac-St-Jean	O
region	O
of	O
Quebec.	O
The	O
most	O
recent	O
ancestors	O
common	O
to	O
obligate	O
carriers	O
of	O
this	O
mutation	O
were	O
from	O
the	O
Charlevoix	O
region	O
of	O
the	O
province	O
of	O
Quebec.	O
This	O
mutation	O
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	O
than	O
the	O
exon	O
1	O
deletion	O
TSD	Modifier

Recessively	O
inherited	O
multiple	SpecificDisease
epiphyseal	SpecificDisease
dysplasia	SpecificDisease
with	O
normal	O
stature,	O
club	SpecificDisease
foot	SpecificDisease
,	O
and	O
double	DiseaseClass
layered	DiseaseClass
patella	DiseaseClass
caused	O
by	O
a	O
DTDST	O
mutation.	O
We	O
have	O
observed	O
over	O
25	O
different	O
mutations	O
in	O
the	O
diastrophic	Modifier
dysplasia	Modifier
sulphate	O
transporter	O
gene	O
(DTDST)	O
in	O
association	O
with	O
the	O
recessive	DiseaseClass
disorders	DiseaseClass
	O
achondrogenesis	SpecificDisease
1B	SpecificDisease
,	O
atelosteogenesis	SpecificDisease
2	SpecificDisease
,	O
and	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
.	O
The	O
c862t	O
(R279W)	O
transition	O
is	O
the	O
most	O
common	O
mutation	O
in	O
non-Finnish	O
patients,	O
but	O
in	O
these	O
disorders	O
it	O
is	O
usually	O
combined	O
with	O
other	O
DTDST	O
mutations.	O
We	O
had	O
not	O
seen	O
a	O
case	O
of	O
homozygosity	O
for	O
c862t	O
(R279W)	O
until	O
we	O
analysed	O
DNA	O
from	O
a	O
36	O
year	O
old	O
male	O
with	O
tall-normal	O
stature	O
(180	O
cm)	O
who	O
asked	O
for	O
genetic	O
counselling	O
for	O
suspected	O
multiple	SpecificDisease
epiphyseal	SpecificDisease
dysplasia	SpecificDisease
.	O
He	O
was	O
treated	O
for	O
club	SpecificDisease
foot	SpecificDisease
and	O
hip	SpecificDisease
dysplasia	SpecificDisease
at	O
birth.	O
Skeletal	O
changes	O
consistent	O
with	O
multiple	SpecificDisease
epiphyseal	SpecificDisease
dysplasia	SpecificDisease
,	O
with	O
the	O
peculiar	O
finding	O
of	O
a	O
double	DiseaseClass
layered	DiseaseClass
patella	DiseaseClass
,	O
were	O
recognised	O
during	O
childhood.	O
Cleft	SpecificDisease
palate	SpecificDisease
,	O
swelling	DiseaseClass
of	DiseaseClass
the	DiseaseClass
ear	DiseaseClass
pinna	DiseaseClass
,	O
and	O
hitch	DiseaseClass
hiker	DiseaseClass
thumb	DiseaseClass
were	O
absent.	O
He	O
was	O
found	O
to	O
be	O
homozygous,	O
and	O
both	O
healthy	O
parents	O
heterozygous,	O
for	O
the	O
R279W	O
mutation	O
in	O
DTDST,	O
and	O
his	O
fibroblasts	O
showed	O
a	O
sulphate	O
incorporation	O
defect	O
typical	O
of	O
DTDST	SpecificDisease
disorders	SpecificDisease
.	O
Counselling	O
was	O
given	O
for	O
a	O
recessive	DiseaseClass
disorder	DiseaseClass
,	O
thereby	O
considerably	O
reducing	O
the	O
probability	O
of	O
affected	O
offspring.	O
Multiple	SpecificDisease
epiphyseal	SpecificDisease
dysplasia	SpecificDisease
is	O
more	O
frequently	O
caused	O
by	O
dominant	O
mutations	O
in	O
the	O
COMP	O
(	O
EDM1	SpecificDisease
,	O
McKusick	O
132400)	O
and	O
COL9A2	O
genes	O
(	O
EDM2	SpecificDisease
,	O
McKusick	O
600204).	O
A	O
few	O
other	O
patients	O
and	O
families	O
with	O
features	O
similar	O
to	O
our	O
proband	O
have	O
been	O
described	O
previously	O
and	O
considered	O
to	O
have	O
autosomal	O
recessive	O
MED	SpecificDisease
(	O
EDM4	SpecificDisease

Myotonic	SpecificDisease
dystrophy	SpecificDisease
:	O
size-	O
and	O
sex-dependent	O
dynamics	O
of	O
CTG	O
meiotic	O
instability,	O
and	O
somatic	O
mosaicism.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
a	O
progressive	O
neuromuscular	DiseaseClass
disorder	DiseaseClass
which	O
results	O
from	O
elongations	O
of	O
an	O
unstable	O
(CTG)	O
n	O
repeat,	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	Modifier
gene.	O
A	O
correlation	O
has	O
been	O
demonstrated	O
between	O
the	O
increase	O
in	O
the	O
repeat	O
number	O
of	O
this	O
sequence	O
and	O
the	O
severity	O
of	O
the	O
disease.	O
However,	O
the	O
clinical	O
status	O
of	O
patients	O
cannot	O
be	O
unambiguously	O
ascertained	O
solely	O
on	O
the	O
basis	O
of	O
the	O
number	O
of	O
CTG	O
repeats.	O
Moreover,	O
the	O
exclusive	O
maternal	O
inheritance	O
of	O
the	O
congenital	O
form	O
remains	O
unexplained.	O
Our	O
observation	O
of	O
differently	O
sized	O
repeats	O
in	O
various	O
DM	Modifier
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	O
of	O
the	O
mutation	O
observed	O
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	O
and	O
nature	O
of	O
symptoms.	O
Through	O
a	O
molecular	O
and	O
genetic	O
study	O
of	O
142	O
families	O
including	O
418	O
DM	Modifier

Fatal	O
pyoderma	SpecificDisease
gangrenosum	SpecificDisease
in	O
association	O
with	O
C7	SpecificDisease
deficiency	SpecificDisease
.	O
Although	O
pyoderma	SpecificDisease
gangrenosum	SpecificDisease
(	O
PG	SpecificDisease
)	O
is	O
often	O
associated	O
with	O
systemic	DiseaseClass
diseases	DiseaseClass
,	O
it	O
has	O
not	O
been	O
reported	O
in	O
association	O
with	O
congenital	DiseaseClass
complement	DiseaseClass
deficiencies	DiseaseClass
.	O
We	O
describe	O
an	O
aggressive	O
and	O
ultimately	O
fatal	O
case	O
of	O
PG	SpecificDisease
in	O
a	O
patient	O
with	O
a	O
congenital	O
C7	SpecificDisease
deficiency	SpecificDisease
.	O
Deficiencies	SpecificDisease
of	SpecificDisease
C7	SpecificDisease
can	O
be	O
associated	O
with	O
decreased	O
neutrophil	O
chemotaxis,	O
phagocytosis,	O
and	O
opsonization,	O
similar	O
to	O
the	O
immunologic	DiseaseClass
abnormalities	DiseaseClass
described	O
in	O
patients	O
with	O
PG	SpecificDisease
.	O
Our	O
patients	O
decreased	O
complement	O
level,	O
if	O
not	O
directly	O
related	O
to	O
the	O
development	O
of	O
PG	SpecificDisease

Emerin	SpecificDisease
deficiency	SpecificDisease
at	O
the	O
nuclear	O
membrane	O
in	O
patients	O
with	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
Mutations	O
in	O
the	O
STA	O
gene	O
at	O
the	O
Xq28	O
locus	O
have	O
been	O
found	O
in	O
patients	O
with	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
).	O
This	O
gene	O
encodes	O
a	O
hitherto	O
unknown	O
protein	O
named	O
emerin.	O
To	O
elucidate	O
the	O
subcellular	O
localization	O
of	O
emerin,	O
we	O
raised	O
two	O
antisera	O
against	O
synthetic	O
peptide	O
fragments	O
predicted	O
from	O
emerin	O
cDNA.	O
Using	O
both	O
antisera,	O
we	O
found	O
positive	O
nuclear	O
membrane	O
staining	O
in	O
skeletal,	O
cardiac	O
and	O
smooth	O
muscles	O
in	O
the	O
normal	O
controls	O
and	O
in	O
patients	O
with	O
neuromuscular	DiseaseClass
diseases	DiseaseClass
other	O
than	O
EDMD	SpecificDisease
.	O
In	O
contrast,	O
a	O
deficiency	O
in	O
immunofluorescent	O
staining	O
of	O
skeletal	O
and	O
cardiac	O
muscle	O
from	O
EDMD	Modifier
patients	O
was	O
observed.	O
A	O
34	O
kD	O
protein	O
is	O
immunoreactive	O
with	O
the	O
antisera--the	O
protein	O
is	O
equivalent	O
to	O
that	O
predicted	O
for	O
emerin.	O
Together,	O
our	O
findings	O
suggest	O
the	O
specific	O
deficiency	SpecificDisease
of	SpecificDisease
emerin	SpecificDisease
in	O
the	O
nuclear	O
membrane	O
of	O
muscle	O
cells	O
in	O
patients	O
with	O
EDMD	SpecificDisease

A	O
p16INK4a-insensitive	O
CDK4	O
mutant	O
targeted	O
by	O
cytolytic	O
T	O
lymphocytes	O
in	O
a	O
human	O
melanoma	SpecificDisease
.	O
A	O
mutated	O
cyclin-dependent	O
kinase	O
4	O
(CDK4)	O
was	O
identified	O
as	O
a	O
tumor	Modifier
-specific	O
antigen	O
recognized	O
by	O
HLA-A2.	O
1-restricted	O
autologous	O
cytolytic	O
T	O
lymphocytes	O
(CTLs)	O
in	O
a	O
human	O
melanoma	SpecificDisease
.	O
The	O
mutated	O
CDK4	O
allele	O
was	O
present	O
in	O
autologous	O
cultured	O
melanoma	Modifier
cells	O
and	O
metastasis	O
tissue,	O
but	O
not	O
in	O
the	O
patients	O
lymphocytes.	O
The	O
mutation,	O
an	O
arginine-to-cysteine	O
exchange	O
at	O
residue	O
24,	O
was	O
part	O
of	O
the	O
CDK4	O
peptide	O
recognized	O
by	O
CTLs	O
and	O
prevented	O
binding	O
of	O
the	O
CDK4	O
inhibitor	O
p16INK4a,	O
but	O
not	O
of	O
p21	O
or	O
of	O
p27KIP1.	O
The	O
same	O
mutation	O
was	O
found	O
in	O
one	O
additional	O
melanoma	SpecificDisease
among	O
28	O
melanomas	SpecificDisease
analyzed.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
CDK4	O
can	O
create	O
a	O
tumor	Modifier
-specific	O
antigen	O
and	O
can	O
disrupt	O
the	O
cell-cycle	O
regulation	O
exerted	O
by	O
the	O
tumor	Modifier

Molecular	O
analysis	O
in	O
familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
:	O
early	O
diagnosis	O
of	O
an	O
asymptomatic	O
carrier.	O
Familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
(	O
FNDI	SpecificDisease
)	O
is	O
an	O
inherited	O
deficiency	DiseaseClass
of	DiseaseClass
the	DiseaseClass
hormone	DiseaseClass
arginine	DiseaseClass
vasopressin	DiseaseClass
(AVP)	O
and	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait.	O
In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
AVP-neurophysin	O
II	O
(AVP-NPII)	O
gene	O
in	O
a	O
Spanish	O
kindred.	O
Studies	O
were	O
performed	O
on	O
seven	O
members	O
(four	O
clinically	O
affected)	O
of	O
the	O
family.	O
Patients	O
were	O
diagnosed	O
at	O
the	O
Hospital	O
Universitario	O
Gregorio	O
Maranon	O
(Madrid,	O
Spain).	O
The	O
entire	O
coding	O
region	O
of	O
the	O
AVP-NPII	O
gene	O
of	O
all	O
family	O
members	O
was	O
amplified	O
by	O
PCR	O
and	O
sequenced.	O
All	O
affected	O
individuals	O
presented	O
a	O
missense	O
mutation	O
(G1757--	O
>	O
A)	O
that	O
replaces	O
glycine	O
at	O
position	O
23	O
with	O
arginine	O
within	O
the	O
NPII	O
domain.	O
The	O
substitution	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
and	O
was	O
present	O
in	O
heterozygosis.	O
Additionally,	O
one	O
of	O
the	O
asymptomatic	O
relatives	O
(a	O
girl	O
8	O
months	O
old	O
at	O
the	O
time	O
of	O
study)	O
was	O
identified	O
as	O
carrier	O
of	O
the	O
same	O
mutation	O
and	O
developed	O
the	O
disease	O
3	O
months	O
later.	O
The	O
alteration	O
found	O
in	O
the	O
second	O
exon	O
of	O
the	O
gene	O
in	O
this	O
family	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
disease,	O
as	O
all	O
individuals	O
harboring	O
the	O
mutation	O
had	O
been	O
previously	O
diagnosed	O
or	O
have	O
eventually	O
developed	O
FNDI	SpecificDisease
.	O
Identification	O
of	O
the	O
molecular	O
defect	O
underlying	O
FNDI	SpecificDisease

Sialophorin,	O
a	O
surface	O
sialoglycoprotein	O
defective	O
in	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
,	O
is	O
involved	O
in	O
human	O
T	O
lymphocyte	O
proliferation.	O
The	O
mAb	O
L10	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
and	O
the	O
function	O
of	O
sialophorin,	O
the	O
heavily	O
glycosylated	O
surface	O
molecule	O
that	O
is	O
deficient/defective	O
in	O
lymphocytes	O
of	O
patients	O
with	O
the	O
X-linked	SpecificDisease
immunodeficiency	SpecificDisease
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease

Characterization	O
of	O
the	O
rat	O
spinocerebellar	O
ataxia	O
type	O
3	O
gene.	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
)	O
belongs	O
to	O
a	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
neurodegenerative	DiseaseClass
disorders	DiseaseClass
characterized	O
by	O
progressive	SpecificDisease
cerebellar	SpecificDisease
ataxia	SpecificDisease
.	O
The	O
disease-causing	O
mutation	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
and	O
expanded	O
(CAG)	O
n	O
trinucleotide	O
repeat	O
in	O
a	O
novel	O
gene	O
of	O
unknown	O
function.	O
In	O
Caucasians,	O
repeat	O
expansions	O
in	O
the	O
MJD1	O
gene	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
the	O
clinically	O
distinct	O
autosomal	O
dominant	O
spinocerebellar	SpecificDisease
ataxia	SpecificDisease
type	SpecificDisease
3	SpecificDisease
(	O
SCA3	SpecificDisease
).	O
In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
biology	O
of	O
the	O
MJD1/SCA3	O
gene	O
we	O
cloned	O
the	O
rat	O
homologue	O
and	O
studied	O
its	O
expression.	O
The	O
rat	O
and	O
human	O
ataxin-3	O
genes	O
are	O
highly	O
homologous	O
with	O
an	O
overall	O
sequence	O
identity	O
of	O
approximately	O
88%.	O
However,	O
the	O
C-terminal	O
end	O
of	O
the	O
putative	O
protein	O
differs	O
strongly	O
from	O
the	O
published	O
human	O
sequence.	O
The	O
(CAG)	O
n	O
block	O
in	O
the	O
rat	O
cDNA	O
consists	O
of	O
just	O
three	O
interrupted	O
units	O
suggesting	O
that	O
a	O
long	O
polyglutamine	O
stretch	O
is	O
not	O
essential	O
for	O
the	O
normal	O
function	O
of	O
the	O
ataxin-3	O
protein	O
in	O
rodents.	O
The	O
expression	O
pattern	O
of	O
the	O
SCA3	O
gene	O
in	O
various	O
rat	O
and	O
human	O
tissues	O
was	O
investigated	O
by	O
Northern	O
blot	O
analyses.	O
The	O
mature	O
transcript	O
is	O
approximately	O
6	O
kb	O
in	O
length.	O
In	O
rat	O
testis,	O
a	O
smaller	O
transcript	O
of	O
1.	O
3	O
kb	O
was	O
identified.	O
Transcription	O
of	O
rsca3	O
was	O
detected	O
in	O
most	O
rat	O
tissues	O
including	O
brain.	O
Analyzing	O
the	O
expression	O
level	O
of	O
the	O
SCA3	O
gene	O
in	O
several	O
human	O
brain	O
sections	O
revealed	O
no	O
significant	O
higher	O
mRNA	O
level	O
in	O
regions	O
predominantly	O
affected	O
in	O
MJD	SpecificDisease
.	O
Thus	O
additional	O
molecules	O
and/or	O
regulatory	O
events	O
are	O
necessary	O
to	O
explain	O
the	O
exclusive	O
degeneration	DiseaseClass
of	DiseaseClass
certain	DiseaseClass
brain	DiseaseClass
areas	DiseaseClass

The	O
alveolar	Modifier
rhabdomyosarcoma	Modifier
PAX3/FKHR	O
fusion	O
protein	O
is	O
a	O
transcriptional	O
activator.	O
Chimeric	O
transcription	O
factors,	O
created	O
by	O
gene	O
fusions	O
as	O
the	O
result	O
of	O
chromosomal	O
translocations,	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
pathologically	O
disparate	O
solid	DiseaseClass
tumors	DiseaseClass
.	O
The	O
PAX3/FKHR	O
fusion	O
gene,	O
formed	O
by	O
a	O
t	O
(2;	O
13)	O
(q35;	O
q14)	O
in	O
alveolar	SpecificDisease
rhabdomyosarcoma	SpecificDisease
,	O
encodes	O
a	O
hybrid	O
protein	O
that	O
contains	O
both	O
PAX3	O
DNA	O
binding	O
domains,	O
the	O
paired	O
box	O
and	O
homeodomain,	O
linked	O
to	O
the	O
bisected	O
DNA	O
binding	O
domain	O
of	O
FKHR,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors.	O
Here	O
we	O
report	O
that	O
PAX3	O
and	O
PAX3/FKHR	O
display	O
similar,	O
but	O
not	O
identical	O
transactivation	O
activities	O
when	O
tested	O
with	O
model	O
Pax	O
recognition	O
sequences.	O
No	O
functional	O
role	O
could	O
be	O
ascribed	O
solely	O
to	O
the	O
residual	O
FKHR	O
binding	O
domain	O
present	O
in	O
the	O
fusion	O
protein,	O
but	O
FKHR	O
was	O
found	O
to	O
contribute	O
a	O
strong	O
carboxyl	O
terminal	O
activation	O
domain	O
replacing	O
the	O
one	O
located	O
in	O
the	O
unrearranged	O
PAX3	O
gene.	O
We	O
show	O
that	O
the	O
native	O
PAX3/FKHR	O
protein	O
present	O
in	O
tumor	Modifier

Myotonia	SpecificDisease
levior	SpecificDisease
is	O
a	O
chloride	DiseaseClass
channel	DiseaseClass
disorder	DiseaseClass
.	O
The	O
group	O
of	O
dominant	DiseaseClass
non-dystrophic	DiseaseClass
myotonias	DiseaseClass
,	O
comprising	O
disorders	O
characterized	O
by	O
clinically	O
similar	O
forms	O
of	O
myogenic	O
muscle	O
stiffness,	O
is	O
genetically	O
inhomogeneous.	O
Dominant	SpecificDisease
myotonia	SpecificDisease
congenita	SpecificDisease
(	O
Thomsens	SpecificDisease
disease	SpecificDisease
)	O
is	O
linked	O
to	O
CLCN1,	O
the	O
gene	O
encoding	O
the	O
major	O
muscle	O
chloride	O
channel,	O
localized	O
on	O
chromosome	O
7q35.	O
In	O
contrast,	O
dominant	DiseaseClass
myotonias	DiseaseClass
sensitive	O
to	O
potassium	O
are	O
caused	O
by	O
point	O
mutations	O
in	O
SCN4A	O
on	O
chromosome	O
17q,	O
the	O
gene	O
for	O
the	O
alpha	O
subunit	O
of	O
the	O
adult	O
skeletal	O
muscle	O
sodium	O
channel.	O
No	O
linkage	O
or	O
molecular	O
genetic	O
data	O
are	O
as	O
yet	O
available	O
on	O
myotonia	SpecificDisease
levior	SpecificDisease
characterized	O
by	O
milder	O
symptoms	O
and	O
later	O
onset	O
of	O
myotonia	DiseaseClass
than	O
in	O
Thomsens	SpecificDisease
disease	SpecificDisease
,	O
and	O
absence	O
of	O
muscle	SpecificDisease
hypertrophy	SpecificDisease
.	O
We	O
report	O
a	O
CLCN1	O
Gln-552-Arg	O
substitution	O
for	O
a	O
family	O
with	O
dominant	O
inheritance	O
previously	O
diagnosed	O
to	O
have	O
myotonia	SpecificDisease
levior	SpecificDisease
.	O
Thus,	O
this	O
disorder	O
appears	O
as	O
a	O
variant	O
of	O
Thomsens	SpecificDisease
disease	SpecificDisease
due	O
to	O
mutations	O
leading	O
to	O
low	O
clinical	O
expressivity.	O
In	O
addition,	O
we	O
report	O
a	O
novel	O
Ile-290-Met	O
CLCN1	O
mutation	O
for	O
a	O
typical	O
Thomsen	O
pedigree.	O
In	O
another	O
family	O
previously	O
diagnosed	O
as	O
having	O
Thomsens	SpecificDisease
disease	SpecificDisease
,	O
we	O
unexpectedly	O
found	O
a	O
CLCN1	O
14	O
bp	O
deletion	O
known	O
to	O
cause	O
recessive	DiseaseClass
myotonia	DiseaseClass

Markedly	O
accelerated	O
catabolism	O
of	O
apolipoprotein	O
A-II	O
(ApoA-II)	O
and	O
high	O
density	O
lipoproteins	O
containing	O
ApoA-II	O
in	O
classic	O
lecithin:	O
cholesterol	SpecificDisease
acyltransferase	SpecificDisease
deficiency	SpecificDisease
and	O
fish-eye	SpecificDisease
disease	SpecificDisease
.	O
Classic	CompositeMention
(complete)	CompositeMention
lecithin	CompositeMention
	CompositeMention
cholesterol	CompositeMention
acyltransferase	CompositeMention
(LCAT)	CompositeMention
deficiency	CompositeMention
and	O
Fish-eye	SpecificDisease
disease	SpecificDisease
(	O
partial	SpecificDisease
LCAT	SpecificDisease
deficiency	SpecificDisease
)	O
are	O
genetic	O
syndromes	O
associated	O
with	O
markedly	O
decreased	O
plasma	O
levels	O
of	O
high	O
density	O
lipoprotein	O
(HDL)	O
cholesterol	O
but	O
not	O
with	O
an	O
increased	O
risk	O
of	O
atherosclerotic	SpecificDisease
cardiovascular	SpecificDisease
disease	SpecificDisease
.	O
We	O
investigated	O
the	O
metabolism	O
of	O
the	O
HDL	O
apolipoproteins	O
(apo)	O
apoA-I	O
and	O
apoA-II	O
in	O
a	O
total	O
of	O
five	O
patients	O
with	O
LCAT	SpecificDisease
deficiency	SpecificDisease
,	O
one	O
with	O
classic	SpecificDisease
LCAT	SpecificDisease
deficiency	SpecificDisease
and	O
four	O
with	O
Fish-eye	SpecificDisease
disease	SpecificDisease
.	O
Plasma	O
levels	O
of	O
apoA-II	O
were	O
decreased	O
to	O
a	O
proportionately	O
greater	O
extent	O
(23%	O
of	O
normal)	O
than	O
apoA-I	O
(30%	O
of	O
normal).	O
In	O
addition,	O
plasma	O
concentrations	O
of	O
HDL	O
particles	O
containing	O
both	O
apoA-I	O
and	O
apoA-II	O
(LpA-I	O
	O
A-II)	O
were	O
much	O
lower	O
(18%	O
of	O
normal)	O
than	O
those	O
of	O
particles	O
containing	O
only	O
apoA-I	O
(LpA-I)	O
(51%	O
of	O
normal).	O
The	O
metabolic	O
basis	O
for	O
the	O
low	O
levels	O
of	O
apoA-II	O
and	O
LpA-I	O
	O
A-II	O
was	O
investigated	O
in	O
all	O
five	O
patients	O
using	O
both	O
exogenous	O
radiotracer	O
and	O
endogenous	O
stable	O
isotope	O
labeling	O
techniques.	O
The	O
mean	O
plasma	O
residence	O
time	O
of	O
apoA-I	O
was	O
decreased	O
at	O
2.	O
08	O
+/-	O
0.	O
27	O
d	O
(controls	O
4.	O
74	O
+/-	O
0.	O
65	O
days);	O
however,	O
the	O
residence	O
time	O
of	O
apoA-II	O
was	O
even	O
shorter	O
at	O
1.	O
66	O
+/-	O
0.	O
24	O
d	O
(controls	O
5.	O
25	O
+/-	O
0.	O
61	O
d).	O
In	O
addition,	O
the	O
catabolism	O
of	O
apoA-I	O
in	O
LpA-I	O
	O
A-II	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
apoA-I	O
in	O
LpA-I.	O
In	O
summary,	O
genetic	O
syndromes	O
of	O
either	O
complete	CompositeMention
or	CompositeMention
partial	CompositeMention
LCAT	CompositeMention
deficiency	CompositeMention
result	O
in	O
low	O
levels	O
of	O
HDL	O
through	O
preferential	O
hypercatabolism	O
of	O
apoA-II	O
and	O
HDL	O
particles	O
containing	O
apoA-II.	O
Because	O
LpA-I	O
has	O
been	O
proposed	O
to	O
be	O
more	O
protective	O
than	O
LpA-I	O
	O
A-II	O
against	O
atherosclerosis	SpecificDisease
,	O
this	O
selective	O
effect	O
on	O
the	O
metabolism	O
of	O
LpA-I	O
	O
A-II	O
may	O
provide	O
a	O
potential	O
explanation	O
why	O
patients	O
with	O
classic	SpecificDisease
LCAT	SpecificDisease
deficiency	SpecificDisease
and	O
Fish-eye	SpecificDisease
disease	SpecificDisease
are	O
not	O
at	O
increased	O
risk	O
for	O
premature	O
atherosclerosis	SpecificDisease

The	O
identical	O
5'	O
splice-site	O
acceptor	O
mutation	O
in	O
five	O
attenuated	Modifier
APC	Modifier
families	O
from	O
Newfoundland	O
demonstrates	O
a	O
founder	O
effect.	O
Inherited	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
predispose	O
carriers	O
to	O
multiple	O
adenomatous	CompositeMention
polyps	CompositeMention
of	CompositeMention
the	CompositeMention
colon	CompositeMention
and	CompositeMention
rectum	CompositeMention
and	O
to	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
Mutations	O
located	O
at	O
the	O
extreme	O
5	O
end	O
of	O
the	O
APC	Modifier
gene,	O
however,	O
are	O
associated	O
with	O
a	O
less	O
severe	O
disease	O
known	O
as	O
attenuated	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
AAPC	SpecificDisease
).	O
Many	O
individuals	O
with	O
AAPC	SpecificDisease
develop	O
relatively	O
few	O
colorectal	SpecificDisease
polyps	SpecificDisease
but	O
are	O
still	O
at	O
high	O
risk	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
We	O
report	O
here	O
the	O
identification	O
of	O
a	O
5	O
APC	Modifier
germline	O
mutation	O
in	O
five	O
separately	O
ascertained	O
AAPC	Modifier
families	O
from	O
Newfoundland,	O
Canada.	O
This	O
disease-causing	O
mutation	O
is	O
a	O
single	O
basepair	O
change	O
(G	O
to	O
A)	O
in	O
the	O
splice-acceptor	O
region	O
of	O
APC	Modifier
intron	O
3	O
that	O
creates	O
a	O
mutant	O
RNA	O
without	O
exon	O
4	O
of	O
APC.	O
The	O
observation	O
of	O
the	O
same	O
APC	Modifier
mutation	O
in	O
five	O
families	O
from	O
the	O
same	O
geographic	O
area	O
demonstrates	O
a	O
founder	O
effect.	O
Furthermore,	O
the	O
identification	O
of	O
this	O
germline	O
mutation	O
strengthens	O
the	O
correlation	O
between	O
the	O
5	O
location	O
of	O
an	O
APC	Modifier
disease-causing	O
mutation	O
and	O
the	O
attenuated	Modifier
polyposis	Modifier

Linkage	O
of	O
aspartylglucosaminuria	SpecificDisease
(	O
AGU	SpecificDisease
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4.	O
Aspartylglucosaminuria	SpecificDisease
(	O
AGU	SpecificDisease
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(AGA).	O
The	O
structural	O
gene	O
for	O
AGA	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21-qter	O
of	O
chromosome	O
4.	O
We	O
have	O
studied	O
the	O
map	O
position	O
of	O
the	O
AGU	O
locus	O
in	O
relation	O
to	O
other	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
using	O
linkage	O
analyses.	O
Restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
ADH2,	O
ADH3,	O
EGF,	O
FG	O
alpha	O
and	O
FG	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
MNS	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
Finnish	O
AGU	Modifier
families.	O
The	O
heterozygous	O
family	O
members	O
were	O
identified	O
by	O
reduced	O
activity	O
of	O
AGA	O
in	O
lymphocytes.	O
Linkage	O
studies	O
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	O
analyses.	O
Loose	O
linkage	O
of	O
the	O
AGU	Modifier

Linkage	O
analysis	O
in	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
and	O
application	O
in	O
post-	O
and	O
prenatal	O
diagnosis.	O
We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(F8C),	O
in	O
several	O
large	O
families	O
with	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
).	O
The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22.	O
5	O
at	O
1	O
cM.	O
F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	SpecificDisease
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7.	O
8	O
without	O
recombination.	O
Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304,	O
DXS52,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	SpecificDisease
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52.	O
In	O
four	O
patients	O
with	O
ALD	SpecificDisease
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed;	O
in	O
particular,	O
there	O
were	O
no	O
abnormalities	DiseaseClass
in	DiseaseClass
the	DiseaseClass
vision	DiseaseClass
blindness	DiseaseClass
genes	DiseaseClass

Multicentric	O
origin	O
of	O
hemochromatosis	Modifier
gene	O
(HFE)	O
mutations.	O
Genetic	SpecificDisease
hemochromatosis	SpecificDisease
(	O
GH	SpecificDisease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry.	O
In	O
northwestern	O
Europe,	O
>	O
80%	O
of	O
GH	Modifier
patients	O
are	O
homozygous	O
for	O
one	O
mutation,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(C282Y)	O
in	O
the	O
unprocessed	O
protein.	O
In	O
a	O
proportion	O
of	O
GH	Modifier
patients,	O
two	O
mutations	O
are	O
present,	O
C282Y	O
and	O
H63D.	O
The	O
clinical	O
significance	O
of	O
this	O
second	O
mutation	O
is	O
such	O
that	O
it	O
appears	O
to	O
predispose	O
1%	O
-2%	O
of	O
compound	O
heterozygotes	O
to	O
expression	O
of	O
the	O
disease.	O
The	O
distribution	O
of	O
the	O
two	O
mutations	O
differ,	O
C282Y	O
being	O
limited	O
to	O
those	O
of	O
northwestern	O
European	O
ancestry	O
and	O
H63D	O
being	O
found	O
at	O
allele	O
frequencies	O
>	O
5%,	O
in	O
Europe,	O
in	O
countries	O
bordering	O
the	O
Mediterranean,	O
in	O
the	O
Middle	O
East,	O
and	O
in	O
the	O
Indian	O
subcontinent.	O
The	O
C282Y	O
mutation	O
occurs	O
on	O
a	O
haplotype	O
that	O
extends	O
</=	O
6	O
Mb,	O
suggesting	O
that	O
this	O
mutation	O
has	O
arisen	O
during	O
the	O
past	O
2,	O
000	O
years.	O
The	O
H63D	O
mutation	O
is	O
older	O
and	O
does	O
not	O
occur	O
on	O
such	O
a	O
large	O
extended	O
haplotype,	O
the	O
haplotype	O
in	O
this	O
case	O
extending	O
</=	O
700	O
kb.	O
Here	O
we	O
report	O
the	O
finding	O
of	O
the	O
H63D	O
and	O
C282Y	O
mutations	O
on	O
new	O
haplotypes.	O
In	O
Sri	O
Lanka	O
we	O
have	O
found	O
H63D	O
on	O
three	O
new	O
haplotypes	O
and	O
have	O
found	O
C282Y	O
on	O
one	O
new	O
haplotype,	O
demonstrating	O
that	O
these	O
mutations	O
have	O
arisen	O
independently	O
on	O
this	O
island.	O
These	O
results	O
suggest	O
that	O
the	O
HFE	O
gene	O
has	O
been	O
the	O
subject	O
of	O
selection	O
pressure.	O
These	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	DiseaseClass
diseases	DiseaseClass
,	O
environmental	O
conditions,	O
	O
or	O
other	O
genetic	DiseaseClass
disorders	DiseaseClass
such	O
as	O
anemia	DiseaseClass

Identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
Lesch-Nyhan	Modifier
locus	O
by	O
ribonuclease	O
A	O
cleavage.	O
Many	O
mutations	O
leading	O
to	O
human	O
disease	O
are	O
the	O
result	O
of	O
single	O
DNA	O
base	O
pair	O
changes	O
that	O
cannot	O
be	O
identified	O
by	O
Southern	O
analysis.	O
This	O
has	O
prompted	O
the	O
development	O
of	O
alternative	O
assays	O
for	O
point	O
mutation	O
detection.	O
The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure,	O
with	O
a	O
polyuridylic	O
acid-paper	O
affinity	O
chromatography	O
step,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	O
lesions	O
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(HPRT)	O
messenger	O
RNAs	O
of	O
patients	O
with	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
RNA	O
from	O
5	O
of	O
14	O
Lesch-Nyhan	Modifier
patients	O
who	O
were	O
chosen	O
because	O
no	O
HPRT	O
Southern	O
or	O
Northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found.	O
This	O
approach	O
now	O
allows	O
HPRT	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

MEFV-Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
:	O
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype-genetic	O
and	O
therapeutic	O
implications.	O
Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
is	O
a	O
recessively	DiseaseClass
inherited	DiseaseClass
disorder	DiseaseClass
that	O
is	O
common	O
in	O
patients	O
of	O
Armenian	O
ancestry.	O
To	O
date,	O
its	O
diagnosis,	O
which	O
can	O
be	O
made	O
only	O
retrospectively,	O
is	O
one	O
of	O
exclusion,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	SpecificDisease
inflammation	SpecificDisease
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery.	O
Renal	SpecificDisease
amyloidosis	SpecificDisease
,	O
prevented	O
by	O
colchicine,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
FMF	SpecificDisease
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
MEFV	O
gene.	O
To	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV-gene	O
analysis,	O
we	O
investigated	O
90	O
Armenian	O
FMF	Modifier
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic-linkage	O
analysis.	O
Eight	O
mutations,	O
one	O
of	O
which	O
(R408Q)	O
is	O
new,	O
were	O
found	O
to	O
account	O
for	O
93%	O
of	O
the	O
163	O
independent	O
FMF	Modifier
alleles,	O
with	O
both	O
FMF	Modifier
alleles	O
identified	O
in	O
89%	O
of	O
the	O
patients.	O
In	O
several	O
instances,	O
family	O
studies	O
provided	O
molecular	O
evidence	O
for	O
pseudodominant	O
transmission	O
and	O
incomplete	O
penetrance	O
of	O
the	O
disease	O
phenotype.	O
The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	SpecificDisease
amyloidosis	SpecificDisease
and	O
arthritis	SpecificDisease

Identification	O
and	O
localization	O
of	O
huntingtin	O
in	O
brain	O
and	O
human	O
lymphoblastoid	O
cell	O
lines	O
with	O
anti-fusion	O
protein	O
antibodies.	O
The	O
Huntington	Modifier
disease	Modifier
(	O
HD	Modifier
)	O
phenotype	O
is	O
associated	O
with	O
expansion	O
of	O
a	O
trinucleotide	O
repeat	O
in	O
the	O
IT15	O
gene,	O
which	O
is	O
predicted	O
to	O
encode	O
a	O
348-kDa	O
protein	O
named	O
huntington.	O
We	O
used	O
polyclonal	O
and	O
monoclonal	O
anti-fusion	O
protein	O
antibodies	O
to	O
identify	O
native	O
huntingtin	O
in	O
rat,	O
monkey,	O
and	O
human.	O
Western	O
blots	O
revealed	O
a	O
protein	O
with	O
the	O
expected	O
molecular	O
weight	O
which	O
is	O
present	O
in	O
the	O
soluble	O
fraction	O
of	O
rat	O
and	O
monkey	O
brain	O
tissues	O
and	O
lymphoblastoid	O
cells	O
from	O
control	O
cases.	O
In	O
lymphoblastoid	O
cell	O
lines	O
from	O
juvenile-onset	O
heterozygote	O
HD	Modifier
cases,	O
both	O
normal	O
and	O
mutant	O
huntingtin	O
are	O
expressed,	O
and	O
increasing	O
repeat	O
expansion	O
leads	O
to	O
lower	O
levels	O
of	O
the	O
mutant	O
protein.	O
Immunocytochemistry	O
indicates	O
that	O
huntingtin	O
is	O
located	O
in	O
neurons	O
throughout	O
the	O
brain,	O
with	O
the	O
highest	O
levels	O
evident	O
in	O
larger	O
neurons.	O
In	O
the	O
human	O
striatum,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch-like	O
distribution,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	O
in	O
HD	SpecificDisease

Correlation	O
between	O
the	O
location	O
of	O
germ-line	O
mutations	O
in	O
the	O
APC	Modifier
gene	O
and	O
the	O
number	O
of	O
colorectal	SpecificDisease
polyps	SpecificDisease
in	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
patients.	O
Recently	O
we	O
have	O
isolated	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
which	O
causes	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
),	O
and	O
its	O
germ-line	O
mutations	O
in	O
a	O
substantial	O
number	O
of	O
FAP	Modifier
patients	O
have	O
been	O
identified.	O
On	O
the	O
basis	O
of	O
this	O
information,	O
we	O
compared	O
the	O
location	O
of	O
germ-line	O
mutations	O
in	O
the	O
APC	Modifier
gene	O
in	O
22	O
unrelated	O
patients	O
(12	O
of	O
whom	O
have	O
been	O
reported	O
previously)	O
with	O
the	O
number	O
of	O
colorectal	SpecificDisease
polyps	SpecificDisease
developed	O
in	O
FAP	Modifier
patients;	O
17	O
were	O
sparse	O
types	O
and	O
five	O
were	O
profuse	O
types.	O
All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
considered	O
to	O
cause	O
truncation	O
of	O
the	O
gene	O
product	O
by	O
frame-shift	O
due	O
to	O
deletion	O
(14	O
cases)	O
or	O
nonsense	O
mutation	O
(seven	O
cases).	O
The	O
location	O
of	O
the	O
germ-line	O
mutations	O
seems	O
to	O
correlate	O
with	O
the	O
two	O
clinical	O
types;	O
germ-line	O
mutations	O
in	O
five	O
FAP	Modifier
patients	O
with	O
profuse	O
polyps	DiseaseClass
were	O
observed	O
between	O
codon	O
1250	O
and	O
codon	O
1464,	O
whereas	O
mutations	O
in	O
17	O
FAP	Modifier
patients	O
with	O
fewer	O
polyps	DiseaseClass
were	O
observed	O
in	O
the	O
other	O
regions	O
of	O
the	O
APC	Modifier
gene.	O
The	O
result	O
suggests	O
that	O
the	O
number	O
of	O
colorectal	SpecificDisease
polyps	SpecificDisease
in	O
FAP	Modifier
patients	O
may	O
be	O
associated	O
with	O
a	O
difference	O
in	O
the	O
stability	O
or	O
biological	O
function	O
of	O
the	O
truncated	O
APC	Modifier

Duchenne/Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
:	O
correlation	O
of	O
phenotype	O
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	O
mutations.	O
The	O
dark-adapted	O
electroretinogram	O
(ERG)	O
of	O
patients	O
with	O
Duchenne	CompositeMention
and	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
(	O
DMD	SpecificDisease
/	O
BMD	SpecificDisease
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b-wave	O
amplitude.	O
Genotype-phenotype	O
studies	O
of	O
mouse	O
models	O
for	O
DMD	SpecificDisease
show	O
position-specific	O
effects	O
of	O
the	O
mutations	O
upon	O
the	O
phenotype	O
	O
mice	O
with	O
5	O
defects	O
of	O
dystrophin	O
have	O
normal	O
ERGs,	O
those	O
with	O
defects	O
in	O
the	O
central	O
region	O
have	O
a	O
normal	O
b-wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b-wave	O
and	O
oscillatory	O
potentials,	O
and	O
mice	O
with	O
3	O
defects	O
have	O
a	O
phenotype	O
similar	O
to	O
that	O
seen	O
in	O
DMD	Modifier
/	O
BMD	Modifier
patients.	O
The	O
mouse	O
studies	O
suggest	O
a	O
key	O
role	O
for	O
the	O
carboxyl	O
terminal	O
dystrophin	O
isoform,	O
Dp260,	O
in	O
retinal	O
electrophysiology.	O
We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
DMD	Modifier
/	O
BMD	Modifier
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position-specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man.	O
We	O
have	O
found	O
that,	O
in	O
man,	O
a	O
wider	O
variation	O
of	O
DMD	DiseaseClass
defects	DiseaseClass
correlate	O
with	O
reductions	O
in	O
the	O
b-wave	O
amplitude.	O
Individuals	O
with	O
normal	O
ERGs	O
have	O
mutations	O
predominantly	O
located	O
5	O
of	O
the	O
transcript	O
initiation	O
site	O
of	O
Dp260.	O
Our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	O
b-wave	O
phenotype	O
is	O
the	O
mutation	O
position,	O
rather	O
than	O
muscle	Modifier
disease	Modifier

Molecular	O
characterization	O
of	O
two	O
galactosemia	Modifier
mutations	O
and	O
one	O
polymorphism:	O
implications	O
for	O
structure-function	O
analysis	O
of	O
human	O
galactose-1-phosphate	O
uridyltransferase.	O
We	O
report	O
here	O
the	O
molecular	O
characterization	O
of	O
two	O
galactosemia	Modifier
mutations,	O
L74P	O
and	O
F171S,	O
and	O
one	O
polymorphism,	O
S135L,	O
in	O
human	O
galactose-1-phosphate	O
uridyltransferase	O
(GALT).	O
Both	O
galactosemia	Modifier
mutations	O
result	O
in	O
reduced	O
enzymatic	O
activity	O
when	O
reconstructed	O
in	O
the	O
cDNA	O
and	O
overexpressed.	O
The	O
polymorphism,	O
in	O
contrast,	O
has	O
near	O
normal	O
activity.	O
Both	O
mutations	O
affect	O
evolutionarily	O
conserved	O
residues,	O
suggesting	O
that	O
they	O
are	O
functionally	O
important,	O
while	O
the	O
polymorphism	O
occurs	O
in	O
a	O
nonconserved	O
domain	O
which	O
is	O
presumably	O
not	O
critical	O
for	O
enzymatic	O
function.	O
The	O
F171S	O
mutation	O
is	O
close	O
to	O
the	O
putative	O
active-site	O
nucleophile.	O
Our	O
data	O
further	O
support	O
the	O
notion	O
of	O
molecular	O
heterogeneity	O
of	O
galactosemia	SpecificDisease
and	O
suggest	O
that	O
galactosemia	Modifier

Gaucher	SpecificDisease
disease	SpecificDisease
:	O
the	O
origins	O
of	O
the	O
Ashkenazi	O
Jewish	O
N370S	O
and	O
84GG	O
acid	O
beta-glucosidase	O
mutations.	O
Type	O
1	O
Gaucher	SpecificDisease
disease	SpecificDisease
(	O
GD	SpecificDisease
),	O
a	O
non-neuronopathic	O
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass

Investigation	O
of	O
thermoregulatory	O
characteristics	O
in	O
patients	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
A	O
survey	O
instrument	O
is	O
used	O
to	O
assess	O
temperature	O
regulation	O
characteristics	O
in	O
children	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
compared	O
to	O
3	O
control	O
groups	O
	O
sibs	O
of	O
PWS	Modifier
patients	O
(SIB),	O
neurodevelopmentally	Modifier
handicapped	Modifier
children	O
(ND),	O
and	O
age	O
and	O
gender	O
matched	O
well	O
children	O
(WC).	O
Significant	O
differences	O
were	O
found	O
between	O
PWS	Modifier
patients,	O
SIB	O
controls,	O
and	O
WC	O
controls	O
in	O
the	O
prevalence	O
of	O
febrile	O
convulsions,	O
fever-associated	O
symptoms,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
F.	O
No	O
differences	O
were	O
noted	O
in	O
any	O
variable	O
between	O
the	O
PWS	Modifier
patients	O
and	O
the	O
ND	O
controls,	O
suggesting	O
that	O
these	O
abnormalities	O
are	O
not	O
unique	O
to	O
PWS	SpecificDisease
,	O
but	O
can	O
occur	O
in	O
any	O
neurodevelopmentally	Modifier
handicapped	Modifier
individual,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome-specific	O
hypothalamic	DiseaseClass
abnormalities	DiseaseClass

Abnormal	O
high	O
density	O
lipoproteins	O
in	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
.	O
The	O
plasma	O
lipoprotein	O
profiles	O
and	O
high	O
density	O
lipoproteins	O
(HDL)	O
were	O
characterized	O
in	O
patients	O
with	O
the	O
genetic	DiseaseClass
disease	DiseaseClass
	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
).	O
Abnormalities	DiseaseClass
in	DiseaseClass
the	DiseaseClass
HDL	DiseaseClass
may	O
contribute	O
to	O
their	O
increased	O
atherogenesis	O
and	O
excessive	O
deposits	O
of	O
tissue	O
sterols	O
in	O
the	O
presence	O
of	O
low	O
or	O
low-normal	O
concentrations	O
of	O
plasma	O
cholesterol	O
(165	O
+/-	O
25	O
mg/dl)	O
and	O
low	O
density	O
lipoproteins	O
(LDL).	O
The	O
mean	O
HDL-cholesterol	O
concentration	O
in	O
the	O
CTX	Modifier
plasmas	O
was	O
14.	O
5	O
+/-	O
3.	O
2	O
mg/dl,	O
about	O
one-third	O
the	O
normal	O
value.	O
The	O
low	O
HDL-cholesterol	O
reflects	O
a	O
low	O
concentration	O
and	O
an	O
abnormal	O
lipid	O
composition	O
of	O
the	O
plasma	O
HDL.	O
Relative	O
to	O
normal	O
HDL,	O
the	O
cholesteryl	O
esters	O
are	O
low,	O
free	O
cholesterol	O
and	O
phospholipids	O
essentially	O
normal,	O
and	O
triglycerides	O
increased.	O
The	O
ratio	O
of	O
apoprotein	O
(apo)	O
to	O
total	O
cholesterol	O
in	O
the	O
HDL	O
of	O
CTX	SpecificDisease
was	O
two	O
to	O
three	O
times	O
greater	O
than	O
normal.	O
In	O
the	O
CTX	Modifier
HDL,	O
the	O
ratio	O
of	O
apoAI	O
to	O
apoAII	O
was	O
high,	O
the	O
proportion	O
of	O
apoC	O
low,	O
and	O
a	O
normally	O
minor	O
form	O
of	O
apoAI	O
increased	O
relative	O
to	O
other	O
forms.	O
The	O
HDL	O
in	O
electron	O
micrographs	O
appeared	O
normal	O
morphologically	O
and	O
in	O
particle	O
size.	O
The	O
abnormalities	O
in	O
lipoprotein	O
distribution	O
profile	O
and	O
composition	O
of	O
the	O
plasma	O
HDL	O
result	O
from	O
metabolic	O
defects	O
that	O
are	O
not	O
understood	O
but	O
may	O
be	O
linked	O
to	O
the	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
bile	O
acid	O
synthesis	O
in	O
CTX	SpecificDisease

Splicing	O
defects	O
in	O
the	O
ataxia-telangiectasia	Modifier
gene,	O
ATM:	O
underlying	O
mutations	O
and	O
consequences.	O
Mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(30/62	O
[48%])	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
patients	O
with	O
ataxia-telangiectasia	SpecificDisease
(	O
AT	SpecificDisease
)	O
that	O
were	O
detected	O
by	O
the	O
protein-truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
DNA.	O
Fewer	O
than	O
half	O
of	O
the	O
splicing	O
mutations	O
involved	O
the	O
canonical	O
AG	O
splice-acceptor	O
site	O
or	O
GT	O
splice-donor	O
site.	O
A	O
higher	O
percentage	O
of	O
mutations	O
occurred	O
at	O
less	O
stringently	O
conserved	O
sites,	O
including	O
silent	O
mutations	O
of	O
the	O
last	O
nucleotide	O
of	O
exons,	O
mutations	O
in	O
nucleotides	O
other	O
than	O
the	O
conserved	O
AG	O
and	O
GT	O
in	O
the	O
consensus	O
splice	O
sites,	O
and	O
creation	O
of	O
splice-acceptor	O
or	O
splice-donor	O
sites	O
in	O
either	O
introns	O
or	O
exons.	O
These	O
splicing	O
mutations	O
led	O
to	O
a	O
variety	O
of	O
consequences,	O
including	O
exon	O
skipping	O
and,	O
to	O
a	O
lesser	O
degree,	O
intron	O
retention,	O
activation	O
of	O
cryptic	O
splice	O
sites,	O
or	O
creation	O
of	O
new	O
splice	O
sites.	O
In	O
addition,	O
5	O
of	O
12	O
nonsense	O
mutations	O
and	O
1	O
missense	O
mutation	O
were	O
associated	O
with	O
deletion	O
in	O
the	O
cDNA	O
of	O
the	O
exons	O
in	O
which	O
the	O
mutations	O
occurred.	O
No	O
ATM	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
AT	Modifier

Mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
are	O
responsible	O
for	O
Papillon-Lefevre	SpecificDisease
syndrome	SpecificDisease
.	O
Papillon-Lefevre	SpecificDisease
syndrome	SpecificDisease
(	O
PLS	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterised	O
by	O
palmoplantar	SpecificDisease
hyperkeratosis	SpecificDisease
and	O
severe	O
early	O
onset	O
periodontitis	SpecificDisease
that	O
results	O
in	O
the	O
premature	O
loss	O
of	O
the	O
primary	O
and	O
secondary	O
dentitions.	O
A	O
major	O
gene	O
locus	O
for	O
PLS	SpecificDisease
has	O
been	O
mapped	O
to	O
a	O
2.	O
8	O
cM	O
interval	O
on	O
chromosome	O
11q14.	O
Correlation	O
of	O
physical	O
and	O
genetic	O
maps	O
of	O
this	O
interval	O
indicate	O
it	O
includes	O
at	O
least	O
40	O
ESTs	O
and	O
six	O
known	O
genes	O
including	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
gene	O
(CTSC).	O
The	O
CTSC	O
message	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
a	O
variety	O
of	O
immune	O
cells	O
including	O
polymorphonuclear	O
leucocytes,	O
macrophages,	O
and	O
their	O
precursors.	O
By	O
RT-PCR,	O
we	O
found	O
CTSC	O
is	O
also	O
expressed	O
in	O
epithelial	O
regions	O
commonly	O
affected	O
by	O
PLS	SpecificDisease
,	O
including	O
the	O
palms,	O
soles,	O
knees,	O
and	O
oral	O
keratinised	O
gingiva.	O
The	O
4.	O
7	O
kb	O
CTSC	O
gene	O
consists	O
of	O
two	O
exons.	O
Sequence	O
analysis	O
of	O
CTSC	O
from	O
subjects	O
affected	O
with	O
PLS	SpecificDisease
from	O
five	O
consanguineous	O
Turkish	O
families	O
identified	O
four	O
different	O
mutations.	O
An	O
exon	O
1	O
nonsense	O
mutation	O
(856C--	O
>	O
T)	O
introduces	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
286.	O
Three	O
exon	O
2	O
mutations	O
were	O
identified,	O
including	O
a	O
single	O
nucleotide	O
deletion	O
(2692delA)	O
of	O
codon	O
349	O
introducing	O
a	O
frameshift	O
and	O
premature	O
termination	O
codon,	O
a	O
2	O
bp	O
deletion	O
(2673-2674delCT)	O
that	O
results	O
in	O
introduction	O
of	O
a	O
stop	O
codon	O
at	O
amino	O
acid	O
343,	O
and	O
a	O
G--	O
>	O
A	O
substitution	O
in	O
codon	O
429	O
(2931G--	O
>	O
A)	O
introducing	O
a	O
premature	O
termination	O
codon.	O
All	O
PLS	Modifier
patients	O
were	O
homozygous	O
for	O
cathepsin	O
C	O
mutations	O
inherited	O
from	O
a	O
common	O
ancestor.	O
Parents	O
and	O
sibs	O
heterozygous	O
for	O
cathepsin	O
C	O
mutations	O
do	O
not	O
show	O
either	O
the	O
palmoplantar	SpecificDisease
hyperkeratosis	SpecificDisease
or	O
severe	O
early	O
onset	O
periodontitis	SpecificDisease
characteristic	O
of	O
PLS	SpecificDisease
.	O
A	O
more	O
complete	O
understanding	O
of	O
the	O
functional	O
physiology	O
of	O
cathepsin	O
C	O
carries	O
significant	O
implications	O
for	O
understanding	O
normal	O
and	O
abnormal	O
skin	O
development	O
and	O
periodontal	Modifier
disease	Modifier

Identification	O
of	O
a	O
single	O
nucleotide	O
change	O
in	O
the	O
hypoxanthine-guanine	O
phosphoribosyltransferase	O
gene	O
(HPRTYale)	O
responsible	O
for	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
Complete	O
deficiency	SpecificDisease
of	SpecificDisease
hypoxanthine-guanine	SpecificDisease
phosphoribosyltransferase	SpecificDisease
(HPRT)	O
causes	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
Previous	O
characterization	O
of	O
a	O
mutant	O
form	O
of	O
HPRT,	O
HPRTYale,	O
from	O
a	O
subject	O
with	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

Molecular	O
detection	O
of	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	Modifier
susceptibility	O
locus.	O
A	O
candidate	O
DNA	O
sequence	O
with	O
many	O
of	O
the	O
properties	O
predicted	O
for	O
the	O
retinoblastoma	Modifier
susceptibility	O
(RB1)	O
locus	O
has	O
been	O
cloned	O
(S.	O
H.	O
Friend,	O
R.	O
Bernards,	O
S.	O
Rogelj,	O
R.	O
A.	O
Weinberg,	O
J.	O
M.	O
Rapaport,	O
D.	O
M.	O
Albert,	O
and	O
T.	O
P.	O
Dryja,	O
Nature	O
[London]	O
323	O
	O
643-645,	O
1986).	O
The	O
large	O
size	O
of	O
this	O
gene	O
(ca.	O
200	O
kilobases	O
[kb])	O
and	O
its	O
multiple	O
dispersed	O
exons	O
(Wiggs	O
et	O
al.,	O
N.	O
Engl.	O
J.	O
Med.	O
318	O
	O
151-157,	O
1988)	O
complicate	O
molecular	O
screening	O
strategies	O
important	O
in	O
prenatal	O
and	O
presymptomatic	O
diagnosis	O
and	O
in	O
carrier	O
detection.	O
Here	O
we	O
used	O
field	O
inversion	O
gel	O
electrophoresis	O
(FIGE)	O
to	O
construct	O
a	O
restriction	O
map	O
of	O
approximately	O
1,	O
000	O
kb	O
of	O
DNA	O
surrounding	O
the	O
RB1	O
locus	O
and	O
to	O
detect	O
the	O
translocation	O
breakpoints	O
in	O
three	O
retinoblastoma	Modifier
patients.	O
DNA	O
probes	O
from	O
either	O
the	O
5	O
or	O
3	O
end	O
of	O
the	O
gene	O
were	O
used	O
to	O
detect	O
a	O
250-kb	O
EagI	O
restriction	O
fragment	O
in	O
DNA	O
from	O
unaffected	O
individuals.	O
Both	O
probes	O
identified	O
an	O
additional	O
hybridizing	O
fragment	O
in	O
the	O
DNA	O
from	O
each	O
patient,	O
permitting	O
the	O
breakpoints	O
in	O
all	O
three	O
to	O
be	O
mapped	O
within	O
the	O
cloned	O
RB1	O
gene.	O
Analysis	O
of	O
the	O
breakpoint	O
in	O
one	O
translocation	O
cell	O
line	O
allowed	O
the	O
RB1	O
gene	O
to	O
be	O
oriented	O
with	O
its	O
5	O
end	O
toward	O
the	O
centromere.	O
The	O
5	O
end	O
of	O
the	O
gene	O
also	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
clustering	O
of	O
sites	O
for	O
several	O
infrequently	O
cleaving	O
restriction	O
enzymes,	O
indicating	O
the	O
presence	O
of	O
an	O
HpaII	O
tiny	O
fragment	O
island.	O
The	O
detection	O
and	O
mapping	O
of	O
the	O
translocation	O
breakpoints	O
of	O
all	O
three	O
retinoblastoma	Modifier

Constitutional	O
mutations	O
in	O
the	O
WT1	O
gene	O
in	O
patients	O
with	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
is	O
characterised	O
by	O
a	O
typical	O
nephropathy	DiseaseClass
,	O
genital	DiseaseClass
abnormalities	DiseaseClass
and	O
also	O
predisposes	O
to	O
the	O
development	O
of	O
Wilms	SpecificDisease
tumor	SpecificDisease
.	O
These	O
patients	O
eventually	O
go	O
into	O
end	O
stage	O
renal	SpecificDisease
failure	SpecificDisease
.	O
A	O
candidate	O
Wilms	Modifier
tumor	Modifier

Four	O
novel	O
PEPD	O
alleles	O
causing	O
prolidase	SpecificDisease
deficiency	SpecificDisease
.	O
Mutations	O
at	O
the	O
PEPD	O
locus	O
cause	O
prolidase	SpecificDisease
deficiency	SpecificDisease
(McKusick	O
170100),	O
a	O
rare	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
iminodipeptiduria	SpecificDisease
,	O
skin	SpecificDisease
ulcers	SpecificDisease
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
recurrent	O
infections.	O
Four	O
PEPD	O
mutations	O
from	O
five	O
severely	O
affected	O
individuals	O
were	O
characterized	O
by	O
analysis	O
of	O
reverse-transcribed,	O
PCR-amplified	O
(RT-PCR)	O
cDNA.	O
We	O
used	O
SSCP	O
analysis	O
on	O
four	O
overlapping	O
cDNA	O
fragments	O
covering	O
the	O
entire	O
coding	O
region	O
of	O
the	O
PEPD	O
gene	O
and	O
detected	O
abnormal	O
SSCP	O
bands	O
for	O
the	O
fragment	O
spanning	O
all	O
or	O
part	O
of	O
exons	O
13-15	O
in	O
three	O
of	O
the	O
probands.	O
Direct	O
sequencing	O
of	O
the	O
mutant	O
cDNAs	O
showed	O
a	O
G--	O
>	O
A,	O
1342	O
substitution	O
(G448R)	O
in	O
two	O
patients	O
and	O
a	O
3-bp	O
deletion	O
(delta	O
E452	O
or	O
delta	O
E453)	O
in	O
another.	O
In	O
the	O
other	O
two	O
probands	O
the	O
amplified	O
products	O
were	O
of	O
reduced	O
size.	O
Direct	O
sequencing	O
of	O
these	O
mutant	O
cDNAs	O
revealed	O
a	O
deletion	O
of	O
exon	O
5	O
in	O
one	O
patient	O
and	O
of	O
exon	O
7	O
in	O
the	O
other.	O
Intronic	O
sequences	O
flanking	O
exons	O
5	O
and	O
7	O
were	O
identified	O
using	O
inverse	O
PCR	O
followed	O
by	O
direct	O
sequencing.	O
Conventional	O
PCR	O
and	O
direct	O
sequencing	O
then	O
established	O
the	O
intron-exon	O
borders	O
of	O
the	O
mutant	O
genomic	O
DNA	O
revealing	O
two	O
splice	O
acceptor	O
mutations	O
	O
a	O
G--	O
>	O
C	O
substitution	O
at	O
position	O
-1	O
of	O
intron	O
4	O
and	O
an	O
A--	O
>	O
G	O
substitution	O
at	O
position	O
-2	O
of	O
intron	O
6.	O
Our	O
results	O
indicate	O
that	O
the	O
severe	O
form	O
of	O
prolidase	SpecificDisease
deficiency	SpecificDisease

Translocation	O
t(5;11)(q13.1;p13)	O
associated	O
with	O
familial	O
isolated	SpecificDisease
aniridia	SpecificDisease
.	O
A	O
father	O
and	O
daughter	O
with	O
isolated	SpecificDisease
aniridia	SpecificDisease
were	O
observed	O
to	O
have	O
an	O
apparently	O
balanced,	O
reciprocal	O
translocation	O
involving	O
chromosomes	O
5	O
and	O
11	O
[t	O
(5;	O
11)	O
(q13.	O
1;	O
p13)].	O
No	O
other	O
clinical	O
characteristics	O
often	O
associated	O
with	O
the	O
deletion	O
of	O
11p13	O
were	O
observed	O
in	O
this	O
family.	O
This	O
finding,	O
in	O
association	O
with	O
3	O
other	O
instances	O
of	O
single	O
breaks	O
at	O
11p13	O
and	O
aniridia	SpecificDisease

Genotype-phenotype	O
analysis	O
in	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
and	O
identification	O
of	O
a	O
missense	O
mutation	O
associated	O
with	O
a	O
milder	O
phenotype.	O
Direct	O
sequencing	O
of	O
the	O
emerin	O
gene	O
in	O
22	O
families	O
with	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EMD	SpecificDisease
)	O
revealed	O
mutations	O
in	O
21	O
(95%),	O
confirming	O
that	O
emerin	O
mutations	O
can	O
be	O
identified	O
in	O
the	O
majority	O
of	O
families	O
with	O
X-linked	SpecificDisease
EMD	SpecificDisease
.	O
Most	O
emerin	O
mutations	O
result	O
in	O
absence	O
of	O
the	O
protein.	O
In	O
this	O
study	O
three	O
mutations	O
(a	O
missense	O
mutation	O
Pro183Thr	O
and	O
two	O
in-frame	O
deletions	O
removing	O
residues	O
95-99	O
and	O
236-241,	O
respectively)	O
were	O
unusual	O
in	O
being	O
associated	O
with	O
expression	O
of	O
mutant	O
protein.	O
The	O
phenotype	O
in	O
these	O
families	O
was	O
compared	O
in	O
detail	O
with	O
the	O
clinical	O
features	O
in	O
cases	O
with	O
typical	O
null	O
mutations.	O
For	O
the	O
in-frame	O
deletions	O
there	O
were	O
no	O
significant	O
differences.	O
In	O
the	O
family	O
with	O
the	O
missense	O
mutation	O
the	O
phenotype	O
was	O
milder.	O
Age	O
at	O
onset	O
was	O
later	O
for	O
first	O
symptoms	O
and	O
for	O
development	O
of	O
ankle	DiseaseClass
contractures	DiseaseClass
and	O
muscle	DiseaseClass
weakness	DiseaseClass

Asef,	O
a	O
link	O
between	O
the	O
tumor	Modifier
suppressor	O
APC	O
and	O
G-protein	O
signaling.	O
The	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
gene	O
(APC)	O
is	O
mutated	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
and	O
in	O
sporadic	O
colorectal	SpecificDisease
tumors	SpecificDisease
.	O
Here	O
the	O
APC	Modifier

Localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
locus	O
on	O
the	O
mouse	O
X	O
chromosome.	O
Recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
Duchenne	CompositeMention
and	CompositeMention
the	CompositeMention
milder	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophies	CompositeMention
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1,	O
000	O
to	O
2,	O
000	O
kilobases	O
(kb).	O
To	O
study	O
how	O
mutations	O
in	O
this	O
gene	O
affect	O
muscle	O
development	O
and	O
integrity,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	O
model	O
of	O
the	O
human	O
disease.	O
The	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	SpecificDisease
syndrome	SpecificDisease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
Duchenne/Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
in	O
man.	O
Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene	O
that	O
cross-hybridize	O
to	O
mouse	O
X-linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
DMD	SpecificDisease
in	O
the	O
mouse.	O
Both	O
sequences	O
map	O
to	O
the	O
region	O
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(Ta)	O
and	O
St14-1	O
(DxPas8)	O
loci,	O
close	O
to	O
the	O
phosphorylase	O
b	O
kinase	O
locus	O
(Phk).	O
By	O
analogy	O
with	O
the	O
human	O
X-chromosome,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
G6pd	O
and	O
St14-1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	DiseaseClass
	O
Emery	SpecificDisease
Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
St14-1	O
in	O
man	O
and	O
the	O
DMD	Modifier

Molecular	O
basis	O
of	O
hexosaminidase	SpecificDisease
A	SpecificDisease
deficiency	SpecificDisease
and	O
pseudodeficiency	O
in	O
the	O
Berks	O
County	O
Pennsylvania	O
Dutch.	O
Following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
),	O
a	O
non-Jewish,	O
Pennsylvania	O
Dutch	O
kindred	O
was	O
screened	O
for	O
TSD	Modifier
carriers	O
using	O
the	O
biochemical	O
assay.	O
A	O
high	O
frequency	O
of	O
individuals	O
who	O
appeared	O
to	O
be	O
TSD	Modifier
heterozygotes	O
was	O
detected	O
(Kelly	O
et	O
al.,	O
1975).	O
Clinical	O
and	O
biochemical	O
evidence	O
suggested	O
that	O
the	O
increased	O
carrier	O
frequency	O
was	O
due	O
to	O
at	O
least	O
two	O
altered	O
alleles	O
for	O
the	O
hexosaminidase	O
A	O
alpha-subunit.	O
We	O
now	O
report	O
two	O
mutant	O
alleles	O
in	O
this	O
Pennsylvania	O
Dutch	O
kindred,	O
and	O
one	O
polymorphism.	O
One	O
allele,	O
reported	O
originally	O
in	O
a	O
French	O
TSD	Modifier

Gene	O
transfer	O
and	O
expression	O
of	O
human	O
phenylalanine	O
hydroxylase.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
caused	O
by	O
a	O
genetic	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
enzyme	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
A	O
full-length	O
complementary	O
DNA	O
clone	O
of	O
human	O
PAH	O
was	O
inserted	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
and	O
transferred	O
into	O
mouse	O
NIH3T3	O
cells	O
which	O
do	O
not	O
normally	O
express	O
PAH.	O
The	O
transformed	O
mouse	O
cells	O
expressed	O
PAH	O
messenger	O
RNA,	O
immunoreactive	O
protein,	O
and	O
enzymatic	O
activity	O
that	O
are	O
characteristic	O
of	O
the	O
normal	O
human	O
liver	O
products,	O
demonstrating	O
that	O
a	O
single	O
gene	O
contains	O
all	O
of	O
the	O
necessary	O
genetic	O
information	O
to	O
code	O
for	O
functional	O
PAH.	O
These	O
results	O
support	O
the	O
use	O
of	O
the	O
human	O
PAH	O
probe	O
in	O
prenatal	O
diagnosis	O
and	O
detection	O
of	O
carriers,	O
to	O
provide	O
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	O
of	O
normal	O
and	O
mutant	O
enzymes,	O
and	O
in	O
the	O
investigation	O
of	O
alternative	O
genetic	O
therapies	O
for	O
PKU	SpecificDisease

Macular	SpecificDisease
dystrophy	SpecificDisease
associated	O
with	O
mutations	O
at	O
codon	O
172	O
in	O
the	O
human	O
retinal	Modifier
degeneration	Modifier
slow	O
gene.	O
BACKGROUND	O
	O
Recently,	O
mutations	O
in	O
the	O
retinal	Modifier
degeneration	Modifier
slow	O
(rds)	O
gene	O
which	O
codes	O
for	O
peripherin-rds	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
autosomal	SpecificDisease
dominant	SpecificDisease
retinitis	SpecificDisease
pigmentosa	SpecificDisease
.	O
Because	O
this	O
gene	O
is	O
expressed	O
in	O
both	O
rods	O
and	O
cones,	O
mutations	O
in	O
the	O
rds	O
gene	O
might	O
be	O
expected	O
to	O
cause	O
degeneration	O
affecting	O
either	O
the	O
scotopic	O
or	O
photopic	O
systems.	O
Mutations	O
at	O
codon	O
172	O
of	O
the	O
rds	O
gene	O
have	O
been	O
identified	O
in	O
three	O
families	O
with	O
autosomal	O
dominantly	O
inherited,	O
progressive	O
macular	SpecificDisease
dystrophy	SpecificDisease
.	O
METHODS	O
	O
Affected	O
individuals	O
underwent	O
ophthalmic	O
examination,	O
scotopic	O
perimetry,	O
dark	O
adaptometry,	O
measurement	O
of	O
color-contrast	O
sensitivity,	O
and	O
electroretinography	O
to	O
characterize	O
the	O
photoreceptor	O
dysfunction.	O
RESULTS	O
	O
In	O
all	O
but	O
one	O
affected	O
member,	O
symptoms	O
of	O
progressive	O
central	O
visual	SpecificDisease
loss	SpecificDisease
developed	O
in	O
the	O
third	O
or	O
fourth	O
decade	O
of	O
life	O
accompanied	O
by	O
central	SpecificDisease
scotoma	SpecificDisease
and	O
well-demarcated	O
atrophy	SpecificDisease
of	SpecificDisease
the	SpecificDisease
retinal	SpecificDisease
pigment	SpecificDisease
epithelium	SpecificDisease
and	O
choriocapillaris	SpecificDisease
of	SpecificDisease
the	SpecificDisease
macula	SpecificDisease
.	O
In	O
general,	O
cone	O
and	O
rod	O
thresholds	O
were	O
elevated,	O
and	O
color-contrast	O
sensitivity	O
was	O
absent	O
in	O
the	O
central	O
visual	O
field.	O
Peripherally,	O
the	O
scotopic	O
sensitivities	O
were	O
normal,	O
as	O
was	O
the	O
recovery	O
from	O
bleach.	O
Cone	O
electroretinograms	O
were	O
diminished	O
in	O
amplitude,	O
and	O
delayed	O
in	O
all	O
affected	O
adults	O
except	O
one.	O
Rod	O
electroretinograms	O
were	O
normal	O
or	O
near	O
normal	O
in	O
amplitude,	O
and	O
had	O
normal	O
implicit	O
times.	O
Affected	O
asymptomatic	O
children	O
had	O
macular	O
changes,	O
abnormal	O
color-contrast	O
sensitivity,	O
and	O
reduced	O
pattern	O
and	O
cone	O
electroretinograms.	O
CONCLUSION	O
	O
These	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
rds	O
gene	O
can	O
be	O
expressed	O
as	O
a	O
macular	SpecificDisease
dystrophy	SpecificDisease
,	O
with	O
evidence	O
of	O
primary	O
cone	DiseaseClass
dysfunction	DiseaseClass

Glucose	O
6-phosphate	O
dehydrogenase	O
variants:	O
Gd	O
(+)	O
Alexandra	O
associated	O
with	O
neonatal	SpecificDisease
jaundice	SpecificDisease
and	O
Gd	O
(-)	O
Camperdown	O
in	O
a	O
young	O
man	O
with	O
lamellar	SpecificDisease
cataracts	SpecificDisease
.	O
Two	O
male	O
subjects	O
are	O
described,	O
with	O
unusual	O
clinical	O
presentations	O
and	O
with	O
hitherto	O
undescribed	O
G6PD	O
variants.	O
The	O
first,	O
of	O
Italian	O
extraction,	O
suffered	O
from	O
severe	O
neonatal	SpecificDisease
jaundice	SpecificDisease
following	O
maternal	O
ingestion	O
of	O
fresh	O
broad	O
beans	O
(Vicia	O
fava)	O
both	O
prenatally	O
and	O
postnatally	O
	O
the	O
expression	O
of	O
the	O
enzymatic	O
defect	O
was	O
much	O
more	O
severe	O
in	O
the	O
neonatal	O
period	O
than	O
on	O
retesting	O
in	O
adolescence,	O
when	O
biochemical	O
characterization	O
showed	O
unique	O
features	O
which	O
justify	O
designation	O
as	O
a	O
new	O
variant	O
Gd	O
(+)	O
Alexandra.	O
The	O
second	O
patient,	O
a	O
boy	O
of	O
Maltese	O
extraction	O
who	O
was	O
found	O
to	O
have	O
bilateral	SpecificDisease
lamellar	SpecificDisease
cataracts	SpecificDisease
at	O
the	O
age	O
of	O
4	O
years,	O
was	O
identified	O
as	O
G6PD	SpecificDisease
deficient	SpecificDisease
only	O
as	O
a	O
result	O
of	O
a	O
survey	O
of	O
children	O
of	O
Mediterranean	O
origin	O
with	O
unexplained	O
cataract	Modifier
formation;	O
he	O
has	O
approximately	O
15%	O
of	O
normal	O
enzyme	O
activity,	O
with	O
another	O
unique	O
combination	O
of	O
biochemical	O
characteristics	O
which	O
has	O
led	O
to	O
its	O
designation	O
as	O
Gd	O
(-)	O
Camperdown.	O
Although	O
this	O
association	O
may	O
be	O
coincidental,	O
it	O
prompts	O
further	O
attention	O
to	O
the	O
possibility	O
that	O
under	O
certain	O
circumstances	O
G6PD	SpecificDisease
deficiency	SpecificDisease
may	O
favor	O
cataract	Modifier

DNA	O
restriction	O
fragments	O
associated	O
with	O
alpha	O
1-antitrypsin	O
indicate	O
a	O
single	O
origin	O
for	O
deficiency	O
allele	O
PI	O
Z.	O
The	O
alpha	O
1-protease	O
inhibitor,	O
or	O
alpha-antitrypsin	O
(AAT),	O
a	O
major	O
plasma	O
inhibitor	O
of	O
leukocyte	O
elastase	O
and	O
bacterial	O
proteases,	O
is	O
encoded	O
at	O
the	O
PI	O
locus	O
on	O
chromosome	O
14	O
(14q24.	O
3-q32.	O
1).	O
A	O
deficiency	SpecificDisease
of	SpecificDisease
AAT	SpecificDisease
in	O
individuals	O
homozygous	O
for	O
the	O
PI	O
Z	O
allele	O
occurs	O
in	O
about	O
1	O
in	O
2,	O
000-8,	O
000	O
caucasians	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
adult	O
onset	O
emphysema	DiseaseClass
and	O
liver	DiseaseClass
disease	DiseaseClass

Myotonic	SpecificDisease
dystrophy	SpecificDisease
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
),	O
the	O
most	O
common	O
form	O
of	O
muscular	SpecificDisease
dystrophy	SpecificDisease
in	O
adult	O
humans,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene.	O
The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(mRNA)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus.	O
We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice.	O
Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	DiseaseClass
and	O
myopathy	DiseaseClass
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not.	O
Thus,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	Modifier

Submicroscopic	O
deletion	O
in	O
cousins	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern:	O
effects	O
of	O
imprinting.	O
The	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
critical	O
region	O
on	O
15q11-q13	O
is	O
subject	O
to	O
imprinting.	O
PWS	SpecificDisease
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed.	O
Familial	SpecificDisease
PWS	SpecificDisease
is	O
rare.	O
We	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	SpecificDisease
with	O
cytogenetically	O
normal	O
karyotypes.	O
Fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
analysis	O
shows	O
a	O
submicroscopic	O
deletion	O
of	O
SNRPN,	O
but	O
not	O
the	O
closely	O
associated	O
loci	O
D15S10,	O
D15S11,	O
D15S63,	O
and	O
GABRB3.	O
The	O
cousins	O
fathers	O
and	O
two	O
paternal	O
aunts	O
have	O
the	O
same	O
deletion	O
and	O
are	O
clinically	O
normal.	O
The	O
grandmother	O
of	O
the	O
cousins	O
is	O
deceased	O
and	O
not	O
available	O
for	O
study,	O
and	O
their	O
grandfather	O
is	O
not	O
deleted	O
for	O
SNRPN.	O
DNA	O
methylation	O
analysis	O
of	O
D15S63	O
is	O
consistent	O
with	O
an	O
abnormality	O
of	O
the	O
imprinting	O
center	O
associated	O
with	O
PWS	SpecificDisease
.	O
"	O
Grandmatrilineal	O
"	O
inheritance	O
occurs	O
when	O
a	O
woman	O
with	O
deletion	O
of	O
an	O
imprinted,	O
paternally	O
expressed	O
gene	O
is	O
at	O
risk	O
of	O
having	O
affected	O
grandchildren	O
through	O
her	O
sons.	O
In	O
this	O
case,	O
PWS	SpecificDisease

Expression	O
and	O
imprinting	O
of	O
MAGEL2	O
suggest	O
a	O
role	O
in	O
Prader-willi	SpecificDisease
syndrome	SpecificDisease
and	O
the	O
homologous	O
murine	O
imprinting	O
phenotype.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
is	O
caused	O
by	O
the	O
loss	O
of	O
expression	O
of	O
imprinted	O
genes	O
in	O
chromosome	O
15q11-q13.	O
Affected	O
individuals	O
exhibit	O
neonatal	SpecificDisease
hypotonia	SpecificDisease
,	O
developmental	DiseaseClass
delay	DiseaseClass
and	O
childhood-onset	DiseaseClass
obesity	DiseaseClass
.	O
Necdin,	O
a	O
protein	O
implicated	O
in	O
the	O
terminal	O
differentiation	O
of	O
neurons,	O
is	O
the	O
only	O
PWS	Modifier
candidate	O
gene	O
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	O
model.	O
In	O
this	O
study,	O
we	O
have	O
characterized	O
MAGEL2	O
(also	O
known	O
as	O
NDNL1),	O
a	O
gene	O
with	O
51%	O
amino	O
acid	O
sequence	O
similarity	O
to	O
necdin	O
and	O
located	O
41	O
kb	O
distal	O
to	O
NDN	O
in	O
the	O
PWS	Modifier
deletion	O
region.	O
MAGEL2	O
is	O
expressed	O
predominantly	O
in	O
brain,	O
the	O
primary	O
tissue	O
affected	O
in	O
PWS	SpecificDisease
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	O
by	O
northern	O
blot	O
analysis.	O
MAGEL2	O
is	O
imprinted	O
with	O
monoallelic	O
expression	O
in	O
control	O
brain,	O
and	O
paternal-only	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
as	O
demonstrated	O
by	O
its	O
lack	O
of	O
expression	O
in	O
brain	O
from	O
a	O
PWS	Modifier
-affected	O
individual.	O
The	O
orthologous	O
mouse	O
gene	O
(Magel2)	O
is	O
located	O
within	O
150	O
kb	O
of	O
NDN	O
,	O
is	O
imprinted	O
with	O
paternal-only	O
expression	O
and	O
is	O
expressed	O
predominantly	O
in	O
late	O
developmental	O
stages	O
and	O
adult	O
brain	O
as	O
shown	O
by	O
northern	O
blotting,	O
RT-PCR	O
and	O
whole-mount	O
RNA	O
in	O
situ	O
hybridization.	O
Magel2	O
distribution	O
partially	O
overlaps	O
that	O
of	O
NDN	O
,	O
with	O
strong	O
expression	O
being	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
in	O
mid-gestation	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization.	O
We	O
hypothesize	O
that,	O
although	O
loss	O
of	O
necdin	O
expression	O
may	O
be	O
important	O
in	O
the	O
neonatal	O
presentation	O
of	O
PWS	SpecificDisease
,	O
loss	O
of	O
MAGEL2	O
may	O
be	O
critical	O
to	O
abnormalities	DiseaseClass
in	DiseaseClass
brain	DiseaseClass
development	DiseaseClass
and	O
dysmorphic	DiseaseClass
features	DiseaseClass
in	O
individuals	O
with	O
PWS	SpecificDisease

A	O
single	O
origin	O
of	O
phenylketonuria	SpecificDisease
in	O
Yemenite	O
Jews.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
a	O
metabolic	DiseaseClass
disease	DiseaseClass
caused	O
by	O
recessive	O
mutations	O
of	O
the	O
gene	O
encoding	O
the	O
hepatic	O
enzyme	O
phenylalanine	O
hydroxylase	O
(PAH).	O
The	O
incidence	O
of	O
PKU	SpecificDisease
varies	O
widely	O
across	O
different	O
geographic	O
areas,	O
and	O
is	O
highest	O
(about	O
1	O
in	O
5,	O
000	O
live	O
births)	O
in	O
Ireland	O
and	O
western	O
Scotland,	O
and	O
among	O
Yemenite	O
Jews.	O
A	O
limited	O
number	O
of	O
point	O
mutations	O
account	O
for	O
most	O
of	O
the	O
PKU	Modifier
cases	O
in	O
the	O
European	O
population.	O
Here	O
we	O
report	O
that	O
a	O
single	O
molecular	O
defect--a	O
deletion	O
spanning	O
the	O
third	O
exon	O
of	O
the	O
PAH	O
gene--is	O
responsible	O
for	O
all	O
the	O
PKU	Modifier
cases	O
among	O
the	O
Yemenite	O
Jews.	O
Examination	O
of	O
a	O
random	O
sample	O
of	O
Yemenite	O
Jews	O
using	O
a	O
molecular	O
probe	O
that	O
detects	O
the	O
carriers	O
of	O
this	O
deletion	O
indicated	O
a	O
high	O
frequency	O
of	O
the	O
defective	O
gene	O
in	O
this	O
community.	O
Although	O
the	O
deleted	O
PAH	O
gene	O
was	O
traced	O
to	O
25	O
different	O
locations	O
throughout	O
Yemen,	O
family	O
histories	O
and	O
official	O
documents	O
of	O
the	O
Yemenite	O
Jewish	O
community	O
showed	O
that	O
the	O
common	O
ancestor	O
of	O
all	O
the	O
carriers	O
of	O
this	O
genetic	DiseaseClass
defect	DiseaseClass

High	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
mutation.	O
The	O
mutation	O
causing	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(CTG)	O
n	O
repeat	O
in	O
over	O
99%	O
of	O
the	O
global	O
DM	Modifier
population.	O
It	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
Alu	O
element	O
polymorphism	O
within	O
the	O
DM	Modifier
kinase	O
gene,	O
suggesting	O
that	O
DM	SpecificDisease
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations.	O
A	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker,	O
suggested	O
that	O
similar	O
to	O
Fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
DM	SpecificDisease
exhibited	O
a	O
founder	O
effect	O
(Imbert	O
et	O
al.,	O
1993	O
Nature	O
Genet.	O
4,	O
72-76).	O
In	O
contrast,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
DM	SpecificDisease
(the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations.	O
We	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
DM	Modifier
locus	O
using	O
PCR	O
based	O
assays	O
of	O
nine	O
polymorphisms,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	Modifier
kinase	O
gene.	O
The	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
DM	Modifier
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	Modifier

Identification	O
and	O
rapid	O
detection	O
of	O
three	O
Tay-Sachs	Modifier
mutations	O
in	O
the	O
Moroccan	O
Jewish	O
population.	O
Infantile	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
result	O
in	O
the	O
complete	O
absence	O
of	O
beta-hexosaminidase	O
A	O
activity.	O
It	O
is	O
well	O
known	O
that	O
an	O
elevated	O
frequency	O
of	O
TSD	Modifier
mutations	O
exists	O
among	O
Ashkenazi	O
Jews.	O
More	O
recently	O
it	O
has	O
become	O
apparent	O
that	O
elevated	O
carrier	O
frequencies	O
for	O
TSD	SpecificDisease
also	O
occur	O
in	O
several	O
other	O
ethnic	O
groups,	O
including	O
Moroccan	O
Jews,	O
a	O
subgroup	O
of	O
Sephardic	O
Jews.	O
Elsewhere	O
we	O
reported	O
an	O
in-frame	O
deletion	O
of	O
one	O
of	O
the	O
two	O
adjacent	O
phenylalanine	O
codons	O
at	O
position	O
304	O
or	O
305	O
(delta	O
F304/305)	O
in	O
one	O
HEXA	O
allele	O
of	O
a	O
Moroccan	O
Jewish	O
TSD	Modifier
patient	O
and	O
in	O
three	O
obligate	O
carriers	O
from	O
six	O
unrelated	O
Moroccan	O
Jewish	O
families.	O
We	O
have	O
now	O
identified	O
two	O
additional	O
mutations	O
within	O
exon	O
5	O
of	O
the	O
HEXA	O
gene	O
that	O
account	O
for	O
the	O
remaining	O
TSD	Modifier
alleles	O
in	O
the	O
patient	O
and	O
carriers.	O
One	O
of	O
the	O
mutations	O
is	O
a	O
novel	O
C-to-G	O
transversion,	O
resulting	O
in	O
a	O
replacement	O
of	O
Tyr180	O
by	O
a	O
stop	O
codon.	O
The	O
other	O
mutation	O
is	O
a	O
G-to-A	O
transition	O
resulting	O
in	O
an	O
Arg170-to-Gln	O
substitution.	O
This	O
mutation	O
is	O
at	O
a	O
CpG	O
site	O
in	O
a	O
Japanese	O
infant	O
with	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease

Mapping	O
of	O
the	O
mouse	O
homologue	O
of	O
the	O
Wilson	Modifier
disease	Modifier
gene	O
to	O
mouse	O
chromosome	O
8.	O
ATP7B,	O
the	O
gene	O
altered	O
in	O
Wilson	Modifier
disease	Modifier
(	O
WD	Modifier
)	O
patients,	O
lies	O
in	O
a	O
block	O
of	O
homology	O
shared	O
between	O
human	O
chromosome	O
13q14	O
and	O
the	O
central	O
region	O
of	O
mouse	O
chromosome	O
14.	O
However,	O
we	O
have	O
mapped	O
the	O
murine	O
homologue	O
of	O
ATP7B	O
(Atp7b)	O
to	O
mouse	O
chromosome	O
8	O
by	O
somatic	O
cell	O
hybrid	O
analysis.	O
Analysis	O
of	O
80	O
interspecific	O
backcross	O
offspring	O
was	O
used	O
to	O
position	O
Atp7b	O
close	O
to	O
D8Mit3	O
and	O
another	O
ATPase	O
locus,	O
Atp4b,	O
on	O
mouse	O
chromosome	O
8.	O
ATP4B	O
lies	O
in	O
13q34	O
and	O
is	O
separated	O
from	O
ATP7B	O
by	O
several	O
loci	O
whose	O
mouse	O
homologues	O
map	O
to	O
mouse	O
chromosome	O
14.	O
The	O
assignment	O
of	O
Atp7b	O
to	O
mouse	O
chromosome	O
8	O
identifies	O
a	O
previously	O
unrecognized	O
region	O
of	O
homology	O
between	O
this	O
chromosome	O
and	O
human	O
chromosome	O
13.	O
This	O
assignment	O
suggests	O
a	O
possible	O
location	O
for	O
the	O
toxic	O
milk	O
mutation	O
in	O
the	O
mouse,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
homologue	O
of	O
WD	SpecificDisease

Characteristics	O
of	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
In	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
),	O
the	O
size	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
DM	Modifier
kinase	O
gene	O
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	O
evidence	O
of	O
anticipation.	O
However,	O
there	O
have	O
also	O
been	O
cases	O
with	O
an	O
intergenerational	O
contraction	O
of	O
the	O
repeat.	O
We	O
examined	O
1,	O
489	O
DM	Modifier
parent-offspring	O
pairs,	O
of	O
which	O
95	O
(6.	O
4%)	O
showed	O
such	O
contractions	O
in	O
peripheral	O
blood	O
leukocytes	O
(PBL).	O
In	O
56	O
of	O
the	O
95	O
pairs,	O
clinical	O
data	O
allowed	O
an	O
analysis	O
of	O
their	O
anticipation	O
status.	O
It	O
is	O
surprising	O
that	O
anticipation	O
occurred	O
in	O
27	O
(48%)	O
of	O
these	O
56	O
pairs,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	O
of	O
DM	SpecificDisease
in	O
the	O
symptomatic	O
offspring.	O
The	O
contraction	O
occurred	O
in	O
76	O
(10%)	O
of	O
753	O
paternal	O
transmissions	O
and	O
in	O
19	O
(3%)	O
of	O
736	O
maternal	O
transmissions.	O
Anticipation	O
was	O
observed	O
more	O
frequently	O
in	O
maternal	O
(85%)	O
than	O
in	O
paternal	O
(37%)	O
transmissions	O
(P	O
<.	O
001).	O
The	O
parental	O
repeat	O
size	O
correlated	O
with	O
the	O
size	O
of	O
intergenerational	O
contraction	O
(r2	O
=.	O
50,	O
P	O
<	O
<.	O
001),	O
and	O
the	O
slope	O
of	O
linear	O
regression	O
was	O
steeper	O
in	O
paternal	O
(-.	O
62)	O
than	O
in	O
maternal	O
(-.	O
30)	O
transmissions	O
(P	O
<	O
<.	O
001).	O
Sixteen	O
DM	Modifier
parents	O
had	O
multiple	O
DM	Modifier
offspring	O
with	O
the	O
CTG	O
repeat	O
contractions.	O
This	O
frequency	O
was	O
higher	O
than	O
the	O
frequency	O
expected	O
from	O
the	O
probability	O
of	O
the	O
repeat	O
contractions	O
(6.	O
4%)	O
and	O
the	O
size	O
of	O
DM	Modifier
sib	O
population	O
(1.	O
54	O
DM	Modifier
offspring	O
per	O
DM	Modifier
parent,	O
in	O
968	O
DM	Modifier
parents).	O
We	O
conclude	O
that	O
(1)	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
leukocyte	O
DNA	O
frequently	O
accompanies	O
apparent	O
anticipation,	O
especially	O
when	O
DM	SpecificDisease

Splice-site	O
mutation	O
in	O
the	O
PDS	Modifier
gene	O
may	O
result	O
in	O
intrafamilial	O
variability	O
for	O
deafness	SpecificDisease
in	O
Pendred	SpecificDisease
syndrome	SpecificDisease
.	O
Pendred	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
recessive	DiseaseClass
inherited	DiseaseClass
disorder	DiseaseClass
that	O
consists	O
of	O
developmental	DiseaseClass
abnormalities	DiseaseClass
of	DiseaseClass
the	DiseaseClass
cochlea	DiseaseClass
,	O
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
,	O
and	O
diffuse	SpecificDisease
thyroid	SpecificDisease
enlargement	SpecificDisease
(	O
goiter	SpecificDisease
).	O
This	O
disorder	O
may	O
account	O
for	O
up	O
to	O
10%	O
of	O
cases	O
of	O
hereditary	SpecificDisease
deafness	SpecificDisease
.	O
The	O
disease	O
gene	O
(	O
PDS	SpecificDisease
)	O
has	O
been	O
mapped	O
to	O
chromosome	O
7q22-q31,	O
and	O
encodes	O
a	O
chloride-iodide	O
transport	O
protein.	O
We	O
performed	O
mutation	O
analysis	O
of	O
individual	O
exons	O
of	O
the	O
PDS	Modifier
gene	O
in	O
one	O
Spanish	O
family	O
that	O
shows	O
intrafamilial	O
variability	O
of	O
the	O
deafness	Modifier
phenotype	O
(two	O
patients	O
with	O
profound	O
and	O
one	O
with	O
moderate-severe	O
deafness	SpecificDisease
).	O
We	O
identified	O
a	O
new	O
splice-site	O
mutation	O
affecting	O
intron	O
4	O
of	O
the	O
PDS	Modifier
gene,	O
at	O
nucleotide	O
position	O
639	O
+	O
7.	O
RNA	O
analysis	O
from	O
lymphocytes	O
of	O
the	O
affected	O
patients	O
showed	O
that	O
mutation	O
639	O
+	O
7A--	O
>	O
G	O
generates	O
a	O
new	O
donor	O
splice	O
site,	O
leading	O
to	O
an	O
mRNA	O
with	O
an	O
insertion	O
of	O
six	O
nucleotides	O
from	O
intron	O
4	O
of	O
PDS.	O
Since	O
the	O
newly	O
created	O
donor	O
splice	O
site	O
is	O
likely	O
to	O
compete	O
with	O
the	O
normal	O
one,	O
variations	O
of	O
the	O
levels	O
of	O
normal	O
and	O
aberrant	O
transcripts	O
of	O
the	O
PDS	Modifier
gene	O
in	O
the	O
cochlea	O
may	O
explain	O
the	O
variability	O
in	O
the	O
deafness	Modifier

Heterozygous	O
loss	O
of	O
Six5	O
in	O
mice	O
is	O
sufficient	O
to	O
cause	O
ocular	O
cataracts	SpecificDisease
.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorde	DiseaseClass
r	O
characterized	O
by	O
skeletal	O
muscle	SpecificDisease
wasting	SpecificDisease
,	O
myotonia	DiseaseClass
,	O
cardiac	DiseaseClass
arrhythmia	DiseaseClass
,	O
hyperinsulinaemia	SpecificDisease
,	O
mental	DiseaseClass
retardation	DiseaseClass
and	O
ocular	O
cataracts	SpecificDisease
.	O
The	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
DM	SpecificDisease
is	O
a	O
CTG	O
repeat	O
expansion	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
DMPK	O
and	O
5	O
of	O
a	O
homeodomain-encoding	O
gene,	O
SIX5	O
(formerly	O
DMAHP;	O
refs	O
2-5).	O
There	O
are	O
three	O
mechanisms	O
by	O
which	O
CTG	O
expansion	O
can	O
result	O
in	O
DM	SpecificDisease
.	O
First,	O
repeat	O
expansion	O
may	O
alter	O
the	O
processing	O
or	O
transport	O
of	O
the	O
mutant	O
DMPK	O
mRNA	O
and	O
consequently	O
reduce	O
DMPK	O
levels.	O
Second,	O
CTG	O
expansion	O
may	O
establish	O
a	O
region	O
of	O
heterochromatin	O
3	O
of	O
the	O
repeat	O
sequence	O
and	O
decrease	O
SIX5	O
transcription.	O
Third,	O
toxic	O
effects	O
of	O
the	O
repeat	O
expansion	O
may	O
be	O
intrinsic	O
to	O
the	O
repeated	O
elements	O
at	O
the	O
level	O
of	O
DNA	O
or	O
RNA	O
(refs	O
10,	O
11).	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
dose-dependent	O
loss	O
of	O
Dm15	O
(the	O
mouse	O
DMPK	O
homologue)	O
in	O
mice	O
produces	O
a	O
partial	O
DM	Modifier
phenotype	O
characterized	O
by	O
decreased	O
development	O
of	O
skeletal	O
muscle	O
force	O
and	O
cardiac	DiseaseClass
conduction	DiseaseClass
disorders	DiseaseClass
.	O
To	O
test	O
the	O
role	O
of	O
Six5	O
loss	O
in	O
DM	SpecificDisease
,	O
we	O
have	O
analysed	O
a	O
strain	O
of	O
mice	O
in	O
which	O
Six5	O
was	O
deleted.	O
Our	O
results	O
demonstrate	O
that	O
the	O
rate	O
and	O
severity	O
of	O
cataract	Modifier
formation	O
is	O
inversely	O
related	O
to	O
Six5	O
dosage	O
and	O
is	O
temporally	O
progressive.	O
Six5	O
+/-	O
and	O
Six5-/-	O
mice	O
show	O
increased	O
steady-state	O
levels	O
of	O
the	O
Na	O
+/K	O
+	O
-ATPase	O
alpha-1	O
subunit	O
and	O
decreased	O
Dm15	O
mRNA	O
levels.	O
Thus,	O
altered	O
ion	O
homeostasis	O
within	O
the	O
lens	O
may	O
contribute	O
to	O
cataract	Modifier
formation.	O
As	O
ocular	O
cataracts	SpecificDisease
are	O
a	O
characteristic	O
feature	O
of	O
DM	SpecificDisease
,	O
these	O
results	O
demonstrate	O
that	O
decreased	O
SIX5	O
transcription	O
is	O
important	O
in	O
the	O
aetiology	O
of	O
DM	SpecificDisease
.	O
Our	O
data	O
support	O
the	O
hypothesis	O
that	O
DM	SpecificDisease

Cis	O
and	O
trans	O
effects	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
)	O
mutation	O
in	O
a	O
cell	O
culture	O
model.	O
The	O
mutation	O
causing	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
has	O
been	O
identified	O
as	O
a	O
CTG	O
expansion	O
in	O
the	O
3-untranslated	O
region	O
(3-UTR)	O
of	O
the	O
DM	Modifier
protein	O
kinase	O
gene	O
(DMPK),	O
but	O
the	O
mechanism	O
(s)	O
of	O
pathogenesis	O
remain	O
unknown.	O
Studies	O
using	O
DM	Modifier
patient	O
materials	O
have	O
often	O
produced	O
confusing	O
results.	O
Therefore,	O
to	O
study	O
the	O
effects	O
of	O
the	O
DM	Modifier
mutation	O
in	O
a	O
controlled	O
environment,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
C2C12	O
mouse	O
myoblasts.	O
By	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	O
fused	O
to	O
a	O
human	O
DMPK	O
3-UTR,	O
we	O
identified	O
both	O
cis	O
and	O
trans	O
effects	O
that	O
are	O
mediated	O
by	O
the	O
DM	Modifier
mutation.	O
Our	O
data	O
show	O
that	O
a	O
mutant	O
DMPK	O
3-UTR,	O
with	O
as	O
few	O
as	O
57	O
CTGs,	O
had	O
a	O
negative	O
cis	O
effect	O
on	O
protein	O
expression	O
and	O
resulted	O
in	O
the	O
aggregation	O
of	O
reporter	O
transcripts	O
into	O
discrete	O
nuclear	O
foci.	O
We	O
determined	O
by	O
deletion	O
analysis	O
that	O
an	O
expanded	O
(CTG)	O
(n)	O
tract	O
alone	O
was	O
sufficient	O
to	O
mediate	O
these	O
cis	O
effects.	O
Furthermore,	O
in	O
contrast	O
to	O
the	O
normal	O
DMPK	O
3-UTR	O
mRNA,	O
a	O
mutant	O
DMPK	O
3-UTR	O
mRNA	O
with	O
(CUG)	O
(200)	O
selectively	O
inhibited	O
myogenic	O
differentiation	O
of	O
C2C12	O
myoblasts.	O
Genetic	O
analysis	O
and	O
the	O
Cre-	O
loxP	O
system	O
were	O
used	O
to	O
clearly	O
demonstrate	O
that	O
the	O
myoblast	O
fusion	O
defect	O
could	O
be	O
rescued	O
by	O
eliminating	O
the	O
expression	O
of	O
the	O
mutant	O
DMPK	O
3-UTR	O
transcript.	O
Characterization	O
of	O
spontaneous	O
deletion	O
events	O
mapped	O
the	O
inhibitory	O
effect	O
to	O
the	O
(CTG)	O
(n)	O
expansion	O
and/or	O
the	O
3	O
end	O
of	O
the	O
DMPK	O
3-UTR.	O
These	O
results	O
provide	O
evidence	O
that	O
the	O
DM	Modifier
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(consistent	O
with	O
DMPK	SpecificDisease
haploinsufficiency	SpecificDisease

Intelligence	O
quotient	O
profile	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
intergenerational	O
deficit,	O
and	O
correlation	O
with	O
CTG	O
amplification.	O
An	O
abbreviated	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
Revised	O
(WAIS-R)	O
was	O
used	O
to	O
assess	O
verbal	O
and	O
arithmetical	O
cognitive	O
performance	O
in	O
55	O
subjects	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
),	O
covering	O
all	O
grades	O
of	O
disease	O
severity,	O
and	O
31	O
controls	O
at	O
50%	O
risk	O
of	O
inheriting	O
DM	SpecificDisease
.	O
Scaled	O
scores	O
from	O
the	O
assessment	O
were	O
converted	O
into	O
an	O
intelligence	O
quotient	O
(IQ)	O
estimation	O
on	O
each	O
person.	O
Significant	O
IQ	O
differences	O
were	O
found	O
between	O
	O
(1)	O
all	O
55	O
DM	Modifier
subjects	O
(mean	O
90.	O
2,	O
SD	O
16.	O
1)	O
and	O
31	O
controls	O
(102.	O
6,	O
SD	O
9.	O
4),	O
with	O
no	O
sex	O
differences	O
in	O
either	O
group;	O
(2)	O
15	O
affected	O
parents	O
(99.	O
3,	O
SD	O
12.	O
2)	O
and	O
their	O
affected	O
children	O
(88.	O
1,	O
SD	O
17.	O
2),	O
where	O
significance	O
was	O
dependent	O
on	O
parental	O
sex	O
being	O
female;	O
and	O
(3)	O
15	O
pairs	O
of	O
affected	O
sibs	O
(89.	O
6,	O
SD	O
13.	O
2)	O
and	O
their	O
normal	O
sibs	O
(100.	O
2,	O
SD	O
7.	O
6).	O
IQ	O
steadily	O
declined	O
as	O
(1)	O
the	O
age	O
of	O
onset	O
of	O
signs	O
and	O
symptoms	O
decreased,	O
and	O
(2)	O
the	O
CTG	O
expansion	O
size	O
increased.	O
The	O
correlation	O
appeared	O
to	O
be	O
more	O
linear	O
with	O
age	O
of	O
onset.	O
The	O
correlation	O
of	O
IQ	O
difference	O
and	O
CTG	O
expansion	O
difference	O
in	O
both	O
the	O
DM	Modifier
parent-child	O
pairs	O
and	O
normal	O
sib-affected	O
sib	O
pairs	O
was	O
poor,	O
indicating	O
that	O
CTG	O
expansion	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
IQ	O
either	O
in	O
individual	O
persons	O
or	O
families.	O
Further	O
analysis	O
of	O
cognitive	O
function	O
in	O
DM	SpecificDisease

Complement	SpecificDisease
factor	SpecificDisease
2	SpecificDisease
deficiency	SpecificDisease
:	O
a	O
clinical	O
and	O
serological	O
family	O
study.	O
Inherited	DiseaseClass
complement	DiseaseClass
deficiencies	DiseaseClass
are	O
associated	O
with	O
a	O
variety	O
of	O
connective	O
tissue	O
diseases.	O
A	O
family	O
with	O
inherited	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
factor	SpecificDisease
2	SpecificDisease
(C2)	O
is	O
described	O
in	O
which	O
two	O
family	O
members	O
with	O
homozygous	O
C2	SpecificDisease
deficiency	SpecificDisease
developed	O
cutaneous	SpecificDisease
vasculitis	SpecificDisease
and	O
sicca	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
other	O
family	O
members	O
had	O
heterozygous	O
C2	SpecificDisease
deficiency	SpecificDisease
and	O
each	O
member	O
had	O
the	O
HLA-A25,	O
B18,	O
DR2	O
(w15)	O
haplotype.	O
The	O
mother	O
had	O
seropositive	SpecificDisease
rheumatoid	SpecificDisease
arthritis	SpecificDisease

Oncogenic	O
point	O
mutations	O
in	O
exon	O
20	O
of	O
the	O
RB1	O
gene	O
in	O
families	O
showing	O
incomplete	O
penetrance	O
and	O
mild	O
expression	O
of	O
the	O
retinoblastoma	Modifier
phenotype.	O
The	O
retinoblastoma	Modifier
-predisposition	O
gene,	O
RB1,	O
segregates	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
high	O
(90%)	O
penetrance.	O
Certain	O
families,	O
however,	O
show	O
an	O
unusual	O
low-penetrance	O
phenotype	O
with	O
many	O
individuals	O
being	O
unaffected,	O
unilaterally	O
affected,	O
or	O
with	O
evidence	O
of	O
spontaneously	O
regressed	O
tumors	DiseaseClass

Identification	O
of	O
a	O
novel	O
R21X	O
mutation	O
in	O
the	O
liver-type	O
arginase	O
gene	O
(ARG1)	O
in	O
four	O
Portuguese	O
patients	O
with	O
argininemia	SpecificDisease
.	O
Argininemia	SpecificDisease
is	O
a	O
rare	O
autossomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
deficiency	DiseaseClass
in	DiseaseClass
the	DiseaseClass
cytosolic	DiseaseClass
liver-type	DiseaseClass
arginase	DiseaseClass
enzyme	DiseaseClass
(L-arginine	O
urea-hydrolase;	O
E.	O
C.	O
3.	O
5.	O
3.	O
1).	O
In	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
for	O
argininemia	SpecificDisease

A	O
mutation	O
in	O
the	O
pleckstrin	O
homology	O
(PH)	O
domain	O
of	O
the	O
FGD1	O
gene	O
in	O
an	O
Italian	O
family	O
with	O
faciogenital	SpecificDisease
dysplasia	SpecificDisease
(	O
Aarskog-Scott	SpecificDisease
syndrome	SpecificDisease
).	O
Aarskog-Scott	SpecificDisease
Syndrome	SpecificDisease
(	O
AAS	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
disorder	DiseaseClass
characterised	O
by	O
short	DiseaseClass
stature	DiseaseClass
and	O
multiple	O
facial,	CompositeMention
limb	CompositeMention
and	CompositeMention
genital	CompositeMention
abnormalities	CompositeMention
.	O
A	O
gene,	O
FGD1,	O
altered	O
in	O
a	O
patient	O
with	O
AAS	Modifier
phenotype,	O
has	O
been	O
identified	O
and	O
found	O
to	O
encode	O
a	O
protein	O
with	O
homology	O
to	O
Rho/Rac	O
guanine	O
nucleotide	O
exchange	O
factors	O
(Rho/Rac	O
GEF).	O
However,	O
since	O
this	O
original	O
report	O
on	O
identification	O
of	O
a	O
mutated	O
FGD1	O
gene	O
in	O
an	O
AAS	Modifier
patient,	O
no	O
additional	O
mutations	O
in	O
the	O
FGD1	O
gene	O
have	O
been	O
described.	O
We	O
analysed	O
13	O
independent	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
AAS	SpecificDisease
.	O
One	O
patient	O
presented	O
a	O
mutation	O
that	O
results	O
in	O
a	O
nucleotide	O
change	O
in	O
exon	O
10	O
of	O
the	O
FGD1	O
gene	O
(G2559	O
>	O
A)	O
substituting	O
a	O
Gln	O
for	O
Arg	O
in	O
position	O
610.	O
The	O
mutation	O
was	O
found	O
to	O
segregate	O
with	O
the	O
AAS	Modifier
phenotype	O
in	O
affected	O
males	O
and	O
carrier	O
females	O
in	O
the	O
family	O
of	O
this	O
patient.	O
Interestingly,	O
Arg-610	O
is	O
located	O
within	O
one	O
of	O
the	O
two	O
pleckstrin	O
homology	O
(PH)	O
domains	O
of	O
the	O
FGD1	O
gene	O
and	O
it	O
corresponds	O
to	O
a	O
highly	O
conserved	O
residue	O
which	O
has	O
been	O
involved	O
in	O
InsP	O
binding	O
in	O
PH	O
domains	O
of	O
other	O
proteins.	O
The	O
same	O
residue	O
is	O
often	O
mutated	O
in	O
the	O
Brutons	O
tyrosine	O
kinase	O
(Btk)	O
gene	O
in	O
patients	O
with	O
an	O
X-linked	SpecificDisease
agammaglobulinemia	SpecificDisease

Localization	O
of	O
histidase	O
to	O
human	O
chromosome	O
region	O
12q22----q24.1	O
and	O
mouse	O
chromosome	O
region	O
10C2----D1.	O
The	O
human	O
gene	O
for	O
histidase	O
(histidine	O
ammonia-lyase;	O
HAL),	O
the	O
enzyme	O
deficient	O
in	O
histidinemia	SpecificDisease

Noninvasive	O
test	O
for	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
using	O
hair	O
root	O
analysis.	O
Identification	O
of	O
the	O
FMR1	O
gene	O
and	O
the	O
repeat-amplification	O
mechanism	O
causing	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
led	O
to	O
development	O
of	O
reliable	O
DNA-based	O
diagnostic	O
methods,	O
including	O
Southern	O
blot	O
hybridization	O
and	O
PCR.	O
Both	O
methods	O
are	O
performed	O
on	O
DNA	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
measure	O
the	O
repeat	O
size	O
in	O
FMR1.	O
Using	O
an	O
immunocytochemical	O
technique	O
on	O
blood	O
smears,	O
we	O
recently	O
developed	O
a	O
novel	O
test	O
for	O
identification	O
of	O
patients	O
with	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
.	O
This	O
method,	O
also	O
called	O
"	O
antibody	O
test,	O
"	O
uses	O
monoclonal	O
antibodies	O
against	O
the	O
FMR1	O
gene	O
product	O
(FMRP)	O
and	O
is	O
based	O
on	O
absence	O
of	O
FMRP	O
in	O
patients	O
cells.	O
Here	O
we	O
describe	O
a	O
new	O
diagnostic	O
test	O
to	O
identify	O
male	O
patients	O
with	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
on	O
the	O
basis	O
of	O
lack	O
of	O
FMRP	O
in	O
their	O
hair	O
roots.	O
Expression	O
of	O
FMRP	O
in	O
hair	O
roots	O
was	O
studied	O
by	O
use	O
of	O
an	O
FMRP-specific	O
antibody	O
test,	O
and	O
the	O
percentage	O
of	O
FMRP-expressing	O
hair	O
roots	O
in	O
controls	O
and	O
in	O
male	O
fragile	Modifier
X	Modifier
patients	O
was	O
determined.	O
Control	O
individuals	O
showed	O
clear	O
expression	O
of	O
FMRP	O
in	O
nearly	O
every	O
hair	O
root,	O
whereas	O
male	O
fragile	Modifier
X	Modifier
patients	O
lacked	O
expression	O
of	O
FMRP	O
in	O
almost	O
all	O
their	O
hair	O
roots.	O
Mentally	Modifier
retarded	Modifier
female	O
patients	O
with	O
a	O
full	O
mutation	O
showed	O
FMRP	O
expression	O
in	O
only	O
some	O
of	O
their	O
hair	O
roots	O
(<	O
55%),	O
and	O
no	O
overlap	O
with	O
normal	O
female	O
controls	O
was	O
observed.	O
The	O
advantages	O
of	O
this	O
test	O
are	O
(1)	O
plucking	O
of	O
hair	O
follicles	O
does	O
no	O
appreciable	O
harm	O
to	O
the	O
mentally	Modifier
retarded	Modifier
patient,	O
(2)	O
hairs	O
can	O
be	O
sent	O
in	O
a	O
simple	O
envelope	O
to	O
a	O
diagnostic	O
center,	O
and	O
(3)	O
the	O
result	O
of	O
the	O
test	O
is	O
available	O
within	O
5	O
h	O
of	O
plucking.	O
In	O
addition,	O
this	O
test	O
enabled	O
us	O
to	O
identify	O
two	O
fragile	Modifier
X	Modifier

Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
:	O
detection	O
of	O
mutations	O
Thr181----Pro	O
and	O
Leu223----Pro	O
in	O
the	O
proteolipid	O
protein	O
gene,	O
and	O
prenatal	O
diagnosis.	O
A	O
family	O
with	O
an	O
apparent	O
history	O
of	O
X-linked	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
presented	O
for	O
genetic	O
counseling,	O
requesting	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis.	O
RFLP	O
analysis	O
using	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
probe	O
was	O
uninformative	O
in	O
this	O
family.	O
A	O
prenatal	O
diagnosis	O
on	O
a	O
chorionic	O
villus	O
sample	O
(CVS)	O
was	O
carried	O
out	O
using	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
of	O
a	O
variant	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene.	O
The	O
fetus	O
was	O
predicted	O
to	O
be	O
unaffected.	O
Sequencing	O
of	O
the	O
exon	O
from	O
the	O
CVS,	O
the	O
predicted-carrier	O
mother,	O
and	O
the	O
obligate-carrier	O
grandmother	O
revealed	O
an	O
A-to-C	O
change	O
at	O
nucleotide	O
541	O
in	O
the	O
two	O
women	O
but	O
not	O
in	O
the	O
fetus.	O
As	O
this	O
change	O
results	O
in	O
a	O
Thr-to-Pro	O
change	O
at	O
amino	O
acid	O
181	O
in	O
a	O
region	O
of	O
the	O
gene	O
predicted	O
to	O
be	O
part	O
of	O
a	O
transmembrane	O
segment,	O
it	O
was	O
concluded	O
that	O
this	O
was	O
the	O
mutation	O
causing	O
the	O
disease	O
in	O
this	O
family.	O
In	O
addition,	O
in	O
a	O
second	O
family,	O
an	O
exon	O
5	O
variant	O
band	O
pattern	O
on	O
SSCP	O
analysis	O
was	O
shown	O
by	O
sequencing	O
to	O
be	O
due	O
to	O
a	O
T-to-C	O
change	O
at	O
nucleotide	O
668.	O
This	O
results	O
in	O
a	O
Leu-to-Pro	O
change	O
in	O
a	O
carrier	O
mother	O
and	O
in	O
her	O
two	O
affected	O
sons.	O
These	O
results	O
provide	O
further	O
examples	O
of	O
mutations	O
in	O
PLP	O
that	O
cause	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease

A	O
normal	O
male	O
with	O
an	O
inherited	O
deletion	O
of	O
one	O
exon	O
within	O
the	O
DMD	Modifier
gene.	O
We	O
describe	O
two	O
brothers	O
with	O
identical	O
inherited	O
deletions	O
of	O
one	O
single	O
exon	O
within	O
the	O
middle	O
of	O
the	O
DMD	Modifier
gene;	O
one	O
brother	O
has	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
diagnosed	O
at	O
11	O
years	O
of	O
age,	O
whereas	O
the	O
older	O
brother	O
is	O
normal	O
at	O
18.	O
These	O
results	O
have	O
implications	O
for	O
genetic	O
counselling	O
and	O
prenatal	O
diagnosis	O
in	O
families	O
with	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease

Small	O
deletions	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produce	O
kniest	SpecificDisease
dysplasia	SpecificDisease
.	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
is	O
a	O
moderately	O
severe	O
type	DiseaseClass
II	DiseaseClass
collagenopathy	DiseaseClass
,	O
characterized	O
by	O
short	O
trunk	O
and	O
limbs,	O
kyphoscoliosis	DiseaseClass
,	O
midface	SpecificDisease
hypoplasia	SpecificDisease
,	O
severe	O
myopia	DiseaseClass
,	O
and	O
hearing	DiseaseClass
loss	DiseaseClass
.	O
Mutations	O
in	O
the	O
gene	O
that	O
encodes	O
type	O
II	O
collagen	O
(COL2A1),	O
the	O
predominant	O
protein	O
of	O
cartilage,	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
individuals	O
with	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
.	O
All	O
but	O
two	O
of	O
these	O
previously	O
described	O
mutations	O
cause	O
in-frame	O
deletions	O
in	O
type	O
II	O
collagen,	O
either	O
by	O
small	O
deletions	O
in	O
the	O
gene	O
or	O
splice	O
site	O
alterations.	O
Furthermore,	O
all	O
but	O
one	O
of	O
these	O
mutations	O
is	O
located	O
between	O
exons	O
12	O
and	O
24	O
in	O
the	O
COL2A1	O
gene.	O
We	O
used	O
heteroduplex	O
analysis	O
to	O
identify	O
sequence	O
anomalies	O
in	O
five	O
individuals	O
with	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
.	O
Sequencing	O
of	O
the	O
index	O
patients	O
genomic	O
DNA	O
identified	O
four	O
new	O
dominant	O
mutations	O
in	O
COL2A1	O
that	O
result	O
in	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
a	O
21-bp	O
deletion	O
in	O
exon	O
16,	O
an	O
18-bp	O
deletion	O
in	O
exon	O
19,	O
and	O
4-bp	O
deletions	O
in	O
the	O
splice	O
donor	O
sites	O
of	O
introns	O
14	O
and	O
20.	O
A	O
previously	O
described	O
28-bp	O
deletion	O
at	O
the	O
COL2A1	O
exon	O
12-intron	O
12	O
junction,	O
deleting	O
the	O
splice	O
donor	O
site,	O
was	O
identified	O
in	O
the	O
fifth	O
case.	O
The	O
latter	O
three	O
mutations	O
are	O
predicted	O
to	O
result	O
in	O
exon	O
skipping	O
in	O
the	O
mRNA	O
encoded	O
from	O
the	O
mutant	O
allele.	O
These	O
data	O
suggest	O
that	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
results	O
from	O
shorter	O
type	O
II	O
collagen	O
monomers,	O
and	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
specific	O
COL2A1	O
domain,	O
which	O
may	O
span	O
from	O
exons	O
12	O
to	O
24,	O
leads	O
to	O
the	O
Kniest	Modifier
dysplasia	Modifier

Adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
and	O
a	O
cytogenetic	O
deletion	O
of	O
chromosome	O
5	O
resulting	O
from	O
a	O
maternal	O
intrachromosomal	O
insertion.	O
We	O
present	O
the	O
clinical	O
and	O
laboratory	O
findings	O
in	O
an	O
institutionalised	O
adult	O
patient	O
originally	O
referred	O
for	O
autism	SpecificDisease
.	O
A	O
high	O
risk	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
was	O
predicted	O
when	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5,	O
del	O
(5)	O
(q15q22.	O
3),	O
was	O
detected	O
in	O
her	O
lymphocytes	O
and	O
deletion	O
of	O
the	O
MCC	O
and	O
APC	Modifier
genes	O
confirmed	O
by	O
molecular	O
analysis.	O
Adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
and	O
carcinoma	SpecificDisease
of	SpecificDisease
the	SpecificDisease
rectum	SpecificDisease
were	O
subsequently	O
diagnosed	O
in	O
the	O
patient.	O
She	O
was	O
profoundly	O
mentally	Modifier
retarded	Modifier
,	O
autistic	Modifier
,	O
and	O
had	O
minor	O
dysmorphic	SpecificDisease
features	SpecificDisease
consistent	O
with	O
those	O
of	O
previous	O
patients	O
with	O
similar	O
deletions.	O
The	O
deletion	O
arose	O
as	O
a	O
result	O
of	O
recombination	O
within	O
the	O
small	O
insertion	O
loop	O
formed	O
at	O
meiosis	O
by	O
the	O
direct	O
insertion	O
(dir	O
ins	O
(5)	O
(q22.	O
3q14.	O
2q15))	O
found	O
in	O
the	O
patients	O
mother.	O
This	O
family	O
further	O
confirms	O
the	O
cytogenetic	O
mapping	O
of	O
both	O
MCC	O
and	O
APC	Modifier

Somatic	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
in	O
colorectal	DiseaseClass
tumors	DiseaseClass
:	O
mutation	O
cluster	O
region	O
in	O
the	O
APC	Modifier
gene.	O
We	O
examined	O
somatic	O
mutations	O
of	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
in	O
63	O
colorectal	DiseaseClass
tumors	DiseaseClass
(16	O
adenomas	DiseaseClass
and	O
47	O
carcinomas	DiseaseClass
)	O
developed	O
in	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
(	O
FAP	Modifier
)	O
and	O
non-FAP	O
patients.	O
In	O
addition	O
to	O
loss	O
of	O
heterozygosity	O
(LOH)	O
at	O
the	O
APC	Modifier
locus	O
in	O
30	O
tumors	DiseaseClass
,	O
43	O
other	O
somatic	O
mutations	O
were	O
detected.	O
Twenty-one	O
of	O
them	O
were	O
point	O
mutations;	O
16	O
nonsense	O
and	O
two	O
missense	O
mutations,	O
and	O
three	O
occurred	O
in	O
introns	O
at	O
the	O
splicing	O
site.	O
Twenty-two	O
tumors	DiseaseClass
had	O
frameshift	O
mutations	O
due	O
to	O
deletion	O
or	O
insertion;	O
nineteen	O
of	O
them	O
were	O
deletions	O
of	O
one	O
to	O
31	O
bp	O
and	O
three	O
were	O
a	O
1-bp	O
insertion.	O
One	O
tumor	DiseaseClass
had	O
a	O
1-bp	O
deletion	O
in	O
an	O
intron	O
near	O
the	O
splicing	O
site.	O
Hence,	O
41	O
(95%)	O
of	O
43	O
mutations	O
resulted	O
in	O
truncation	O
of	O
the	O
APC	Modifier
protein.	O
Over	O
60%	O
of	O
the	O
somatic	O
mutations	O
in	O
the	O
APC	Modifier
gene	O
were	O
clustered	O
within	O
a	O
small	O
region	O
of	O
exon	O
15,	O
designated	O
as	O
MCR	O
(mutation	O
cluster	O
region),	O
which	O
accounted	O
for	O
less	O
than	O
10%	O
of	O
the	O
coding	O
region.	O
Combining	O
these	O
data	O
and	O
the	O
results	O
of	O
LOH,	O
more	O
than	O
80%	O
of	O
tumors	DiseaseClass
(14	O
adenomas	DiseaseClass
and	O
39	O
carcinomas	DiseaseClass
)	O
had	O
at	O
least	O
one	O
mutation	O
in	O
the	O
APC	Modifier
gene,	O
of	O
which	O
more	O
than	O
60%	O
(9	O
adenomas	DiseaseClass
and	O
23	O
carcinomas	DiseaseClass
)	O
had	O
two	O
mutations.	O
These	O
results	O
strongly	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
are	O
associated	O
with	O
development	O
of	O
a	O
great	O
majority	O
of	O
colorectal	DiseaseClass
tumors	DiseaseClass

Identification	O
of	O
an	O
altered	O
splice	O
site	O
in	O
Ashkenazi	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
.	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha-subunit	O
of	O
the	O
lysosomal	O
enzyme,	O
beta-N-acetylhexosaminidase	O
A	O
(ref.	O
1).	O
A	O
relatively	O
high	O
frequency	O
of	O
carriers	O
(1/27)	O
of	O
a	O
lethal,	O
infantile	O
form	O
of	O
the	O
disease	O
is	O
found	O
in	O
the	O
Ashkenazi	O
Jewish	O
population,	O
but	O
it	O
is	O
not	O
yet	O
evident	O
whether	O
this	O
has	O
resulted	O
from	O
a	O
founder	O
effect	O
and	O
random	O
genetic	O
drift	O
or	O
from	O
a	O
selective	O
advantage	O
of	O
heterozygotes.	O
We	O
have	O
identified	O
a	O
single-base	O
mutation	O
in	O
a	O
cloned	O
fragment	O
of	O
the	O
HEXA	O
gene	O
from	O
an	O
Ashkenazi	O
Jewish	O
patient.	O
This	O
change,	O
the	O
substitution	O
of	O
a	O
C	O
for	O
G	O
in	O
the	O
first	O
nucleotide	O
of	O
intron	O
12	O
is	O
expected	O
to	O
result	O
in	O
defective	O
splicing	O
of	O
the	O
messenger	O
RNA.	O
A	O
test	O
for	O
the	O
mutant	O
allele	O
based	O
on	O
amplification	O
of	O
DNA	O
by	O
the	O
polymerase	O
chain	O
rection	O
and	O
cleavage	O
of	O
a	O
DdeI	O
restriction	O
site	O
generated	O
by	O
the	O
mutation	O
revealed	O
that	O
this	O
case	O
and	O
two	O
other	O
cases	O
of	O
the	O
Ashkenazi,	O
infantile	O
form	O
of	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease

Coats'	SpecificDisease
disease	SpecificDisease
of	O
the	O
retina	O
(	O
unilateral	SpecificDisease
retinal	SpecificDisease
telangiectasis	SpecificDisease
)	O
caused	O
by	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene:	O
a	O
role	O
for	O
norrin	O
in	O
retinal	O
angiogenesis.	O
Coats	SpecificDisease
disease	SpecificDisease
is	O
characterized	O
by	O
abnormal	DiseaseClass
retinal	DiseaseClass
vascular	DiseaseClass
development	DiseaseClass
(so-called	O
retinal	SpecificDisease
telangiectasis	SpecificDisease
)	O
which	O
results	O
in	O
massive	O
intraretinal	CompositeMention
and	CompositeMention
subretinal	CompositeMention
lipid	CompositeMention
accumulation	CompositeMention
(	O
exudative	DiseaseClass
retinal	DiseaseClass
detachment	DiseaseClass
).	O
The	O
classical	O
form	O
of	O
Coats	SpecificDisease
disease	SpecificDisease
is	O
almost	O
invariably	O
isolated,	O
unilateral	O
and	O
seen	O
in	O
males.	O
A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	SpecificDisease
disease	SpecificDisease
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
Norrie	SpecificDisease
disease	SpecificDisease
.	O
Both	O
carried	O
a	O
missense	O
mutation	O
within	O
the	O
NDP	O
gene	O
on	O
chromosome	O
Xp11.	O
2	O
2.	O
Subsequently	O
analysis	O
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	O
with	O
Coats	SpecificDisease
disease	SpecificDisease
demonstrated	O
in	O
one	O
a	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
was	O
not	O
present	O
within	O
non-retinal	O
tissue.	O
We	O
suggest	O
that	O
Coats	SpecificDisease
telangiectasis	SpecificDisease
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
results	O
in	O
a	O
deficiency	DiseaseClass
of	DiseaseClass
norrin	DiseaseClass

Trisomy	SpecificDisease
15	SpecificDisease
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
due	O
to	O
maternal	SpecificDisease
disomy	SpecificDisease
.	O
Uniparental	SpecificDisease
disomy	SpecificDisease
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders,	O
including	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	SpecificDisease
disomy	SpecificDisease
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	SpecificDisease
disomy	SpecificDisease
in	O
a	O
fetus.	O
Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	SpecificDisease
15	SpecificDisease
in	O
all	O
direct	O
and	O
cultured	O
cells,	O
though	O
the	O
fetus	O
appeared	O
normal.	O
Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied.	O
The	O
child	O
was	O
hypotonic	SpecificDisease
at	O
birth,	O
and	O
high-resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11-13,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50%	O
-70%	O
of	O
patients	O
with	O
PWS	SpecificDisease
.	O
Over	O
time,	O
typical	O
features	O
of	O
PWS	SpecificDisease
developed.	O
Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy.	O
Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	SpecificDisease
disomy	SpecificDisease
in	O
this	O
case	O
of	O
PWS	SpecificDisease

Genetic	O
defect	SpecificDisease
in	SpecificDisease
secretion	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
C5	SpecificDisease
in	O
mice.	O
A	O
genetic	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
(C5)	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement1-3	SpecificDisease
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(MW)	O
220,	O
000	O
(ref.	O
4),	O
has	O
been	O
found	O
in	O
39%	O
of	O
inbred	O
strains	O
of	O
mice3.	O
Sera	O
of	O
deficient	O
mice	O
lack	O
detectable	O
C5	O
activity	O
and	O
protein2,	O
3.	O
In	O
addition	O
deficient	O
mice	O
produce	O
antibody	O
to	O
mouse	O
C5	O
when	O
injected	O
with	O
sera	O
from	O
C5	O
sufficient	O
(normal)	O
strains.	O
Levy	O
et	O
al.	O
5	O
showed	O
that	O
somatic	O
cell	O
hybrids	O
between	O
C5	O
deficient	O
(B10.	O
D2/old	O
line)	O
macrophages	O
and	O
either	O
C5	O
sufficient	O
(B10.	O
D2/new	O
line)	O
mouse	O
kidney	O
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	O
mouse	O
C5	O
in	O
vitro.	O
Several	O
possible	O
molecular	O
mechanisms	O
to	O
account	O
for	O
the	O
findings	O
were	O
considered,	O
but	O
insufficient	O
direct	O
data	O
were	O
available	O
to	O
choose	O
among	O
them.	O
We	O
recently	O
reported	O
that	O
mouse	O
(CD.	O
1	O
strain)	O
peritoneal	O
cells	O
in	O
culture	O
synthesise	O
and	O
secrete	O
a	O
single	O
chain	O
precursor,	O
pro-C5	O
(MW	O
approximately	O
210,	O
000),	O
of	O
the	O
two-chain	O
(alpha	O
chain,	O
125,	O
000	O
and	O
beta	O
chain	O
83,	O
000	O
MW)	O
C5	O
protein6.	O
Radiolabelled	O
precursor	O
C5	O
was	O
contained	O
within	O
the	O
cells	O
and	O
was	O
secreted	O
into	O
the	O
tissue	O
culture	O
media.	O
Using	O
similar	O
methods,	O
we	O
now	O
find	O
that	O
C5	SpecificDisease
deficiency	SpecificDisease

WASP	O
gene	O
mutations	O
in	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
and	O
X-linked	SpecificDisease
thrombocytopenia	SpecificDisease
.	O
The	O
WASP	O
gene	O
has	O
been	O
recently	O
cloned	O
from	O
Xp11.	O
23	O
and	O
shown	O
to	O
be	O
mutated	O
in	O
three	O
patients	O
with	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
).	O
We	O
have	O
developed	O
a	O
screening	O
protocol	O
for	O
identifying	O
WASP	O
gene	O
alterations	O
in	O
genomic	O
DNA	O
and	O
have	O
identified	O
a	O
spectrum	O
of	O
novel	O
mutations	O
in	O
12	O
additional	O
unrelated	O
families.	O
These	O
missense,	O
nonsense	O
and	O
frameshift	O
mutations	O
involve	O
eight	O
of	O
the	O
12	O
exons	O
of	O
the	O
gene.	O
Two	O
mutations	O
creating	O
premature	O
termination	O
codons	O
were	O
associated	O
with	O
lack	O
of	O
detectable	O
mRNA	O
on	O
Northern	O
blots.	O
Four	O
amino	O
acid	O
substitutions,	O
Leu27Phe,	O
Thr48Ile,	O
Val75Met	O
and	O
Arg477Lys,	O
were	O
found	O
in	O
patients	O
with	O
congenital	SpecificDisease
thrombocytopenia	SpecificDisease
and	O
no	O
clinically	O
evident	O
immune	O
defect	O
indicating	O
that	O
the	O
WASP	O
gene	O
is	O
the	O
site	O
for	O
mutations	O
in	O
X-linked	SpecificDisease
thrombocytopenia	SpecificDisease
as	O
well	O
as	O
in	O
WAS	SpecificDisease
.	O
A	O
T-cell	O
line	O
from	O
a	O
WAS	Modifier

Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP.	O
A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene.	O
Co-amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	Modifier
and	Modifier
Becker	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
/	O
BMD	Modifier
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis.	O
We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	Modifier

Molecular	O
mechanisms	O
of	O
oncogenic	O
mutations	O
in	O
tumors	DiseaseClass
from	O
patients	O
with	O
bilateral	CompositeMention
and	CompositeMention
unilateral	CompositeMention
retinoblastoma	CompositeMention
.	O
The	O
RB1	O
gene	O
from	O
12	O
human	O
retinoblastoma	SpecificDisease
tumors	SpecificDisease
has	O
been	O
analyzed	O
exon-by-exon	O
with	O
the	O
single-strand	O
conformation	O
polymorphism	O
technique.	O
Mutations	O
were	O
found	O
in	O
all	O
tumors	DiseaseClass
,	O
and	O
one-third	O
of	O
the	O
tumors	DiseaseClass
had	O
independent	O
mutations	O
in	O
both	O
alleles	O
neither	O
of	O
which	O
were	O
found	O
in	O
the	O
germ	O
line,	O
confirming	O
their	O
true	O
sporadic	O
nature.	O
In	O
the	O
remaining	O
two-thirds	O
of	O
the	O
tumors	DiseaseClass

PAX6	O
gene	O
dosage	O
effect	O
in	O
a	O
family	O
with	O
congenital	SpecificDisease
cataracts	SpecificDisease
,	O
aniridia	SpecificDisease
,	O
anophthalmia	SpecificDisease
and	O
central	DiseaseClass
nervous	DiseaseClass
system	DiseaseClass
defects	DiseaseClass
.	O
The	O
human	O
eye	O
malformation	O
aniridia	SpecificDisease
results	O
from	O
haploinsufficiency	SpecificDisease
of	SpecificDisease
PAX6	SpecificDisease
,	O
a	O
paired	O
box	O
DNA-binding	O
protein.	O
To	O
study	O
this	O
dosage	O
effect,	O
we	O
characterized	O
two	O
PAX6	O
mutations	O
in	O
a	O
family	O
segregating	O
aniridia	SpecificDisease
and	O
a	O
milder	O
syndrome	O
consisting	O
of	O
congenital	SpecificDisease
cataracts	SpecificDisease
and	O
late	O
onset	O
corneal	SpecificDisease
dystrophy	SpecificDisease
.	O
The	O
nonsense	O
mutations,	O
at	O
codons	O
103	O
and	O
353,	O
truncate	O
PAX6	O
within	O
the	O
N-terminal	O
paired	O
and	O
C-terminal	O
PST	O
domains,	O
respectively.	O
The	O
wild-type	O
PST	O
domain	O
activates	O
transcription	O
autonomously	O
and	O
the	O
mutant	O
form	O
has	O
partial	O
activity.	O
A	O
compound	O
heterozygote	O
had	O
severe	O
craniofacial	CompositeMention
and	CompositeMention
central	CompositeMention
nervous	CompositeMention
system	CompositeMention
defects	CompositeMention
and	O
no	DiseaseClass
eyes	DiseaseClass

Hereditary	SpecificDisease
C7	SpecificDisease
deficiency	SpecificDisease
.	O
Diagnosis	O
and	O
HLA	O
studies	O
in	O
a	O
French-Canadian	O
family.	O
The	O
serum	O
of	O
a	O
44-yr-old	O
woman	O
of	O
French-Canadian	O
descent	O
having	O
a	O
B-27	O
positive	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
was	O
deficient	SpecificDisease
in	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C7)	O
as	O
determined	O
by	O
hemolytic	O
and	O
immunochemical	O
methods.	O
No	O
inhibitor	O
against	O
C7	O
was	O
detected,	O
and	O
the	O
levels	O
of	O
all	O
other	O
complement	O
components	O
were	O
normal.	O
No	O
deficiency	O
in	O
the	O
opsonic	O
activity	O
of	O
the	O
serum	O
was	O
found,	O
and	O
the	O
results	O
of	O
basic	O
coagulation	O
studies	O
of	O
the	O
plasma	O
were	O
normal.	O
On	O
investigation	O
of	O
the	O
patients	O
family,	O
two	O
sisters	O
were	O
found	O
to	O
have	O
the	O
same	O
deficiency	O
but	O
were	O
otherwise	O
in	O
good	O
health.	O
The	O
seven	O
other	O
siblings	O
were	O
heterozygous	O
for	O
C7	SpecificDisease
deficiency	SpecificDisease
,	O
while	O
the	O
paternal	O
aunt	O
had	O
a	O
normal	O
C7	O
level.	O
In	O
the	O
third	O
generation,	O
six	O
children	O
of	O
the	O
three	O
homozygous	O
sisters	O
and	O
five	O
children	O
of	O
heterozygotes	O
were	O
available	O
for	O
testing.	O
Studies	O
of	O
the	O
HLA	O
antigens	O
in	O
all	O
the	O
22	O
subjects	O
and	O
in	O
three	O
spouses	O
indicated	O
no	O
close	O
linkage	O
between	O
the	O
CM	SpecificDisease
deficienty	SpecificDisease
and	O
the	O
HLA	O
system.	O
In	O
addition,	O
the	O
simultaneous	O
occurrence	O
of	O
two	O
hereditary	O
complement	CompositeMention
deficiencies	CompositeMention
(C2	CompositeMention
and	CompositeMention
C7)	CompositeMention

Alstrom	SpecificDisease
syndrome	SpecificDisease
:	O
further	O
evidence	O
for	O
linkage	O
to	O
human	O
chromosome	O
2p13.	O
Alstrom	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
rare	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
retinal	SpecificDisease
degeneration	SpecificDisease
,	O
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
,	O
early-onset	O
obesity	SpecificDisease
,	O
and	O
non-insulin-dependent	SpecificDisease
diabetes	SpecificDisease
mellitus	SpecificDisease
.	O
The	O
gene	O
for	O
Alstrom	SpecificDisease
syndrome	SpecificDisease
(ALMS1)	O
has	O
been	O
previously	O
localized	O
to	O
human	O
chromosome	O
2p13	O
by	O
homozygosity	O
mapping	O
in	O
two	O
distinct	O
isolated	O
populations	O
-	O
French	O
Acadian	O
and	O
North	O
African.	O
Pair-wise	O
analyses	O
resulted	O
in	O
maximum	O
lod	O
(logarithm	O
of	O
the	O
odds	O
ratio)	O
scores	O
of	O
3.	O
84	O
and	O
2.	O
9,	O
respectively.	O
To	O
confirm	O
these	O
findings,	O
a	O
large	O
linkage	O
study	O
was	O
performed	O
in	O
twelve	O
additional	O
families	O
segregating	O
for	O
Alstrom	SpecificDisease
syndrome	SpecificDisease

Haplotype	O
and	O
multipoint	O
linkage	O
analysis	O
in	O
Finnish	O
choroideremia	Modifier
families.	O
Multipoint	O
linkage	O
analysis	O
of	O
choroideremia	SpecificDisease
(	O
TCD	SpecificDisease
)	O
and	O
seven	O
X	O
chromosomal	O
restriction	O
fragment	O
length	O
polymorphisms	O
(RFLPs)	O
was	O
carried	O
out	O
in	O
18	O
Finnish	O
TCD	Modifier
families.	O
The	O
data	O
place	O
TCD	SpecificDisease
distal	O
to	O
PGK	O
and	O
DXS72,	O
very	O
close	O
to	O
DXYS1	O
and	O
DXYS5	O
(Zmax	O
=	O
24	O
at	O
theta	O
=	O
0)	O
and	O
proximal	O
to	O
DXYS4	O
and	O
DXYS12.	O
This	O
agrees	O
with	O
the	O
data	O
obtained	O
from	O
other	O
linkage	O
studies	O
and	O
from	O
physical	O
mapping.	O
All	O
the	O
TCD	Modifier
males	O
and	O
carrier	O
females	O
studied	O
have	O
the	O
same	O
DXYS1	O
allele	O
in	O
coupling	O
with	O
TCD	SpecificDisease
.	O
In	O
Northeastern	O
Finland,	O
66/69	O
chromosomes	O
carrying	O
TCD	SpecificDisease
had	O
the	O
same	O
haplotype	O
at	O
loci	O
DXS72,	O
DXYS1,	O
DXYS4,	O
and	O
DXYS12.	O
The	O
same	O
haplotype	O
is	O
seen	O
in	O
only	O
15/99	O
chromosomes	O
not	O
carrying	O
TCD	SpecificDisease
.	O
Moreover,	O
in	O
71/104	O
non-TCD	O
chromosomes,	O
the	O
haplotype	O
at	O
six	O
marker	O
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
TCD	Modifier
chromosomes.	O
This	O
supports	O
the	O
previously	O
described	O
hypothesis	O
that	O
the	O
large	O
Northern	O
Finnish	O
choroideremia	Modifier
pedigrees,	O
comprising	O
a	O
total	O
of	O
over	O
80	O
living	O
patients	O
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
TCD	Modifier

Genetic	O
heterogeneity	O
at	O
the	O
glucose-6-phosphate	O
dehydrogenase	O
locus	O
in	O
southern	O
Italy:	O
a	O
study	O
on	O
a	O
population	O
from	O
the	O
Matera	O
district.	O
Glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
has	O
been	O
analyzed	O
by	O
gel	O
electrophoresis	O
and	O
by	O
quantitative	O
assay	O
in	O
an	O
unselected	O
sample	O
of	O
1524	O
schoolboys	O
from	O
the	O
province	O
of	O
Matera	O
(Lucania)	O
in	O
southern	O
Italy.	O
We	O
have	O
identified	O
43	O
subjects	O
with	O
a	O
G6PD	O
variant.	O
Of	O
these,	O
31	O
had	O
severe	O
G6PD	SpecificDisease
deficiency	SpecificDisease
,	O
nine	O
had	O
mild	O
to	O
moderate	O
deficiency,	O
and	O
three	O
had	O
a	O
non-deficient	O
electrophoretic	O
variant.	O
The	O
overall	O
rate	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
was	O
2.	O
6%.	O
The	O
frequency	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
,	O
ranging	O
from	O
7.	O
2%	O
on	O
the	O
Ionian	O
Coast	O
to	O
zero	O
on	O
the	O
eastern	O
side	O
of	O
the	O
Lucanian	O
Apennines,	O
appears	O
to	O
be	O
inversely	O
related	O
to	O
the	O
distance	O
of	O
each	O
town	O
examined	O
from	O
the	O
Ionian	O
Coast,	O
suggesting	O
that	O
this	O
geographic	O
distribution	O
may	O
reflect,	O
at	O
least	O
in	O
part,	O
gene	O
flow	O
from	O
Greek	O
settlers.	O
Biochemical	O
characterization	O
has	O
shown	O
that	O
most	O
of	O
the	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
this	O
population	O
is	O
accounted	O
for	O
by	O
G6PD	O
Mediterranean.	O
In	O
addition,	O
we	O
have	O
found	O
several	O
examples	O
of	O
two	O
other	O
known	O
polymorphic	O
variants	O
(G6PD	O
Cagliari	O
and	O
G6PD	O
A-);	O
three	O
new	O
polymorphic	O
variants,	O
G6PD	O
Metaponto	O
(class	O
III),	O
G6PD	O
Montalbano	O
(class	O
III),	O
and	O
G6PD	O
Pisticci	O
(class	O
IV);	O
and	O
two	O
sporadic	O
variants,	O
G6PD	O
Tursi	O
(class	O
III)	O
and	O
G6PD	O
Ferrandina	O
(class	O
II).	O
These	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
marked	O
genetic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Defective	O
CTLA-4	O
cycling	O
pathway	O
in	O
Chediak-Higashi	SpecificDisease
syndrome	SpecificDisease
:	O
a	O
possible	O
mechanism	O
for	O
deregulation	O
of	O
T	O
lymphocyte	O
activation.	O
Cytotoxic	O
T	O
lymphocyte-associated	O
antigen	O
4	O
(CTLA-4,	O
also	O
known	O
as	O
CD152)	O
has	O
been	O
shown	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
activation.	O
Its	O
membrane	O
expression	O
is	O
highly	O
regulated	O
by	O
endocytosis	O
and	O
trafficking	O
through	O
the	O
secretory	O
lysosome	O
pathway.	O
Chediak-Higashi	SpecificDisease
syndrome	SpecificDisease
(	O
CHS	SpecificDisease
)	O
is	O
an	O
inherited	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
trafficking	O
regulator	O
gene,	O
LYST.	O
It	O
results	O
in	O
defective	O
membrane	O
targeting	O
of	O
the	O
proteins	O
present	O
in	O
secretory	O
lysosomes,	O
and	O
it	O
is	O
associated	O
with	O
a	O
variety	O
of	O
features,	O
including	O
a	O
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
with	O
hemophagocytosis	DiseaseClass
.	O
The	O
murine	O
equivalent	O
of	O
CHS	SpecificDisease
,	O
beige	O
mice,	O
present	O
similar	O
characteristics	O
but	O
do	O
not	O
develop	O
the	O
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease
.	O
We	O
show	O
herein	O
that	O
CTLA-4	O
is	O
present	O
in	O
enlarged,	O
abnormal	O
vesicles	O
in	O
CHS	Modifier
T	O
cells	O
and	O
is	O
not	O
properly	O
expressed	O
at	O
the	O
cell	O
surface	O
after	O
T	O
cell	O
activation,	O
whereas	O
its	O
surface	O
expression	O
is	O
not	O
impaired.	O
It	O
is	O
therefore	O
proposed	O
that	O
the	O
defective	O
surface	O
expression	O
of	O
CTLA-4	O
by	O
CHS	Modifier
T	O
cells	O
is	O
involved	O
in	O
the	O
generation	O
of	O
lymphoproliferative	SpecificDisease
disease	SpecificDisease

Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	SpecificDisease
.	O
Hepatoblastoma	SpecificDisease
is	O
a	O
rare	O
malignant	DiseaseClass
tumor	DiseaseClass
of	DiseaseClass
the	DiseaseClass
liver	DiseaseClass
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years.	O
Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	Modifier
type	O
in	O
families	O
affected	O
by	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
.	O
In	O
addition	O
to	O
the	O
epidemiologic	O
data,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	Modifier
tumor	Modifier
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	Modifier
tumorigenesis.	O
A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta-catenin,	O
a	O
transcription-activating	O
protein	O
with	O
oncogenic	O
potential.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta-catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	Modifier
types	O
that	O
are	O
associated	O
with	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
,	O
we	O
observed	O
increased	O
beta-catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	SpecificDisease
.	O
Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(CTNNB1)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	Modifier
samples.	O
Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta-catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	SpecificDisease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	Modifier

Sequence	O
of	O
DNA	O
flanking	O
the	O
exons	O
of	O
the	O
HEXA	O
gene,	O
and	O
identification	O
of	O
mutations	O
in	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
.	O
The	O
rapid	O
identification	O
of	O
mutations	O
causing	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
requires	O
the	O
capacity	O
to	O
readily	O
screen	O
the	O
regions	O
of	O
the	O
HEXA	O
gene	O
most	O
likely	O
to	O
be	O
affected	O
by	O
mutation.	O
We	O
have	O
sequenced	O
the	O
portions	O
of	O
the	O
introns	O
flanking	O
each	O
of	O
the	O
14	O
HEXA	O
exons	O
in	O
order	O
to	O
specify	O
oligonucleotide	O
primers	O
for	O
the	O
PCR-dependent	O
amplification	O
of	O
each	O
exon	O
and	O
splice-junction	O
sequence.	O
The	O
amplified	O
products	O
were	O
analyzed,	O
by	O
electrophoresis	O
in	O
nondenaturing	O
polyacrylamide	O
gels,	O
for	O
the	O
presence	O
of	O
either	O
heteroduplexes,	O
derived	O
from	O
the	O
annealing	O
of	O
normal	O
and	O
mutant	O
DNA	O
strands,	O
or	O
single-strand	O
conformational	O
polymorphisms	O
(SSCP),	O
derived	O
from	O
the	O
renaturation	O
of	O
single-stranded	O
DNA.	O
Five	O
novel	O
mutations	O
from	O
Tay-Sachs	Modifier
disease	Modifier

In	O
vivo	O
modulation	O
of	O
Hmgic	O
reduces	O
obesity	SpecificDisease
.	O
The	O
HMGI	O
family	O
of	O
proteins	O
consists	O
of	O
three	O
members,	O
HMGIC,	O
HMGI	O
and	O
HMGI	O
(Y),	O
that	O
function	O
as	O
architectural	O
factors	O
and	O
are	O
essential	O
components	O
of	O
the	O
enhancesome.	O
HMGIC	O
is	O
predominantly	O
expressed	O
in	O
proliferating,	O
undifferentiated	O
mesenchymal	O
cells	O
and	O
is	O
not	O
detected	O
in	O
adult	O
tissues.	O
It	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	O
of	O
mesenchymal	Modifier
tumour	Modifier
cell	O
types,	O
including	O
fat-cell	DiseaseClass
tumours	DiseaseClass
(	O
lipomas	DiseaseClass
).	O
In	O
addition	O
Hmgic-/-	O
mice	O
have	O
a	O
deficiency	O
in	O
fat	O
tissue.	O
To	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	SpecificDisease
,	O
we	O
examined	O
Hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult,	O
obese	Modifier
mice.	O
Mice	O
with	O
a	O
partial	CompositeMention
or	CompositeMention
complete	CompositeMention
deficiency	CompositeMention
of	CompositeMention
Hmgic	CompositeMention
resisted	O
diet-induced	O
obesity	SpecificDisease
.	O
Disruption	O
of	O
Hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	SpecificDisease
induced	O
by	O
leptin	SpecificDisease
deficiency	SpecificDisease
(Lepob/Lepob)	O
in	O
a	O
gene-dose-dependent	O
manner.	O
Our	O
studies	O
implicate	O
a	O
role	O
for	O
HMGIC	O
in	O
fat-cell	O
proliferation,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose-specific	O
target	O
for	O
the	O
treatment	O
of	O
obesity	SpecificDisease

Prenatal	O
diagnosis	O
by	O
FISH	O
in	O
a	O
family	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
caused	O
by	O
duplication	O
of	O
PLP	O
gene.	O
A	O
diagnosis	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
(MIM	O
312080)	O
was	O
made	O
in	O
a	O
young	O
boy.	O
No	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
had	O
been	O
found.	O
The	O
boys	O
maternal	O
aunt	O
came	O
for	O
prenatal	O
diagnosis	O
when	O
16	O
+	O
weeks	O
pregnant	O
and	O
carrying	O
a	O
male	O
fetus.	O
Samples	O
were	O
tested	O
for	O
duplication	O
of	O
the	O
PLP	O
gene,	O
by	O
interphase	O
FISH,	O
in	O
lymphocyte	O
preparations	O
from	O
the	O
proband,	O
his	O
aunt	O
and	O
an	O
amniotic	O
fluid	O
cell	O
preparation	O
from	O
the	O
fetus.	O
The	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
Pelizaeus	SpecificDisease
Merzbacher	SpecificDisease
disease	SpecificDisease

Somatic	O
rearrangement	O
of	O
chromosome	O
14	O
in	O
human	O
lymphocytes.	O
Ataxia-telangiectasia	SpecificDisease
is	O
a	O
rare	O
genetic	DiseaseClass
disorder	DiseaseClass
associated	O
with	O
immune	DiseaseClass
deficiency	DiseaseClass
,	O
chromosome	DiseaseClass
instability	DiseaseClass
,	O
and	O
a	O
predisposition	O
to	O
lymphoid	SpecificDisease
malignancy	SpecificDisease
.	O
We	O
have	O
detected	O
chromosomally	O
anomalous	O
clones	O
of	O
lymphocytes	O
in	O
eight	O
patients	O
with	O
this	O
disorder.	O
Chromosome	O
banding	O
disclosed	O
that	O
the	O
clones	O
are	O
consistently	O
marked	O
by	O
structural	O
rearrangement	O
of	O
the	O
long	O
arm	O
(q)	O
of	O
chromosome	O
14.	O
A	O
translocation	O
involving	O
14q	O
was	O
found	O
in	O
clones	O
obtained	O
from	O
seven	O
of	O
the	O
eight	O
patients	O
whereas	O
a	O
ring	O
14	O
chromosome	O
was	O
found	O
in	O
a	O
clone	O
obtained	O
from	O
the	O
other.	O
These	O
findings	O
as	O
well	O
as	O
data	O
obtained	O
by	O
others	O
for	O
patients	O
with	O
ataxia-telangiectasia	SpecificDisease
suggest	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
the	O
initial	O
chromosomal	O
change	O
in	O
lymphocyte	O
clones	O
of	O
patients	O
with	O
this	O
disorder.	O
Chromosomes	O
of	O
lymphocytes	O
from	O
one	O
of	O
the	O
patients	O
were	O
studied	O
before	O
and	O
after	O
the	O
onset	O
of	O
chronic	SpecificDisease
lymphocytic	SpecificDisease
leukemia	SpecificDisease
.	O
Before	O
leukemia	DiseaseClass
was	O
diagnosed,	O
the	O
patient	O
had	O
a	O
lymphocyte	O
clone	O
with	O
a	O
14q	O
translocation.	O
This	O
clone	O
appears	O
to	O
have	O
given	O
rise	O
to	O
the	O
leukemic	Modifier
cells.	O
We	O
hypothesize	O
that	O
structural	O
rearrangement	O
of	O
14q	O
is	O
directly	O
related	O
to	O
abnormal	O
growth	O
of	O
lymphocytes	O
and	O
that	O
it	O
may	O
be	O
a	O
step	O
toward	O
the	O
development	O
of	O
lymphoid	SpecificDisease
malignancies	SpecificDisease
.	O
Increasing	O
evidence,	O
provided	O
by	O
others,	O
for	O
the	O
nonrandom	O
involvement	O
of	O
14q	O
in	O
African-type	O
Burkitts	SpecificDisease
lymphoma	SpecificDisease
and	O
other	O
lymphoid	DiseaseClass
neoplasms	DiseaseClass

Two	O
missense	O
mutations	O
causing	O
mild	O
hyperphenylalaninemia	DiseaseClass
associated	O
with	O
DNA	O
haplotype	O
12.	O
The	O
genetic	DiseaseClass
defects	DiseaseClass
responsible	O
for	O
most	O
phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
and	O
hyperphenylalaninemia	DiseaseClass
(	O
HPA	DiseaseClass
)	O
cases	O
are	O
located	O
in	O
the	O
phenylalanine	O
hydroxylase	O
(PAH)	O
gene.	O
Approximately	O
50-60	O
mutations	O
have	O
been	O
reported	O
in	O
Caucasians	O
and	O
are	O
reflected	O
in	O
a	O
wide	O
range	O
of	O
clinical	O
severities.	O
Most	O
mutations	O
are	O
linked	O
to	O
specific	O
haplotypes,	O
as	O
defined	O
by	O
eight	O
polymorphic	O
restriction	O
sites	O
in	O
the	O
PAH	O
gene.	O
We	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	O
linked	O
to	O
haplotype	O
12	O
in	O
the	O
Swedish	O
PKU	Modifier
/	O
HPA	Modifier
population,	O
since	O
7	O
of	O
8	O
patients	O
carrying	O
haplotype	O
12	O
had	O
mild	O
HPA	DiseaseClass

Genomic	O
organization	O
of	O
the	O
adrenoleukodystrophy	Modifier
gene.	O
Adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
),	O
the	O
most	O
frequent	O
peroxisomal	DiseaseClass
disorder	DiseaseClass
,	O
is	O
a	O
severe	O
neurodegenerative	DiseaseClass
disease	DiseaseClass
associated	O
with	O
an	O
impairment	DiseaseClass
of	DiseaseClass
very	DiseaseClass
long	DiseaseClass
chain	DiseaseClass
fatty	DiseaseClass
acids	DiseaseClass
beta-oxidation	DiseaseClass
.	O
We	O
have	O
recently	O
identified	O
by	O
positional	O
cloning	O
the	O
gene	O
responsible	O
for	O
ALD	SpecificDisease
,	O
located	O
in	O
Xq28.	O
It	O
encodes	O
a	O
new	O
member	O
of	O
the	O
"	O
ABC	O
"	O
superfamily	O
of	O
membrane-associated	O
transporters	O
that	O
shows,	O
in	O
particular,	O
significant	O
homology	O
to	O
the	O
70-kDa	O
peroxisomal	O
membrane	O
protein	O
(PMP70).	O
We	O
report	O
here	O
a	O
detailed	O
characterization	O
of	O
the	O
ALD	Modifier
gene	O
structure.	O
It	O
extends	O
over	O
21	O
kb	O
and	O
consists	O
of	O
10	O
exons.	O
To	O
facilitate	O
the	O
detection	O
of	O
mutations	O
in	O
ALD	Modifier
patients,	O
we	O
have	O
determined	O
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	O
of	O
the	O
3	O
untranslated	O
region	O
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region.	O
Sequences	O
present	O
in	O
distal	O
exons	O
cross-hybridize	O
strongly	O
to	O
additional	O
sequences	O
in	O
the	O
human	O
genome.	O
The	O
ALD	Modifier
gene	O
has	O
been	O
positioned	O
on	O
a	O
pulsed-field	O
map	O
between	O
DXS15	O
and	O
the	O
L1CAM	O
gene,	O
about	O
650	O
kb	O
upstream	O
from	O
the	O
color	O
pigment	O
genes.	O
The	O
frequent	O
occurrence	O
of	O
color	O
vision	O
anomalies	O
observed	O
in	O
patients	O
with	O
adrenomyeloneuropathy	SpecificDisease
(the	O
adult	O
onset	O
form	O
of	O
ALD	SpecificDisease
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	DiseaseClass
gene	DiseaseClass
syndrome	DiseaseClass
but	O
a	O
secondary	O
manifestation	O
of	O
ALD	SpecificDisease

BRCA1	O
interacts	O
with	O
components	O
of	O
the	O
histone	O
deacetylase	O
complex.	O
Germ-line	O
mutations	O
in	O
the	O
BRCA1	O
tumor-suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

Deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
in	O
a	O
patient	O
with	O
piebaldism	SpecificDisease
.	O
We	O
have	O
previously	O
shown	O
that	O
human	O
piebaldism	SpecificDisease
results	O
from	O
mutations	O
of	O
the	O
KIT	O
gene,	O
which	O
encodes	O
the	O
receptor	O
for	O
the	O
mast/stem	O
cell	O
growth	O
factor	O
and	O
is	O
located	O
in	O
chromosome	O
segment	O
4q12.	O
Using	O
DNA	O
of	O
a	O
patient	O
with	O
piebaldism	SpecificDisease
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
multiple	DiseaseClass
congenital	DiseaseClass
anomalies	DiseaseClass
associated	O
with	O
a	O
46,	O
XY,	O
del	O
(4)	O
(q12q21.	O
1)	O
karyotype,	O
we	O
carried	O
out	O
quantitative	O
Southern	O
blot	O
hybridization	O
analyses	O
of	O
the	O
KIT	O
gene	O
and	O
the	O
adjacent	O
PDGFRA	O
(platelet-derived	O
growth	O
factor	O
receptor	O
alpha	O
subunit)	O
genes.	O
The	O
patient	O
was	O
hemizygous	O
for	O
both	O
the	O
KIT	O
and	O
PDGFRA	O
genes,	O
indicating	O
that	O
both	O
of	O
these	O
genes	O
are	O
included	O
within	O
the	O
deleted	O
region.	O
Therefore,	O
deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
may	O
account	O
for	O
the	O
piebald	Modifier

Glucose-6-phosphate	O
dehydrogenase	O
variants	O
and	O
their	O
frequency	O
in	O
Guangdong,	O
China.	O
Erythrocyte	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
was	O
characterized	O
in	O
blood	O
samples	O
obtained	O
from	O
97	O
randomly	O
selected	O
males	O
with	O
enzyme	DiseaseClass
deficiency	DiseaseClass
from	O
various	O
regions	O
of	O
Guangdong	O
Province,	O
China.	O
Nine	O
new	O
variants	O
(Gd	O
Kaiping,	O
Gd	O
Boluo,	O
Gd	O
Huiyang,	O
Gd	O
Gaomin,	O
Gd	O
Qing-Baijiang,	O
Gd	O
Gaozhou,	O
Gd	O
Huazhou,	O
Gd	O
Nanhai,	O
and	O
Gd	O
Guangzhou)	O
were	O
identified.	O
Of	O
the	O
31	O
variants	O
found	O
in	O
this	O
province,	O
Gd	O
Kaiping,	O
Gd	O
Taiwan-Hakka,	O
Gd	O
Haad	O
Yai,	O
Gd	O
Haad	O
Yai-like	O
and	O
Gd	O
Huiyang	O
occurred	O
most	O
frequently.	O
The	O
frequency	O
of	O
each	O
variant	O
was	O
calculated.	O
The	O
results	O
demonstrated	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

A	O
common	O
molecular	O
basis	O
for	O
rearrangement	DiseaseClass
disorders	DiseaseClass
on	O
chromosome	O
22q11.	O
The	O
chromosome	O
22q11	O
region	O
is	O
susceptible	O
to	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	DiseaseClass
anomaly	DiseaseClass
disorders	DiseaseClass
and	O
malignant	DiseaseClass
tumors	DiseaseClass
.	O
Three	O
congenital	DiseaseClass
anomaly	DiseaseClass
disorders	DiseaseClass
,	O
cat-eye	SpecificDisease
syndrome	SpecificDisease
,	O
der	SpecificDisease
()	SpecificDisease
syndrome	SpecificDisease
and	O
velo-cardio-facial	SpecificDisease
syndrome	SpecificDisease
/	O
DiGeorge	SpecificDisease
syndrome	SpecificDisease
(	O
VCFS	SpecificDisease
/	O
DGS	SpecificDisease
)	O
are	O
associated	O
with	O
tetrasomy,	O
trisomy	O
or	O
monosomy,	O
respectively,	O
for	O
part	O
of	O
chromosome	O
22q11.	O
VCFS	SpecificDisease
/	O
DGS	SpecificDisease
is	O
the	O
most	O
common	O
syndrome	O
associated	O
with	O
22q11	O
rearrangements.	O
In	O
order	O
to	O
determine	O
whether	O
there	O
are	O
particular	O
regions	O
on	O
22q11	O
that	O
are	O
prone	O
to	O
rearrangements,	O
the	O
deletion	O
end-points	O
in	O
a	O
large	O
number	O
of	O
VCFS	Modifier
/	O
DGS	Modifier
patients	O
were	O
defined	O
by	O
haplotype	O
analysis.	O
Most	O
VCFS	Modifier
/	O
DGS	Modifier
patients	O
have	O
a	O
similar	O
3	O
Mb	O
deletion,	O
some	O
have	O
a	O
nested	O
distal	O
deletion	O
breakpoint	O
resulting	O
in	O
a	O
1.	O
5	O
Mb	O
deletion	O
and	O
a	O
few	O
rare	O
patients	O
have	O
unique	O
deletions	O
or	O
translocations.	O
The	O
high	O
prevalence	O
of	O
the	O
disorder	O
in	O
the	O
population	O
and	O
the	O
fact	O
that	O
most	O
cases	O
occur	O
sporadically	O
suggest	O
that	O
sequences	O
at	O
or	O
near	O
the	O
breakpoints	O
confer	O
susceptibility	O
to	O
chromosome	O
rearrangements.	O
To	O
investigate	O
this	O
hypothesis,	O
we	O
developed	O
hamster-human	O
somatic	O
hybrid	O
cell	O
lines	O
from	O
VCFS	Modifier
/	O
DGS	Modifier
patients	O
with	O
all	O
three	O
classes	O
of	O
deletions	O
and	O
we	O
now	O
show	O
that	O
the	O
breakpoints	O
occur	O
within	O
similar	O
low	O
copy	O
repeats,	O
termed	O
LCR22s.	O
To	O
support	O
this	O
idea	O
further,	O
we	O
identified	O
a	O
family	O
that	O
carries	O
an	O
interstitial	O
duplication	O
of	O
the	O
same	O
3	O
Mb	O
region	O
that	O
is	O
deleted	O
in	O
VCFS	Modifier
/	O
DGS	Modifier
patients.	O
We	O
present	O
models	O
to	O
explain	O
how	O
the	O
LCR22s	O
can	O
mediate	O
different	O
homologous	O
recombination	O
events,	O
thereby	O
generating	O
a	O
number	O
of	O
rearrangements	O
that	O
are	O
associated	O
with	O
congenital	DiseaseClass
anomaly	DiseaseClass
disorders	DiseaseClass

Typical	O
and	O
partial	O
cat	SpecificDisease
eye	SpecificDisease
syndrome	SpecificDisease
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH.	O
Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	SpecificDisease
eye	SpecificDisease
syndrome	SpecificDisease
(	O
CES	SpecificDisease
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	SpecificDisease
because	O
of	O
absence	O
of	O
coloboma,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH.	O
Using	O
a	O
genomic	O
library,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11,	O
partial	O
tetrasomy	DiseaseClass

An	O
intrachromosomal	O
insertion	O
causing	O
5q22	O
deletion	O
and	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
in	O
two	O
generations.	O
We	O
report	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
FAPC	SpecificDisease
)	O
with	O
epidermoid	SpecificDisease
cysts	SpecificDisease
,	O
osteomata	SpecificDisease
,	O
and	O
areas	O
of	O
congenital	SpecificDisease
hypertrophy	SpecificDisease
of	SpecificDisease
the	SpecificDisease
retinal	SpecificDisease
pigment	SpecificDisease
epithelium	SpecificDisease
(	O
CHRPEs	SpecificDisease
)	O
in	O
a	O
male	O
patient	O
and	O
his	O
maternal	O
aunt,	O
both	O
of	O
whom	O
suffered	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
mental	DiseaseClass
handicap	DiseaseClass
.	O
Both	O
had	O
an	O
interstitial	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
(del	O
(5)	O
(q22q23.	O
2)).	O
Two	O
other	O
normal	O
family	O
members	O
had	O
the	O
underlying	O
direct	O
insertion	O
of	O
chromosome	O
5	O
(dir	O
ins	O
(5)	O
(q31.	O
3q22q23	O
3q22q23.	O
2)).	O
Molecular	O
genetic	O
and	O
fluorescent	O
hybridisation	O
studies	O
have	O
shown	O
that	O
loci	O
D5S37	O
and	O
D5S98	O
are	O
outside	O
the	O
deletion	O
whereas	O
loci	O
detected	O
by	O
probes	O
EF5.	O
44	O
and	O
YN5.	O
48	O
are	O
lost.	O
As	O
expected,	O
the	O
molecular	O
analyses	O
indicate	O
loss	O
of	O
one	O
allele	O
at	O
the	O
MCC	O
and	O
APC	Modifier
loci.	O
The	O
APC	Modifier

Cloning	O
of	O
the	O
Huntington	Modifier
disease	Modifier
region	O
in	O
yeast	O
artificial	O
chromosomes.	O
The	O
gene	O
responsible	O
for	O
Huntington	SpecificDisease
disease	SpecificDisease
has	O
been	O
localized	O
to	O
a	O
2.	O
5	O
million	O
base	O
pair	O
(Mb)	O
region	O
between	O
the	O
loci	O
D4S10	O
and	O
D4S168	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
4.	O
As	O
part	O
of	O
a	O
strategy	O
to	O
clone	O
the	O
HD	Modifier
gene	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location,	O
we	O
isolated	O
genomic	O
DNA	O
from	O
the	O
HD	Modifier
region	O
as	O
a	O
set	O
of	O
overlapping	O
yeast	O
artificial	O
chromosome	O
(YAC)	O
clones.	O
Twenty-eight	O
YAC	O
clones	O
were	O
identified	O
by	O
screening	O
human	O
YAC	O
libraries	O
with	O
twelve	O
PCR-based	O
sequence-tagged	O
sites	O
(STSs)	O
from	O
the	O
region.	O
We	O
assembled	O
the	O
YAC	O
clones	O
into	O
overlapping	O
sets	O
by	O
hybridizing	O
them	O
to	O
a	O
large	O
number	O
of	O
DNA	O
probes	O
from	O
the	O
HD	Modifier
region,	O
including	O
the	O
STSs.	O
In	O
addition,	O
we	O
isolated	O
the	O
ends	O
of	O
the	O
human	O
DNA	O
inserts	O
of	O
most	O
of	O
the	O
YAC	O
clones	O
to	O
assist	O
in	O
the	O
construction	O
of	O
the	O
contig.	O
Although	O
almost	O
half	O
of	O
the	O
YACs	O
appear	O
to	O
contain	O
chimeric	O
inserts	O
and	O
several	O
contain	O
internal	O
deletions	O
or	O
other	O
rearrangements,	O
we	O
were	O
able	O
to	O
obtain	O
over	O
2.	O
2	O
Mb	O
of	O
the	O
HD	Modifier
region	O
in	O
YACs,	O
including	O
one	O
continuous	O
segment	O
of	O
2.	O
0	O
Mb	O
covering	O
the	O
region	O
that	O
most	O
likely	O
contains	O
the	O
HD	Modifier
gene.	O
Ten	O
of	O
the	O
twenty	O
eight	O
YAC	O
clones	O
comprise	O
a	O
minimal	O
set	O
spanning	O
the	O
2.	O
2	O
Mb.	O
These	O
clones	O
provide	O
reagents	O
for	O
the	O
complete	O
characterization	O
of	O
this	O
region	O
of	O
the	O
genome	O
and	O
for	O
the	O
eventual	O
isolation	O
of	O
the	O
HD	Modifier

Three	O
novel	O
mutations	O
in	O
five	O
unrelated	O
subjects	O
with	O
hereditary	O
protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
type	SpecificDisease
I	SpecificDisease
.	O
A	O
panel	O
of	O
eight	O
unrelated	O
subjects	O
with	O
inherited	O
type	SpecificDisease
I	SpecificDisease
protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
was	O
screened	O
for	O
mutations	O
in	O
the	O
PROS1	O
gene.	O
In	O
five	O
subjects	O
an	O
abnormality	O
was	O
found	O
but	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
remaining	O
three	O
subjects.	O
Two	O
subjects	O
shared	O
a	O
G--	O
>	O
A	O
transition	O
at	O
position	O
+	O
5	O
of	O
the	O
donor	O
splice	O
site	O
consensus	O
sequence	O
of	O
intron	O
10.	O
Also	O
in	O
two	O
subjects	O
an	O
A--	O
>	O
T	O
transversion	O
was	O
detected	O
in	O
the	O
stopcodon	O
of	O
the	O
PROS1	O
gene;	O
this	O
transversion	O
predicts	O
a	O
protein	O
S	O
molecule	O
that	O
is	O
extended	O
by	O
14	O
amino	O
acids.	O
The	O
fifth	O
subject	O
was	O
found	O
to	O
possess	O
two	O
sequence	O
abnormalities.	O
One	O
allele	O
carried	O
a	O
G--	O
>	O
A	O
transition	O
near	O
the	O
donor	O
splice	O
junction	O
of	O
intron	O
2,	O
but	O
this	O
abnormality	O
is	O
probably	O
neutral,	O
since	O
it	O
was	O
inherited	O
from	O
the	O
parent	O
with	O
normal	O
protein	O
S	O
antigen	O
levels.	O
In	O
the	O
other	O
allele	O
a	O
single	O
T	O
insertion	O
in	O
codon	O
-25	O
was	O
found.	O
Analysis	O
of	O
platelet	O
RNA	O
showed	O
that	O
only	O
the	O
mRNA	O
with	O
the	O
A--	O
>	O
T	O
mutation	O
in	O
the	O
stopcodon	O
is	O
present	O
in	O
amounts	O
comparable	O
to	O
wildtype	O
RNA.	O
mRNA	O
from	O
the	O
alleles	O
with	O
the	O
other	O
two	O
mutations	O
was	O
either	O
undetectable	O
or	O
present	O
in	O
greatly	O
reduced	O
amounts.	O
The	O
latter	O
indicates	O
that	O
a	O
mRNA	O
based	O
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	O
analysis	O
of	O
protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
type	SpecificDisease
I	SpecificDisease

A	O
potential	O
animal	O
model	O
for	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
through	O
introduction	O
of	O
HPRT	O
mutations	O
into	O
mice.	O
The	O
human	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
rare	O
neurological	DiseaseClass
and	DiseaseClass
behavioural	DiseaseClass
disorder	DiseaseClass
,	O
affecting	O
only	O
males,	O
which	O
is	O
caused	O
by	O
an	O
inherited	DiseaseClass
deficiency	DiseaseClass
in	O
the	O
level	O
of	O
activity	O
of	O
the	O
purine	O
salvage	O
enzyme	O
hypoxanthine-guanosine	O
phosphoribosyl	O
transferase	O
(HPRT).	O
How	O
the	O
resulting	O
alterations	O
in	O
purine	O
metabolism	O
lead	O
to	O
the	O
severe	O
symptoms	O
characteristic	O
of	O
Lesch-Nyhan	Modifier
patients	O
is	O
still	O
not	O
understood.	O
No	O
mutations	O
at	O
the	O
Hprt	O
locus	O
leading	O
to	O
loss	O
of	O
activity	O
have	O
been	O
described	O
in	O
laboratory	O
animals.	O
To	O
derive	O
an	O
animal	O
model	O
for	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
,	O
we	O
have	O
used	O
cultured	O
mouse	O
embryonic	O
stem	O
cells,	O
mutagenized	O
by	O
retroviral	O
insertion	O
and	O
selected	O
for	O
loss	O
of	O
HPRT	O
activity,	O
to	O
construct	O
chimaeric	O
mice.	O
Two	O
clonal	O
lines	O
carrying	O
different	O
mutant	O
Hprt	O
alleles	O
have	O
given	O
rise	O
to	O
germ	O
cells	O
in	O
chimaeras,	O
allowing	O
the	O
derivation	O
of	O
strains	O
of	O
mutant	O
mice	O
having	O
the	O
same	O
biochemical	O
defect	O
as	O
Lesch-Nyhan	Modifier

Duplicational	O
mutation	O
at	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
locus:	O
its	O
frequency,	O
distribution,	O
origin,	O
and	O
phenotypegenotype	O
correlation.	O
Partial	O
gene	O
deletion	O
is	O
the	O
major	O
cause	O
of	O
mutation	O
leading	O
to	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
and	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
BMD	SpecificDisease
).	O
Partial	O
gene	O
duplication	O
has	O
also	O
been	O
recognized	O
in	O
a	O
few	O
cases.	O
We	O
have	O
conducted	O
a	O
survey	O
for	O
duplication	O
in	O
72	O
unrelated	O
nondeletion	O
patients,	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
with	O
clones	O
representing	O
the	O
entire	O
DMD	Modifier
cDNA.	O
With	O
careful	O
quantitative	O
analysis	O
of	O
hybridization	O
band	O
intensity,	O
10	O
cases	O
were	O
found	O
to	O
carry	O
a	O
duplication	O
of	O
part	O
of	O
the	O
gene,	O
a	O
frequency	O
of	O
14%	O
for	O
nondeletion	O
cases	O
(10/72),	O
or	O
6%	O
for	O
all	O
cases	O
(10/181).	O
The	O
extent	O
of	O
these	O
duplications	O
has	O
been	O
characterized	O
according	O
to	O
the	O
published	O
exon-containing	O
HindIII	O
fragment	O
map,	O
and	O
in	O
six	O
of	O
the	O
10	O
duplications	O
a	O
novel	O
restriction	O
fragment	O
that	O
spanned	O
the	O
duplication	O
junction	O
was	O
detected.	O
The	O
resulting	O
translational	O
reading	O
frame	O
of	O
mRNA	O
has	O
been	O
predicted	O
for	O
nine	O
duplications.	O
A	O
shift	O
of	O
the	O
reading	O
frame	O
was	O
predicted	O
in	O
four	O
of	O
the	O
six	O
DMD	Modifier
cases	O
and	O
in	O
one	O
of	O
the	O
two	O
intermediate	O
cases,	O
while	O
the	O
reading	O
frame	O
remained	O
uninterrupted	O
in	O
both	O
BMD	Modifier

Molecular	O
evidence	O
for	O
new	O
mutation	O
at	O
the	O
hprt	O
locus	O
in	O
Lesch-Nyhan	Modifier
patients.	O
Hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT;	O
EC2.	O
4.	O
2.	O
8),	O
which	O
functions	O
in	O
the	O
metabolic	O
salvage	O
of	O
purines,	O
is	O
encoded	O
by	O
an	O
X-linked	O
gene	O
in	O
man.	O
Partial	O
HPRT	DiseaseClass
deficiencies	DiseaseClass
are	O
associated	O
with	O
gouty	SpecificDisease
arthritis	SpecificDisease
,	O
while	O
absence	O
of	O
activity	O
results	O
in	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
(	O
L-N	SpecificDisease
).	O
L-N	Modifier
patients	O
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	O
state	O
appears	O
to	O
confer	O
no	O
selective	O
advantage.	O
Thus,	O
Haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
must	O
occur	O
frequently	O
in	O
order	O
for	O
L-N	SpecificDisease
syndrome	SpecificDisease
to	O
be	O
maintained	O
in	O
the	O
population.	O
This	O
constant	O
introduction	O
of	O
new	O
mutations	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	DiseaseClass
lesions	DiseaseClass
,	O
some	O
of	O
which	O
may	O
be	O
novel.	O
As	O
we	O
report	O
here,	O
the	O
mutations	O
in	O
the	O
hprt	O
gene	O
of	O
seven	O
L-N	Modifier

The	O
mapping	O
of	O
a	O
cDNA	O
from	O
the	O
human	O
X-linked	Modifier
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
to	O
the	O
mouse	O
X	O
chromosome.	O
The	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene	O
in	O
humans	O
has	O
opened	O
up	O
the	O
possibility	O
of	O
a	O
detailed	O
molecular	O
analysis	O
of	O
the	O
genes	O
in	O
humans	O
and	O
in	O
related	O
mammalian	O
species.	O
Until	O
relatively	O
recently,	O
there	O
was	O
no	O
obvious	O
mouse	O
model	O
of	O
this	O
genetic	DiseaseClass
disease	DiseaseClass
for	O
the	O
development	O
of	O
therapeutic	O
strategies.	O
The	O
identification	O
of	O
a	O
mouse	O
X-linked	O
mutant	O
showing	O
muscular	SpecificDisease
dystrophy	SpecificDisease
,	O
mdx,	O
has	O
provided	O
a	O
candidate	O
mouse	O
genetic	O
homologue	O
to	O
the	O
DMD	Modifier
locus;	O
the	O
relatively	O
mild	O
pathological	O
features	O
of	O
mdx	O
suggest	O
it	O
may	O
have	O
more	O
in	O
common	O
with	O
mutations	O
of	O
the	O
Becker	Modifier
muscular	Modifier
dystrophy	Modifier
type	O
at	O
the	O
same	O
human	O
locus,	O
however.	O
But	O
the	O
close	O
genetic	O
linkage	O
of	O
mdx	O
to	O
G6PD	O
and	O
Hprt	O
on	O
the	O
mouse	O
X	O
chromosome,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	O
may	O
instead	O
correspond	O
to	O
Emery	SpecificDisease
Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
which	O
itself	O
is	O
closely	O
linked	O
to	O
DNA	O
markers	O
at	O
Xq28-qter	O
in	O
the	O
region	O
of	O
G6PD	O
on	O
the	O
human	O
X	O
chromosome.	O
Using	O
an	O
interspecific	O
mouse	O
domesticus/spretus	O
cross,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	O
on	O
the	O
mouse	O
X	O
chromosome,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	O
X	O
chromosome	O
sequences	O
homologous	O
to	O
a	O
DMD	Modifier
cDNA	O
clone.	O
These	O
sequences	O
map	O
provocatively	O
close	O
to	O
the	O
mdx	O
mutation	O
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur,	O
spf,	O
the	O
mouse	O
homologue	O
of	O
OTC	O
(ornithine	O
transcarbamylase)	O
which	O
is	O
closely	O
linked	O
to	O
DMD	SpecificDisease

Identification	O
of	O
the	O
mutation	O
in	O
the	O
alkaptonuria	Modifier
mouse	O
model.	O
Alkaptonuria	SpecificDisease
(	O
aku	SpecificDisease
),	O
an	O
inborn	DiseaseClass
error	DiseaseClass
of	DiseaseClass
metabolism	DiseaseClass

Common	O
sequence	O
motifs	O
at	O
the	O
rearrangement	O
sites	O
of	O
a	O
constitutional	O
X/autosome	O
translocation	O
and	O
associated	O
deletion.	O
Reciprocal	O
chromosome	O
translocations	O
are	O
common	O
de	O
novo	O
rearrangements	O
that	O
occur	O
randomly	O
throughout	O
the	O
human	O
genome.	O
To	O
learn	O
about	O
causative	O
mechanisms,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
breakpoints	O
of	O
a	O
cytologically	O
balanced	O
constitutional	O
reciprocal	O
translocation,	O
t	O
(X;	O
4)	O
(p21.	O
2;	O
q31.	O
22),	O
present	O
in	O
a	O
girl	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
Physical	O
mapping	O
of	O
the	O
derivative	O
chromosomes,	O
after	O
their	O
separation	O
in	O
somatic	O
cell	O
hybrids,	O
reveals	O
that	O
the	O
translocation	O
disrupts	O
the	O
DMD	Modifier

The	O
human	O
factor	O
IX	O
gene	O
as	O
germline	O
mutagen	O
test:	O
samples	O
from	O
Mainland	O
China	O
have	O
the	O
putatively	O
endogenous	O
pattern	O
of	O
mutation.	O
Germline	O
mutations	O
are	O
the	O
major	O
source	O
of	O
genetic	O
variation	O
that	O
allows	O
a	O
species	O
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
Mendelian	DiseaseClass
disease	DiseaseClass
and	O
genetic	O
predisposition	O
to	O
multifactorial	DiseaseClass
diseases	DiseaseClass
.	O
Previous	O
analyses	O
have	O
revealed	O
that	O
the	O
pattern	O
of	O
germline	O
mutations	O
in	O
the	O
factor	O
IX	O
gene	O
(F9)	O
is	O
similar	O
among	O
a	O
variety	O
of	O
ethnically	O
and	O
geographically	O
diverse	O
populations	O
and	O
compatible	O
with	O
the	O
ancient	O
pattern	O
that	O
has	O
shaped	O
the	O
mammalian	O
genome.	O
Here,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	Modifier
B	Modifier

Phenotype	O
heterogeneity	O
among	O
hemizygotes	O
in	O
a	O
family	O
biochemically	O
screened	O
for	O
adrenoleukodystrophy	SpecificDisease
.	O
We	O
report	O
on	O
two	O
clinically,	O
neurologically	O
normal	O
relatives	O
of	O
a	O
boy	O
affected	O
by	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
);	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	O
of	O
an	O
ALD	Modifier
hemizygote.	O
The	O
assay	O
consisted	O
in	O
the	O
determination	O
of	O
very-long-chain	O
fatty	O
acids	O
in	O
lyophilized	O
and	O
reconstituted	O
plasma.	O
While	O
no	O
evidence	O
of	O
neurologic	DiseaseClass
disease	DiseaseClass
(	O
leukodystrophy	SpecificDisease
or	O
myeloneuropathy	SpecificDisease
)	O
was	O
present	O
in	O
these	O
hemizygotes,	O
adrenocortical	DiseaseClass
insufficiency	DiseaseClass
provoking	O
compensatory	O
high	O
ACTH	O
release	O
was	O
found	O
in	O
both.	O
These	O
findings	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	O
families	O
in	O
which	O
cases	O
with	O
clinically	O
expressed	O
ALD	SpecificDisease

Novel	O
mutations	O
of	O
the	O
ATP7B	O
gene	O
in	O
Japanese	O
patients	O
with	O
Wilson	SpecificDisease
disease	SpecificDisease
.	O
Wilson	SpecificDisease
disease	SpecificDisease
(	O
WD	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
copper	O
accumulation	O
in	O
the	O
liver,	O
brain,	O
kidneys,	O
and	O
corneas,	O
and	O
culminating	O
in	O
copper	O
toxication	O
in	O
these	O
organs.	O
In	O
this	O
study,	O
we	O
analyzed	O
mutations	O
of	O
the	O
responsible	O
gene,	O
ATP7B,	O
in	O
four	O
Japanese	O
patients	O
with	O
WD	SpecificDisease
.	O
By	O
direct	O
sequencing,	O
we	O
identified	O
five	O
mutations,	O
of	O
which	O
two	O
were	O
novel,	O
and	O
16	O
polymorphisms,	O
of	O
which	O
6	O
were	O
novel.	O
The	O
mutations	O
2871delC	O
and	O
2513delA	O
shift	O
the	O
reading	O
frame	O
so	O
that	O
truncated	O
abnormal	O
protein	O
is	O
expected.	O
In	O
contrast	O
to	O
these	O
mutations	O
found	O
in	O
patients	O
with	O
hepatic-type	O
of	O
early	O
onset,	O
the	O
mutations	O
A874V,	O
R778L,	O
and	O
3892delGTC	O
were	O
either	O
missense	O
mutations	O
or	O
in	O
frame	O
1-amino	O
acid	O
deletion,	O
and	O
occurred	O
in	O
the	O
patients	O
with	O
hepato-neurologic	O
type	O
of	O
late	O
onset.	O
The	O
mutations	O
2871delC	O
and	O
R778L	O
have	O
been	O
previously	O
reported	O
in	O
a	O
relatively	O
large	O
number	O
of	O
Japanese	O
patients.	O
In	O
particular,	O
R778L	O
is	O
known	O
to	O
be	O
more	O
prevalent	O
in	O
Asian	O
countries	O
than	O
in	O
other	O
countries	O
of	O
the	O
world.	O
Our	O
data	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
the	O
mutations	O
tend	O
to	O
occur	O
in	O
a	O
population-specific	O
manner.	O
Therefore,	O
the	O
accumulation	O
of	O
the	O
types	O
of	O
mutations	O
in	O
Japanese	O
patients	O
with	O
WD	SpecificDisease
will	O
facilitate	O
the	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
of	O
WD	SpecificDisease

Structural	O
analysis	O
of	O
the	O
5'	O
region	O
of	O
mouse	O
and	O
human	O
Huntington	Modifier
disease	Modifier
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di-	O
and	O
trinucleotide	O
polymorphisms.	O
We	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
Huntington	Modifier
disease	Modifier
(	O
HD	Modifier
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16.	O
3	O
3.	O
Here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(Hdh)	O
and	O
human	O
HD	Modifier
genes	O
encompassing	O
the	O
first	O
five	O
exons.	O
We	O
show	O
that	O
in	O
this	O
region	O
these	O
two	O
genes	O
share	O
identical	O
exon	O
boundaries,	O
but	O
have	O
different-size	O
introns.	O
Two	O
dinucleotide	O
(CT)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	O
in	O
the	O
HD	Modifier
gene	O
were	O
identified.	O
Comparison	O
of	O
940-bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(78.	O
8%	O
nucleotide	O
identity)	O
between	O
Hdh	O
and	O
the	O
HD	Modifier
gene	O
from	O
nucleotide	O
-56	O
to	O
-206	O
(of	O
Hdh).	O
Neither	O
Hdh	O
nor	O
the	O
HD	Modifier
gene	O
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	O
site	O
and	O
numerous	O
potential	O
Sp1	O
binding	O
sites.	O
The	O
high	O
sequence	O
identity	O
between	O
Hdh	O
and	O
the	O
HD	Modifier
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
Huntington	Modifier
disease	Modifier

Complement	SpecificDisease
deficiency	SpecificDisease
and	O
nephritis	SpecificDisease
.	O
A	O
report	O
of	O
a	O
family.	O
A	O
family	O
is	O
described	O
in	O
which	O
three	O
children	O
had	O
homozygous	O
deficiency	SpecificDisease
of	SpecificDisease
C3	SpecificDisease
and	O
in	O
which	O
both	O
parents	O
and	O
two	O
other	O
children	O
were	O
heterozygous	O
for	O
the	O
C3	O
null	O
gene.	O
One	O
child	O
with	O
heterozygous	O
C3	SpecificDisease
deficiency	SpecificDisease
was	O
found	O
to	O
have	O
membranoproliferative	O
glomerulonephritis	SpecificDisease
;	O
proteinuria	SpecificDisease
and/or	O
microscopical	O
haematuria	SpecificDisease
was	O
present	O
in	O
all	O
three	O
homozygous	O
C3-deficient	Modifier
children.	O
All	O
children	O
with	O
homozygous	O
or	O
heterozygous	O
C3	SpecificDisease
deficiency	SpecificDisease
were,	O
to	O
a	O
varying	O
degree,	O
susceptible	O
to	O
infection.	O
The	O
only	O
child	O
of	O
the	O
family	O
with	O
normal	O
complement	O
had	O
no	O
increased	O
risk	O
of	O
infection	O
and	O
no	O
renal	DiseaseClass
disease	DiseaseClass
.	O
This	O
family	O
study	O
provides	O
further	O
support	O
for	O
the	O
proposal	O
that	O
C3	SpecificDisease
deficiency	SpecificDisease
predisposes	O
to	O
nephritis	SpecificDisease

Cytogenetic	O
investigations	O
in	O
families	O
with	O
ataxia-telangiectasia	SpecificDisease
.	O
Chromosomal	O
studies	O
were	O
performed	O
on	O
peripheral	O
blood	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
five	O
Israeli-Moroccan	O
families	O
with	O
ataxia-telangiectasia	SpecificDisease

Predominance	O
of	O
the	O
adrenomyeloneuropathy	Modifier
phenotype	O
of	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
in	O
The	O
Netherlands:	O
a	O
survey	O
of	O
30	O
kindreds.	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
X-ALD	SpecificDisease
)	O
is	O
an	O
inherited	DiseaseClass
disorder	DiseaseClass
of	O
peroxisomal	O
beta-oxidation	O
associated	O
with	O
accumulation	O
of	O
saturated	O
very	O
long-chain	O
fatty	O
acids,	O
which	O
results	O
in	O
central	O
and	O
peripheral	O
demyelination	DiseaseClass
and	O
in	O
impaired	CompositeMention
function	CompositeMention
of	CompositeMention
adrenal	CompositeMention
cortex	CompositeMention
and	CompositeMention
testes	CompositeMention
.	O
The	O
phenotypic	O
expression	O
is	O
highly	O
variable,	O
childhood	SpecificDisease
cerebral	SpecificDisease
ALD	SpecificDisease
(	O
CCALD	SpecificDisease
)	O
and	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
)	O
being	O
the	O
main	O
variants.	O
We	O
explored	O
the	O
30	O
Dutch	O
kindreds	O
well	O
known	O
to	O
the	O
Dutch	O
X-ALD	Modifier
/	O
AMN	Modifier
Study	O
Group	O
and	O
phenotyped	O
77	O
male	O
patients	O
	O
35	O
(46%)	O
had	O
AMN	SpecificDisease
and	O
24	O
(31%)	O
CCALD	SpecificDisease
or	O
adolescent	SpecificDisease
cerebral	SpecificDisease
ALD	SpecificDisease
(	O
AdolCALD	SpecificDisease
).	O
These	O
percentages	O
differ	O
significantly	O
from	O
previous	O
reports,	O
in	O
which	O
25	O
to	O
28%	O
of	O
the	O
patients	O
developed	O
AMN	SpecificDisease
and	O
53	O
to	O
57%	O
CCALD	SpecificDisease
or	O
AdolCALD	SpecificDisease
.	O
Our	O
findings	O
indicate	O
that--at	O
least	O
in	O
the	O
Netherlands--	O
AMN	SpecificDisease
may	O
be	O
the	O
most	O
frequent	O
phenotype	O
of	O
X-ALD	SpecificDisease

Three	O
novel	O
aniridia	Modifier
mutations	O
in	O
the	O
human	O
PAX6	O
gene.	O
Aniridia	SpecificDisease
(	O
iris	SpecificDisease
hypoplasia	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
congenital	DiseaseClass
disorder	DiseaseClass
of	DiseaseClass
the	DiseaseClass
eye	DiseaseClass
.	O
Mutations	O
in	O
the	O
human	O
aniridia	Modifier
(PAX6)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups.	O
In	O
the	O
study	O
reported	O
here	O
we	O
describe	O
PAX6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	SpecificDisease
.	O
Of	O
the	O
four	O
different	O
mutations	O
identified,	O
one	O
was	O
identical	O
to	O
a	O
previously	O
reported	O
mutation	O
(C--	O
>	O
T	O
transition	O
at	O
codon	O
240),	O
and	O
three	O
were	O
novel	O
	O
two	O
in	O
the	O
glycine-rich	O
region	O
and	O
one	O
in	O
the	O
proline/serine/threonine-rich	O
(PST)	O
region.	O
One	O
PAX6	O
mutation	O
found	O
in	O
the	O
PST	O
region	O
was	O
associated	O
with	O
cataracts	SpecificDisease
in	O
an	O
aniridia	Modifier
family.	O
Another	O
splice	O
mutation	O
in	O
the	O
PST	O
domain	O
occurred	O
in	O
an	O
aniridia	Modifier
patient	O
with	O
anosmia	SpecificDisease
(inability	O
to	O
smell).	O
The	O
six	O
new	O
aniridia	Modifier
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
PAX6	O
proteins.	O
These	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	SpecificDisease
is	O
caused	O
by	O
haploinsufficiency	SpecificDisease
of	SpecificDisease
PAX6	SpecificDisease

Hepatoblastoma	SpecificDisease
,	O
pigmented	DiseaseClass
ocular	DiseaseClass
fundus	DiseaseClass
lesions	DiseaseClass
and	O
jaw	DiseaseClass
lesions	DiseaseClass
in	O
Gardner	SpecificDisease
syndrome	SpecificDisease
.	O
Hepatoblastoma	SpecificDisease
is	O
a	O
rare	O
neoplasm	DiseaseClass
of	O
infants	O
and	O
children	O
only	O
recently	O
documented	O
in	O
association	O
with	O
hereditary	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
of	SpecificDisease
the	SpecificDisease
colon	SpecificDisease
[Kingston	O
et	O
al.,	O
1983].	O
We	O
report	O
four	O
children	O
with	O
hepatoblastoma	SpecificDisease
from	O
four	O
unrelated	O
families	O
with	O
Gardner	SpecificDisease
syndrome	SpecificDisease
(	O
GS	SpecificDisease
).	O
One	O
child,	O
now	O
19	O
years	O
old,	O
survived	O
after	O
a	O
resection	O
of	O
a	O
hepatoblastoma	SpecificDisease
in	O
infancy	O
and	O
recently	O
was	O
found	O
to	O
have	O
GS	SpecificDisease
.	O
He	O
has	O
an	O
associated	O
odontoma	SpecificDisease
and	O
pigmented	DiseaseClass
ocular	DiseaseClass
fundus	DiseaseClass
lesions	DiseaseClass
,	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
be	O
clinical	O
markers	O
of	O
GS	SpecificDisease
.	O
Many	O
individuals	O
in	O
these	O
four	O
GS	Modifier
families,	O
both	O
affected	O
and	O
at	O
risk,	O
have	O
osteomatous	DiseaseClass
jaw	DiseaseClass
lesions	DiseaseClass
and	O
pigmented	DiseaseClass
ocular	DiseaseClass
fundus	DiseaseClass
lesions	DiseaseClass
.	O
A	O
search	O
for	O
colonic	DiseaseClass
polyps	DiseaseClass
should	O
be	O
made	O
in	O
families	O
of	O
infants	O
and	O
children	O
with	O
hepatoblastoma	SpecificDisease
.	O
If	O
the	O
child	O
survives,	O
he	O
or	O
she	O
should	O
be	O
monitored	O
for	O
the	O
later	O
appearance	O
of	O
colonic	DiseaseClass
polyps	DiseaseClass
.	O
The	O
finding	O
of	O
jaw	DiseaseClass
lesions	DiseaseClass
and/or	O
pigmented	DiseaseClass
ocular	DiseaseClass
fundus	DiseaseClass
lesions	DiseaseClass
in	O
relatives	O
at	O
risk	O
are	O
indications	O
of	O
the	O
possible	O
presence	O
of	O
the	O
GS	Modifier

Mutation	O
spectrum	O
in	O
the	O
CHM	Modifier
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	Modifier
patients.	O
The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	Modifier
(	O
CHM	Modifier
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon-intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	SpecificDisease
.	O
We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single-strand	O
conformation	O
polymorphism	O
(PCR-SSCP)	O
technique.	O
Causative	O
mutations	O
in	O
the	O
CHM	Modifier
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach.	O
In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found.	O
Thus,	O
in	O
one	O
patient,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	Modifier
gene.	O
Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21.	O
In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR-SSCP	O
analysis	O
and	O
direct	O
sequencing.	O
Interestingly,	O
all	O
CHM	Modifier
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	Modifier

Diverse	O
point	O
mutations	O
result	O
in	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
polymorphism	O
in	O
Taiwan.	O
Glucose-6-PHOSPHATE	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD;	SpecificDisease
EC	SpecificDisease
1.1.	SpecificDisease
1.	SpecificDisease
49)	SpecificDisease
deficiency	SpecificDisease
is	O
the	O
most	O
common	O
human	O
enzymopathy	DiseaseClass
,	O
affecting	O
more	O
than	O
200	O
million	O
people	O
worldwide.	O
Although	O
greater	O
than	O
400	O
variants	O
have	O
been	O
described	O
based	O
on	O
clinical	O
and	O
biochemical	O
criteria,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
basis	O
of	O
these	O
G6PD	SpecificDisease
deficiencies	SpecificDisease
.	O
Recently,	O
the	O
gene	O
that	O
encodes	O
human	O
G6PD	O
has	O
been	O
cloned	O
and	O
sequenced,	O
which	O
enables	O
us	O
to	O
examine	O
directly	O
the	O
heterogeneity	O
of	O
G6PD	O
at	O
the	O
DNA	O
level.	O
During	O
the	O
past	O
10	O
years,	O
we	O
examined	O
the	O
G6PD	O
activity	O
in	O
21,	O
271	O
newborn	O
Chinese	O
infants	O
(11,	O
400	O
males	O
and	O
9,	O
871	O
females)	O
and	O
identified	O
314	O
(2.	O
8%)	O
males	O
and	O
246	O
(2.	O
5%)	O
females	O
having	O
low	O
G6PD	O
activity.	O
The	O
G6PD	O
gene	O
from	O
10	O
randomly	O
selected	O
affected	O
individuals	O
and	O
their	O
relatives	O
was	O
polymerase	O
chain	O
reaction	O
(PCR)	O
amplified,	O
subcloned,	O
and	O
sequenced.	O
Our	O
results	O
indicate	O
that	O
at	O
least	O
four	O
types	O
of	O
mutation	O
are	O
responsible	O
for	O
the	O
G6PD	O
polymorphism	O
in	O
Taiwan.	O
The	O
first	O
type	O
of	O
mutation	O
(487	O
G----A)	O
was	O
found	O
in	O
an	O
affected	O
Chinese	O
with	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
487,	O
which	O
results	O
in	O
a	O
(163)	O
Gly	O
to	O
Ser	O
substitution.	O
The	O
second	O
type	O
of	O
mutation	O
(493	O
A----G)	O
is	O
a	O
novel	O
mutation	O
that	O
has	O
not	O
been	O
reported	O
in	O
any	O
other	O
ethnic	O
group	O
and	O
was	O
identified	O
in	O
two	O
affected	O
Chinese.	O
This	O
mutation	O
causes	O
an	O
A	O
to	O
G	O
change	O
at	O
nucleotide	O
position	O
493,	O
producing	O
an	O
(165)	O
Asn	O
to	O
Asp	O
substitution.	O
Interestingly,	O
the	O
487	O
G----A	O
and	O
493	O
A----G	O
mutations	O
create	O
Alu	O
I	O
and	O
Ava	O
II	O
recognition	O
sites,	O
respectively,	O
which	O
enabled	O
us	O
to	O
rapidly	O
detect	O
these	O
two	O
mutations	O
by	O
PCR/restriction	O
enzyme	O
(RE)	O
digestion	O
method.	O
The	O
third	O
mutation	O
(1376	O
G----T)	O
was	O
found	O
in	O
four	O
affected	O
Chinese.	O
This	O
mutation	O
causes	O
a	O
G	O
to	O
T	O
change	O
at	O
nucleotide	O
position	O
1376	O
that	O
results	O
in	O
an	O
(459)	O
Arg	O
to	O
Leu	O
substitution.	O
The	O
1376	O
G----T	O
mutation	O
seems	O
to	O
be	O
the	O
dominant	O
allele	O
that	O
causes	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
Taiwan.	O
Finally,	O
two	O
affected	O
Chinese	O
were	O
identified	O
as	O
having	O
the	O
fourth	O
mutation	O
(1388	O
G----A).	O
This	O
mutation	O
causes	O
a	O
G	O
to	O
A	O
change	O
at	O
nucleotide	O
1388	O
that	O
produces	O
an	O
(463)	O
Arg	O
to	O
His	O
substitution.	O
Our	O
studies	O
provide	O
the	O
direct	O
proof	O
of	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Fas	O
preassociation	O
required	O
for	O
apoptosis	O
signaling	O
and	O
dominant	O
inhibition	O
by	O
pathogenic	O
mutations.	O
Heterozygous	O
mutations	O
encoding	O
abnormal	O
forms	O
of	O
the	O
death	O
receptor	O
Fas	O
dominantly	O
interfere	O
with	O
Fas-induced	O
lymphocyte	O
apoptosis	O
in	O
human	O
autoimmune	SpecificDisease
lymphoproliferative	SpecificDisease
syndrome	SpecificDisease

Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
in	O
the	O
colchicine	O
era:	O
the	O
fate	O
of	O
one	O
family.	O
In	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
),	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
FMF	SpecificDisease
.	O
Each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	SpecificDisease
kidney	SpecificDisease
disease	SpecificDisease
of	O
FMF	SpecificDisease

Two	O
new	O
arylsulfatase	O
A	O
(ARSA)	O
mutations	O
in	O
a	O
juvenile	O
metachromatic	Modifier
leukodystrophy	Modifier
(	O
MLD	Modifier
)	O
patient.	O
Fragments	O
of	O
the	O
arylsulfatase	O
A	O
(ARSA)	O
gene	O
from	O
a	O
patient	O
with	O
juvenile-onset	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
)	O
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
into	O
MP13	O
cloning	O
vectors.	O
Clones	O
hybridizing	O
with	O
cDNA	O
for	O
human	O
ARSA	O
were	O
selected,	O
examined	O
for	O
appropriate	O
size	O
inserts,	O
and	O
used	O
to	O
prepare	O
single-stranded	O
phage	O
DNA.	O
Examination	O
of	O
the	O
entire	O
coding	O
and	O
most	O
of	O
the	O
intronic	O
sequence	O
revealed	O
two	O
putative	O
disease-related	O
mutations.	O
One,	O
a	O
point	O
mutation	O
in	O
exon	O
3,	O
resulted	O
in	O
the	O
substitution	O
of	O
isoleucine	O
by	O
serine.	O
Introduction	O
of	O
this	O
alteration	O
into	O
the	O
normal	O
ARSA	O
cDNA	O
sequence	O
resulted	O
in	O
a	O
substantial	O
decrease	O
in	O
ARSA	O
activity	O
on	O
transient	O
expression	O
in	O
cultured	O
baby	O
hamster	O
kidney	O
cells.	O
About	O
5%	O
of	O
the	O
control	O
expression	O
was	O
observed,	O
suggesting	O
a	O
small	O
residual	O
activity	O
in	O
the	O
mutated	O
ARSA.	O
The	O
second	O
mutation,	O
a	O
G-to-A	O
transition,	O
occurred	O
in	O
the	O
other	O
allele	O
and	O
resulted	O
in	O
an	O
altered	O
splice-recognition	O
sequence	O
between	O
exon	O
7	O
and	O
the	O
following	O
intron.	O
The	O
mutation	O
also	O
resulted	O
in	O
the	O
loss	O
of	O
a	O
restriction	O
site.	O
Apparently	O
normal	O
levels	O
of	O
mRNA	O
were	O
generated	O
from	O
this	O
allele,	O
but	O
no	O
ARSA	O
activity	O
or	O
immuno-cross-reactive	O
material	O
could	O
be	O
detected.	O
A	O
collection	O
of	O
DNA	O
samples	O
from	O
known	O
or	O
suspected	O
MLD	Modifier
patients,	O
members	O
of	O
their	O
families,	O
and	O
normal	O
controls	O
was	O
screened	O
for	O
these	O
mutations.	O
Four	O
additional	O
individuals	O
carrying	O
each	O
of	O
the	O
mutations	O
were	O
found	O
among	O
the	O
nearly	O
100	O
MLD	Modifier
patients	O
in	O
the	O
sample.	O
Gene	O
segregation	O
in	O
the	O
original	O
patients	O
family	O
was	O
consistent	O
with	O
available	O
clinical	O
and	O
biochemical	O
data.	O
No	O
individuals	O
homozygous	O
for	O
either	O
of	O
these	O
two	O
mutations	O
were	O
identified.	O
However,	O
combinations	O
with	O
other	O
MLD	Modifier
mutations	O
suggest	O
that	O
the	O
point	O
mutation	O
in	O
exon	O
3	O
does	O
result	O
in	O
some	O
residual	O
enzyme	O
activity	O
and	O
is	O
associated	O
with	O
late-onset	O
forms	O
of	O
the	O
disease.	O
The	O
splice-site	O
mutation	O
following	O
exon	O
7	O
produces	O
late-infantile	O
MLD	SpecificDisease

Null	O
mutation	O
of	O
the	O
murine	O
ATP7B	O
(	O
Wilson	SpecificDisease
disease	SpecificDisease
)	O
gene	O
results	O
in	O
intracellular	DiseaseClass
copper	DiseaseClass
accumulation	DiseaseClass
and	O
late-onset	DiseaseClass
hepatic	DiseaseClass
nodular	DiseaseClass
transformation	DiseaseClass
.	O
The	O
Atp7b	O
protein	O
is	O
a	O
copper-transporting	O
ATPase	O
expressed	O
predominantly	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
most	O
other	O
tissues.	O
Mutations	O
in	O
the	O
ATP7B	O
gene	O
lead	O
to	O
Wilson	SpecificDisease
disease	SpecificDisease
,	O
a	O
copper	DiseaseClass
toxicity	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
dramatic	O
build-up	O
of	O
intracellular	O
hepatic	O
copper	O
with	O
subsequent	O
hepatic	CompositeMention
and	CompositeMention
neuro-logical	CompositeMention
abnormalities	CompositeMention
.	O
Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(null)	O
for	O
the	O
Wilson	Modifier
disease	Modifier
gene.	O
The	O
ATP7B	O
null	O
mice	O
display	O
a	O
gradual	O
accumulation	O
of	O
hepatic	O
copper	O
that	O
increases	O
to	O
a	O
level	O
60-fold	O
greater	O
than	O
normal	O
by	O
5	O
months	O
of	O
age.	O
An	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney,	O
brain,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo-zygous	O
mutants,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	DiseaseClass
deficient	DiseaseClass
.	O
Morphological	DiseaseClass
abnormalities	DiseaseClass
resembling	O
cirrhosis	SpecificDisease
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age.	O
Progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	DiseaseClass
abnormalities	DiseaseClass
and	O
growth	DiseaseClass
retardation	DiseaseClass
characteristic	O
of	O
copper	SpecificDisease
deficiency	SpecificDisease
.	O
Copper	O
concentration	O
in	O
the	O
livers	O
of	O
the	O
newborn	O
homozygous	O
null	O
mutants	O
was	O
decreased	O
dramatically.	O
In	O
summary,	O
inactivation	O
of	O
the	O
murine	O
ATP7B	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	DiseaseClass
liver	DiseaseClass
disease	DiseaseClass
that	O
resembles	O
Wilson	SpecificDisease
disease	SpecificDisease

Adrenoleukodystrophy	SpecificDisease
and	O
adrenomyeloneuropathy	SpecificDisease
associated	O
with	O
partial	O
adrenal	DiseaseClass
insufficiency	DiseaseClass
in	O
three	O
generations	O
of	O
a	O
kindred.	O
Four	O
cases	O
of	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
and	O
one	O
case	O
of	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
)	O
have	O
developed	O
in	O
a	O
kindred	O
over	O
three	O
generations	O
demonstrating	O
that	O
AMN	SpecificDisease
is	O
a	O
clinical	O
variant	O
of	O
ALD	SpecificDisease
.	O
Pituitary-adrenal	O
function	O
studies	O
were	O
performed	O
in	O
10	O
family	O
members,	O
including	O
two	O
affected	O
males	O
and	O
four	O
females	O
identified	O
as	O
carriers	O
of	O
ALD	SpecificDisease
/	O
AMN	SpecificDisease
.	O
No	O
pituitary-adrenal	DiseaseClass
abnormality	DiseaseClass
was	O
found	O
in	O
the	O
carriers.	O
However,	O
basal	O
morning	O
plasma	O
adrenocorticotropic	O
hormone	O
(ACTH)	O
levels	O
were	O
markedly	O
elevated	O
in	O
the	O
two	O
males	O
with	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
,	O
despite	O
the	O
fact	O
that	O
they	O
had	O
no	O
clinical	O
signs	O
of	O
adrenal	DiseaseClass
insufficiency	DiseaseClass
and	O
that	O
morning	O
plasma	O
cortisol	O
levels	O
and	O
their	O
response	O
to	O
maximal	O
exogenous	O
ACTH	O
stimulation	O
appeared	O
to	O
be	O
normal.	O
In	O
addition,	O
the	O
integrated	O
24-hour	O
response	O
to	O
the	O
administration	O
were	O
also	O
subnormal	O
in	O
these	O
two	O
cases.	O
Thus,	O
people	O
with	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
may	O
have	O
subclinical	O
partial	O
adrenocrotical	DiseaseClass
insufficiency	DiseaseClass
.	O
No	O
other	O
endocrinologic	DiseaseClass
dysfunction	DiseaseClass

Identification	O
of	O
mutations	O
in	O
the	O
ALD-gene	O
of	O
20	O
families	O
with	O
adrenoleukodystrophy	SpecificDisease
/	O
adrenomyeloneuropathy	SpecificDisease
.	O
Adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
),	O
an	O
X-linked	DiseaseClass
inherited	DiseaseClass
metabolic	DiseaseClass
disorder	DiseaseClass
,	O
is	O
the	O
most	O
frequent	O
inborn	DiseaseClass
peroxisomal	DiseaseClass
disease	DiseaseClass
.	O
It	O
leads	O
to	O
demyelination	DiseaseClass
in	DiseaseClass
the	DiseaseClass
central	DiseaseClass
and	DiseaseClass
peripheral	DiseaseClass
nervous	DiseaseClass
system	DiseaseClass
.	O
Defective	O
beta-oxidation	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
(VLCFAs;	O
C22	O
	O
0-C26	O
	O
0)	O
in	O
peroxisomes	O
has	O
been	O
shown	O
to	O
lead	O
to	O
an	O
accumulation	O
of	O
VLCFAs	O
in	O
leukoid	O
areas	O
of	O
the	O
central	O
nervous	O
system,	O
peripheral	O
nerves,	O
adrenal	O
gland,	O
and	O
blood.	O
The	O
ALD	Modifier
gene	O
has	O
been	O
recently	O
identified	O
and	O
encodes	O
a	O
745-amino-acid	O
protein.	O
We	O
screened	O
patients	O
with	O
adrenoleukodystrophy	SpecificDisease
/	O
adrenomyeloneuropathy	SpecificDisease
(	O
ALD	SpecificDisease
/	O
AMN	SpecificDisease
)	O
from	O
20	O
kindreds	O
for	O
mutations	O
in	O
the	O
ALD	Modifier
gene.	O
Eleven	O
missense	O
and	O
two	O
nonsense	O
mutations,	O
five	O
deletions,	O
and	O
one	O
insertion	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
eight	O
reverse	O
transcribed	O
fragments	O
of	O
the	O
ALD	Modifier
-gene	O
mRNA.	O
Four	O
mutations	O
could	O
be	O
shown	O
to	O
be	O
de	O
novo.	O
All	O
mutations	O
could	O
be	O
confirmed	O
in	O
carriers	O
by	O
sequencing	O
genomic	O
DNA.	O
No	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
could	O
be	O
observed.	O
The	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
ALD	Modifier

Gonosomal	O
mosaicism	O
in	O
myotonic	Modifier
dystrophy	Modifier
patients:	O
involvement	O
of	O
mitotic	O
events	O
in	O
(CTG)n	O
repeat	O
variation	O
and	O
selection	O
against	O
extreme	O
expansion	O
in	O
sperm.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
caused	O
by	O
abnormal	O
expansion	O
of	O
a	O
polymorphic	O
(CTG)	O
n	O
repeat,	O
located	O
in	O
the	O
DM	Modifier
protein	O
kinase	O
gene.	O
We	O
determined	O
the	O
(CTG)	O
n	O
repeat	O
lengths	O
in	O
a	O
broad	O
range	O
of	O
tissue	O
DNAs	O
from	O
patients	O
with	O
mild,	O
classical,	O
or	O
congenital	O
manifestation	O
of	O
DM	Modifier
.	O
Differences	O
in	O
the	O
repeat	O
length	O
were	O
seen	O
in	O
somatic	O
tissues	O
from	O
single	O
DM	Modifier
individuals	O
and	O
twins.	O
Repeats	O
appeared	O
to	O
expand	O
to	O
a	O
similar	O
extent	O
in	O
tissues	O
originating	O
from	O
the	O
same	O
embryonal	O
origin.	O
In	O
most	O
male	O
patients	O
carrying	O
intermediate-	O
or	O
small-sized	O
expansions	O
in	O
blood,	O
the	O
repeat	O
lengths	O
covered	O
a	O
markedly	O
wider	O
range	O
in	O
sperm.	O
In	O
contrast,	O
male	O
patients	O
with	O
large	O
allele	O
expansions	O
in	O
blood	O
(>	O
700	O
CTGs)	O
had	O
similar	O
or	O
smaller	O
repeats	O
in	O
sperm,	O
when	O
detectable.	O
Sperm	O
alleles	O
with	O
>	O
1,	O
000	O
CTGs	O
were	O
not	O
seen.	O
We	O
conclude	O
that	O
DM	Modifier
patients	O
can	O
be	O
considered	O
gonosomal	O
mosaics,	O
i.	O
e	O
e.,	O
combined	O
somatic	O
and	O
germ-line	O
tissue	O
mosaics.	O
Most	O
remarkably,	O
we	O
observed	O
multiple	O
cases	O
where	O
the	O
length	O
distributions	O
of	O
intermediate-	O
or	O
small-sized	O
alleles	O
in	O
fathers	O
sperm	O
were	O
significantly	O
different	O
from	O
that	O
in	O
their	O
offsprings	O
blood.	O
Our	O
combined	O
findings	O
indicate	O
that	O
intergenerational	O
length	O
changes	O
in	O
the	O
unstable	O
CTG	O
repeat	O
are	O
most	O
likely	O
to	O
occur	O
during	O
early	O
embryonic	O
mitotic	O
divisions	O
in	O
both	O
somatic	O
and	O
germ-line	O
tissue	O
formation.	O
Both	O
the	O
initial	O
CTG	O
length,	O
the	O
overall	O
number	O
of	O
cell	O
divisions	O
involved	O
in	O
tissue	O
formation,	O
and	O
perhaps	O
a	O
specific	O
selection	O
process	O
in	O
spermatogenesis	O
may	O
influence	O
the	O
dynamics	O
of	O
this	O
process.	O
A	O
model	O
explaining	O
mitotic	O
instability	O
and	O
sex-dependent	O
segregation	O
phenomena	O
in	O
DM	Modifier

Combined	O
analysis	O
of	O
hereditary	Modifier
prostate	Modifier
cancer	Modifier
linkage	O
to	O
1q24-25:	O
results	O
from	O
772	O
hereditary	Modifier
prostate	Modifier
cancer	Modifier
families	O
from	O
the	O
International	O
Consortium	O
for	O
Prostate	Modifier
Cancer	Modifier
Genetics.	O
A	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	Modifier
cancer	Modifier
-susceptibility	O
locus	O
at	O
1q24-25.	O
Subsequent	O
reports	O
in	O
additional	O
collections	O
of	O
families	O
have	O
yielded	O
conflicting	O
results.	O
In	O
addition,	O
evidence	O
for	O
locus	O
heterogeneity	O
has	O
been	O
provided	O
by	O
the	O
identification	O
of	O
other	O
putative	O
hereditary	Modifier
prostate	Modifier
cancer	Modifier
loci	O
on	O
Xq27-28,	O
1q42-43,	O
and	O
1p36.	O
The	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24-25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
International	O
Consortium	O
for	O
Prostate	Modifier
Cancer	Modifier
Genetics	O
(ICPCG)	O
from	O
North	O
America,	O
Australia,	O
Finland,	O
Norway,	O
Sweden,	O
and	O
the	O
United	O
Kingdom.	O
Overall,	O
there	O
was	O
some	O
evidence	O
for	O
linkage,	O
with	O
a	O
peak	O
parametric	O
multipoint	O
LOD	O
score	O
assuming	O
heterogeneity	O
(HLOD)	O
of	O
1.	O
40	O
(P	O
=.	O
01)	O
at	O
D1S212.	O
The	O
estimated	O
proportion	O
of	O
families	O
(alpha)	O
linked	O
to	O
the	O
locus	O
was.	O
06	O
(1-LOD	O
support	O
interval.	O
01-.	O
12).	O
This	O
evidence	O
was	O
not	O
observed	O
by	O
a	O
nonparametric	O
approach,	O
presumably	O
because	O
of	O
the	O
extensive	O
heterogeneity.	O
Further	O
parametric	O
analysis	O
revealed	O
a	O
significant	O
effect	O
of	O
the	O
presence	O
of	O
male-to-male	O
disease	O
transmission	O
within	O
the	O
families.	O
In	O
the	O
subset	O
of	O
491	O
such	O
families,	O
the	O
peak	O
HLOD	O
was	O
2.	O
In	O
the	O
subset	O
of	O
491	O
such	O
families,	O
the	O
peak	O
HLOD	O
was	O
2.	O
56	O
(P	O
=.	O
0006)	O
and	O
alpha	O
=.	O
11	O
(1-LOD	O
support	O
interval.	O
04-.	O
19),	O
compared	O
with	O
HLODs	O
of	O
0	O
in	O
the	O
remaining	O
281	O
families.	O
Within	O
the	O
families	O
with	O
male-to-male	O
disease	O
transmission,	O
alpha	O
increased	O
with	O
the	O
early	O
mean	O
age	O
at	O
diagnosis	O
(<	O
65	O
years,	O
alpha	O
=.	O
19,	O
with	O
1-LOD	O
support	O
interval.	O
06-.	O
34)	O
and	O
the	O
number	O
of	O
affected	O
family	O
members	O
(five	O
or	O
more	O
family	O
members,	O
alpha	O
=.	O
15,	O
with	O
1-LOD	O
support	O
interval.	O
04-.	O
28).	O
The	O
highest	O
value	O
of	O
alpha	O
was	O
observed	O
for	O
the	O
48	O
families	O
that	O
met	O
all	O
three	O
criteria	O
(peak	O
HLOD	O
=	O
2.	O
25,	O
P	O
=.	O
001,	O
alpha	O
=.	O
29,	O
with	O
1-LOD	O
support	O
interval.	O
08-.	O
53).	O
These	O
results	O
support	O
the	O
finding	O
of	O
a	O
prostate	Modifier
cancer	Modifier
-susceptibility	O
gene	O
linked	O
to	O
1q24-25,	O
albeit	O
in	O
a	O
defined	O
subset	O
of	O
prostate	Modifier
cancer	Modifier
families.	O
Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease

A	O
novel	O
disease	O
with	O
deficiency	SpecificDisease
of	SpecificDisease
mitochondrial	SpecificDisease
very-long-chain	SpecificDisease
acyl-CoA	SpecificDisease
dehydrogenase	SpecificDisease
.	O
Palmitoyl-CoA	O
dehydrogenase	O
activity	O
in	O
skin	O
fibroblasts	O
from	O
seven	O
patients	O
with	O
unidentified	O
defects	O
of	O
fatty	O
acid	O
oxidation	O
was	O
measured	O
in	O
the	O
presence	O
and	O
absence	O
of	O
antibodies	O
against	O
medium-chain,	O
long-chain,	O
and	O
very-long-chain	O
acyl-CoA	O
dehydrogenases	O
(VLCAD).	O
Two	O
of	O
the	O
patients,	O
4-5	O
month	O
old	O
boys,	O
were	O
found	O
to	O
have	O
a	O
novel	O
disease,	O
VLCAD	SpecificDisease
deficiency	SpecificDisease

Inherited	O
WT1	O
mutation	O
in	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
.	O
Patients	O
with	O
the	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
(	O
Wilms	SpecificDisease
tumor	SpecificDisease
,	O
genital	DiseaseClass
anomalies	DiseaseClass
,	O
and	O
nephropathy	SpecificDisease
)	O
have	O
been	O
demonstrated	O
to	O
carry	O
de	O
novo	O
constitutional	O
mutations	O
in	O
WT1,	O
the	O
Wilms	Modifier
tumor	Modifier
gene	O
at	O
chromosome	O
11p13.	O
We	O
report	O
three	O
new	O
cases,	O
two	O
carrying	O
a	O
previously	O
described	O
WT1	O
exon	O
9	O
mutation	O
and	O
one	O
with	O
a	O
novel	O
WT1	O
exon	O
8	O
mutation.	O
However,	O
unlike	O
patients	O
in	O
previous	O
reports,	O
one	O
of	O
our	O
three	O
patients	O
inherited	O
the	O
affected	O
allele	O
from	O
his	O
phenotypically	O
unaffected	O
father.	O
This	O
observation	O
indicates	O
that	O
the	O
WT1	O
exon	O
9	O
mutation	O
affecting	O
394Arg	O
demonstrated	O
in	O
over	O
one-half	O
of	O
the	O
patients	O
with	O
the	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease

Glucose/galactose	SpecificDisease
malabsorption	SpecificDisease
caused	O
by	O
a	O
defect	O
in	O
the	O
Na+/glucose	O
cotransporter.	O
Glucose/galactose	SpecificDisease
malabsorption	SpecificDisease
(	O
GGM	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
manifesting	O
within	O
the	O
first	O
weeks	O
of	O
life	O
and	O
characterized	O
by	O
a	O
selective	O
failure	O
to	O
absorb	O
dietary	O
glucose	O
and	O
galactose	O
from	O
the	O
intestine.	O
The	O
consequent	O
severe	O
diarrhoea	SpecificDisease
and	O
dehydration	SpecificDisease
are	O
usually	O
fatal	O
unless	O
these	O
sugars	O
are	O
eliminated	O
from	O
the	O
diet.	O
Intestinal	O
biopsies	O
of	O
GGM	Modifier
patients	O
have	O
revealed	O
a	O
specific	O
defect	O
in	O
Na	O
(+)	O
-dependent	O
absorption	O
of	O
glucose	O
in	O
the	O
brush	O
border.	O
Normal	O
glucose	O
absorption	O
is	O
mediated	O
by	O
the	O
Na	O
+/glucose	O
cotransporter	O
in	O
the	O
brush	O
border	O
membrane	O
of	O
the	O
intestinal	O
epithelium.	O
Cellular	O
influx	O
is	O
driven	O
by	O
the	O
transmembrane	O
Na	O
+	O
electrochemical	O
potential	O
gradient;	O
thereafter	O
the	O
sugar	O
moves	O
to	O
the	O
blood	O
across	O
the	O
basolateral	O
membrane	O
via	O
the	O
facilitated	O
glucose	O
carrier.	O
We	O
have	O
previously	O
cloned	O
and	O
sequenced	O
a	O
Na	O
+/glucose	O
cotransporter	O
from	O
normal	O
human	O
ileum	O
and	O
shown	O
that	O
this	O
gene,	O
SGLT1,	O
resides	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22.	O
We	O
have	O
now	O
amplified	O
SGLT1	O
complementary	O
DNA	O
and	O
genomic	O
DNA	O
from	O
members	O
of	O
a	O
family	O
affected	O
with	O
GGM	SpecificDisease
by	O
the	O
polymerase	O
chain	O
reaction.	O
Sequence	O
analysis	O
of	O
the	O
amplified	O
products	O
has	O
revealed	O
a	O
single	O
missense	O
mutation	O
in	O
SGLT1	O
which	O
cosegregates	O
with	O
the	O
GGM	Modifier

Atm	O
and	O
Bax	O
cooperate	O
in	O
ionizing	O
radiation-induced	O
apoptosis	O
in	O
the	O
central	O
nervous	O
system.	O
Ataxia-telangiectasia	SpecificDisease
is	O
a	O
hereditary	DiseaseClass
multisystemic	DiseaseClass
disease	DiseaseClass
resulting	O
from	O
mutations	O
of	O
ataxia	SpecificDisease
telangiectasia	SpecificDisease
,	O
mutated	O
(ATM)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	DiseaseClass
,	O
cancer	DiseaseClass
,	O
immune	DiseaseClass
defects	DiseaseClass
,	O
and	O
hypersensitivity	DiseaseClass
to	DiseaseClass
ionizing	DiseaseClass
radiation	DiseaseClass
.	O
The	O
molecular	O
details	O
of	O
ATM	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear,	O
although	O
the	O
neurological	DiseaseClass
lesion	DiseaseClass
in	O
ataxia-telangiectasia	SpecificDisease

Novel	O
Tay-Sachs	Modifier
disease	Modifier
mutations	O
from	O
China.	O
We	O
describe	O
three	O
HEXA	O
mutations	O
associated	O
with	O
infantile	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
in	O
three	O
unrelated	O
nonconsanguineous	O
Chinese	O
families.	O
Novel	O
mutations	O
were	O
found	O
in	O
two	O
of	O
these	O
families.	O
The	O
third	O
is	O
a	O
previously	O
reported	O
mutation	O
(G--	O
>	O
A	O
transition	O
at	O
nt	O
1444)	O
(Nakano	O
et	O
al.,	O
1988).	O
Direct	O
sequencing	O
of	O
PCR	O
products	O
identified	O
a	O
novel	O
insertion	O
of	O
an	O
A	O
after	O
nt	O
547	O
in	O
family	O
1.	O
This	O
change	O
generates	O
an	O
early	O
termination	O
codon	O
6	O
bp	O
downstream	O
from	O
the	O
insertion	O
site.	O
Allele-specific	O
oligonucleotide	O
hybridization	O
confirmed	O
homozygosity	O
in	O
the	O
proband.	O
Single	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
amplified	O
exon	O
13	O
revealed	O
a	O
T--	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
with	O
the	O
corresponding	O
amino	O
acid	O
substitution	O
W485R	O
in	O
the	O
second	O
family.	O
This	O
mutation	O
creates	O
an	O
Fnu4HI	O
restriction	O
site.	O
The	O
proband	O
is	O
homozygous	O
for	O
this	O
allele.	O
When	O
the	O
site-specific	O
mutagenized	O
alpha	O
cDNA	O
carrying	O
the	O
T--	O
>	O
C	O
transition	O
at	O
nt	O
1453	O
was	O
expressed	O
in	O
COS	O
1	O
cells	O
hexosaminidase	O
S	O
activity	O
was	O
not	O
detectable	O
above	O
background.	O
A	O
G--	O
>	O
A	O
transition	O
at	O
nt	O
1444	O
(exon	O
13)	O
corresponding	O
to	O
the	O
E482K	O
substitution	O
was	O
found	O
in	O
the	O
third	O
family.	O
This	O
mutation	O
occurs	O
at	O
a	O
CpG	O
dinucleotide.	O
It	O
has	O
been	O
reported	O
in	O
an	O
Italian	O
TSD	Modifier

Glucose	SpecificDisease
6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
and	O
incidence	O
of	O
hematologic	DiseaseClass
malignancy	DiseaseClass
.	O
We	O
have	O
evaluated	O
the	O
hypothesis	O
of	O
a	O
negative	O
association	O
between	O
glucose	SpecificDisease
6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
and	O
cancer	DiseaseClass
in	O
a	O
cohort	O
of	O
481	O
Sardinian	O
males	O
with	O
hematological	DiseaseClass
malignancies	DiseaseClass
.	O
The	O
frequency	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
the	O
patients	O
was	O
not	O
different	O
from	O
the	O
incidence	O
in	O
a	O
group	O
of	O
16,	O
219	O
controls.	O
The	O
same	O
conclusion	O
resulted	O
from	O
the	O
comparison	O
of	O
the	O
frequency	O
of	O
expression	O
of	O
the	O
GdB	O
gene	O
in	O
23	O
heterozygous	O
women	O
having	O
a	O
clonal	O
hematologic	DiseaseClass
disease	DiseaseClass
and	O
a	O
control	O
group	O
of	O
37	O
healthy	O
heterozygotes.	O
Therefore	O
at	O
present	O
there	O
is	O
no	O
evidence	O
that	O
G6PD	SpecificDisease
deficiency	SpecificDisease
has	O
a	O
protective	O
effect	O
against	O
development	O
of	O
hematologic	DiseaseClass
neoplasms	DiseaseClass

A	O
physical	O
map	O
and	O
candidate	O
genes	O
in	O
the	O
BRCA1	O
region	O
on	O
chromosome	O
17q12-21.	O
We	O
have	O
constructed	O
a	O
physical	O
map	O
of	O
a	O
4	O
cM	O
region	O
on	O
chromosome	O
17q12-21	O
that	O
contains	O
the	O
hereditary	Modifier
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
gene	O
BRCA1.	O
The	O
map	O
comprises	O
a	O
contig	O
of	O
137	O
overlapping	O
yeast	O
artificial	O
chromosomes	O
and	O
P1	O
clones,	O
onto	O
which	O
we	O
have	O
placed	O
112	O
PCR	O
markers.	O
We	O
have	O
localized	O
more	O
than	O
20	O
genes	O
on	O
this	O
map,	O
ten	O
of	O
which	O
had	O
not	O
been	O
mapped	O
to	O
the	O
region	O
previously,	O
and	O
have	O
isolated	O
30	O
cDNA	O
clones	O
representing	O
partial	O
sequences	O
of	O
as	O
yet	O
unidentified	O
genes.	O
Two	O
genes	O
that	O
lie	O
within	O
a	O
narrow	O
region	O
defined	O
by	O
meiotic	O
breakpoints	O
in	O
BRCA1	O
patients	O
have	O
been	O
sequenced	O
in	O
breast	Modifier
cancer	Modifier

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	Modifier
syndrome	Modifier
thyrocytes.	O
Pendred	SpecificDisease
syndrome	SpecificDisease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	DiseaseClass
deafness	DiseaseClass
,	O
characterized	O
by	O
dyshormonogenic	SpecificDisease
goiter	SpecificDisease
associated	O
with	O
sensory-neural	DiseaseClass
deafness	DiseaseClass
.	O
The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	SpecificDisease
)	O
has	O
been	O
cloned,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	DiseaseClass
goiter	DiseaseClass
and	O
sensory-neural	DiseaseClass
deafness	DiseaseClass
remains	O
an	O
enigma.	O
PDS	O
codes	O
for	O
a	O
novel	O
protein,	O
pendrin,	O
which	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
sufate	O
transporters.	O
Mechanisms	O
by	O
which	O
abnormal	O
sulfate	O
transport	O
could	O
deleteriously	O
affect	O
iodide	O
organification	O
have	O
been	O
proposed.	O
We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	Modifier
syndrome	Modifier

Spinal	SpecificDisease
xanthomatosis	SpecificDisease
:	O
a	O
variant	O
of	O
cerebrotendinous	DiseaseClass
xanthomatosis	DiseaseClass
.	O
We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive,	O
mainly	O
spinal	SpecificDisease
cord	SpecificDisease
syndrome	SpecificDisease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
).	O
MRI	O
demonstrated	O
white	DiseaseClass
matter	DiseaseClass
abnormalities	DiseaseClass
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord.	O
Post-mortem	O
examination	O
of	O
one	O
of	O
the	O
patients	O
showed	O
extensive	O
myelin	O
loss	O
in	O
these	O
columns.	O
An	O
array	O
of	O
genotypes	O
was	O
found	O
in	O
these	O
patients.	O
We	O
conclude	O
that	O
spinal	SpecificDisease
xanthomatosis	SpecificDisease
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
CTX	SpecificDisease
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	DiseaseClass
myelopathy	DiseaseClass

The	O
exon	O
13	O
duplication	O
in	O
the	O
BRCA1	O
gene	O
is	O
a	O
founder	O
mutation	O
present	O
in	O
geographically	O
diverse	O
populations.	O
The	O
BRCA1	O
Exon	O
13	O
Duplication	O
Screening	O
Group.	O
Recently,	O
a	O
6-kb	O
duplication	O
of	O
exon	O
13,	O
which	O
creates	O
a	O
frameshift	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
BRCA1	O
gene,	O
has	O
been	O
described	O
in	O
three	O
unrelated	O
U.	O
S	O
S.	O
families	O
of	O
European	O
ancestry	O
and	O
in	O
one	O
Portuguese	O
family.	O
Here,	O
our	O
goal	O
was	O
to	O
estimate	O
the	O
frequency	O
and	O
geographic	O
diversity	O
of	O
carriers	O
of	O
this	O
duplication.	O
To	O
do	O
this,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early-onset	O
breast	Modifier
and/or	Modifier
ovarian	Modifier
cancer	Modifier

Germline	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
in	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
families	O
provide	O
evidence	O
for	O
a	O
genotype-phenotype	O
correlation.	O
Mutations	O
in	O
the	O
BRCA1	O
gene,	O
discovered	O
in	O
1994,	O
are	O
associated	O
with	O
an	O
80-90%	O
lifetime	O
risk	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
We	O
have	O
analysed	O
60	O
families	O
with	O
a	O
history	O
of	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
for	O
germline	O
mutations	O
in	O
BRCA1.	O
Twenty-two	O
different	O
mutations	O
were	O
detected	O
in	O
32	O
families	O
(53%),	O
of	O
which	O
14	O
are	O
previously	O
unreported.	O
We	O
observed	O
a	O
significant	O
correlation	O
between	O
the	O
location	O
of	O
the	O
mutation	O
in	O
the	O
gene	O
and	O
the	O
ratio	O
of	O
breast	Modifier
to	Modifier
ovarian	Modifier
cancer	Modifier
incidence	O
within	O
each	O
family.	O
Our	O
data	O
suggest	O
a	O
transition	O
in	O
risk	O
such	O
that	O
mutations	O
in	O
the	O
3	O
third	O
of	O
the	O
gene	O
are	O
associated	O
with	O
a	O
lower	O
proportion	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease

Inactivation	O
of	O
the	O
Friedreich	Modifier
ataxia	Modifier
mouse	O
gene	O
leads	O
to	O
early	O
embryonic	SpecificDisease
lethality	SpecificDisease
without	O
iron	O
accumulation.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
),	O
the	O
most	O
common	O
autosomal	DiseaseClass
recessive	DiseaseClass
ataxia	DiseaseClass
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis.	O
Yeast	O
knockout	O
models,	O
and	O
histological	O
and	O
biochemical	O
data	O
from	O
patient	O
heart	O
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	O
defect	O
causes	O
a	O
specific	O
iron-sulfur	SpecificDisease
protein	SpecificDisease
deficiency	SpecificDisease
and	O
mitochondrial	O
iron	O
accumulation	O
leading	O
to	O
the	O
pathological	O
changes.	O
Affected	O
human	O
tissues	O
are	O
rarely	O
available	O
to	O
further	O
examine	O
this	O
hypothesis.	O
To	O
study	O
the	O
mechanism	O
of	O
the	O
disease,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
Frda	Modifier
gene	O
product.	O
We	O
show	O
that	O
homozygous	O
deletions	O
cause	O
embryonic	SpecificDisease
lethality	SpecificDisease

A	O
glycine250-->	O
aspartate	O
substitution	O
in	O
the	O
alpha-subunit	O
of	O
hexosaminidase	O
A	O
causes	O
juvenile-onset	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
in	O
a	O
Lebanese-Canadian	O
family.	O
The	O
mutation	O
causing	O
juvenile	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
in	O
two	O
sibs	O
of	O
Lebanese-Maronite	O
origin	O
is	O
described.	O
An	O
mRNA-containing	O
extract	O
of	O
cultured	O
fibroblasts	O
obtained	O
from	O
one	O
of	O
the	O
probands	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
coding	O
sequence	O
of	O
the	O
hexosaminidase	O
A	O
(Hex	O
A)	O
alpha-subunit.	O
Sequencing	O
of	O
amplified	O
cDNA	O
fragments	O
revealed	O
a	O
single	O
alteration,	O
guanine	O
to	O
adenine	O
at	O
nt	O
749	O
creating	O
a	O
G250D	O
mutation.	O
The	O
mutation	O
introduces	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
enzyme	O
Eco	O
RV,	O
permitting	O
identification	O
of	O
heterozygotes	O
for	O
this	O
allele	O
following	O
PCR	O
amplification	O
and	O
Eco	O
RV	O
digestion	O
of	O
exon	O
7	O
sequences	O
from	O
genomic	O
DNA	O
templates.	O
In	O
order	O
to	O
test	O
the	O
effect	O
of	O
this	O
substitution,	O
an	O
in	O
vitro	O
mutagenized	O
cDNA	O
construct	O
was	O
introduced	O
into	O
a	O
mammalian	O
expression	O
vector	O
and	O
transfected	O
into	O
monkey	O
Cos-1	O
cells	O
separately	O
or	O
along	O
with	O
a	O
beta-cDNA	O
expression	O
vector.	O
When	O
the	O
mutant	O
alpha-cDNA	O
was	O
the	O
only	O
gene	O
introduced	O
into	O
COS	O
cells	O
no	O
enzymatic	O
activity	O
above	O
endogenous	O
COS	O
cell	O
activity	O
was	O
detected.	O
Cotransfection	O
of	O
normal	O
alpha-cDNA	O
and	O
beta-cDNA	O
followed	O
by	O
immunoprecipitation	O
of	O
human	O
Hex	O
A	O
resulted	O
in	O
20-fold	O
increase	O
in	O
the	O
ratio	O
between	O
positive	O
and	O
negative	O
(mock	O
transfection)	O
control	O
values.	O
This	O
allowed	O
the	O
detection	O
of	O
some	O
residual	O
activity	O
(12%	O
of	O
the	O
positive	O
control)	O
when	O
the	O
mutant	O
alpha-cDNA	O
replaced	O
its	O
wild-type	O
counterpart.	O
The	O
predicted	O
protein	O
environment	O
in	O
which	O
the	O
mutation	O
occurs	O
is	O
compared	O
to	O
that	O
of	O
the	O
adult-onset	O
Tay-Sachs	Modifier
disease	Modifier

Restriction	O
of	O
ocular	O
fundus	O
lesions	O
to	O
a	O
specific	O
subgroup	O
of	O
APC	Modifier
mutations	O
in	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
patients.	O
In	O
humans,	O
alteration	O
of	O
the	O
tumor	Modifier
suppressor	O
gene,	O
APC	Modifier
,	O
causes	O
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
,	O
a	O
condition	O
causing	O
predisposition	O
to	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
The	O
syndrome	O
inconsistently	O
associates	O
characteristic	O
patches	O
of	O
congenital	SpecificDisease
hypertrophy	SpecificDisease
of	SpecificDisease
the	SpecificDisease
retinal	SpecificDisease
pigment	SpecificDisease
epithelium	SpecificDisease
(	O
CHRPE	SpecificDisease
).	O
Ocular	O
examination	O
revealed	O
that	O
patients	O
expressing	O
CHRPE	SpecificDisease
tend	O
to	O
cluster	O
within	O
specific	O
families.	O
The	O
exact	O
APC	Modifier
mutation	O
was	O
identified	O
in	O
42	O
unrelated	O
patients.	O
In	O
all	O
cases	O
these	O
mutations	O
were	O
predicted	O
to	O
lead	O
to	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein.	O
The	O
extent	O
of	O
CHRPE	SpecificDisease
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
position	O
of	O
the	O
mutation	O
along	O
the	O
coding	O
sequence.	O
CHRPE	Modifier
lesions	O
are	O
almost	O
always	O
absent	O
if	O
the	O
mutation	O
occurs	O
before	O
exon	O
9,	O
but	O
are	O
systematically	O
present	O
if	O
it	O
occurs	O
after	O
this	O
exon.	O
Thus,	O
the	O
range	O
of	O
phenotypic	O
expression	O
observed	O
among	O
affected	O
patients	O
may	O
result	O
in	O
part	O
from	O
different	O
allelic	O
manifestations	O
of	O
APC	Modifier

Linkage	O
analysis	O
of	O
26	O
Canadian	O
breast	Modifier
and	Modifier
breast-ovarian	Modifier
cancer	Modifier
families.	O
We	O
have	O
examined	O
26	O
Canadian	O
families	O
with	O
hereditary	CompositeMention
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
for	O
linkage	O
to	O
markers	O
flanking	O
the	O
BRCA1	O
gene	O
on	O
chromosome	O
17q12-q21.	O
Of	O
the	O
15	O
families	O
that	O
contain	O
cases	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
,	O
94%	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1.	O
In	O
contrast,	O
there	O
was	O
no	O
overall	O
evidence	O
of	O
linkage	O
in	O
the	O
group	O
of	O
10	O
families	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
without	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
A	O
genetic	O
recombinant	O
in	O
a	O
breast-ovarian	Modifier
cancer	Modifier
family	O
indicates	O
a	O
placement	O
of	O
BRCA1	O
telomeric	O
to	O
D17S776,	O
and	O
helps	O
to	O
define	O
the	O
region	O
of	O
assignment	O
of	O
the	O
cancer	Modifier
susceptibility	O
gene.	O
Other	O
cancers	DiseaseClass
of	O
interest	O
that	O
appeared	O
in	O
the	O
BRCA1-linked	O
families	O
included	O
primary	SpecificDisease
peritoneal	SpecificDisease
cancer	SpecificDisease
,	O
cancer	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fallopian	SpecificDisease
tube	SpecificDisease
,	O
and	O
malignant	SpecificDisease
melanoma	SpecificDisease

Malignant	DiseaseClass
neoplasms	DiseaseClass
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia-telangiectasia	SpecificDisease
.	O
Ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
syndrome	DiseaseClass
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	DiseaseClass
neoplasms	DiseaseClass
in	O
homozygous	O
affected	O
individuals.	O
Heterozygotes	O
for	O
the	O
gene	O
for	O
A-T	SpecificDisease
are	O
thought	O
to	O
comprise	O
about	O
1%	O
of	O
the	O
general	O
population	O
and,	O
therefore,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	DiseaseClass
.	O
Heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
A-T	SpecificDisease
,	O
although	O
individual	O
carriers	O
cannot	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test.	O
For	O
this	O
reason,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	DiseaseClass
neoplasms	DiseaseClass
in	O
2	O
families	O
of	O
patients	O
with	O
A-T	SpecificDisease
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population.	O
There	O
were	O
59	O
deaths	O
from	O
malignant	DiseaseClass
neoplasms	DiseaseClass
in	O
relatives	O
dying	O
before	O
age	O
75,	O
compared	O
to	O
42.	O
6	O
expected	O
(p	O
less	O
than	O
0.	O
02).	O
For	O
A-T	Modifier
heterozygotes	O
younger	O
than	O
age	O
45,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	DiseaseClass
neoplasm	DiseaseClass
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population.	O
A-T	Modifier
heterozygotes	O
may	O
comprise	O
more	O
than	O
5%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	DiseaseClass
before	O
age	O
45.	O
The	O
incidence	O
of	O
ovarian,	CompositeMention
gastric,	CompositeMention
and	CompositeMention
biliary	CompositeMention
system	CompositeMention
carcinomas	CompositeMention
and	O
of	O
leukemia	DiseaseClass
and	O
lymphoma	DiseaseClass
was	O
increased	O
in	O
these	O
A-T	Modifier
families.	O
Other	O
neoplasms	DiseaseClass
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic,	CompositeMention
basal	CompositeMention
cell,	CompositeMention
colonic,	CompositeMention
breast,	CompositeMention
and	CompositeMention
cervical	CompositeMention
carcinomas	CompositeMention

Molecular	O
genetics	O
of	O
PKU	SpecificDisease
in	O
eastern	O
Europe:	O
a	O
nonsense	O
mutation	O
associated	O
with	O
haplotype	O
4	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
a	O
genetic	DiseaseClass
disorder	DiseaseClass
secondary	O
to	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
hepatic	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
Several	O
mutations	O
in	O
the	O
PAH	O
gene	O
have	O
recently	O
been	O
reported,	O
and	O
linkage	O
disequilibrium	O
was	O
observed	O
between	O
RFLP	O
haplotypes	O
and	O
specific	O
mutations.	O
A	O
new	O
molecular	DiseaseClass
lesion	DiseaseClass
has	O
been	O
identified	O
in	O
exon	O
7	O
of	O
the	O
PAH	O
gene	O
in	O
a	O
Hungarian	O
PKU	Modifier

Isolation	O
of	O
the	O
mouse	O
homologue	O
of	O
BRCA1	O
and	O
genetic	O
mapping	O
to	O
mouse	O
chromosome	O
11.	O
The	O
BRCA1	O
gene	O
is	O
in	O
large	O
part	O
responsible	O
for	O
hereditary	CompositeMention
human	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
Here	O
we	O
report	O
the	O
isolation	O
of	O
the	O
murine	O
Brca1	O
homologue	O
cDNA	O
clones.	O
In	O
addition,	O
we	O
identified	O
genomic	O
P1	O
clones	O
that	O
contain	O
most,	O
if	O
not	O
all,	O
of	O
the	O
mouse	O
Brca1	O
locus.	O
DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
mouse	O
and	O
human	O
coding	O
regions	O
are	O
75%	O
identical	O
at	O
the	O
nucleotide	O
level	O
while	O
the	O
predicted	O
amino	O
acid	O
identity	O
is	O
only	O
58%.	O
A	O
DNA	O
sequence	O
variant	O
in	O
the	O
Brca1	O
locus	O
was	O
identified	O
and	O
used	O
to	O
map	O
this	O
gene	O
on	O
a	O
(Mus	O
m.	O
musculus	O
Czech	O
II	O
x	O
C57BL/KsJ)	O
F1	O
x	O
C57BL/KsJ	O
intersubspecific	O
backcross	O
to	O
distal	O
mouse	O
chromosome	O
11.	O
The	O
mapping	O
of	O
this	O
gene	O
to	O
a	O
region	O
highly	O
syntenic	O
with	O
human	O
chromosome	O
17,	O
coupled	O
with	O
Southern	O
and	O
Northern	O
analyses,	O
confirms	O
that	O
we	O
isolated	O
the	O
murine	O
Brca1	O
homologue	O
rather	O
than	O
a	O
related	O
RING	O
finger	O
gene.	O
The	O
isolation	O
of	O
the	O
mouse	O
Brca1	O
homologue	O
will	O
facilitate	O
the	O
creation	O
of	O
mouse	O
models	O
for	O
germline	O
BRCA1	SpecificDisease
defects	SpecificDisease

Human	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
sixth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
a	O
patient	O
with	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
and	O
no	O
haemostasis	DiseaseClass
abnormality	DiseaseClass
.	O
A	O
case	O
of	O
human	O
complete	O
C6	SpecificDisease
deficiency	SpecificDisease
is	O
reported.	O
The	O
patient,	O
a	O
31	O
year	O
old	O
white	O
male,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	O
episode	O
of	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
.	O
Serum	O
complement	O
hemolytic	O
and	O
bactericidal	O
activities	O
were	O
lacking	O
and	O
could	O
be	O
restored	O
to	O
normal	O
by	O
addition	O
of	O
appropriate	O
amounts	O
of	O
purified	O
C6.	O
No	O
hemostatic	DiseaseClass
abnormalities	DiseaseClass

The	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
:	O
refinement	O
of	O
the	O
localization	O
on	O
Xp	O
and	O
identification	O
of	O
another	O
closely	O
linked	O
marker	O
locus,	O
OATL1.	O
The	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
has	O
previously	O
been	O
mapped	O
to	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
between	O
the	O
DXS14	O
and	O
DXS7	O
loci.	O
In	O
this	O
study,	O
further	O
segregation	O
analysis	O
has	O
been	O
performed	O
using	O
a	O
newly	O
identified	O
WAS	Modifier
family	O
as	O
well	O
as	O
an	O
additional	O
marker	O
probe,	O
HOATL1.	O
The	O
results	O
indicate	O
close	O
linkage	O
between	O
the	O
WAS	SpecificDisease
and	O
OATL1	O
loci	O
(Z	O
=	O
6.	O
08	O
at	O
theta	O
=	O
0.	O
00)	O
and	O
localize	O
the	O
TIMP,	O
OATL1,	O
DXS255,	O
and	O
WAS	Modifier
loci	O
distal	O
to	O
DXS146	O
and	O
the	O
OATL1	O
and	O
WAS	Modifier
loci	O
proximal	O
to	O
TIMP.	O
These	O
linkage	O
data	O
narrow	O
the	O
boundaries	O
within	O
which	O
the	O
WAS	Modifier

Hereditary	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
third	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
a	O
child	O
with	O
fever	DiseaseClass
,	O
skin	DiseaseClass
rash	DiseaseClass
,	O
and	O
arthralgias	DiseaseClass
:	O
response	O
to	O
transfusion	O
of	O
whole	O
blood.	O
A	O
previously	O
well	O
34-month-old	O
male	O
presenting	O
with	O
fever	DiseaseClass
,	O
skin	DiseaseClass
rash	DiseaseClass
,	O
and	O
arthralgias	DiseaseClass
was	O
found	O
to	O
lack	O
C3	O
by	O
immunochemical	O
(undetectable)	O
and	O
hemolytic	O
(1%	O
normal)	O
assays.	O
No	O
infectious	O
agent	O
could	O
be	O
demonstrated.	O
Protein	O
levels	O
of	O
Clq.	O
C4,	O
C5,	O
properdin,	O
and	O
C3b-INA	O
and	O
hemolytic	O
activities	O
of	O
complement	O
components	O
C1	O
to	O
C9	O
except	O
C3	O
were	O
normal	O
or	O
elevated;	O
total	O
hemolytic	O
complement	O
activity	O
was	O
13%	O
of	O
normal	O
and	O
was	O
reconstituted	O
by	O
purified	O
C3.	O
Properdin	O
factor	O
B	O
was	O
702	O
(normal	O
175	O
to	O
275)	O
mug/ml,	O
and	O
was	O
not	O
cleaver	O
upon	O
addition	O
of	O
zymosan	O
or	O
cobra	O
venom	O
factor.	O
The	O
serum	O
had	O
normal	O
immune	O
adherence	O
activity,	O
but	O
was	O
deficient	O
in	O
ability	O
to	O
opsonize	O
Candida	O
albicans	O
for	O
uptake	O
and	O
Escherichia	O
coli	O
for	O
killing	O
by	O
neurophils,	O
generate	O
neutrophil	O
chemotactic	O
factors	O
and	O
inhibit	O
the	O
growth	O
of	O
E.	O
coli;	O
these	O
activities	O
were	O
restored	O
by	O
purified	O
C3.	O
A	O
transfusion	O
of	O
320	O
ml	O
1-hour-old	O
normal	O
whole	O
blood	O
on	O
the	O
fifty-second	O
day	O
resulted	O
in	O
transitory	O
elevation	O
of	O
the	O
C3	O
level	O
to	O
25	O
mg/dl	O
with	O
a	O
fall-off	O
(approximately	O
2	O
1/2%	O
per	O
hour)	O
to	O
undetectable	O
levels	O
by	O
69	O
hours;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	DiseaseClass
rash	DiseaseClass
and	O
arthralgias	DiseaseClass
and	O
return	O
to	O
normal	O
of	O
the	O
previously	O
elevated	O
temperature	O
and	O
CRP	O
levels.	O
C3	O
levels	O
in	O
family	O
members	O
(seven	O
of	O
24	O
half-normal),	O
lack	O
of	O
anti-C3	O
activity,	O
normal	O
C3b-INA	O
levels	O
and	O
a	O
normal	O
rate	O
of	O
catabolism	O
of	O
transfused	O
C3	O
indicated	O
that	O
the	O
deficiency	O
was	O
inherited	O
with	O
autosomal	O
codominance	O
and	O
involved	O
decreased	DiseaseClass
synthesis	DiseaseClass
of	DiseaseClass
C3	DiseaseClass
.	O
Thus,	O
this	O
child	O
is	O
a	O
unique	O
individual	O
with	O
inherited	SpecificDisease
C3	SpecificDisease
deficiency	SpecificDisease
presenting	O
with	O
absence	O
of	O
repeated	O
infections,	O
whose	O
symptoms	O
of	O
fever	DiseaseClass
,	O
skin	DiseaseClass
rash	DiseaseClass
,	O
and	O
arthralgia	DiseaseClass

Cloning	O
of	O
breakpoints	O
of	O
a	O
chromosome	O
translocation	O
identifies	O
the	O
AN2	O
locus.	O
Chromosome	O
translocations	O
involving	O
11p13	O
have	O
been	O
associated	O
with	O
familial	SpecificDisease
aniridia	SpecificDisease
in	O
two	O
kindreds	O
highlighting	O
the	O
chromosomal	O
localization	O
of	O
the	O
AN2	O
locus.	O
This	O
locus	O
is	O
also	O
part	O
of	O
the	O
WAGR	Modifier
complex	O
(	O
Wilms	SpecificDisease
tumor	SpecificDisease
,	O
aniridia	SpecificDisease
,	O
genitourinary	DiseaseClass
abnormalities	DiseaseClass
,	O
and	O
mental	DiseaseClass
retardation	DiseaseClass

Study	O
of	O
the	O
voltage-gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(SCN1B)	O
in	O
the	O
benign	SpecificDisease
familial	SpecificDisease
infantile	SpecificDisease
convulsions	SpecificDisease
syndrome	SpecificDisease
(	O
BFIC	SpecificDisease
).	O
Benign	SpecificDisease
familial	SpecificDisease
infantile	SpecificDisease
convulsions	SpecificDisease
(	O
BFIC	SpecificDisease
)	O
is	O
a	O
rare	O
autosomal	DiseaseClass
dominant	DiseaseClass
epilepsy	DiseaseClass
syndrome	DiseaseClass
.	O
This	O
syndrome	O
has	O
been	O
recently	O
described	O
in	O
Italian	O
and	O
French	O
pedigrees.	O
Patients	O
present	O
with	O
partial,	O
then	O
generalized	O
seizures,	O
with	O
onset	O
at	O
age	O
three	O
months.	O
The	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment,	O
leaving	O
no	O
neurological	DiseaseClass
abnormalities	DiseaseClass
.	O
We	O
have	O
mapped	O
BFIC	SpecificDisease
to	O
chromosome	O
19q	O
in	O
five	O
Italian	O
pedigrees.	O
The	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(SCN1B)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
Australian	O
pedigree	O
with	O
generalized	SpecificDisease
epilepsy	SpecificDisease
and	SpecificDisease
febrile	SpecificDisease
seizures	SpecificDisease
"	SpecificDisease
plus	SpecificDisease
"	SpecificDisease
(GEFS	O
+).	O
In	O
this	O
family,	O
a	O
missense	O
mutation	O
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	O
+	O
phenotype.	O
BFIC	SpecificDisease
and	O
GEFS	O
+	O
have	O
clinical	O
features	O
in	O
common,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	O
gene	O
for	O
BFIC	SpecificDisease
.	O
We	O
studied	O
SCN1B	O
exons	O
1,	O
2,	O
3,	O
4,	O
and	O
5,	O
using	O
four	O
SSCP	O
methods	O
in	O
10	O
Caucasian	O
BFIC	Modifier
probands	O
of	O
Western	O
Europe.	O
We	O
found	O
no	O
exon	O
variants.	O
One	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(IVS5-10C	O
>	O
G),	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	SpecificDisease
and	O
was	O
observed	O
in	O
9.	O
2%	O
controls.	O
A	O
second	O
variant	O
in	O
intron	O
5	O
was	O
identified	O
(IVS5	O
+	O
30G	O
>	O
A).	O
It	O
was	O
rare,	O
as	O
not	O
observed	O
in	O
controls,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	Modifier

Brain	DiseaseClass
disease	DiseaseClass
and	O
molecular	O
analysis	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
Abnormal	O
amplification	O
of	O
a	O
CTG	O
repeat	O
on	O
chromosome	O
19	O
is	O
the	O
molecular	O
basis	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
).	O
Expansion	O
of	O
the	O
repeat	O
has	O
been	O
correlated	O
with	O
severity	O
of	O
several	O
clinical	O
features	O
of	O
the	O
disease.	O
We	O
performed	O
extensive	O
cognitive	O
testing,	O
cerebral	O
magnetic	O
resonance	O
imaging	O
(MRI)	O
and	O
a	O
molecular	O
analysis	O
in	O
28	O
cases	O
of	O
DM	SpecificDisease
to	O
determine	O
the	O
relationship	O
between	O
the	O
molecular	O
defect	O
and	O
brain	DiseaseClass
disease	DiseaseClass
.	O
Performance	O
in	O
two	O
or	O
more	O
cognitive	O
tests	O
was	O
pathological	O
in	O
10	O
cases.	O
Fourteen	O
patients	O
had	O
subcortical	O
white	DiseaseClass
matter	DiseaseClass
lesions	DiseaseClass
on	O
MRI,	O
14	O
had	O
cerebral	SpecificDisease
atrophy	SpecificDisease
.	O
Amplification	O
of	O
the	O
CTG	O
repeat	O
showed	O
a	O
strong	O
correlation	O
with	O
cognitive	O
test	O
deficits	O
when	O
exceeding	O
a	O
length	O
of	O
over	O
1000	O
trinucleotides.	O
MRI	O
lesions	O
were	O
associated	O
with	O
impaired	O
psychometric	O
performance,	O
but	O
MRI	O
and	O
molecular	O
findings	O
were	O
only	O
weakly	O
related.	O
Disease	O
duration	O
influenced	O
the	O
appearance	O
and	O
amount	O
of	O
white	DiseaseClass
matter	DiseaseClass
lesions	DiseaseClass
on	O
MRI.	O
Quantification	O
of	O
CTG	O
repeat	O
size	O
may	O
allow	O
an	O
early	O
estimate	O
on	O
the	O
probability	O
of	O
brain	O
involvement	O
in	O
DM	SpecificDisease
;	O
cognitive	DiseaseClass
dysfunction	DiseaseClass
is	O
associated	O
with	O
white	DiseaseClass
matter	DiseaseClass
lesions	DiseaseClass
and	O
cerebral	SpecificDisease
atrophy	SpecificDisease

A	O
highly	O
accurate,	O
low	O
cost	O
test	O
for	O
BRCA1	O
mutations.	O
The	O
hereditary	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
syndrome	CompositeMention

Germline	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
in	O
Korean	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
patients.	O
We	O
extensively	O
analyzed	O
genomic	O
DNA	O
and	O
messenger	O
RNA	O
(mRNA)	O
from	O
62	O
unrelated	O
Korean	O
patients	O
with	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
)	O
for	O
identification	O
of	O
germline	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
mutations.	O
We	O
adopted	O
both	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
and	O
a	O
method	O
of	O
analysis	O
involving	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(RT-PCR)	O
followed	O
by	O
a	O
protein	O
truncation	O
test	O
(PTT).	O
DNA	O
sequencing	O
confirmed	O
all	O
alterations	O
represented	O
by	O
aberrant	O
bands.	O
Germline	O
mutations	O
were	O
identified	O
in	O
38	O
patients	O
(61%).	O
Nineteen	O
of	O
the	O
detected	O
mutations	O
were	O
presumed	O
to	O
be	O
novel,	O
thus	O
emphasizing	O
the	O
heterogeneity	O
of	O
the	O
mutational	O
spectrum	O
in	O
Korean	O
FAP	Modifier
patients.	O
In	O
the	O
initial	O
48	O
patients,	O
SSCP	O
analysis	O
was	O
followed	O
by	O
PTT	O
for	O
those	O
patients	O
for	O
whom	O
no	O
detectable	O
mutations	O
were	O
found	O
by	O
SSCP.	O
Using	O
this	O
combined	O
approach,	O
we	O
identified	O
germline	O
APC	Modifier
gene	O
mutations	O
in	O
29	O
of	O
the	O
48	O
FAP	Modifier
patients	O
(60%),	O
including	O
6	O
patients	O
in	O
whom	O
SSCP	O
analysis	O
failed	O
to	O
distinguish	O
the	O
mutant	O
allele.	O
In	O
the	O
14	O
later	O
patients,	O
we	O
identified	O
truncating	O
mutations	O
in	O
9	O
patients	O
(64%)	O
using	O
PTT	O
only.	O
Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
in	O
FAP	Modifier

Homozygosity	O
mapping	O
in	O
a	O
family	O
with	O
microcephaly	DiseaseClass
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
short	DiseaseClass
stature	DiseaseClass
to	O
a	O
Cohen	Modifier
syndrome	Modifier
region	O
on	O
8q21.3-8q22.1:	O
redefining	O
a	O
clinical	O
entity.	O
A	O
syndrome	O
of	O
microcephaly	DiseaseClass
,	O
progressive	O
postnatal	DiseaseClass
growth	DiseaseClass
deficiency	DiseaseClass
,	O
and	O
mental	DiseaseClass
retardation	DiseaseClass
was	O
observed	O
in	O
two	O
brothers	O
and	O
their	O
cousin	O
from	O
a	O
multiply	O
consanguineous	O
kindred	O
of	O
Lebanese	O
descent.	O
Hypotonia	DiseaseClass
,	O
chorioretinal	DiseaseClass
dystrophy	DiseaseClass
,	O
and	O
myopia	DiseaseClass
were	O
also	O
identified.	O
The	O
severity	O
of	O
the	O
condition	O
varied	O
among	O
the	O
closely	O
related	O
patients.	O
Because	O
of	O
absence	O
of	O
a	O
distinctive	O
facial	O
appearance,	O
the	O
degree	O
of	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
short	DiseaseClass
stature	DiseaseClass
,	O
the	O
initially	O
considered	O
clinical	O
diagnosis	O
of	O
Cohen	SpecificDisease
syndrome	SpecificDisease
was	O
withdrawn	O
and	O
a	O
novel	O
genetic	O
entity	O
was	O
assumed.	O
Homozygosity	O
mapping	O
in	O
this	O
family	O
assigned	O
the	O
gene	O
to	O
a	O
26.	O
8-cM	O
region	O
on	O
the	O
chromosome	O
band	O
8q21.	O
3	O
-22.	O
1,	O
between	O
the	O
microsatellites	O
at	O
D8S270	O
and	O
D8S514.	O
The	O
maximum	O
two-point	O
LOD	O
score	O
was	O
found	O
for	O
marker	O
at	O
D8S267	O
(Zmax	O
=	O
3..	O
237	O
at	O
Omax	O
=	O
0.	O
00).	O
Intriguingly	O
enough,	O
the	O
identified	O
gene	O
region	O
overlaps	O
the	O
refined	O
gene	O
region	O
for	O
Cohen	SpecificDisease
syndrome	SpecificDisease
(COH1)	O
[Kolehmainen	O
et	O
al.,	O
1997	O
	O
Euro	O
J	O
Hum	O
Genet	O
5	O
	O
206-213].	O
This	O
fact	O
encourages	O
the	O
hypothesis	O
that	O
the	O
described	O
kindred	O
segregates	O
for	O
a	O
variant	O
of	O
Cohen	SpecificDisease
syndrome	SpecificDisease

Spontaneous	O
reversion	O
of	O
novel	O
Lesch-Nyhan	Modifier
mutation	O
by	O
HPRT	O
gene	O
rearrangement.	O
Molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
HPRT	O
gene	O
duplication.	O
We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
mutant	O
HPRT	O
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	O
of	O
exons	O
2	O
and	O
3.	O
This	O
mutation	O
is	O
the	O
result	O
of	O
an	O
internal	O
duplication	O
of	O
16-20	O
kilobases	O
of	O
the	O
gene.	O
The	O
structure	O
of	O
the	O
mutant	O
gene	O
suggests	O
that	O
the	O
duplication	O
was	O
not	O
generated	O
by	O
a	O
single	O
unequal	O
crossing-over	O
event	O
between	O
two	O
normal	O
HPRT	O
alleles.	O
Growth	O
of	O
Epstein-Barr	Modifier
virus-transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
HPRT	O
+	O
revertants	O
of	O
this	O
mutation.	O
The	O
reversion	O
event	O
involves	O
a	O
second	O
major	O
HPRT	O
gene	O
rearrangement	O
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	O
of	O
the	O
mutant	O
gene	O
is	O
deleted.	O
The	O
original	O
mutation	O
therefore	O
has	O
the	O
potential	O
for	O
spontaneous	O
somatic	O
reversion.	O
This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

Nephropathy	SpecificDisease
in	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
.	O
Nephropathy	SpecificDisease
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(TF)	O
therapy.	O
In	O
two	O
patients,	O
nephropathy	SpecificDisease
was	O
present	O
before	O
TF	O
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	O
therapy.	O
One	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	SpecificDisease
failure	SpecificDisease
requiring	O
dialysis	O
beginning	O
5	O
1/2	O
years	O
after	O
TF	O
therapy.	O
In	O
two	O
patients,	O
decreased	O
renal	O
function	O
appeared	O
very	O
soon	O
after	O
the	O
administration	O
of	O
TF.	O
One	O
patient	O
showed	O
gradually	O
decreasing	O
renal	O
function	O
beginning	O
after	O
two	O
years	O
of	O
TF	O
therapy.	O
An	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	SpecificDisease
failure	SpecificDisease
without	O
having	O
received	O
TF.	O
The	O
results	O
suggest	O
that	O
renal	SpecificDisease
failure	SpecificDisease
occurs	O
in	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	SpecificDisease
disease	SpecificDisease

Aniridia	Modifier
-associated	O
cytogenetic	O
rearrangements	O
suggest	O
that	O
a	O
position	O
effect	O
may	O
cause	O
the	O
mutant	O
phenotype.	O
Current	O
evidence	O
suggests	O
that	O
aniridia	SpecificDisease
(	O
absence	SpecificDisease
of	SpecificDisease
iris	SpecificDisease
)	O
is	O
caused	O
by	O
loss	O
of	O
function	O
of	O
one	O
copy	O
of	O
the	O
PAX6	O
gene,	O
which	O
maps	O
to	O
11p13.	O
We	O
present	O
the	O
further	O
characterisation	O
of	O
two	O
aniridia	Modifier

Genetic	O
cholesteryl	SpecificDisease
ester	SpecificDisease
transfer	SpecificDisease
protein	SpecificDisease
deficiency	SpecificDisease
caused	O
by	O
two	O
prevalent	O
mutations	O
as	O
a	O
major	O
determinant	O
of	O
increased	O
levels	O
of	O
high	O
density	O
lipoprotein	O
cholesterol.	O
Genetic	O
determinants	O
of	O
HDL	O
cholesterol	O
(HDL-C)	O
levels	O
in	O
the	O
general	O
population	O
are	O
poorly	O
understood.	O
We	O
previously	O
described	O
plasma	O
cholesteryl	SpecificDisease
ester	SpecificDisease
transfer	SpecificDisease
protein	SpecificDisease
(CETP)	SpecificDisease
deficiency	SpecificDisease
due	O
to	O
an	O
intron	O
14	O
G	O
(+	O
1)	O
-to-A	O
mutation	O
(Int14	O
A)	O
in	O
several	O
families	O
with	O
very	O
high	O
HDL-C	O
levels	O
in	O
Japan.	O
Subjects	O
with	O
HDL-C	O
>	O
or	O
=	O
100	O
mg/dl	O
(n	O
=	O
130)	O
were	O
screened	O
by	O
PCR	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
the	O
CETP	O
gene.	O
Two	O
other	O
mutations	O
were	O
identified	O
by	O
DNA	O
sequencing	O
or	O
primer-mediated	O
restriction	O
map	O
modification	O
of	O
PCR	O
products	O
	O
a	O
novel	O
intron	O
14	O
splice	O
donor	O
site	O
mutation	O
caused	O
by	O
a	O
T	O
insertion	O
at	O
position	O
+	O
3	O
from	O
the	O
exon14/intron14	O
boundary	O
(Int14	O
T)	O
and	O
a	O
missense	O
mutation	O
(Asp442	O
to	O
Gly)	O
within	O
exon	O
15	O
(D442G).	O
The	O
Int14	O
T	O
mutation	O
was	O
only	O
found	O
in	O
one	O
family.	O
However,	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
highly	O
prevalent	O
in	O
subjects	O
with	O
HDL-C	O
>	O
or	O
=	O
60	O
mg/dl,	O
with	O
combined	O
allele	O
frequencies	O
of	O
9%,	O
12%,	O
21%	O
and	O
43%	O
for	O
HDL-C	O
60-79,	O
80-99,	O
100-119,	O
and	O
>	O
or	O
=	O
120	O
mg/dl,	O
respectively.	O
Furthermore,	O
prevalences	O
of	O
the	O
D442G	O
and	O
Int14	O
A	O
mutations	O
were	O
extremely	O
high	O
in	O
a	O
general	O
sample	O
of	O
Japanese	O
men	O
(n	O
=	O
236),	O
with	O
heterozygote	O
frequencies	O
of	O
7%	O
and	O
2%,	O
respectively.	O
These	O
two	O
mutations	O
accounted	O
for	O
about	O
10%	O
of	O
the	O
total	O
variance	O
of	O
HDL-C	O
in	O
this	O
population.	O
The	O
phenotype	O
in	O
a	O
genetic	O
compound	O
heterozygote	O
(Int14	O
T	O
and	O
Int14	O
A)	O
was	O
similar	O
to	O
that	O
of	O
Int14	O
A	O
homozygotes	O
(no	O
detectable	O
CETP	O
and	O
markedly	O
increased	O
HDL-C),	O
indicating	O
that	O
the	O
Int14	O
T	O
produces	O
a	O
null	O
allele.	O
In	O
four	O
D442G	O
homozygotes,	O
mean	O
HDL-C	O
levels	O
(86	O
+/-	O
26	O
mg/dl)	O
were	O
lower	O
than	O
in	O
Int14	O
A	O
homozygotes	O
(158	O
+/-	O
35	O
mg/dl),	O
reflecting	O
residual	O
CETP	O
activity	O
in	O
plasma.	O
In	O
47	O
D442G	O
heterozygotes,	O
mean	O
HDL-C	O
levels	O
were	O
91	O
+/-	O
23	O
mg/dl,	O
similar	O
to	O
the	O
level	O
in	O
D442G	O
homozygotes,	O
and	O
significantly	O
greater	O
than	O
mean	O
HDL-C	O
levels	O
in	O
Int14	O
A	O
heterozygotes	O
(69	O
+/-	O
15	O
mg/dl).	O
Thus,	O
the	O
D442G	O
mutation	O
acts	O
differently	O
to	O
the	O
null	O
mutations	O
with	O
weaker	O
effects	O
on	O
HDL	O
in	O
the	O
homozygous	O
state	O
and	O
stronger	O
effects	O
in	O
the	O
heterozygotes,	O
suggesting	O
dominant	O
expression	O
of	O
a	O
partially	O
defective	O
allele.	O
CETP	SpecificDisease
deficiency	SpecificDisease
,	O
reflecting	O
two	O
prevalent	O
mutations	O
(D442G	O
and	O
Int14	O
A),	O
is	O
the	O
first	O
example	O
of	O
a	O
genetic	Modifier
deficiency	Modifier

X-linked	SpecificDisease
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
in	O
Mus	O
musculus.	O
A	O
mouse	O
with	O
X-linked	SpecificDisease
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1-ethyl-1-nitrosourea-treated	O
male	O
mice.	O
The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts.	O
Hemizygous,	O
heterozygous,	O
and	O
homozygous	O
mutants	O
have,	O
respectively,	O
about	O
15,	O
60,	O
and	O
15%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type.	O
Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types.	O
The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration,	O
the	O
isoelectric	O
point,	O
or	O
the	O
thermal	O
stability.	O
Kinetic	O
properties,	O
such	O
as	O
the	O
Km	O
for	O
glucose-6-phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino-NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants.	O
This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X-linked	SpecificDisease
G6PD	SpecificDisease
deficiency	SpecificDisease

Human	O
glycine	O
decarboxylase	O
gene	O
(GLDC)	O
and	O
its	O
highly	O
conserved	O
processed	O
pseudogene	O
(psiGLDC):	O
their	O
structure	O
and	O
expression,	O
and	O
the	O
identification	O
of	O
a	O
large	O
deletion	O
in	O
a	O
family	O
with	O
nonketotic	SpecificDisease
hyperglycinemia	SpecificDisease
.	O
Mutations	O
in	O
the	O
glycine	O
decarboxylase	O
gene	O
(GLDC)	O
cause	O
nonketotic	SpecificDisease
hyperglycinemia	SpecificDisease
(	O
NKH	SpecificDisease
),	O
an	O
in-born	DiseaseClass
error	DiseaseClass
of	DiseaseClass
metabolism	DiseaseClass
characterized	O
by	O
severe	O
neurological	DiseaseClass
disturbance	DiseaseClass
.	O
We	O
have	O
determined	O
the	O
structure	O
of	O
GLDC	O
and	O
of	O
its	O
pseudogene	O
(psiGLDC)	O
and	O
studied	O
their	O
expression	O
for	O
a	O
molecular	O
analysis	O
of	O
NKH	SpecificDisease
.	O
The	O
GLDC	O
gene	O
spans	O
at	O
least	O
135	O
kb	O
and	O
consists	O
of	O
25	O
exons.	O
All	O
donor	O
and	O
acceptor	O
sites	O
adhere	O
to	O
the	O
canonical	O
GT-AG	O
rule,	O
except	O
for	O
the	O
donor	O
site	O
of	O
intron	O
21,	O
where	O
a	O
variant	O
form	O
GC	O
is	O
used	O
instead	O
of	O
GT.	O
The	O
transcription	O
initiation	O
site	O
has	O
been	O
assigned	O
to	O
a	O
residue	O
163	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
triplet	O
by	O
primer	O
extension	O
analysis.	O
The	O
psiGLDC	O
gene	O
has	O
no	O
intron	O
and	O
shares	O
97.	O
5%	O
homology	O
with	O
the	O
coding	O
region	O
of	O
functional	O
GLDC,	O
suggesting	O
that	O
psiGLDC	O
is	O
a	O
processed	O
pseudogene	O
that	O
arose	O
from	O
the	O
GLDC	O
transcript	O
about	O
4-8	O
million	O
years	O
ago.	O
RNA	O
blotting	O
analysis	O
has	O
revealed	O
that	O
GLDC	O
is	O
expressed	O
in	O
human	O
liver,	O
kidney,	O
brain,	O
and	O
placenta.	O
We	O
have	O
also	O
examined	O
a	O
patient	O
with	O
NKH	SpecificDisease
with	O
no	O
detectable	O
GLDC	O
mRNA	O
in	O
his	O
lymphoblasts.	O
Exons	O
1-3	O
of	O
the	O
functional	O
GLDC	O
gene	O
from	O
this	O
patient	O
are	O
not	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR),	O
whereas	O
those	O
from	O
control	O
subjects	O
are.	O
These	O
results	O
suggest	O
a	O
large	O
homozygous	O
deletion	O
(at	O
least	O
30	O
kb)	O
in	O
the	O
patient.	O
Furthermore,	O
we	O
have	O
devised	O
a	O
semi-quantitative	O
PCR	O
to	O
estimate	O
the	O
number	O
of	O
GLDC	O
alleles	O
by	O
using	O
psiGLDC	O
as	O
an	O
internal	O
control	O
and	O
have	O
confirmed	O
the	O
homozygosity	O
and	O
heterozygosity	O
of	O
the	O
deletion	O
in	O
the	O
patient	O
and	O
his	O
parents,	O
respectively.	O
Structural	O
information	O
of	O
GLDC	O
and	O
psiGLDC	O
should	O
facilitate	O
the	O
molecular	O
analysis	O
of	O
NKH	SpecificDisease

Growth	DiseaseClass
retardation	DiseaseClass
and	O
tumour	Modifier
inhibition	O
by	O
BRCA1.	O
Inherited	O
mutations	O
in	O
BRCA1	O
predispose	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
,	O
but	O
the	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
has	O
previously	O
been	O
elusive.	O
Here,	O
we	O
show	O
that	O
retroviral	O
transfer	O
of	O
the	O
wild-type	O
BRCA1	O
gene	O
inhibits	O
growth	O
in	O
vitro	O
of	O
all	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
cell	O
lines	O
tested,	O
but	O
not	O
colon	Modifier
or	Modifier
lung	Modifier
cancer	Modifier
cells	O
or	O
fibroblasts.	O
Mutant	O
BRCA1	O
has	O
no	O
effect	O
on	O
growth	O
of	O
breast	Modifier
cancer	Modifier
cells;	O
ovarian	Modifier
cancer	Modifier
cell	O
growth	O
is	O
not	O
affected	O
by	O
BRCA1	O
mutations	O
in	O
the	O
5	O
portion	O
of	O
the	O
gene,	O
but	O
is	O
inhibited	O
by	O
3	O
BRCA1	O
mutations.	O
Development	O
of	O
MCF-7	DiseaseClass
tumours	DiseaseClass
in	O
nude	O
mice	O
is	O
inhibited	O
when	O
MCF-7	O
cells	O
are	O
transfected	O
with	O
wild-type,	O
but	O
not	O
mutant,	O
BRCA1.	O
Most	O
importantly,	O
among	O
mice	O
with	O
established	O
MCF-7	DiseaseClass
tumours	DiseaseClass
,	O
peritoneal	O
treatment	O
with	O
a	O
retroviral	O
vector	O
expressing	O
wild-type	O
BRCA1	O
significantly	O
inhibits	O
tumour	Modifier

Striking	O
prevalence	O
of	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
in	O
"healthy"	O
w27	O
positive	O
males	O
and	O
females.	O
Ankylosing	SpecificDisease
spondylitis	SpecificDisease
is	O
diagnosed	O
once	O
or	O
twice	O
in	O
each	O
1000	O
males	O
and	O
one	O
tenth	O
as	O
frequently	O
in	O
females,	O
but	O
the	O
true	O
prevalence	O
is	O
unknown.	O
Indentification	O
of	O
genetic	O
marker,	O
HL-A	O
W27,	O
for	O
susceptible	O
persons	O
has	O
provided	O
a	O
tool	O
facilitating	O
epidemiologic	O
studies	O
and	O
allowing	O
identification	O
of	O
"	O
control	O
"	O
populations	O
without	O
the	O
marker.	O
Evaluation	O
by	O
postal	O
questionnaires,	O
and	O
pelvic	O
radiography	O
of	O
78	O
HL-A	O
27W-positive	O
blood	O
donors	O
selected	O
from	O
a	O
group	O
of	O
apparently	O
healthy	O
subjects	O
revealed	O
14	O
who	O
satisfied	O
the	O
criteria	O
for	O
definite	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
.	O
The	O
prevalence	O
was	O
similar	O
in	O
both	O
sexes.	O
One	O
hundred	O
and	O
twenty-six	O
W27-negative	O
controls	O
matched	O
for	O
race,	O
sex,	O
and	O
age	O
failed	O
to	O
yield	O
a	O
single	O
case.	O
For	O
a	O
person	O
of	O
either	O
sex	O
with	O
HL-A	O
W27,	O
there	O
appears	O
to	O
be	O
about	O
a	O
20	O
per	O
cent	O
chance	O
that	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease

Rapid	O
detection	O
of	O
BRCA1	O
mutations	O
by	O
the	O
protein	O
truncation	O
test.	O
More	O
than	O
75%	O
of	O
the	O
reported	O
mutations	O
in	O
the	O
hereditary	Modifier
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
gene,	O
BRCA1,	O
result	O
in	O
truncated	O
proteins.	O
We	O
have	O
used	O
the	O
protein	O
truncation	O
test	O
(PTT)	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
11,	O
which	O
encodes	O
61%	O
of	O
BRCA1.	O
In	O
45	O
patients	O
from	O
breast	Modifier
and/or	Modifier
ovarian	Modifier
cancer	Modifier

New	O
variant	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
in	O
a	O
family	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
.	O
A	O
C--greater	O
than	O
G	O
transversion	O
has	O
been	O
found	O
in	O
exon	O
3	O
of	O
the	O
PLP	O
gene	O
of	O
affected	O
males	O
and	O
their	O
mother	O
in	O
a	O
single	O
sibship	O
with	O
Pelizaeus-merzbacher	SpecificDisease
disease	SpecificDisease
(	O
PMD	SpecificDisease
).	O
The	O
transversion	O
should	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
in	O
the	O
protein	O
but	O
it	O
does	O
result	O
in	O
the	O
loss	O
of	O
a	O
HaeIII	O
restriction	O
endonuclease	O
cleavage	O
site.	O
It	O
is	O
concordant	O
with	O
the	O
disease	O
in	O
this	O
family.	O
One-hundred-ten	O
unrelated	O
X	O
chromosomes	O
are	O
negative	O
for	O
this	O
mutation.	O
No	O
other	O
sequence	O
defect	O
was	O
found	O
in	O
the	O
PLP	O
exons	O
of	O
the	O
affected	O
males.	O
The	O
cause	O
of	O
disease	O
in	O
this	O
family	O
remains	O
unknown,	O
but	O
the	O
association	O
between	O
this	O
rare	O
mutation	O
and	O
PMD	SpecificDisease

Variants	O
of	O
erythrocyte	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
in	O
Bulgarian	O
populations.	O
Ten	O
variants	O
of	O
erythrocyte	O
glucose-6-phosphate	O
dehydrogenase	O
were	O
identified	O
in	O
22	O
patients	O
with	O
G6PD	SpecificDisease
deficiency	SpecificDisease

The	O
C282Y	O
mutation	O
causing	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
does	O
not	O
produce	O
a	O
null	O
allele.	O
Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	Modifier
gene	O
(Hfe)	O
locus.	O
The	O
first	O
mutation	O
deletes	O
a	O
large	O
portion	O
of	O
the	O
coding	O
sequence,	O
generating	O
a	O
null	O
allele.	O
The	O
second	O
mutation	O
introduces	O
a	O
missense	O
mutation	O
(C282Y)	O
into	O
the	O
Hfe	O
locus,	O
but	O
otherwise	O
leaves	O
the	O
gene	O
intact.	O
This	O
mutation	O
is	O
identical	O
to	O
the	O
disease-causing	O
mutation	O
in	O
patients	O
with	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease

Regional	O
localisation	O
of	O
the	O
Friedreich	Modifier
ataxia	Modifier
locus	O
to	O
human	O
chromosome	O
9q13----q21.1.	O
We	O
have	O
previously	O
assigned	O
the	O
Friedreich	Modifier
ataxia	Modifier

Mxi1	O
mutations	O
in	O
human	O
neurofibrosarcomas	SpecificDisease
.	O
Mxi1	O
is	O
thought	O
to	O
negatively	O
regulate	O
Myc	O
function	O
and	O
may	O
therefore	O
be	O
a	O
potential	O
tumor	Modifier
suppressor	O
gene.	O
Little	O
effort	O
has	O
yet	O
been	O
made	O
to	O
find	O
alterations	O
involving	O
this	O
gene	O
in	O
human	O
solid	DiseaseClass
tumors	DiseaseClass
.	O
We	O
screened	O
31	O
human	O
gastric	SpecificDisease
cancers	SpecificDisease
,	O
7	O
esophageal	SpecificDisease
cancers	SpecificDisease
,	O
85	O
bone	CompositeMention
and	CompositeMention
soft	CompositeMention
tissue	CompositeMention
tumors	CompositeMention
of	O
various	O
types,	O
including	O
4	O
neurofibrosarcomas	SpecificDisease
.	O
We	O
also	O
examined	O
29	O
human	O
tumor	Modifier
cell	O
lines	O
consisting	O
of	O
12	O
esophageal	SpecificDisease
cancers	SpecificDisease
,	O
7	O
glioma	SpecificDisease
/	O
glioblastomas	SpecificDisease
and	O
10	O
others	O
for	O
Mxi1	O
mutations	O
in	O
exons	O
1,	O
2,	O
4	O
(HLH	O
domain),	O
5	O
and	O
6.	O
Polymerase	O
chain	O
reaction-single-strand	O
conformation	O
polymorphism	O
(PCR-SSCP)	O
and	O
subsequent	O
sequencing	O
revealed	O
three	O
distinct	O
polymorphisms	O
in	O
the	O
intron-exon	O
boundary	O
upstream	O
from	O
exon	O
6.	O
We	O
discovered	O
a	O
missense	O
mutation,	O
GCA	O
to	O
GTA	O
(Ala	O
54	O
Val),	O
in	O
exon	O
2	O
in	O
a	O
neurofibrosarcoma	Modifier
patient	O
(case	O
1),	O
two	O
missense	O
mutations,	O
AAA	O
to	O
CAA	O
(Lys	O
118	O
Gln)	O
and	O
GAA	O
to	O
GGA	O
(Glu	O
154	O
Gly)	O
in	O
exon	O
5	O
of	O
another	O
neurofibrosarcoma	Modifier
patient	O
(case	O
2),	O
and	O
3	O
amino	O
acid	O
substitutions,	O
GTG	O
to	O
GCG	O
(Val	O
179	O
Ala),	O
GTT	O
to	O
GCT	O
(Val	O
181	O
Ala)	O
and	O
TTC	O
to	O
CTC	O
(Phe	O
186	O
Leu),	O
in	O
a	O
third	O
neurofibrosarcoma	Modifier
patient	O
(case	O
3).	O
In	O
case	O
3,	O
loss	O
of	O
heterozygosity	O
was	O
also	O
demonstrated	O
by	O
informative	O
(TTC)	O
3/(TTC)	O
2	O
polymorphism.	O
Our	O
data	O
demonstrate	O
that	O
mutations	O
occur	O
in	O
the	O
Mxi1	O
gene	O
in	O
neurofibrosarcoma	SpecificDisease
.	O
Missense	O
mutations	O
in	O
the	O
functional	O
domain	O
of	O
Mxi1	O
in	O
these	O
cases	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neurofibrosarcoma	SpecificDisease

Molecular	O
basis	O
of	O
essential	SpecificDisease
fructosuria	SpecificDisease
:	O
molecular	O
cloning	O
and	O
mutational	O
analysis	O
of	O
human	O
ketohexokinase	O
(fructokinase).	O
Essential	SpecificDisease
fructosuria	SpecificDisease
is	O
one	O
of	O
the	O
oldest	O
known	O
inborn	DiseaseClass
errors	DiseaseClass
of	DiseaseClass
metabolism	DiseaseClass
.	O
It	O
is	O
a	O
benign	O
condition	O
which	O
is	O
believed	O
to	O
result	O
from	O
deficiency	SpecificDisease
of	SpecificDisease
hepatic	SpecificDisease
fructokinase	SpecificDisease
(ketohexokinase,	O
KHK,	O
E.	O
C.	O
2.	O
7.	O
1.	O
3).	O
This	O
enzyme	O
catalyses	O
the	O
first	O
step	O
of	O
metabolism	O
of	O
dietary	O
fructose,	O
conversion	O
of	O
fructose	O
to	O
fructose-1-phosphate.	O
Despite	O
the	O
early	O
recognition	O
of	O
this	O
disorder,	O
the	O
primary	O
structure	O
of	O
human	O
KHK	O
and	O
the	O
molecular	O
basis	O
of	O
essential	SpecificDisease
fructosuria	SpecificDisease
have	O
not	O
been	O
previously	O
defined.	O
In	O
this	O
report,	O
the	O
isolation	O
and	O
sequencing	O
of	O
full-length	O
cDNA	O
clones	O
encoding	O
human	O
ketohexokinase	O
are	O
described.	O
Alternative	O
mRNA	O
species	O
and	O
alternative	O
KHK	O
isozymes	O
are	O
produced	O
by	O
alternative	O
polyadenylation	O
and	O
splicing	O
of	O
the	O
KHK	O
gene.	O
The	O
KHK	O
proteins	O
show	O
a	O
high	O
level	O
of	O
sequence	O
conservation	O
relative	O
to	O
rat	O
KHK.	O
Direct	O
evidence	O
that	O
mutation	O
of	O
the	O
KHK	O
structural	O
gene	O
is	O
the	O
cause	O
of	O
essential	SpecificDisease
fructosuria	SpecificDisease
was	O
also	O
obtained.	O
In	O
a	O
well-characterized	O
family,	O
in	O
which	O
three	O
of	O
eight	O
siblings	O
have	O
fructosuria	DiseaseClass

Loss	O
of	O
the	O
ataxia-telangiectasia	Modifier
gene	O
product	O
causes	O
oxidative	O
damage	O
in	O
target	O
organs.	O
Ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
)	O
is	O
characterized	O
by	O
a	O
markedly	O
increased	O
sensitivity	O
to	O
ionizing	O
radiation,	O
increased	O
incidence	O
of	O
cancer	DiseaseClass
,	O
and	O
neurodegeneration	DiseaseClass
,	O
especially	O
of	O
the	O
cerebellar	O
Purkinje	O
cells.	O
Ionizing	O
radiation	O
oxidizes	O
macromolecules	O
and	O
causes	O
tissue	O
damage	O
through	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(ROS).	O
We	O
therefore	O
hypothesized	O
that	O
A-T	SpecificDisease
is	O
due	O
to	O
oxidative	O
damage	O
resulting	O
from	O
loss	O
of	O
function	O
of	O
the	O
A-T	Modifier
gene	O
product.	O
To	O
assess	O
this	O
hypothesis,	O
we	O
employed	O
an	O
animal	O
model	O
of	O
A-T	SpecificDisease
,	O
the	O
mouse	O
with	O
a	O
disrupted	O
Atm	O
gene.	O
We	O
show	O
that	O
organs	O
which	O
develop	O
pathologic	O
changes	O
in	O
the	O
Atm-deficient	O
mice	O
are	O
targets	O
of	O
oxidative	O
damage,	O
and	O
that	O
cerebellar	O
Purkinje	O
cells	O
are	O
particularly	O
affected.	O
These	O
observations	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
A-T	Modifier

Family	O
studies	O
in	O
Bechterew's	SpecificDisease
syndrome	SpecificDisease
(	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
)	O
III.	O
Genetics.	O
The	O
results	O
of	O
segregation	O
analyses	O
in	O
75	O
families	O
where	O
the	O
proband	O
had	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
,	O
are	O
presented.	O
Of	O
the	O
278	O
adult,	O
living	O
first	O
degree	O
relatives,	O
approximately	O
85%	O
cooperated	O
in	O
the	O
study.	O
Clinical	O
and	O
radiographical	O
examinations	O
were	O
performed	O
and	O
HLA	O
typing	O
was	O
conducted.	O
The	O
results	O
were	O
in	O
agreement	O
with	O
our	O
hypothesis	O
that	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
is	O
part	O
of	O
a	O
syndrome	O
where	O
different	O
genetic	O
factors	O
interact.	O
Such	O
known	O
factors	O
are	O
HLA	O
B27	O
associated	O
disease	O
susceptibility,	O
susceptibility	O
to	O
psoriatic	SpecificDisease
arthropathy	SpecificDisease
and	O
susceptibility	O
to	O
entero-arthropathy	SpecificDisease
.	O
Radiographical	O
sacro-iliitis	SpecificDisease
was	O
restricted	O
to	O
HLA	O
B27	O
positive	O
relatives,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	O
to	O
probands	O
with	O
psoriasis	SpecificDisease
than	O
in	O
relatives	O
to	O
probands	O
without	O
psoriasis	SpecificDisease
.	O
Environmental	O
factors	O
(intestinal	O
bacteria)	O
are	O
known	O
to	O
trigger	O
the	O
disease	O
at	O
least	O
in	O
some	O
persons,	O
and	O
we	O
have	O
postulated	O
that	O
all	O
or	O
most	O
of	O
them	O
have	O
the	O
predisposition	O
to	O
develop	O
disease.	O
Thus,	O
the	O
syndrome	O
has	O
a	O
multifactorial	O
etiology.	O
The	O
phenotypic	O
expressions	O
of	O
the	O
different	O
genetic	O
predispositions	O
involved,	O
include	O
sacro-iliitis	SpecificDisease
,	O
psoriasis	SpecificDisease
,	O
acute	SpecificDisease
anterior	SpecificDisease
uveitis	SpecificDisease
,	O
peripheral	O
arthropathy	SpecificDisease
and	O
inflammatory	SpecificDisease
bowel	SpecificDisease
disease	SpecificDisease
.	O
We	O
suggest	O
the	O
descriptive	O
name	O
HEREDITARY	SpecificDisease
MULTIFOCAL	SpecificDisease
RELAPSING	SpecificDisease
INFLAMMATION	SpecificDisease
(	O
HEMRI	SpecificDisease
)	O
for	O
this	O
syndrome.	O
Ankylosing	SpecificDisease
spondylitis	SpecificDisease
,	O
psoriatic	SpecificDisease
arthropathy	SpecificDisease
and	O
entero-arthropathy	SpecificDisease

Chromosome	O
mapping	O
of	O
the	O
rod	O
photoreceptor	O
cGMP	O
phosphodiesterase	O
beta-subunit	O
gene	O
in	O
mouse	O
and	O
human:	O
tight	O
linkage	O
to	O
the	O
Huntington	Modifier
disease	Modifier
region	O
(4p16.3).	O
The	O
retinal	Modifier
degeneration	Modifier
mouse	O
(gene	O
symbol,	O
rd)	O
is	O
an	O
animal	O
model	O
for	O
certain	O
forms	O
of	O
human	O
hereditary	DiseaseClass
retinopathies	DiseaseClass
.	O
Recent	O
findings	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
rd	O
mouse	O
PDE	O
beta-subunit	O
gene	O
(Pdeb)	O
prompted	O
us	O
to	O
investigate	O
the	O
chromosome	O
locations	O
of	O
the	O
mouse	O
and	O
human	O
genes.	O
We	O
have	O
utilized	O
backcross	O
analysis	O
in	O
mice	O
to	O
verify	O
and	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
Pdeb	O
locus	O
6.	O
1	O
+/-	O
2.	O
3	O
cM	O
distal	O
of	O
Mgsa	O
on	O
mouse	O
chromosome	O
5.	O
We	O
have	O
determined	O
that	O
the	O
human	O
gene	O
(PDEB)	O
maps	O
to	O
4p16.	O
3,	O
very	O
close	O
to	O
the	O
Huntington	Modifier
disease	Modifier
(	O
HD	Modifier
)	O
region.	O
Analysis	O
of	O
the	O
comparative	O
map	O
for	O
mice	O
and	O
humans	O
shows	O
that	O
the	O
mouse	O
homologue	O
of	O
the	O
HD	Modifier
gene	O
will	O
reside	O
on	O
chromosome	O
5.	O
Linkage	O
of	O
the	O
mouse	O
Pdeb	O
locus	O
with	O
other	O
homologues	O
in	O
the	O
human	O
4p16.	O
3	O
region	O
is	O
maintained	O
but	O
gene	O
order	O
is	O
not,	O
suggesting	O
at	O
least	O
three	O
possible	O
sites	O
for	O
the	O
corresponding	O
mouse	O
HD	Modifier

Hereditary	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
man.	O
II.	O
Biological	O
properties	O
of	O
C5-deficient	Modifier
human	O
serum.	O
The	O
first	O
known	O
human	O
kindred	O
with	O
hereditary	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C5)	O
was	O
documented	O
in	O
the	O
accompanying	O
report.	O
This	O
study	O
examines	O
several	O
biological	O
properties	O
of	O
C5-deficient	Modifier
(	O
C5D	Modifier
)	O
human	O
serum,	O
particularly	O
sera	O
obtained	O
from	O
two	O
C5D	Modifier
homozygotes.	O
The	O
proband,	O
who	O
has	O
inactive	O
systemic	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
is	O
completely	O
lacking	O
C5,	O
while	O
her	O
healthy	O
half-sister	O
has	O
1-2%	O
of	O
normal	O
levels.	O
Both	O
sera	O
were	O
severely	O
impaired	O
in	O
their	O
ability	O
to	O
generate	O
chemotactic	O
activity	O
for	O
normal	O
human	O
neutrophils	O
upon	O
incubation	O
with	O
aggregated	O
human	O
gamma-globulin	O
or	O
Escherichia	O
coli	O
endotoxin.	O
This	O
function	O
was	O
fully	O
restored	O
in	O
the	O
siblings	O
serum,	O
and	O
substantially	O
improved	O
in	O
the	O
probands	O
serum,	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
to	O
normal	O
serum	O
concentrations.	O
Sera	O
from	O
eight	O
family	O
members	O
who	O
were	O
apparently	O
heterozygous	O
for	O
C5	SpecificDisease
deficiency	SpecificDisease
gave	O
normal	O
chemotactic	O
scores.	O
The	O
ability	O
of	O
C5D	Modifier
serum	O
to	O
opsonize	O
Saccharomyces	O
cerevisiae	O
(bakers	O
yeast)	O
or	O
Candida	O
albicans	O
for	O
ingestion	O
by	O
normal	O
neutrophils	O
was	O
completely	O
normal.	O
In	O
addition,	O
C5D	Modifier
serum	O
was	O
capable	O
of	O
promoting	O
normal	O
phagocytosis	O
and	O
intracellular	O
killing	O
of	O
Staphylococcus	O
aureus.	O
The	O
probands	O
serum	O
was	O
incapable	O
of	O
mediating	O
lysis	O
of	O
erythrocytes	O
from	O
a	O
patient	O
with	O
paroxysmal	SpecificDisease
nocturnal	SpecificDisease
hemoglobinuria	SpecificDisease

The	O
gene	O
for	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
,	O
MEFV,	O
is	O
expressed	O
in	O
early	O
leukocyte	O
development	O
and	O
is	O
regulated	O
in	O
response	O
to	O
inflammatory	O
mediators.	O
Familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
is	O
a	O
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
episodes	O
of	O
fever	DiseaseClass
and	O
neutrophil-mediated	SpecificDisease
serosal	SpecificDisease
inflammation	SpecificDisease
.	O
We	O
recently	O
identified	O
the	O
gene	O
causing	O
FMF	SpecificDisease
,	O
designated	O
MEFV,	O
and	O
found	O
it	O
to	O
be	O
expressed	O
in	O
mature	O
neutrophils,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
inflammatory	O
regulator.	O
To	O
facilitate	O
our	O
understanding	O
of	O
the	O
normal	O
function	O
of	O
MEFV,	O
we	O
extended	O
our	O
previous	O
studies.	O
MEFV	O
messenger	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
in	O
bone	O
marrow	O
leukocytes,	O
with	O
differential	O
expression	O
observed	O
among	O
cells	O
by	O
in	O
situ	O
hybridization.	O
CD34	O
hematopoietic	O
stem-cell	O
cultures	O
induced	O
toward	O
the	O
granulocytic	O
lineage	O
expressed	O
MEFV	O
at	O
the	O
myelocyte	O
stage,	O
concurrently	O
with	O
lineage	O
commitment.	O
The	O
prepromyelocytic	O
cell	O
line	O
HL60	O
expressed	O
MEFV	O
only	O
at	O
granulocytic	O
and	O
monocytic	O
differentiation.	O
MEFV	O
was	O
also	O
expressed	O
in	O
the	O
monocytic	O
cell	O
lines	O
U937	O
and	O
THP-1.	O
Among	O
peripheral	O
blood	O
leukocytes,	O
MEFV	O
expression	O
was	O
detected	O
in	O
neutrophils,	O
eosinophils,	O
and	O
to	O
varying	O
degrees,	O
monocytes.	O
Consistent	O
with	O
the	O
tissue	O
specificity	O
of	O
expression,	O
complete	O
sequencing	O
and	O
analysis	O
of	O
upstream	O
regulatory	O
regions	O
of	O
MEFV	O
revealed	O
homology	O
to	O
myeloid-specific	O
promoters	O
and	O
to	O
more	O
broadly	O
expressed	O
inflammatory	O
promoter	O
elements.	O
In	O
vitro	O
stimulation	O
of	O
monocytes	O
with	O
the	O
proinflammatory	O
agents	O
interferon	O
(IFN)	O
gamma,	O
tumor	Modifier

Spectrum	O
of	O
hSNF5/INI1	O
somatic	O
mutations	O
in	O
human	O
cancer	DiseaseClass
and	O
genotype-phenotype	O
correlations.	O
The	O
hSNF5/INI1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
SWI/SNF	O
chromatin	O
ATP-dependent	O
remodeling	O
complex,	O
is	O
a	O
new	O
tumor	Modifier
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11.	O
2	O
and	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
malignant	DiseaseClass
rhabdoid	DiseaseClass
tumors	DiseaseClass
.	O
We	O
have	O
searched	O
for	O
hSNF5/INI1	O
mutations	O
in	O
229	O
tumors	DiseaseClass
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high-performance	O
liquid	O
chromatography.	O
A	O
total	O
of	O
31	O
homozygous	O
deletions	O
and	O
36	O
point	O
alterations	O
were	O
identified.	O
Point	O
mutations	O
were	O
scattered	O
along	O
the	O
coding	O
sequence	O
and	O
included	O
15	O
nonsense,	O
15	O
frameshift,	O
three	O
splice	O
site,	O
two	O
missense	O
and	O
one	O
editing	O
mutations.	O
Mutations	O
were	O
retrieved	O
in	O
most	O
rhabdoid	DiseaseClass
tumors	DiseaseClass
,	O
whatever	O
their	O
sites	O
of	O
occurrence,	O
indicating	O
the	O
common	O
pathogenetic	O
origin	O
of	O
these	O
tumors	DiseaseClass
.	O
Recurrent	O
hSNF5/INI1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	SpecificDisease
plexus	SpecificDisease
carcinomas	SpecificDisease
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	DiseaseClass
tumors	DiseaseClass
(cPNETs)	O
and	O
medulloblastomas	SpecificDisease
.	O
In	O
contrast,	O
hSNF5/INI1	O
point	O
mutations	O
were	O
not	O
detected	O
in	O
breast	SpecificDisease
cancers	SpecificDisease
,	O
Wilms	SpecificDisease
tumors	SpecificDisease
,	O
gliomas	SpecificDisease
,	O
ependymomas	SpecificDisease
,	O
sarcomas	DiseaseClass
and	O
other	O
tumor	Modifier
types,	O
even	O
though	O
most	O
analyzed	O
cases	O
harbored	O
loss	O
of	O
heterozygosity	O
at	O
22q11.	O
2	O
loci.	O
These	O
results	O
suggest	O
that	O
rhabdoid	DiseaseClass
tumors	DiseaseClass
,	O
choroid	SpecificDisease
plexus	SpecificDisease
carcinomas	SpecificDisease
and	O
a	O
subset	O
of	O
medulloblastomas	SpecificDisease
and	O
cPNETs	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hSNF5/INI1	O
alteration	O
and	O
that	O
hSNF5/INI1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	DiseaseClass
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently,	O
but	O
not	O
always,	O
exhibiting	O
a	O
rhabdoid	Modifier

Heterogeneity	O
of	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
in	O
Algeria.	O
Study	O
in	O
Northern	O
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
was	O
found	O
in	O
3.	O
2%	O
of	O
the	O
male	O
population	O
living	O
in	O
the	O
urban	O
area	O
of	O
Algiers.	O
The	O
deficient	O
subjects	O
originated	O
from	O
multiple	O
geographic	O
regions	O
of	O
Northern	O
Algeria,	O
with	O
prevalence	O
of	O
individuals	O
of	O
Berber-Kabyle	O
origin.	O
Red	O
blood	O
cell	O
G6PD	O
was	O
partially	O
purified	O
and	O
characterized	O
in	O
deficient	O
males	O
from	O
17	O
families,	O
and	O
six	O
different	O
variants	O
were	O
found.	O
Among	O
them,	O
only	O
one,	O
the	O
Gd	O
(-)	O
Kabyle	O
variant,	O
had	O
been	O
previously	O
described.	O
It	O
was	O
detected	O
in	O
nine	O
families.	O
The	O
other	O
five	O
variants	O
were	O
new	O
	O
Gd	O
(-)	O
Laghouat	O
(four	O
cases),	O
Gd	O
(-)	O
Blida	O
(one	O
case),	O
Gd	O
(-)	O
Thenia	O
(one	O
case),	O
Gd	O
(-)	O
Titteri	O
(one	O
case),	O
and	O
Gd	O
(-)	O
Alger	O
(two	O
brothers).	O
Strikingly,	O
the	O
common	O
Mediterranean	O
variant	O
was	O
not	O
found.	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
without	O
CCG	O
amplification	O
has	O
an	O
FMR1	O
deletion.	O
We	O
describe	O
a	O
patient	O
with	O
typical	O
clinical	O
features	O
of	O
the	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
but	O
without	O
cytogenetic	O
expression	O
of	O
the	O
fragile	SpecificDisease
X	SpecificDisease
or	O
an	O
amplified	O
CCG	O
trinucleotide	O
repeat	O
fragment.	O
The	O
patient	O
has	O
a	O
previously	O
uncharacterized	O
submicroscopic	O
deletion	O
encompassing	O
the	O
CCG	O
repeat,	O
the	O
entire	O
FMR1	O
gene	O
and	O
about	O
2.	O
5	O
megabases	O
of	O
flanking	O
sequences.	O
This	O
finding	O
confirms	O
that	O
the	O
fragile	Modifier
X	Modifier
phenotype	O
can	O
exist,	O
without	O
amplification	O
of	O
the	O
CCG	O
repeat	O
or	O
cytogenetic	O
expression	O
of	O
the	O
fragile	SpecificDisease
X	SpecificDisease
,	O
and	O
that	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease

Confirmation	O
of	O
linkage	O
of	O
Van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
to	O
chromosome	O
1q32:	O
evidence	O
of	O
association	O
with	O
STR	O
alleles	O
suggests	O
possible	O
unique	O
origin	O
of	O
the	O
disease	O
mutation.	O
Van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
(	O
VWS	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
craniofacial	DiseaseClass
disorder	DiseaseClass
with	O
high	O
penetrance	O
and	O
variable	O
expression.	O
Its	O
clinical	O
features	O
are	O
variably	O
expressed,	O
but	O
include	O
cleft	SpecificDisease
lip	SpecificDisease
and/or	O
cleft	SpecificDisease
palate	SpecificDisease
,	O
lip	SpecificDisease
pits	SpecificDisease
and	O
hypodontia	SpecificDisease
.	O
All	O
VWS	Modifier
families	O
studied	O
to	O
date	O
map	O
the	O
disease	O
gene	O
to	O
a	O
<	O
2	O
cM	O
region	O
of	O
chromosome	O
1q32,	O
with	O
no	O
evidence	O
of	O
locus	O
heterogeneity.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
refine	O
the	O
localization	O
of	O
the	O
VWS	Modifier
gene	O
and	O
to	O
further	O
assess	O
possible	O
heterogeneity.	O
We	O
analyzed	O
four	O
multiplex	O
VWS	Modifier
families.	O
All	O
available	O
members	O
were	O
clinically	O
assessed	O
and	O
genotyped	O
for	O
19	O
short	O
tandem	O
repeat	O
markers	O
on	O
chromosome	O
1	O
in	O
the	O
VWS	Modifier
candidate	O
gene	O
region.	O
We	O
performed	O
two-point	O
and	O
multipoint	O
limit	O
of	O
detection	O
(LOD)	O
score	O
analyses	O
using	O
a	O
high	O
penetrance	O
autosomal	O
dominant	O
model.	O
All	O
families	O
showed	O
positive	O
LOD	O
scores	O
without	O
any	O
recombination	O
in	O
the	O
candidate	O
region.	O
The	O
largest	O
two-point	O
LOD	O
score	O
was	O
5.	O
87	O
87.	O
Our	O
assay	O
method	O
for	O
short	O
tandem	O
repeat	O
(STR)	O
markers	O
provided	O
highly	O
accurate	O
size	O
estimation	O
of	O
marker	O
allele	O
fragment	O
sizes,	O
and	O
therefore	O
enabled	O
us	O
to	O
determine	O
the	O
specific	O
alleles	O
segregating	O
with	O
the	O
VWS	Modifier
gene	O
in	O
each	O
of	O
our	O
four	O
families.	O
We	O
observed	O
a	O
striking	O
pattern	O
of	O
STR	O
allele	O
sharing	O
at	O
several	O
closely	O
linked	O
loci	O
among	O
our	O
four	O
Caucasian	O
VWS	Modifier
families	O
recruited	O
at	O
three	O
different	O
locations	O
in	O
the	O
US.	O
These	O
results	O
suggest	O
the	O
possibility	O
of	O
a	O
unique	O
origin	O
for	O
a	O
mutation	O
responsible	O
for	O
many	O
or	O
most	O
cases	O
of	O
VWS	SpecificDisease

The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals.	O
Since	O
BRCA1,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
,	O
was	O
cloned,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
In	O
high-risk	O
pedigrees,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80-90%	O
lifetime	O
risk	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
,	O
and	O
a	O
40-50%	O
risk	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
However,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
has	O
not	O
been	O
determined,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	DiseaseClass
as	O
in	O
individuals	O
from	O
the	O
high-risk	O
families	O
studied	O
so	O
far.	O
Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast/ovarian	O
families,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	DiseaseClass
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin.	O
We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0.	O
9%	O
of	O
Ashkenazim	O
(95%	O
confidence	O
limit,	O
0.	O
4-1.	O
8%)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples.	O
Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

Targeted	O
modification	O
of	O
the	O
apolipoprotein	O
B	O
gene	O
results	O
in	O
hypobetalipoproteinemia	SpecificDisease
and	O
developmental	DiseaseClass
abnormalities	DiseaseClass
in	O
mice.	O
Familial	SpecificDisease
hypobetalipoproteinemia	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
codominant	DiseaseClass
disorder	DiseaseClass
resulting	O
in	O
a	O
dramatic	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
apolipoprotein	O
(apo)	O
B,	O
cholesterol,	O
and	O
beta-migrating	O
lipoproteins.	O
A	O
benefit	O
of	O
hypobetalipoproteinemia	SpecificDisease
is	O
that	O
mildly	O
affected	O
individuals	O
may	O
be	O
protected	O
from	O
coronary	DiseaseClass
vascular	DiseaseClass
disease	DiseaseClass
.	O
We	O
have	O
used	O
gene	O
targeting	O
to	O
generate	O
mice	O
with	O
a	O
modified	O
Apob	O
allele.	O
Mice	O
containing	O
this	O
allele	O
display	O
all	O
of	O
the	O
hallmarks	O
of	O
human	O
hypobetalipoproteinemia	SpecificDisease
they	O
produce	O
a	O
truncated	O
apoB	O
protein,	O
apoB70,	O
and	O
have	O
markedly	O
decreased	O
plasma	O
concentrations	O
of	O
apoB,	O
beta-lipoproteins,	O
and	O
total	O
cholesterol.	O
In	O
addition,	O
the	O
mice	O
manifest	O
several	O
characteristics	O
that	O
are	O
occasionally	O
observed	O
in	O
human	O
hypobetalipoproteinemia	SpecificDisease
,	O
including	O
reduced	O
plasma	O
triglyceride	O
concentrations,	O
fasting	O
chylomicronemia	SpecificDisease
,	O
and	O
reduced	O
high	O
density	O
lipoprotein	O
cholesterol.	O
An	O
unexpected	O
finding	O
is	O
that	O
the	O
modified	O
Apob	O
allele	O
is	O
strongly	O
associated	O
with	O
exencephalus	SpecificDisease
and	O
hydrocephalus	SpecificDisease
.	O
These	O
mice	O
should	O
help	O
increase	O
our	O
understanding	O
of	O
hypobetalipoproteinemia	SpecificDisease
,	O
atherogenesis	DiseaseClass
,	O
and	O
the	O
etiology	O
of	O
exencephalus	SpecificDisease
and	O
hydrocephalus	SpecificDisease

Common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
do	O
not	O
contribute	O
to	O
early	O
prostate	SpecificDisease
cancer	SpecificDisease
in	O
Jewish	O
men.	O
BACKGROUND	O
	O
Families	O
with	O
a	O
high	O
incidence	O
of	O
hereditary	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
,	O
and	O
subsequently	O
shown	O
to	O
have	O
terminating	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2,	O
appear	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
prostate	SpecificDisease
cancer	SpecificDisease
among	O
male	O
relatives.	O
We	O
aimed	O
to	O
determine	O
whether	O
the	O
common	O
germline	O
mutations	O
of	O
BRCA1	O
or	O
BRCA2	O
in	O
Ashkenazi	O
Jewish	O
men	O
predisposed	O
them	O
to	O
prostate	SpecificDisease
cancer	SpecificDisease
.	O
METHODS	O
	O
We	O
examined	O
genomic	O
DNA	O
from	O
83	O
(for	O
BRCA1	O
185delAG)	O
or	O
82	O
(for	O
BRCA2	O
6174delT)	O
Ashkenazi	O
Jewish	O
prostate	Modifier
cancer	Modifier
patients,	O
most	O
of	O
whom	O
were	O
treated	O
at	O
a	O
relatively	O
young	O
age,	O
for	O
the	O
most	O
common	O
germline	O
mutation	O
in	O
each	O
gene	O
seen	O
in	O
the	O
Ashkenazi	O
population.	O
RESULTS	O
	O
Our	O
study	O
should	O
have	O
been	O
able	O
to	O
detect	O
a	O
4-5-fold	O
increase	O
in	O
the	O
risk	O
of	O
prostate	SpecificDisease
cancer	SpecificDisease
due	O
to	O
mutation	O
of	O
BRCA1	O
or	O
BRCA2.	O
However,	O
only	O
one	O
(1.	O
15%;	O
95%	O
confidence	O
interval,	O
0-3.	O
6%)	O
of	O
the	O
patients	O
was	O
heterozygous	O
for	O
the	O
BRCA1	O
mutant	O
allele,	O
and	O
only	O
two	O
were	O
heterozygous	O
for	O
the	O
BRCA2	O
mutation	O
(2.	O
4%;	O
95%	O
confidence	O
interval,	O
0-6.	O
2%).	O
CONCLUSIONS	O
	O
The	O
incidence	O
of	O
each	O
of	O
the	O
germline	O
mutations	O
in	O
these	O
prostate	Modifier
cancer	Modifier
patients	O
closely	O
matched	O
their	O
incidence	O
(about	O
1%)	O
in	O
the	O
general	O
Ashkenazi	O
Jewish	O
population.	O
This	O
suggests	O
that	O
unlike	O
cases	O
of	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
,	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
do	O
not	O
significantly	O
predispose	O
men	O
to	O
prostate	SpecificDisease
cancer	SpecificDisease

Two	O
new	O
variants	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
associated	O
with	O
hereditary	SpecificDisease
non-spherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
:	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron.	O
Two	O
new	O
deficient	O
variants	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
causing	O
hereditary	SpecificDisease
nonspherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
(	O
HNSHA	SpecificDisease
)	O
are	O
described.	O
Both	O
of	O
these	O
are	O
unique	O
and	O
they	O
have	O
been	O
named	O
G6PD	O
Wayne	O
and	O
G6PD	O
Huron.	O
Patients	O
with	O
G6PD	O
Wayne	O
underwent	O
splenectomy	O
and	O
no	O
objective	O
improvement	O
was	O
noted.	O
The	O
patients	O
with	O
G6PD	O
Huron	O
were	O
under	O
medical	O
observation	O
for	O
a	O
considerable	O
period	O
of	O
time	O
without	O
the	O
diagnosis	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
being	O
entertained	O
because	O
the	O
family	O
was	O
of	O
Northern	O
European	O
origin.	O
Since	O
sporadic	O
variants	O
of	O
G6PD	O
causing	O
HNSHA	SpecificDisease
show	O
no	O
special	O
racial	O
predilection,	O
the	O
diagnosis	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

The	O
Tay-Sachs	Modifier
disease	Modifier
gene	O
in	O
North	O
American	O
Jewish	O
populations:	O
geographic	O
variations	O
and	O
origin.	O
From	O
data	O
collected	O
in	O
a	O
North	O
American	O
Tay-Sachs	Modifier
disease	Modifier
(	O
TSD	Modifier
)	O
heterozygote	O
screening	O
program,	O
the	O
TSD	Modifier
carrier	O
frequency	O
among	O
46,	O
304	O
Jewish	O
individuals	O
was	O
found	O
to	O
be.	O
0324	O
(1	O
in	O
31	O
individuals).	O
This	O
frequency	O
is	O
consistent	O
with	O
earlier	O
estimates	O
based	O
on	O
TSD	Modifier
incidence	O
data.	O
TSD	Modifier
carrier	O
frequencies	O
were	O
then	O
examined	O
by	O
single	O
country	O
and	O
single	O
region	O
of	O
origin	O
in	O
28,	O
029	O
Jews	O
within	O
this	O
sample	O
for	O
whom	O
such	O
data	O
were	O
available	O
for	O
analysis.	O
Jews	O
with	O
Polish	O
and/or	O
Russian	O
ancestry	O
constituted	O
88%	O
of	O
this	O
sample	O
and	O
had	O
a	O
TSD	Modifier
carrier	O
frequency	O
of.	O
0327.	O
No	O
TSD	Modifier
carriers	O
were	O
observed	O
among	O
the	O
166	O
Jews	O
of	O
Near	O
Eastern	O
origins.	O
Relative	O
to	O
Jews	O
of	O
Polish	O
and	O
Russian	O
origins,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
the	O
TSD	Modifier
carrier	O
frequency	O
in	O
Jews	O
of	O
Austrian,	O
Hungarian,	O
and	O
Czechoslovakian	O
origins	O
(P	O
less	O
than.	O
005).	O
These	O
findings	O
suggest	O
that	O
the	O
TSD	Modifier

Novel	O
inherited	O
mutations	O
and	O
variable	O
expressivity	O
of	O
BRCA1	O
alleles,	O
including	O
the	O
founder	O
mutation	O
185delAG	O
in	O
Ashkenazi	O
Jewish	O
families.	O
Thirty-seven	O
families	O
with	O
four	O
or	O
more	O
cases	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
or	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
were	O
analyzed	O
for	O
mutations	O
in	O
BRCA1.	O
Twelve	O
different	O
germ-line	O
mutations,	O
four	O
novel	O
and	O
eight	O
previously	O
observed,	O
were	O
detected	O
in	O
16	O
families.	O
Five	O
families	O
of	O
Ashkenazi	O
Jewish	O
descent	O
carried	O
the	O
185delAG	O
mutation	O
and	O
shared	O
the	O
same	O
haplotype	O
at	O
eight	O
polymorphic	O
markers	O
spanning	O
approximately	O
850	O
kb	O
at	O
BRCA1.	O
Expressivity	O
of	O
185delAG	O
in	O
these	O
families	O
varied,	O
from	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
without	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
Mutation	O
4184delTCAA	O
occurred	O
independently	O
in	O
two	O
families.	O
In	O
one	O
family,	O
penetrance	O
was	O
complete,	O
with	O
females	O
developing	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
or	O
ovarian	SpecificDisease
cancer	SpecificDisease
and	O
the	O
male	O
carrier	O
developing	O
prostatic	SpecificDisease
cancer	SpecificDisease
,	O
whereas,	O
in	O
the	O
other	O
family,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	SpecificDisease
cancer	SpecificDisease
occurred,	O
diagnosed	O
at	O
ages	O
38-81	O
years.	O
Two	O
novel	O
nonsense	O
mutations	O
led	O
to	O
the	O
loss	O
of	O
mutant	O
BRCA1	O
transcript	O
in	O
families	O
with	O
10	O
and	O
6	O
cases	O
of	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
and	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
A	O
665-nt	O
segment	O
of	O
the	O
BRCA1	O
3-UTR	O
and	O
1.	O
3	O
kb	O
of	O
genomic	O
sequence	O
including	O
the	O
putative	O
promoter	O
region	O
were	O
invariant	O
by	O
single-strand	O
conformation	O
analysis	O
in	O
13	O
families	O
without	O
coding-sequence	O
mutations.	O
Overall	O
in	O
our	O
series,	O
BRCA1	O
mutations	O
have	O
been	O
detected	O
in	O
26	O
families	O
	O
16	O
with	O
positive	O
BRCA1	O
lod	O
scores,	O
7	O
with	O
negative	O
lod	O
scores	O
(reflecting	O
multiple	O
sporadic	O
breast	SpecificDisease
cancers	SpecificDisease

Transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
CTG	O
repeat	O
mimic	O
closely	O
the	O
DM	Modifier
CTG	O
repeat	O
intergenerational	O
and	O
somatic	O
instability.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
caused	O
by	O
a	O
CTG	O
repeat	O
expansion	O
in	O
the	O
3UTR	O
of	O
the	O
DM	Modifier
protein	O
kinase	O
(DMPK)	O
gene.	O
A	O
very	O
high	O
level	O
of	O
instability	O
is	O
observed	O
through	O
successive	O
generations	O
and	O
the	O
size	O
of	O
the	O
repeat	O
is	O
generally	O
correlated	O
with	O
the	O
severity	O
of	O
the	O
disease	O
and	O
with	O
age	O
at	O
onset.	O
Furthermore,	O
tissues	O
from	O
DM	Modifier
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age.	O
We	O
generated	O
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
20,	O
55	O
or	O
>	O
300	O
CTG,	O
cloned	O
from	O
patients	O
from	O
the	O
same	O
affected	O
DM	Modifier
family.	O
Using	O
large	O
human	O
flanking	O
sequences	O
and	O
a	O
large	O
amplification,	O
we	O
demonstrate	O
that	O
the	O
intergenerational	O
CTG	O
repeat	O
instability	O
is	O
reproduced	O
in	O
mice,	O
with	O
a	O
strong	O
bias	O
towards	O
expansions	O
and	O
with	O
the	O
same	O
sex-	O
and	O
size-dependent	O
characteristics	O
as	O
in	O
humans.	O
Moreover,	O
a	O
high	O
level	O
of	O
instability,	O
increasing	O
with	O
age,	O
can	O
be	O
observed	O
in	O
tissues	O
and	O
in	O
sperm.	O
Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	O
repeats)	O
as	O
in	O
congenital	O
forms	O
of	O
DM	SpecificDisease
,	O
our	O
model	O
carrying	O
>	O
300	O
CTG	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
DM	Modifier

Linkage	O
of	O
gene	O
for	O
C2	SpecificDisease
deficiency	SpecificDisease
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man.	O
Family	O
study	O
of	O
a	O
further	O
case.	O
Close	O
linkage	O
between	O
HL-A	O
and	O
C2	SpecificDisease
deficiency	SpecificDisease
was	O
first	O
reported	O
by	O
FU	O
and	O
co-workers	O
in	O
1974.	O
We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31-year-old	O
C2-deficient	Modifier
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	SpecificDisease
disease	SpecificDisease
.	O
The	O
following	O
markers	O
were	O
tested	O
	O
C2	O
levels,	O
factor	O
B	O
polymorphism,	O
blood	O
groups,	O
and	O
enzyme	O
typing.	O
In	O
addition	O
to	O
close	O
linkage	O
between	O
HL-A	O
and	O
C2	SpecificDisease
deficiency	SpecificDisease
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(HL-A	O
linked,	O
electrophoretic	O
variation	O
of	O
B).	O
The	O
two	O
HL-A	O
haplotypes	O
closely	O
linked	O
to	O
C2	SpecificDisease
deficiency	SpecificDisease

Age	O
of	O
onset	O
in	O
Huntington	SpecificDisease
disease	SpecificDisease
:	O
sex	O
specific	O
influence	O
of	O
apolipoprotein	O
E	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length.	O
Age	O
of	O
onset	O
(AO)	O
of	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	Modifier
gene.	O
Apolipoprotein	O
E	O
(APOE)	O
genotype,	O
in	O
turn,	O
is	O
known	O
to	O
influence	O
AO	O
in	O
Alzheimer	SpecificDisease
disease	SpecificDisease
,	O
rendering	O
the	O
APOE	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
AO	O
in	O
other	O
neurological	DiseaseClass
diseases	DiseaseClass
too.	O
We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	Modifier
gene	O
for	O
138	O
HD	Modifier
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length.	O
Genotyping	O
for	O
APOE	O
was	O
performed	O
blind	O
to	O
clinical	O
information.	O
In	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
AO	O
in	O
maternally	O
inherited	O
HD	SpecificDisease
and	O
in	O
male	O
patients,	O
we	O
show	O
that	O
the	O
APOE	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
AO	O
in	O
males	O
than	O
in	O
females.	O
Such	O
a	O
sex	O
difference	O
in	O
AO	O
was	O
not	O
apparent	O
for	O
any	O
of	O
the	O
other	O
APOE	O
genotypes.	O
Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	DiseaseClass
in	O
HD	SpecificDisease

Genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
around	O
the	O
gene	O
for	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
on	O
chromosome	O
5.	O
A	O
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
close	O
to	O
the	O
gene	O
(APC)	O
for	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
)	O
on	O
chromosome	O
5q	O
is	O
reported.	O
One	O
hundred	O
fifty-five	O
typed	O
members	O
of	O
nine	O
FAP	Modifier
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	O
analysis.	O
A	O
number	O
of	O
crucial	O
recombination	O
events	O
have	O
been	O
identified	O
which	O
are	O
informative	O
at	O
three	O
or	O
more	O
loci,	O
allowing	O
confident	O
ordering	O
of	O
parts	O
of	O
the	O
map.	O
There	O
was	O
no	O
evidence	O
of	O
genetic	O
heterogeneity,	O
with	O
all	O
families	O
showing	O
linkage	O
of	O
at	O
least	O
one	O
chromosome	O
5	O
marker	O
to	O
the	O
gene.	O
Recombination	O
data	O
and	O
two-point	O
linkage	O
analysis	O
support	O
a	O
locus	O
order	O
of	O
centromere-pi	O
227-C11P11-ECB27-L5.	O
62-APC-EF5	O
62-APC-EF5.	O
44-YN5	O
44-YN5.	O
48-telomer	O
e,	O
although	O
EF5.	O
44	O
could	O
lie	O
in	O
the	O
interval	O
L5.	O
62-APC	O
or	O
ECB27-L5.	O
62.	O
No	O
recombinants	O
were	O
identified	O
between	O
APC	O
and	O
either	O
EF5.	O
44	O
or	O
YN5.	O
48,	O
but	O
published	O
deletion	O
mapping	O
in	O
colorectal	SpecificDisease
carcinomas	SpecificDisease
and	O
linkage	O
analysis	O
in	O
FAP	SpecificDisease
suggest	O
that	O
YN5.	O
48	O
is	O
1-3	O
cM	O
from	O
APC.	O
The	O
present	O
study	O
suggests	O
that	O
YN5.	O
48	O
and	O
L5.	O
62	O
delineate	O
a	O
small	O
region	O
of	O
chromosome	O
5	O
within	O
which	O
the	O
EF5.	O
44	O
locus	O
lies	O
very	O
close	O
to	O
the	O
APC	Modifier
gene.	O
These	O
data	O
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	SpecificDisease
but	O
also	O
provide	O
a	O
high-density	O
map	O
of	O
the	O
region	O
for	O
isolation	O
of	O
the	O
APC	Modifier
gene	O
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	O
of	O
chromosome	O
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	O
colorectal	SpecificDisease
cancer	SpecificDisease

Detection	O
of	O
a	O
novel	O
arginine	O
vasopressin	O
defect	O
by	O
dideoxy	O
fingerprinting.	O
Autosomal	SpecificDisease
dominant	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
is	O
a	O
familial	O
form	O
of	O
diabetes	DiseaseClass
insipidus	DiseaseClass
.	O
This	O
disorder	O
is	O
associated	O
with	O
variable	O
levels	O
of	O
arginine	O
vasopressin	O
(AVP)	O
and	O
diabetes	DiseaseClass
insipidus	DiseaseClass
of	O
varying	O
severity,	O
which	O
responds	O
to	O
exogenous	O
AVP.	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
autosomal	SpecificDisease
dominant	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease

Association	O
of	O
the	O
APC	Modifier
tumor	Modifier
suppressor	O
protein	O
with	O
catenins.	O
Mutations	O
of	O
APC	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
Although	O
these	O
mutations	O
have	O
been	O
well	O
characterized,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
APC	Modifier
gene	O
product.	O
Two	O
cellular	O
proteins	O
that	O
associate	O
with	O
APC	SpecificDisease
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
E-cadherin-associated	O
proteins	O
alpha-	O
and	O
beta-catenin.	O
A	O
27-residue	O
fragment	O
of	O
APC	O
containing	O
a	O
15-amino	O
acid	O
repeat	O
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins.	O
These	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	Modifier

Myotonic	SpecificDisease
dystrophy	SpecificDisease
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle-type	O
creatine	O
kinase	O
(CKMM).	O
We	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(CKMM)	O
and	O
the	O
gene	O
for	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
).	O
In	O
a	O
panel	O
of	O
65	O
myotonic	Modifier
dystrophy	Modifier
families	O
from	O
Canada	O
and	O
the	O
Netherlands,	O
a	O
maximum	O
lod	O
score	O
(Zmax)	O
of	O
22.	O
8	O
at	O
a	O
recombination	O
frequency	O
(theta)	O
of	O
0.	O
03	O
was	O
obtained.	O
Tight	O
linkage	O
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	O
for	O
apolipoprotein	O
C2	O
(ApoC2).	O
This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	SpecificDisease
dystrophy	SpecificDisease

Discordant	O
clinical	O
outcome	O
in	O
myotonic	Modifier
dystrophy	Modifier
relatives	O
showing	O
(CTG)n	O
>	O
700	O
repeats.	O
A	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
)	O
family	O
is	O
described	O
in	O
which	O
discordant	O
DM	Modifier
phenotypes	O
were	O
found	O
in	O
the	O
children	O
of	O
two	O
affected	O
sisters	O
with	O
similar	O
CTG	O
expansion	O
and	O
clinical	O
manifestations.	O
In	O
this	O
family,	O
congenital	O
as	O
well	O
as	O
early	O
severe	O
childhood	O
and	O
later	O
childhood	O
onset	O
DM	SpecificDisease
coexist.	O
This	O
observation	O
strengthens	O
the	O
limited	O
ability	O
of	O
lymphocytes	O
CTG	O
repeat	O
number	O
analysis	O
in	O
predicting	O
genotype-phenotype	O
correlations	O
in	O
DM	Modifier

Constitutional	O
von	Modifier
Hippel-Lindau	Modifier
(	O
VHL	Modifier
)	O
gene	O
deletions	O
detected	O
in	O
VHL	Modifier
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization.	O
von	SpecificDisease
Hippel-Lindau	SpecificDisease
(VHL)	SpecificDisease
disease	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
dominantly	DiseaseClass
inherited	DiseaseClass
cancer	DiseaseClass
syndrome	DiseaseClass
predisposing	O
to	O
a	O
variety	O
of	O
tumor	Modifier
types	O
that	O
include	O
retinal	O
hemangioblastomas	DiseaseClass
,	O
hemangioblastomas	DiseaseClass
of	O
the	O
central	O
nervous	O
system,	O
renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
,	O
pancreatic	CompositeMention
cysts	CompositeMention
and	CompositeMention
tumors	CompositeMention
,	O
pheochromocytomas	DiseaseClass
,	O
endolymphatic	DiseaseClass
sac	DiseaseClass
tumors	DiseaseClass
,	O
and	O
epididymal	DiseaseClass
cystadenomas	DiseaseClass
[W.	O
M.	O
Linehan	O
et	O
al.,	O
J.	O
Am.	O
Med.	O
Assoc.,	O
273	O
	O
564-570,	O
1995;	O
E.	O
A.	O
Maher	O
and	O
W.	O
G.	O
Kaelin,	O
Jr.,	O
Medicine	O
(Baltimore),	O
76	O
	O
381-391,	O
1997;	O
W.	O
M.	O
Linehan	O
and	O
R.	O
D.	O
Klausner,	O
In	O
	O
B.	O
Vogelstein	O
and	O
K.	O
Kinzler	O
(eds.),	O
The	O
Genetic	O
Basis	O
of	O
Human	O
Cancer,	O
pp.	O
455-473,	O
McGraw-Hill,	O
1998].	O
The	O
VHL	Modifier
gene	O
was	O
localized	O
to	O
chromosome	O
3p25-26	O
and	O
cloned	O
[F.	O
Latif	O
et	O
al.,	O
Science	O
(Washington	O
DC),	O
260	O
	O
1317-1320,	O
1993].	O
Germline	O
mutations	O
in	O
the	O
VHL	Modifier
gene	O
have	O
been	O
detected	O
in	O
the	O
majority	O
of	O
VHL	Modifier
kindreds.	O
The	O
reported	O
frequency	O
of	O
detection	O
of	O
VHL	Modifier
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80%	O
(J.	O
M.	O
Whaley	O
et	O
al.,	O
Am.	O
J.	O
Hum.	O
Genet.,	O
55	O
	O
1092-1102,	O
1994;	O
Clinical	O
Research	O
Group	O
for	O
Japan,	O
Hum.	O
Mol.	O
Genet.,	O
4	O
	O
2233-2237,	O
1995;	O
F.	O
Chen	O
et	O
al.,	O
Hum.	O
Mutat.,	O
5	O
	O
66-75,	O
1995;	O
E.	O
R.	O
Maher	O
et	O
al.,	O
J.	O
Med.	O
Genet.,	O
33	O
	O
328-332,	O
1996;	O
B.	O
Zbar,	O
Cancer	O
Surv.,	O
25	O
	O
219-232,	O
1995).	O
Recently	O
a	O
quantitative	O
Southern	O
blotting	O
procedure	O
was	O
found	O
to	O
improve	O
this	O
frequency	O
(C.	O
Stolle	O
et	O
al.,	O
Hum.	O
Mutat.,	O
12	O
	O
417-423,	O
1998).	O
In	O
the	O
present	O
study,	O
we	O
report	O
the	O
use	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
as	O
a	O
method	O
to	O
detect	O
and	O
characterize	O
VHL	Modifier
germline	O
deletions.	O
We	O
reexamined	O
a	O
group	O
of	O
VHL	Modifier
patients	O
shown	O
previously	O
by	O
single-strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
VHL	Modifier
locus.	O
We	O
found	O
constitutional	O
deletions	O
in	O
29	O
of	O
30	O
VHL	Modifier
patients	O
in	O
this	O
group	O
using	O
cosmid	O
and	O
P1	O
probes	O
that	O
cover	O
the	O
VHL	Modifier
locus.	O
We	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
VHL	Modifier
families	O
	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion-free.	O
In	O
addition,	O
germline	O
mosaicism	O
of	O
the	O
VHL	Modifier
gene	O
was	O
identified	O
in	O
one	O
family.	O
In	O
sum,	O
FISH	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
VHL	Modifier
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
VHL	SpecificDisease
gene	SpecificDisease
abnormality	SpecificDisease

Aberrant	O
subcellular	O
localization	O
of	O
BRCA1	O
in	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
The	O
BRCA1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220-kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells,	O
including	O
breast	O
ductal	O
epithelial	O
cells,	O
and	O
in	O
18	O
of	O
20	O
tumor	Modifier
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary.	O
In	O
16	O
of	O
17	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions,	O
however,	O
BRCA1	O
localized	O
mainly	O
in	O
cytoplasm.	O
Absence	O
of	O
BRCA1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	Modifier
cancer	Modifier
biopsies.	O
These	O
findings	O
suggest	O
that	O
BRCA1	DiseaseClass
abnormalities	DiseaseClass
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	SpecificDisease
cancers	SpecificDisease

HLA	O
B27	O
and	O
the	O
genetics	O
of	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
.	O
One	O
hundred	O
and	O
twenty-eight	O
of	O
145	O
patients	O
with	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
(	O
AS	SpecificDisease
)	O
were	O
found	O
to	O
be	O
HLA	O
B27	O
positive.	O
Five	O
patients	O
had	O
evidence	O
of	O
a	O
sero-negative	O
peripheral	SpecificDisease
arthritis	SpecificDisease
resembling	O
peripheral	SpecificDisease
psoriatic	SpecificDisease
arthritis	SpecificDisease
and	O
3	O
of	O
these	O
were	O
B27	O
negative.	O
One	O
further	O
B27	O
negative	O
patients	O
had	O
a	O
sister	O
with	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
and	O
ulcerative	SpecificDisease
colitis	SpecificDisease
and	O
a	O
mother	O
with	O
ulcerative	SpecificDisease
colitis	SpecificDisease
.	O
There	O
was	O
evidence	O
of	O
a	O
somewhat	O
later	O
age	O
of	O
onset	O
of	O
symptoms	O
in	O
B27	O
negative	O
patients.	O
These	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
with	O
genes	O
for	O
psoriasis	SpecificDisease
and	O
inflammatory	SpecificDisease
bowel	SpecificDisease
disease	SpecificDisease
being	O
important	O
in	O
some	O
individuals,	O
particularly	O
those	O
who	O
are	O
B27	O
negative.	O
Twenty-five	O
first-degree	O
relatives	O
with	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
were	O
all	O
B27	O
positive.	O
The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	O
and	O
spondylitis	SpecificDisease
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	SpecificDisease
colitis	SpecificDisease
as	O
well	O
as	O
spondylitis	SpecificDisease
.	O
Of	O
13	O
B27	O
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
(23%).	O
These	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease

Late	O
infantile	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
in	O
Israel.	O
Metachromatic	SpecificDisease
Leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
)	O
is	O
a	O
neurodegenerative	DiseaseClass
disease	DiseaseClass
in	O
which	O
the	O
lysosomal	O
enzyme,	O
Aryl	O
sulfatase	O
A	O
(ARSA)	O
is	O
deficient.	O
The	O
disease	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
its	O
frequency	O
is	O
estimated	O
to	O
be	O
1/40,	O
000	O
live	O
births.	O
The	O
gene	O
of	O
ARSA	O
has	O
been	O
cloned	O
and	O
up	O
to	O
now	O
eight	O
mutations	O
causing	O
MLD	SpecificDisease
have	O
been	O
reported.	O
Another	O
mutation,	O
PD,	O
leads	O
to	O
the	O
deficiency	O
of	O
the	O
enzyme	O
in	O
vitro	O
(pseudodeficiency)	O
without	O
any	O
known	O
clinical	O
effect.	O
The	O
PD	O
mutation	O
is	O
frequent	O
in	O
all	O
populations.	O
In	O
Israel,	O
late	O
infantile	O
MLD	SpecificDisease
was	O
found	O
to	O
be	O
very	O
frequent	O
in	O
a	O
small	O
Jewish	O
isolate,	O
the	O
Habbanite	O
Jews	O
(1/75	O
live	O
births).	O
The	O
molecular	O
analysis	O
demonstrated	O
that	O
in	O
the	O
Habbanite	O
population,	O
the	O
mutation	O
occurred	O
on	O
an	O
allele	O
with	O
the	O
PD	O
mutation.	O
The	O
loss	O
of	O
ARSA	O
activity	O
is	O
due	O
to	O
a	O
point	O
mutation	O
C	O
>	O
T	O
leading	O
to	O
a	O
change	O
of	O
proline	O
to	O
leucine.	O
MLD	SpecificDisease
is	O
also	O
frequent	O
among	O
Moslem	O
Arabs	O
in	O
Jerusalem.	O
The	O
mutation	O
is	O
a	O
transition	O
G	O
>	O
A	O
destroying	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
2.	O
This	O
mutation	O
has	O
been	O
reported	O
in	O
patients	O
with	O
the	O
late	O
infantile	O
MLD	SpecificDisease
from	O
different	O
ethnic	O
groups.	O
The	O
Christian	O
Arabs	O
in	O
Israel	O
also	O
have	O
a	O
high	O
incidence	O
of	O
the	O
disease	O
(1/10,	O
000	O
live	O
births);	O
the	O
mutation	O
in	O
this	O
population	O
is	O
still	O
unknown.	O
Knowledge	O
of	O
the	O
different	O
mutations	O
causing	O
MLD	SpecificDisease

Genomic	O
rearrangements	O
of	O
the	O
APC	Modifier
tumor	Modifier
-suppressor	O
gene	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
.	O
Germline	O
mutations	O
of	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(APC)	Modifier
tumor	Modifier
-suppressor	O
gene	O
result	O
in	O
the	O
hereditary	SpecificDisease
colorectal	SpecificDisease
cancer	SpecificDisease
syndrome	SpecificDisease
	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
).	O
Almost	O
all	O
APC	Modifier
mutations	O
that	O
have	O
been	O
identified	O
are	O
single-nucleotide	O
alterations,	O
small	O
insertions,	O
or	O
small	O
deletions	O
that	O
would	O
truncate	O
the	O
protein	O
product	O
of	O
the	O
gene.	O
No	O
well-characterized	O
intragenic	O
rearrangement	O
of	O
APC	O
has	O
been	O
described,	O
and	O
the	O
prevalence	O
of	O
this	O
type	O
of	O
mutation	O
in	O
FAP	Modifier
patients	O
is	O
not	O
clear.	O
We	O
screened	O
49	O
potential	O
FAP	Modifier
families	O
and	O
identified	O
26	O
different	O
germline	O
APC	Modifier
mutations	O
in	O
30	O
families.	O
Four	O
of	O
these	O
mutations	O
were	O
genomic	O
rearrangements	O
resulting	O
from	O
homologous	O
and	O
nonhomologous	O
recombinations	O
mediated	O
by	O
Alu	O
elements.	O
Two	O
of	O
these	O
four	O
rearrangements	O
were	O
complex,	O
involving	O
deletion	O
and	O
insertion	O
of	O
nucleotides.	O
Of	O
these	O
four	O
rearrangements,	O
one	O
resulted	O
in	O
the	O
deletion	O
of	O
exons	O
11	O
and	O
12	O
and	O
two	O
others	O
resulted	O
in	O
either	O
complete	O
or	O
partial	O
deletion	O
of	O
exon	O
14.	O
The	O
fourth	O
rearrangement	O
grossly	O
altered	O
the	O
sequence	O
within	O
intron	O
14.	O
Although	O
this	O
rearrangement	O
did	O
not	O
affect	O
any	O
coding	O
sequence	O
of	O
APC	O
at	O
the	O
genomic	O
DNA	O
level,	O
it	O
caused	O
inappropriate	O
splicing	O
of	O
exon	O
14.	O
These	O
rearrangements	O
were	O
initially	O
revealed	O
by	O
analyzing	O
cDNAs	O
and	O
could	O
not	O
have	O
been	O
identified	O
by	O
using	O
mutation	O
detection	O
methods	O
that	O
screened	O
each	O
exon	O
individually.	O
The	O
identification	O
of	O
a	O
rearrangement	O
that	O
did	O
not	O
alter	O
any	O
coding	O
exons	O
yet	O
affected	O
the	O
splicing	O
further	O
underscores	O
the	O
importance	O
of	O
using	O
cDNA	O
for	O
mutation	O
analysis.	O
The	O
identification	O
of	O
four	O
genomic	O
rearrangements	O
among	O
30	O
mutations	O
suggests	O
that	O
genomic	O
rearrangements	O
are	O
frequent	O
germline	O
APC	Modifier

Familial	SpecificDisease
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
is	O
not	O
linked	O
to	O
the	O
BRCA1	O
locus	O
on	O
chromosome	O
17q.	O
Breast	SpecificDisease
cancer	SpecificDisease
in	O
men	O
is	O
about	O
a	O
hundredfold	O
less	O
common	O
than	O
in	O
women	O
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	O
basis.	O
We	O
have	O
examined	O
22	O
families	O
with	O
at	O
least	O
one	O
case	O
of	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
for	O
linkage	O
to	O
the	O
hereditary	Modifier
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
locus,	O
BRCA1,	O
on	O
chromosome	O
17q.	O
We	O
found	O
strong	O
evidence	O
against	O
linkage	O
to	O
BRCA1	O
(lod	O
score-16.	O
63)	O
and	O
the	O
best	O
estimate	O
of	O
the	O
proportion	O
of	O
linked	O
families	O
was	O
0%	O
(95%	O
CI	O
0-18%).	O
Our	O
results	O
indicate	O
that	O
there	O
is	O
a	O
gene	O
(s)	O
other	O
than	O
BRCA1	O
which	O
predisposes	O
to	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
in	O
women	O
and	O
which	O
confers	O
a	O
higher	O
risk	O
of	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
.	O
Identification	O
of	O
additional	O
pedigrees	O
that	O
include	O
cases	O
of	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease

Evidence	O
for	O
inter-generational	O
instability	O
in	O
the	O
CAG	O
repeat	O
in	O
the	O
MJD1	O
gene	O
and	O
for	O
conserved	O
haplotypes	O
at	O
flanking	O
markers	O
amongst	O
Japanese	O
and	O
Caucasian	O
subjects	O
with	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
.	O
The	O
size	O
of	O
the	O
(CAG)n	O
repeat	O
array	O
in	O
the	O
3'	O
end	O
of	O
the	O
MJD1	O
gene	O
and	O
the	O
haplotype	O
at	O
a	O
series	O
of	O
microsatellite	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
were	O
examined	O
in	O
a	O
large	O
cohort	O
of	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
).	O
Our	O
data	O
provide	O
five	O
novel	O
observations.	O
First,	O
MJD	SpecificDisease
is	O
associated	O
with	O
expansion	O
fo	O
the	O
array	O
from	O
the	O
normal	O
range	O
of	O
14-37	O
repeats	O
to	O
68-84	O
repeats	O
in	O
most	O
Japanese	O
and	O
Caucasian	O
subjects,	O
but	O
no	O
subjects	O
were	O
observed	O
with	O
expansions	O
intermediate	O
in	O
size	O
between	O
those	O
of	O
the	O
normal	O
and	O
MJD	Modifier
affected	O
groups.	O
Second,	O
the	O
expanded	O
allele	O
associated	O
with	O
MJD	SpecificDisease
displays	O
inter-generational	O
instability,	O
particularly	O
in	O
male	O
meioses,	O
and	O
this	O
instability	O
was	O
associated	O
with	O
the	O
clinical	O
phenomenon	O
of	O
anticipation.	O
Third,	O
the	O
size	O
of	O
the	O
expanded	O
allele	O
is	O
not	O
only	O
inversely	O
correlated	O
with	O
the	O
age-of-onset	O
of	O
MJD	SpecificDisease
(r	O
=	O
-0.738,	O
p	O
<	O
0.001),	O
but	O
is	O
also	O
correlated	O
with	O
the	O
frequency	O
of	O
other	O
clinical	O
features	O
[e.g.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	O
were	O
more	O
frequent	O
in	O
subjects	O
with	O
large	O
repeats	O
(p	O
<	O
0.001	O
and	O
p	O
<	O
0.05	O
respectively)].	O
Fourth,	O
the	O
disease	O
phenotype	O
is	O
significantly	O
more	O
severe	O
and	O
had	O
an	O
early	O
age	O
of	O
onset	O
(16	O
years)	O
in	O
a	O
subject	O
homozygous	O
for	O
the	O
expanded	O
allele,	O
which	O
contrasts	O
with	O
Huntington	SpecificDisease
disease	SpecificDisease
and	O
suggests	O
that	O
the	O
expanded	O
allele	O
in	O
the	O
MJD1	O
gene	O
could	O
exert	O
its	O
effect	O
either	O
by	O
a	O
dominant	O
negative	O
effect	O
(putatively	O
excluded	O
in	O
HD	SpecificDisease
)	O
or	O
by	O
a	O
gain	O
of	O
function	O
effect	O
as	O
proposed	O
for	O
HD	SpecificDisease
.	O
Finally,	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
MJD	SpecificDisease
	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
.	O
The	O
size	O
of	O
the	O
(CAG)n	O
repeat	O
array	O
in	O
the	O
3'	O
end	O
of	O
the	O
MJD1	O
gene	O
and	O
the	O
haplotype	O
at	O
a	O
series	O
of	O
microsatellite	O
markers	O
surrounding	O
the	O
MJD1	O
gene	O
were	O
examined	O
in	O
a	O
large	O
cohort	O
of	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
).	O
Our	O
data	O
provide	O
five	O
novel	O
observations.	O
First,	O
MJD	SpecificDisease
is	O
associated	O
with	O
expansion	O
fo	O
the	O
array	O
from	O
the	O
normal	O
range	O
of	O
14-37	O
repeats	O
to	O
68-84	O
repeats	O
in	O
most	O
Japanese	O
and	O
Caucasian	O
subjects,	O
but	O
no	O
subjects	O
were	O
observed	O
with	O
expansions	O
intermediate	O
in	O
size	O
between	O
those	O
of	O
the	O
normal	O
and	O
MJD	Modifier
affected	O
groups.	O
Second,	O
the	O
expanded	O
allele	O
associated	O
with	O
MJD	SpecificDisease
displays	O
inter-generational	O
instability,	O
particularly	O
in	O
male	O
meioses,	O
and	O
this	O
instability	O
was	O
associated	O
with	O
the	O
clinical	O
phenomenon	O
of	O
anticipation.	O
Third,	O
the	O
size	O
of	O
the	O
expanded	O
allele	O
is	O
not	O
only	O
inversely	O
correlated	O
with	O
the	O
age-of-onset	O
of	O
MJD	SpecificDisease
(r	O
=	O
-0.738,	O
p	O
<	O
0.001),	O
but	O
is	O
also	O
correlated	O
with	O
the	O
frequency	O
of	O
other	O
clinical	O
features	O
[e.g.	O
pseudoexophthalmos	O
and	O
pyramidal	O
signs	O
were	O
more	O
frequent	O
in	O
subjects	O
with	O
large	O
repeats	O
(p	O
<	O
0.001	O
and	O
p	O
<	O
0.05	O
respectively)].	O
Fourth,	O
the	O
disease	O
phenotype	O
is	O
significantly	O
more	O
severe	O
and	O
had	O
an	O
early	O
age	O
of	O
onset	O
(16	O
years)	O
in	O
a	O
subject	O
homozygous	O
for	O
the	O
expanded	O
allele,	O
which	O
contrasts	O
with	O
Huntington	SpecificDisease
disease	SpecificDisease
and	O
suggests	O
that	O
the	O
expanded	O
allele	O
in	O
the	O
MJD1	O
gene	O
could	O
exert	O
its	O
effect	O
either	O
by	O
a	O
dominant	O
negative	O
effect	O
(putatively	O
excluded	O
in	O
HD	SpecificDisease
)	O
or	O
by	O
a	O
gain	O
of	O
function	O
effect	O
as	O
proposed	O
for	O
HD	SpecificDisease
.	O
Finally,	O
Japanese	O
and	O
Caucasian	O
subjects	O
affected	O
with	O
MJD	SpecificDisease

Familial	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
with	O
apparently	O
normal	O
chromosomes.	O
We	O
report	O
on	O
4	O
sibs	O
(2F,	O
2M)	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
Diagnosis	O
was	O
made	O
clinically	O
on	O
the	O
basis	O
of	O
history,	O
behavior,	O
and	O
physical	O
findings	O
in	O
3	O
of	O
the	O
sibs.	O
The	O
other	O
child	O
had	O
died	O
at	O
age	O
10	O
months	O
with	O
a	O
history	O
and	O
clinical	O
findings	O
typical	O
of	O
first	O
phase	O
of	O
PWS	SpecificDisease
.	O
Results	O
of	O
chromosome	O
studies	O
on	O
the	O
parents	O
and	O
surviving	O
sibs	O
were	O
normal.	O
The	O
implications	O
of	O
this	O
unusual	O
familial	O
occurrence	O
for	O
our	O
understanding	O
of	O
PWS	SpecificDisease

Age	O
at	O
diagnosis	O
as	O
an	O
indicator	O
of	O
eligibility	O
for	O
BRCA1	O
DNA	O
testing	O
in	O
familial	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
.	O
We	O
searched	O
for	O
criteria	O
that	O
could	O
indicate	O
breast	Modifier
cancer	Modifier
families	O
with	O
a	O
high	O
prior	O
probability	O
of	O
being	O
caused	O
by	O
the	O
breast/ovarian	Modifier
cancer	Modifier
susceptibility	O
locus	O
BRCA1	O
on	O
chromosome	O
17.	O
To	O
this	O
end,	O
we	O
performed	O
a	O
linkage	O
study	O
with	O
59	O
consecutively	O
collected	O
Dutch	O
breast	Modifier
cancer	Modifier
families,	O
including	O
16	O
with	O
at	O
least	O
one	O
case	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
We	O
used	O
an	O
intake	O
cut-off	O
of	O
at	O
least	O
three	O
first-degree	O
relatives	O
with	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
at	O
any	O
age.	O
Significant	O
evidence	O
for	O
linkage	O
was	O
found	O
only	O
among	O
the	O
13	O
breast	Modifier
cancer	Modifier
families	O
with	O
a	O
mean	O
age	O
at	O
diagnosis	O
of	O
less	O
than	O
45	O
years.	O
An	O
unexpectedly	O
low	O
proportion	O
of	O
the	O
breast-ovarian	Modifier
cancer	Modifier
families	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1,	O
which	O
could	O
be	O
due	O
to	O
a	O
founder	O
effect	O
in	O
the	O
Dutch	O
population.	O
Given	O
the	O
expected	O
logistical	O
problems	O
in	O
clinical	O
management	O
now	O
that	O
BRCA1	O
has	O
been	O
identified,	O
we	O
propose	O
an	O
interim	O
period	O
in	O
which	O
only	O
families	O
with	O
a	O
strong	O
positive	O
family	O
history	O
for	O
early	O
onset	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

Some	O
Mexican	O
glucose-6-phosphate	O
dehydrogenase	O
variants	O
revisited.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
appears	O
to	O
be	O
fairly	O
common	O
in	O
Mexico.	O
We	O
have	O
now	O
examined	O
the	O
DNA	O
of	O
three	O
previously	O
reported	O
electrophoretically	O
fast	O
Mexican	O
G6PD	O
variants,	O
-G6PD	O
Distrito	O
Federal,	O
G6PD	O
Tepic,	O
and	O
G6PD	O
Castilla.	O
All	O
three	O
of	O
these	O
variants,	O
believed	O
on	O
the	O
basis	O
of	O
biochemical	O
characterization	O
and	O
population	O
origin	O
to	O
be	O
unique,	O
have	O
the	O
G----A	O
transition	O
at	O
nucleotide	O
202	O
and	O
the	O
A----G	O
transition	O
at	O
nucleotide	O
376,	O
mutations	O
that	O
we	O
now	O
recognize	O
to	O
be	O
characteristic	O
of	O
G6PD	O
A-.	O
Two	O
other	O
Mexican	O
males	O
with	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Inactivation	O
of	O
germline	O
mutant	O
APC	Modifier
alleles	O
by	O
attenuated	O
somatic	O
mutations:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	SpecificDisease
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
.	O
Germline	O
mutations	O
of	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(APC)	Modifier
tumor	Modifier
-suppressor	O
gene	O
result	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
).	O
Patients	O
with	O
FAP	SpecificDisease
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	SpecificDisease
colorectal	SpecificDisease
tumors	SpecificDisease
and	O
early-onset	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
A	O
subset	O
of	O
germline	O
APC	Modifier
mutations	O
results	O
in	O
an	O
attenuated	Modifier
FAP	Modifier
(	O
AFAP	Modifier
)	O
phenotype,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	DiseaseClass
and	O
develop	O
them	O
at	O
an	O
older	O
age.	O
Although	O
a	O
genotype-phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
APC	Modifier
germline	O
mutations	O
and	O
the	O
development	O
of	O
AFAP	SpecificDisease
has	O
been	O
well	O
documented,	O
the	O
mechanism	O
for	O
AFAP	SpecificDisease
has	O
not	O
been	O
well	O
defined.	O
We	O
investigated	O
the	O
mechanism	O
for	O
AFAP	SpecificDisease
in	O
patients	O
carrying	O
a	O
mutant	O
APC	Modifier
allele	O
(APC	O
(AS9))	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9.	O
APC	O
(AS9)	O
was	O
found	O
to	O
down-regulate	O
beta-catenin-regulated	O
transcription,	O
the	O
major	O
tumor	Modifier
-suppressor	O
function	O
of	O
APC,	O
as	O
did	O
the	O
wild-type	O
APC.	O
Mutation	O
analysis	O
showed	O
that	O
both	O
APC	O
(AS9)	O
and	O
the	O
wild-type	O
APC	Modifier
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	SpecificDisease
tumors	SpecificDisease
from	O
these	O
patients.	O
Functional	O
analysis	O
showed	O
that	O
4666insA,	O
a	O
common	O
somatic	O
mutation	O
in	O
APC	O
(AS9)	O
in	O
these	O
tumors	DiseaseClass
,	O
did	O
not	O
inactivate	O
the	O
wild-type	O
APC.	O
Our	O
results	O
indicate	O
that	O
carriers	O
of	O
APC	O
(AS9)	O
develop	O
fewer	O
colorectal	SpecificDisease
tumors	SpecificDisease
than	O
do	O
typical	O
patients	O
with	O
FAP	SpecificDisease
because	O
somatic	O
inactivation	O
of	O
both	O
APC	Modifier
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis.	O
However,	O
these	O
patients	O
develop	O
colorectal	SpecificDisease
tumors	SpecificDisease

Submicroscopic	O
deletions	O
at	O
the	O
WAGR	Modifier
locus,	O
revealed	O
by	O
nonradioactive	O
in	O
situ	O
hybridization.	O
Fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
with	O
biotin-labeled	O
probes	O
mapping	O
to	O
11p13	O
has	O
been	O
used	O
for	O
the	O
molecular	O
analysis	O
of	O
deletions	O
of	O
the	O
WAGR	Modifier
(	O
Wilms	Modifier
tumor	Modifier
,	O
aniridia	Modifier
,	O
genitourinary	Modifier
abnormalities	Modifier
,	O
and	O
mental	Modifier
retardation	Modifier
)	O
locus.	O
We	O
have	O
detected	O
a	O
submicroscopic	O
11p13	O
deletion	O
in	O
a	O
child	O
with	O
inherited	O
aniridia	SpecificDisease
who	O
subsequently	O
presented	O
with	O
Wilms	SpecificDisease
tumor	SpecificDisease
in	O
a	O
horseshoe	O
kidney,	O
only	O
revealed	O
at	O
surgery.	O
The	O
mother,	O
who	O
has	O
aniridia	SpecificDisease
,	O
was	O
also	O
found	O
to	O
carry	O
a	O
deletion	O
including	O
both	O
the	O
aniridia	Modifier
candidate	O
gene	O
(AN2)	O
and	O
the	O
Wilms	Modifier
tumor	Modifier
predisposition	O
gene	O
(WT1).	O
This	O
is	O
therefore	O
a	O
rare	O
case	O
of	O
an	O
inherited	O
WAGR	Modifier
deletion.	O
Wilms	SpecificDisease
tumor	SpecificDisease
has	O
so	O
far	O
only	O
been	O
associated	O
with	O
sporadic	O
de	O
novo	O
aniridia	Modifier
cases.	O
We	O
have	O
shown	O
that	O
a	O
cosmid	O
probe	O
for	O
a	O
candidate	O
aniridia	Modifier
gene,	O
homologous	O
to	O
the	O
mouse	O
Pax-6	O
gene,	O
is	O
deleted	O
in	O
cell	O
lines	O
from	O
aniridia	Modifier
patients	O
with	O
previously	O
characterized	O
deletions	O
at	O
11p13,	O
while	O
another	O
cosmid	O
marker	O
mapping	O
between	O
two	O
aniridia	Modifier

Haplotype	O
studies	O
in	O
Wilson	SpecificDisease
disease	SpecificDisease
.	O
In	O
51	O
families	O
with	O
Wilson	SpecificDisease
disease	SpecificDisease
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(CA	O
repeats)	O
in	O
the	O
13q14.	O
3	O
region,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	Modifier
disease	Modifier
gene	O
(	O
WND	SpecificDisease
).	O
In	O
addition	O
to	O
a	O
marker	O
(D13S133)	O
described	O
elsewhere,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(D13S314,	O
D13S315,	O
and	O
D13S316)	O
close	O
to	O
the	O
WND	SpecificDisease
locus.	O
We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314,	O
D13S133,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	SpecificDisease
mutation.	O
We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	SpecificDisease
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families.	O
These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	SpecificDisease
disease	SpecificDisease

Growth	O
hormone	O
treatment	O
increases	O
CO(2)	O
response,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
We	O
studied	O
whether	O
the	O
beneficial	O
effects	O
of	O
growth	O
hormone	O
(GH)	O
treatment	O
on	O
growth	O
and	O
body	O
composition	O
in	O
PWS	SpecificDisease
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function.	O
We	O
measured	O
resting	O
ventilation,	O
airway	O
occlusion	O
pressure	O
(P	O
(0.	O
1))	O
and	O
ventilatory	O
response	O
to	O
CO	O
(2)	O
in	O
nine	O
children,	O
aged	O
7-14	O
years,	O
before	O
and	O
6-9	O
months	O
after	O
the	O
start	O
of	O
GH	O
treatment.	O
During	O
GH	O
treatment,	O
resting	O
ventilation	O
increased	O
by	O
26%,	O
P	O
(0.	O
1)	O
by	O
72%	O
and	O
the	O
response	O
to	O
CO	O
(2)	O
by	O
65%	O
(P	O
<	O
0.	O
002,	O
<	O
0.	O
04	O
and	O
<	O
0.	O
02,	O
respectively).	O
This	O
observed	O
increase	O
in	O
ventilatory	O
output	O
was	O
not	O
correlated	O
to	O
changes	O
in	O
body	O
mass	O
index.	O
CONCLUSION	O
	O
Treatment	O
of	O
children	O
with	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures.	O
The	O
observed	O
increase	O
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	O
to	O
the	O
improved	O
activity	O
level	O
reported	O
by	O
parents	O
of	O
PWS	Modifier

Somatic	O
von	Modifier
Hippel-Lindau	Modifier
mutation	O
in	O
clear	O
cell	O
papillary	SpecificDisease
cystadenoma	SpecificDisease
of	SpecificDisease
the	SpecificDisease
epididymis	SpecificDisease
.	O
Papillary	SpecificDisease
cystadenoma	SpecificDisease
of	SpecificDisease
the	SpecificDisease
epididymis	SpecificDisease
is	O
an	O
uncommon	O
benign	O
lesion	O
that	O
may	O
occur	O
sporadically	O
or	O
as	O
a	O
manifestation	O
of	O
von	SpecificDisease
Hippel-Lindau	SpecificDisease
(VHL)	SpecificDisease
disease	SpecificDisease
.	O
Neither	O
immunohistochemical	O
studies	O
nor	O
molecular	O
genetic	O
analyses	O
of	O
the	O
VHL	Modifier
gene	O
have	O
been	O
reported	O
previously	O
for	O
this	O
lesion.	O
The	O
authors	O
describe	O
two	O
cases	O
of	O
clear	O
cell	O
papillary	SpecificDisease
cystadenoma	SpecificDisease
of	SpecificDisease
the	SpecificDisease
epididymis	SpecificDisease
,	O
both	O
of	O
which	O
were	O
initially	O
confused	O
with	O
metastatic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
.	O
Both	O
lesions	O
showed	O
positive	O
immunohistochemical	O
staining	O
for	O
low	O
and	O
intermediate	O
molecular	O
weight	O
keratins	O
(Cam	O
5.	O
2	O
and	O
AE1/AE3),	O
EMA,	O
vimentin,	O
alpha	O
1-antitrypsin,	O
and	O
alpha	O
1-antichymotrypsin.	O
Each	O
was	O
negative	O
for	O
CEA.	O
Because	O
clear	O
cell	O
papillary	SpecificDisease
cystadenoma	SpecificDisease
is	O
similar	O
to	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
histologically,	O
and	O
because	O
both	O
occur	O
as	O
components	O
of	O
the	O
von	Modifier
Hippel-Lindau	Modifier
disease	Modifier
complex,	O
the	O
authors	O
analyzed	O
both	O
cases	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
VHL	Modifier
gene.	O
A	O
somatic	O
VHL	Modifier
gene	O
mutation	O
was	O
detected	O
in	O
one	O
of	O
the	O
two	O
tumors	DiseaseClass
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis.	O
Direct	O
sequencing	O
revealed	O
a	O
cytosine	O
to	O
thymine	O
transition	O
at	O
nucleotide	O
694,	O
resulting	O
in	O
the	O
replacement	O
of	O
an	O
arginine	O
with	O
a	O
stop	O
codon	O
after	O
the	O
sixth	O
amino	O
acid	O
of	O
exon	O
3.	O
As	O
the	O
VHL	Modifier
gene	O
is	O
believed	O
to	O
function	O
as	O
a	O
tumor	Modifier
suppressor	O
gene,	O
VHL	Modifier
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
tumorigenesis	O
in	O
sporadic	O
cystadenomas	SpecificDisease
of	SpecificDisease
the	SpecificDisease
epididymis	SpecificDisease

An	O
evaluation	O
of	O
genetic	O
heterogeneity	O
in	O
145	O
breast-ovarian	Modifier
cancer	Modifier
families.	O
Breast	Modifier
Cancer	Modifier
Linkage	O
Consortium.	O
The	O
breast-ovary	SpecificDisease
cancer-family	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
dominant	O
predisposition	O
to	O
cancer	CompositeMention
of	CompositeMention
the	CompositeMention
breast	CompositeMention
and	CompositeMention
ovaries	CompositeMention
which	O
has	O
been	O
mapped	O
to	O
chromosome	O
region	O
17q12-q21.	O
The	O
majority,	O
but	O
not	O
all,	O
of	O
breast-ovary	Modifier
cancer	Modifier
families	O
show	O
linkage	O
to	O
this	O
susceptibility	O
locus,	O
designated	O
BRCA1.	O
We	O
report	O
here	O
the	O
results	O
of	O
a	O
linkage	O
analysis	O
of	O
145	O
families	O
with	O
both	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
These	O
families	O
contain	O
either	O
a	O
total	O
of	O
three	O
or	O
more	O
cases	O
of	O
early-onset	O
(before	O
age	O
60	O
years)	O
breast	SpecificDisease
cancer	SpecificDisease
or	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
All	O
families	O
contained	O
at	O
least	O
one	O
case	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
Overall,	O
an	O
estimated	O
76%	O
of	O
the	O
145	O
families	O
are	O
linked	O
to	O
the	O
BRCA1	O
locus.	O
None	O
of	O
the	O
13	O
families	O
with	O
cases	O
of	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
appear	O
to	O
be	O
linked,	O
but	O
it	O
is	O
estimated	O
that	O
92%	O
(95%	O
confidence	O
interval	O
76%	O
-100%)	O
of	O
families	O
with	O
no	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
and	O
with	O
two	O
or	O
more	O
ovarian	SpecificDisease
cancers	SpecificDisease
are	O
linked	O
to	O
BRCA1.	O
These	O
data	O
suggest	O
that	O
the	O
breast-ovarian	SpecificDisease
cancer-family	SpecificDisease
syndrome	SpecificDisease
is	O
genetically	O
heterogeneous.	O
However,	O
the	O
large	O
majority	O
of	O
families	O
with	O
early-onset	O
breast	SpecificDisease
cancer	SpecificDisease
and	O
with	O
two	O
or	O
more	O
cases	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease

Genetic	O
analysis	O
in	O
families	O
with	O
van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
.	O
We	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(including	O
three	O
new	O
pedigrees)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
(	O
VWS	SpecificDisease
).	O
Both	O
types	O
of	O
oral	SpecificDisease
cleft	SpecificDisease
,	O
cleft	SpecificDisease
palate	SpecificDisease
(	O
CP	SpecificDisease
)	O
and	O
cleft	SpecificDisease
lip	SpecificDisease
with	O
or	O
without	O
CP	SpecificDisease
(	O
CLP	SpecificDisease
),	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	SpecificDisease
pits	SpecificDisease
or	O
fistulae	SpecificDisease
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
K	O
=.	O
89	O
and.	O
99	O
by	O
different	O
methods.	O
Cleft	O
types	O
(	O
CLP	SpecificDisease
and	O
CP	SpecificDisease
)	O
occur	O
in	O
VWS	SpecificDisease
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non-VWS	O
population,	O
ie,	O
about	O
twice	O
as	O
many	O
cleft-bearing	O
individuals	O
have	O
CLP	SpecificDisease
as	O
have	O
CP	SpecificDisease
.	O
On	O
the	O
other	O
hand,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
CP	SpecificDisease
and	O
excess	O
of	O
males	O
with	O
CLP	SpecificDisease
;	O
in	O
VWS	SpecificDisease
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal.	O
Lip	SpecificDisease
pits	SpecificDisease
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes.	O
Affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	SpecificDisease
.	O
However,	O
there	O
is	O
an	O
excess	O
of	O
less	O
severely	O
affected	O
individuals	O
among	O
transmitters	O
and	O
a	O
deficiency	O
of	O
more	O
severely	O
affected,	O
brought	O
about	O
by	O
a	O
proband	O
bias	O
and	O
differential	O
fecundity.	O
The	O
expression	O
of	O
VWS	SpecificDisease
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children.	O
For	O
a	O
VWS	Modifier
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26.	O
45%;	O
that	O
of	O
transmitting	O
lower	O
lip	SpecificDisease
pits	SpecificDisease
is	O
23.	O
55%.	O
Three	O
pedigrees	O
of	O
lip	SpecificDisease
pits	SpecificDisease
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals.	O
Control	O
of	O
gene	O
expression	O
in	O
VWS	SpecificDisease
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated.	O
Mutation	O
rate	O
of	O
the	O
VWS	Modifier

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion-rich	O
region	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene.	O
Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)or	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
BMD	SpecificDisease
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion-rich	O
region	O
of	O
the	O
DMD	Modifier
locus.	O
This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b-7,	O
all	O
exons	O
detected	O
by	O
cDNA8,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9.	O
These	O
80	O
individuals	O
account	O
for	O
approximately	O
75%	O
of	O
109	O
deletions	O
of	O
the	O
gene,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA.	O
Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes,	O
p20	O
(DXS269;	O
Wapenaar	O
et	O
al.)	O
and	O
GMGX11	O
(DXS239;	O
present	O
paper).	O
Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype.	O
Thirty-eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	SpecificDisease
,	O
BMD	SpecificDisease
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron/exon	O
boundaries.	O
Of	O
these,	O
eight	O
BMD	Modifier
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact,	O
while	O
21	O
DMD	Modifier
patients,	O
7	O
intermediate	O
patients,	O
and	O
1	O
BMD	Modifier

Proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
Pelizaeus-Merzbacher	SpecificDisease
Disease	SpecificDisease
:	O
duplications,	O
the	O
major	O
cause	O
of	O
the	O
disease,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells,	O
but	O
point	O
mutations	O
do	O
not.	O
The	O
Clinical	O
European	O
Network	O
on	O
Brain	DiseaseClass
Dysmyelinating	DiseaseClass
Disease	DiseaseClass
.	O
Pelizaeus-Merzbacher	SpecificDisease
Disease	SpecificDisease
(	O
PMD	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
developmental	DiseaseClass
defect	DiseaseClass
of	DiseaseClass
myelination	DiseaseClass
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(PLP)	O
locus.	O
Investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
PMD	SpecificDisease

Haplotype	O
analysis	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
Turkish	O
phenylketonuria	Modifier
families.	O
We	O
have	O
estimated	O
the	O
haplotype	O
distribution	O
of	O
mutant	O
and	O
normal	O
phenylalanine	O
hydroxylase	O
(PAH)	O
alleles	O
for	O
17	O
Turkish	O
phenylketonuria	Modifier
(	O
PKU	Modifier
)	O
families	O
	O
20	O
normal	O
and	O
27	O
mutated	O
PAH	O
alleles	O
could	O
be	O
identified.	O
Of	O
the	O
latter,	O
the	O
most	O
prevalent	O
were	O
associated	O
with	O
haplotype	O
6	O
(29.	O
6%),	O
1	O
(18.	O
5%)	O
and	O
36	O
(11.	O
1%),	O
while	O
the	O
normal	O
alleles	O
were	O
preferentially	O
associated	O
with	O
haplotype	O
1	O
(20%).	O
Of	O
the	O
19	O
different	O
haplotypes	O
observed,	O
5	O
have	O
not	O
been	O
described	O
previously.	O
The	O
haplotype	O
distribution	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
Northern	O
European	O
population.	O
Two	O
of	O
the	O
eight	O
polymorphic	O
sites	O
were	O
in	O
association	O
with	O
PKU	SpecificDisease

Cloning	O
of	O
human	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients.	O
Two	O
overlapping	O
cDNA	O
clones	O
(1,	O
991	O
bp	O
and	O
736	O
bp,	O
respectively)	O
encoding	O
the	O
precursor	O
of	O
human	O
mitochondrial	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
(VLCAD)	O
were	O
cloned	O
and	O
sequenced.	O
The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2,	O
177	O
bases,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids,	O
including	O
a	O
40-amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615-amino	O
acid	O
mature	O
polypeptide.	O
PCR-amplified	O
VLCAD	O
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD-deficient	Modifier
patients.	O
In	O
both	O
patients,	O
a	O
105-bp	O
deletion	O
encompassing	O
bases	O
1078-1182	O
in	O
VLCAD	O
cDNA	O
was	O
identified.	O
The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	O
pre-mRNA.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
.	O
Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	O
VLCAD	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts,	O
using	O
vaccinia	O
viral	O
system,	O
which	O
demonstrated	O
that	O
the	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
normal	SpecificDisease
VLCAD	SpecificDisease
protein	SpecificDisease
causes	O
impaired	O
long-chain	O
fatty	O
acid	O
beta-oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts.	O
In	O
patient	O
fibroblasts,	O
raising	O
VLCAD	O
activity	O
to	O
approximately	O
20%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	O
acid	O
beta-oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	SpecificDisease
deficiency	SpecificDisease

Mutations	O
in	O
the	O
RB1	O
gene	O
and	O
their	O
effects	O
on	O
transcription.	O
Inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
during	O
normal	O
retinal	O
development	O
initiates	O
the	O
formation	O
of	O
a	O
retinoblastoma	SpecificDisease
(RB)	SpecificDisease
tumor	SpecificDisease
.	O
To	O
identify	O
the	O
mutations	O
which	O
inactivate	O
RB1,	O
21	O
RB	SpecificDisease
tumors	SpecificDisease
isolated	O
from	O
19	O
patients	O
were	O
analyzed	O
with	O
the	O
polymerase	O
chain	O
reaction	O
or	O
an	O
RNase	O
protection	O
assay	O
or	O
both.	O
Mutations	O
were	O
identified	O
in	O
13	O
of	O
21	O
RB	SpecificDisease
tumors	SpecificDisease
;	O
in	O
8	O
tumors	DiseaseClass
,	O
the	O
precise	O
errors	O
in	O
nucleotide	O
sequence	O
were	O
characterized.	O
Each	O
of	O
four	O
germ	O
line	O
mutations	O
involved	O
a	O
small	O
deletion	O
or	O
duplication,	O
while	O
three	O
somatic	O
mutations	O
were	O
point	O
mutations	O
leading	O
to	O
splice	O
alterations	O
and	O
loss	O
of	O
an	O
exon	O
from	O
the	O
mature	O
RB1	O
mRNA.	O
We	O
were	O
unable	O
to	O
detect	O
expression	O
of	O
the	O
mutant	O
allele	O
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	O
patients,	O
although	O
the	O
mutation	O
was	O
present	O
in	O
the	O
genomic	O
DNA	O
and	O
transcripts	O
containing	O
the	O
mutations	O
were	O
obvious	O
in	O
the	O
RB	SpecificDisease
tumors	SpecificDisease

Resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	O
dominant	O
aniridia	SpecificDisease
,	O
AN1	O
and	O
AN2,	O
to	O
a	O
single	O
locus	O
on	O
chromosome	O
11p13.	O
Two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	SpecificDisease
;	O
AN1	O
for	O
autosomal	O
dominant	O
aniridia	SpecificDisease
on	O
chromosome	O
2p	O
and	O
AN2	O
for	O
the	O
aniridia	SpecificDisease
in	O
the	O
WAGR	SpecificDisease
contiguous	SpecificDisease
gene	SpecificDisease
syndrome	SpecificDisease
on	O
chromosome	O
11p13.	O
In	O
this	O
report,	O
the	O
kindred	O
segregating	O
for	O
autosomal	O
dominant	O
aniridia	SpecificDisease
,	O
which	O
suggested	O
linkage	O
to	O
acid	O
phosphatase-1	O
(ACP1)	O
and	O
led	O
to	O
the	O
assignment	O
of	O
the	O
AN1	O
locus	O
on	O
chromosome	O
2p,	O
has	O
been	O
updated	O
and	O
expanded.	O
Linkage	O
analysis	O
between	O
the	O
aniridia	SpecificDisease
phenotype	O
and	O
ACP1	O
does	O
not	O
support	O
the	O
original	O
linkage	O
results,	O
excluding	O
linkage	O
up	O
to	O
theta	O
=	O
0.	O
17	O
with	O
Z	O
=	O
-2.	O
Tests	O
for	O
linkage	O
to	O
other	O
chromosome	O
2p	O
markers.	O
APOB,	O
D2S71,	O
D2S5,	O
and	O
D2S1,	O
also	O
excluded	O
linkage	O
to	O
aniridia	SpecificDisease
.	O
Markers	O
that	O
have	O
been	O
isolated	O
from	O
the	O
chromosome	O
11p13	O
region	O
were	O
then	O
analyzed	O
in	O
this	O
aniridia	Modifier
family.	O
Two	O
RFLPs	O
at	O
the	O
D11S323	O
locus	O
give	O
significant	O
evidence	O
for	O
linkage.	O
The	O
PvuII	O
polymorphism	O
detected	O
by	O
probe	O
p5S1.	O
6	O
detects	O
no	O
recombinants,	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
6.	O
97	O
at	O
theta	O
=	O
0.	O
00	O
00.	O
The	O
HaeIII	O
polymorphism	O
detected	O
by	O
the	O
probe	O
p5BE1.	O
2	O
gives	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
2.	O
57	O
at	O
theta	O
=	O
0.	O
00	O
00.	O
Locus	O
D11S325	O
gives	O
a	O
lod	O
score	O
of	O
Z	O
=	O
1.	O
53	O
at	O
theta	O
=	O
0.	O
00	O
00.	O
These	O
data	O
suggest	O
that	O
a	O
locus	O
for	O
aniridia	SpecificDisease
(AN1)	O
on	O
chromosome	O
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	O
dominant	O
aniridia	Modifier
family	O
is	O
segregating	O
for	O
an	O
aniridia	Modifier

GT	O
to	O
AT	O
transition	O
at	O
a	O
splice	O
donor	O
site	O
causes	O
skipping	O
of	O
the	O
preceding	O
exon	O
in	O
phenylketonuria	SpecificDisease
.	O
Classical	SpecificDisease
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
human	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
hepatic	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
We	O
isolated	O
several	O
mutant	O
PAH	O
cDNA	O
clones	O
from	O
a	O
PKU	Modifier

Clinical	O
and	O
molecular	O
genetic	O
analysis	O
of	O
19	O
Wolfram	Modifier
syndrome	Modifier
kindreds	O
demonstrating	O
a	O
wide	O
spectrum	O
of	O
mutations	O
in	O
WFS1.	O
Wolfram	SpecificDisease
syndrome	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
neurodegenerative	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
juvenile-onset	SpecificDisease
diabetes	SpecificDisease
mellitus	SpecificDisease
and	O
progressive	O
optic	SpecificDisease
atrophy	SpecificDisease
.	O
mtDNA	O
deletions	O
have	O
been	O
described,	O
and	O
a	O
gene	O
(WFS1)	O
recently	O
has	O
been	O
identified,	O
on	O
chromosome	O
4p16,	O
encoding	O
a	O
predicted	O
890	O
amino	O
acid	O
transmembrane	O
protein.	O
Direct	O
DNA	O
sequencing	O
was	O
done	O
to	O
screen	O
the	O
entire	O
coding	O
region	O
of	O
the	O
WFS1	O
gene	O
in	O
30	O
patients	O
from	O
19	O
British	O
kindreds	O
with	O
Wolfram	SpecificDisease
syndrome	SpecificDisease
.	O
DNA	O
was	O
also	O
screened	O
for	O
structural	O
rearrangements	O
(deletions	O
and	O
duplications)	O
and	O
point	O
mutations	O
in	O
mtDNA.	O
No	O
pathogenic	O
mtDNA	O
mutations	O
were	O
found	O
in	O
our	O
cohort.	O
We	O
identified	O
24	O
mutations	O
in	O
the	O
WFS1	O
gene	O
	O
8	O
nonsense	O
mutations,	O
8	O
missense	O
mutations,	O
3	O
in-frame	O
deletions,	O
1	O
in-frame	O
insertion,	O
and	O
4	O
frameshift	O
mutations.	O
Of	O
these,	O
23	O
were	O
novel	O
mutations,	O
and	O
most	O
occurred	O
in	O
exon	O
8.	O
The	O
majority	O
of	O
patients	O
were	O
compound	O
heterozygotes	O
for	O
two	O
mutations,	O
and	O
there	O
was	O
no	O
common	O
founder	O
mutation.	O
The	O
data	O
were	O
also	O
analyzed	O
for	O
genotype-phenotype	O
relationships.	O
Although	O
some	O
interesting	O
cases	O
were	O
noted,	O
consideration	O
of	O
the	O
small	O
sample	O
size	O
and	O
frequency	O
of	O
each	O
mutation	O
indicated	O
no	O
clear-cut	O
correlations	O
between	O
any	O
of	O
the	O
observed	O
mutations	O
and	O
disease	O
severity.	O
There	O
were	O
no	O
obvious	O
mutation	O
hot	O
spots	O
or	O
clusters.	O
Hence,	O
molecular	O
screening	O
for	O
Wolfram	SpecificDisease
syndrome	SpecificDisease
in	O
affected	O
families	O
and	O
for	O
Wolfram	Modifier
syndrome	Modifier
-carrier	O
status	O
in	O
subjects	O
with	O
psychiatric	DiseaseClass
disorders	DiseaseClass
or	O
diabetes	SpecificDisease
mellitus	SpecificDisease

Maternal	SpecificDisease
uniparental	SpecificDisease
disomy	SpecificDisease
for	SpecificDisease
chromosome	SpecificDisease
14	SpecificDisease
in	O
a	O
boy	O
with	O
a	O
normal	O
karyotype.	O
We	O
report	O
on	O
a	O
boy	O
with	O
a	O
maternal	SpecificDisease
uniparental	SpecificDisease
disomy	SpecificDisease
for	SpecificDisease
chromosome	SpecificDisease
14	SpecificDisease
(	O
UPD	SpecificDisease
(14)).	O
At	O
7	O
years	O
of	O
age	O
he	O
was	O
referred	O
to	O
us	O
by	O
the	O
paediatrician	O
because	O
of	O
symptoms	O
of	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
He	O
showed	O
short	DiseaseClass
stature	DiseaseClass
,	O
obesity	SpecificDisease
,	O
mild	O
developmental	DiseaseClass
delay	DiseaseClass
,	O
cryptorchidism	SpecificDisease
,	O
and	O
some	O
mild	O
dysmorphic	DiseaseClass
features	DiseaseClass
.	O
The	O
history	O
further	O
indicated	O
intrauterine	DiseaseClass
growth	DiseaseClass
retardation	DiseaseClass
at	O
the	O
end	O
of	O
the	O
pregnancy.	O
His	O
mother	O
was	O
44	O
years	O
of	O
age	O
at	O
the	O
time	O
of	O
his	O
birth.	O
After	O
birth	O
he	O
showed	O
hypotonia	DiseaseClass
with	O
poor	O
sucking,	O
for	O
which	O
gavage	O
feeding	O
was	O
needed.	O
Motor	O
development	O
was	O
delayed.	O
After	O
1	O
year	O
he	O
became	O
obese	Modifier
despite	O
a	O
normal	O
appetite.	O
Recurrent	O
middle	SpecificDisease
ear	SpecificDisease
infections	SpecificDisease
,	O
a	O
high	O
pain	O
threshold,	O
and	O
a	O
great	O
skill	O
with	O
jigsaw	O
puzzles	O
were	O
reported.	O
There	O
were	O
no	O
behavioural	O
problems	O
or	O
sleep	O
disturbance.	O
Chromosomal	O
analysis	O
was	O
normal	O
(46,	O
XY).	O
DNA	O
analysis	O
for	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
showed	O
no	O
abnormalities.	O
Two	O
years	O
later	O
he	O
was	O
re-examined	O
because	O
we	O
thought	O
his	O
features	O
fitted	O
the	O
PWS	Modifier
-like	O
phenotype	O
associated	O
with	O
maternal	O
UPD	SpecificDisease
(14).	O
At	O
that	O
time	O
precocious	O
puberty	O
was	O
evident.	O
DNA	O
analysis	O
showed	O
maternal	DiseaseClass
heterodisomy	DiseaseClass
for	O
chromosome	O
14.	O
In	O
all	O
the	O
previously	O
described	O
11	O
cases	O
with	O
maternal	O
UPD	SpecificDisease
(14),	O
a	O
Robertsonian	O
translocation	O
involving	O
chromosome	O
14	O
was	O
detected	O
cytogenetically	O
before	O
DNA	O
analysis.	O
This	O
is	O
the	O
first	O
report	O
of	O
diagnosis	O
of	O
maternal	O
UPD	SpecificDisease
(14)	O
based	O
on	O
clinical	O
features.	O
This	O
finding	O
underlines	O
the	O
importance	O
of	O
DNA	O
analysis	O
for	O
maternal	O
UPD	O
(14)	O
in	O
patients	O
with	O
a	O
similar	O
PWS	Modifier

Detection	O
of	O
eight	O
BRCA1	O
mutations	O
in	O
10	O
breast/ovarian	Modifier
cancer	Modifier
families,	O
including	O
1	O
family	O
with	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
.	O
Genetic	O
epidemiological	O
evidence	O
suggests	O
that	O
mutations	O
in	O
BRCA1	O
may	O
be	O
responsible	O
for	O
approximately	O
one	O
half	O
of	O
early	O
onset	O
familial	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
and	O
the	O
majority	O
of	O
familial	CompositeMention
breast/ovarian	CompositeMention
cancer	CompositeMention
.	O
The	O
recent	O
cloning	O
of	O
BRCA1	O
allows	O
for	O
the	O
direct	O
detection	O
of	O
mutations,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	O
for	O
cancer	Modifier
susceptibility	O
is	O
unknown.	O
We	O
analyzed	O
genomic	O
DNA	O
from	O
one	O
affected	O
individual	O
from	O
each	O
of	O
24	O
families	O
with	O
at	O
least	O
three	O
cases	O
of	O
ovarian	CompositeMention
or	CompositeMention
breast	CompositeMention
cancer	CompositeMention
,	O
using	O
SSCP	O
assays.	O
Variant	O
SSCP	O
bands	O
were	O
subcloned	O
and	O
sequenced.	O
Allele-specific	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
verify	O
sequence	O
changes	O
and	O
to	O
screen	O
DNA	O
from	O
control	O
individuals.	O
Six	O
frameshift	O
and	O
two	O
missense	O
mutations	O
were	O
detected	O
in	O
10	O
different	O
families.	O
A	O
frameshift	O
mutation	O
was	O
detected	O
in	O
a	O
male	O
proband	O
affected	O
with	O
both	O
breast	CompositeMention
and	CompositeMention
prostate	CompositeMention
cancer	CompositeMention
.	O
A	O
40-bp	O
deletion	O
was	O
detected	O
in	O
a	O
patient	O
who	O
developed	O
intra-abdominal	DiseaseClass
carcinomatosis	DiseaseClass
1	O
year	O
after	O
prophylactic	O
oophorectomy.	O
Mutations	O
were	O
detected	O
throughout	O
the	O
gene,	O
and	O
only	O
one	O
was	O
detected	O
in	O
more	O
than	O
a	O
single	O
family.	O
These	O
results	O
provide	O
further	O
evidence	O
that	O
inherited	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
can	O
occur	O
as	O
a	O
consequence	O
of	O
a	O
wide	O
array	O
of	O
BRCA1	O
mutations.	O
These	O
results	O
suggests	O
that	O
development	O
of	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
will	O
be	O
technically	O
challenging.	O
The	O
finding	O
of	O
a	O
mutation	O
in	O
a	O
family	O
with	O
male	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease

Color	DiseaseClass
vision	DiseaseClass
defects	DiseaseClass
in	O
adrenomyeloneuropathy	SpecificDisease
.	O
The	O
relationship	O
between	O
abnormal	DiseaseClass
color	DiseaseClass
vision	DiseaseClass
and	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
)	O
was	O
investigated	O
in	O
27	O
AMN	Modifier
patients	O
and	O
31	O
age-matched	O
controls	O
by	O
using	O
the	O
Farnsworth-Munsell	O
100	O
Hue	O
test.	O
Twelve	O
(44%)	O
of	O
27	O
patients	O
showed	O
test	O
scores	O
significantly	O
above	O
normal.	O
The	O
axes	O
of	O
bipolarity	O
determined	O
by	O
the	O
testing	O
differed	O
widely	O
between	O
the	O
patients	O
with	O
abnormal	O
scores,	O
compatible	O
with	O
the	O
notion	O
that	O
different	O
alterations	O
in	O
visual	O
pigment	O
genes	O
occur	O
in	O
different	O
AMN	Modifier
kindreds.	O
These	O
observations	O
confirm	O
our	O
earlier	O
impression	O
that	O
the	O
frequency	O
of	O
abnormal	DiseaseClass
color	DiseaseClass
vision	DiseaseClass
is	O
increased	O
in	O
these	O
kindreds,	O
and	O
it	O
supports	O
our	O
contentions	O
that	O
(1)	O
AMN	SpecificDisease
(and	O
its	O
companion,	O
adrenoleukodystrophy	DiseaseClass
)	O
are	O
very	O
closely	O
linked	O
to	O
the	O
visual	O
pigment	O
loci	O
at	O
Xq28	O
and	O
(2)	O
this	O
proximity	O
might	O
provide	O
the	O
opportunity	O
to	O
observe	O
contiguous	DiseaseClass
gene	DiseaseClass
defects	DiseaseClass

Patterns	O
of	O
exon	O
deletions	O
in	O
Duchenne	CompositeMention
and	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
.	O
A	O
panel	O
of	O
patients	O
with	O
Duchenne	CompositeMention
and	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
(	O
DMD	SpecificDisease
and	O
BMD	SpecificDisease
)	O
has	O
been	O
screened	O
with	O
the	O
cDNA	O
probes	O
Cf56a	O
and	O
Cf23a,	O
which	O
detect	O
exons	O
in	O
the	O
central	O
part	O
of	O
the	O
DMD	Modifier
gene.	O
One	O
or	O
more	O
exons	O
were	O
deleted	O
in	O
60%	O
of	O
patients.	O
The	O
deletions	O
were	O
mapped	O
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	O
and	O
extent,	O
particularly	O
in	O
DMD	SpecificDisease
.	O
Deletions	O
specific	O
to	O
DMD	SpecificDisease
and	O
to	O
BMD	SpecificDisease
are	O
described.	O
Half	O
of	O
all	O
BMD	Modifier
patients	O
have	O
a	O
deletion	O
of	O
one	O
particular	O
small	O
group	O
of	O
exons;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	O
produce	O
the	O
more	O
severe	O
DMD	SpecificDisease

The	O
LEC	O
rat	O
has	O
a	O
deletion	O
in	O
the	O
copper	O
transporting	O
ATPase	O
gene	O
homologous	O
to	O
the	O
Wilson	Modifier
disease	Modifier
gene.	O
The	O
Long-Evans	O
Cinnamon	O
(LEC)	O
rat	O
shows	O
similarity	O
to	O
Wilson	SpecificDisease
disease	SpecificDisease
in	O
many	O
clinical	O
and	O
biochemical	O
features.	O
We	O
have	O
cloned	O
cDNAs	O
for	O
the	O
rat	O
gene	O
(Atp7b)	O
homologous	O
to	O
the	O
human	O
Wilson	Modifier
disease	Modifier
gene	O
(ATP7B)	O
and	O
have	O
used	O
them	O
to	O
identify	O
a	O
partial	O
deletion	O
in	O
the	O
Atp7b	O
gene	O
in	O
the	O
LEC	O
rat.	O
The	O
deletion	O
removes	O
at	O
least	O
900	O
bp	O
of	O
the	O
coding	O
region	O
at	O
the	O
3	O
end,	O
includes	O
the	O
crucial	O
ATP	O
binding	O
domain	O
and	O
extends	O
downstream	O
of	O
the	O
gene.	O
Our	O
results	O
provide	O
convincing	O
evidence	O
for	O
defining	O
the	O
LEC	O
rat	O
as	O
an	O
animal	O
model	O
for	O
Wilson	SpecificDisease
disease	SpecificDisease
.	O
This	O
model	O
will	O
be	O
important	O
for	O
studying	O
liver	O
pathophysiology,	O
for	O
developing	O
therapy	O
for	O
Wilson	SpecificDisease
disease	SpecificDisease

Detection	O
of	O
a	O
new	O
submicroscopic	O
Norrie	Modifier
disease	Modifier
deletion	O
interval	O
with	O
a	O
novel	O
DNA	O
probe	O
isolated	O
by	O
differential	O
Alu	O
PCR	O
fingerprint	O
cloning.	O
Differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
was	O
used	O
to	O
isolate	O
a	O
DNA	O
probe	O
from	O
the	O
Xp11.	O
4--	O
>	O
p11.	O
21	O
region	O
of	O
the	O
human	O
X	O
chromosome.	O
This	O
novel	O
sequence,	O
cpXr318	O
(DXS742),	O
detects	O
a	O
new	O
submicroscopic	O
deletion	O
interval	O
at	O
the	O
Norrie	Modifier
disease	Modifier
locus	O
(NDP).	O
Combining	O
our	O
data	O
with	O
the	O
consensus	O
genetic	O
map	O
of	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome,	O
we	O
propose	O
the	O
physical	O
order	O
Xcen-DXS14-DXS255-	O
(DXS426,	O
TIMP)	O
-	O
(DXS742-	O
([MAOB-MAOA-DXS7],	O
NDP)	O
-DXS77-DXS228)	O
-DXS209-DXS148-DXS196-	O
+	O
+	O
+	O
Xpter.	O
The	O
cpXr318	O
probe	O
and	O
a	O
subclone	O
from	O
a	O
cosmid	O
corresponding	O
to	O
the	O
DXS7	O
locus	O
were	O
converted	O
into	O
sequence-tagged	O
sites.	O
Finally,	O
DXS742,	O
DSX7,	O
DXS77,	O
and	O
MAOA	O
were	O
integrated	O
into	O
a	O
physical	O
map	O
spanning	O
the	O
Norrie	Modifier
disease	Modifier

Genetic	O
analysis	O
of	O
a	O
Japanese	O
family	O
with	O
normotriglyceridemic	SpecificDisease
abetalipoproteinemia	SpecificDisease
indicates	O
a	O
lack	O
of	O
linkage	O
to	O
the	O
apolipoprotein	O
B	O
gene.	O
Normotriglyceridemic	SpecificDisease
abetalipoproteinemia	SpecificDisease
is	O
a	O
rare	O
familial	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
an	O
isolated	O
deficiency	SpecificDisease
of	SpecificDisease
apoB-100	SpecificDisease
.	O
We	O
have	O
previously	O
reported	O
a	O
patient	O
with	O
this	O
disease,	O
who	O
had	O
normal	O
apoB-48	O
but	O
no	O
apoB-100.	O
To	O
elucidate	O
the	O
genetic	DiseaseClass
abnormalities	DiseaseClass

Founder	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
Polish	O
families	O
with	O
breast-ovarian	CompositeMention
cancer	CompositeMention
.	O
We	O
have	O
undertaken	O
a	O
hospital-based	O
study,	O
to	O
identify	O
possible	O
BRCA1	O
and	O
BRCA2	O
founder	O
mutations	O
in	O
the	O
Polish	O
population.	O
The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	DiseaseClass
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	CompositeMention
or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
and	O
who	O
had	O
cancer	DiseaseClass
diagnosed,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females,	O
at	O
age	O
<	O
50	O
years.	O
A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
,	O
4	O
families	O
had	O
ovarian	SpecificDisease
cancers	SpecificDisease
only,	O
and	O
36	O
families	O
had	O
breast	SpecificDisease
cancers	SpecificDisease
only.	O
Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	O
from	O
each	O
family.	O
The	O
entire	O
coding	O
region	O
of	O
BRCA1	O
and	O
BRCA2	O
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants.	O
Mutations	O
were	O
found	O
in	O
35	O
(53%)	O
of	O
the	O
66	O
families	O
studied.	O
All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	O
gene.	O
BRCA1	DiseaseClass
abnormalities	DiseaseClass
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	SpecificDisease
cancer	SpecificDisease
only,	O
in	O
67%	O
of	O
27	O
families	O
with	O
both	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
,	O
and	O
in	O
34%	O
of	O
35	O
families	O
with	O
breast	SpecificDisease
cancer	SpecificDisease
only.	O
The	O
single	O
family	O
with	O
a	O
BRCA2	O
mutation	O
had	O
the	O
breast-ovarian	SpecificDisease
cancer	SpecificDisease
syndrome	SpecificDisease
.	O
Seven	O
distinct	O
mutations	O
were	O
identified;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families.	O
In	O
total,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(94%)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations.	O
Three	O
BRCA1	DiseaseClass
abnormalities	DiseaseClass

New	O
founder	O
haplotypes	O
at	O
the	O
myotonic	Modifier
dystrophy	Modifier
locus	O
in	O
southern	O
Africa.	O
The	O
association	O
between	O
normal	O
alleles	O
at	O
the	O
CTG	O
repeat	O
and	O
two	O
nearby	O
polymorphisms	O
in	O
the	O
myotonin	O
protein	O
kinase	O
gene,	O
the	O
Alu	O
insertion/deletion	O
polymorphism	O
and	O
the	O
myotonic	Modifier
dystrophy	Modifier
kinase	O
(DMK)	O
(G/T)	O
intron	O
9/HinfI	O
polymorphism,	O
has	O
been	O
analyzed	O
in	O
South	O
African	O
Negroids,	O
a	O
population	O
in	O
which	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
has	O
not	O
been	O
described.	O
South	O
African	O
Negroids	O
have	O
a	O
CTG	O
allelic	O
distribution	O
that	O
is	O
significantly	O
different	O
from	O
that	O
in	O
Caucasoids	O
and	O
Japanese	O
	O
the	O
CTG	O
repeat	O
lengths	O
of	O
>	O
or	O
=	O
19	O
are	O
very	O
rare.	O
The	O
striking	O
linkage	O
disequilibrium	O
between	O
specific	O
alleles	O
at	O
the	O
Alu	O
polymorphism	O
(Alu	O
(ins)	O
and	O
Alu	O
(del)),	O
the	O
HinfI	O
polymorphism	O
(HinfI-1	O
and	O
HinfI-2),	O
and	O
the	O
CTG	O
repeat	O
polymorphism	O
seen	O
in	O
Caucasoid	O
(Europeans	O
and	O
Canadians)	O
populations	O
was	O
also	O
found	O
in	O
the	O
South	O
African	O
Negroid	O
population.	O
Numerous	O
haplotypes,	O
not	O
previously	O
described	O
in	O
Europeans,	O
were,	O
however,	O
found.	O
It	O
thus	O
seems	O
likely	O
that	O
only	O
a	O
small	O
number	O
of	O
these	O
"	O
African	O
"	O
chromosomes	O
were	O
present	O
in	O
the	O
progenitors	O
of	O
all	O
non-African	O
peoples.	O
These	O
data	O
provide	O
support	O
for	O
the	O
"	O
out	O
of	O
Africa	O
"	O
model	O
for	O
the	O
origin	O
of	O
modern	O
humans	O
and	O
suggest	O
that	O
the	O
rare	O
ancestral	O
DM	Modifier
mutation	O
event	O
may	O
have	O
occurred	O
after	O
the	O
migration	O
from	O
Africa,	O
hence	O
the	O
absence	O
of	O
DM	SpecificDisease

Marked	O
phenotypic	O
heterogeneity	O
associated	O
with	O
expansion	O
of	O
a	O
CAG	O
repeat	O
sequence	O
at	O
the	O
spinocerebellar	Modifier
ataxia	Modifier
3/Machado-Joseph	Modifier
disease	Modifier
locus.	O
The	O
spinocerebellar	Modifier
ataxia	Modifier
3	Modifier
locus	O
(	O
SCA3	SpecificDisease
)	O
for	O
type	SpecificDisease
I	SpecificDisease
autosomal	SpecificDisease
dominant	SpecificDisease
cerebellar	SpecificDisease
ataxia	SpecificDisease
(	O
ADCA	SpecificDisease
type	SpecificDisease
I	SpecificDisease
),	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	DiseaseClass
disorders	DiseaseClass
,	O
has	O
been	O
mapped	O
to	O
chromosome	O
14q32.	O
1	O
1.	O
ADCA	Modifier
type	Modifier
I	Modifier
patients	O
from	O
families	O
segregating	O
SCA3	SpecificDisease
share	O
clinical	O
features	O
in	O
common	O
with	O
those	O
with	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
),	O
the	O
gene	O
of	O
which	O
maps	O
to	O
the	O
same	O
region.	O
We	O
show	O
here	O
that	O
the	O
disease	O
gene	O
segregating	O
in	O
each	O
of	O
three	O
French	O
ADCA	Modifier
type	Modifier
I	Modifier
kindreds	O
and	O
in	O
a	O
French	O
family	O
with	O
neuropathological	O
findings	O
suggesting	O
the	O
ataxochoreic	O
form	O
of	O
dentatorubropallidoluysian	SpecificDisease
atrophy	SpecificDisease
carries	O
an	O
expanded	O
CAG	O
repeat	O
sequence	O
located	O
at	O
the	O
same	O
locus	O
as	O
that	O
for	O
MJD	SpecificDisease

The	O
red-green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy	SpecificDisease
.	O
Although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very-long-chain	O
fatty	O
acyl-CoA	O
synthetase	O
is	O
defective	O
in	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
),	O
the	O
ALD	Modifier
gene	O
is	O
still	O
unidentified.	O
The	O
ALD	Modifier
locus	O
has	O
been	O
mapped	O
to	O
Xq28,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes.	O
Abnormal	DiseaseClass
color	DiseaseClass
vision	DiseaseClass
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
),	O
a	O
milder	O
form	O
of	O
ALD	SpecificDisease
.	O
Furthermore,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	Modifier
kindreds.	O
This	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
DNA	O
rearrangement	O
could	O
underlie	O
both	O
ALD	SpecificDisease
and	O
abnormal	SpecificDisease
color	SpecificDisease
vision	SpecificDisease
in	O
these	O
patients.	O
Study	O
of	O
34	O
French	O
ALD	Modifier
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green/red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red/green	O
color	O
vision	O
gene	O
complex.	O
The	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
"	O
abnormal	O
"	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	SpecificDisease
color	SpecificDisease
vision	SpecificDisease
defects	SpecificDisease
.	O
The	O
red/green	O
color	O
pigment	O
(R/GCP)	O
region	O
was	O
studied	O
by	O
pulsed-field	O
gel	O
electrophoresis	O
in	O
14	O
of	O
these	O
patients,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	O
size	O
difference	O
between	O
the	O
patients	O
and	O
normal	O
individuals	O
who	O
have	O
the	O
same	O
number	O
of	O
pigment	O
genes.	O
The	O
R/GCP	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
French	O
and	O
seven	O
North	O
American	O
ALD	Modifier
patients	O
by	O
using	O
six	O
genomic	O
DNA	O
probes,	O
isolated	O
from	O
a	O
cosmid	O
walk,	O
that	O
flank	O
the	O
color	O
vision	O
genes.	O
No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	O
genes.	O
One	O
of	O
the	O
eight	O
previously	O
reported	O
ALD	Modifier
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy.	O
This	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
AMN	SpecificDisease
may	O
suggest	O
that	O
the	O
ALD	Modifier
/	O
AMN	Modifier
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	DiseaseClass
vision	DiseaseClass
anomalies	DiseaseClass
owe	O
their	O
origin	O
to	O
deleted	O
DNA	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision.	O
It	O
is	O
possible,	O
however,	O
that	O
phenotypic	O
color	DiseaseClass
vision	DiseaseClass
anomalies	DiseaseClass
in	O
AMN	SpecificDisease

Haim-Munk	SpecificDisease
syndrome	SpecificDisease
and	O
Papillon-Lefevre	SpecificDisease
syndrome	SpecificDisease
are	O
allelic	O
mutations	O
in	O
cathepsin	O
C.	O
Of	O
the	O
many	O
palmoplantar	DiseaseClass
keratoderma	DiseaseClass
(PPK)	DiseaseClass
conditions	DiseaseClass
,	O
only	O
Papillon-Lefevre	SpecificDisease
syndrome	SpecificDisease
(	O
PLS	SpecificDisease
)	O
and	O
Haim-Munk	SpecificDisease
syndrome	SpecificDisease
(	O
HMS	SpecificDisease
)	O
are	O
associated	O
with	O
premature	O
periodontal	O
destruction.	O
Although	O
both	O
PLS	SpecificDisease
and	O
HMS	SpecificDisease
share	O
the	O
cardinal	O
features	O
of	O
PPK	DiseaseClass
and	O
severe	O
periodontitis	SpecificDisease
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
HMS	SpecificDisease
including	O
arachnodactyly	SpecificDisease
,	O
acro-osteolysis	SpecificDisease
,	O
atrophic	SpecificDisease
changes	SpecificDisease
of	SpecificDisease
the	SpecificDisease
nails	SpecificDisease
,	O
and	O
a	O
radiographic	SpecificDisease
deformity	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fingers	SpecificDisease
.	O
While	O
PLS	Modifier
cases	O
have	O
been	O
identified	O
throughout	O
the	O
world,	O
HMS	SpecificDisease
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
Cochin,	O
India.	O
Parental	O
consanguinity	O
is	O
a	O
characteristic	O
of	O
many	O
cases	O
of	O
both	O
conditions.	O
Although	O
autosomal	O
recessive	O
transmission	O
of	O
PLS	SpecificDisease
is	O
evident,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
HMS	SpecificDisease
.	O
Recently,	O
mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
have	O
been	O
identified	O
as	O
the	O
underlying	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
PLS	SpecificDisease
.	O
To	O
determine	O
if	O
a	O
cathepsin	O
C	O
mutation	O
is	O
also	O
responsible	O
for	O
HMS	SpecificDisease
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	Modifier
and	O
HMS	Modifier
phenotypes	O
appear.	O
Here	O
we	O
report	O
identification	O
of	O
a	O
mutation	O
of	O
cathepsin	O
C	O
(exon	O
6,	O
2127A--	O
>	O
G)	O
that	O
changes	O
a	O
highly	O
conserved	O
amino	O
acid	O
in	O
the	O
cathepsin	O
C	O
peptide.	O
This	O
mutation	O
segregates	O
with	O
HMS	SpecificDisease
in	O
four	O
nuclear	O
families.	O
Additionally,	O
the	O
existence	O
of	O
a	O
shared	O
common	O
haplotype	O
for	O
genetic	O
loci	O
flanking	O
the	O
cathepsin	O
C	O
gene	O
suggests	O
that	O
affected	O
subjects	O
descended	O
from	O
the	O
Cochin	O
isolate	O
are	O
homozygous	O
for	O
a	O
mutation	O
inherited	O
"	O
identical	O
by	O
descent	O
"	O
from	O
a	O
common	O
ancestor.	O
This	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
HMS	SpecificDisease
in	O
these	O
families.	O
We	O
also	O
report	O
a	O
mutation	O
of	O
the	O
same	O
exon	O
6	O
CTSC	O
codon	O
(2126C--	O
>	O
T)	O
in	O
a	O
Turkish	O
family	O
with	O
classical	O
PLS	SpecificDisease
.	O
These	O
findings	O
provide	O
evidence	O
that	O
PLS	SpecificDisease
and	O
HMS	SpecificDisease

X	O
inactivation	O
and	O
somatic	O
cell	O
selection	O
rescue	O
female	O
mice	O
carrying	O
a	O
Piga-null	O
mutation.	O
A	O
somatic	O
mutation	O
in	O
the	O
X	O
linked	O
PIGA	O
gene	O
is	O
responsible	O
for	O
the	O
deficiency	DiseaseClass
of	DiseaseClass
glycosyl	DiseaseClass
phosphatidylinositol	DiseaseClass
(GPI)	DiseaseClass
-anchored	DiseaseClass
proteins	DiseaseClass
on	O
blood	O
cells	O
from	O
patients	O
with	O
paroxysmal	SpecificDisease
nocturnal	SpecificDisease
hemoglobinuria	SpecificDisease
.	O
No	O
inherited	O
form	O
of	O
GPI-anchor	SpecificDisease
deficiency	SpecificDisease
has	O
been	O
described.	O
Because	O
conventional	O
Piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	SpecificDisease
lethality	SpecificDisease
in	O
chimeric	O
mice,	O
we	O
used	O
the	O
Cre/loxP	O
system.	O
We	O
generated	O
mice	O
in	O
which	O
two	O
loxP	O
sites	O
flank	O
part	O
of	O
Piga	O
exon	O
2.	O
After	O
crossbreeding	O
with	O
female	O
mice	O
of	O
the	O
EIIa-cre	O
strain,	O
the	O
floxed	O
allele	O
undergoes	O
Cre-mediated	O
recombination	O
with	O
high	O
efficiency	O
during	O
early	O
embryonic	O
development.	O
Because	O
of	O
X	O
chromosome	O
inactivation,	O
female	O
offspring	O
are	O
mosaic	O
for	O
cells	O
that	O
express	O
or	O
lack	O
GPI-linked	O
proteins.	O
Analysis	O
of	O
mosaic	O
mice	O
showed	O
that	O
in	O
heart,	O
lung,	O
kidney,	O
brain,	O
and	O
liver,	O
mainly	O
wild-type	O
Piga	O
is	O
active,	O
suggesting	O
that	O
these	O
tissues	O
require	O
GPI-linked	O
proteins.	O
The	O
salient	O
exceptions	O
were	O
spleen,	O
thymus,	O
and	O
red	O
blood	O
cells,	O
which	O
had	O
almost	O
equal	O
numbers	O
of	O
cells	O
expressing	O
the	O
wild-type	O
or	O
the	O
recombined	O
allele,	O
implying	O
that	O
GPI-linked	O
proteins	O
are	O
not	O
essential	O
for	O
the	O
derivation	O
of	O
these	O
tissues.	O
PIGA	O
(-)	O
cells	O
had	O
no	O
growth	O
advantage,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	SpecificDisease
nocturnal	SpecificDisease
hemoglobinuria	SpecificDisease

The	O
Norrie	Modifier
disease	Modifier
gene	O
maps	O
to	O
a	O
150	O
kb	O
region	O
on	O
chromosome	O
Xp11.3.	O
Norrie	SpecificDisease
disease	SpecificDisease
is	O
a	O
human	O
X-linked	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
of	O
unknown	O
etiology	O
characterized	O
by	O
congenital	SpecificDisease
blindness	SpecificDisease
,	O
sensory	SpecificDisease
neural	SpecificDisease
deafness	SpecificDisease
and	O
mental	DiseaseClass
retardation	DiseaseClass
.	O
This	O
disease	O
gene	O
was	O
previously	O
linked	O
to	O
the	O
DXS7	O
(L1.	O
28)	O
locus	O
and	O
the	O
MAO	O
genes	O
in	O
band	O
Xp11.	O
3	O
3.	O
We	O
report	O
here	O
fine	O
physical	O
mapping	O
of	O
the	O
obligate	O
region	O
containing	O
the	O
Norrie	Modifier
disease	Modifier
gene	O
(NDP)	O
defined	O
by	O
a	O
recombination	O
and	O
by	O
the	O
smallest	O
submicroscopic	O
chromosomal	O
deletion	O
associated	O
with	O
Norrie	SpecificDisease
disease	SpecificDisease

Molecular	O
genetics	O
of	O
the	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
Mediterranean	O
variant	O
and	O
description	O
of	O
a	O
new	O
G6PD	O
mutant,	O
G6PD	O
Andalus1361A.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD;	SpecificDisease
E.	SpecificDisease
C.	SpecificDisease
1.	SpecificDisease
1.	SpecificDisease
1.	SpecificDisease
49)	SpecificDisease
deficiency	SpecificDisease
is	O
the	O
most	O
common	O
human	O
enzymopathy	DiseaseClass
;	O
more	O
than	O
300	O
different	O
biochemical	O
variants	O
of	O
the	O
enzyme	O
have	O
been	O
described.	O
In	O
many	O
parts	O
of	O
the	O
world	O
the	O
Mediterranean	O
type	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(SNRPN),	O
an	O
expressed	O
gene	O
in	O
the	O
Prader-Willi	Modifier
syndrome	Modifier
critical	O
region.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
is	O
associated	O
with	O
paternally	O
derived	O
chromosomal	O
deletions	O
in	O
region	O
15q11-13	O
or	O
with	O
maternal	SpecificDisease
disomy	SpecificDisease
for	SpecificDisease
chromosome	SpecificDisease
15	SpecificDisease
.	O
Therefore,	O
loss	O
of	O
the	O
expressed	O
paternal	O
alleles	O
of	O
maternally	O
imprinted	O
genes	O
must	O
be	O
responsible	O
for	O
the	O
PWS	Modifier
phenotype.	O
We	O
have	O
mapped	O
the	O
gene	O
encoding	O
the	O
small	O
nuclear	O
RNA	O
associated	O
polypeptide	O
SmN	O
(SNRPN)	O
to	O
human	O
chromosome	O
15q12	O
and	O
a	O
processed	O
pseudogene	O
SNRPNP1	O
to	O
chromosome	O
region	O
6pter-p21.	O
Furthermore,	O
SNRPN	O
was	O
mapped	O
to	O
the	O
minimal	O
deletion	O
interval	O
that	O
is	O
critical	O
for	O
PWS	SpecificDisease
.	O
The	O
fact	O
that	O
the	O
mouse	O
Snrpn	O
gene	O
is	O
maternally	O
imprinted	O
in	O
brain	O
suggests	O
that	O
loss	O
of	O
the	O
paternally	O
derived	O
SNRPN	O
allele	O
may	O
be	O
involved	O
in	O
the	O
PWS	Modifier

Increased	O
incidence	O
of	O
cancer	DiseaseClass
in	O
patients	O
with	O
cartilage-hair	SpecificDisease
hypoplasia	SpecificDisease
.	O
OBJECTIVE	O
	O
Previous	O
reports	O
have	O
suggested	O
an	O
increased	O
risk	O
of	O
cancer	DiseaseClass
among	O
patients	O
with	O
cartilage-hair	SpecificDisease
hypoplasia	SpecificDisease
(	O
CHH	SpecificDisease
).	O
This	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
CHH	SpecificDisease
and	O
their	O
first-degree	O
relatives.	O
STUDY	O
DESIGN	O
	O
One	O
hundred	O
twenty-two	O
patients	O
with	O
CHH	SpecificDisease
were	O
identified	O
through	O
2	O
countrywide	O
epidemiologic	O
surveys	O
in	O
1974	O
and	O
in	O
1986.	O
Their	O
parents	O
and	O
nonaffected	O
siblings	O
were	O
identified	O
through	O
the	O
Population	O
Register	O
Center.	O
This	O
cohort	O
underwent	O
follow-up	O
for	O
cancer	Modifier
incidence	O
through	O
the	O
Finnish	O
Cancer	O
Registry	O
to	O
the	O
end	O
of	O
1995.	O
RESULTS	O
	O
A	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	DiseaseClass
was	O
seen	O
among	O
the	O
patients	O
with	O
CHH	SpecificDisease
(standardized	O
incidence	O
ratio	O
6.	O
9,	O
95%	O
confidence	O
interval	O
2.	O
3	O
to	O
16),	O
which	O
was	O
mainly	O
attributable	O
to	O
non-Hodgkins	SpecificDisease
lymphoma	SpecificDisease
(standardized	O
incidence	O
ratio	O
90,	O
95%	O
confidence	O
interval	O
18	O
to	O
264).	O
In	O
addition,	O
a	O
significant	O
excess	O
risk	O
of	O
basal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
was	O
seen	O
(standardized	O
incidence	O
ratio	O
35,	O
95%	O
confidence	O
interval	O
7.	O
2	O
to	O
102).	O
The	O
cancer	Modifier
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	Modifier
incidence	O
in	O
the	O
Finnish	O
population.	O
CONCLUSIONS	O
	O
This	O
study	O
confirms	O
an	O
increased	O
risk	O
of	O
cancer	DiseaseClass
,	O
especially	O
non-Hodgkins	SpecificDisease
lymphoma	SpecificDisease
,	O
probably	O
attributable	O
to	O
defective	O
immunity,	O
among	O
patients	O
with	O
CHH	SpecificDisease

Genetic	O
polymorphism	O
of	O
G6PD	O
in	O
a	O
Bulgarian	O
population.	O
Considerable	O
genetic	O
heterogeneity	O
in	O
G6PD	O
was	O
found	O
in	O
the	O
Bulgarian	O
population-14	O
G6PD	O
variants	O
isolated	O
from	O
117	O
hemizygous	O
carriers	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

A	O
genetic	O
etiology	O
for	O
DiGeorge	SpecificDisease
syndrome	SpecificDisease
:	O
consistent	O
deletions	O
and	O
microdeletions	O
of	O
22q11.	O
DiGeorge	SpecificDisease
syndrome	SpecificDisease
(	O
DGS	SpecificDisease
),	O
a	O
developmental	O
field	O
defect	O
of	O
the	O
third	O
and	O
fourth	O
pharyngeal	O
pouches,	O
is	O
characterized	O
by	O
aplasia	CompositeMention
or	CompositeMention
hypoplasia	CompositeMention
of	CompositeMention
the	CompositeMention
thymus	CompositeMention
and	CompositeMention
parathyroid	CompositeMention
glands	CompositeMention
and	O
by	O
conotruncal	SpecificDisease
cardiac	SpecificDisease
malformations	SpecificDisease
.	O
Cytogenetic	O
studies	O
support	O
the	O
presence	O
of	O
a	O
DGS	Modifier
critical	O
region	O
in	O
band	O
22q11.	O
In	O
the	O
present	O
study,	O
we	O
report	O
the	O
results	O
of	O
clinical,	O
cytogenetic,	O
and	O
molecular	O
studies	O
of	O
14	O
patients	O
with	O
DGS	SpecificDisease
.	O
Chromosome	O
analysis,	O
utilizing	O
high-resolution	O
banding	O
techniques,	O
detected	O
interstitial	O
deletions	O
in	O
five	O
probands	O
and	O
was	O
inconclusive	O
for	O
a	O
deletion	O
in	O
three	O
probands.	O
The	O
remaining	O
six	O
patients	O
had	O
normal	O
karyotypes.	O
In	O
contrast,	O
molecular	O
analysis	O
detected	O
DNA	O
deletions	O
in	O
all	O
14	O
probands.	O
Two	O
of	O
10	O
loci	O
tested,	O
D22S75	O
and	O
D22S259,	O
are	O
deleted	O
in	O
all	O
14	O
patients.	O
A	O
third	O
locus,	O
D22S66,	O
is	O
deleted	O
in	O
the	O
eight	O
DGS	Modifier
probands	O
tested.	O
Physical	O
mapping	O
using	O
somatic	O
cell	O
hybrids	O
places	O
D22S66	O
between	O
D22S75	O
and	O
D22S259,	O
suggesting	O
that	O
it	O
should	O
be	O
deleted	O
in	O
the	O
remaining	O
six	O
cases.	O
Parent-of-origin	O
studies	O
were	O
performed	O
in	O
five	O
families.	O
Four	O
probands	O
failed	O
to	O
inherit	O
a	O
maternal	O
allele,	O
and	O
one	O
failed	O
to	O
inherit	O
a	O
paternal	O
allele.	O
On	O
the	O
basis	O
of	O
these	O
families,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	O
unbalanced-translocation	O
DGS	Modifier
probands	O
in	O
the	O
literature,	O
parent	O
of	O
origin	O
or	O
imprinting	O
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
DGS	SpecificDisease
.	O
Deletion	O
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
DGS	Modifier
probands	O
begins	O
to	O
delineate	O
the	O
region	O
of	O
chromosome	O
22	O
critical	O
for	O
DGS	SpecificDisease

Characterisation	O
of	O
a	O
new	O
rare	O
fragile	O
site	O
easily	O
confused	O
with	O
the	O
fragile	SpecificDisease
X	SpecificDisease
.	O
A	O
new	O
fragile	O
site	O
(FRAXE)	O
in	O
Xq28	O
is	O
described.	O
It	O
appears	O
to	O
be	O
a	O
typical	O
folate	O
sensitive	O
fragile	O
site.	O
The	O
fragile	O
site	O
is	O
not	O
associated	O
with	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	O
when	O
subjected	O
to	O
Southern	O
analysis	O
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
DNA	O
sequence	O
characteristic	O
of	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
.	O
In	O
situ	O
hybridization	O
mapping	O
locates	O
the	O
fragile	O
site	O
between	O
150	O
kb	O
and	O
600	O
kb	O
distal	O
to	O
FRAXA.	O
The	O
distinction	O
between	O
the	O
two	O
fragile	O
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	O
detection	O
of	O
FRAXE,	O
without	O
molecular	O
analysis,	O
could	O
result	O
in	O
misdiagnosis	O
of	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease

BRCA1	O
mutations	O
in	O
primary	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
carcinomas	CompositeMention
.	O
Loss	O
of	O
heterozygosity	O
data	O
from	O
familial	DiseaseClass
tumors	DiseaseClass
suggest	O
that	O
BRCA1,	O
a	O
gene	O
that	O
confers	O
susceptibility	O
to	O
ovarian	CompositeMention
and	CompositeMention
early-onset	CompositeMention
	O
breast	CompositeMention
cancer	CompositeMention
,	O
encodes	O
a	O
tumor	Modifier
suppressor.	O
The	O
BRCA1	O
region	O
is	O
also	O
subject	O
to	O
allelic	O
loss	O
in	O
sporadic	SpecificDisease
breast	SpecificDisease
and	SpecificDisease
ovarian	SpecificDisease
cancers	SpecificDisease
,	O
an	O
indication	O
that	O
BRCA1	O
mutations	O
may	O
occur	O
somatically	O
in	O
these	O
tumors	DiseaseClass
.	O
The	O
BRCA1	O
coding	O
region	O
was	O
examined	O
for	O
mutations	O
in	O
primary	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
tumors	CompositeMention
that	O
show	O
allele	O
loss	O
at	O
the	O
BRCA1	O
locus.	O
Mutations	O
were	O
detected	O
in	O
3	O
of	O
32	O
breast	O
and	O
1	O
of	O
12	O
ovarian	SpecificDisease
carcinomas	SpecificDisease
;	O
all	O
four	O
mutations	O
were	O
germline	O
alterations	O
and	O
occurred	O
in	O
early-onset	O
cancers	DiseaseClass
.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
BRCA1	O
may	O
not	O
be	O
critical	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention

Genomic	O
structure	O
of	O
the	O
EWS	O
gene	O
and	O
its	O
relationship	O
to	O
EWSR1,	O
a	O
site	O
of	O
tumor	Modifier
-associated	O
chromosome	O
translocation.	O
The	O
EWS	O
gene	O
has	O
been	O
identified	O
based	O
on	O
its	O
location	O
at	O
the	O
chromosome	O
22	O
breakpoint	O
of	O
the	O
t	O
(11;	O
22)	O
(q24;	O
q12)	O
translocation	O
that	O
characterizes	O
Ewing	SpecificDisease
sarcoma	SpecificDisease
and	O
related	O
neuroectodermal	SpecificDisease
tumors	SpecificDisease
.	O
The	O
EWS	O
gene	O
spans	O
about	O
40	O
kb	O
of	O
DNA	O
and	O
is	O
encoded	O
by	O
17	O
exons.	O
The	O
nucleotide	O
sequence	O
of	O
the	O
exons	O
is	O
identical	O
to	O
that	O
of	O
the	O
previously	O
described	O
cDNA.	O
The	O
first	O
7	O
exons	O
encode	O
the	O
N-terminal	O
domain	O
of	O
EWS,	O
which	O
consists	O
of	O
a	O
repeated	O
degenerated	O
polypeptide	O
of	O
7	O
to	O
12	O
residues	O
rich	O
in	O
tyrosine,	O
serine,	O
threonine,	O
glycine,	O
and	O
glutamine.	O
Exons	O
11,	O
12,	O
and	O
13	O
encode	O
the	O
putative	O
RNA	O
binding	O
domain.	O
The	O
three	O
glycine-	O
and	O
arginine-rich	O
motifs	O
of	O
the	O
gene	O
are	O
mainly	O
encoded	O
by	O
exons	O
8-9,	O
14,	O
and	O
16.	O
The	O
DNA	O
sequence	O
in	O
the	O
5	O
region	O
of	O
the	O
gene	O
has	O
features	O
of	O
a	O
CpG-rich	O
island	O
and	O
lacks	O
canonical	O
promoter	O
elements,	O
such	O
as	O
TATA	O
and	O
CCAAT	O
consensus	O
sequences.	O
Positions	O
of	O
the	O
chromosome	O
22	O
breakpoints	O
were	O
determined	O
for	O
19	O
Ewing	DiseaseClass
tumors	DiseaseClass

PAX6	O
mutations	O
in	O
aniridia	SpecificDisease
.	O
Aniridia	SpecificDisease
is	O
a	O
congenital	DiseaseClass
malformation	DiseaseClass
of	DiseaseClass
the	DiseaseClass
eye	DiseaseClass
,	O
chiefly	O
characterised	O
by	O
iris	SpecificDisease
hypoplasia	SpecificDisease
,	O
which	O
can	O
cause	O
blindness	SpecificDisease
.	O
The	O
PAX6	O
gene	O
was	O
isolated	O
as	O
a	O
candidate	O
aniridia	Modifier
gene	O
by	O
positional	O
cloning	O
from	O
the	O
smallest	O
region	O
of	O
overlap	O
of	O
aniridia	Modifier
-associated	O
deletions.	O
Subsequently	O
PAX6	O
intragenic	O
mutations	O
were	O
demonstrated	O
in	O
Smalleye,	O
a	O
mouse	O
mutant	O
which	O
is	O
an	O
animal	O
model	O
for	O
aniridia	SpecificDisease
,	O
and	O
six	O
human	O
aniridia	Modifier
patients.	O
In	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
PAX6	O
point	O
mutations	O
in	O
aniridia	Modifier
patients,	O
both	O
sporadic	O
and	O
familial.	O
These	O
mutations	O
highlight	O
regions	O
of	O
the	O
gene	O
which	O
are	O
essential	O
for	O
normal	O
PAX6	O
function.	O
In	O
addition,	O
the	O
frequency	O
at	O
which	O
we	O
have	O
found	O
PAX6	O
mutations	O
suggests	O
that	O
lesions	O
in	O
PAX6	O
will	O
account	O
for	O
most	O
cases	O
of	O
aniridia	SpecificDisease

Mutations	O
in	O
the	O
PAX6	O
gene	O
in	O
patients	O
with	O
hereditary	O
aniridia	SpecificDisease
.	O
The	O
14	O
exons	O
of	O
the	O
PAX6	O
gene	O
have	O
been	O
analysed	O
exon-by-exon	O
using	O
SSCP	O
in	O
6	O
aniridia	Modifier
families.	O
In	O
each	O
family	O
band	O
shifts	O
were	O
observed	O
on	O
the	O
SSCP	O
gels	O
for	O
only	O
one	O
exon	O
and	O
direct	O
PCR-sequencing	O
revealed	O
mutations	O
in	O
each	O
case.	O
Two	O
mutations	O
involved	O
C--	O
>	O
T	O
transitions	O
in	O
CGAarg	O
codons	O
in	O
exons	O
9	O
and	O
11.	O
Another	O
C--	O
>	O
T	O
transition	O
converted	O
a	O
CAG-glutamine	O
to	O
a	O
TAG-stop	O
in	O
exon	O
7.	O
Small	O
insertions	O
created	O
frameshifts	O
which	O
produced	O
downstream	O
stop	O
codons	O
in	O
another	O
two	O
patients	O
and	O
an	O
A--	O
>	O
T	O
mutation	O
disrupted	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
5	O
in	O
the	O
remaining	O
family.	O
Thus,	O
complete	O
inactivation	O
of	O
the	O
PAX6	O
gene	O
is	O
predicted	O
in	O
all	O
cases.	O
Analysis	O
of	O
other	O
affected	O
members	O
of	O
the	O
families	O
showed	O
that,	O
in	O
each	O
case,	O
all	O
affected	O
individuals	O
carried	O
the	O
same	O
family-specific	O
mutation.	O
One	O
polymorphism	O
was	O
found	O
in	O
exon	O
7.	O
This	O
data	O
strongly	O
supports	O
the	O
candidature	O
of	O
PAX6	O
as	O
the	O
gene	O
responsible	O
for	O
hereditary	O
aniridia	SpecificDisease

Locus	O
heterogeneity	O
in	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	DiseaseClass
recessive	DiseaseClass
ataxia	DiseaseClass
.	O
The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene,	O
STM7/X25,	O
has	O
been	O
isolated.	O
To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	SpecificDisease
.	O
We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	Modifier
locus.	O
Studying	O
two	O
siblings	O
with	O
FRDA	SpecificDisease
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7/X25.	O
Haplotype	O
analysis	O
of	O
the	O
STM7/X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients.	O
Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	SpecificDisease
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes.	O
In	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
FRDA	SpecificDisease
caused	O
by	O
the	O
second	O
locus,	O
FRDA2,	O
we	O
studied	O
an	O
unrelated	O
FRDA	Modifier
patient	O
with	O
retained	O
tendon	O
reflexes.	O
The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7/X25	O
(GAA	O
expansions)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	SpecificDisease

Haploinsufficiency	CompositeMention
of	CompositeMention
the	CompositeMention
transcription	CompositeMention
factors	CompositeMention
FOXC1	CompositeMention
and	CompositeMention
FOXC2	CompositeMention
results	O
in	O
aberrant	O
ocular	O
development.	O
Anterior	DiseaseClass
segment	DiseaseClass
developmental	DiseaseClass
disorders	DiseaseClass
,	O
including	O
Axenfeld-Rieger	SpecificDisease
anomaly	SpecificDisease
(	O
ARA	SpecificDisease
),	O
variably	O
associate	O
with	O
harmfully	O
elevated	O
intraocular	O
pressure	O
(IOP),	O
which	O
causes	O
glaucoma	SpecificDisease
.	O
Clinically	O
observed	O
dysgenesis	O
does	O
not	O
correlate	O
with	O
IOP,	O
however,	O
and	O
the	O
etiology	O
of	O
glaucoma	Modifier
development	O
is	O
not	O
understood.	O
The	O
forkhead	O
transcription	O
factor	O
genes	O
Foxc1	O
(formerly	O
Mf1)	O
and	O
Foxc2	O
(formerly	O
Mfh1)	O
are	O
expressed	O
in	O
the	O
mesenchyme	O
from	O
which	O
the	O
ocular	O
drainage	O
structures	O
derive.	O
Mutations	O
in	O
the	O
human	O
homolog	O
of	O
Foxc1,	O
FKHL7,	O
cause	O
dominant	O
anterior	DiseaseClass
segment	DiseaseClass
defects	DiseaseClass
and	O
glaucoma	SpecificDisease
in	O
various	O
families.	O
We	O
show	O
that	O
Foxc1	O
(+/-)	O
mice	O
have	O
anterior	DiseaseClass
segment	DiseaseClass
abnormalities	DiseaseClass
similar	O
to	O
those	O
reported	O
in	O
human	O
patients.	O
These	O
abnormalities	O
include	O
small	O
or	O
absent	O
Schlemms	O
canal,	O
aberrantly	O
developed	O
trabecular	O
meshwork,	O
iris	SpecificDisease
hypoplasia	SpecificDisease
,	O
severely	O
eccentric	O
pupils	O
and	O
displaced	O
Schwalbes	O
line.	O
The	O
penetrance	O
of	O
clinically	O
obvious	O
abnormalities	O
varies	O
with	O
genetic	O
background.	O
In	O
some	O
affected	O
eyes,	O
collagen	O
bundles	O
were	O
half	O
normal	O
diameter,	O
or	O
collagen	O
and	O
elastic	O
tissue	O
were	O
very	O
sparse.	O
Thus,	O
abnormalities	O
in	O
extracellular	O
matrix	O
synthesis	O
or	O
organization	O
may	O
contribute	O
to	O
development	O
of	O
the	O
ocular	O
phenotypes.	O
Despite	O
the	O
abnormalities	O
in	O
ocular	O
drainage	O
structures	O
in	O
Foxc1	O
(+/-)	O
mice,	O
IOP	O
was	O
normal	O
in	O
almost	O
all	O
mice	O
analyzed,	O
on	O
all	O
genetic	O
backgrounds	O
and	O
at	O
all	O
ages.	O
Similar	O
abnormalities	O
were	O
found	O
in	O
Foxc2	O
(+/-)	O
mice,	O
but	O
no	O
disease-associated	O
mutations	O
were	O
identified	O
in	O
the	O
human	O
homolog	O
FKHL14	O
in	O
32	O
ARA	Modifier
patients.	O
Foxc1	O
(+/-)	O
and	O
Foxc2	O
(+/-)	O
mice	O
are	O
useful	O
models	O
for	O
studying	O
anterior	O
segment	O
development	O
and	O
its	O
anomalies,	O
and	O
may	O
allow	O
identification	O
of	O
genes	O
that	O
interact	O
with	O
Foxc1	O
and	O
Foxc2	O
(or	O
FKHL7	O
and	O
FKHL14)	O
to	O
produce	O
a	O
phenotype	O
with	O
elevated	O
IOP	O
and	O
glaucoma	SpecificDisease

The	O
dermatofibrosarcoma	Modifier
protuberans	Modifier
-associated	O
collagen	O
type	O
Ialpha1/platelet-derived	O
growth	O
factor	O
(PDGF)	O
B-chain	O
fusion	O
gene	O
generates	O
a	O
transforming	O
protein	O
that	O
is	O
processed	O
to	O
functional	O
PDGF-BB.	O
Dermatofibrosarcoma	SpecificDisease
protuberans	SpecificDisease
(	O
DFSP	SpecificDisease
)	O
displays	O
chromosomal	O
rearrangements	O
involving	O
chromosome	O
17	O
and	O
22,	O
which	O
fuse	O
the	O
collagen	O
type	O
Ialpha1	O
(COLIA1)	O
gene	O
to	O
the	O
platelet-derived	O
growth	O
factor	O
(PDGF)	O
B-chain	O
(PDGFB)	O
gene.	O
To	O
characterize	O
the	O
functional	O
and	O
structural	O
properties	O
of	O
the	O
COLIA1/PDGFB	O
fusion	O
protein,	O
we	O
generated	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
contained	O
a	O
tumor-derived	O
chimeric	O
gene	O
resulting	O
from	O
a	O
COIA1	O
intron	O
7-PDGFB	O
intron	O
1	O
fusion.	O
Expression	O
of	O
the	O
fusion	O
protein	O
led	O
to	O
morphological	O
transformation	O
and	O
increased	O
growth	O
rate	O
of	O
these	O
cells.	O
The	O
PDGF	O
receptor	O
kinase	O
inhibitor	O
CGP57148B	O
reversed	O
the	O
transformed	O
phenotype	O
and	O
reduced	O
the	O
growth	O
rate	O
of	O
COLIA1/PDGFB-expressing	O
cells	O
but	O
had	O
no	O
effects	O
on	O
control	O
cells.	O
The	O
presence	O
of	O
dimeric	O
COLIA1/PDGFB	O
precursors	O
was	O
demonstrated	O
through	O
PDGFB	O
immunoprecipitations	O
of	O
metabolically	O
labeled	O
cells	O
and	O
also	O
by	O
PDGFB	O
immunoprecipitations	O
followed	O
by	O
immunoblotting	O
with	O
COLIA1	O
antibodies.	O
Pulse-chase	O
studies	O
demonstrated	O
that	O
the	O
COLIA1/PDGFB	O
precursor	O
was	O
processed	O
to	O
an	O
end	O
product	O
that	O
was	O
indistinguishable	O
from	O
wild-type	O
PDGF-BB.	O
Finally,	O
COLIA1/PDGFB-expressing	O
cells	O
generated	O
tumors	DiseaseClass
after	O
s.	O
c	O
c.	O
injection	O
into	O
nude	O
mice,	O
and	O
tumor	Modifier
growth	O
was	O
reduced	O
by	O
treatment	O
with	O
CGP57148B.	O
We	O
conclude	O
that	O
the	O
COLIA1/PDGFB	O
fusion	O
associated	O
with	O
DFSP	SpecificDisease
contributes	O
to	O
tumor	Modifier
development	O
through	O
ectopic	O
production	O
of	O
PDGF-BB	O
and	O
the	O
formation	O
of	O
an	O
autocrine	O
loop.	O
Our	O
findings,	O
thus,	O
suggest	O
that	O
PDGF	O
receptors	O
could	O
be	O
a	O
target	O
for	O
pharmacological	O
treatment	O
of	O
DFSP	SpecificDisease
and	O
giant	SpecificDisease
cell	SpecificDisease
fibroblastoma	SpecificDisease

Founder	O
effect	O
of	O
a	O
prevalent	O
phenylketonuria	Modifier
mutation	O
in	O
the	O
Oriental	O
population.	O
A	O
missense	O
mutation	O
has	O
been	O
identified	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
[PAH;	O
phenylalanine	O
4-monooxygenase;	O
L-phenylalanine,	O
tetrahydrobiopterin	O
	O
oxygen	O
oxidoreductase	O
(4-hydroxylating),	O
EC	O
1.	O
14.	O
16.	O
1]	O
gene	O
in	O
a	O
Chinese	O
patient	O
with	O
classic	O
phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
).	O
A	O
G-to-C	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
413	O
in	O
exon	O
12	O
of	O
the	O
gene	O
results	O
in	O
the	O
substitution	O
of	O
Pro413	O
for	O
Arg413	O
in	O
the	O
mutant	O
protein.	O
This	O
mutation	O
(R413P)	O
results	O
in	O
negligible	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
heterologous	O
mammalian	O
cells	O
and	O
is	O
compatible	O
with	O
a	O
classic	O
PKU	Modifier
phenotype	O
in	O
the	O
patient.	O
Population	O
genetic	O
studies	O
reveal	O
that	O
this	O
mutation	O
is	O
tightly	O
linked	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
haplotype	O
4,	O
which	O
is	O
the	O
predominant	O
haplotype	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
Oriental	O
population.	O
It	O
accounts	O
for	O
13.	O
8%	O
of	O
northern	O
Chinese	O
and	O
27%	O
of	O
Japanese	O
PKU	Modifier
alleles,	O
but	O
it	O
is	O
rare	O
in	O
southern	O
Chinese	O
(2.	O
2%)	O
and	O
is	O
absent	O
in	O
the	O
Caucasian	O
population.	O
The	O
data	O
demonstrate	O
unambiguously	O
that	O
the	O
mutation	O
occurred	O
after	O
racial	O
divergence	O
of	O
Orientals	O
and	O
Caucasians	O
and	O
suggest	O
that	O
the	O
allele	O
has	O
spread	O
throughout	O
the	O
Orient	O
by	O
a	O
founder	O
effect.	O
Previous	O
protein	O
polymorphism	O
studies	O
in	O
eastern	O
Asia	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
"	O
northern	O
Mongoloids	O
"	O
represented	O
a	O
founding	O
population	O
in	O
Asia.	O
Our	O
results	O
are	O
compatible	O
with	O
this	O
hypothesis	O
in	O
that	O
the	O
PKU	Modifier

Late-onset	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
):	O
a	O
subset	O
with	O
distinct	O
clinical,	O
demographic,	O
and	O
molecular	O
genetic	O
characteristics.	O
To	O
determine	O
the	O
prevalence	O
and	O
characterize	O
demographic,	O
clinical,	O
and	O
genetic	O
features	O
of	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
FMF	SpecificDisease
)	O
of	O
late	O
onset,	O
all	O
patients	O
experiencing	O
their	O
first	O
FMF	Modifier
attack	O
at	O
age	O
40	O
years	O
or	O
more	O
were	O
identified	O
using	O
the	O
computerized	O
registry	O
of	O
our	O
FMF	Modifier
clinic,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined.	O
The	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
FMF	Modifier
patients,	O
who	O
arrived	O
at	O
the	O
FMF	Modifier
clinic	O
for	O
their	O
regular	O
follow-up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination.	O
The	O
severity	O
of	O
the	O
disease	O
in	O
patients	O
and	O
controls	O
was	O
determined	O
using	O
a	O
modified	O
score,	O
developed	O
previously.	O
Mutational	O
analysis	O
in	O
the	O
FMF	Modifier
gene	O
was	O
performed	O
using	O
a	O
commercial	O
kit.	O
Only	O
20	O
of	O
4000	O
(0.	O
5%)	O
patients	O
had	O
late-onset	O
FMF	SpecificDisease
.	O
These	O
patients	O
were	O
mostly	O
men,	O
of	O
non-North	O
African	O
origin,	O
P	O
<	O
0.	O
05	O
compared	O
to	O
controls.	O
All	O
had	O
abdominal	O
attacks	O
and	O
in	O
most	O
these	O
were	O
the	O
only	O
manifestation	O
of	O
their	O
disease,	O
P	O
<	O
0.	O
001	O
001.	O
None	O
had	O
chronic	O
or	O
prolonged	O
manifestations	O
of	O
FMF	SpecificDisease
,	O
for	O
example,	O
amyloidosis	SpecificDisease
,	O
chronic	SpecificDisease
arthritis	SpecificDisease
,	O
or	O
protracted	O
myalgia	SpecificDisease
,	O
P	O
<	O
0.	O
001.	O
The	O
response	O
to	O
treatment	O
was	O
good	O
despite	O
using	O
low	O
colchicine	O
dose,	O
P	O
<	O
0.	O
05.	O
The	O
overall	O
severity	O
score	O
indicated	O
a	O
mild	O
disease,	O
P	O
<	O
0.	O
001.	O
Mutational	O
analysis	O
revealed	O
absence	O
of	O
M694V	O
homozygosity,	O
P	O
<	O
0.	O
01,	O
compared	O
to	O
our	O
regular	O
FMF	Modifier
population.	O
We	O
conclude	O
that	O
the	O
onset	O
of	O
FMF	SpecificDisease

Structure	O
of	O
the	O
human	O
Na+/glucose	O
cotransporter	O
gene	O
SGLT1.	O
Intestinal	O
uptake	O
of	O
dietary	O
glucose	O
and	O
galactose	O
is	O
mediated	O
by	O
the	O
SGLT1	O
Na	O
+/glucose	O
cotransporter	O
of	O
the	O
brush	O
border.	O
An	O
SGLT1	O
missense	O
mutation	O
underlies	O
hereditary	SpecificDisease
glucose/galactose	SpecificDisease
malabsorption	SpecificDisease
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	SpecificDisease
;	O
conversely,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life-threatening	O
diarrhea	SpecificDisease
of	O
infectious	O
origin.	O
We	O
have	O
mapped	O
the	O
entire	O
human	O
SGLT1	O
Na	O
+/glucose	O
cotransporter	O
gene	O
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	O
region	O
of	O
112	O
kilobases.	O
Transcription	O
initiation	O
occurred	O
from	O
a	O
site	O
27	O
base	O
pairs	O
3	O
of	O
a	O
TATAA	O
sequence.	O
All	O
exon-flanking	O
regions	O
were	O
sequenced,	O
and	O
the	O
entire	O
112-kilobase	O
region	O
mapped	O
with	O
four	O
restriction	O
enzymes.	O
SGLT1	O
is	O
comprised	O
of	O
15	O
exons	O
(spanning	O
72	O
kilobases);	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six-membrane-span	O
ancestral	O
precursor	O
via	O
a	O
gene	O
duplication	O
event	O
is	O
suggested	O
from	O
comparison	O
of	O
exons	O
against	O
protein	O
secondary	O
structure	O
and	O
from	O
sequence	O
considerations.	O
A	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose/galactose	SpecificDisease
malabsorption	SpecificDisease
is	O
also	O
described.	O
This	O
is	O
the	O
first	O
Na	O
(+)	O
-dependent	O
cotransporter	O
gene	O
structure	O
reported.	O
These	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose/galactose	Modifier
malabsorption	Modifier

ATM	O
phosphorylates	O
p95/nbs1	O
in	O
an	O
S-phase	O
checkpoint	O
pathway.	O
The	O
rare	DiseaseClass
diseases	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
AT	SpecificDisease
),	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene,	O
and	O
Nijmegen	SpecificDisease
breakage	SpecificDisease
syndrome	SpecificDisease
(	O
NBS	SpecificDisease
),	O
with	O
mutations	O
in	O
the	O
p95/nbs1	O
gene,	O
share	O
a	O
variety	O
of	O
phenotypic	DiseaseClass
abnormalities	DiseaseClass
such	O
as	O
chromosomal	DiseaseClass
instability	DiseaseClass
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell-cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation.	O
The	O
ATM	O
gene	O
encodes	O
a	O
protein	O
kinase	O
that	O
is	O
activated	O
by	O
ionizing	O
radiation	O
or	O
radiomimetic	O
drugs,	O
whereas	O
p95/nbs1	O
is	O
part	O
of	O
a	O
protein	O
complex	O
that	O
is	O
involved	O
in	O
responses	O
to	O
DNA	O
double-strand	O
breaks.	O
Here,	O
because	O
of	O
the	O
similarities	O
between	O
AT	SpecificDisease
and	O
NBS	SpecificDisease
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
ATM	O
and	O
p95/nbs1.	O
Activation	O
of	O
the	O
ATM	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
ATM-dependent	O
responses	O
in	O
NBS	Modifier
cells	O
indicated	O
that	O
p95/nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
ATM	O
after	O
ionizing	O
radiation.	O
However,	O
p95/nbs1	O
was	O
phosphorylated	O
on	O
serine	O
343	O
in	O
an	O
ATM-dependent	O
manner	O
in	O
vitro	O
and	O
in	O
vivo	O
after	O
ionizing	O
radiation.	O
A	O
p95/nbs1	O
construct	O
mutated	O
at	O
the	O
ATM	O
phosphorylation	O
site	O
abrogated	O
an	O
S-phase	O
checkpoint	O
induced	O
by	O
ionizing	O
radiation	O
in	O
normal	O
cells	O
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	O
in	O
NBS	Modifier

Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	SpecificDisease
.	O
Classical	SpecificDisease
phenylketonuria	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
hepatic	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	O
gene	O
(exon	O
7)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(272gly----stop	O
and	O
273ser----phe,	O
respectively).	O
Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles.	O
The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	SpecificDisease
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	SpecificDisease
deficiencies	SpecificDisease

Functional	O
link	O
between	O
ataxia-telangiectasia	Modifier
and	O
Nijmegen	Modifier
breakage	Modifier
syndrome	Modifier
gene	O
products.	O
Ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
)	O
and	O
Nijmegen	SpecificDisease
breakage	SpecificDisease
syndrome	SpecificDisease
(	O
NBS	SpecificDisease
)	O
are	O
recessive	DiseaseClass
genetic	DiseaseClass
disorders	DiseaseClass
with	O
susceptibility	O
to	O
cancer	DiseaseClass
and	O
similar	O
cellular	O
phenotypes.	O
The	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
A-T	SpecificDisease
,	O
designated	O
ATM,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy-terminal	O
phosphatidylinositol	O
3-kinase-like	O
domain.	O
The	O
NBS1	O
protein	O
is	O
specifically	O
mutated	O
in	O
patients	O
with	O
Nijmegen	SpecificDisease
breakage	SpecificDisease
syndrome	SpecificDisease
and	O
forms	O
a	O
complex	O
with	O
the	O
DNA	O
repair	O
proteins	O
Rad50	O
and	O
Mrel1.	O
Here	O
we	O
show	O
that	O
phosphorylation	O
of	O
NBS1,	O
induced	O
by	O
ionizing	O
radiation,	O
requires	O
catalytically	O
active	O
ATM.	O
Complexes	O
containing	O
ATM	O
and	O
NBS1	O
exist	O
in	O
vivo	O
in	O
both	O
untreated	O
cells	O
and	O
cells	O
treated	O
with	O
ionizing	O
radiation.	O
We	O
have	O
identified	O
two	O
residues	O
of	O
NBS1,	O
Ser	O
278	O
and	O
Ser	O
343	O
that	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
ATM	O
and	O
whose	O
modification	O
in	O
vivo	O
is	O
essential	O
for	O
the	O
cellular	O
response	O
to	O
DNA	O
damage.	O
This	O
response	O
includes	O
S-phase	O
checkpoint	O
activation,	O
formation	O
of	O
the	O
NBS1/Mrel1/Rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	DiseaseClass
to	DiseaseClass
ionizing	DiseaseClass
radiation	DiseaseClass
.	O
Together,	O
these	O
results	O
demonstrate	O
a	O
biochemical	O
link	O
between	O
cell-cycle	O
checkpoints	O
activated	O
by	O
DNA	O
damage	O
and	O
DNA	O
repair	O
in	O
two	O
genetic	DiseaseClass
diseases	DiseaseClass

Structure	O
and	O
genomic	O
sequence	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
kinase)	O
gene.	O
The	O
mutation	O
causing	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
CTG	O
trinucleotide	O
repeat	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
protein	O
with	O
putative	O
serine-threonine	O
protein	O
kinase	O
activity.	O
In	O
this	O
report	O
we	O
present	O
the	O
genomic	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
DM	Modifier
kinase	O
gene.	O
A	O
comparison	O
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cDNA	O
sequences	O
from	O
both	O
species,	O
led	O
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon,	O
as	O
well	O
as	O
determine	O
the	O
organization	O
of	O
the	O
DM	Modifier
kinase	O
gene.	O
Several	O
polymorphisms	O
within	O
the	O
human	O
DM	Modifier
kinase	O
gene	O
have	O
been	O
identified,	O
and	O
PCR	O
assays	O
to	O
detect	O
two	O
of	O
these	O
are	O
described.	O
The	O
complete	O
sequence	O
and	O
characterization	O
of	O
the	O
structure	O
of	O
the	O
DM	Modifier
kinase	O
gene,	O
as	O
well	O
as	O
the	O
identification	O
of	O
novel	O
polymorphisms	O
within	O
the	O
gene,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	O
of	O
the	O
genetics	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease

Identification	O
of	O
novel	O
imprinted	O
transcripts	O
in	O
the	O
Prader-Willi	Modifier
syndrome	Modifier
and	O
Angelman	Modifier
syndrome	Modifier
deletion	O
region:	O
further	O
evidence	O
for	O
regional	O
imprinting	O
control.	O
Deletions	O
and	O
other	O
abnormalities	O
of	O
human	O
chromosome	O
15q11-q13	O
are	O
associated	O
with	O
two	O
developmental	O
disorders,	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
and	O
Angelman	SpecificDisease
syndrome	SpecificDisease
(	O
AS	SpecificDisease
).	O
Loss	O
of	O
expression	O
of	O
imprinted,	O
paternally	O
expressed	O
genes	O
has	O
been	O
implicated	O
in	O
PWS	SpecificDisease
.	O
However,	O
the	O
number	O
of	O
imprinted	O
genes	O
that	O
contribute	O
to	O
PWS	SpecificDisease
,	O
and	O
the	O
range	O
over	O
which	O
the	O
imprinting	O
signal	O
acts	O
to	O
silence	O
one	O
copy	O
of	O
the	O
gene	O
in	O
a	O
parent-of-origin-specific	O
manner,	O
are	O
unknown.	O
To	O
identify	O
additional	O
imprinted	O
genes	O
that	O
could	O
contribute	O
to	O
the	O
PWS	Modifier

Penetrances	O
of	O
BRCA1	O
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	SpecificDisease
cancer	SpecificDisease
and	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
For	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	CompositeMention
breast-ovarian	CompositeMention
cancer	CompositeMention
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known.	O
We	O
have	O
previously	O
reported	O
two	O
BRCA1	O
founder	O
mutations	O
in	O
the	O
Norwegian	O
population.	O
Index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	SpecificDisease
cancers	SpecificDisease
(n	O
=	O
16)	O
and	O
through	O
our	O
family	O
cancer	Modifier
clinic	O
(n	O
=	O
14).	O
Altogether,	O
20	O
of	O
the	O
patients	O
had	O
BRCA1	O
1675delA,	O
and	O
10	O
had	O
1135insA.	O
Their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence/presence	O
of	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
Of	O
133	O
living	O
female	O
relatives,	O
83	O
(62%)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
a	O
mutation.	O
No	O
difference,	O
in	O
penetrance	O
and	O
expression,	O
between	O
the	O
two	O
mutations	O
were	O
found,	O
whereas	O
differences	O
according	O
to	O
method	O
of	O
ascertainment	O
were	O
seen.	O
The	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48%	O
of	O
the	O
mutation-carrying	O
women	O
had	O
experienced	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
More	O
ovarian	SpecificDisease
cancers	SpecificDisease
than	O
breast	SpecificDisease
cancers	SpecificDisease
were	O
recorded.	O
Both	O
penetrance	O
and	O
expression	O
(	O
breast	SpecificDisease
cancer	SpecificDisease
vs.	O
ovarian	SpecificDisease
cancer	SpecificDisease

Molecular	O
basis	O
of	O
subtotal	SpecificDisease
complement	SpecificDisease
C6	SpecificDisease
deficiency	SpecificDisease
.	O
A	O
carboxy-terminally	O
truncated	O
but	O
functionally	O
active	O
C6.	O
Individuals	O
with	O
subtotal	SpecificDisease
complement	SpecificDisease
C6	SpecificDisease
deficiency	SpecificDisease
possess	O
a	O
C6	O
molecule	O
that	O
is	O
14%	O
shorter	O
than	O
normal	O
C6	O
and	O
present	O
in	O
low	O
but	O
detectable	O
concentrations	O
(1-2%	O
of	O
the	O
normal	O
mean).	O
We	O
now	O
show	O
that	O
this	O
dysmorphic	O
C6	O
is	O
bactericidally	O
active	O
and	O
lacks	O
an	O
epitope	O
that	O
was	O
mapped	O
to	O
the	O
most	O
carboxy-terminal	O
part	O
of	O
C6	O
using	O
C6	O
cDNA	O
fragments	O
expressed	O
as	O
fusion	O
proteins	O
in	O
the	O
pUEX	O
expression	O
system.	O
We	O
thus	O
predicted	O
that	O
the	O
abnormal	O
C6	O
molecule	O
might	O
be	O
carboxy-terminally	O
truncated	O
and	O
sought	O
a	O
mutation	O
in	O
an	O
area	O
approximately	O
14%	O
from	O
the	O
carboxy-terminal	O
end	O
of	O
the	O
coding	O
sequence.	O
By	O
sequencing	O
PCR-amplified	O
products	O
from	O
this	O
region,	O
we	O
found,	O
in	O
three	O
individuals	O
from	O
two	O
families,	O
a	O
mutation	O
that	O
might	O
plausibly	O
be	O
responsible	O
for	O
the	O
defect.	O
All	O
three	O
have	O
an	O
abnormal	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15,	O
which	O
would	O
probably	O
prevent	O
splicing.	O
An	O
in-frame	O
stop	O
codon	O
is	O
found	O
17	O
codons	O
downstream	O
from	O
the	O
intron	O
boundary,	O
which	O
would	O
lead	O
to	O
a	O
truncated	O
polypeptide	O
13.	O
5%	O
smaller	O
than	O
normal	O
C6.	O
This	O
result	O
was	O
unexpected,	O
as	O
earlier	O
studies	O
mapped	O
the	O
C5b	O
binding	O
site,	O
or	O
a	O
putative	O
enzymatic	O
region,	O
to	O
this	O
part	O
of	O
C6.	O
Interestingly,	O
all	O
three	O
subjects	O
were	O
probably	O
heterozygous	O
for	O
both	O
subtotal	CompositeMention
C6	CompositeMention
and	CompositeMention
complete	CompositeMention
C6	CompositeMention
deficiency	CompositeMention

Mutations	O
of	O
the	O
VHL	Modifier
gene	O
in	O
sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
:	O
definition	O
of	O
a	O
risk	O
factor	O
for	O
VHL	Modifier
patients	O
to	O
develop	O
an	O
RCC	SpecificDisease
.	O
To	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	Modifier
Hippel-Lindau	Modifier
(	O
VHL	Modifier
)	O
mutations,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
for	O
mutations	O
of	O
the	O
VHL	Modifier
tumor	Modifier
suppressor	O
gene,	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
single-strand	O
conformational	O
polymorphism	O
analysis	O
(SSCP)	O
of	O
DNA.	O
We	O
detected	O
abnormal	O
SSCP	O
pattern	O
in	O
73	O
samples.	O
After	O
sequencing,	O
we	O
identified	O
microdeletions	O
in	O
58%	O
of	O
cases,	O
microinsertions	O
in	O
17%,	O
nonsense	O
mutations	O
in	O
8%,	O
and	O
missense	O
mutations	O
in	O
17%.	O
Among	O
these	O
mutations,	O
50%	O
correspond	O
to	O
new	O
mutations.	O
VHL	Modifier
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	Modifier
renal	Modifier
cell	Modifier
carcinoma	Modifier
(	O
RCC	Modifier
)	O
subtype,	O
as	O
previously	O
reported.	O
To	O
compare	O
somatic	O
and	O
germline	O
mutations,	O
we	O
used	O
the	O
VHL	Modifier
database,	O
which	O
includes	O
507	O
mutations.	O
The	O
study	O
of	O
mutational	O
events	O
revealed	O
a	O
significant	O
difference	O
between	O
somatic	O
and	O
germline	O
mutations	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
observed	O
in	O
78%	O
of	O
somatic	O
mutations	O
vs	O
only	O
37%	O
in	O
germline	O
mutations	O
(P	O
<	O
0.	O
001).	O
We	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
VHL	Modifier
mutations	O
is	O
associated	O
with	O
sporadic	SpecificDisease
RCC	SpecificDisease
.	O
This	O
pattern	O
corresponds	O
to	O
mutations	O
leading	O
mainly	O
to	O
truncated	O
proteins	O
with	O
few	O
specific	O
missense	O
mutations.	O
We	O
then	O
analyzed	O
the	O
occurrence	O
of	O
RCC	SpecificDisease
in	O
VHL	Modifier
families,	O
based	O
on	O
the	O
nature	O
of	O
mutations.	O
We	O
observed	O
RCC	SpecificDisease
in	O
at	O
least	O
one	O
member	O
of	O
the	O
VHL	Modifier
families	O
in	O
77%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55%	O
in	O
cases	O
with	O
missense	O
mutations	O
(P	O
<	O
0.	O
05).	O
Thus,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
RCC	SpecificDisease
in	O
VHL	Modifier

Myotonic	SpecificDisease
dystrophy	SpecificDisease
:	O
the	O
role	O
of	O
the	O
CUG	O
triplet	O
repeats	O
in	O
splicing	O
of	O
a	O
novel	O
DMPK	O
exon	O
and	O
altered	O
cytoplasmic	O
DMPK	O
mRNA	O
isoform	O
ratios.	O
The	O
mechanism	O
by	O
which	O
(CTG)	O
n	O
expansion	O
in	O
the	O
3	O
UTR	O
of	O
the	O
DMPK	O
gene	O
causes	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
unknown.	O
We	O
identified	O
four	O
RNA	O
splicing	O
factors--hnRNP	O
C,	O
U2AF	O
(U2	O
auxiliary	O
factor),	O
PTB	O
(polypyrimidine	O
tract	O
binding	O
protein),	O
and	O
PSF	O
(PTB	O
associated	O
splicing	O
factor)	O
--that	O
bind	O
to	O
two	O
short	O
regions	O
3	O
of	O
the	O
(CUG)	O
n,	O
and	O
found	O
a	O
novel	O
3	O
DMPK	O
exon	O
resulting	O
in	O
an	O
mRNA	O
lacking	O
the	O
repeats.	O
We	O
propose	O
that	O
the	O
(CUG)	O
n	O
is	O
an	O
essential	O
cis	O
acting	O
element	O
for	O
this	O
splicing	O
event.	O
In	O
contrast	O
to	O
(CUG)	O
n	O
containing	O
mRNAs,	O
the	O
novel	O
isoform	O
is	O
not	O
retained	O
in	O
the	O
nucleus	O
in	O
DM	Modifier

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1.	O
Hereditary	SpecificDisease
hemochromatosis	SpecificDisease
(	O
HH	SpecificDisease
)	O
is	O
a	O
common	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption.	O
We	O
recently	O
reported	O
that	O
HFE,	O
the	O
protein	O
defective	O
in	O
HH	SpecificDisease
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(TfR)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
HFE	O
attenuate	O
the	O
uptake	O
of	O
transferrin-bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells,	O
leading	O
to	O
up-regulation	O
of	O
transporters	O
for	O
dietary	O
iron.	O
Here,	O
we	O
tested	O
the	O
hypothesis	O
that	O
HFE-/-	O
mice	O
have	O
increased	O
duodenal	O
expression	O
of	O
the	O
divalent	O
metal	O
transporter	O
(DMT1).	O
By	O
4	O
weeks	O
of	O
age,	O
the	O
HFE-/-	O
mice	O
demonstrated	O
iron	O
loading	O
when	O
compared	O
with	O
HFE	O
+/+	O
littermates,	O
with	O
elevated	O
transferrin	O
saturations	O
(68.	O
4%	O
vs.	O
49.	O
8%)	O
and	O
elevated	O
liver	O
iron	O
concentrations	O
(985	O
micrograms	O
vs.	O
381	O
micrograms).	O
By	O
using	O
Northern	O
blot	O
analyses,	O
we	O
quantitated	O
duodenal	O
expression	O
of	O
both	O
classes	O
of	O
DMT1	O
transcripts	O
	O
one	O
containing	O
an	O
iron	O
responsive	O
element	O
(IRE),	O
called	O
DMT1	O
(IRE),	O
and	O
one	O
containing	O
no	O
IRE,	O
called	O
DMT1	O
(non-IRE).	O
The	O
positive	O
control	O
for	O
DMT1	O
up-regulation	O
was	O
a	O
murine	O
model	O
of	O
dietary	SpecificDisease
iron	SpecificDisease
deficiency	SpecificDisease

Yeast	O
artificial	O
chromosomes	O
for	O
the	O
molecular	O
analysis	O
of	O
the	O
familial	Modifier
polyposis	Modifier
APC	Modifier
gene	O
region.	O
Two	O
yeast	O
artificial	O
chromosomes	O
(YACs)	O
spanning	O
a	O
total	O
distance	O
of	O
1.	O
1	O
megabase	O
pairs	O
of	O
DNA	O
around	O
the	O
MCC	O
(for	O
mutated	O
in	O
colorectal	SpecificDisease
carcinoma	SpecificDisease
)	O
and	O
APC	Modifier
(for	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
)	O
genes	O
at	O
5q21	O
have	O
been	O
isolated	O
and	O
characterized.	O
Starting	O
from	O
the	O
MCC	O
gene,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	O
constitutional	O
submicroscopic	O
deletions	O
in	O
familial	Modifier
adenomatous	Modifier
polyposis	Modifier
patients	O
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	O
of	O
the	O
APC	Modifier
gene.	O
To	O
this	O
end,	O
YACs	O
identified	O
by	O
the	O
MCC	O
gene	O
were	O
screened	O
across	O
a	O
chromosome	O
5-specific	O
cosmid	O
library	O
to	O
provide	O
a	O
source	O
of	O
DNA	O
probes	O
for	O
genomic	O
scanning.	O
The	O
cosmids	O
isolated	O
from	O
these	O
experiments	O
were	O
used	O
to	O
screen	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
containing	O
chromosome	O
5	O
segregated	O
from	O
patients	O
suspected	O
to	O
carry	O
putative	O
interstitial	O
deletions.	O
This	O
screening	O
approach	O
led	O
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	O
deletion	O
in	O
a	O
polyposis	Modifier
patient	O
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	O
YACs.	O
This	O
YAC	O
has	O
been	O
shown	O
to	O
contain	O
the	O
entire	O
APC	Modifier
gene,	O
in	O
addition	O
to	O
a	O
significant	O
portion	O
of	O
DNA	O
flanking	O
the	O
5	O
end	O
of	O
the	O
gene,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	O
by	O
transfer	O
to	O
colorectal	Modifier
tumor	Modifier

Analbuminemia	SpecificDisease
in	O
an	O
American	O
Indian	O
girl.	O
Analbuminemia	SpecificDisease
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12-year-old	O
American	O
Indian	O
girl	O
with	O
atopic	SpecificDisease
dermatitis	SpecificDisease
,	O
mild	O
bronchial	SpecificDisease
asthma	SpecificDisease
,	O
a	O
mild	O
seizure	SpecificDisease
disorder	SpecificDisease
,	O
and	O
hyperlipoproteinemia	SpecificDisease
with	O
a	O
corneal	SpecificDisease
arcus	SpecificDisease
.	O
Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(17	O
mg/100	O
ml)	O
of	O
apparently	O
normal	O
serum	O
albumin.	O
The	O
patients	O
parents	O
were	O
remotely	O
related.	O
The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	SpecificDisease
.	O
Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin.	O
The	O
Gc-locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus.	O
Gc-protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	SpecificDisease
.	O
Gc-types	O
in	O
the	O
family	O
were	O
compatible	O
with,	O
but	O
did	O
not	O
prove,	O
linkage	O
of	O
analbuminemia	SpecificDisease
to	O
the	O
Gc-locus.	O
These	O
findings	O
suggest	O
a	O
"	O
thalassemia	Modifier

Treatment	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
with	O
growth	O
hormone	O
inhibitors.	O
A	O
controlled,	O
double-blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol,	O
a	O
growth	O
hormone	O
inhibitor,	O
was	O
performed	O
in	O
a	O
pair	O
of	O
7	O
1/2	O
year-old	O
monozygotic	O
twins,	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
The	O
rationale	O
for	O
this	O
trial	O
was	O
based	O
on	O
a	O
patient	O
(reported	O
previously)	O
affected	O
simultaneously	O
with	O
DMD	SpecificDisease
and	O
growth	SpecificDisease
hormone	SpecificDisease
(GH)	SpecificDisease
deficiency	SpecificDisease
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	DiseaseClass
process	DiseaseClass
and	O
is	O
still	O
walking	O
at	O
18	O
years.	O
One	O
of	O
the	O
twins	O
received	O
2	O
mg	O
of	O
mazindol	O
daily,	O
while	O
the	O
other	O
received	O
a	O
placebo.	O
The	O
assessment,	O
repeated	O
every	O
2	O
months,	O
included	O
weight	O
and	O
height	O
measurements,	O
functional	O
and	O
motor	O
ability	O
tests,	O
ergometry	O
and	O
determinations	O
of	O
serum	O
enzymes	O
and	O
GH	O
levels.	O
After	O
one	O
year	O
of	O
trial	O
the	O
code	O
was	O
broken	O
and	O
it	O
was	O
seen	O
that	O
the	O
twin	O
under	O
placebo	O
treatment	O
was	O
strikingly	O
worse	O
than	O
his	O
brother,	O
the	O
progression	O
of	O
whose	O
condition	O
was	O
practically	O
arrested.	O
These	O
results	O
strongly	O
suggest	O
that	O
treatment	O
with	O
a	O
GH	O
inhibitor	O
is	O
beneficial	O
for	O
DMD	Modifier

Identification	O
of	O
WASP	O
mutations	O
in	O
patients	O
with	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
and	O
isolated	SpecificDisease
thrombocytopenia	SpecificDisease
reveals	O
allelic	O
heterogeneity	O
at	O
the	O
WAS	Modifier
locus.	O
Mutation	O
in	O
the	O
gene	O
encoding	O
the	O
recently	O
isolated	O
WASP	O
protein	O
has	O
now	O
been	O
identified	O
as	O
the	O
genetic	DiseaseClass
defect	DiseaseClass
responsible	O
for	O
the	O
X-linked	SpecificDisease
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
),	O
a	O
primary	O
immunodeficiency	DiseaseClass
disease	DiseaseClass
associated	O
with	O
extensive	O
phenotypic	O
variability.	O
To	O
elucidate	O
the	O
range	O
of	O
WASP	O
mutations	O
responsible	O
for	O
WAS	SpecificDisease
,	O
we	O
used	O
PCR-SSCP	O
analysis	O
to	O
screen	O
for	O
WASP	O
gene	O
mutation	O
in	O
19	O
unrelated	O
boys	O
with	O
the	O
diagnosis	O
of	O
classical	O
or	O
attenuated	O
WAS	SpecificDisease
or	O
isolated	SpecificDisease
thrombocytopenia	SpecificDisease
.	O
All	O
19	O
patients	O
had	O
WASP	O
mutations,	O
each	O
of	O
which	O
localized	O
to	O
the	O
initial	O
three	O
or	O
terminal	O
three	O
exons	O
of	O
the	O
gene,	O
and	O
the	O
majority	O
of	O
which	O
were	O
unique	O
in	O
each	O
case.	O
However,	O
a	O
missense	O
mutation	O
which	O
results	O
in	O
substitution	O
of	O
the	O
arginine	O
at	O
WAS	Modifier
codon	O
86	O
was	O
identified	O
in	O
three	O
boys	O
with	O
severe	O
WAS	SpecificDisease
as	O
well	O
as	O
in	O
one	O
boy	O
presenting	O
with	O
thrombocytopenia	SpecificDisease
alone.	O
While	O
the	O
three	O
mutations	O
found	O
in	O
the	O
isolated	Modifier
thrombocytopenia	Modifier
patients	O
leave	O
the	O
reading	O
frame	O
intact,	O
about	O
one-half	O
of	O
the	O
gene	O
alterations	O
detected	O
in	O
both	O
severe	O
and	O
attenuated	O
WAS	SpecificDisease
patients	O
result	O
in	O
frameshifted	O
transcript	O
and	O
premature	O
translation	O
termination.	O
These	O
findings	O
therefore	O
confirm	O
the	O
association	O
of	O
WAS	SpecificDisease
with	O
WASP	O
mutation	O
and	O
identify	O
WASP	O
mutation	O
as	O
a	O
cause	O
for	O
isolated	O
congenital	SpecificDisease
thrombocytopenia	SpecificDisease
in	O
males.	O
While	O
the	O
WASP	O
gene	O
defects	O
responsible	O
for	O
isolated	SpecificDisease
thrombocytopenia	SpecificDisease
and	O
other	O
mild	O
presentations	O
of	O
WAS	SpecificDisease
do	O
not	O
appear	O
distinct	O
from	O
those	O
resulting	O
in	O
severe	O
WAS	SpecificDisease
,	O
these	O
data	O
indicate	O
that	O
analysis	O
of	O
WASP	O
gene	O
mutation	O
provides	O
a	O
valuable	O
tool	O
for	O
distinguishing	O
the	O
spectrum	O
of	O
WAS	Modifier
patients	O
and	O
the	O
subset	O
of	O
males	O
with	O
isolated	SpecificDisease
thrombocytopenia	SpecificDisease
who	O
represent	O
mild	O
cases	O
of	O
WAS	SpecificDisease

Huntington	SpecificDisease
disease	SpecificDisease
without	O
CAG	O
expansion:	O
phenocopies	O
or	O
errors	O
in	O
assignment?	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
CAG	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16.	O
3	O
(IT15).	O
A	O
total	O
of	O
30	O
of	O
1,	O
022	O
affected	O
persons	O
(2.	O
9%	O
of	O
our	O
cohort)	O
did	O
not	O
have	O
an	O
expanded	O
CAG	O
in	O
the	O
disease	O
range.	O
The	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
HD	SpecificDisease
.	O
Here	O
we	O
show	O
that	O
the	O
majority	O
(18)	O
of	O
the	O
individuals	O
with	O
normal	O
sized	O
alleles	O
represent	O
misdiagnosis,	O
sample	O
mix-up,	O
or	O
clerical	O
error.	O
The	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
HD	SpecificDisease
.	O
In	O
at	O
least	O
four	O
cases,	O
family	O
studies	O
of	O
these	O
phenocopies	O
excluded	O
4p16.	O
3	O
as	O
the	O
region	O
responsible	O
for	O
the	O
phenotype.	O
Mutations	O
in	O
the	O
HD	Modifier
gene	O
that	O
are	O
other	O
than	O
CAG	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases;	O
however,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
HD	SpecificDisease
.	O
This	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other,	O
as-yet-undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
HD	SpecificDisease

Allelic	O
exclusion	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
T	O
lymphocytes	O
from	O
a	O
Wiskott-Aldrich	Modifier
syndrome	Modifier
carrier.	O
An	O
obligate	O
carrier	O
of	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
who	O
was	O
also	O
heterozygous	O
for	O
the	O
A	O
and	O
B	O
types	O
of	O
X-linked	O
glucose-6-phosphate	O
dehydrogenase	O
was	O
found.	O
With	O
her	O
it	O
became	O
possible	O
to	O
determine	O
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell-types	O
of	O
the	O
WAS	Modifier
carrier.	O
If	O
so,	O
the	O
remaining	O
cells	O
of	O
a	O
particular	O
cell-type	O
would	O
express	O
only	O
the	O
normal	O
X	O
chromosome	O
and	O
only	O
one	O
glucose-6-phosphate	O
dehydrogenase	O
isoenzyme	O
would	O
be	O
demonstrable.	O
This	O
carrier	O
had	O
only	O
the	O
B	O
isoenzyme	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
thymus-derived	O
T	O
lymphocytes,	O
although	O
both	O
isoenzymes	O
A	O
and	O
B	O
were	O
present	O
in	O
erythrocytes	O
and	O
neutrophils.	O
These	O
findings	O
suggest	O
that	O
selection	O
against	O
the	O
WAS	Modifier
gene	O
occurs	O
in	O
platelets	O
and	O
thymus-derived	O
T	O
lymphocytes	O
and	O
that	O
the	O
defects	O
associated	O
with	O
WAS	SpecificDisease
expressed	O
in	O
these	O
cell-types	O
may	O
be	O
implicated	O
in	O
the	O
genesis	O
of	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease

A	O
novel	O
mutation	O
in	O
the	O
sodium/iodide	O
symporter	O
gene	O
in	O
the	O
largest	O
family	O
with	O
iodide	DiseaseClass
transport	DiseaseClass
defect	DiseaseClass
.	O
We	O
previously	O
reported	O
nine	O
children	O
with	O
an	O
autosomally	O
recessive	O
form	O
of	O
congenital	SpecificDisease
hypothyroidism	SpecificDisease
due	O
to	O
an	O
iodide	DiseaseClass
transport	DiseaseClass
defect	DiseaseClass
in	O
a	O
large	O
Hutterite	O
family	O
with	O
extensive	O
consanguinity	O
living	O
in	O
central	O
Canada.	O
Since	O
the	O
original	O
report,	O
we	O
have	O
diagnosed	O
congenital	SpecificDisease
hypothyroidism	SpecificDisease
by	O
newborn	O
TSH	O
screening	O
in	O
9	O
additional	O
children	O
from	O
the	O
family.	O
We	O
performed	O
direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
of	O
each	O
NIS	O
(sodium/iodide	O
symporter)	O
gene	O
exon	O
with	O
flanking	O
introns	O
amplified	O
from	O
genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
cells	O
of	O
the	O
patients.	O
We	O
identified	O
a	O
novel	O
NIS	O
gene	O
mutation,	O
G395R	O
(Gly395--	O
>	O
Arg;	O
GGA--	O
>	O
AGA),	O
in	O
10	O
patients	O
examined	O
in	O
the	O
present	O
study.	O
All	O
of	O
the	O
parents	O
tested	O
were	O
heterozygous	O
for	O
the	O
mutation,	O
suggesting	O
that	O
the	O
patients	O
were	O
homozygous.	O
The	O
mutation	O
was	O
located	O
in	O
the	O
10th	O
transmembrane	O
helix.	O
Expression	O
experiments	O
by	O
transfection	O
of	O
the	O
mutant	O
NIS	O
complimentary	O
DNA	O
into	O
COS-7	O
cells	O
showed	O
no	O
perchlorate-sensitive	O
iodide	O
uptake,	O
confirming	O
that	O
the	O
mutation	O
is	O
the	O
direct	O
cause	O
of	O
the	O
iodide	DiseaseClass
transport	DiseaseClass
defect	DiseaseClass
in	O
these	O
patients.	O
A	O
patient	O
who	O
showed	O
an	O
intermediate	O
saliva/serum	O
technetium	O
ratio	O
(14.	O
0;	O
normal,	O
>	O
or	O
=	O
20)	O
and	O
was	O
considered	O
to	O
have	O
a	O
partial	O
or	O
less	O
severe	O
defect	O
in	O
the	O
previous	O
report	O
(IX-24)	O
did	O
not	O
have	O
a	O
NIS	O
gene	O
mutation.	O
It	O
is	O
now	O
possible	O
to	O
use	O
gene	O
diagnostics	O
of	O
this	O
unique	O
NIS	O
mutation	O
to	O
identify	O
patients	O
with	O
congenital	SpecificDisease
hypothyroidism	SpecificDisease
due	O
to	O
an	O
iodide	DiseaseClass
transport	DiseaseClass
defect	DiseaseClass

Determination	O
of	O
the	O
mutations	O
responsible	O
for	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
in	O
17	O
subjects.	O
Hypoxanthine--guanine	O
phosphoribosyltransferase	O
(HPRT)	O
is	O
a	O
purine	O
salvage	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
hypoxanthine	O
to	O
inosine	O
monophosphate	O
and	O
guanine	O
to	O
guanosine	O
monophosphate.	O
Previous	O
studies	O
of	O
mutant	O
HPRT	O
proteins	O
analyzed	O
at	O
the	O
molecular	O
level	O
have	O
shown	O
a	O
significant	O
heterogeneity.	O
This	O
investigation	O
further	O
verifies	O
this	O
heterogeneity	O
and	O
identifies	O
insertions,	O
deletions,	O
and	O
point	O
mutations.	O
The	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction-amplified	O
product	O
of	O
reverse-transcribed	O
HPRT	O
mRNA	O
enabled	O
the	O
rapid	O
identification	O
of	O
the	O
mutations	O
found	O
in	O
17	O
previously	O
uncharacterized	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

A	O
new	O
CT	O
pattern	O
in	O
adrenoleukodystrophy	SpecificDisease
.	O
A	O
new	O
CT	O
pattern	O
was	O
observed	O
in	O
2	O
patients	O
with	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
).	O
This	O
pattern,	O
which	O
the	O
authors	O
call	O
Type	O
II,	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
posterior	O
periventricular	O
areas	O
of	O
decreased	O
attenuation	O
around	O
the	O
trigone	O
on	O
non-contrast	O
scans	O
	O
after	O
contrast	O
infusion,	O
however,	O
there	O
is	O
striking	O
enhancement	O
of	O
various	O
white-matter	O
structures	O
(tracts	O
or	O
fiber	O
systems)	O
such	O
as	O
the	O
internal	O
capsules,	O
corpus	O
callosum,	O
corona	O
radiata,	O
forceps	O
major,	O
and	O
cerebral	O
peduncles.	O
This	O
is	O
different	O
from	O
numerous	O
previous	O
descriptions	O
of	O
the	O
CT	O
pattern	O
in	O
ALD	SpecificDisease
.	O
Type	SpecificDisease
II	SpecificDisease
ALD	SpecificDisease
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	DiseaseClass
and	O
is	O
probably	O
specific	O
for	O
a	O
phenotypic	O
variant	O
or	O
an	O
evolving	O
stage	O
of	O
ALD	SpecificDisease

Genetic	O
analysis,	O
phenotypic	O
diagnosis,	O
and	O
risk	O
of	O
venous	SpecificDisease
thrombosis	SpecificDisease
in	O
families	O
with	O
inherited	O
deficiencies	SpecificDisease
of	SpecificDisease
protein	SpecificDisease
S	SpecificDisease
.	O
Protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	SpecificDisease
thrombosis	SpecificDisease
.	O
Of	O
all	O
the	O
inherited	O
thrombophilic	DiseaseClass
conditions	DiseaseClass
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results.	O
We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	O
of	O
patients	O
from	O
a	O
single	O
center	O
where	O
the	O
diagnosis	O
was	O
confirmed	O
at	O
the	O
genetic	O
level.	O
Twenty-eight	O
index	O
patients	O
with	O
protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
and	O
a	O
PROS1	SpecificDisease
gene	SpecificDisease
defect	SpecificDisease
were	O
studied,	O
together	O
with	O
109	O
first-degree	O
relatives.	O
To	O
avoid	O
selection	O
bias,	O
we	O
confined	O
analysis	O
of	O
total	O
and	O
free	O
protein	O
S	O
levels	O
and	O
thrombotic	O
risk	O
to	O
the	O
patients	O
relatives.	O
In	O
this	O
group	O
of	O
relatives,	O
a	O
low	O
free	O
protein	O
S	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	SpecificDisease
gene	SpecificDisease
defect	SpecificDisease
(sensitivity	O
97.	O
7%,	O
specificity	O
100%).	O
First-degree	O
relatives	O
with	O
a	O
PROS1	SpecificDisease
gene	SpecificDisease
defect	SpecificDisease
had	O
a	O
5.	O
0-fold	O
higher	O
risk	O
of	O
thrombosis	SpecificDisease
(95%	O
confidence	O
interval,	O
1.	O
5-16.	O
8)	O
than	O
those	O
with	O
a	O
normal	O
PROS1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	SpecificDisease
defect	SpecificDisease
.	O
Although	O
pregnancy/puerperium	O
and	O
immobility/	O
trauma	SpecificDisease
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	SpecificDisease
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous.	O
Relatives	O
with	O
splice-site	O
or	O
major	O
structural	O
defects	SpecificDisease
in	SpecificDisease
the	SpecificDisease
PROS1	SpecificDisease
gene	SpecificDisease
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
S	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations.	O
We	O
conclude	O
that	O
persons	O
with	O
PROS1	SpecificDisease
gene	SpecificDisease
defects	SpecificDisease
and	O
protein	SpecificDisease
S	SpecificDisease
deficiency	SpecificDisease
are	O
at	O
increased	O
risk	O
of	O
thrombosis	SpecificDisease

Severe	O
clinical	O
expression	O
in	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
X-linked	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
)	O
is	O
a	O
relatively	O
rare	O
benign	DiseaseClass
neuromuscular	DiseaseClass
disorder	DiseaseClass
which	O
can	O
vary	O
remarkably	O
in	O
onset,	O
course	O
and	O
severity.	O
In	O
the	O
present	O
study,	O
a	O
TCTAC	O
deletion	O
spanning	O
the	O
nucleotides	O
631-635	O
of	O
the	O
emerin	O
gene	O
caused	O
an	O
unusually	O
severe	O
disease	O
phenotype	O
including	O
loss	DiseaseClass
of	DiseaseClass
ambulation	DiseaseClass
and	O
severe	O
muscle	DiseaseClass
wasting	DiseaseClass
in	O
two	O
affected	O
brothers.	O
The	O
same	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
an	O
unrelated	O
family	O
showing	O
a	O
significantly	O
milder	O
phenotype.	O
The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease

The	O
gene	O
for	O
spinal	Modifier
cerebellar	Modifier
ataxia	Modifier
3	O
(SCA3)	O
is	O
located	O
in	O
a	O
region	O
of	O
approximately	O
3	O
cM	O
on	O
chromosome	O
14q24.3-q32.2.	O
SCA3,	O
the	O
gene	O
for	O
spinal	Modifier
cerebellar	Modifier
ataxia	Modifier
3,	O
was	O
recently	O
mapped	O
to	O
a	O
15-cM	O
interval	O
between	O
D14S67	O
and	O
D14S81	O
on	O
chromosome	O
14q,	O
by	O
linkage	O
analysis	O
in	O
two	O
families	O
of	O
French	O
ancestry.	O
The	O
SCA3	O
candidate	O
region	O
has	O
now	O
been	O
refined	O
by	O
linkage	O
analysis	O
with	O
four	O
new	O
microsatellite	O
markers	O
(D14S256,	O
D14S291,	O
D14S280,	O
and	O
AFM343vf1)	O
in	O
the	O
same	O
two	O
families,	O
in	O
which	O
19	O
additional	O
individuals	O
were	O
genotyped,	O
and	O
in	O
a	O
third	O
French	O
family.	O
Combined	O
two-point	O
linkage	O
analyses	O
show	O
that	O
the	O
new	O
markers,	O
D14S280	O
and	O
AFM343vf1,	O
are	O
tightly	O
linked	O
to	O
the	O
SCA3	O
locus,	O
with	O
maximal	O
lod	O
scores,	O
at	O
recombination	O
fraction,	O
(theta)	O
=.	O
00,	O
of	O
7.	O
05	O
and	O
13.	O
70,	O
respectively.	O
Combined	O
multipoint	O
and	O
recombinant	O
haplotype	O
analyses	O
localize	O
the	O
SCA3	O
locus	O
to	O
a	O
3-cM	O
interval	O
flanked	O
by	O
D14S291	O
and	O
D14S81.	O
The	O
same	O
allele	O
for	O
D14S280	O
segregates	O
with	O
the	O
disease	O
locus	O
in	O
the	O
three	O
kindreds.	O
This	O
allele	O
is	O
frequent	O
in	O
the	O
French	O
population,	O
however,	O
and	O
linkage	O
disequilibrium	O
is	O
not	O
clearly	O
established.	O
The	O
SCA3	O
locus	O
remains	O
within	O
the	O
29-cM	O
region	O
on	O
14q24.	O
3-q32.	O
2	O
containing	O
the	O
gene	O
for	O
the	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease

Huntington	SpecificDisease
disease	SpecificDisease
and	O
childhood-onset	O
Tourette	SpecificDisease
syndrome	SpecificDisease
.	O
A	O
40-year-old	O
man	O
with	O
childhood-onset	O
Tourette	SpecificDisease
syndrome	SpecificDisease
(	O
TS	SpecificDisease
)	O
developed	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
).	O
We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood-onset	O
TS	SpecificDisease
with	O
adult	O
onset	O
HD	SpecificDisease

The	O
protein	O
deficient	O
in	O
Lowe	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
phosphatidylinositol-4,5-bisphosphate	O
5-phosphatase.	O
Lowe	SpecificDisease
syndrome	SpecificDisease
,	O
also	O
known	O
as	O
oculocerebrorenal	SpecificDisease
syndrome	SpecificDisease
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
chromosome-encoded	O
OCRL	O
gene.	O
The	O
OCRL	O
protein	O
is	O
51%	O
identical	O
to	O
inositol	O
polyphosphate	O
5-phosphatase	O
II	O
(5-phosphatase	O
II)	O
from	O
human	O
platelets	O
over	O
a	O
span	O
of	O
744	O
aa,	O
suggesting	O
that	O
OCRL	O
may	O
be	O
a	O
similar	O
enzyme.	O
We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	O
cDNA	O
that	O
encodes	O
amino	O
acids	O
homologous	O
to	O
the	O
platelet	O
5-phosphatase	O
for	O
expression	O
in	O
baculovirus-infected	O
Sf9	O
insect	O
cells.	O
This	O
cDNA	O
encodes	O
aa	O
264-968	O
of	O
the	O
OCRL	O
protein.	O
The	O
recombinant	O
protein	O
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	O
5-phosphatase	O
II.	O
Thus	O
OCRL	O
converts	O
inositol	O
1,	O
4,	O
5-trisphosphate	O
to	O
inositol	O
1,	O
4-bisphosphate,	O
and	O
it	O
converts	O
inositol	O
1,	O
3,	O
4,	O
5-tetrakisphosphate	O
to	O
inositol	O
1,	O
3,	O
4-trisphosphate.	O
Most	O
important,	O
the	O
enzyme	O
converts	O
phosphatidylinositol	O
4,	O
5-bisphosphate	O
to	O
phosphatidylinositol	O
4-phosphate.	O
The	O
relative	O
ability	O
of	O
OCRL	O
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5-phosphatase	O
II	O
and	O
from	O
that	O
of	O
another	O
5-phosphatase	O
isoenzyme	O
from	O
platelets,	O
5-phosphatase	O
I.	O
The	O
recombinant	O
OCRL	O
protein	O
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10-	O
to	O
30-fold	O
better	O
than	O
5-phosphatase	O
II,	O
and	O
5-phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all.	O
We	O
also	O
show	O
that	O
OCRL	O
functions	O
as	O
a	O
phosphatidylinositol	O
4,	O
5-bisphosphate	O
5-phosphatase	O
in	O
OCRL-expressing	O
Sf9	O
cells.	O
These	O
results	O
suggest	O
that	O
OCRL	O
is	O
mainly	O
a	O
lipid	O
phosphatase	O
that	O
may	O
control	O
cellular	O
levels	O
of	O
a	O
critical	O
metabolite,	O
phosphatidylinositol	O
4,	O
5-bisphosphate.	O
Deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
Lowe	SpecificDisease
syndrome	SpecificDisease

Microdeletions	O
at	O
chromosome	O
bands	O
1q32-q41	O
as	O
a	O
cause	O
of	O
Van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
.	O
Van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
(	O
VWS	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorder	DiseaseClass
comprising	O
cleft	SpecificDisease
lip	SpecificDisease
and/or	O
cleft	SpecificDisease
palate	SpecificDisease
and	O
lip	SpecificDisease
pits	SpecificDisease
.	O
We	O
reported	O
previously	O
a	O
family	O
whose	O
underlying	O
mutation	O
is	O
a	O
500-800	O
kb	O
deletion	O
localized	O
to	O
chromosome	O
bands	O
1q32-q41	O
[Sander	O
et	O
al.,	O
1994	O
	O
Hum	O
Mol	O
Genet	O
3	O
	O
576-578].	O
Along	O
with	O
cleft	CompositeMention
lip/palate	CompositeMention
and	O
lip	SpecificDisease
pits	SpecificDisease
,	O
affected	O
relatives	O
exhibit	O
developmental	DiseaseClass
delays	DiseaseClass
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted.	O
To	O
further	O
localize	O
the	O
VWS	Modifier
gene	O
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
VWS	SpecificDisease
.	O
An	O
allele	O
loss	O
assay	O
was	O
performed	O
using	O
a	O
novel	O
highly	O
polymorphic	O
marker,	O
D1S3753.	O
From	O
a	O
panel	O
of	O
37	O
unrelated	O
individuals,	O
we	O
detected	O
an	O
allele	O
loss	O
in	O
one	O
family,	O
indicating	O
the	O
presence	O
of	O
a	O
deletion.	O
In	O
this	O
family,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	SpecificDisease
.	O
Surprisingly,	O
mapping	O
of	O
the	O
new	O
deletion	O
showed	O
that	O
it	O
extended	O
0.	O
2-1	O
Mb	O
beyond	O
the	O
proximal	O
breakpoint	O
for	O
the	O
deletion	O
described	O
previously.	O
No	O
deletions	O
were	O
detected	O
in	O
seven	O
cases	O
of	O
popliteal	SpecificDisease
pterygia	SpecificDisease
syndrome	SpecificDisease
,	O
76	O
cases	O
of	O
mixed	O
syndromic	CompositeMention
forms	CompositeMention
of	CompositeMention
cleft	CompositeMention
lip	CompositeMention
and	CompositeMention
palate	CompositeMention
,	O
and	O
178	O
cases	O
of	O
nonsyndromic	CompositeMention
cleft	CompositeMention
lip	CompositeMention
and	CompositeMention
palate	CompositeMention

Mucopolysaccharidosis	SpecificDisease
type	SpecificDisease
IVA	SpecificDisease
:	O
common	O
double	O
deletion	O
in	O
the	O
N-acetylgalactosamine-6-sulfatase	O
gene	O
(GALNS).	O
Mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
(	O
MPS	SpecificDisease
IVA	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
in	SpecificDisease
N-acetylgalactosamine-6-sulfatase	SpecificDisease

Segregation	O
analysis	O
of	O
a	O
marker	O
localised	O
Xp21.2-Xp21.3	O
in	O
Duchenne	CompositeMention
and	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
families.	O
A	O
DNA	O
marker	O
C7,	O
localised	O
Xp21.	O
1-Xp21.	O
3,	O
has	O
been	O
studied	O
in	O
kindreds	O
segregating	O
for	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
and	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
BMD	SpecificDisease
).	O
In	O
DMD	Modifier
families	O
four	O
crossovers	O
were	O
observed	O
in	O
38	O
informative	O
meioses	O
between	O
C7	O
and	O
the	O
DMD	Modifier
locus	O
(theta	O
=	O
0.	O
12,	O
z	O
max	O
=	O
+	O
2.	O
72).	O
In	O
BMD	Modifier
families	O
no	O
recombinants	O
were	O
observed	O
in	O
the	O
16	O
informative	O
meioses	O
studied.	O
These	O
data	O
are	O
consistent	O
with	O
the	O
localisation	O
of	O
the	O
mutations	O
in	O
these	O
disorders	O
being	O
in	O
the	O
same	O
region	O
of	O
Xp21.	O
Studies	O
in	O
families	O
also	O
segregating	O
for	O
the	O
DNA	O
marker	O
754	O
support	O
the	O
previously	O
reported	O
physical	O
order	O
of	O
these	O
loci	O
as	O
X	O
centromere-754-DMD-BMD-C7-X	O
telomere.	O
A	O
recombination	O
fraction	O
of	O
0.	O
11	O
(z	O
max	O
=	O
+	O
5.	O
58)	O
was	O
found	O
between	O
DMD-754	O
by	O
combining	O
our	O
previously	O
published	O
data	O
with	O
the	O
data	O
presented	O
here.	O
C7	O
and	O
754	O
thus	O
provide	O
good	O
bridging	O
markers	O
for	O
the	O
diagnosis	O
of	O
DMD	SpecificDisease
and	O
BMD	SpecificDisease

Genetic	O
analysis	O
of	O
the	O
BRCA1	O
region	O
in	O
a	O
large	O
breast/ovarian	O
family:	O
refinement	O
of	O
the	O
minimal	O
region	O
containing	O
BRCA1.	O
We	O
have	O
analyzed	O
a	O
single	O
multi-affected	O
breast/ovarian	Modifier
cancer	Modifier
pedigree	O
(BOV3)	O
and	O
have	O
shown	O
consistent	O
inheritance	O
of	O
markers	O
on	O
chromosome	O
17q	O
with	O
the	O
disease	O
confirming	O
that	O
this	O
family	O
is	O
due	O
to	O
the	O
BRCA1	O
gene.	O
Analysis	O
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	O
event	O
in	O
a	O
bilateral	O
breast	Modifier
cancer	Modifier
case	O
which	O
suggests	O
that	O
the	O
BRCA1	O
gene	O
lies	O
distal	O
to	O
D17S857;	O
D17S857	O
is	O
thus	O
the	O
new	O
proximal	O
boundary	O
for	O
the	O
region	O
containing	O
BRCA1.	O
Combining	O
this	O
information	O
with	O
previously	O
published	O
mapping	O
information	O
suggests	O
that	O
BRCA1	O
is	O
contained	O
in	O
a	O
region	O
estimated	O
at	O
1-1.	O
5	O
Mb	O
in	O
length.	O
All	O
seven	O
breast	Modifier
tumour	Modifier
/blood	O
pairs	O
examined	O
from	O
this	O
family	O
show	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tumours	DiseaseClass
.	O
The	O
allel	O
retained	O
in	O
each	O
tumour	DiseaseClass
was	O
from	O
the	O
disease-bearing	O
chromosome	O
implicating	O
BRCA1	O
as	O
a	O
tumour	Modifier

A	O
point	O
mutation	O
Thr(799)Met	O
on	O
the	O
alpha(2)	O
integrin	O
leads	O
to	O
the	O
formation	O
of	O
new	O
human	O
platelet	O
alloantigen	O
Sit(a)	O
and	O
affects	O
collagen-induced	O
aggregation.	O
A	O
new	O
platelet-specific	O
alloantigen,	O
termed	O
Sit	O
(a),	O
was	O
identified	O
in	O
a	O
severe	O
case	O
of	O
neonatal	SpecificDisease
alloimmune	SpecificDisease
thrombocytopenia	SpecificDisease

Estimation	O
of	O
the	O
male	O
to	O
female	O
ratio	O
of	O
mutation	O
rates	O
from	O
the	O
segregation	O
of	O
X-chromosomal	O
DNA	O
haplotypes	O
in	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
families.	O
A	O
novel	O
procedure	O
is	O
presented	O
to	O
estimate	O
the	O
ratio	O
of	O
male	O
to	O
female	O
mutation	O
rates	O
for	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
X-specific	O
restriction	O
fragment	O
length	O
polymorphisms	O
are	O
used	O
to	O
establish	O
DNA	O
haplotypes	O
in	O
three-generation	O
DMD	Modifier
families.	O
From	O
the	O
proportion	O
of	O
DMD	Modifier

Genetic	O
analysis	O
of	O
an	O
inherited	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
third	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
Brittany	O
spaniel	O
dogs.	O
Genetically	O
determined	O
C3	SpecificDisease
deficiency	SpecificDisease
in	O
Brittany	O
spaniel	O
dogs	O
shares	O
a	O
number	O
of	O
biochemical	O
and	O
clinical	O
characteristics	O
with	O
the	O
human	O
disorder.	O
In	O
humans,	O
the	O
gene	O
for	O
C3	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
null	O
gene	O
that	O
is	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3	O
and	O
is	O
not	O
linked	O
to	O
the	O
major	O
histocompatibility	O
locus.	O
The	O
current	O
study	O
used	O
allotype	O
analysis	O
of	O
canine	O
C3	O
in	O
order	O
to	O
demonstrate	O
that	O
the	O
gene	O
for	O
C3	SpecificDisease
deficiency	SpecificDisease
in	O
these	O
dogs	O
is	O
also	O
a	O
null	O
gene	O
allelic	O
to	O
the	O
structural	O
gene	O
for	O
C3.	O
In	O
addition,	O
preliminary	O
pedigree	O
analysis	O
suggests	O
that	O
the	O
gene	O
for	O
canine	O
C3	SpecificDisease
deficiency	SpecificDisease
is	O
apparently	O
not	O
closely	O
linked	O
to	O
the	O
major	O
histocompatibility	O
complex	O
of	O
the	O
dog.	O
Thus,	O
it	O
appears	O
that	O
C3	SpecificDisease
deficiency	SpecificDisease
in	O
Brittany	O
spaniel	O
dogs	O
not	O
only	O
shares	O
biochemical	O
and	O
clinical	O
features	O
with	O
C3	SpecificDisease
deficiency	SpecificDisease

A	O
novel	O
frameshift	O
mutation	O
in	O
the	O
McLeod	Modifier
syndrome	Modifier
gene	O
in	O
a	O
Japanese	O
family.	O
We	O
report	O
a	O
novel	O
mutation	O
in	O
the	O
XK	O
gene	O
(XK)	O
in	O
a	O
Japanese	O
patient	O
with	O
McLeod	SpecificDisease
syndrome	SpecificDisease
.	O
A	O
50-year-old	O
man	O
showed	O
progressive	O
muscular	DiseaseClass
atrophy	DiseaseClass
,	O
choreic	DiseaseClass
movement	DiseaseClass
,	O
elevated	O
level	O
of	O
serum	O
creatinine	O
kinase,	O
and	O
acanthocytosis	SpecificDisease
.	O
The	O
expression	O
level	O
of	O
all	O
the	O
Kell	O
antigens	O
in	O
erythrocyte	O
was	O
decreased	O
and	O
molecular	O
analysis	O
revealed	O
a	O
single-base	O
(T)	O
deletion	O
at	O
the	O
nucleotide	O
position	O
1095	O
in	O
XK.	O
This	O
deletion	O
caused	O
a	O
frameshift	O
in	O
translation,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
the	O
amino	O
acid	O
position	O
408.	O
We	O
conclude	O
this	O
single-base	O
deletion	O
causes	O
defective	O
Kx	O
protein,	O
which	O
is	O
responsible	O
for	O
the	O
McLeod	Modifier

Alpha-cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	SpecificDisease
hypertrophic	SpecificDisease
cardiomyopathy	SpecificDisease
.	O
We	O
identified	O
the	O
alpha-cardiac	O
actin	O
gene	O
(ACTC)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	SpecificDisease
hypertrophic	SpecificDisease
cardiomyopathy	SpecificDisease
(	O
FHC	SpecificDisease
).	O
Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	Modifier
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied,	O
with	O
lod	O
scores	O
varying	O
between	O
-2.	O
5	O
and	O
-6.	O
0	O
0.	O
Further	O
linkage	O
analyses	O
of	O
plausible	O
candidate	O
genes	O
highly	O
expressed	O
in	O
the	O
adult	O
human	O
heart	O
identified	O
ACTC	O
as	O
the	O
most	O
likely	O
disease	O
gene,	O
showing	O
a	O
maximal	O
lod	O
score	O
of	O
3.	O
6	O
6.	O
Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	SpecificDisease
dilated	SpecificDisease
cardiomyopathy	SpecificDisease
(	O
IDC	SpecificDisease

The	O
EWS	O
gene,	O
involved	O
in	O
Ewing	DiseaseClass
family	DiseaseClass
of	DiseaseClass
tumors	DiseaseClass
,	O
malignant	DiseaseClass
melanoma	DiseaseClass
of	DiseaseClass
soft	DiseaseClass
parts	DiseaseClass
and	O
desmoplastic	SpecificDisease
small	SpecificDisease
round	SpecificDisease
cell	SpecificDisease
tumors	SpecificDisease
,	O
codes	O
for	O
an	O
RNA	O
binding	O
protein	O
with	O
novel	O
regulatory	O
domains.	O
The	O
EWS	O
gene,	O
which	O
maps	O
to	O
band	O
q12	O
of	O
human	O
chromosome	O
22,	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
human	O
solid	DiseaseClass
tumors	DiseaseClass
including	O
Ewing	SpecificDisease
sarcoma	SpecificDisease
,	O
related	O
primitive	O
neuroectodermal	DiseaseClass
tumors	DiseaseClass
,	O
malignant	DiseaseClass
melanoma	DiseaseClass
of	DiseaseClass
soft	DiseaseClass
parts	DiseaseClass
and	O
desmoplastic	DiseaseClass
small	DiseaseClass
round	DiseaseClass
cell	DiseaseClass
tumors	DiseaseClass
.	O
In	O
these	O
tumors	DiseaseClass
,	O
the	O
EWS	O
is	O
fused	O
to	O
genes	O
encoding	O
transcriptional	O
activators/repressors,	O
like	O
Fli-1	O
or	O
erg	O
or	O
ATF	O
1	O
or	O
wt1.	O
To	O
better	O
understand	O
the	O
function	O
of	O
the	O
EWS	O
protein,	O
we	O
cloned	O
the	O
EWS	O
cDNA.	O
Sequence	O
analysis	O
of	O
this	O
cDNA	O
revealed	O
differential	O
splicing	O
involving	O
two	O
exons	O
encoding	O
72	O
amino	O
acids.	O
Both	O
alternatively	O
spliced	O
transcripts,	O
EWS	O
and	O
EWS-b,	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cells.	O
Because	O
EWS	O
proteins	O
contain	O
putative	O
conserved	O
RNA	O
binding	O
motifs,	O
we	O
studied	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
EWS	O
protein.	O
The	O
EWS-b	O
protein	O
binds	O
to	O
RNA	O
in	O
vitro	O
and,	O
specifically,	O
to	O
poly	O
G	O
and	O
poly	O
U.	O
The	O
RNA	O
binding	O
activity	O
was	O
localized	O
to	O
the	O
carboxy	O
terminal	O
86	O
amino	O
acids,	O
which	O
constitute	O
RGG	O
box.	O
Thus	O
the	O
amino	O
terminal	O
domain	O
of	O
EWS	O
(NTD-EWS),	O
which	O
is	O
involved	O
in	O
chromosome	O
translocation	O
may	O
regulate	O
the	O
specificity	O
of	O
RNA	O
binding	O
activity	O
of	O
EWS.	O
An	O
EWS-erg	O
chimeric	O
protein,	O
which	O
is	O
found	O
in	O
Ewings	Modifier
sarcoma	Modifier

A	O
mutation	O
common	O
in	O
non-Jewish	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
:	O
frequency	O
and	O
RNA	O
studies.	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha-subunit	O
of	O
the	O
lysosomal	O
enzyme,	O
beta-N-acetylhexosaminidase	O
A	O
(Hex	O
A).	O
We	O
have	O
discovered	O
that	O
a	O
Tay-Sachs	Modifier
mutation,	O
IVS-9	O
+	O
1	O
G--	O
>	O
A,	O
first	O
detected	O
by	O
Akli	O
et	O
al.	O
(Genomics	O
11	O
	O
124-134,	O
1991),	O
is	O
a	O
common	O
disease	O
allele	O
in	O
non-Jewish	O
Caucasians	O
(10/58	O
alleles	O
examined).	O
A	O
PCR-based	O
diagnostic	O
test,	O
which	O
detects	O
an	O
NlaIII	O
site	O
generated	O
by	O
the	O
mutation,	O
revealed	O
a	O
frequency	O
among	O
enzyme-defined	O
carriers	O
of	O
9/64	O
(14%).	O
Most	O
of	O
those	O
carrying	O
the	O
allele	O
trace	O
their	O
origins	O
to	O
the	O
United	O
Kingdom,	O
Ireland,	O
or	O
Western	O
Europe.	O
It	O
was	O
not	O
identified	O
among	O
12	O
Black	O
American	O
TSD	Modifier
alleles	O
or	O
in	O
any	O
of	O
18	O
Ashkenazi	O
Jewish,	O
enzyme-defined	O
carriers	O
who	O
did	O
not	O
carry	O
any	O
of	O
the	O
mutations	O
common	O
to	O
this	O
population.	O
No	O
normally	O
spliced	O
RNA	O
was	O
detected	O
in	O
PCR	O
products	O
generated	O
from	O
reverse	O
transcription	O
of	O
RNA	O
carrying	O
the	O
IVS-9	O
mutation.	O
Instead,	O
the	O
low	O
levels	O
of	O
mRNA	O
from	O
this	O
allele	O
were	O
comprised	O
of	O
aberrant	O
species	O
resulting	O
from	O
the	O
use	O
of	O
either	O
of	O
two	O
cryptic	O
donor	O
sites,	O
one	O
truncating	O
exon	O
9	O
and	O
the	O
other	O
within	O
IVS-9,	O
spliced	O
to	O
exon	O
10.	O
Numerous	O
additional	O
splice	O
products	O
were	O
detected,	O
most	O
involving	O
skipping	O
of	O
one	O
or	O
more	O
surrounding	O
exons.	O
Together	O
with	O
a	O
recently	O
identified	O
allele	O
responsible	O
for	O
Hex	O
A	O
pseudodeficiency	O
(Triggs-Raine	O
et	O
al.	O
Am	O
J	O
Hum	O
Genet,	O
1992),	O
these	O
two	O
alleles	O
accounted	O
for	O
almost	O
50%	O
(29/64)	O
of	O
TSD	Modifier

Characterization	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
region	O
predicts	O
multiple	O
protein	O
isoform-encoding	O
mRNAs.	O
The	O
mutation	O
underlying	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
has	O
been	O
identified	O
as	O
an	O
expansion	O
of	O
a	O
polymorphic	O
CTG-repeat	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
activity.	O
Brain	O
and	O
heart	O
transcripts	O
of	O
the	O
DM-kinase	O
(DMR-B15)	O
gene	O
are	O
subject	O
to	O
alternative	O
RNA	O
splicing	O
in	O
both	O
human	O
and	O
mouse.	O
The	O
unstable	O
[CTG]	O
5-30	O
motif	O
is	O
found	O
uniquely	O
in	O
humans,	O
although	O
the	O
flanking	O
nucleotides	O
are	O
also	O
present	O
in	O
mouse.	O
Characterization	O
of	O
the	O
DM	Modifier
region	O
of	O
both	O
species	O
reveals	O
another	O
active	O
gene	O
(DMR-N9)	O
in	O
close	O
proximity	O
to	O
the	O
kinase	O
gene.	O
DMR-N9	O
transcripts,	O
mainly	O
expressed	O
in	O
brain	O
and	O
testis,	O
possess	O
a	O
single,	O
large	O
open	O
reading	O
frame,	O
but	O
the	O
function	O
of	O
its	O
protein	O
product	O
is	O
unknown.	O
Clinical	O
manifestation	O
of	O
DM	SpecificDisease

Paroxysmal	SpecificDisease
nocturnal	SpecificDisease
haemoglobinuria	SpecificDisease
with	O
coexisting	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
ninth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
:	O
lack	O
of	O
massive	O
haemolytic	SpecificDisease
attack	SpecificDisease
.	O
A	O
47-year-old	O
woman	O
with	O
paroxysmal	SpecificDisease
nocturnal	SpecificDisease
haemoglobinuria	SpecificDisease
(	O
PNH	SpecificDisease
)	O
was	O
found	O
to	O
have	O
an	O
inherited	SpecificDisease
deficiency	SpecificDisease
in	SpecificDisease
the	SpecificDisease
ninth	SpecificDisease
complement	SpecificDisease
component	SpecificDisease
(C9).	O
In	O
complement-sensitivity	O
lysis	O
tests,	O
80%	O
of	O
her	O
erythrocytes	O
were	O
markedly	O
complement-sensitive	O
(PNH-III).	O
Laser	O
cytofluorimetry	O
with	O
a	O
monoclonal	O
antibody	O
against	O
decay-accelerating	O
factor	O
(DAF)	O
revealed	O
that	O
95%	O
of	O
her	O
erythrocytes	O
were	O
DAF-negative.	O
Surprisingly,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	SpecificDisease
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	SpecificDisease
.	O
Gross	O
haemoglobinuria	SpecificDisease
and	O
jaundice	SpecificDisease
occurred	O
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood.	O
In	O
her	O
serum,	O
C9	O
was	O
not	O
detectable	O
either	O
by	O
immunological	O
or	O
by	O
functional	O
assays.	O
Both	O
the	O
Ham	O
test	O
and	O
the	O
sugar	O
water	O
test	O
using	O
normal	O
human	O
serum	O
or	O
plasma	O
yielded	O
marked	O
haemolysis	O
of	O
the	O
patients	O
erythrocytes.	O
When	O
the	O
patients	O
serum	O
or	O
plasma	O
was	O
used,	O
only	O
a	O
trace	O
of	O
lysis	O
was	O
detected.	O
Addition	O
of	O
purified	O
human	O
C9	O
to	O
her	O
plasma	O
fully	O
restored	O
haemolysis.	O
These	O
observations	O
indicated	O
that	O
C9	O
may	O
play	O
a	O
critical	O
role	O
in	O
haemolytic	DiseaseClass
attacks	DiseaseClass
in	O
patients	O
with	O
PNH	SpecificDisease
and	O
that	O
characteristic	O
haemolysis	SpecificDisease
in	O
PNH	SpecificDisease
may	O
be	O
tempered	O
by	O
coexisting	O
C9	SpecificDisease
deficiency	SpecificDisease

BRCA1	O
is	O
associated	O
with	O
a	O
human	O
SWI/SNF-related	O
complex:	O
linking	O
chromatin	O
remodeling	O
to	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
Germline	O
mutations	O
in	O
the	O
tumor	Modifier
suppressor	O
gene,	O
BRCA1,	O
predispose	O
individuals	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
.	O
Using	O
a	O
combination	O
of	O
affinity-	O
and	O
conventional	O
chromatographic	O
techniques,	O
we	O
have	O
isolated	O
a	O
predominant	O
form	O
of	O
a	O
multiprotein	O
BRCA1-containing	O
complex	O
from	O
human	O
cells	O
displaying	O
chromatin-remodeling	O
activity.	O
Mass	O
spectrometric	O
sequencing	O
of	O
components	O
of	O
this	O
complex	O
indicated	O
that	O
BRCA1	O
is	O
associated	O
with	O
a	O
SWI/SNF-related	O
complex.	O
We	O
show	O
that	O
BRCA1	O
can	O
directly	O
interact	O
with	O
the	O
BRG1	O
subunit	O
of	O
the	O
SWI/SNF	O
complex.	O
Moreover,	O
p53-mediated	O
stimulation	O
of	O
transcription	O
by	O
BRCA1	O
was	O
completely	O
abrogated	O
by	O
either	O
a	O
dominant-negative	O
mutant	O
of	O
BRG1	O
or	O
the	O
cancer	DiseaseClass

Germinal	O
mosaicism	O
in	O
a	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
family:	O
implications	O
for	O
genetic	O
counselling.	O
In	O
this	O
study	O
we	O
describe	O
a	O
three-generation	O
family	O
in	O
which	O
two	O
siblings	O
were	O
affected	O
by	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
Immunohistochemical	O
analysis	O
of	O
muscle	O
dystrophin	O
and	O
haplotype	O
analysis	O
of	O
the	O
DMD	Modifier
locus	O
revealed	O
that	O
the	O
X	O
chromosome	O
carrying	O
the	O
DMD	Modifier
gene	O
was	O
transmitted	O
from	O
the	O
healthy	O
maternal	O
grandfather	O
to	O
his	O
three	O
daughters,	O
including	O
the	O
probands	O
mother.	O
These	O
findings	O
indicate	O
that	O
the	O
grandfather	O
was	O
a	O
germinal	O
mosaic	O
for	O
the	O
DMD	Modifier

Centrosome	O
amplification	O
and	O
a	O
defective	O
G2-M	O
cell	O
cycle	O
checkpoint	O
induce	O
genetic	O
instability	O
in	O
BRCA1	O
exon	O
11	O
isoform-deficient	O
cells.	O
Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	Modifier
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
.	O
To	O
study	O
mechanisms	O
underlying	O
BRCA1-related	O
tumorigenesis,	O
we	O
derived	O
mouse	O
embryonic	O
fibroblast	O
cells	O
carrying	O
a	O
targeted	O
deletion	O
of	O
exon	O
11	O
of	O
the	O
Brca1	O
gene.	O
We	O
show	O
that	O
the	O
mutant	O
cells	O
maintain	O
an	O
intact	O
G1-S	O
cell	O
cycle	O
checkpoint	O
and	O
proliferate	O
poorly.	O
However,	O
a	O
defective	O
G2-M	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	DiseaseClass
abnormalities	DiseaseClass
.	O
Mutant	O
fibroblasts	O
contain	O
multiple,	O
functional	O
centrosomes,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation,	O
abnormal	O
nuclear	O
division,	O
and	O
aneuploidy	SpecificDisease

Aberrant	O
splicing	O
of	O
phenylalanine	O
hydroxylase	O
mRNA:	O
the	O
major	O
cause	O
for	O
phenylketonuria	SpecificDisease
in	O
parts	O
of	O
southern	O
Europe.	O
We	O
report	O
a	O
mutation	O
within	O
the	O
phenylalanine	O
hydroxylase	O
(PAH)	O
gene	O
that	O
causes	O
aberrant	O
splicing	O
of	O
the	O
mRNA	O
and	O
that	O
is	O
in	O
tight	O
association	O
with	O
chromosomal	O
haplotypes	O
6,	O
10,	O
and	O
36.	O
Because	O
of	O
the	O
high	O
frequency	O
of	O
these	O
particular	O
haplotypes	O
in	O
Bulgaria,	O
Italy,	O
and	O
Turkey,	O
it	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequent	O
defects	O
in	O
the	O
PAH	O
gene	O
causing	O
classical	O
phenylketonuria	SpecificDisease

Biochemical	O
and	O
structural	O
analysis	O
of	O
missense	O
mutations	O
in	O
N-acetylgalactosamine-6-sulfate	O
sulfatase	O
causing	O
mucopolysaccharidosis	Modifier
IVA	Modifier
phenotypes.	O
Mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
(	O
MPS	SpecificDisease
IVA	SpecificDisease
;	O
OMIM	O
#	O
253000),	O
a	O
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
N	SpecificDisease
-acetylgalactosamine-6-sulfate	SpecificDisease
sulfatase	SpecificDisease
(GALNS),	O
has	O
variable	O
clinical	O
phenotypes.	O
To	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
MPS	Modifier
IVA	Modifier
patients,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear.	O
We	O
studied	O
17	O
missense	O
mutations	O
using	O
biochemical	O
approaches	O
and	O
32	O
missense	O
mutations,	O
using	O
structural	O
analyses.	O
Fifteen	O
missense	O
mutations	O
and	O
two	O
newly	O
engineered	O
active	O
site	O
mutations	O
(C79S,	O
C79T)	O
were	O
characterized	O
by	O
transient	O
expression	O
analysis.	O
Mutant	O
proteins,	O
except	O
for	O
C79S	O
and	O
C79T,	O
were	O
destabilized	O
and	O
detected	O
as	O
insoluble	O
precursor	O
forms	O
while	O
the	O
C79S	O
and	O
C79T	O
mutants	O
were	O
of	O
a	O
soluble	O
mature	O
size.	O
Mutants	O
found	O
in	O
the	O
severe	O
phenotype	O
had	O
no	O
activity.	O
Mutants	O
found	O
in	O
the	O
mild	O
phenotype	O
had	O
a	O
considerable	O
residual	O
activity	O
(1.	O
3-13.	O
3%	O
of	O
wild-type	O
GALNS	O
activity).	O
Sulfatases,	O
including	O
GALNS,	O
are	O
members	O
of	O
a	O
highly	O
conserved	O
gene	O
family	O
sharing	O
an	O
extensive	O
sequence	O
homology.	O
Thus,	O
a	O
tertiary	O
structural	O
model	O
of	O
human	O
GALNS	O
was	O
constructed	O
from	O
the	O
X-ray	O
crystal	O
structure	O
of	O
N	O
-acetylgalacto-samine-4-sulfatase	O
and	O
arylsulfatase	O
A,	O
using	O
homology	O
modeling,	O
and	O
32	O
missense	O
mutations	O
were	O
investigated.	O
Consequently,	O
we	O
propose	O
that	O
there	O
are	O
at	O
least	O
three	O
different	O
reasons	O
for	O
the	O
severe	O
phenotype	O
	O
(i)	O
destruction	O
of	O
the	O
hydrophobic	O
core	O
or	O
modification	O
of	O
the	O
packing;	O
(ii)	O
removal	O
of	O
a	O
salt	O
bridge	O
to	O
destabilize	O
the	O
entire	O
conformation;	O
(iii)	O
modification	O
of	O
the	O
active	O
site.	O
In	O
contrast,	O
mild	O
mutations	O
were	O
mostly	O
located	O
on	O
the	O
surface	O
of	O
the	O
GALNS	O
protein.	O
These	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype-phenotype	O
correlation	O
of	O
MPS	SpecificDisease
IVA	SpecificDisease

Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
:	O
cellular	O
impairments	O
and	O
their	O
implication	O
for	O
carrier	O
detection.	O
A	O
family	O
in	O
which	O
two	O
male	O
siblings	O
were	O
affected	O
with	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
was	O
studied	O
using	O
G-6-PD	O
isoenzymes	O
as	O
an	O
X-linked	O
marker	O
in	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
cellular	O
abnormalities.	O
Isolated	O
peripheral	O
blood	O
cell	O
types	O
from	O
the	O
doubly	O
heterozygous	O
mother	O
of	O
the	O
affected	O
males	O
seemingly	O
failed	O
to	O
express	O
the	O
G-6-PD	O
allele	O
in	O
cis	O
position	O
with	O
the	O
WAS	Modifier
allele	O
while	O
her	O
cultured	O
skin	O
fibroblasts	O
expressed	O
both	O
G-6-PD	O
alleles.	O
Additionally,	O
a	O
histogram	O
analysis	O
of	O
platelet	O
size	O
revealed	O
a	O
single	O
population	O
of	O
abnormally	O
small	O
platelets	O
in	O
the	O
affected	O
propositus,	O
whereas	O
the	O
heterozygous	O
mother	O
had	O
no	O
appreciable	O
small	O
platelet	O
subpopulation.	O
In	O
vitro	O
culture	O
of	O
hemopoietic	O
progenitor	O
cells	O
of	O
the	O
heterozygous	O
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	O
did	O
not	O
express	O
the	O
WAS	Modifier
allele.	O
However,	O
a	O
small	O
number	O
of	O
cells	O
expressing	O
the	O
G-6-PD	O
type	O
linked	O
with	O
the	O
WAS	Modifier
allele	O
were	O
detected.	O
The	O
proportion	O
of	O
the	O
latter	O
progenitors	O
was	O
significantly	O
higher	O
among	O
more	O
primitive	O
progenitors	O
(those	O
giving	O
rise	O
to	O
later	O
appearing	O
colonies).	O
This	O
observation	O
suggests	O
that	O
selection	O
against	O
cells	O
expressing	O
the	O
Wiskott-Aldrich	SpecificDisease
defect	SpecificDisease
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	O
female	O
and	O
offers	O
a	O
possible	O
means	O
of	O
carrier	O
detection	O
in	O
some	O
women.	O
Linkage	O
studies	O
in	O
this	O
family	O
revealed	O
one	O
example	O
of	O
probable	O
recombination	O
between	O
the	O
loci	O
for	O
WAS	SpecificDisease

Familial	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
associated	O
with	O
recurrent	O
meningococcal	SpecificDisease
infections	SpecificDisease
.	O
We	O
describe	O
an	O
11-year-old	O
girl	O
suffering	O
from	O
recurrent	SpecificDisease
meningitis	SpecificDisease
with	O
a	O
complete	O
absence	SpecificDisease
of	SpecificDisease
the	SpecificDisease
seventh	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complemen	SpecificDisease
t	O
(C7).	O
Diagnosis	O
was	O
established	O
by	O
haemolytic	O
titration	O
and	O
western	O
blotting.	O
The	O
patients	O
serum	O
lacked	O
the	O
85	O
kDa	O
C7	O
chain.	O
Haemolytic	O
activity	O
of	O
serum	O
was	O
reconstituted	O
with	O
either	O
pooled	O
normal	O
human	O
serum	O
or	O
with	O
purified	O
C7.	O
The	O
relatives	O
(parents	O
and	O
one	O
sister)	O
had	O
half-normal	O
levels	O
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	O
C7,	O
indicating	O
a	O
heterozygous	O
state	O
for	O
C7	SpecificDisease
deficiency	SpecificDisease

Non-syndromic	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
associated	O
with	O
enlarged	SpecificDisease
vestibular	SpecificDisease
aqueduct	SpecificDisease
is	O
caused	O
by	O
PDS	Modifier
mutations.	O
Enlarged	SpecificDisease
vestibular	SpecificDisease
aqueduct	SpecificDisease
(	O
EVA	SpecificDisease
),	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	DiseaseClass
ear	DiseaseClass
abnormality	DiseaseClass
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner.	O
The	O
locus	O
for	O
non-syndromic	SpecificDisease
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
with	O
EVA	SpecificDisease
has	O
been	O
mapped	O
to	O
the	O
same	O
chromosomal	O
region,	O
7q31,	O
as	O
the	O
Pendred	Modifier
syndrome	Modifier
locus.	O
In	O
the	O
present	O
study,	O
seven	O
mutations	O
in	O
the	O
PDS	Modifier
gene	O
(PDS),	O
the	O
gene	O
responsible	O
for	O
Pendred	SpecificDisease
syndrome	SpecificDisease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non-syndromic	SpecificDisease
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
with	O
EVA	SpecificDisease
.	O
One	O
family	O
is	O
homozygous,	O
three	O
families	O
are	O
compound	O
heterozygotes,	O
and	O
two	O
families	O
are	O
heterozygous	O
but	O
with	O
no	O
other	O
mutation	O
detected.	O
The	O
present	O
results	O
provide	O
evidence	O
that	O
mutations	O
in	O
PDS	O
cause	O
both	O
syndromic	CompositeMention
and	CompositeMention
non-syndromic	CompositeMention
hearing	CompositeMention
loss	CompositeMention

Deletions	O
of	O
a	O
DNA	O
sequence	O
in	O
retinoblastomas	SpecificDisease
and	O
mesenchymal	DiseaseClass
tumors	DiseaseClass
:	O
organization	O
of	O
the	O
sequence	O
and	O
its	O
encoded	O
protein.	O
Retinoblastoma	SpecificDisease
is	O
a	O
childhood	DiseaseClass
tumor	DiseaseClass
that	O
can	O
arise	O
because	O
of	O
mutant	O
alleles	O
acquired	O
as	O
somatic	O
or	O
germinal	O
mutations.	O
The	O
mutant	O
allele	O
can	O
be	O
carried	O
in	O
the	O
germ	O
line.	O
The	O
mutations	O
creating	O
these	O
alleles	O
act	O
by	O
inactivating	O
copies	O
of	O
a	O
recessive	O
oncogene	O
located	O
within	O
band	O
q14	O
of	O
chromosome	O
13	O
and	O
termed	O
the	O
RB1	O
locus.	O
We	O
have	O
reported	O
isolation	O
of	O
a	O
cDNA	O
fragment	O
that	O
recognizes	O
chromosomal	O
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	Modifier
gene	O
associated	O
with	O
the	O
RB1	O
locus.	O
We	O
now	O
report	O
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	O
mutations	O
in	O
mesenchymal	DiseaseClass
tumors	DiseaseClass
among	O
patients	O
having	O
no	O
apparent	O
predisposition	O
to	O
retinoblastoma	SpecificDisease
and	O
no	O
previous	O
evidence	O
of	O
retinoblastoma	SpecificDisease
.	O
These	O
tumors	DiseaseClass

Genetically	O
determined	O
low	O
C4:	O
a	O
predisposing	O
factor	O
to	O
autoimmune	SpecificDisease
chronic	SpecificDisease
active	SpecificDisease
hepatitis	SpecificDisease
.	O
Of	O
26	O
patients	O
with	O
autoimmune	SpecificDisease
chronic	SpecificDisease
active	SpecificDisease
hepatitis	SpecificDisease
(	O
CAH	SpecificDisease
)	O
starting	O
in	O
childhood	O
18	O
(69%)	O
had	O
low	O
C4	O
and	O
5	O
(19%)	O
had	O
low	O
C3	O
serum	O
levels.	O
Impaired	O
hepatic	O
synthesis	O
and	O
immune-consumption	O
were	O
unlikely	O
since	O
transferrin	O
levels	O
were	O
normal	O
in	O
all	O
patients,	O
albumin	O
levels	O
were	O
persistently	O
low	O
in	O
only	O
3,	O
and	O
only	O
3	O
had	O
raised	O
levels	O
of	O
activation	O
fragment	O
C3d.	O
C4d	O
was	O
normal	O
in	O
all	O
patients	O
studied.	O
In	O
the	O
families	O
of	O
12	O
probands	O
with	O
low	O
C4,	O
7	O
parents	O
had	O
low	O
C4	O
and	O
2	O
had	O
levels	O
which	O
were	O
at	O
the	O
lower	O
limit	O
of	O
normal.	O
5	O
of	O
10	O
siblings	O
from	O
5	O
families	O
had	O
low	O
C4.	O
These	O
results	O
suggest	O
that	O
low	O
C4	O
levels	O
in	O
CAH	SpecificDisease
are	O
genetically	O
determined.	O
C4	O
phenotyping	O
in	O
20	O
patients	O
and	O
in	O
26	O
parents	O
showed	O
that	O
90%	O
and	O
81%,	O
respectively,	O
had	O
null	O
allotypes	O
at	O
either	O
the	O
C4A	O
or	O
C4B	O
locus	O
compared	O
with	O
59%	O
in	O
controls,	O
indicating	O
that	O
defective	O
expression	O
of	O
structural	O
genes	O
may	O
contribute	O
to	O
the	O
observed	O
C4	SpecificDisease
deficiency	SpecificDisease

Tight	O
linkage	O
between	O
myotonic	Modifier
dystrophy	Modifier
and	O
apolipoprotein	O
E	O
genes	O
revealed	O
with	O
allele-specific	O
oligonucleotides.	O
In	O
16	O
families	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
a	O
novel	O
approach	O
based	O
on	O
use	O
of	O
allele-specific	O
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	O
the	O
linkage	O
relationship	O
between	O
the	O
apolipoprotein	O
E	O
(APOE)	O
gene	O
and	O
DM	SpecificDisease
.	O
Synthetic	O
oligonucleotides,	O
designed	O
to	O
discriminate	O
between	O
APOE	O
alleles	O
epsilon	O
3	O
and	O
epsilon	O
4,	O
enabled	O
us	O
to	O
distinguish	O
heterozygous	O
carriers	O
in	O
a	O
hybridization	O
assay.	O
In	O
a	O
subset	O
of	O
families,	O
the	O
relevant	O
segment	O
of	O
the	O
APOE	O
gene	O
was	O
enzymatically	O
amplified	O
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
method.	O
For	O
DM	O
and	O
APOE,	O
a	O
maximum	O
lod	O
score	O
(zmax	O
of	O
7.	O
47	O
was	O
obtained	O
at	O
a	O
recombination	O
frequency	O
(theta)	O
of	O
0.	O
047	O
(male	O
theta	O
=	O
female	O
theta).	O
No	O
recombination	O
(maximum	O
lod	O
score	O
of	O
5.	O
61	O
at	O
theta	O
=	O
0.	O
0)	O
was	O
found	O
between	O
APOE	O
and	O
the	O
apolipoprotein	O
CII	O
(APOC2)	O
gene.	O
These	O
results	O
suggest	O
that,	O
in	O
addition	O
to	O
APOC2,	O
APOE	O
is	O
a	O
useful	O
marker	O
for	O
presymptomatic	O
DM	Modifier

Confirmation	O
of	O
BRCA1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
in	O
ten	O
families.	O
We	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
BRCA1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	Modifier
cancer	Modifier
patients	O
and	O
10	O
ovarian	Modifier
cancer	Modifier
patients	O
in	O
ten	O
families	O
with	O
cancer	DiseaseClass
linked	O
to	O
chromosome	O
17q21.	O
Nine	O
different	O
mutations	O
were	O
detected	O
by	O
screening	O
BRCA1	O
DNA	O
and	O
RNA	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing.	O
Seven	O
mutations	O
lead	O
to	O
protein	O
truncations	O
at	O
sites	O
throughout	O
the	O
gene.	O
One	O
missense	O
mutation	O
(which	O
occurred	O
independently	O
in	O
two	O
families)	O
leads	O
to	O
loss	O
of	O
a	O
cysteine	O
in	O
the	O
zinc	O
binding	O
domain.	O
An	O
intronic	O
single	O
basepair	O
substitution	O
destroys	O
an	O
acceptor	O
site	O
and	O
activates	O
a	O
cryptic	O
splice	O
site,	O
leading	O
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	O
termination.	O
The	O
four	O
families	O
with	O
both	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

Genetic	O
instability	O
in	O
human	O
ovarian	Modifier
cancer	Modifier
cell	O
lines.	O
We	O
have	O
analyzed	O
the	O
stability	O
of	O
microsatellites	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
ovarian	SpecificDisease
cancers	SpecificDisease
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	Modifier
tumor	Modifier
cell	O
lines	O
are	O
genetically	O
unstable	O
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed.	O
In	O
clones	O
and	O
subclones	O
derived	O
serially	O
from	O
one	O
of	O
these	O
cell	O
lines	O
(2774;	O
serous	SpecificDisease
cystadenocarcinoma	SpecificDisease
),	O
a	O
very	O
high	O
proportion	O
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	O
of	O
the	O
genome	O
change	O
their	O
size	O
in	O
a	O
mercurial	O
fashion.	O
We	O
conclude	O
that	O
genomic	O
instability	O
in	O
ovarian	SpecificDisease
tumors	SpecificDisease
is	O
a	O
dynamic	O
and	O
ongoing	O
process	O
whose	O
high	O
frequency	O
may	O
have	O
been	O
previously	O
underestimated	O
by	O
PCR-based	O
allelotyping	O
of	O
bulk	O
tumor	Modifier
tissue.	O
We	O
have	O
identified	O
the	O
source	O
of	O
the	O
genetic	O
instability	O
in	O
one	O
ovarian	SpecificDisease
tumor	SpecificDisease
as	O
a	O
point	O
mutation	O
(R524P)	O
in	O
the	O
human	O
mismatch-repair	O
gene	O
MSH2	O
(Salmonella	O
MutS	O
homologue),	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
involved	O
in	O
hereditary	SpecificDisease
nonpolyposis	SpecificDisease
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
Patient	O
2774	O
was	O
a	O
38-year-old	O
heterozygote,	O
and	O
her	O
normal	O
tissue	O
carried	O
both	O
mutant	O
and	O
wild-type	O
alleles	O
of	O
the	O
human	O
MSH2	O
gene.	O
However	O
the	O
wild-type	O
allele	O
was	O
lost	O
at	O
some	O
point	O
early	O
during	O
tumorigenesis	O
so	O
that	O
DNA	O
isolated	O
either	O
from	O
the	O
patients	O
ovarian	SpecificDisease
tumor	SpecificDisease
or	O
from	O
the	O
2774	O
cell	O
line	O
carries	O
only	O
the	O
mutant	O
allele	O
of	O
the	O
human	O
MSH2	O
gene.	O
The	O
genetic	O
instability	O
observed	O
in	O
the	O
tumor	DiseaseClass
and	O
cell	O
line	O
DNA,	O
together	O
with	O
the	O
germ-line	O
mutation	O
in	O
a	O
mismatch-repair	O
gene,	O
suggest	O
that	O
the	O
MSH2	O
gene	O
is	O
involved	O
in	O
the	O
onset	O
and/or	O
progression	O
in	O
a	O
subset	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease

Retroviral-mediated	O
gene	O
transfer	O
of	O
human	O
phenylalanine	O
hydroxylase	O
into	O
NIH	O
3T3	O
and	O
hepatoma	Modifier
cells.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
caused	O
by	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
hepatic	SpecificDisease
enzyme	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
A	O
full-length	O
human	O
PAH	O
cDNA	O
sequence	O
has	O
been	O
inserted	O
into	O
pzip-neoSV	O
(X),	O
which	O
is	O
a	O
retroviral	O
vector	O
containing	O
the	O
bacterial	O
neo	O
gene.	O
The	O
recombinant	O
has	O
been	O
transfected	O
into	O
psi	O
2	O
cells,	O
which	O
provide	O
synthesis	O
of	O
the	O
retroviral	O
capsid.	O
Recombinant	O
virus	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
of	O
the	O
transfected	O
psi	O
2	O
cells,	O
which	O
is	O
capable	O
of	O
transmitting	O
the	O
human	O
PAH	O
gene	O
into	O
mouse	O
NIH	O
3T3	O
cells	O
by	O
infection	O
leading	O
to	O
stable	O
incorporation	O
of	O
the	O
recombinant	O
provirus.	O
Infected	O
cells	O
express	O
PAH	O
mRNA,	O
immunoreactive	O
PAH	O
protein,	O
and	O
exhibit	O
pterin-dependent	O
phenylalanine	O
hydroxylase	O
activity.	O
The	O
recombinant	O
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	O
hepatoma	Modifier
cell	O
line	O
that	O
does	O
not	O
normally	O
synthesize	O
PAH.	O
PAH	O
activity	O
is	O
present	O
in	O
the	O
cellular	O
extracts	O
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	Modifier
cells	O
infected	O
with	O
the	O
recombinant	O
viruses.	O
Thus,	O
recombinant	O
viruses	O
containing	O
human	O
PAH	O
cDNA	O
provide	O
a	O
means	O
for	O
introducing	O
functional	O
PAH	O
into	O
mammalian	O
cells	O
of	O
hepatic	O
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	O
for	O
somatic	O
gene	O
therapy	O
for	O
PKU	SpecificDisease

Characterisation	O
of	O
molecular	O
defects	O
in	O
X-linked	SpecificDisease
amelogenesis	SpecificDisease
imperfecta	SpecificDisease
(AIH1).	O
Amelogenins	O
are	O
an	O
heterogenous	O
family	O
of	O
proteins	O
produced	O
by	O
ameloblasts	O
of	O
the	O
enamel	O
organ	O
during	O
tooth	O
development.	O
Disturbances	O
of	O
enamel	O
formation	O
occur	O
in	O
amelogenesis	DiseaseClass
imperfecta	DiseaseClass
,	O
a	O
clinically	O
heterogenous	O
group	O
of	O
inherited	DiseaseClass
disorders	DiseaseClass
characterised	O
by	O
defective	O
enamel	O
biomineralisation.	O
An	O
amelogenin	O
gene,	O
AMGX,	O
has	O
been	O
mapped	O
to	O
the	O
short	O
of	O
the	O
X	O
chromosome	O
(Xp22.	O
1-p22.	O
3)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathology	O
of	O
X-linked	SpecificDisease
amelogenesis	SpecificDisease
imperfecta	SpecificDisease
(	O
AIH1	SpecificDisease
).	O
We	O
have	O
identified	O
three	O
families	O
exhibiting	O
AIH1	SpecificDisease

The	O
Pendred	Modifier
syndrome	Modifier
gene	O
encodes	O
a	O
chloride-iodide	O
transport	O
protein.	O
Pendred	SpecificDisease
syndrome	SpecificDisease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	DiseaseClass
deafness	DiseaseClass
and	O
characterized	O
by	O
congenital	O
sensorineural	SpecificDisease
hearing	SpecificDisease
loss	SpecificDisease
and	O
goitre	SpecificDisease
.	O
This	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
Pendred	SpecificDisease
syndrome	SpecificDisease
(	O
PDS	SpecificDisease
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning.	O
PDS	O
encodes	O
a	O
putative	O
transmembrane	O
protein	O
designated	O
pendrin.	O
Pendrin	O
is	O
closely	O
related	O
to	O
a	O
family	O
of	O
sulfate	O
transport	O
proteins	O
that	O
includes	O
the	O
rat	O
sulfate-anion	O
transporter	O
(encoded	O
by	O
Sat-1;	O
29%	O
amino	O
acid	O
sequence	O
identity),	O
the	O
human	O
diastrophic	Modifier
dysplasia	Modifier
sulfate	O
transporter	O
(encoded	O
by	O
DTD;	O
32%)	O
and	O
the	O
human	O
sulfate	O
transporter	O
downregulated	O
in	O
adenoma	DiseaseClass
(encoded	O
by	O
DRA;	O
45%).	O
On	O
the	O
basis	O
of	O
this	O
homology	O
and	O
the	O
presence	O
of	O
a	O
slightly	O
modified	O
sulfate-transporter	O
signature	O
sequence	O
comprising	O
its	O
putative	O
second	O
transmembrane	O
domain,	O
pendrin	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
sulfate	O
transporter.	O
We	O
were	O
unable	O
to	O
detect	O
evidence	O
of	O
sulfate	O
transport	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
Xenopus	O
laevis	O
oocytes	O
by	O
microinjection	O
of	O
PDS	O
cRNA	O
or	O
in	O
Sf9	O
cells	O
following	O
infection	O
with	O
PDS-recombinant	O
baculovirus.	O
The	O
rates	O
of	O
transport	O
for	O
iodide	O
and	O
chloride	O
were	O
significantly	O
increased	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
both	O
cell	O
systems.	O
Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide,	O
but	O
not	O
sulfate,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	SpecificDisease
syndrome	SpecificDisease

Linkage	O
relationship	O
of	O
C2	SpecificDisease
deficiency	SpecificDisease
,	O
HLA	O
and	O
glyoxalase	O
I	O
loci.	O
Immunogenetic	O
analysis	O
of	O
a	O
homozygous	O
C2-deficient	Modifier
individual	O
and	O
family	O
members	O
demonstrated	O
linkage	O
of	O
HLA-A25,	O
B18	O
and	O
C2o.	O
HLA-D	O
typing	O
showed	O
that	O
5	O
members	O
typed	O
with	O
homozygous	O
Dw2	O
typing	O
cells	O
from	O
an	O
individual	O
with	O
C2	SpecificDisease
deficiency	SpecificDisease
but	O
not	O
with	O
Dw2	O
typing	O
cells	O
from	O
2	O
individuals	O
with	O
normal	O
C2.	O
The	O
homozygous	O
C2-deficient	Modifier

A	O
71-kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues.	O
The	O
known	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene	O
products,	O
the	O
muscle-	O
and	O
brain-type	O
dystrophin	O
isoforms,	O
are	O
427-kDa	O
proteins	O
translated	O
from	O
14-kilobase	O
(kb)	O
mRNAs.	O
Recently	O
we	O
described	O
a	O
6.	O
5-kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	Modifier
gene.	O
Cloning	O
and	O
in	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
entire	O
coding	O
region	O
show	O
that	O
the	O
6.	O
5-kb	O
mRNA	O
encodes	O
a	O
70.	O
8-kDa	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
DMD	Modifier
gene.	O
It	O
contains	O
the	O
C-terminal	O
and	O
the	O
cysteine-rich	O
domains	O
of	O
dystrophin,	O
seven	O
additional	O
amino	O
acids	O
at	O
the	O
N	O
terminus,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	O
splicing	O
in	O
the	O
C-terminal	O
domain.	O
It	O
lacks	O
the	O
entire	O
large	O
domain	O
of	O
spectrin-like	O
repeats	O
and	O
the	O
actin-binding	O
N-terminal	O
domain	O
of	O
dystrophin.	O
This	O
protein	O
is	O
the	O
major	O
DMD	Modifier

Histidinemia	SpecificDisease
.	O
Classical	O
and	O
atypical	O
form	O
in	O
siblings.	O
Two	O
brothers,	O
6	O
and	O
13	O
years	O
old,	O
had	O
histidinemia	SpecificDisease

Hypoxanthine-guanine	SpecificDisease
phosphoribosyltransferase	SpecificDisease
deficiency	SpecificDisease
:	O
analysis	O
of	O
HPRT	O
mutations	O
by	O
direct	O
sequencing	O
and	O
allele-specific	O
amplification.	O
The	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
severe	O
X	DiseaseClass
chromosome-linked	DiseaseClass
human	DiseaseClass
disease	DiseaseClass
caused	O
by	O
a	O
virtual	O
absence	SpecificDisease
of	SpecificDisease
hypoxanthine-guanine	SpecificDisease
phosphoribosyltransferase	SpecificDisease
(HPRT)	SpecificDisease
activity	SpecificDisease
.	O
A	O
partial	O
deficiency	O
in	O
the	O
activity	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
gouty	SpecificDisease
arthritis	SpecificDisease
.	O
To	O
determine	O
the	O
genetic	O
basis	O
for	O
reduction	O
or	O
loss	O
of	O
enzyme	O
activity,	O
we	O
have	O
amplified	O
and	O
sequenced	O
the	O
coding	O
region	O
of	O
HPRT	O
cDNA	O
from	O
four	O
patients	O
	O
one	O
with	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
(HPRTPerth)	O
and	O
three	O
with	O
partial	DiseaseClass
deficiencies	DiseaseClass
of	DiseaseClass
HPRT	DiseaseClass
activity	DiseaseClass

Sjogren-Larsson	SpecificDisease
syndrome	SpecificDisease
.	O
Impaired	O
fatty	O
alcohol	O
oxidation	O
in	O
cultured	O
fibroblasts	O
due	O
to	O
deficient	O
fatty	O
alcohol:nicotinamide	O
adenine	O
dinucleotide	O
oxidoreductase	O
activity.	O
Lipid	O
metabolism	O
was	O
studied	O
in	O
cultured	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
inherited	DiseaseClass
disorder	DiseaseClass
,	O
Sjogren-Larsson	SpecificDisease
syndrome	SpecificDisease
(	O
SLS	SpecificDisease
).	O
Intact	O
SLS	Modifier
fibroblasts	O
incubated	O
in	O
the	O
presence	O
of	O
[1-14C]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	O
cells,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered.	O
The	O
hexadecanol	O
content	O
of	O
SLS	Modifier
fibroblasts	O
was	O
abnormally	O
elevated.	O
Hexadecanol	O
accumulation	O
was	O
not	O
due	O
to	O
increased	O
fatty	O
alcohol	O
synthesis	O
nor	O
its	O
deficient	O
utilization	O
for	O
glycerol	O
ether	O
synthesis.	O
The	O
half-life	O
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
SLS	Modifier
fibroblasts	O
was	O
increased	O
(70	O
min)	O
compared	O
with	O
normal	O
(15	O
min),	O
and	O
intact	O
SLS	Modifier
fibroblasts	O
showed	O
impaired	O
oxidation	O
of	O
[14C]	O
-hexadecanol	O
to	O
fatty	O
acid.	O
Fatty	O
alcohol	O
	O
NAD	O
+	O
oxidoreductase,	O
the	O
enzyme	O
catalyzing	O
this	O
reaction,	O
was	O
deficient	O
in	O
SLS	Modifier
fibroblasts.	O
Mean	O
total	O
activity	O
in	O
SLS	Modifier
fibroblasts	O
(n	O
=	O
5)	O
was	O
13%	O
of	O
that	O
in	O
normal	O
fibroblasts,	O
and	O
palmitoyl	O
CoA-inhibitable	O
activity	O
was	O
1%	O
of	O
normal.	O
Fibroblasts	O
from	O
two	O
obligate	O
SLS	Modifier
heterozygotes	O
had	O
enzyme	O
activities	O
intermediate	O
between	O
that	O
in	O
normal	O
fibroblasts	O
and	O
individuals	O
with	O
SLS	SpecificDisease
.	O
These	O
results	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
SLS	SpecificDisease
is	O
deficiency	SpecificDisease
of	SpecificDisease
fatty	SpecificDisease
alcohol	SpecificDisease
	SpecificDisease
NAD	SpecificDisease
+	SpecificDisease
oxidoreductase	SpecificDisease
.	O
SLS	SpecificDisease
represents	O
the	O
first	O
inherited	DiseaseClass
disorder	DiseaseClass
in	O
man	O
associated	O
with	O
an	O
isolated	O
abnormality	DiseaseClass
in	DiseaseClass
fatty	DiseaseClass
alcohol	DiseaseClass
metabolism	DiseaseClass

Glycerol	O
as	O
a	O
correlate	O
of	O
impaired	SpecificDisease
glucose	SpecificDisease
tolerance	SpecificDisease
:	O
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	O
trait.	O
Glycerol	O
kinase	O
(GK)	O
represents	O
the	O
primary	O
entry	O
of	O
glycerol	O
into	O
glucose	O
and	O
triglyceride	O
metabolism.	O
Impaired	SpecificDisease
glucose	SpecificDisease
tolerance	SpecificDisease
(	O
IGT	SpecificDisease
)	O
and	O
hypertriglyceridemia	SpecificDisease
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	SpecificDisease
mellitus	SpecificDisease
and	O
cardiovascular	SpecificDisease
disease	SpecificDisease
.	O
The	O
relationship	O
between	O
glycerol	O
and	O
the	O
risk	O
of	O
IGT	SpecificDisease
,	O
however,	O
is	O
poorly	O
understood.	O
We	O
therefore	O
undertook	O
the	O
study	O
of	O
fasting	O
plasma	O
glycerol	O
levels	O
in	O
a	O
cohort	O
of	O
1,	O
056	O
unrelated	O
men	O
and	O
women	O
of	O
French-Canadian	O
descent.	O
Family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	SpecificDisease

Assignment	O
of	O
the	O
aspartylglucosaminidase	O
gene	O
(AGA)	O
to	O
4q33----q35	O
based	O
on	O
decreased	O
activity	O
in	O
a	O
girl	O
with	O
a	O
46,XX,del(4)(q33)	O
karyotype.	O
Aspartylglucosaminuria	SpecificDisease
(	O
AGU	SpecificDisease
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
due	O
to	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
enzyme	SpecificDisease
aspartylglucosaminidase	SpecificDisease

Mutations	O
in	O
the	O
fibrinogen	O
aalpha	O
gene	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
congenital	SpecificDisease
afibrinogenemia	SpecificDisease
.	O
Congenital	SpecificDisease
afibrinogenemia	SpecificDisease
is	O
a	O
rare,	O
autosomal,	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
fibrinogen.	O
We	O
previously	O
identified	O
the	O
first	O
causative	O
mutations	O
in	O
a	O
nonconsanguineous	O
Swiss	O
family;	O
the	O
4	O
affected	O
persons	O
have	O
homozygous	O
deletions	O
of	O
approximately	O
11	O
kb	O
of	O
the	O
fibrinogen	O
alpha	O
(FGA)	O
gene.	O
Haplotype	O
data	O
implied	O
that	O
these	O
deletions	O
occurred	O
on	O
distinct	O
ancestral	O
chromosomes,	O
suggesting	O
that	O
this	O
region	O
may	O
be	O
susceptible	O
to	O
deletion	O
by	O
a	O
common	O
mechanism.	O
We	O
subsequently	O
showed	O
that	O
all	O
the	O
deletions	O
were	O
identical	O
to	O
the	O
base	O
pair	O
and	O
probably	O
resulted	O
from	O
a	O
nonhomologous	O
recombination	O
mediated	O
by	O
7-bp	O
direct	O
repeats.	O
In	O
this	O
study,	O
we	O
have	O
collected	O
data	O
on	O
13	O
additional	O
unrelated	O
patients	O
to	O
identify	O
the	O
causative	O
mutations	O
and	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
11-kb	O
deletion.	O
A	O
common	O
recurrent	O
mutation,	O
at	O
the	O
donor	O
splice	O
site	O
of	O
FGA	O
intron	O
4	O
(IVS4	O
+	O
1	O
G	O
>	O
T),	O
accounted	O
for	O
14	O
of	O
the	O
26	O
(54%)	O
alleles.	O
One	O
patient	O
was	O
heterozygous	O
for	O
the	O
previously	O
identified	O
deletion.	O
Three	O
more	O
frameshift	O
mutations,	O
2	O
nonsense	O
mutations,	O
and	O
a	O
second	O
splice	O
site	O
mutation	O
were	O
also	O
identified.	O
Consequently,	O
86%	O
of	O
afibrinogenemia	Modifier
alleles	O
analyzed	O
to	O
date	O
have	O
truncating	O
mutations	O
of	O
FGA,	O
though	O
mutations	O
in	O
all	O
3	O
fibrinogen	O
genes,	O
FGG,	O
FGA,	O
and	O
FGB,	O
might	O
be	O
predicted	O
to	O
cause	O
congenital	SpecificDisease
afibrinogenemia	SpecificDisease

Utilization	O
of	O
purines	O
by	O
an	O
HPRT	O
variant	O
in	O
an	O
intelligent,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
patient,	O
H.	O
Chr.	O
B.,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	SpecificDisease
and	O
central	DiseaseClass
nervous	DiseaseClass
system	DiseaseClass
symptoms	DiseaseClass
.	O
He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(HPRT;	O
E.	O
C.	O
2.	O
4.	O
2.	O
8)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
patient	O
had	O
chroeoathetosis	SpecificDisease
,	O
spasticity	SpecificDisease
,	O
dysarthric	SpecificDisease
speech	SpecificDisease
,	O
and	O
hyperuricemia	SpecificDisease
.	O
However,	O
his	O
intelligence	O
was	O
normal	O
and	O
he	O
had	O
no	O
evidence	O
of	O
self-mutilation.	O
There	O
was	O
no	O
activity	O
of	O
HPRT	O
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	O
when	O
analyzed	O
in	O
the	O
usual	O
manner.	O
Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	O
of	O
purine	O
metabolism	O
in	O
intact	O
cultured	O
cells,	O
this	O
patient	O
was	O
found	O
to	O
metabolize	O
some	O
9%	O
of	O
8-14C-hypoxanthine,	O
and	O
90%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	O
nucleotides.	O
In	O
contrast,	O
cells	O
from	O
patients	O
with	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides.	O
The	O
patients	O
fibroblasts	O
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	O
of	O
8-14C-guanine,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27%,	O
over	O
80%	O
of	O
which	O
was	O
converted	O
to	O
guanine	O
and	O
adenine	O
nucleotides.	O
The	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(HAT),	O
whereas	O
the	O
growth	O
of	O
Lesch-Nyhan	Modifier
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally.	O
Similarly	O
in	O
8-azaguanine,	O
6-thioguanine,	O
and	O
8-azahypoxanthine,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
Lesch-Nyhan	Modifier
cells.	O
These	O
observations	O
provide	O
further	O
evidence	O
for	O
genetic	O
heterogeneity	O
among	O
patients	O
with	O
disorders	O
in	O
purine	O
metabolism	O
involving	O
the	O
HPRT	O
gene.	O
They	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
Lesch-Nyhan	SpecificDisease
syndrome	SpecificDisease

Canavan	SpecificDisease
disease	SpecificDisease
:	O
mutations	O
among	O
Jewish	O
and	O
non-Jewish	O
patients.	O
Canavan	SpecificDisease
disease	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
leukodystrophy	DiseaseClass
caused	O
by	O
the	O
deficiency	SpecificDisease
of	SpecificDisease
aspartoacylase	SpecificDisease
(ASPA).	O
Sixty-four	O
probands	O
were	O
analyzed	O
for	O
mutations	O
in	O
the	O
ASPA	O
gene.	O
Three	O
point	O
mutations--693C--	O
>	O
A,	O
854A--	O
>	O
C,	O
and	O
914C--	O
>	O
A--were	O
identified	O
in	O
the	O
coding	O
sequence.	O
The	O
693C--	O
>	O
A	O
and	O
914C--	O
>	O
A	O
base	O
changes,	O
resulting	O
in	O
nonsense	O
tyr231--	O
>	O
ter	O
and	O
missense	O
ala305--	O
>	O
glu	O
mutations,	O
respectively,	O
lead	O
to	O
complete	O
loss	O
of	O
ASPA	O
activity	O
in	O
in	O
vitro	O
expression	O
studies.	O
The	O
854A--	O
>	O
C	O
transversion	O
converted	O
glu	O
to	O
ala	O
in	O
codon	O
285.	O
The	O
glu285--	O
>	O
ala	O
mutant	O
ASPA	O
has	O
2.	O
5%	O
of	O
the	O
activity	O
expressed	O
by	O
the	O
wild-type	O
enzyme.	O
A	O
fourth	O
mutation,	O
433	O
--2	O
(A--	O
>	O
G)	O
transition,	O
was	O
identified	O
at	O
the	O
splice-acceptor	O
site	O
in	O
intron	O
2.	O
The	O
splice-site	O
mutation	O
would	O
lead	O
to	O
skipping	O
of	O
exon	O
3,	O
accompanied	O
by	O
a	O
frameshift,	O
and	O
thus	O
would	O
produce	O
aberrant	O
ASPA.	O
Of	O
the	O
128	O
unrelated	O
Canavan	Modifier
chromosomes	O
analyzed,	O
88	O
were	O
from	O
probands	O
of	O
Ashkenazi	O
Jewish	O
descent.	O
The	O
glu285--	O
>	O
ala	O
mutation	O
was	O
predominant	O
(82.	O
9%)	O
in	O
this	O
population,	O
followed	O
by	O
the	O
tyr231--	O
>	O
ter	O
(14.	O
8%)	O
and	O
433	O
--2	O
(A--	O
>	O
G)	O
(1.	O
1%)	O
mutations.	O
The	O
three	O
mutations	O
account	O
for	O
98.	O
8%	O
of	O
the	O
Canavan	Modifier
chromosomes	O
of	O
Ashkenazi	O
Jewish	O
origin.	O
The	O
ala305--	O
>	O
glu	O
mutation	O
was	O
found	O
exclusively	O
in	O
non-Jewish	O
probands	O
of	O
European	O
descent	O
and	O
constituted	O
60%	O
of	O
the	O
40	O
mutant	O
chromosomes.	O
Predominant	O
occurrence	O
of	O
certain	O
mutations	O
among	O
Ashkenazi	O
Jewish	O
and	O
non-Jewish	O
patients	O
with	O
Canavan	SpecificDisease
disease	SpecificDisease

Identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	Modifier
polyposis	Modifier
locus.	O
Small	O
(100-260	O
kb),	O
nested	O
deletions	O
were	O
characterized	O
in	O
DNA	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
APC	SpecificDisease

Genotype-phenotype	O
correlations	O
in	O
families	O
with	O
deletions	O
in	O
the	O
von	Modifier
Hippel-Lindau	Modifier
(	O
VHL	Modifier
)	O
gene.	O
Von	SpecificDisease
Hippel-Lindau	SpecificDisease
(VHL)	SpecificDisease
disease	SpecificDisease
is	O
a	O
hereditary	DiseaseClass
tumor	DiseaseClass
syndrome	DiseaseClass
characterized	O
by	O
predisposition	O
for	O
bilateral	CompositeMention
and	CompositeMention
multi-centric	CompositeMention
hemangioblastoma	CompositeMention
in	O
the	O
retina	O
and	O
central	O
nervous	O
system,	O
pheochromocytoma	SpecificDisease
,	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
,	O
and	O
cysts	CompositeMention
in	CompositeMention
the	CompositeMention
kidney,	CompositeMention
pancreas,	CompositeMention
and	CompositeMention
epididymis	CompositeMention
.	O
We	O
describe	O
five	O
families	O
for	O
which	O
direct	O
sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
VHL	Modifier
gene	O
had	O
failed	O
to	O
identify	O
the	O
family-specific	O
mutation.	O
Further	O
molecular	O
analysis	O
revealed	O
deletions	O
involving	O
the	O
VHL	Modifier
gene	O
in	O
each	O
of	O
these	O
families.	O
In	O
four	O
families,	O
partial	O
deletions	O
of	O
one	O
or	O
more	O
exons	O
were	O
detected	O
by	O
Southern	O
blot	O
analysis.	O
In	O
the	O
fifth	O
family,	O
FISH	O
analysis	O
demonstrated	O
the	O
deletion	O
of	O
the	O
entire	O
VHL	Modifier
gene.	O
Our	O
results	O
show	O
that	O
(quantitative)	O
Southern	O
blot	O
analysis	O
is	O
a	O
sensitive	O
method	O
for	O
detecting	O
germline	O
deletions	O
of	O
the	O
VHL	Modifier
gene	O
and	O
should	O
be	O
implemented	O
in	O
routine	O
DNA	O
diagnosis	O
for	O
VHL	SpecificDisease
disease	SpecificDisease
.	O
Our	O
data	O
support	O
the	O
previously	O
established	O
observation	O
that	O
families	O
with	O
a	O
germline	O
deletion	O
have	O
a	O
low	O
risk	O
for	O
pheochromocytoma	SpecificDisease
.	O
Further	O
unraveling	O
of	O
genotype-phenotype	O
correlations	O
in	O
VHL	SpecificDisease
disease	SpecificDisease
has	O
revealed	O
that	O
families	O
with	O
a	O
full	O
or	O
partial	O
deletion	O
of	O
the	O
VHL	Modifier
gene	O
exhibit	O
a	O
phenotype	O
with	O
a	O
preponderance	O
of	O
central	SpecificDisease
nervous	SpecificDisease
system	SpecificDisease
hemangioblastoma	SpecificDisease

Understanding	O
the	O
molecular	O
basis	O
of	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
.	O
Fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
a	O
common	O
form	O
of	O
inherited	DiseaseClass
mental	DiseaseClass
retardation	DiseaseClass
,	O
is	O
mainly	O
caused	O
by	O
massive	O
expansion	O
of	O
CGG	O
triplet	O
repeats	O
located	O
in	O
the	O
5-untranslated	O
region	O
of	O
the	O
fragile	Modifier
X	Modifier
mental	Modifier
retardation	Modifier
-1	O
(FMR1)	O
gene.	O
In	O
patients	O
with	O
fragile	SpecificDisease
X	SpecificDisease
syndrome	SpecificDisease
,	O
the	O
expanded	O
CGG	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
FMR1	O
gene	O
is	O
repressed,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
FMR1	O
protein	O
(FMRP)	O
and	O
subsequent	O
mental	DiseaseClass
retardation	DiseaseClass

Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
in	O
Papua	O
New	O
Guinea.	O
The	O
description	O
of	O
13	O
new	O
variants.	O
A	O
total	O
of	O
362	O
males	O
from	O
various	O
regions	O
of	O
Papua	O
New	O
Guinea	O
were	O
screened	O
for	O
red	O
cell	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
activity.	O
Twenty-six	O
G6PD	Modifier
deficient	Modifier
individuals	O
were	O
identified.	O
Biochemical	O
characterization	O
of	O
G6PD	O
purified	O
from	O
these	O
subjects	O
has	O
revealed	O
13	O
new	O
variants	O
and	O
several	O
copies	O
of	O
previously	O
described	O
forms	O
of	O
G6PD.	O
This	O
study	O
illustrates	O
the	O
extreme	O
heterogeneity	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Regional	O
mapping	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
and	O
the	O
phenylketonuria	Modifier
locus	O
in	O
the	O
human	O
genome.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
of	O
amino	O
acid	O
metabolism	O
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
hepatic	SpecificDisease
enzyme	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH;	O
phenylalanine	O
4-monooxygenase,	O
EC	O
1.	O
14.	O
16.	O
1).	O
A	O
cDNA	O
clone	O
for	O
human	O
PAH	O
has	O
previously	O
been	O
used	O
to	O
assign	O
the	O
corresponding	O
gene	O
to	O
human	O
chromosome	O
12.	O
To	O
define	O
the	O
regional	O
map	O
position	O
of	O
the	O
disease	O
locus	O
and	O
the	O
PAH	O
gene	O
on	O
human	O
chromosome	O
12,	O
DNA	O
was	O
isolated	O
from	O
human-hamster	O
somatic	O
cell	O
hybrids	O
with	O
various	O
deletions	O
of	O
human	O
chromosome	O
12	O
and	O
was	O
analyzed	O
by	O
Southern	O
blot	O
analysis	O
using	O
the	O
human	O
cDNA	O
PAH	O
clone	O
as	O
a	O
hybridization	O
probe.	O
From	O
these	O
results,	O
together	O
with	O
detailed	O
biochemical	O
and	O
cytogenetic	O
characterization	O
of	O
the	O
hybrid	O
cells,	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
human	O
PAH	O
gene	O
has	O
been	O
defined	O
as	O
12q14.	O
3----qter	O
3----qter.	O
The	O
PAH	O
map	O
position	O
on	O
chromosome	O
12	O
was	O
further	O
localized	O
by	O
in	O
situ	O
hybridization	O
of	O
125I-labeled	O
human	O
PAH	O
cDNA	O
to	O
chromosomes	O
prepared	O
from	O
a	O
human	O
lymphoblastoid	O
cell	O
line.	O
Results	O
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
PAH	O
gene	O
and	O
the	O
PKU	Modifier

Total	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
plasma	SpecificDisease
cholesteryl	SpecificDisease
ester	SpecificDisease
transfer	SpecificDisease
protein	SpecificDisease
in	O
subjects	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
intron	O
14	O
splicing	O
defect.	O
The	O
molecular	O
basis	O
of	O
cholesteryl	SpecificDisease
ester	SpecificDisease
transfer	SpecificDisease
protein	SpecificDisease
(CETP)	SpecificDisease
deficiency	SpecificDisease
was	O
investigated	O
in	O
4	O
unrelated	O
CETP-deficient	Modifier
families.	O
The	O
high	O
density	O
lipoprotein-cholesterol	O
levels	O
of	O
the	O
probands	O
exceeded	O
150	O
mg/dl.	O
The	O
plasma	O
of	O
the	O
probands	O
was	O
totally	O
deficient	O
in	O
CETP	O
activity	O
and	O
mass.	O
The	O
genomic	O
DNA	O
of	O
the	O
patients	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction,	O
using	O
two	O
oligonucleotide	O
primers	O
located	O
in	O
the	O
intron	O
12	O
and	O
14	O
of	O
the	O
CETP	O
gene,	O
and	O
the	O
amplified	O
products	O
were	O
directly	O
sequenced.	O
Two	O
patients	O
were	O
homozygous	O
for	O
a	O
G-to-A	O
change	O
at	O
the	O
5-splice	O
donor	O
site	O
of	O
the	O
intron	O
14.	O
The	O
G-to-A	O
change	O
would	O
cause	O
impaired	O
splicing	O
of	O
pre-messenger	O
RNA.	O
The	O
other	O
two	O
probands	O
were	O
heterozygous	O
for	O
the	O
mutation,	O
but	O
totally	O
lacked	O
CETP.	O
Their	O
lipoprotein	O
patterns	O
were	O
also	O
similar	O
to	O
those	O
of	O
the	O
two	O
homozygotes.	O
Thus,	O
other	O
genetic	DiseaseClass
defects	DiseaseClass
or	O
metabolic	O
factors	O
influencing	O
CETP	O
expression	O
are	O
implicated.	O
The	O
data	O
suggest	O
that	O
the	O
G-to-A	O
mutation	O
may	O
be	O
common	O
in	O
human	O
plasma	O
CETP	SpecificDisease
deficiency	SpecificDisease

Heterogeneity	O
of	O
type	SpecificDisease
I	SpecificDisease
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
:	O
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	Modifier
Willebrand	Modifier
factor.	O
Type	SpecificDisease
I	SpecificDisease
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
(	O
vWD	SpecificDisease
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	Modifier
Willebrand	Modifier
factor	O
antigen	O
(vWF	O
	O
Ag)	O
and	O
ristocetin	O
cofactor	O
(RiCof)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(SDS)	O
-agarose	O
gel	O
electrophoresis.	O
For	O
17	O
patients	O
(13	O
kindreds)	O
diagnosed	O
with	O
these	O
criteria,	O
we	O
have	O
studied	O
the	O
platelet	O
contents	O
of	O
vWF	O
	O
Ag	O
and	O
RiCof	O
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion.	O
Platelet	O
vWF	O
	O
Ag	O
and	O
RiCof	O
were	O
normal	O
in	O
four	O
kindreds	O
(called	O
"	O
platelet	O
normal	O
"	O
subgroup);	O
following	O
1-deamino-8-D-arginine	O
vasopressin;	O
plasma	O
vWF	O
	O
Ag,	O
RiCof	O
and	O
the	O
bleeding	O
time	O
(BT)	O
became	O
normal.	O
In	O
six	O
kindreds,	O
platelet	O
vWF	O
	O
Ag	O
and	O
RiCof	O
were	O
equally	O
low	O
(platelet	O
low);	O
after	O
DDAVP,	O
plasma	O
vWF	O
	O
Ag	O
and	O
RiCof	O
remained	O
low,	O
and	O
the	O
BT	O
was	O
prolonged.	O
In	O
three	O
additional	O
kindreds,	O
platelets	O
contained	O
normal	O
concentrations	O
of	O
vWF	O
	O
Ag,	O
but	O
RiCof	O
was	O
very	O
low	O
(platelet	O
discordant);	O
even	O
though	O
a	O
complete	O
set	O
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	O
multimers.	O
After	O
DDAVP,	O
plasma	O
vWF	O
	O
Ag	O
became	O
normal,	O
but	O
RiCof	O
remained	O
low	O
and	O
the	O
BT	O
was	O
very	O
prolonged.	O
These	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	O
(RiCof	O
less	O
than	O
vWF	O
	O
Ag)	O
even	O
in	O
type	SpecificDisease
I	SpecificDisease
vWD	SpecificDisease

Characterization	O
of	O
a	O
YAC	O
containing	O
part	O
or	O
all	O
of	O
the	O
Norrie	Modifier
disease	Modifier
locus.	O
It	O
has	O
been	O
shown	O
from	O
pulsed-field	O
gel	O
electrophoresis	O
(PFGE)	O
that	O
the	O
monoamine	O
oxidase	O
genes	O
A	O
and	O
B	O
(MAOA	O
&	O
MAOB)	O
and	O
DXS7	O
loci	O
are	O
physically	O
very	O
close.	O
We	O
have	O
therefore	O
extended	O
studies	O
on	O
their	O
relationship	O
through	O
the	O
characterisation	O
of	O
a	O
650	O
kb	O
YAC	O
isolated	O
using	O
L1.	O
28	O
(recognising	O
the	O
DXS7	O
locus)	O
as	O
a	O
probe.	O
Restriction	O
mapping	O
of	O
the	O
YAC	O
indicates	O
that	O
it	O
contains	O
both	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
addition	O
to	O
the	O
DXS7	O
locus.	O
The	O
map	O
derived	O
from	O
the	O
YL1.	O
28-YAC	O
is	O
compatible	O
both	O
with	O
the	O
map	O
from	O
an	O
independently	O
derived	O
YAC	O
carrying	O
MAOA	O
and	O
B	O
genes	O
and	O
with	O
the	O
long	O
range	O
genomic	O
map	O
for	O
the	O
region.	O
A	O
series	O
of	O
subclones	O
prepared	O
from	O
a	O
phage	O
library	O
(lambda	O
DASH	O
II)	O
of	O
the	O
YAC	O
have	O
been	O
characterised	O
and	O
have	O
been	O
employed	O
to	O
determine	O
the	O
end	O
point	O
of	O
the	O
deletion	O
of	O
a	O
Norrie	Modifier
disease	Modifier
(	O
NDP	Modifier

Identification	O
of	O
mutations	O
in	O
Danish	O
choroideremia	Modifier
families.	O
We	O
have	O
searched	O
for	O
mutations	O
in	O
the	O
choroideremia	Modifier
gene	O
(	O
CHM	Modifier
)	O
in	O
patients	O
from	O
12	O
Danish	O
families	O
in	O
which	O
CHM	SpecificDisease

G130V,	O
a	O
common	O
FRDA	Modifier
point	O
mutation,	O
appears	O
to	O
have	O
arisen	O
from	O
a	O
common	O
founder.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
)	O
is	O
the	O
most	O
common	O
inherited	DiseaseClass
ataxia	DiseaseClass
.	O
About	O
98%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
affected	O
gene,	O
FRDA.	O
The	O
other	O
2%	O
are	O
point	O
mutations.	O
Of	O
the	O
17	O
point	O
mutations	O
so	O
far	O
described,	O
three	O
appear	O
to	O
be	O
more	O
common.	O
One	O
of	O
these	O
is	O
the	O
G130V	O
mutation	O
in	O
exon	O
4	O
of	O
FRDA.	O
G130V,	O
when	O
present	O
with	O
an	O
expanded	O
GAA	O
repeat	O
on	O
the	O
other	O
allele,	O
is	O
associated	O
with	O
an	O
atypical	O
FRDA	Modifier

Frequency	O
of	O
exon	O
15	O
missense	O
mutation	O
(442D:G)	O
in	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
in	O
hyperalphalipoproteinemic	Modifier
Japanese	O
subjects.	O
Cholesteryl	O
ester	O
transfer	O
protein	O
(CETP)	O
transfers	O
cholesteryl	O
ester	O
from	O
high	O
density	O
lipoprotein	O
(HDL)	O
to	O
apo	O
B-containing	O
lipoproteins.	O
The	O
hyperalphalipoproteinemia	SpecificDisease
caused	O
by	O
CETP	SpecificDisease
deficiency	SpecificDisease
is	O
fairly	O
common	O
in	O
Japan	O
and	O
one	O
of	O
the	O
most	O
common	O
mutations	O
in	O
the	O
CETP	O
gene	O
is	O
the	O
splicing	O
defect	O
of	O
the	O
intron	O
14,	O
the	O
allelic	O
frequency	O
of	O
which	O
has	O
been	O
shown	O
to	O
be	O
0.	O
0049	O
in	O
the	O
Japanese	O
general	O
population.	O
Recently,	O
we	O
have	O
reported	O
a	O
missense	O
mutation	O
in	O
exon	O
15	O
of	O
the	O
CETP	O
gene	O
(442D	O
	O
G),	O
showing	O
a	O
dominant	O
effect	O
on	O
the	O
CETP	O
activity	O
and	O
HDL-cholesterol	O
level.	O
In	O
the	O
current	O
study,	O
we	O
determined	O
the	O
frequency	O
of	O
this	O
new	O
mutation	O
in	O
Japanese	O
hyperalphalipoproteinemic	Modifier
(HDL-cholesterol	O
>	O
or	O
=	O
100	O
mg/dl)	O
subjects.	O
A	O
rapid	O
and	O
easy	O
screening	O
method	O
for	O
this	O
new	O
mutation	O
was	O
developed	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(PCR)	O
-mediated	O
site-directed	O
mutagenesis.	O
Among	O
117	O
Japanese	O
hyperalphalipoproteinemic	Modifier
subjects	O
(HDL-cholesterol;	O
116.	O
7	O
+/-	O
16.	O
5	O
mg/dl,	O
mean	O
+/-	O
S.	O
D.)	O
without	O
the	O
intron	O
14	O
splice	O
defect,	O
three	O
homozygotes	O
(2.	O
5%)	O
and	O
34	O
heterozygotes	O
(29.	O
1%)	O
were	O
found	O
to	O
have	O
the	O
442D	O
	O
G	O
mutation.	O
The	O
relative	O
allelic	O
frequency	O
of	O
this	O
mutation	O
was	O
calculated	O
to	O
be	O
0.	O
17.	O
One	O
of	O
the	O
homozygotes	O
for	O
the	O
442D	O
	O
G	O
mutation	O
was	O
the	O
patient	O
previously	O
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	SpecificDisease
with	O
corneal	SpecificDisease
opacity	SpecificDisease
and	O
coronary	SpecificDisease
heart	SpecificDisease
disease	SpecificDisease
.	O
This	O
was	O
the	O
first	O
reported	O
subject	O
homozygous	O
for	O
the	O
CETP	SpecificDisease
deficiency	SpecificDisease
who	O
also	O
demonstrated	O
atherosclerotic	DiseaseClass
symptoms	DiseaseClass

Fibroblast	O
growth	O
factor	O
homologous	O
factor	O
2	O
(FHF2):	O
gene	O
structure,	O
expression	O
and	O
mapping	O
to	O
the	O
Borjeson-Forssman-Lehmann	Modifier
syndrome	Modifier
region	O
in	O
Xq26	O
delineated	O
by	O
a	O
duplication	O
breakpoint	O
in	O
a	O
BFLS	Modifier
-like	O
patient.	O
Borjeson-Forssman-Lehmann	SpecificDisease
syndrome	SpecificDisease
(	O
BFLS	SpecificDisease
)	O
is	O
a	O
syndromal	O
X-linked	DiseaseClass
mental	DiseaseClass
retardation	DiseaseClass
,	O
which	O
maps	O
by	O
linkage	O
to	O
the	O
q26	O
region	O
of	O
the	O
human	O
X	O
chromosome.	O
We	O
have	O
identified	O
a	O
male	O
patient	O
with	O
BFLS	Modifier
-like	O
features	O
and	O
a	O
duplication,	O
46,	O
Y,	O
dup	O
(X)	O
(q26q28),	O
inherited	O
from	O
his	O
phenotypically	O
normal	O
mother.	O
Fluorescence	O
in	O
situ	O
hybridisation	O
using	O
yeast	O
artificial	O
chromosome	O
clones	O
from	O
Xq26	O
localised	O
the	O
duplication	O
breakpoint	O
to	O
an	O
approximately	O
400-kb	O
interval	O
in	O
the	O
Xq26.	O
3	O
region	O
between	O
DXS155	O
and	O
DXS294/DXS730.	O
Database	O
searches	O
and	O
analysis	O
of	O
available	O
genomic	O
DNA	O
sequence	O
from	O
the	O
region	O
revealed	O
the	O
presence	O
of	O
the	O
fibroblast	O
growth	O
factor	O
homologous	O
factor	O
gene,	O
FHF2,	O
within	O
the	O
duplication	O
breakpoint	O
interval.	O
The	O
gene	O
structure	O
of	O
FHF2	O
was	O
determined	O
and	O
two	O
new	O
exons	O
were	O
identified,	O
including	O
a	O
new	O
5	O
end	O
exon,	O
1B.	O
FHF2	O
is	O
a	O
large	O
gene	O
extending	O
over	O
approximately	O
200	O
kb	O
in	O
Xq26.	O
3	O
and	O
is	O
composed	O
of	O
at	O
least	O
seven	O
exons.	O
It	O
shows	O
tissue-specific	O
alternative	O
splicing	O
and	O
alternative	O
transcription	O
starts.	O
Northern	O
blot	O
hybridisation	O
showed	O
highest	O
expression	O
in	O
brain	O
and	O
skeletal	O
muscle.	O
The	O
FHF2	O
gene	O
localisation	O
and	O
tissue-specific	O
expression	O
pattern	O
suggest	O
it	O
to	O
be	O
a	O
candidate	O
gene	O
for	O
familial	O
cases	O
of	O
the	O
BFLS	SpecificDisease
syndrome	SpecificDisease
and	O
other	O
syndromal	O
and	O
non-specific	O
forms	O
of	O
X-linked	DiseaseClass
mental	DiseaseClass
retardation	DiseaseClass

Illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
lymphocytes	O
for	O
identification	O
of	O
mutations	O
in	O
phenylketonuria	SpecificDisease
.	O
Taking	O
advantage	O
of	O
the	O
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(PAH)	O
gene,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
PAH	O
cDNA	O
sequence	O
of	O
hyperphenylalaninemic	Modifier
children	O
in	O
circulating	O
lymphocytes.	O
Using	O
this	O
approach,	O
we	O
have	O
also	O
identified	O
3	O
novel	O
mutations	O
in	O
cDNA	O
from	O
liver	O
and	O
lymphocytes	O
of	O
two	O
patients.	O
One	O
mutation,	O
detected	O
by	O
the	O
abnormal	O
pattern	O
of	O
migration	O
of	O
an	O
amplified	O
fragment,	O
is	O
a	O
C	O
to	O
T	O
transition	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
10,	O
which	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
11	O
with	O
the	O
premature	O
termination	O
of	O
RNA	O
translation	O
downstream	O
from	O
exon	O
12	O
(-3	O
IVS10).	O
The	O
other	O
two	O
mutations	O
are	O
missense	O
mutations	O
in	O
exons	O
10	O
and	O
11	O
(respectively,	O
L333F	O
and	O
E390G).	O
The	O
present	O
study	O
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
PAH	O
gene	O
transcripts	O
whose	O
nucleotide	O
sequence	O
is	O
identical	O
to	O
that	O
reported	O
in	O
liver	O
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
genetic	O
studies	O
in	O
phenylketonuria	SpecificDisease

Function	O
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity.	O
The	O
axonal	O
chemoattractant	O
netrin-1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
DCC	O
(Deleted	O
in	O
Colorectal	SpecificDisease
Cancer	SpecificDisease

Choroideremia	SpecificDisease
:	O
close	O
linkage	O
to	O
DXYS1	O
and	O
DXYS12	O
demonstrated	O
by	O
segregation	O
analysis	O
and	O
historical-genealogical	O
evidence.	O
Linkage	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
were	O
conducted	O
in	O
the	O
X-linked	DiseaseClass
disorder	DiseaseClass
,	O
choroideremia	SpecificDisease
,	O
designated	O
TCD	SpecificDisease
for	O
Progressive	SpecificDisease
Tapeto-Choroidal	SpecificDisease
Dystrophy	SpecificDisease
.	O
Previously	O
demonstrated	O
close	O
linkage	O
with	O
locus	O
DXYS1	O
was	O
confirmed	O
(lod	O
11.	O
44	O
at	O
0	O
recombination	O
distance).	O
In	O
addition,	O
locus	O
DXYS12	O
was	O
found	O
to	O
be	O
closely	O
linked	O
with	O
TCD	SpecificDisease
(lod	O
3.	O
31	O
at	O
0	O
recombination	O
distance).	O
The	O
disease	O
mainly	O
occurs	O
in	O
three	O
large	O
kindreds	O
in	O
remote	O
Northern	O
Finland.	O
While	O
formal	O
genealogical	O
proof	O
is	O
lacking,	O
all	O
presently	O
living	O
(more	O
than	O
80	O
affected	O
males	O
and	O
120	O
carrier	O
females)	O
probably	O
originate	O
from	O
a	O
common	O
founder	O
couple	O
born	O
in	O
1644	O
and	O
1646,	O
twelve	O
generations	O
ago.	O
All	O
36	O
patients	O
and	O
48	O
carriers	O
tested	O
from	O
the	O
three	O
kindreds	O
had	O
the	O
same	O
haplotype	O
(	O
TCD	SpecificDisease
/DXYS1,	O
11kb/DXYS12,	O
1.	O
6kb).	O
Given	O
that	O
at	O
least	O
105	O
female	O
meioses	O
transmitting	O
TCD	SpecificDisease
have	O
occurred	O
since	O
1650	O
in	O
these	O
kindreds,	O
extremely	O
close	O
linkage	O
between	O
TCD	SpecificDisease
,	O
DXYS1	O
and	O
DXYS12	O
is	O
suggested.	O
The	O
above	O
haplotype	O
is	O
a	O
very	O
useful	O
diagnostic	O
tool	O
in	O
these	O
TCD	Modifier

Functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(EGR2)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies	DiseaseClass
.	O
The	O
early	O
growth	O
response	O
2	O
gene	O
(EGR2)	O
is	O
a	O
Cys2His2zinc	O
finger	O
transcription	O
factor	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
peripheral	O
nervous	O
system	O
myelination.	O
This	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
Krox20	O
(Egr2)	O
knockout	O
mice,	O
which	O
display	O
hypomyelination	DiseaseClass
of	DiseaseClass
the	DiseaseClass
PNS	DiseaseClass
and	O
a	O
block	O
of	O
Schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation.	O
Mutations	O
in	O
the	O
human	O
EGR2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	DiseaseClass
peripheral	DiseaseClass
neuropathies	DiseaseClass
	O
Charcot-Marie-Tooth	SpecificDisease
type	SpecificDisease
1	SpecificDisease
,	O
Dejerine-Sottas	SpecificDisease
syndrome	SpecificDisease
and	O
congenital	SpecificDisease
hypomyelinating	SpecificDisease
neuropathy	SpecificDisease

Molecular	O
basis	O
of	O
human	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
:	O
analysis	O
of	O
platelet	O
von	Modifier
Willebrand	Modifier
factor	O
mRNA.	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
(	O
vWD	SpecificDisease
),	O
the	O
most	O
common	O
inherited	DiseaseClass
bleeding	DiseaseClass
disorder	DiseaseClass
in	O
humans,	O
can	O
result	O
from	O
either	O
a	O
quantitative	O
or	O
a	O
qualitative	O
defect	O
in	O
the	O
adhesive	O
glycoprotein,	O
von	Modifier
Willebrand	Modifier
factor	O
(vWF).	O
Molecular	O
studies	O
of	O
vWD	SpecificDisease
have	O
been	O
limited	O
by	O
the	O
large	O
size	O
of	O
the	O
vWF	O
gene	O
and	O
difficulty	O
in	O
obtaining	O
the	O
vWF	O
mRNA	O
from	O
patients.	O
By	O
use	O
of	O
an	O
adaptation	O
of	O
the	O
polymerase	O
chain	O
reaction,	O
vWF	O
mRNA	O
was	O
amplified	O
and	O
sequenced	O
from	O
peripheral	O
blood	O
platelets.	O
A	O
silent	O
vWF	O
allele	O
was	O
identified,	O
resulting	O
from	O
a	O
cis	O
defect	O
in	O
vWF	O
mRNA	O
transcription	O
or	O
processing.	O
In	O
two	O
type	Modifier
IIA	Modifier
vWD	Modifier
patients,	O
two	O
different	O
but	O
adjacent	O
missense	O
mutations	O
were	O
identified,	O
the	O
locations	O
of	O
which	O
may	O
identify	O
an	O
important	O
vWF	O
functional	O
domain.	O
Expression	O
in	O
heterologous	O
cells	O
of	O
recombinant	O
vWF	O
containing	O
one	O
of	O
these	O
latter	O
mutations	O
reproduced	O
the	O
characteristic	O
structural	O
abnormality	O
seen	O
in	O
type	Modifier
IIA	Modifier
vWD	Modifier

A	O
transgene	O
insertion	O
creating	O
a	O
heritable	O
chromosome	O
deletion	O
mouse	O
model	O
of	O
Prader-Willi	CompositeMention
and	CompositeMention
angelman	CompositeMention
syndromes	CompositeMention
.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
and	O
Angelman	SpecificDisease
syndrome	SpecificDisease
(	O
AS	SpecificDisease
)	O
result	O
from	O
the	O
loss	O
of	O
function	O
of	O
imprinted	O
genes	O
in	O
human	O
chromosome	O
15q11-q13.	O
The	O
central	O
part	O
of	O
mouse	O
chromosome	O
7	O
is	O
homologous	O
to	O
human	O
15q11-q13,	O
with	O
conservation	O
of	O
both	O
gene	O
order	O
and	O
imprinted	O
features.	O
We	O
report	O
here	O
the	O
characterization	O
of	O
a	O
transgene	O
insertion	O
(Epstein-Barr	O
virus	O
Latent	O
Membrane	O
Protein	O
2A,	O
LMP2A)	O
into	O
mouse	O
chromosome	O
7C,	O
which	O
has	O
resulted	O
in	O
mouse	O
models	O
for	O
PWS	SpecificDisease
and	O
AS	SpecificDisease
dependent	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent.	O
Epigenotype	O
(allelic	O
expression	O
and	O
DNA	O
methylation)	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
indicate	O
that	O
the	O
transgene-induced	O
mutation	O
has	O
generated	O
a	O
complete	O
deletion	O
of	O
the	O
PWS	Modifier
/	O
AS	Modifier
-homologous	O
region	O
but	O
has	O
not	O
deleted	O
flanking	O
loci.	O
Because	O
the	O
intact	O
chromosome	O
7,	O
opposite	O
the	O
deleted	O
homolog,	O
maintains	O
the	O
correct	O
imprint	O
in	O
somatic	O
cells	O
of	O
PWS	Modifier
and	O
AS	Modifier
mice	O
and	O
establishes	O
the	O
correct	O
imprint	O
in	O
male	O
and	O
female	O
germ	O
cells	O
of	O
AS	Modifier
mice,	O
homologous	O
association	O
and	O
replication	O
asynchrony	O
are	O
not	O
part	O
of	O
the	O
imprinting	O
mechanism.	O
This	O
heritable-deletion	O
mouse	O
model	O
will	O
be	O
particularly	O
useful	O
for	O
the	O
identification	O
of	O
the	O
etiological	O
genes	O
and	O
mechanisms,	O
phenotypic	O
basis,	O
and	O
investigation	O
of	O
therapeutic	O
approaches	O
for	O
PWS	SpecificDisease

Transgenic	O
mice	O
expressing	O
a	O
truncated	O
form	O
of	O
the	O
high	O
mobility	O
group	O
I-C	O
protein	O
develop	O
adiposity	O
and	O
an	O
abnormally	O
high	O
prevalence	O
of	O
lipomas	DiseaseClass
.	O
Chromosomal	O
translocations	O
in	O
human	O
lipomas	DiseaseClass
frequently	O
create	O
fusion	O
transcripts	O
encoding	O
high	O
mobility	O
group	O
(HMG)	O
I-C	O
DNA-binding	O
domains	O
and	O
C-terminal	O
sequences	O
from	O
different	O
presumed	O
transcription	O
factors,	O
suggesting	O
a	O
potential	O
role	O
for	O
HMG	O
I-C	O
in	O
the	O
development	O
of	O
lipomas	DiseaseClass
.	O
To	O
evaluate	O
the	O
role	O
of	O
the	O
HMG	O
I-C	O
component,	O
the	O
three	O
DNA-binding	O
domains	O
of	O
HMG	O
I-C	O
have	O
now	O
been	O
expressed	O
in	O
transgenic	O
mice.	O
Despite	O
the	O
ubiquitous	O
expression	O
of	O
the	O
truncated	O
HMG	O
I-C	O
protein,	O
the	O
transgenic	O
mice	O
develop	O
a	O
selective	O
abundance	O
of	O
fat	O
tissue	O
early	O
in	O
life,	O
show	O
marked	O
adipose	SpecificDisease
tissue	SpecificDisease
inflammation	SpecificDisease
,	O
and	O
have	O
an	O
abnormally	O
high	O
incidence	O
of	O
lipomas	DiseaseClass
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
DNA-binding	O
domains	O
of	O
HMG	O
I-C,	O
in	O
the	O
absence	O
of	O
a	O
C-terminal	O
fusion	O
partner,	O
are	O
sufficient	O
to	O
perturb	O
adipogenesis	O
and	O
predispose	O
to	O
lipomas	DiseaseClass
.	O
We	O
provide	O
data	O
supporting	O
the	O
central	O
utility	O
of	O
this	O
animal	O
model	O
as	O
a	O
tool	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
one	O
of	O
the	O
most	O
common	O
kind	O
of	O
human	O
benign	DiseaseClass
tumors	DiseaseClass

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	Modifier
families:	O
origin,	O
phenotypic	O
expression,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
The	O
frequency,	O
origin,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
MSH2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	SpecificDisease
non-polyposis	SpecificDisease
cancer	SpecificDisease
syndrome	SpecificDisease
(	O
HNPCC	SpecificDisease
)	O
was	O
investigated.	O
The	O
mutation	O
(A--	O
>	O
T	O
at	O
nt943	O
+	O
3)	O
disrupts	O
the	O
3	O
splice	O
site	O
of	O
exon	O
5	O
leading	O
to	O
the	O
deletion	O
of	O
this	O
exon	O
from	O
MSH2	O
mRNA	O
and	O
represents	O
the	O
only	O
frequent	O
MSH2	O
mutation	O
so	O
far	O
reported.	O
Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	Modifier
cancer	Modifier
families	O
analysed	O
from	O
eastern	O
England,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(8%)	O
English	O
HNPCC	Modifier
kindreds	O
analysed.	O
In	O
contrast,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(50%)	O
separately	O
identified	O
colorectal	Modifier
families	O
from	O
Newfoundland.	O
To	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	Modifier
cancer	Modifier
families	O
from	O
England	O
(n	O
=	O
4),	O
Newfoundland	O
(n	O
=	O
10),	O
and	O
the	O
United	O
States	O
(n	O
=	O
3),	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
MSH2	O
was	O
performed.	O
Within	O
the	O
English	O
and	O
US	O
families	O
there	O
was	O
little	O
evidence	O
for	O
a	O
recent	O
common	O
origin	O
of	O
the	O
MSH2	O
splice	O
site	O
mutation	O
in	O
most	O
families.	O
In	O
contrast,	O
a	O
common	O
haplotype	O
was	O
identified	O
at	O
the	O
two	O
flanking	O
markers	O
(CA5	O
and	O
D2S288)	O
in	O
eight	O
of	O
the	O
Newfoundland	O
families.	O
These	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
Newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
MLH1	O
mutations	O
in	O
Finnish	O
HNPCC	Modifier
families.	O
We	O
calculated	O
age	O
related	O
risks	O
of	O
all,	O
colorectal,	CompositeMention
endometrial,	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
in	O
nt943	O
+	O
3	O
A--	O
>	O
T	O
MSH2	O
mutation	O
carriers	O
(n	O
=	O
76)	O
for	O
all	O
patients	O
and	O
for	O
men	O
and	O
women	O
separately.	O
For	O
both	O
sexes	O
combined,	O
the	O
penetrances	O
at	O
age	O
60	O
years	O
for	O
all	O
cancers	DiseaseClass
and	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease
were	O
0.	O
86	O
and	O
0.	O
57,	O
respectively.	O
The	O
risk	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
was	O
significantly	O
higher	O
(p	O
<	O
0.	O
01)	O
in	O
males	O
than	O
females	O
(0.	O
63	O
v	O
0.	O
30	O
and	O
0.	O
84	O
v	O
0.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years,	O
respectively).	O
For	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	SpecificDisease
cancer	SpecificDisease
(0.	O
5	O
at	O
age	O
60	O
years)	O
and	O
premenopausal	SpecificDisease
ovarian	SpecificDisease
cancer	SpecificDisease
(0.	O
2	O
at	O
50	O
years).	O
These	O
intersex	O
differences	O
in	O
colorectal	Modifier
cancer	Modifier
risks	O
have	O
implications	O
for	O
screening	O
programmes	O
and	O
for	O
attempts	O
to	O
identify	O
colorectal	Modifier
cancer	Modifier

Novel	O
mutation	O
at	O
the	O
initiation	O
codon	O
in	O
the	O
Norrie	Modifier
disease	Modifier
gene	O
in	O
two	O
Japanese	O
families.	O
We	O
have	O
identified	O
a	O
new	O
mutation	O
of	O
Norrie	Modifier
disease	Modifier
(	O
ND	Modifier
)	O
gene	O
in	O
two	O
Japanese	O
males	O
from	O
unrelated	O
families;	O
they	O
showed	O
typical	O
ocular	O
features	O
of	O
ND	SpecificDisease
but	O
no	O
mental	DiseaseClass
retardation	DiseaseClass
or	O
hearing	DiseaseClass
impairment	DiseaseClass
.	O
A	O
mutation	O
was	O
found	O
in	O
both	O
patients	O
at	O
the	O
initiation	O
codon	O
of	O
exon	O
2	O
of	O
the	O
ND	Modifier
gene	O
(ATG	O
to	O
GTG),	O
with	O
otherwise	O
normal	O
nucleotide	O
sequences.	O
Their	O
mothers	O
had	O
the	O
normal	O
and	O
mutant	O
types	O
of	O
the	O
gene,	O
which	O
was	O
expected	O
for	O
heterozygotes	O
of	O
the	O
disease.	O
The	O
mutation	O
of	O
the	O
initiation	O
codon	O
would	O
cause	O
the	O
failure	O
of	O
ND	Modifier
gene	O
expression	O
or	O
a	O
defect	O
in	O
translation	O
thereby	O
truncating	O
the	O
amino	O
terminus	O
of	O
ND	Modifier
protein.	O
In	O
view	O
of	O
the	O
rarity	O
and	O
marked	O
heterogeneity	O
of	O
mutations	O
in	O
the	O
ND	Modifier

Haplotype	O
and	O
phenotype	O
analysis	O
of	O
six	O
recurrent	O
BRCA1	O
mutations	O
in	O
61	O
families:	O
results	O
of	O
an	O
international	O
study.	O
Several	O
BRCA1	O
mutations	O
have	O
now	O
been	O
found	O
to	O
occur	O
in	O
geographically	O
diverse	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
families.	O
To	O
investigate	O
mutation	O
origin	O
and	O
mutation-specific	O
phenotypes	O
due	O
to	O
BRCA1,	O
we	O
constructed	O
a	O
haplotype	O
of	O
nine	O
polymorphic	O
markers	O
within	O
or	O
immediately	O
flanking	O
the	O
BRCA1	O
locus	O
in	O
a	O
set	O
of	O
61	O
breast/ovarian	Modifier
cancer	Modifier
families	O
selected	O
for	O
having	O
one	O
of	O
six	O
recurrent	O
BRCA1	O
mutations.	O
Tests	O
of	O
both	O
mutations	O
and	O
family-specific	O
differences	O
in	O
age	O
at	O
diagnosis	O
were	O
not	O
significant.	O
A	O
comparison	O
of	O
the	O
six	O
mutations	O
in	O
the	O
relative	O
proportions	O
of	O
cases	O
of	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
was	O
suggestive	O
of	O
an	O
effect	O
(P	O
=.	O
069),	O
with	O
57%	O
of	O
women	O
presumed	O
affected	O
because	O
of	O
the	O
1294	O
del	O
40	O
BRCA1	O
mutation	O
having	O
ovarian	SpecificDisease
cancer	SpecificDisease

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
variant	O
(G6PD	O
Nagano)	O
associated	O
with	O
congenital	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
.	O
A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
variant	O
associated	O
with	O
chronic	SpecificDisease
nonspherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
was	O
reported.	O
The	O
patient,	O
a	O
6-year-old	O
Japanese	O
male,	O
was	O
noticed	O
to	O
have	O
hemolytic	SpecificDisease
anemia	SpecificDisease
soon	O
after	O
birth,	O
and	O
a	O
diagnosis	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
was	O
made	O
at	O
the	O
age	O
of	O
2.	O
He	O
had	O
episodes	O
of	O
hemolytic	DiseaseClass
crisis	DiseaseClass
several	O
times	O
after	O
upper	SpecificDisease
respiratory	SpecificDisease
infection	SpecificDisease
.	O
G6PD	O
activity	O
of	O
the	O
patient	O
was	O
5.	O
5%	O
of	O
normal.	O
The	O
enzymatic	O
characteristics	O
were	O
examined	O
when	O
he	O
was	O
5	O
years	O
old,	O
and	O
his	O
G6PD	O
showed	O
faster-than-normal	O
electrophoretic	O
mobility,	O
low	O
Km	O
G6P,	O
high	O
Km	O
NADP,	O
low	O
Ki	O
NADPH,	O
normal	O
utilization	O
of	O
substrate	O
analogues,	O
heat	O
instability,	O
and	O
a	O
normal	O
pH	O
optimum	O
curve.	O
From	O
these	O
results,	O
this	O
was	O
considered	O
to	O
be	O
a	O
new	O
variant	O
and	O
was	O
designated	O
G6PD	O
Nagano.	O
Infection-induced	O
hemolysis	SpecificDisease
and	O
chronic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease

Craniofrontonasal	SpecificDisease
dysplasia	SpecificDisease
.	O
We	O
report	O
on	O
nine	O
patients	O
with	O
craniofrontonasal	SpecificDisease
dysplasia	SpecificDisease
(	O
CFND	SpecificDisease
).	O
Seven	O
classical	O
cases	O
had	O
facial	O
features	O
suggestive	O
of	O
frontonasal	SpecificDisease
dysplasia	SpecificDisease
and	O
coronal	SpecificDisease
craniosynostosis	SpecificDisease
.	O
Extracranial	DiseaseClass
abnormalities	DiseaseClass
such	O
as	O
brittle	SpecificDisease
nails	SpecificDisease
with	SpecificDisease
prominent	SpecificDisease
longitudinal	SpecificDisease
grooves	SpecificDisease
or	O
syndactyly	CompositeMention
of	CompositeMention
fingers	CompositeMention
and	CompositeMention
toes	CompositeMention
were	O
observed	O
in	O
individual	O
patients.	O
In	O
two	O
families	O
the	O
father	O
of	O
classical	O
cases	O
showed	O
a	O
milder	O
pattern	O
of	O
abnormalities,	O
consistent	O
with	O
the	O
diagnosis.	O
We	O
present	O
a	O
2-	O
to	O
13-year	O
follow-up	O
on	O
our	O
patients.	O
Hypotonia	SpecificDisease
and	O
laxity	SpecificDisease
of	SpecificDisease
joints	SpecificDisease
are	O
common	O
and	O
may	O
necessitate	O
supportive	O
measures.	O
Mild	O
developmental	DiseaseClass
delay	DiseaseClass
was	O
noted	O
in	O
three	O
out	O
of	O
six	O
classical	O
cases	O
studied	O
in	O
detail.	O
Unlike	O
almost	O
all	O
other	O
X-linked	DiseaseClass
disorders	DiseaseClass
,	O
clinical	O
expression	O
in	O
CFND	SpecificDisease

A	O
new	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
.	O
A	O
C-to-T	O
transition	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
was	O
found	O
in	O
2	O
affected	O
males	O
and	O
two	O
obligate	O
carriers	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease

The	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
and	O
X-linked	SpecificDisease
congenital	SpecificDisease
thrombocytopenia	SpecificDisease
are	O
caused	O
by	O
mutations	O
of	O
the	O
same	O
gene.	O
The	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
thrombocytopenia	SpecificDisease
,	O
small	O
platelets,	O
eczema	SpecificDisease
,	O
recurrent	O
infections,	O
and	O
immunodeficiency	DiseaseClass
.	O
Besides	O
the	O
classic	O
WAS	Modifier
phenotype,	O
there	O
is	O
a	O
group	O
of	O
patients	O
with	O
congenital	SpecificDisease
X-linked	SpecificDisease
thrombocytopenia	SpecificDisease
(	O
XLT	SpecificDisease
)	O
who	O
have	O
small	O
platelets	O
but	O
only	O
transient	O
eczema	SpecificDisease
,	O
if	O
any,	O
and	O
minimal	O
immune	DiseaseClass
deficiency	DiseaseClass
.	O
Because	O
the	O
gene	O
responsible	O
for	O
WAS	SpecificDisease
has	O
been	O
sequenced,	O
it	O
was	O
possible	O
to	O
correlate	O
the	O
WAS	Modifier
phenotypes	O
with	O
WAS	Modifier
gene	O
mutations.	O
Using	O
a	O
fingerprinting	O
screening	O
technique,	O
we	O
determined	O
the	O
approximate	O
location	O
of	O
the	O
mutation	O
in	O
13	O
unrelated	O
WAS	Modifier
patients	O
with	O
mild	O
to	O
severe	O
clinical	O
symptoms.	O
Direct	O
sequence	O
analysis	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
obtained	O
from	O
patient-derived	O
cell	O
lines	O
showed	O
12	O
unique	O
mutations	O
distributed	O
throughout	O
the	O
WAS	Modifier
gene,	O
including	O
insertions,	O
deletions,	O
and	O
point	O
mutations	O
resulting	O
in	O
amino	O
acid	O
substitutions,	O
termination,	O
exon	O
skipping,	O
or	O
splicing	O
defects.	O
Of	O
4	O
unrelated	O
patients	O
with	O
the	O
XLT	Modifier
phenotype,	O
3	O
had	O
missense	O
mutations	O
affecting	O
exon	O
2	O
and	O
1	O
had	O
a	O
splice-site	O
mutation	O
affecting	O
exon	O
9.	O
Patients	O
with	O
classic	O
WAS	SpecificDisease
had	O
more	O
complex	O
mutations,	O
resulting	O
in	O
termination	O
codons,	O
frameshift,	O
and	O
early	O
termination.	O
These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XLT	SpecificDisease
and	O
WAS	SpecificDisease

A	O
3-base	O
pair	O
in-frame	O
deletion	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
results	O
in	O
a	O
kinetic	O
variant	O
of	O
phenylketonuria	SpecificDisease
.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disease	DiseaseClass
due	O
to	O
deficiency	SpecificDisease
of	SpecificDisease
a	SpecificDisease
hepatic	SpecificDisease
enzyme,	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
The	O
absence	O
of	O
PAH	O
activity	O
results	O
in	O
typical	O
PKU	SpecificDisease
while	O
persistence	O
of	O
a	O
residual	O
enzyme	O
activity	O
gives	O
rise	O
to	O
variant	O
forms	O
of	O
the	O
disease.	O
We	O
report	O
here	O
a	O
3-base	O
pair	O
in-frame	O
deletion	O
of	O
the	O
PAH	O
gene	O
(delta	O
194)	O
in	O
a	O
mild	O
variant,	O
with	O
markedly	O
reduced	O
affinity	O
of	O
the	O
enzyme	O
for	O
phenylalanine	O
(Km	O
=	O
160	O
nM),	O
and	O
we	O
provide	O
functional	O
evidence	O
for	O
responsibility	O
of	O
the	O
deletion	O
in	O
the	O
mutant	O
phenotype.	O
Since	O
the	O
deletion	O
was	O
located	O
in	O
the	O
third	O
exon	O
of	O
the	O
gene,	O
which	O
presents	O
no	O
homology	O
with	O
other	O
hydroxylases,	O
we	O
suggest	O
that	O
exon	O
3	O
is	O
involved	O
in	O
the	O
specificity	O
of	O
the	O
enzyme	O
for	O
phenylalanine.	O
Finally,	O
since	O
none	O
of	O
the	O
98	O
PKU	Modifier

Friedreich	SpecificDisease
ataxia	SpecificDisease
:	O
an	O
overview.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
,	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
neurodegenerative	DiseaseClass
disease	DiseaseClass
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	SpecificDisease
ataxias	SpecificDisease
.	O
The	O
recent	O
discovery	O
of	O
the	O
gene	O
that	O
is	O
mutated	O
in	O
this	O
condition,	O
FRDA,	O
has	O
led	O
to	O
rapid	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
.	O
About	O
98%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene.	O
This	O
leads	O
to	O
reduced	O
levels	O
of	O
the	O
protein,	O
frataxin.	O
There	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death.	O
Currently	O
there	O
is	O
no	O
known	O
treatment	O
that	O
alters	O
the	O
natural	O
course	O
of	O
the	O
disease.	O
The	O
discovery	O
of	O
the	O
FRDA	Modifier

Clinical	O
and	O
molecular	O
genetics	O
of	O
primary	DiseaseClass
dystonias	DiseaseClass
.	O
Primary	DiseaseClass
dystonias	DiseaseClass
are	O
movement	DiseaseClass
disorders	DiseaseClass
with	O
dystonia	DiseaseClass
as	O
a	O
major	O
symptom.	O
They	O
are	O
frequently	O
inherited	O
as	O
Mendelian	O
traits.	O
There	O
are	O
at	O
least	O
eight	O
clinically	O
distinct	O
autosomal	O
dominant	O
and	O
two	O
X-linked	O
recessive	O
forms.	O
In	O
addition,	O
pedigree	O
analyses	O
suggest	O
the	O
occurrence	O
of	O
an	O
autosomal	O
recessive	O
variant.	O
The	O
clinical	O
classification	O
is	O
increasingly	O
being	O
replaced	O
by	O
a	O
genetic	O
one.	O
To	O
date	O
gene	O
loci	O
have	O
been	O
identified	O
in	O
at	O
least	O
six	O
autosomal	O
dominant	O
forms,	O
i.	O
e.,	O
in	O
idiopathic	SpecificDisease
torsion	SpecificDisease
dystonia	SpecificDisease
(9q34),	O
focal	SpecificDisease
dystonia	SpecificDisease
(18p),	O
adult-onset	O
idiopathic	SpecificDisease
torsion	SpecificDisease
dystonia	SpecificDisease
of	O
mixed	O
type	O
(8p21-q22),	O
dopa-responsive	SpecificDisease
dystonia	SpecificDisease
(14q22.	O
1-q22.	O
2),	O
and	O
paroxysmal	SpecificDisease
dystonic	SpecificDisease
choreoathetosis	SpecificDisease
(2q25-q33;	O
1p21-p13.	O
3).	O
Gene	O
loci	O
in	O
the	O
X-linked	O
recessive	O
	O
forms	O
have	O
been	O
assigned	O
to	O
Xq13.	O
1	O
in	O
the	O
X-linked	SpecificDisease
dystonia	SpecificDisease
parkinsonism	SpecificDisease
syndrome	SpecificDisease
and	O
to	O
Xq22	O
in	O
X-linked	DiseaseClass
sensorineural	DiseaseClass
deafness	DiseaseClass
,	O
dystonia	DiseaseClass
,	O
and	O
mental	DiseaseClass
retardation	DiseaseClass
.	O
The	O
disease	O
genes	O
have	O
been	O
identified	O
in	O
two	O
autosomal	O
dominant	O
forms	O
and	O
in	O
one	O
X-linked	O
recessive	O
form.	O
Mutations	O
in	O
a	O
gene	O
coding	O
for	O
an	O
ATP-binding	O
protein	O
were	O
detected	O
in	O
idiopathic	SpecificDisease
torsion	SpecificDisease
dystonia	SpecificDisease
(DYT1),	O
and	O
the	O
GTP	O
cyclohydrolase	O
1	O
gene	O
is	O
mutated	O
in	O
dopa-responsive	SpecificDisease
dystonia	SpecificDisease
(DYT5).	O
In	O
sensorineural	DiseaseClass
deafness	DiseaseClass
,	O
dystonia	DiseaseClass
,	O
and	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
DDP	O
coding	O
for	O
a	O
polypeptide	O
of	O
unknown	O
function.	O
This	O
article	O
reviews	O
the	O
clinical	O
and	O
molecular	O
genetics	O
of	O
primary	DiseaseClass
dystonias	DiseaseClass
,	O
critically	O
discusses	O
present	O
findings,	O
and	O
proposes	O
referring	O
to	O
the	O
known	O
forms,	O
most	O
of	O
which	O
can	O
be	O
distinguished	O
by	O
genetic	O
criteria,	O
as	O
dystonias	CompositeMention
1-12	CompositeMention

Clinical	O
and	O
genetic	O
study	O
of	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
in	O
an	O
Australian	O
population.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
FRDA	Modifier
gene	O
that	O
encodes	O
a	O
210-amino	O
acid	O
protein	O
called	O
frataxin.	O
An	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
is	O
present	O
in	O
more	O
than	O
95%	O
of	O
mutant	O
alleles.	O
Of	O
the	O
83	O
people	O
we	O
studied	O
who	O
have	O
mutations	O
in	O
FRDA,	O
78	O
are	O
homozygous	O
for	O
an	O
expanded	O
GAA	O
repeat;	O
the	O
other	O
five	O
patients	O
have	O
an	O
expansion	O
in	O
one	O
allele	O
and	O
a	O
point	O
mutation	O
in	O
the	O
other.	O
Here	O
we	O
present	O
a	O
detailed	O
clinical	O
and	O
genetic	O
study	O
of	O
a	O
subset	O
of	O
51	O
patients	O
homozygous	O
for	O
an	O
expansion	O
of	O
the	O
GAA	O
repeat.	O
We	O
found	O
a	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
of	O
the	O
two	O
expanded	O
alleles	O
and	O
age	O
at	O
onset,	O
age	O
into	O
wheelchair,	O
scoliosis	DiseaseClass
,	O
impaired	O
vibration	O
sense,	O
and	O
the	O
presence	O
of	O
foot	DiseaseClass
deformity	DiseaseClass
.	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
size	O
of	O
the	O
smaller	O
allele	O
and	O
cardiomyopathy	SpecificDisease
,	O
diabetes	SpecificDisease
mellitus	SpecificDisease
,	O
loss	DiseaseClass
of	DiseaseClass
proprioception	DiseaseClass
,	O
or	O
bladder	DiseaseClass
symptoms	DiseaseClass
.	O
The	O
larger	O
allele	O
size	O
correlated	O
with	O
bladder	DiseaseClass
symptoms	DiseaseClass
and	O
the	O
presence	O
of	O
foot	DiseaseClass
deformity	DiseaseClass
.	O
The	O
duration	O
of	O
disease	O
is	O
correlated	O
with	O
wheelchair	O
use	O
and	O
the	O
presence	O
of	O
diabetes	DiseaseClass
,	O
scoliosis	DiseaseClass
,	O
bladder	DiseaseClass
symptoms	DiseaseClass
and	O
impaired	DiseaseClass
proprioception	DiseaseClass

Recurrent	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
with	O
absence	SpecificDisease
of	SpecificDisease
the	SpecificDisease
sixth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
:	O
an	O
evaluation	O
of	O
underlying	O
immunologic	O
mechanisms.	O
A	O
51/2-year-old	O
black	O
girl	O
with	O
recurrent	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
and	O
absence	SpecificDisease
of	SpecificDisease
the	SpecificDisease
sixth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C6)	O
is	O
reported.	O
To	O
explore	O
the	O
pathogenesis	O
of	O
recurrent	O
neisserial	SpecificDisease
infections	SpecificDisease
in	O
C6	SpecificDisease
deficiency	SpecificDisease
,	O
a	O
detailed	O
analysis	O
of	O
her	O
immune	O
competence	O
was	O
conducted.	O
Her	O
serum	O
had	O
normal	O
chemotactic,	O
opsonic,	O
alternative	O
complement	O
pathway,	O
and	O
specific	O
antibody	O
activity,	O
but	O
lacked	O
complement-mediated	O
bacteriolytic	O
activity.	O
In	O
addition,	O
her	O
C6-deficient	Modifier
serum	O
was	O
indistinguishable	O
from	O
normal	O
serum	O
in	O
a	O
complement-dependent	O
assay	O
of	O
phagocyte	O
bactericidal	O
activity.	O
Absent	O
bacteriolysis	O
remains	O
the	O
only	O
consistent	O
defect	O
associated	O
with	O
recurrent	O
neisserial	SpecificDisease
infections	SpecificDisease

Mutation	O
of	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(CYP27)	O
results	O
in	O
truncation	O
of	O
mRNA	O
expressed	O
in	O
leucocytes	O
in	O
a	O
Japanese	O
family	O
with	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
.	O
OBJECTIVES	O
	O
A	O
Japanese	O
family	O
with	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(CYP27).	O
The	O
expression	O
of	O
CYP27	O
has	O
been	O
mostly	O
explored	O
using	O
cultured	O
fibroblasts,	O
prompting	O
the	O
examination	O
of	O
the	O
transcripts	O
from	O
blood	O
leucocytes	O
as	O
a	O
simple	O
and	O
rapid	O
technique.	O
METHODS	O
	O
An	O
alteration	O
in	O
CYP27	O
of	O
the	O
proband	O
was	O
searched	O
for	O
by	O
polymerase	O
chain	O
reaction-single	O
strand	O
conformation	O
polymorphism	O
(PCR-SSCP)	O
analysis	O
and	O
subsequent	O
sequencing.	O
Samples	O
of	O
RNA	O
were	O
subjected	O
to	O
reverse	O
transcription	O
PCR	O
(RT-PCR)	O
and	O
the	O
product	O
of	O
the	O
proband	O
was	O
amplified	O
with	O
nested	O
primers	O
and	O
sequenced.	O
RESULTS	O
	O
A	O
homozygous	O
G	O
to	O
A	O
transition	O
at	O
the	O
5	O
end	O
of	O
intron	O
7	O
was	O
detected	O
in	O
the	O
patient.	O
In	O
RT-PCR	O
analysis,	O
only	O
a	O
truncated	O
transcript	O
was	O
detected	O
in	O
the	O
patient,	O
whereas	O
both	O
normal	O
and	O
truncated	O
transcripts	O
were	O
detected	O
in	O
the	O
siblings.	O
The	O
sequencing	O
of	O
the	O
patients	O
cDNA	O
fragment	O
disclosed	O
a	O
direct	O
conjuction	O
of	O
exon	O
6	O
and	O
exon	O
8.	O
CONCLUSION	O
	O
The	O
mutation	O
at	O
splice	O
donor	O
site	O
and	O
the	O
truncation	O
of	O
mRNA	O
were	O
identical	O
with	O
those	O
of	O
a	O
recently	O
reported	O
Italian	O
patient,	O
although	O
different	O
in	O
symptomatology.	O
The	O
application	O
of	O
blood	O
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	SpecificDisease
of	SpecificDisease
CYP27	SpecificDisease

Frequent	O
detection	O
of	O
codon	O
877	O
mutation	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
advanced	SpecificDisease
prostate	SpecificDisease
cancers	SpecificDisease
.	O
Prostatic	O
tissue	O
specimens	O
derived	O
from	O
transurethral	O
resections	O
of	O
patients	O
with	O
metastatic	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
were	O
analyzed	O
for	O
genetic	O
alterations	O
in	O
the	O
hormone-binding	O
domain	O
of	O
the	O
androgen	O
receptor	O
(AR)	O
gene.	O
Direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction-derived	O
DNAs	O
of	O
6	O
of	O
24	O
specimens	O
revealed	O
a	O
codon	O
877	O
mutation	O
(ACT--	O
>	O
GCT,	O
Thr--	O
>	O
Ala)	O
in	O
the	O
hormone-binding	O
domain	O
of	O
the	O
AR	O
gene.	O
This	O
same	O
AR	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
a	O
metastatic	Modifier
prostate	Modifier
cancer	Modifier
cell	O
line,	O
LNCaP,	O
where	O
this	O
mutation	O
confers	O
upon	O
the	O
AR	O
an	O
altered	O
ligand-binding	O
specificity	O
which	O
is	O
stimulated	O
by	O
estrogens,	O
progestagens,	O
and	O
antiandrogens.	O
It	O
is	O
possible	O
that	O
analogous	O
to	O
an	O
activated/altered	O
growth	O
factor	O
receptor	O
oncogene,	O
codon	O
877	O
mutant	O
AR	O
with	O
altered	O
ligand	O
binding	O
may	O
provide	O
a	O
selective	O
growth	O
advantage	O
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
.	O
Although	O
estrogens	O
are	O
used	O
infrequently,	O
antiandrogens	O
are	O
used	O
increasingly	O
in	O
hormonal	O
therapy	O
for	O
patients	O
with	O
advanced	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease

ATM-dependent	O
phosphorylation	O
of	O
nibrin	O
in	O
response	O
to	O
radiation	O
exposure.	O
Mutations	O
in	O
the	O
gene	O
ATM	O
are	O
responsible	O
for	O
the	O
genetic	DiseaseClass
disorder	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
),	O
which	O
is	O
characterized	O
by	O
cerebellar	DiseaseClass
dysfunction	DiseaseClass
,	O
radiosensitivity,	O
chromosomal	O
instability	O
and	O
cancer	Modifier
predisposition.	O
Both	O
the	O
A-T	Modifier
phenotype	O
and	O
the	O
similarity	O
of	O
the	O
ATM	O
protein	O
to	O
other	O
DNA-damage	O
sensors	O
suggests	O
a	O
role	O
for	O
ATM	O
in	O
biochemical	O
pathways	O
involved	O
in	O
the	O
recognition,	O
signalling	O
and	O
repair	O
of	O
DNA	O
double-strand	O
breaks	O
(DSBs).	O
There	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity,	O
chromosomal	O
instability	O
and	O
cancer	Modifier
predisposition	O
in	O
A-T	SpecificDisease
patients	O
and	O
that	O
in	O
patients	O
with	O
Nijmegen	SpecificDisease
breakage	SpecificDisease
syndrome	SpecificDisease
(	O
NBS	SpecificDisease
).	O
The	O
protein	O
defective	O
in	O
NBS	SpecificDisease
,	O
nibrin	O
(encoded	O
by	O
NBS1),	O
forms	O
a	O
complex	O
with	O
MRE11	O
and	O
RAD50	O
(refs	O
1,	O
2).	O
This	O
complex	O
localizes	O
to	O
DSBs	O
within	O
30	O
minutes	O
after	O
cellular	O
exposure	O
to	O
ionizing	O
radiation	O
(IR)	O
and	O
is	O
observed	O
in	O
brightly	O
staining	O
nuclear	O
foci	O
after	O
a	O
longer	O
period	O
of	O
time.	O
The	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
A-T	SpecificDisease
and	O
NBS	SpecificDisease
suggests	O
that	O
ATM	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway.	O
Here	O
we	O
demonstrate	O
that	O
nibrin	O
is	O
phosphorylated	O
within	O
one	O
hour	O
of	O
treatment	O
of	O
cells	O
with	O
IR.	O
This	O
response	O
is	O
abrogated	O
in	O
A-T	Modifier
cells	O
that	O
either	O
do	O
not	O
express	O
ATM	O
protein	O
or	O
express	O
near	O
full-length	O
mutant	O
protein.	O
We	O
also	O
show	O
that	O
ATM	O
physically	O
interacts	O
with	O
and	O
phosphorylates	O
nibrin	O
on	O
serine	O
343	O
both	O
in	O
vivo	O
and	O
in	O
vitro.	O
Phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(S343A)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
NBS	Modifier
cells.	O
ATM	O
phosphorylation	O
of	O
nibrin	O
does	O
not	O
affect	O
nibrin-MRE11-RAD50	O
association	O
as	O
revealed	O
by	O
radiation-induced	O
foci	O
formation.	O
Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A-T	SpecificDisease
and	O
NBS	SpecificDisease

Detection	O
of	O
an	O
unstable	O
fragment	O
of	O
DNA	O
specific	O
to	O
individuals	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	SpecificDisease
dystrophy	SpecificDisease
,	O
with	O
a	O
prevalence	O
of	O
2-14	O
per	O
100,	O
000	O
individuals.	O
The	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	DiseaseClass
weakness	DiseaseClass
and	O
sustained	DiseaseClass
muscle	DiseaseClass
contraction	DiseaseClass
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms.	O
The	O
age	O
at	O
onset	O
and	O
severity	O
of	O
the	O
disease	O
show	O
extreme	O
variation,	O
both	O
within	O
and	O
between	O
families.	O
Despite	O
its	O
clinical	O
variability,	O
this	O
dominant	O
condition	O
segregates	O
as	O
a	O
single	O
locus	O
at	O
chromosome	O
19q13.	O
3	O
in	O
every	O
population	O
studied.	O
It	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ERCC1	O
proximally	O
and	O
D19S51	O
distally;	O
these	O
define	O
the	O
DM	Modifier
critical	O
region.	O
We	O
report	O
the	O
isolation	O
of	O
an	O
expressed	O
sequence	O
from	O
this	O
region	O
which	O
detects	O
a	O
DNA	O
fragment	O
that	O
is	O
larger	O
in	O
affected	O
individuals	O
than	O
in	O
normal	O
siblings	O
or	O
unaffected	O
controls.	O
The	O
size	O
of	O
this	O
fragment	O
varies	O
between	O
affected	O
siblings,	O
and	O
increases	O
in	O
size	O
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	O
of	O
the	O
disease.	O
We	O
postulate	O
that	O
this	O
unstable	O
DNA	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
DM	SpecificDisease

Detection	O
of	O
a	O
novel	O
missense	O
mutation	O
and	O
second	O
recurrent	O
mutation	O
in	O
the	O
CACNA1A	O
gene	O
in	O
individuals	O
with	O
EA-2	SpecificDisease
and	O
FHM	SpecificDisease
.	O
Mutations	O
in	O
the	O
brain	O
specific	O
P/Q	O
type	O
Ca2	O
+	O
channel	O
alpha1	O
subunit	O
gene,	O
CACNA1A,	O
have	O
been	O
identified	O
in	O
three	O
clinically	O
distinct	O
disorders,	O
viz.	O
episodic	SpecificDisease
ataxia	SpecificDisease
type	SpecificDisease
2	SpecificDisease
(	O
EA-2	SpecificDisease
),	O
familial	SpecificDisease
hemiplegic	SpecificDisease
migraine	SpecificDisease
(	O
FHM	SpecificDisease
)	O
and	O
spinocerebellar	SpecificDisease
ataxia	SpecificDisease
6	SpecificDisease
(	O
SCA6	SpecificDisease
).	O
For	O
individuals	O
with	O
EA-2	SpecificDisease
,	O
the	O
mutations	O
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	O
in	O
a	O
truncated	O
protein	O
product.	O
Several	O
different	O
missense	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
FHM	SpecificDisease
.	O
At	O
least	O
two	O
of	O
these	O
mutations	O
have	O
been	O
identified	O
on	O
two	O
different	O
chromosome	O
19p13	O
haplotypes	O
and	O
thus	O
represent	O
recurrent	O
mutations.	O
In	O
the	O
present	O
study,	O
we	O
have	O
screened	O
several	O
individuals	O
for	O
mutations	O
in	O
all	O
47	O
exons	O
in	O
the	O
CACNA1A	O
gene	O
by	O
single-strand	O
conformation	O
analysis.	O
We	O
have	O
characterised	O
a	O
novel	O
missense	O
mutation,	O
G5260A,	O
in	O
exon	O
32	O
in	O
a	O
family	O
segregating	O
for	O
EA-2	SpecificDisease
.	O
The	O
consequence	O
of	O
this	O
mutation	O
is	O
an	O
amino	O
acid	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
within	O
the	O
CACNA1A	O
gene.	O
This	O
represents	O
the	O
first	O
point	O
mutation	O
not	O
resulting	O
in	O
a	O
proposed	O
truncated	O
protein.	O
Furthermore,	O
this	O
mutation	O
has	O
been	O
detected	O
in	O
a	O
family	O
member	O
with	O
mild	O
clinical	O
signs	O
including	O
only	O
migraine	SpecificDisease
.	O
Additionally,	O
a	O
second	O
previously	O
identified	O
recurrent	O
muta	O
tion,	O
C2272T,	O
in	O
exon	O
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	O
with	O
FHM	SpecificDisease

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation:	O
a	O
possible	O
explanation	O
for	O
genotype-phenotype	O
correlations	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
.	O
Inactivation	O
of	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis.	O
Patients	O
with	O
familial	SpecificDisease
APC	SpecificDisease
(	O
FAP	SpecificDisease
)	O
carry	O
germ-line	O
mutations	O
in	O
the	O
APC	Modifier
gene	O
and	O
develop	O
multiple	O
colorectal	SpecificDisease
adenomas	SpecificDisease
and	O
subsequent	O
carcinomas	DiseaseClass
early	O
in	O
life.	O
The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	Modifier
mutation	O
(genotype-phenotype	O
correlation).	O
Together	O
with	O
the	O
fact	O
that	O
both	O
germ-line	O
and	O
sporadic	O
APC	Modifier
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	Modifier
gene,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	Modifier
mutants.	O
Loss	O
of	O
APC	Modifier
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta-catenin-/Tcf-mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells.	O
Here,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	Modifier
gene	O
products	O
associated	O
with	O
severe	O
polyposis	SpecificDisease
.	O
Wild-type	O
APC	Modifier
activity	O
in	O
beta-catenin-/Tcf-mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	Modifier
that	O
is	O
truncated	O
at	O
codon	O
1309.	O
In	O
contrast,	O
mutant	O
APC	Modifier
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	SpecificDisease
polyposis	SpecificDisease
(codon	O
386	O
or	O
1465)	O
interfered	O
only	O
weakly	O
with	O
wild-type	O
APC	Modifier
activity.	O
These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype-phenotype	O
correlation	O
in	O
FAP	Modifier
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	Modifier
tumor	Modifier

Mutation	O
of	O
the	O
KIT	O
(mast/stem	O
cell	O
growth	O
factor	O
receptor)	O
protooncogene	O
in	O
human	O
piebaldism	SpecificDisease
.	O
Piebaldism	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
cogenital	O
patches	O
of	O
skin	O
and	O
hair	O
from	O
which	O
melanocytes	O
are	O
completely	O
absent.	O
A	O
similar	O
disorder	O
of	O
mouse,	O
dominant	O
white	O
spotting	O
(W),	O
results	O
from	O
mutations	O
of	O
the	O
c-Kit	O
protooncogene,	O
which	O
encodes	O
and	O
receptor	O
for	O
mast/stem	O
cell	O
growth	O
factor.	O
We	O
identified	O
a	O
KIT	O
gene	O
mutation	O
in	O
a	O
proband	O
with	O
classic	O
autosomal	O
dominant	O
piebaldism	SpecificDisease
.	O
This	O
mutation	O
results	O
in	O
a	O
Gly----Arg	O
substitution	O
at	O
codon	O
664,	O
within	O
the	O
tyrosine	O
kinase	O
domain.	O
This	O
substitution	O
was	O
not	O
seen	O
in	O
any	O
normal	O
individuals	O
and	O
was	O
completely	O
linked	O
to	O
the	O
piebald	Modifier
phenotype	O
in	O
the	O
probands	O
family.	O
Piebaldism	SpecificDisease

An	O
arylsulfatase	O
A	O
(ARSA)	O
missense	O
mutation	O
(T274M)	O
causing	O
late-infantile	SpecificDisease
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
.	O
Metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
arylsulfatase	SpecificDisease
A	SpecificDisease
(ARSA;	O
EC	O
3.	O
1.	O
6.	O
8).	O
The	O
8	O
ARSA	O
exons	O
and	O
adjacent	O
intron	O
boundaries	O
from	O
a	O
patient	O
with	O
late-infantile	SpecificDisease
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
were	O
polymerase	O
chain	O
reaction	O
(PCR)	O
amplified	O
in	O
seven	O
discrete	O
reactions.	O
Amplified	O
ARSA	O
exons	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
sequence	O
alterations	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis,	O
followed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
products.	O
The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
C--	O
>	O
T	O
transition	O
in	O
exon	O
IV	O
that	O
results	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
threonine	O
residue	O
at	O
amino	O
acid	O
274	O
with	O
a	O
methionine	O
(T274M).	O
Analysis	O
of	O
a	O
further	O
29	O
MLD	Modifier

Mutations	O
in	O
the	O
gene	O
for	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
in	O
patients	O
with	O
different	O
clinical	O
phenotypes.	O
Recently,	O
the	O
gene	O
for	O
the	O
most	O
common	O
peroxisomal	DiseaseClass
disorder	DiseaseClass
,	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
X-ALD	SpecificDisease
),	O
has	O
been	O
described	O
encoding	O
a	O
peroxisomal	O
membrane	O
transporter	O
protein.	O
We	O
analyzed	O
the	O
entire	O
protein-coding	O
sequence	O
of	O
this	O
gene	O
by	O
reverse-transcription	O
PCR,	O
SSCP,	O
and	O
DNA	O
sequencing	O
in	O
five	O
patients	O
with	O
different	O
clinical	O
expression	O
of	O
X-ALD	SpecificDisease
and	O
in	O
their	O
female	O
relatives;	O
these	O
clinical	O
expressions	O
were	O
cerebral	O
childhood	O
ALD	SpecificDisease
,	O
adrenomyeloneuropathy	SpecificDisease
(	O
AMN	SpecificDisease
),	O
and	O
"	O
Addison	Modifier
disease	Modifier
only	Modifier
"	O
(	O
ADO	Modifier
)	O
phenotype.	O
In	O
the	O
three	O
patients	O
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	O
childhood	O
ALD	SpecificDisease
we	O
identified	O
in	O
the	O
5	O
portion	O
of	O
the	O
X-ALD	Modifier
gene	O
a	O
38-bp	O
deletion	O
that	O
causes	O
a	O
frameshift	O
mutation,	O
a	O
3-bp	O
deletion	O
leading	O
to	O
a	O
deletion	O
of	O
an	O
amino	O
acid	O
in	O
the	O
ATP-binding	O
domain	O
of	O
the	O
ALD	Modifier
protein,	O
and	O
a	O
missense	O
mutation.	O
In	O
the	O
patient	O
with	O
the	O
clinical	O
phenotype	O
of	O
AMN	SpecificDisease
,	O
a	O
nonsense	O
mutation	O
in	O
codon	O
212,	O
along	O
with	O
a	O
second	O
site	O
mutation	O
at	O
codon	O
178,	O
was	O
observed.	O
Analysis	O
of	O
the	O
patient	O
with	O
the	O
ADO	Modifier
phenotype	O
revealed	O
a	O
further	O
missense	O
mutation	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
ALDP/PMP70	O
comparison.	O
The	O
disruptive	O
nature	O
of	O
two	O
mutations	O
(i.	O
e.,	O
the	O
frameshift	O
and	O
the	O
nonsense	O
mutation)	O
in	O
patients	O
with	O
biochemically	O
proved	O
childhood	O
ALD	SpecificDisease
and	O
AMN	SpecificDisease
further	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
alterations	O
in	O
this	O
gene	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
X-ALD	SpecificDisease
.	O
Since	O
the	O
current	O
biochemical	O
techniques	O
for	O
X-ALD	Modifier

Atelosteogenesis	SpecificDisease
type	SpecificDisease
II	SpecificDisease
is	O
caused	O
by	O
mutations	O
in	O
the	O
diastrophic	Modifier
dysplasia	Modifier
sulfate-transporter	O
gene	O
(DTDST):	O
evidence	O
for	O
a	O
phenotypic	O
series	O
involving	O
three	O
chondrodysplasias	DiseaseClass
.	O
Atelosteogenesis	SpecificDisease
type	SpecificDisease
II	SpecificDisease
(	O
AO	SpecificDisease
II	SpecificDisease
)	O
is	O
a	O
neonatally	O
lethal	O
chondrodysplasia	DiseaseClass
whose	O
clinical	O
and	O
histological	O
characteristics	O
resemble	O
those	O
of	O
another	O
chondrodysplasia	DiseaseClass
,	O
the	O
much	O
less	O
severe	O
diastrophic	SpecificDisease
dysplasia	SpecificDisease
(	O
DTD	SpecificDisease
).	O
The	O
similarity	O
suggests	O
a	O
shared	O
pathogenesis	O
involving	O
lesions	O
in	O
the	O
same	O
biochemical	O
pathway	O
and	O
perhaps	O
the	O
same	O
gene.	O
DTD	SpecificDisease
is	O
caused	O
by	O
mutations	O
in	O
the	O
recently	O
identified	O
diastrophic	Modifier
dysplasia	Modifier
sulfate-transporter	O
gene	O
(DTDST).	O
Here,	O
we	O
report	O
that	O
AOII	Modifier
patients	O
also	O
have	O
DTDST	O
mutations,	O
which	O
lead	O
to	O
defective	O
uptake	O
of	O
inorganic	O
sulfate	O
and	O
insufficient	O
sulfation	O
of	O
macromolecules	O
by	O
patient	O
mesenchymal	O
cells	O
in	O
vitro.	O
Together	O
with	O
our	O
recent	O
observation	O
that	O
a	O
third	O
even	O
more	O
severe	O
chondrodysplasia	DiseaseClass
,	O
achondrogenesis	O
type	O
IB,	O
is	O
also	O
caused	O
by	O
mutations	O
in	O
DTDST,	O
these	O
results	O
demonstrate	O
a	O
phenotypic	O
series	O
of	O
three	O
chondrodysplasias	DiseaseClass

Emerin,	SpecificDisease
deficiency	SpecificDisease
of	O
which	O
causes	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
,	O
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane.	O
X-linked	SpecificDisease
recessive	SpecificDisease
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
)	O
is	O
an	O
inherited	DiseaseClass
muscle	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
progressive	O
wasting	SpecificDisease
of	SpecificDisease
humero-peroneal	SpecificDisease
muscles	SpecificDisease
,	O
early	O
contractures	CompositeMention
of	CompositeMention
the	CompositeMention
elbows,	CompositeMention
Achilles	CompositeMention
tendons	CompositeMention
and	CompositeMention
postcervical	CompositeMention
muscles	CompositeMention
,	O
and	O
cardiac	SpecificDisease
conduction	SpecificDisease
block	SpecificDisease
with	O
a	O
high	O
risk	O
of	O
sudden	SpecificDisease
death	SpecificDisease
.	O
The	O
gene	O
for	O
EDMD	SpecificDisease

Identification	O
of	O
a	O
common	O
PEX1	O
mutation	O
in	O
Zellweger	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
Zellweger	DiseaseClass
spectrum	DiseaseClass
of	DiseaseClass
disease	DiseaseClass
,	O
encompassing	O
Zellweger	SpecificDisease
syndrome	SpecificDisease
and	O
the	O
progressively	O
milder	O
phenotypes	O
of	O
neonatal	SpecificDisease
adrenoleukodystrophy	SpecificDisease
and	O
infantile	SpecificDisease
Refsum	SpecificDisease
disease	SpecificDisease
,	O
is	O
due	O
to	O
a	O
failure	O
to	O
form	O
functional	O
peroxisomes.	O
Cell	O
fusion	O
complementation	O
studies	O
demonstrated	O
that	O
these	O
diseases	O
are	O
genetically	O
heterogeneous,	O
with	O
two-thirds	O
of	O
all	O
patients	O
lying	O
within	O
a	O
single	O
complementation	O
group,	O
CG1.	O
Molecular	O
genetic	O
and	O
cell	O
biology	O
studies	O
have	O
shown	O
that	O
PEX1	O
is	O
deficient	O
in	O
many	O
CG1	O
patients.	O
However,	O
previous	O
studies	O
have	O
focused	O
on	O
mildly	O
affected	O
patients	O
and	O
there	O
is	O
still	O
no	O
report	O
of	O
two	O
mutant	O
PEX1	O
alleles	O
in	O
any	O
Zellweger	Modifier
syndrome	Modifier
patient.	O
Furthermore,	O
mutations	O
in	O
the	O
PMP70	O
gene	O
have	O
also	O
been	O
identified	O
in	O
two	O
Zellweger	Modifier
syndrome	Modifier
patients	O
from	O
CG1,	O
raising	O
the	O
possibility	O
that	O
CG1	O
patients	O
may	O
represent	O
a	O
mixture	O
of	O
PEX1-deficient	O
and	O
PMP70-deficient	O
individuals.	O
To	O
address	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
Zellweger	Modifier
syndrome	Modifier
patients	O
from	O
CG1,	O
we	O
examined	O
all	O
24	O
PEX1	O
exons	O
in	O
four	O
patients,	O
including	O
both	O
patients	O
that	O
have	O
mutations	O
in	O
PMP70.	O
PEX1	O
mutations	O
were	O
detected	O
in	O
all	O
four	O
patients,	O
including	O
a	O
1-bp	O
insertion	O
(c.	O
2097insT)	O
in	O
exon	O
13	O
that	O
was	O
present	O
in	O
three	O
of	O
the	O
four	O
patients.	O
Subsequent	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
is	O
present	O
in	O
one-half	O
of	O
all	O
CG1	O
patients	O
and	O
correlates	O
with	O
the	O
Zellweger	Modifier
syndrome	Modifier
phenotype.	O
As	O
this	O
mutation	O
leads	O
to	O
a	O
loss	O
of	O
protein	O
function	O
its	O
frequency	O
makes	O
it	O
the	O
most	O
common	O
cause	O
of	O
Zellweger	SpecificDisease
syndrome	SpecificDisease

Polymorphisms	O
of	O
the	O
CYP2D6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
.	O
Ankylosing	SpecificDisease
spondylitis	SpecificDisease
(	O
AS	SpecificDisease
)	O
is	O
a	O
common	O
and	O
highly	O
familial	O
rheumatic	DiseaseClass
disorder	DiseaseClass
.	O
The	O
sibling	O
recurrence	O
risk	O
ratio	O
for	O
the	O
disease	O
is	O
63	O
and	O
heritability	O
assessed	O
in	O
twins	O
>	O
90%.	O
Although	O
MHC	O
genes,	O
including	O
HLA-B27,	O
contribute	O
only	O
20-50%	O
of	O
the	O
genetic	O
risk	O
for	O
the	O
disease,	O
no	O
non-MHC	O
gene	O
has	O
yet	O
been	O
convincingly	O
demonstrated	O
to	O
influence	O
either	O
susceptibility	O
to	O
the	O
disease	O
or	O
its	O
phenotypic	O
expression.	O
Previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
AS	SpecificDisease
close	O
to,	O
or	O
within,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	O
(CYP2D6,	O
debrisoquine	O
hydroxylase)	O
located	O
at	O
chromosome	O
22q13.1.	O
We	O
performed	O
a	O
linkage	O
study	O
of	O
chromosome	O
22	O
in	O
200	O
families	O
with	O
AS	SpecificDisease
affected	O
sibling-pairs.	O
Association	O
of	O
alleles	O
of	O
the	O
CYP2D6	O
gene	O
was	O
examined	O
by	O
both	O
case-control	O
and	O
within-family	O
means.	O
For	O
case-control	O
studies,	O
617	O
unrelated	O
individuals	O
with	O
AS	SpecificDisease
(361	O
probands	O
from	O
sibling-pair	O
and	O
parent-case	O
trio	O
families	O
and	O
256	O
unrelated	O
non-familial	O
sporadic	O
cases)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed.	O
For	O
within-family	O
association	O
studies,	O
361	O
families	O
including	O
161	O
parent-case	O
trios	O
and	O
200	O
affected	O
sibling-pair	O
families	O
were	O
employed.	O
Homozygosity	O
for	O
poor	O
metabolizer	O
alleles	O
was	O
found	O
to	O
be	O
associated	O
with	O
AS	SpecificDisease
.	O
Heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(CYP2D6*4)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
AS	SpecificDisease
.	O
Significant	O
within-family	O
association	O
of	O
CYP2D6*4	O
alleles	O
and	O
AS	SpecificDisease
was	O
demonstrated.	O
Weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	SpecificDisease
.	O
We	O
postulate	O
that	O
altered	O
metabolism	O
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
CYP2D6	O
gene	O
may	O
increase	O
susceptibility	O
to	O
AS	SpecificDisease

Molecular	O
analysis	O
of	O
the	O
genotype-phenotype	O
relationship	O
in	O
factor	SpecificDisease
X	SpecificDisease
deficiency	SpecificDisease
.	O
Factor	SpecificDisease
X	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
rare	O
haemorrhagic	DiseaseClass
condition	DiseaseClass
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait,	O
in	O
which	O
a	O
variable	O
clinical	O
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype.	O
The	O
factor	O
X	O
(F10)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	SpecificDisease
X	SpecificDisease
deficiency	SpecificDisease

Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	Modifier
degeneration	Modifier
slow	O
mice	O
by	O
gene	O
therapy.	O
The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor-specific	O
membrane	O
glycoprotein,	O
peripherin-2	O
(also	O
known	O
as	O
peripherin/rds),	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom-1	O
(ref.	O
2).	O
The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture.	O
Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	DiseaseClass
dystrophies	DiseaseClass
,	O
including	O
autosomal	SpecificDisease
dominant	SpecificDisease
retinitis	SpecificDisease
pigmentosa	SpecificDisease
and	O
macular	SpecificDisease
dystrophy	SpecificDisease
.	O
A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function,	O
also	O
seen	O
in	O
the	O
retinal	Modifier
degeneration	Modifier

Phenylalanine	O
hydroxylase	O
gene	O
haplotypes	O
in	O
Polynesians:	O
evolutionary	O
origins	O
and	O
absence	O
of	O
alleles	O
associated	O
with	O
severe	O
phenylketonuria	SpecificDisease
.	O
A	O
total	O
of	O
630	O
haplotypes	O
for	O
the	O
phenylalanine	O
hydroxylase	O
(PAH)	O
gene	O
locus	O
were	O
established	O
in	O
five	O
groups	O
of	O
Polynesians	O
comprising	O
Samoans,	O
Tongans,	O
Cook	O
Islanders,	O
Maori,	O
and	O
Niueans.	O
Considerable	O
genetic	O
continuity	O
was	O
demonstrated	O
between	O
these	O
widely	O
dispersed	O
populations,	O
since	O
three	O
common	O
haplotypes	O
(4,	O
1,	O
and	O
7)	O
constituted	O
over	O
95%	O
of	O
alleles.	O
A	O
control	O
group	O
of	O
individuals	O
from	O
Southeast	O
Asia	O
shared	O
the	O
same	O
major	O
haplotypes,	O
4,	O
1,	O
and	O
7,	O
with	O
Polynesians.	O
These	O
data	O
provide	O
further	O
support	O
for	O
the	O
theories	O
of	O
genetic	O
homogeneity	O
and	O
of	O
Asian	O
affinities	O
of	O
the	O
Polynesian	O
precursor	O
populations.	O
The	O
absence	O
of	O
severe	O
phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
in	O
both	O
Polynesians	O
and	O
Southeast	O
Asians	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
PAH	O
haplotypes	O
2	O
and	O
3,	O
on	O
which	O
the	O
severe	O
PKU	Modifier

cDNA	O
microarrays	O
detect	O
activation	O
of	O
a	O
myogenic	O
transcription	O
program	O
by	O
the	O
PAX3-FKHR	O
fusion	O
oncogene.	O
Alveolar	SpecificDisease
rhabdomyosarcoma	SpecificDisease
is	O
an	O
aggressive	O
pediatric	SpecificDisease
cancer	SpecificDisease
of	SpecificDisease
striated	SpecificDisease
muscle	SpecificDisease
characterized	O
in	O
60%	O
of	O
cases	O
by	O
a	O
t	O
(2;	O
13)	O
(q35;	O
q14).	O
This	O
results	O
in	O
the	O
fusion	O
of	O
PAX3,	O
a	O
developmental	O
transcription	O
factor	O
required	O
for	O
limb	O
myogenesis,	O
with	O
FKHR,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors.	O
The	O
resultant	O
PAX3-FKHR	O
gene	O
possesses	O
transforming	O
properties;	O
however,	O
the	O
effects	O
of	O
this	O
chimeric	O
oncogene	O
on	O
gene	O
expression	O
are	O
largely	O
unknown.	O
To	O
investigate	O
the	O
actions	O
of	O
these	O
transcription	O
factors,	O
both	O
Pax3	O
and	O
PAX3-FKHR	O
were	O
introduced	O
into	O
NIH	O
3T3	O
cells,	O
and	O
the	O
resultant	O
gene	O
expression	O
changes	O
were	O
analyzed	O
with	O
a	O
murine	O
cDNA	O
microarray	O
containing	O
2,	O
225	O
elements.	O
We	O
found	O
that	O
PAX3-FKHR	O
but	O
not	O
PAX3	O
activated	O
a	O
myogenic	O
transcription	O
program	O
including	O
the	O
induction	O
of	O
transcription	O
factors	O
MyoD,	O
Myogenin,	O
Six1,	O
and	O
Slug	O
as	O
well	O
as	O
a	O
battery	O
of	O
genes	O
involved	O
in	O
several	O
aspects	O
of	O
muscle	O
function.	O
Notable	O
among	O
this	O
group	O
were	O
the	O
growth	O
factor	O
gene	O
Igf2	O
and	O
its	O
binding	O
protein	O
Igfbp5.	O
Relevance	O
of	O
this	O
model	O
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	O
(IGFBP5,	O
HSIX1,	O
and	O
Slug)	O
were	O
also	O
expressed	O
in	O
alveolar	Modifier
rhabdomyosarcoma	Modifier

Re-evaluation	O
of	O
the	O
sublocalization	O
of	O
esterase	O
D	O
and	O
its	O
relation	O
to	O
the	O
retinoblastoma	Modifier
locus	O
by	O
in	O
situ	O
hybridization.	O
In	O
situ	O
hybridization	O
of	O
a	O
cDNA	O
probe	O
for	O
the	O
esterase	O
D	O
gene	O
(ESD)	O
was	O
carried	O
out	O
on	O
human	O
chromosomes.	O
The	O
probe	O
hybridized	O
most	O
strongly	O
to	O
13q14.	O
2	O
and	O
13q14.	O
3.	O
This	O
observation	O
raises	O
doubts	O
concerning	O
the	O
most	O
recently	O
published	O
assignment	O
of	O
ESD	O
to	O
13q14.	O
1.	O
A	O
deletion	O
in	O
an	O
individual	O
with	O
retinoblastoma	SpecificDisease
was	O
reported	O
to	O
separate	O
the	O
closely	O
linked	O
ESD	O
and	O
retinoblastoma	Modifier

The	O
DNA	O
double-strand	O
break	O
repair	O
gene	O
hMRE11	O
is	O
mutated	O
in	O
individuals	O
with	O
an	O
ataxia-telangiectasia-like	SpecificDisease
disorder	SpecificDisease
.	O
We	O
show	O
that	O
hypomorphic	O
mutations	O
in	O
hMRE11,	O
but	O
not	O
in	O
ATM,	O
are	O
present	O
in	O
certain	O
individuals	O
with	O
an	O
ataxia-telangiectasia-like	SpecificDisease
disorder	SpecificDisease
(	O
ATLD	SpecificDisease
).	O
The	O
cellular	O
features	O
resulting	O
from	O
these	O
hMRE11	O
mutations	O
are	O
similar	O
to	O
those	O
seen	O
in	O
A-T	SpecificDisease
as	O
well	O
as	O
NBS	SpecificDisease
and	O
include	O
hypersensitivity	SpecificDisease
to	SpecificDisease
ionizing	SpecificDisease
radiation	SpecificDisease
,	O
radioresistant	O
DNA	O
synthesis,	O
and	O
abrogation	O
of	O
ATM-dependent	O
events,	O
such	O
as	O
the	O
activation	O
of	O
Jun	O
kinase	O
following	O
exposure	O
to	O
gamma	O
irradiation.	O
Although	O
the	O
mutant	O
hMre11	O
proteins	O
retain	O
some	O
ability	O
to	O
interact	O
with	O
hRad50	O
and	O
Nbs1,	O
formation	O
of	O
ionizing	O
radiation-induced	O
hMre11	O
and	O
Nbs1	O
foci	O
was	O
absent	O
in	O
hMRE11	O
mutant	O
cells.	O
These	O
data	O
demonstrate	O
that	O
ATM	O
and	O
the	O
hMre11/hRad50/Nbs1	O
protein	O
complex	O
act	O
in	O
the	O
same	O
DNA	O
damage	O
response	O
pathway	O
and	O
link	O
hMre11	O
to	O
the	O
complex	O
pathology	O
of	O
A-T	SpecificDisease

Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
expression	O
in	O
normal	O
and	O
diseased	O
human	O
muscle.	O
A	O
probe	O
for	O
the	O
5	O
end	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene	O
was	O
used	O
to	O
study	O
expression	O
of	O
the	O
gene	O
in	O
normal	O
human	O
muscle,	O
myogenic	O
cell	O
cultures,	O
and	O
muscle	O
from	O
patients	O
with	O
DMD	SpecificDisease
.	O
Expression	O
was	O
found	O
in	O
RNA	O
from	O
normal	O
fetal	O
muscle,	O
adult	O
cardiac	O
and	O
skeletal	O
muscle,	O
and	O
cultured	O
muscle	O
after	O
myoblast	O
fusion.	O
In	O
DMD	Modifier

Localisation	O
of	O
the	O
Becker	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences.	O
A	O
linkage	O
study	O
in	O
30	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
BMD	SpecificDisease
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(RFLPs),	O
suggests	O
that	O
the	O
BMD	Modifier
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome,	O
in	O
the	O
p21	O
region.	O
The	O
genes	O
for	O
Becker	CompositeMention
and	CompositeMention
Duchenne	CompositeMention
dystrophies	CompositeMention

Age	O
of	O
the	O
intronic	O
GAA	O
triplet	O
repeat	O
expansion	O
mutation	O
in	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
),	O
the	O
most	O
frequently	O
inherited	DiseaseClass
ataxia	DiseaseClass
,	O
is	O
due	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
to	O
a	O
large	O
expansion	O
of	O
an	O
intronic	O
GAA	O
repeat.	O
Using	O
linkage	O
disequilibrium	O
analysis	O
based	O
on	O
haplotype	O
data	O
of	O
seven	O
polymorphic	O
markers	O
close	O
to	O
the	O
frataxin	O
gene,	O
the	O
age	O
of	O
FRDA	Modifier

The	O
human	O
MAGEL2	O
gene	O
and	O
its	O
mouse	O
homologue	O
are	O
paternally	O
expressed	O
and	O
mapped	O
to	O
the	O
Prader-Willi	Modifier
region.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
is	O
a	O
complex	O
neurogenetic	DiseaseClass
disorder	DiseaseClass
.	O
The	O
phenotype	O
is	O
likely	O
to	O
be	O
a	O
contiguous	DiseaseClass
gene	DiseaseClass
syndrome	DiseaseClass
involving	O
genes	O
which	O
are	O
paternally	O
expressed	O
only,	O
located	O
in	O
the	O
human	O
15q11-q13	O
region.	O
Four	O
mouse	O
models	O
of	O
PWS	SpecificDisease
have	O
been	O
reported	O
but	O
these	O
do	O
not	O
definitively	O
allow	O
the	O
delineation	O
of	O
the	O
critical	O
region	O
and	O
the	O
associated	O
genes	O
involved	O
in	O
the	O
aetiology	O
of	O
PWS	SpecificDisease
.	O
Moreover,	O
targeted	O
mutagenesis	O
of	O
mouse	O
homologues	O
of	O
the	O
human	O
candidate	O
PWS	Modifier
genes	O
does	O
not	O
appear	O
to	O
result	O
in	O
any	O
of	O
the	O
features	O
of	O
PWS	SpecificDisease
.	O
Therefore,	O
the	O
isolation	O
of	O
new	O
genes	O
in	O
this	O
region	O
remains	O
crucial	O
for	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
PWS	SpecificDisease
.	O
In	O
this	O
manuscript,	O
we	O
report	O
the	O
characterization	O
of	O
MAGEL2	O
and	O
its	O
mouse	O
homologue	O
Magel2.	O
These	O
are	O
located	O
in	O
the	O
human	O
15q11-q13	O
and	O
mouse	O
7C	O
regions,	O
in	O
close	O
proximity	O
to	O
NDN/Ndn.	O
By	O
northern	O
blot	O
analysis	O
we	O
did	O
not	O
detect	O
any	O
expression	O
of	O
MAGEL2/Magel2	O
but	O
by	O
RT-PCR	O
analysis,	O
specific	O
expression	O
was	O
detected	O
in	O
fetal	O
and	O
adult	O
brain	O
and	O
in	O
placenta.	O
Both	O
genes	O
are	O
intronless	O
with	O
tandem	O
direct	O
repeat	O
sequences	O
contained	O
within	O
a	O
CpG	O
island	O
in	O
the	O
5-untranscribed	O
region.	O
The	O
transcripts	O
encode	O
putative	O
proteins	O
that	O
are	O
homologous	O
to	O
the	O
MAGE	O
proteins	O
and	O
NDN.	O
Moreover,	O
MAGEL2/Magel2	O
are	O
expressed	O
only	O
from	O
the	O
paternal	O
allele	O
in	O
brain,	O
suggesting	O
a	O
potential	O
role	O
in	O
the	O
aetiology	O
of	O
PWS	SpecificDisease

Multiple	O
origins	O
for	O
phenylketonuria	SpecificDisease
in	O
Europe.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
),	O
a	O
disorder	DiseaseClass
of	DiseaseClass
amino	DiseaseClass
acid	DiseaseClass
metabolism	DiseaseClass
prevalent	O
among	O
Caucasians	O
and	O
other	O
ethnic	O
groups,	O
is	O
caused	O
primarily	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
hepatic	SpecificDisease
enzyme	SpecificDisease
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
(PAH).	O
PKU	SpecificDisease
is	O
a	O
highly	O
heterogeneous	O
disorder,	O
with	O
more	O
than	O
60	O
molecular	O
lesions	O
identified	O
in	O
the	O
PAH	O
gene.	O
The	O
haplotype	O
associations,	O
relative	O
frequencies,	O
and	O
distributions	O
of	O
five	O
prevalent	O
PAH	O
mutations	O
(R158Q,	O
R261Q,	O
IVS10nt546,	O
R408W,	O
and	O
IVS12n1)	O
were	O
established	O
in	O
a	O
comprehensive	O
European	O
sample	O
population	O
and	O
subsequently	O
were	O
examined	O
to	O
determine	O
the	O
potential	O
roles	O
of	O
several	O
genetic	O
mechanisms	O
in	O
explaining	O
the	O
present	O
distribution	O
of	O
the	O
major	O
PKU	Modifier
alleles.	O
Each	O
of	O
these	O
five	O
mutations	O
was	O
strongly	O
associated	O
with	O
only	O
one	O
of	O
the	O
more	O
than	O
70	O
chromosomal	O
haplotypes	O
defined	O
by	O
eight	O
RFLPs	O
in	O
or	O
near	O
the	O
PAH	O
gene.	O
These	O
findings	O
suggest	O
that	O
each	O
of	O
these	O
mutations	O
arose	O
through	O
a	O
single	O
founding	O
event	O
that	O
occurred	O
within	O
time	O
periods	O
ranging	O
from	O
several	O
hundred	O
to	O
several	O
thousand	O
years	O
ago.	O
From	O
the	O
significant	O
differences	O
observed	O
in	O
the	O
relative	O
frequencies	O
and	O
distributions	O
of	O
these	O
five	O
alleles	O
throughout	O
Europe,	O
four	O
of	O
these	O
putative	O
founding	O
events	O
could	O
be	O
localized	O
to	O
specific	O
ethnic	O
subgroups.	O
Together,	O
these	O
data	O
suggest	O
that	O
there	O
were	O
multiple,	O
geographically	O
and	O
ethnically	O
distinct	O
origins	O
for	O
PKU	SpecificDisease

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott-Aldrich	Modifier
syndrome	Modifier
protein.	O
The	O
Rho-family	O
GTPase,	O
Cdc42,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott-Aldrich	Modifier
syndrome	Modifier

Localisation	O
of	O
the	O
gene	O
for	O
Norrie	SpecificDisease
disease	SpecificDisease
to	O
between	O
DXS7	O
and	O
DXS426	O
on	O
Xp.	O
A	O
highly	O
informative	O
microsatellite	O
marker,	O
DXS426,	O
which	O
maps	O
proximal	O
to	O
DXS7	O
in	O
the	O
interval	O
Xp11.	O
4-Xp11	O
4-Xp11.	O
23,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	O
for	O
Norrie	SpecificDisease
disease	SpecificDisease
(	O
NDP	SpecificDisease
).	O
The	O
results	O
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
NDP	Modifier
gene	O
proximal	O
to	O
DXS7.	O
In	O
conjunction	O
with	O
information	O
from	O
2	O
NDP	Modifier
patients	O
who	O
have	O
a	O
deletion	O
for	O
DXS7	O
but	O
not	O
for	O
DSX426,	O
our	O
data	O
indicate	O
that	O
the	O
NDP	Modifier

Molecular	O
basis	O
of	O
human	O
mitochondrial	O
very-long-chain	SpecificDisease
acyl-CoA	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
causing	O
cardiomyopathy	SpecificDisease
and	O
sudden	SpecificDisease
death	SpecificDisease
in	O
childhood.	O
beta-Oxidation	O
of	O
long-chain	O
fatty	O
acids	O
provides	O
the	O
major	O
source	O
of	O
energy	O
in	O
the	O
heart.	O
Defects	O
in	O
enzymes	O
of	O
the	O
beta-oxidation	O
pathway	O
cause	O
sudden,	SpecificDisease
unexplained	SpecificDisease
death	SpecificDisease
in	O
childhood,	O
acute	O
hepatic	SpecificDisease
encephalopathy	SpecificDisease
or	O
liver	SpecificDisease
failure	SpecificDisease
,	O
skeletal	SpecificDisease
myopathy	SpecificDisease
,	O
and	O
cardiomyopathy	SpecificDisease
.	O
Very-long-chain	O
acyl-CoA	O
dehydrogenase	O
[VLCAD;	O
very-long-chain-acyl-CoA	O
	O
(acceptor)	O
2,	O
3-oxidoreductase,	O
EC	O
1.	O
3	O
3.	O
99	O
99.	O
13]	O
catalyzes	O
the	O
first	O
step	O
in	O
beta-oxidation.	O
We	O
have	O
isolated	O
the	O
human	O
VLCAD	O
cDNA	O
and	O
gene	O
and	O
determined	O
the	O
complete	O
nucleotide	O
sequences.	O
Polymerase	O
chain	O
reaction	O
amplification	O
of	O
VLCAD	O
mRNA	O
and	O
genomic	O
exons	O
defined	O
the	O
molecular	O
defects	O
in	O
two	O
patients	O
with	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
who	O
presented	O
with	O
unexplained	O
cardiac	SpecificDisease
arrest	SpecificDisease
and	O
cardiomyopathy	SpecificDisease
.	O
In	O
one,	O
a	O
homozygous	O
mutation	O
in	O
the	O
consensus	O
dinucleotide	O
of	O
the	O
donor	O
splice	O
site	O
(g	O
+	O
1--	O
>	O
a)	O
was	O
associated	O
with	O
universal	O
skipping	O
of	O
the	O
prior	O
exon	O
(exon	O
11).	O
The	O
second	O
patient	O
was	O
a	O
compound	O
heterozygote,	O
with	O
a	O
missense	O
mutation,	O
C1837--	O
>	O
T,	O
changing	O
the	O
arginine	O
at	O
residue	O
613	O
to	O
tryptophan	O
on	O
one	O
allele	O
and	O
a	O
single	O
base	O
deletion	O
at	O
the	O
intron-exon	O
6	O
boundary	O
as	O
the	O
second	O
mutation.	O
This	O
initial	O
delineation	O
of	O
human	O
mutations	O
in	O
VLCAD	O
suggests	O
that	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
reduces	O
myocardial	O
fatty	O
acid	O
beta-oxidation	O
and	O
energy	O
production	O
and	O
is	O
associated	O
with	O
cardiomyopathy	SpecificDisease
and	O
sudden	SpecificDisease
death	SpecificDisease

An	O
error	O
in	O
dystrophin	O
mRNA	O
processing	O
in	O
golden	SpecificDisease
retriever	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
,	O
an	O
animal	O
homologue	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
Golden	SpecificDisease
retriever	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
GRMD	SpecificDisease
)	O
is	O
a	O
spontaneous,	O
X-linked,	O
progressively	O
fatal	O
disease	O
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
Two-thirds	O
of	O
DMD	Modifier
patients	O
carry	O
detectable	O
deletions	O
in	O
their	O
dystrophin	O
gene.	O
The	O
defect	O
underlying	O
the	O
remaining	O
one-third	O
of	O
DMD	Modifier
patients	O
is	O
undetermined.	O
Analysis	O
of	O
the	O
canine	O
dystrophin	O
gene	O
in	O
normal	O
and	O
GRMD	Modifier
dogs	O
has	O
failed	O
to	O
demonstrate	O
any	O
detectable	O
loss	O
of	O
exons.	O
Here,	O
we	O
have	O
demonstrated	O
a	O
RNA	O
processing	O
error	O
in	O
GRMD	SpecificDisease
that	O
results	O
from	O
a	O
single	O
base	O
change	O
in	O
the	O
3	O
consensus	O
splice	O
site	O
of	O
intron	O
6.	O
The	O
seventh	O
exon	O
is	O
then	O
skipped,	O
which	O
predicts	O
a	O
termination	O
of	O
the	O
dystrophin	O
reading	O
frame	O
within	O
its	O
N-terminal	O
domain	O
in	O
exon	O
8.	O
This	O
is	O
the	O
first	O
example	O
of	O
dystrophin	SpecificDisease
deficiency	SpecificDisease

Serum	O
amyloid	O
A	O
and	O
P	O
protein	O
genes	O
in	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
.	O
Two	O
recent	O
studies	O
have	O
suggested	O
the	O
involvement	O
of	O
serum	O
amyloid	O
A	O
(SAA)	O
and	O
P	O
(APCS)	O
genes	O
in	O
familial	SpecificDisease
Mediterranean	SpecificDisease
fever	SpecificDisease
(	O
MEF	SpecificDisease
).	O
To	O
test	O
the	O
role	O
of	O
SAA	O
and	O
APCS	O
in	O
MEF	SpecificDisease
and	O
MEF-amyloidosis	SpecificDisease
,	O
we	O
studied	O
17	O
informative	O
families	O
(15	O
Armenians,	O
2	O
non-Ashkenazi	O
Jews)	O
and	O
8	O
MEF	Modifier
patients	O
with	O
amyloidosis	DiseaseClass
using	O
a	O
candidate	O
gene	O
approach.	O
No	O
evidence	O
for	O
any	O
MEF	Modifier
-associated	O
polymorphism	O
was	O
found	O
in	O
any	O
of	O
the	O
41	O
Armenian	O
and	O
Jewish	O
MEF	Modifier
patients	O
tested.	O
Our	O
family	O
studies	O
allowed	O
us	O
to	O
rule	O
out	O
tight	O
linkage	O
between	O
SAA	O
and	O
MEF	SpecificDisease
(lod	O
score	O
=	O
-2.	O
16,	O
theta	O
less	O
than	O
or	O
equal	O
to	O
0.	O
06).	O
For	O
APCS	O
we	O
found	O
that	O
the	O
allele	O
frequency	O
in	O
the	O
MEF-amyloidosis	Modifier
patients	O
was	O
similar	O
to	O
that	O
in	O
18	O
unrelated	O
MEF	Modifier
patients	O
without	O
amyloidosis	DiseaseClass

Glucose-6-phosphate	O
dehydrogenase	O
variants	O
from	O
Italian	O
subjects	O
associated	O
with	O
severe	SpecificDisease
neonatal	SpecificDisease
jaundice	SpecificDisease
.	O
Screening	O
for	O
the	O
G6PD	SpecificDisease
deficiency	SpecificDisease
was	O
carried	O
out	O
at	O
the	O
Maternity	O
Division	O
of	O
the	O
Galliera	O
Hospital	O
in	O
Genoa,	O
Italy.	O
Two	O
groups	O
of	O
subjects	O
with	O
hyperbilirubinaemia	DiseaseClass
of	O
non-immunological	O
origin	O
were	O
examined	O
	O
(a)	O
302	O
newborn	O
babies	O
of	O
Sardinian	O
extraction	O
(on	O
cord	O
blood)	O
and	O
(b)	O
201	O
newborn	O
babies	O
of	O
south	O
Italian	O
ancestry	O
(on	O
peripheral	O
blood).	O
Among	O
503	O
subjects,	O
43	O
showed	O
an	O
enzyme	O
deficiency;	O
in	O
39	O
the	O
defect	O
was	O
of	O
the	O
Mediterranean	O
type.	O
In	O
one	O
case,	O
previously	O
described,	O
the	O
enzyme	O
was	O
of	O
the	O
A-	O
type.	O
In	O
the	O
remaining	O
cases	O
three	O
different	O
variants	O
were	O
identified.	O
In	O
the	O
present	O
work	O
these	O
three	O
cases,	O
each	O
with	O
severe	SpecificDisease
neonatal	SpecificDisease
jaundice	SpecificDisease

Loss	O
of	O
normal	O
allele	O
of	O
the	O
APC	Modifier
gene	O
in	O
an	O
adrenocortical	SpecificDisease
carcinoma	SpecificDisease
from	O
a	O
patient	O
with	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
.	O
Endocrine	DiseaseClass
neoplasms	DiseaseClass
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
).	O
An	O
adrenocorotical	SpecificDisease
carcinoma	SpecificDisease
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
FAP	SpecificDisease
.	O
Loss	O
of	O
heterozygosity	O
(LOH)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	DiseaseClass
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
APC	Modifier
gene.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	O
at	O
the	O
APC	Modifier
locus	O
in	O
adrenocortical	SpecificDisease
tumors	SpecificDisease
.	O
The	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
LOH	O
in	O
a	O
recurring	O
desmoid	SpecificDisease
tumor	SpecificDisease
suggest	O
that	O
the	O
heterozygous	O
mutant/wild-type	O
condition	O
of	O
the	O
APC	Modifier
gene	O
may	O
give	O
rise	O
to	O
benign	DiseaseClass
tumors	DiseaseClass
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	DiseaseClass
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	Modifier

Heterozygous	O
C2-deficiency	SpecificDisease
and	O
myasthenia	SpecificDisease
gravis	SpecificDisease
.	O
Complement	Modifier
deficiency	Modifier
states	O
in	O
myasthenia	SpecificDisease
gravis	SpecificDisease
(	O
MG	SpecificDisease
)	O
have	O
not	O
been	O
reported	O
previously.	O
We	O
describe	O
a	O
19-year-old	O
woman	O
with	O
typical	O
MG	SpecificDisease
and	O
heterozygous	O
C2	SpecificDisease
deficiency	SpecificDisease

Large	O
heterozygous	O
deletion	O
masquerading	O
as	O
homozygous	O
missense	O
mutation:	O
a	O
pitfall	O
in	O
diagnostic	O
mutation	O
analysis.	O
The	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	DiseaseClass
disorders	DiseaseClass
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient.	O
This	O
can	O
be	O
problematic	O
when	O
only	O
part	O
of	O
the	O
gene	O
is	O
examined	O
or	O
when	O
relevant	O
DNA	O
alterations	O
are	O
not	O
recognized	O
by	O
standard	O
methods.	O
We	O
present	O
a	O
child	O
in	O
whom	O
phenylketonuria	SpecificDisease

Two	O
point	O
mutations	O
are	O
responsible	O
for	O
G6PD	O
polymorphism	O
in	O
Sardinia.	O
The	O
human	O
X-linked	O
gene	O
encoding	O
glucose	O
6-phosphate	O
dehydrogenase	O
(G6PD)	O
is	O
highly	O
polymorphic;	O
more	O
than	O
300	O
G6PD	O
variants	O
have	O
been	O
identified.	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
different	O
geographical	O
areas	O
appears	O
to	O
have	O
arisen	O
through	O
independent	O
mutational	O
events,	O
but	O
within	O
the	O
same	O
population	O
it	O
may	O
also	O
be	O
heterogeneous.	O
One	O
example	O
is	O
the	O
island	O
of	O
Sardinia,	O
where	O
careful	O
clinical	O
and	O
biochemical	O
studies	O
have	O
identified	O
four	O
different	O
G6PD	O
variants.	O
We	O
cloned	O
and	O
sequenced	O
the	O
four	O
G6PD	O
variants	O
from	O
Sardinia	O
and	O
found	O
that	O
only	O
two	O
mutations	O
are	O
responsible	O
for	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
this	O
area	O
	O
one	O
mutation	O
is	O
the	O
cause	O
of	O
the	O
G6PD	SpecificDisease
Seattle-like	SpecificDisease
phenotype	SpecificDisease
,	O
a	O
milder	O
form	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
;	O
the	O
other	O
mutation	O
is	O
responsible	O
for	O
all	O
forms	O
of	O
very	O
severe	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Familial	SpecificDisease
discoid	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
associated	O
with	O
heterozygote	O
C2	SpecificDisease
deficiency	SpecificDisease
.	O
Two	O
siblings	O
with	O
chronic	SpecificDisease
discoid	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	SpecificDisease
deficiency	SpecificDisease
.	O
An	O
association	O
with	O
histocompatibility	O
markers	O
HLA-B18	O
and	O
HLA-Dw2	O
was	O
demonstrated,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present.	O
Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	Modifier
deficiency	Modifier

A	O
strong	O
candidate	O
for	O
the	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
gene	O
BRCA1.	O
A	O
strong	O
candidate	O
for	O
the	O
17q-linked	O
BRCA1	O
gene,	O
which	O
influences	O
susceptibility	O
to	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
,	O
has	O
been	O
identified	O
by	O
positional	O
cloning	O
methods.	O
Probable	O
predisposing	O
mutations	O
have	O
been	O
detected	O
in	O
five	O
of	O
eight	O
kindreds	O
presumed	O
to	O
segregate	O
BRCA1	O
susceptibility	O
alleles.	O
The	O
mutations	O
include	O
an	O
11-base	O
pair	O
deletion,	O
a	O
1-base	O
pair	O
insertion,	O
a	O
stop	O
codon,	O
a	O
missense	O
substitution,	O
and	O
an	O
inferred	O
regulatory	O
mutation.	O
The	O
BRCA1	O
gene	O
is	O
expressed	O
in	O
numerous	O
tissues,	O
including	O
breast	O
and	O
ovary,	O
and	O
encodes	O
a	O
predicted	O
protein	O
of	O
1863	O
amino	O
acids.	O
This	O
protein	O
contains	O
a	O
zinc	O
finger	O
domain	O
in	O
its	O
amino-terminal	O
region,	O
but	O
is	O
otherwise	O
unrelated	O
to	O
previously	O
described	O
proteins.	O
Identification	O
of	O
BRCA1	O
should	O
facilitate	O
early	O
diagnosis	O
of	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
in	O
some	O
individuals	O
as	O
well	O
as	O
a	O
better	O
understanding	O
of	O
breast	Modifier
cancer	Modifier

Recombinations	O
in	O
individuals	O
homozygous	O
by	O
descent	O
localize	O
the	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
locus	O
in	O
a	O
cloned	O
450-kb	O
interval.	O
The	O
locus	O
for	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
),	O
a	O
severe	O
neurodegenerative	DiseaseClass
disease	DiseaseClass
,	O
is	O
tightly	O
linked	O
to	O
markers	O
D9S5	O
and	O
D9S15,	O
and	O
analysis	O
of	O
rare	O
recombination	O
events	O
has	O
suggested	O
the	O
order	O
cen-FRDA-D9S5-D9S15-qter.	O
We	O
report	O
here	O
the	O
construction	O
of	O
a	O
YAC	O
contig	O
extending	O
800	O
kb	O
centromeric	O
to	O
D9S5	O
and	O
the	O
isolation	O
of	O
five	O
new	O
microsatellite	O
markers	O
from	O
this	O
region.	O
In	O
order	O
to	O
map	O
these	O
markers	O
with	O
respect	O
to	O
the	O
FRDA	Modifier
locus,	O
all	O
within	O
a	O
1-cM	O
confidence	O
interval,	O
we	O
sought	O
to	O
increase	O
the	O
genetic	O
information	O
of	O
available	O
FRDA	Modifier
families	O
by	O
considering	O
homozygosity	O
by	O
descent	O
and	O
association	O
with	O
founder	O
haplotypes	O
in	O
isolated	O
populations.	O
This	O
approach	O
allowed	O
us	O
to	O
identify	O
one	O
phase-known	O
recombination	O
and	O
one	O
probable	O
historic	O
recombination	O
on	O
haplotypes	O
from	O
Reunion	O
Island	O
patients,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	O
proximal	O
to	O
FRDA	SpecificDisease
.	O
This	O
represents	O
the	O
first	O
identification	O
of	O
close	O
FRDA	Modifier
flanking	O
markers	O
on	O
the	O
centromeric	O
side.	O
The	O
two	O
other	O
markers	O
allowed	O
us	O
to	O
narrow	O
the	O
breakpoint	O
of	O
a	O
previously	O
identified	O
distal	O
recombination	O
that	O
is	O
>	O
180	O
kb	O
from	O
D9S5	O
(26P).	O
Taken	O
together,	O
the	O
results	O
place	O
the	O
FRDA	Modifier

Further	O
mapping	O
of	O
an	O
ataxia-telangiectasia	Modifier
locus	O
to	O
the	O
chromosome	O
11q23	O
region.	O
We	O
recently	O
mapped	O
the	O
gene	O
for	O
ataxia-telangiectasia	Modifier
group	O
A	O
(ATA)	O
to	O
chromosome	O
11q22-23	O
by	O
linkage	O
analysis,	O
using	O
the	O
genetic	O
markers	O
THY1	O
and	O
pYNB3.	O
12	O
(D11S144).	O
The	O
most	O
likely	O
order	O
was	O
cent-AT-S144-THY1.	O
The	O
present	O
paper	O
describes	O
further	O
mapping	O
of	O
the	O
AT	Modifier
locus	O
by	O
means	O
of	O
a	O
panel	O
of	O
10	O
markers	O
that	O
span	O
approximately	O
60	O
cM	O
in	O
the	O
11q22-23	O
region	O
centered	O
around	O
S144	O
and	O
THY1.	O
Location	O
scores	O
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[S144-THY1]	O
segment,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
THY1,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
AT	Modifier
locus,	O
while	O
the	O
more	O
centromeric	O
[STMY-S144]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
AT	Modifier
locus.	O
These	O
data,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	O
and	O
physical	O
maps	O
of	O
11q22-23,	O
place	O
the	O
AT	Modifier

Proliferation-related	O
expression	O
of	O
p19/nm23	O
nucleoside	O
diphosphate	O
kinase.	O
High	O
level	O
expression	O
of	O
the	O
nm23-H1	O
gene,	O
which	O
encodes	O
for	O
a	O
nucleoside	O
diphosphate	O
kinase,	O
has	O
been	O
found	O
to	O
correlate	O
with	O
diminished	O
metastasis	O
in	O
some	O
tumors	DiseaseClass
but	O
not	O
in	O
others.	O
We	O
have	O
previously	O
identified	O
the	O
protein	O
product	O
of	O
the	O
nm23-H1	O
gene	O
in	O
two-dimensional	O
electrophoretic	O
gels	O
and	O
have	O
designated	O
it	O
p19/nm23.	O
In	O
neuroblastoma	SpecificDisease
,	O
higher	O
levels	O
of	O
p19/nm23,	O
which	O
are	O
associated	O
with	O
amplification	O
of	O
the	O
N-myc	O
oncogene,	O
large	O
tumor	Modifier
mass,	O
and	O
metastasis,	O
were	O
observed	O
in	O
advanced	O
stage	O
tumors	DiseaseClass
compared	O
with	O
limited	O
stage	O
disease.	O
Because	O
of	O
the	O
variable	O
expression	O
of	O
nm23-H1	O
in	O
different	O
tumors	DiseaseClass
,	O
we	O
have	O
investigated	O
the	O
relationship	O
between	O
amounts	O
of	O
the	O
protein	O
and	O
cell	O
proliferation.	O
The	O
levels	O
of	O
p19/nm23	O
were	O
compared	O
between	O
resting	O
and	O
mitotically	O
stimulated	O
normal	O
human	O
PBLs	O
and	O
in	O
leukemia	Modifier
cells.	O
The	O
amount	O
of	O
p19/nm23	O
increased	O
in	O
normal	O
lymphocytes	O
in	O
response	O
to	O
mitotic	O
stimulation	O
and	O
paralleled	O
the	O
increase	O
in	O
DNA	O
synthesis.	O
In	O
leukemia	Modifier
cells	O
obtained	O
from	O
patients	O
with	O
different	O
subtypes	O
of	O
acute	SpecificDisease
leukemia	SpecificDisease
,	O
p19/nm23	O
levels	O
were	O
also	O
increased	O
relative	O
to	O
resting	O
normal	O
lymphocytes.	O
Treatment	O
of	O
mitotically	O
stimulated	O
lymphocytes	O
with	O
cyclosporin,	O
which	O
inhibits	O
proliferation,	O
blocked	O
the	O
increase	O
in	O
p19/nm23;	O
treatment	O
of	O
the	O
leukemia	Modifier

Carrier	O
detection	O
of	O
pyruvate	SpecificDisease
carboxylase	SpecificDisease
deficiency	SpecificDisease
in	O
fibroblasts	O
and	O
lymphocytes.	O
Pyruvate	O
carboxylase	O
(E.	O
C.	O
6.	O
4.	O
1.	O
1)	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic,	O
cerebral,	O
renal	O
cortical,	O
leukocyte,	O
and	O
fibroblast	O
pyruvate	SpecificDisease
carboxylase	SpecificDisease
deficiency	SpecificDisease
(	O
PC	SpecificDisease
Portland	SpecificDisease
deficiency	SpecificDisease

Complex	SpecificDisease
glycerol	SpecificDisease
kinase	SpecificDisease
deficiency	SpecificDisease
:	O
molecular-genetic,	O
cytogenetic,	O
and	O
clinical	O
studies	O
of	O
five	O
Japanese	O
patients.	O
Five	O
male	O
Japanese	O
patients	O
with	O
complex	SpecificDisease
glycerol	SpecificDisease
kinase	SpecificDisease
deficiency	SpecificDisease
(	O
CGKD	SpecificDisease
)	O
and	O
their	O
relatives	O
were	O
studied	O
clinically,	O
cytogenetically,	O
and	O
molecular-genetically.	O
All	O
patients	O
had	O
muscular	DiseaseClass
dystrophy	DiseaseClass
or	O
muscle	DiseaseClass
weakness	DiseaseClass
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
congenital	SpecificDisease
adrenal	SpecificDisease
hypoplasia	SpecificDisease
,	O
and	O
glycerol	DiseaseClass
kinase	DiseaseClass
deficiency	DiseaseClass
.	O
High-resolution	O
GTG-banded	O
chromosomes	O
showed	O
a	O
microdeletion	O
in	O
the	O
Xp21	O
region	O
in	O
all	O
four	O
patients	O
examined	O
and	O
in	O
all	O
five	O
mothers.	O
Southern	O
hybridizations,	O
after	O
digestions	O
by	O
restriction	O
endonucleases,	O
with	O
various	O
cloned	O
DNAs	O
(D2,	O
99-6,	O
B24,	O
C7,	O
L1-4,	O
cDMD13-14,	O
J66-HI,	O
P20,	O
J-Bir,	O
ERT87-30,	O
ERT87-15,	O
ERT87-8,	O
ERT87-1,	O
XJ-1.	O
1,	O
754,	O
cx5.	O
7,	O
and	O
OTC-1)	O
that	O
are	O
located	O
around	O
Xp21	O
also	O
showed	O
a	O
deletion	O
in	O
the	O
genome	O
of	O
all	O
patients	O
and	O
mothers.	O
Although	O
the	O
deletion	O
differed	O
in	O
size	O
among	O
patients,	O
a	O
segment	O
commonly	O
absent	O
was	O
located	O
between	O
the	O
genomic	O
sequences	O
corresponding	O
to	O
L1-4	O
and	O
cDMD13-14.	O
This	O
finding	O
indicated	O
that	O
the	O
gene	O
coding	O
for	O
glycerol	O
kinase	O
(GK)	O
is	O
located	O
within	O
this	O
segment.	O
A	O
comparison	O
of	O
the	O
clinical	O
manifestations	O
of	O
the	O
present	O
five	O
patients	O
and	O
reported	O
CGKD	Modifier
or	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
patients	O
with	O
DNA	O
deletion	O
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	O
responsible	O
for	O
gonadotropin	SpecificDisease
deficiency	SpecificDisease
(	O
GTD	SpecificDisease
).	O
The	O
result	O
of	O
the	O
present	O
study	O
and	O
results	O
of	O
previous	O
studies	O
suggest	O
that	O
genes	O
for	O
ornithine	O
transcarbamylase	O
(OTC),	O
DMD	SpecificDisease
,	O
and	O
GK	O
and	O
putative	O
genes	O
responsible	O
for	O
congenital	SpecificDisease
adrenal	SpecificDisease
hypoplasia	SpecificDisease
(	O
AHC	SpecificDisease
)	O
and	O
GTD	SpecificDisease

Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
and	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
in	O
the	O
same	O
patient.	O
We	O
report	O
on	O
the	O
first	O
patient	O
identified	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
and	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
).	O
The	O
family	O
of	O
the	O
propositus	O
had	O
a	O
strong	O
history	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	O
of	O
the	O
responsible	O
CTG	O
repeat	O
between	O
the	O
mildly	O
affected	O
mother	O
(160	O
repeats;	O
normal	O
27	O
repeats)	O
and	O
her	O
more	O
severely	O
affected	O
son	O
(650	O
repeats),	O
and	O
his	O
sister	O
(650	O
repeats).	O
The	O
propositus	O
was	O
an	O
isolated	O
case	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
with	O
marked	O
dystrophin	SpecificDisease
deficiency	SpecificDisease
in	O
muscle	O
biopsy.	O
The	O
patient	O
was	O
still	O
ambulatory	O
post	O
age	O
16.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	O
of	O
Duchenne	SpecificDisease
dystrophy	SpecificDisease
.	O
However,	O
other	O
interpretations	O
are	O
possible.	O
Twelve	O
percent	O
of	O
dystrophin	O
revertant	O
fibers	O
as	O
observed	O
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
DMD	Modifier

Autosomal	O
recessive	O
transmission	O
of	O
hemophilia	SpecificDisease
A	SpecificDisease
due	O
to	O
a	O
von	Modifier
Willebrand	Modifier
factor	O
mutation.	O
The	O
differential	O
diagnosis	O
of	O
the	O
genetic	DiseaseClass
bleeding	DiseaseClass
disorders	DiseaseClass
,	O
hemophilia	SpecificDisease
A	SpecificDisease
and	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	O
molecular	O
relationship	O
of	O
coagulation	O
factor	O
VIII	O
and	O
von	Modifier
Willebrand	Modifier
factor	O
(vWF).	O
This	O
report	O
describes	O
the	O
autosomal	O
inheritance	O
of	O
a	O
hemophilia	Modifier
A	Modifier
phenotype	O
due	O
to	O
a	O
mutation	O
of	O
vWF	O
that	O
results	O
in	O
defective	O
factor	O
VIII	O
binding.	O
The	O
proband	O
was	O
a	O
female	O
patient	O
with	O
low	O
levels	O
of	O
factor	O
VIII	O
activity.	O
Polymerase	O
chain	O
reaction	O
(PCR)	O
amplification	O
and	O
DNA	O
sequencing	O
were	O
employed	O
to	O
examine	O
exons	O
encoding	O
the	O
putative	O
factor	O
VIII	O
binding	O
domain	O
of	O
vWF.	O
The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
point	O
mutation	O
causing	O
a	O
Thr--	O
>	O
Met	O
substitution	O
at	O
amino	O
acid	O
position	O
28	O
in	O
the	O
mature	O
vWF	O
subunit.	O
The	O
phenotypic	O
expression	O
of	O
the	O
mutation	O
was	O
determined	O
to	O
be	O
recessive	O
because	O
heterozygous	O
family	O
members	O
were	O
clinically	O
unaffected.	O
Recombinant	O
vWF	O
containing	O
the	O
observed	O
amino	O
acid	O
substitution	O
was	O
expressed	O
in	O
COS-1	O
cells.	O
The	O
mutant	O
vWF	O
was	O
processed	O
and	O
secreted	O
normally,	O
and	O
was	O
functionally	O
equivalent	O
to	O
wild-type	O
vWF	O
in	O
its	O
ability	O
to	O
bind	O
to	O
platelets.	O
However,	O
the	O
mutant	O
failed	O
to	O
bind	O
factor	O
VIII,	O
demonstrating	O
that	O
the	O
mutation	O
was	O
functionally	O
related	O
to	O
the	O
observed	O
hemophilia	Modifier
phenotype.	O
The	O
family	O
we	O
describe	O
demonstrates	O
the	O
recessive	O
inheritance	O
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	O
bleeding	O
disorders,	O
we	O
call	O
"	O
autosomal	O
hemophilia	SpecificDisease
.	O
"	O
We	O
conclude	O
that	O
vWF	O
mutation	O
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	SpecificDisease

Determination	O
of	O
30	O
X-linked	Modifier
adrenoleukodystrophy	Modifier
mutations,	O
including	O
15	O
not	O
previously	O
described.	O
X-linked	SpecificDisease
Adrenoleukodystrophy	SpecificDisease
(	O
X-ALD	SpecificDisease
)	O
is	O
the	O
most	O
frequent	O
peroxisomal	DiseaseClass
disease	DiseaseClass
.	O
It	O
mainly	O
involves	O
the	O
nervous	O
system	O
white	O
matter,	O
adrenal	O
cortex	O
and	O
testes.	O
Several	O
distinct	O
clinical	O
phenotypes	O
are	O
known.	O
The	O
principal	O
biochemical	O
abnormality	O
is	O
the	O
accumulation	O
of	O
saturated	O
very-long-chain	O
fatty	O
acids	O
(VLCFAs	O
	O
>	O
C22	O
	O
0,	O
mainly	O
C26	O
	O
0),	O
which	O
is	O
due	O
to	O
impaired	O
capacity	O
for	O
beta-oxidation	O
in	O
peroxisomes.	O
Diagnosis	O
is	O
usually	O
based	O
on	O
the	O
VLCFA	O
levels	O
in	O
plasma	O
or	O
cultured	O
skin	O
fibroblasts	O
in	O
both	O
patients	O
and	O
carriers.	O
In	O
0.	O
1%	O
of	O
affected	O
males,	O
however,	O
the	O
plasma	O
C26	O
	O
0	O
level	O
is	O
borderline	O
normal,	O
and	O
15%	O
of	O
obligate	O
female	O
carriers	O
have	O
normal	O
results.	O
Effective	O
mutation	O
detection	O
in	O
these	O
families	O
is	O
therefore	O
fundamental	O
to	O
unambiguously	O
determine	O
the	O
genetic	O
status	O
of	O
each	O
individual	O
at	O
risk.	O
Of	O
particular	O
concern	O
are	O
female	O
members	O
of	O
kindreds	O
segregating	O
X-ALD	Modifier
mutations,	O
because	O
normal	O
VLCFA	O
levels	O
do	O
not	O
guarantee	O
lack	O
of	O
carrier	O
status.	O
We	O
describe	O
a	O
fast	O
method	O
for	O
detection	O
of	O
X-ALD	Modifier
mutations.	O
The	O
method	O
is	O
based	O
on	O
SSCP	O
analysis	O
of	O
nested	O
PCR	O
fragments	O
followed	O
by	O
sequence-determination	O
reactions.	O
Using	O
this	O
methodology	O
we	O
have	O
found	O
X-ALD	Modifier

Mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
families	O
with	O
early-onset	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
We	O
analysed	O
50	O
probands	O
with	O
a	O
family	O
history	O
of	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
for	O
germline	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
BRCA1	O
candidate	O
gene,	O
using	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
on	O
PCR-amplified	O
genomic	O
DNA.	O
A	O
total	O
of	O
eight	O
putative	O
disease-causing	O
alterations	O
were	O
identified	O
	O
four	O
of	O
these	O
are	O
frameshifts	O
and	O
two	O
are	O
nonsense	O
mutations.	O
In	O
addition,	O
we	O
found	O
two	O
missense	O
mutations,	O
one	O
of	O
which	O
changes	O
the	O
final	O
cysteine	O
of	O
the	O
BRCA1	O
zinc	O
finger	O
motif	O
to	O
glycine.	O
These	O
data	O
are	O
consistent	O
with	O
a	O
tumour	Modifier

Screening	O
for	O
carriers	O
of	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
among	O
Ashkenazi	O
Jews.	O
A	O
comparison	O
of	O
DNA-based	O
and	O
enzyme-based	O
tests.	O
BACKGROUND	O
AND	O
METHODS.	O
The	O
prevention	O
of	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
GM2	SpecificDisease
gangliosidosis,	SpecificDisease
type	SpecificDisease
1	SpecificDisease
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
.	O
We	O
compared	O
the	O
enzyme-based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
DNA.	O
We	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
Ashkenazi	O
Jews	O
	O
two	O
mutations	O
cause	O
infantile	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
,	O
and	O
the	O
third	O
causes	O
the	O
adult-onset	O
form	O
of	O
the	O
disease.	O
DNA	O
segments	O
containing	O
these	O
mutation	O
sites	O
were	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
mutations.	O
RESULTS.	O
Among	O
62	O
Ashkenazi	O
obligate	O
carriers	O
of	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(98	O
percent).	O
In	O
216	O
Ashkenazi	O
carriers	O
identified	O
by	O
the	O
enzyme	O
test,	O
DNA	O
analysis	O
showed	O
that	O
177	O
(82	O
percent)	O
had	O
one	O
of	O
the	O
identified	O
mutations.	O
Of	O
the	O
177,	O
79	O
percent	O
had	O
the	O
exon	O
11	O
insertion	O
mutation,	O
18	O
percent	O
had	O
the	O
intron	O
12	O
splice-junction	O
mutation,	O
and	O
3	O
percent	O
had	O
the	O
less	O
severe	O
exon	O
7	O
mutation	O
associated	O
with	O
adult-onset	O
disease.	O
The	O
results	O
of	O
the	O
enzyme	O
tests	O
in	O
the	O
39	O
subjects	O
(18	O
percent)	O
who	O
were	O
defined	O
as	O
carriers	O
but	O
in	O
whom	O
DNA	O
analysis	O
did	O
not	O
identify	O
a	O
mutant	O
allele	O
were	O
probably	O
false	O
positive	O
(although	O
there	O
remains	O
some	O
possibility	O
of	O
unidentified	O
mutations).	O
In	O
addition,	O
of	O
152	O
persons	O
defined	O
as	O
noncarriers	O
by	O
the	O
enzyme-based	O
test,	O
1	O
was	O
identified	O
as	O
a	O
carrier	O
by	O
DNA	O
analysis	O
(i.	O
e	O
e.,	O
a	O
false	O
negative	O
enzyme-test	O
result).	O
CONCLUSIONS.	O
The	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA-based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease

Adrenoleukodystrophy	Modifier
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein.	O
An	O
antibody	O
against	O
the	O
synthetic	O
C-terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X-linked	SpecificDisease
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	Modifier
gene.	O
The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ALD	SpecificDisease
(#	O
163),	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	Modifier
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis.	O
The	O
293T	O
cells	O
transfected	O
with	O
the	O
full-coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein,	O
as	O
detected	O
by	O
Western	O
blot.	O
In	O
an	O
immunocytological	O
study,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern,	O
in	O
the	O
normal	O
fibroblasts.	O
However,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells.	O
These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	Modifier

Preferential	O
germline	O
mutation	O
of	O
the	O
paternal	O
allele	O
in	O
retinoblastoma	SpecificDisease
.	O
The	O
event	O
triggering	O
malignant	O
proliferation	O
in	O
70%	O
of	O
retinoblastoma	SpecificDisease
tumours	SpecificDisease
is	O
loss	O
of	O
heterozygosity	O
for	O
chromosome	O
13q14,	O
whereby	O
the	O
normal	O
retinoblastoma	Modifier
gene	O
(RB1)	O
allele	O
is	O
lost	O
and	O
an	O
already	O
mutated	O
RB1	O
allele	O
remains	O
in	O
the	O
tumour	DiseaseClass
.	O
The	O
first	O
allele	O
suffers	O
a	O
mutational	O
event--deletion,	O
duplication	O
or	O
point	O
mutation	O
(manuscript	O
in	O
preparation)	O
--either	O
in	O
the	O
germ	O
line	O
(all	O
bilateral	O
patients)	O
or	O
in	O
a	O
somatic	O
retinal	O
cell	O
(most	O
unilateral	O
patients).	O
Most	O
bilateral	O
patients	O
have	O
no	O
family	O
history	O
of	O
retinoblastoma	SpecificDisease
and	O
are	O
presumed	O
to	O
have	O
new	O
germline	O
mutations	O
which	O
arose	O
in	O
the	O
egg,	O
sperm	O
or	O
early	O
embryo.	O
We	O
have	O
determined	O
the	O
parental	O
origin	O
of	O
the	O
retained	O
allele	O
in	O
nine	O
retinoblastoma	SpecificDisease
tumours	SpecificDisease
from	O
eight	O
unrelated	O
non-familial	O
cases	O
by	O
using	O
RB1-linked	O
genetic	O
markers.	O
Six	O
tumours	DiseaseClass
retained	O
the	O
paternal	O
allele	O
and	O
three	O
retained	O
the	O
maternal	O
allele.	O
Of	O
the	O
three	O
unilateral	DiseaseClass
tumours	DiseaseClass
,	O
only	O
one	O
retained	O
the	O
paternal	O
RB1	O
allele.	O
Thus,	O
there	O
is	O
no	O
evidence	O
that	O
the	O
paternal	O
RB1	O
allele	O
is	O
preferentially	O
retained	O
in	O
retinoblastoma	SpecificDisease
,	O
as	O
has	O
been	O
suggested	O
to	O
be	O
the	O
case	O
in	O
osteosarcoma	SpecificDisease
.	O
By	O
contrast,	O
tumours	DiseaseClass

Mutations	O
at	O
the	O
ataxia-telangiectasia	Modifier
locus	O
and	O
clinical	O
phenotypes	O
of	O
A-T	Modifier
patients.	O
Mutations	O
at	O
the	O
ataxia-telangiectasia	Modifier
(	O
A-T	Modifier
)	O
locus	O
on	O
chromosome	O
band	O
11q22	O
cause	O
a	O
distinctive	O
autosomal	DiseaseClass
recessive	DiseaseClass
syndrome	DiseaseClass
in	O
homozygotes	O
and	O
predispose	O
heterozygotes	O
to	O
cancer	DiseaseClass
,	O
ischemic	SpecificDisease
heart	SpecificDisease
disease	SpecificDisease
,	O
and	O
early	O
mortality.	O
PCR	O
amplification	O
from	O
genomic	O
DNA	O
and	O
automated	O
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
(66	O
exons)	O
and	O
splice	O
junctions	O
detected	O
77	O
mutations	O
(85%)	O
in	O
90	O
A-T	Modifier
chromosomes.	O
Heteroduplex	O
analysis	O
detected	O
another	O
42	O
mutations	O
at	O
the	O
A-T	Modifier
locus.	O
Out	O
of	O
a	O
total	O
of	O
71	O
unique	O
mutations,	O
50	O
were	O
found	O
only	O
in	O
a	O
single	O
family,	O
and	O
51	O
had	O
not	O
been	O
reported	O
previously.	O
Most	O
(58/71,	O
82%)	O
mutations	O
were	O
frameshift	O
and	O
nonsense	O
mutations	O
that	O
are	O
predicted	O
to	O
cause	O
truncation	O
of	O
the	O
A-T	Modifier
protein;	O
the	O
less	O
common	O
mutation	O
types	O
were	O
missense	O
(9/71,	O
13%),	O
splicing	O
(3/71,	O
4%)	O
and	O
one	O
in-frame	O
deletion,	O
2546	O
3	O
(1/71,	O
1%).	O
The	O
mean	O
survival	O
and	O
height	O
distribution	O
of	O
134	O
A-T	Modifier
patients	O
correlated	O
significantly	O
with	O
the	O
specific	O
mutations	O
present	O
in	O
the	O
patients.	O
Patients	O
homozygous	O
for	O
a	O
single	O
truncating	O
mutation,	O
typically	O
near	O
the	O
N-terminal	O
end	O
of	O
the	O
gene,	O
or	O
heterozygous	O
for	O
the	O
in-frame	O
deletion	O
2546	O
3,	O
were	O
shorter	O
and	O
had	O
significantly	O
shorter	O
survival	O
than	O
those	O
heterozygous	O
for	O
a	O
splice	O
site	O
or	O
missense	O
mutation,	O
or	O
heterozygous	O
for	O
two	O
truncating	O
mutations.	O
Alterations	O
of	O
the	O
length	O
or	O
amino	O
acid	O
composition	O
of	O
the	O
A-T	Modifier
gene	O
product	O
affect	O
the	O
A-T	Modifier
clinical	O
phenotype	O
in	O
different	O
ways.	O
Mutation	O
analysis	O
at	O
the	O
A-T	Modifier
locus	O
may	O
help	O
estimate	O
the	O
prognosis	O
of	O
A-T	Modifier

Anticipation	O
resulting	O
in	O
elimination	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
gene:	O
a	O
follow	O
up	O
study	O
of	O
one	O
extended	O
family.	O
We	O
have	O
re-examined	O
an	O
extended	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
)	O
family,	O
previously	O
described	O
in	O
1955,	O
in	O
order	O
to	O
study	O
the	O
long	O
term	O
effects	O
of	O
anticipation	O
in	O
DM	SpecificDisease
and	O
in	O
particular	O
the	O
implications	O
for	O
families	O
affected	O
by	O
this	O
disease.	O
This	O
follow	O
up	O
study	O
provides	O
data	O
on	O
35	O
gene	O
carriers	O
and	O
46	O
asymptomatic	O
at	O
risk	O
family	O
members	O
in	O
five	O
generations.	O
Clinical	O
anticipation,	O
defined	O
as	O
the	O
cascade	O
of	O
mild,	O
adult,	O
childhood,	O
or	O
congenital	DiseaseClass
disease	DiseaseClass
in	O
subsequent	O
generations,	O
appeared	O
to	O
be	O
a	O
relentless	O
process,	O
occurring	O
in	O
all	O
affected	O
branches	O
of	O
the	O
family.	O
The	O
cascade	O
was	O
found	O
to	O
proceed	O
asynchronously	O
in	O
the	O
different	O
branches,	O
mainly	O
because	O
of	O
an	O
unequal	O
number	O
of	O
generations	O
with	O
mild	O
disease.	O
The	O
transition	O
from	O
the	O
mild	O
to	O
the	O
adult	O
type	O
was	O
associated	O
with	O
transmission	O
through	O
a	O
male	O
parent.	O
Stable	O
transmission	O
of	O
the	O
asymptomatic/mild	O
phenotype	O
showed	O
a	O
female	O
transmission	O
bias.	O
We	O
further	O
examined	O
the	O
extent	O
and	O
causes	O
of	O
gene	O
loss	O
in	O
this	O
pedigree.	O
Gene	O
loss	O
in	O
the	O
patient	O
group	O
was	O
complete,	O
owing	O
to	O
infertility	DiseaseClass
of	O
the	O
male	O
patients	O
with	O
adult	O
onset	O
disease	O
and	O
the	O
fact	O
that	O
mentally	DiseaseClass
retarded	DiseaseClass
patients	O
did	O
not	O
procreate.	O
Out	O
of	O
the	O
46	O
at	O
risk	O
subjects	O
in	O
the	O
two	O
youngest	O
generations,	O
only	O
one	O
was	O
found	O
to	O
have	O
a	O
full	O
mutation.	O
This	O
is	O
the	O
only	O
subject	O
who	O
may	O
transmit	O
the	O
gene	O
to	O
the	O
sixth	O
generation.	O
No	O
protomutation	O
carriers	O
were	O
found	O
in	O
the	O
fourth	O
and	O
fifth	O
generations.	O
Therefore	O
it	O
is	O
highly	O
probable	O
that	O
the	O
DM	Modifier
gene	O
will	O
be	O
eliminated	O
from	O
this	O
pedigree	O
within	O
one	O
generation.	O
The	O
high	O
population	O
frequency	O
of	O
DM	SpecificDisease

Exon	O
9	O
mutations	O
in	O
the	O
WT1	O
gene,	O
without	O
influencing	O
KTS	O
splice	O
isoforms,	O
are	O
also	O
responsible	O
for	O
Frasier	SpecificDisease
syndrome	SpecificDisease
.	O
We	O
report	O
new	O
mutations	O
in	O
exon	O
9	O
of	O
the	O
WT1	O
gene	O
that	O
did	O
not	O
alter	O
the	O
ratio	O
of	O
+/-	O
KTS	O
splice	O
isoforms	O
in	O
two	O
unrelated	O
patients	O
with	O
Frasier	SpecificDisease
syndrome	SpecificDisease
(	O
FS	SpecificDisease
).	O
The	O
mutation	O
of	O
intron	O
9	O
inducing	O
defective	O
alternative	O
splicing	O
was	O
reported	O
to	O
be	O
responsible	O
for	O
this	O
syndrome.	O
The	O
mutations	O
found	O
in	O
our	O
cases	O
occurred	O
in	O
the	O
same	O
exon	O
of	O
the	O
WT1	O
gene	O
as	O
detected	O
in	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
(	O
DDS	SpecificDisease
)	O
and	O
could	O
not	O
be	O
explained	O
by	O
the	O
previously	O
proposed	O
mechanism.	O
The	O
results	O
suggest	O
that	O
the	O
two	O
syndromes	O
originate	O
from	O
the	O
same	O
WT1	SpecificDisease
gene	SpecificDisease
abnormality	SpecificDisease
.	O
From	O
a	O
molecular	O
biological	O
point	O
of	O
view,	O
we	O
concluded	O
that	O
the	O
two	O
diseases	O
were	O
not	O
separable,	O
and	O
that	O
FS	SpecificDisease
should	O
be	O
included	O
as	O
an	O
atypical	O
form	O
of	O
DDS	SpecificDisease

Deficit	O
of	O
in	O
vivo	O
mitochondrial	O
ATP	O
production	O
in	O
patients	O
with	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
(	O
FRDA	SpecificDisease
),	O
the	O
most	O
common	O
of	O
the	O
inherited	DiseaseClass
ataxias	DiseaseClass
,	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
degenerative	DiseaseClass
disorder	DiseaseClass
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	CompositeMention
gait	CompositeMention
and	CompositeMention
limb	CompositeMention
ataxia	CompositeMention
,	O
absence	DiseaseClass
of	DiseaseClass
deep	DiseaseClass
tendon	DiseaseClass
reflexes	DiseaseClass
,	O
extensor	DiseaseClass
plantar	DiseaseClass
responses	DiseaseClass
,	O
and	O
loss	CompositeMention
of	CompositeMention
position	CompositeMention
and	CompositeMention
vibration	CompositeMention
sense	CompositeMention
in	O
the	O
lower	O
limbs.	O
FRDA	SpecificDisease
is	O
caused	O
by	O
a	O
GAA	O
triplet	O
expansion	O
in	O
the	O
first	O
intron	O
of	O
the	O
FRDA	Modifier
gene	O
on	O
chromosome	O
9q13	O
in	O
97%	O
of	O
patients.	O
The	O
FRDA	Modifier
gene	O
encodes	O
a	O
widely	O
expressed	O
210-aa	O
protein,	O
frataxin,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	Modifier
patients.	O
Frataxin	O
function	O
is	O
still	O
unknown	O
but	O
the	O
knockout	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
gene	O
(YFH1)	O
showed	O
a	O
severe	O
defect	O
of	O
mitochondrial	O
respiration	O
and	O
loss	O
of	O
mtDNA	O
associated	O
with	O
elevated	O
intramitochondrial	O
iron.	O
Here	O
we	O
report	O
in	O
vivo	O
evidence	O
of	O
impaired	O
mitochondrial	O
respiration	O
in	O
skeletal	O
muscle	O
of	O
FRDA	Modifier
patients.	O
Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
ATP	O
production	O
(V	O
(max))	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
FRDA	Modifier
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
V	O
(max)	O
and	O
the	O
number	O
of	O
GAA	O
repeats	O
in	O
the	O
smaller	O
allele.	O
Our	O
results	O
show	O
that	O
FRDA	SpecificDisease
is	O
a	O
nuclear-encoded	O
mitochondrial	DiseaseClass
disorder	DiseaseClass

Chronic	SpecificDisease
nonspherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
(	O
CNSHA	SpecificDisease
)	O
and	O
glucose	SpecificDisease
6	SpecificDisease
phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
a	O
patient	O
with	O
familial	SpecificDisease
amyloidotic	SpecificDisease
polyneuropathy	SpecificDisease
(	O
FAP	SpecificDisease
).	O
Molecular	O
study	O
of	O
a	O
new	O
variant	O
(G6PD	O
Clinic)	O
with	O
markedly	O
acidic	O
pH	O
optimum.	O
A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
(G6PD)	O
variant	O
with	O
severe	O
erythrocytic	SpecificDisease
G6PD	SpecificDisease
deficiency	SpecificDisease
and	O
a	O
unique	O
pH	O
optimum	O
is	O
described	O
in	O
a	O
young	O
patient	O
with	O
chronic	SpecificDisease
nonspherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
(	O
CNSHA	SpecificDisease
)	O
and	O
familial	SpecificDisease
amyloidotic	SpecificDisease
polyneuropathy	SpecificDisease
(	O
FAP	SpecificDisease
).	O
Chronic	SpecificDisease
hemolysis	SpecificDisease

Regional	O
localization	O
of	O
polymorphic	O
DNA	O
loci	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
using	O
deletions	O
associated	O
with	O
choroideremia	SpecificDisease
.	O
In	O
two	O
unrelated	O
families,	O
males	O
have	O
been	O
identified	O
who	O
suffer	O
from	O
choroideremia	SpecificDisease
and	O
at	O
the	O
same	O
time	O
have	O
an	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
the	O
X	O
chromosome.	O
By	O
high-resolution	O
banding	O
we	O
have	O
characterized	O
the	O
deletion	O
chromosomes	O
as	O
del	O
(X)	O
(q21.	O
1-q21	O
1-q21.	O
33)	O
and	O
del	O
(X)	O
(q21.	O
2-q21	O
2-q21.	O
31)	O
respectively.	O
By	O
Southern	O
blot	O
analysis	O
we	O
have	O
mapped	O
ten	O
different	O
polymorphic	O
DNA	O
loci	O
relative	O
to	O
the	O
position	O
of	O
the	O
deletion	O
and	O
the	O
choroideremia	Modifier

A	O
de	O
novo	O
unbalanced	O
reciprocal	O
translocation	O
identified	O
as	O
paternal	O
in	O
origin	O
in	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
Interstitial	O
cytogenetic	O
deletions	O
involving	O
the	O
paternally	O
derived	O
chromosome	O
15q11-13	O
have	O
been	O
described	O
in	O
patients	O
with	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
We	O
report	O
a	O
child	O
with	O
PWS	SpecificDisease
and	O
a	O
de	O
novo	O
unbalanced	O
karyotype	O
-45,	O
XY,	O
-9,	O
-15,	O
+	O
der	O
(9)	O
t	O
(9;	O
15)	O
(q34;	O
q13).	O
Molecular	O
studies	O
with	O
the	O
DNA	O
probe	O
pML34	O
confirmed	O
that	O
only	O
a	O
single	O
Prader	Modifier
Willi	Modifier

Clinicopathologic	O
features	O
of	O
BRCA-linked	CompositeMention
and	CompositeMention
sporadic	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
.	O
CONTEXT	O
	O
Most	O
hereditary	SpecificDisease
ovarian	SpecificDisease
cancers	SpecificDisease
are	O
associated	O
with	O
germline	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2.	O
Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	SpecificDisease
cancer	SpecificDisease
have	O
produced	O
conflicting	O
results,	O
especially	O
regarding	O
survival.	O
OBJECTIVE	O
	O
To	O
determine	O
whether	O
hereditary	SpecificDisease
ovarian	SpecificDisease
cancers	SpecificDisease
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	SpecificDisease
(nonhereditary)	SpecificDisease
ovarian	SpecificDisease
cancers	SpecificDisease
.	O
DESIGN	O
AND	O
SETTING	O
	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	SpecificDisease
cancers	SpecificDisease
diagnosed	O
and	O
treated	O
at	O
our	O
institution,	O
which	O
is	O
a	O
comprehensive	O
cancer	Modifier
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	Modifier
Institute,	O
over	O
a	O
12-year	O
period	O
(December	O
1986	O
to	O
August	O
1998).	O
PATIENTS	O
	O
The	O
study	O
was	O
restricted	O
to	O
patients	O
of	O
Jewish	O
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	O
and	O
BRCA2	O
genotyping	O
in	O
this	O
ethnic	O
group.	O
From	O
the	O
189	O
patients	O
who	O
identified	O
themselves	O
as	O
Jewish,	O
88	O
hereditary	O
cases	O
were	O
identified	O
with	O
the	O
presence	O
of	O
a	O
germline	O
founder	O
mutation	O
in	O
BRCA1	O
or	O
BRCA2.	O
The	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
BRCA	O
mutation	O
and	O
2	O
additional	O
groups	O
(Gynecologic	O
Oncology	O
Group	O
protocols	O
52	O
and	O
111)	O
with	O
ovarian	SpecificDisease
cancer	SpecificDisease
from	O
clinical	O
trials	O
(for	O
the	O
survival	O
analysis)	O
were	O
included	O
for	O
comparison.	O
MAIN	O
OUTCOME	O
MEASURES	O
	O
Age	O
at	O
diagnosis,	O
surgical	O
stage,	O
histologic	O
cell	O
type	O
and	O
grade,	O
and	O
surgical	O
outcome;	O
and	O
response	O
to	O
chemotherapy	O
and	O
survival	O
for	O
advanced-stage	O
(II	O
and	O
IV)	O
cases.	O
RESULTS	O
Hereditary	DiseaseClass
cancers	DiseaseClass
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1-	O
vs	O
BRCA2-linked	O
patients	O
(54	O
vs	O
62	O
years;	O
P	O
=.	O
04).	O
Histology,	O
grade,	O
stage,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	O
for	O
hereditary	O
and	O
sporadic	O
cases.	O
The	O
hereditary	O
group	O
had	O
a	O
longer	O
disease-free	O
interval	O
following	O
primary	O
chemotherapy	O
in	O
comparison	O
with	O
the	O
nonhereditary	O
group,	O
with	O
a	O
median	O
time	O
to	O
recurrence	O
of	O
14	O
months	O
and	O
7	O
months,	O
respectively	O
(P	O
<.	O
001).	O
Those	O
with	O
hereditary	DiseaseClass
cancers	DiseaseClass
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(P	O
=.	O
004).	O
For	O
stage	DiseaseClass
III	DiseaseClass
cancers	DiseaseClass
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(P	O
=.	O
03).	O
CONCLUSIONS	O
	O
Although	O
BRCA-associated	SpecificDisease
hereditary	SpecificDisease
ovarian	SpecificDisease
cancers	SpecificDisease
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	DiseaseClass
cancers	DiseaseClass
,	O
advanced-stage	Modifier
hereditary	Modifier
cancer	Modifier
patients	O
survive	O
longer	O
than	O
nonhereditary	Modifier
cancer	Modifier
patients.	O
Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1-linked	CompositeMention
than	CompositeMention
for	CompositeMention
BRCA2-linked	CompositeMention
cancers	CompositeMention

Germline	O
intronic	O
and	O
exonic	O
mutations	O
in	O
the	O
Wilms'	Modifier
tumour	Modifier
gene	O
(WT1)	O
affecting	O
urogenital	O
development.	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
rare	O
human	O
developmental	DiseaseClass
disorder	DiseaseClass
affecting	O
the	O
urogenital	O
system	O
and	O
leading	O
to	O
renal	DiseaseClass
failure	DiseaseClass
,	O
intersex	DiseaseClass
disorders	DiseaseClass
and	O
Wilms	SpecificDisease
tumour	SpecificDisease
.	O
In	O
this	O
report,	O
four	O
individuals	O
with	O
this	O
syndrome	O
are	O
described	O
carrying	O
germline	O
point	O
mutations	O
in	O
the	O
Wilms	Modifier
tumour	Modifier

Analysis	O
of	O
deletions	O
in	O
DNA	O
from	O
patients	O
with	O
Becker	CompositeMention
and	CompositeMention
Duchenne	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
.	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
recessive	DiseaseClass
genetic	DiseaseClass
disorder	DiseaseClass
for	O
which	O
the	O
biochemical	O
defect	O
is	O
as	O
yet	O
unknown.	O
Recently,	O
two	O
cloned	O
segments	O
of	O
human	O
X-chromosome	O
DNA	O
have	O
been	O
described	O
which	O
detect	O
structural	O
alterations	O
within	O
or	O
near	O
the	O
genetic	O
locus	O
responsible	O
for	O
the	O
disorder.	O
Both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	O
linked	O
to	O
the	O
locus	O
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
DNA	O
of	O
boys	O
affected	O
with	O
DMD	SpecificDisease
.	O
In	O
an	O
attempt	O
to	O
determine	O
more	O
precisely	O
the	O
occurrence	O
of	O
these	O
deletions	O
within	O
a	O
large	O
population	O
of	O
DMD	Modifier
patients	O
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments,	O
DXS164	O
(pERT87),	O
in	O
determining	O
the	O
inheritance	O
of	O
the	O
DMD	Modifier
X	O
chromosome,	O
the	O
subclones	O
1,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world.	O
Here	O
we	O
describe	O
the	O
combined	O
results	O
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	O
of	O
deletions	O
at	O
the	O
DXS164	O
locus	O
in	O
DNA	O
samples	O
isolated	O
from	O
patients	O
with	O
DMD	SpecificDisease
and	O
Becker	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
BMD	SpecificDisease
).	O
The	O
results	O
indicate	O
that	O
the	O
DXS164	O
locus	O
apparently	O
recombines	O
with	O
DMD	SpecificDisease
5%	O
of	O
the	O
time,	O
but	O
is	O
probably	O
located	O
between	O
independent	O
sites	O
of	O
mutation	O
which	O
yield	O
DMD	SpecificDisease
.	O
The	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
DXS164	O
locus,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
DMD	Modifier

Additional	O
case	O
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
due	O
to	O
opposite	O
X-chromosome	O
inactivation.	O
A	O
pair	O
of	O
female	O
monozygotic	O
(MZ)	O
twins,	O
heterozygous	O
carriers	O
for	O
a	O
deletion	O
in	O
the	O
DMD	Modifier
gene	O
and	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
,	O
were	O
analyzed	O
by	O
molecular	O
studies,	O
in	O
situ	O
hybridization,	O
and	O
methylation	O
pattern	O
of	O
X	O
chromosomes	O
to	O
search	O
for	O
opposite	O
X	O
inactivation	O
as	O
an	O
explanation	O
of	O
their	O
clinical	O
discordance.	O
Results	O
in	O
lymphocytes	O
and	O
skin	O
fibroblast	O
cell	O
lines	O
suggest	O
a	O
partial	O
mirror	O
inactivation	O
with	O
the	O
normal	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
unaffected	O
twin,	O
and	O
the	O
maternal	O
deleted	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
affected	O
twin.	O
A	O
review	O
shows	O
that	O
MZ	O
female	O
twins	O
discordant	O
for	O
X-linked	DiseaseClass
diseases	DiseaseClass

Analbuminemia	SpecificDisease
in	O
a	O
neonate.	O
A	O
small-for-gestational-age	O
infant,	O
found	O
to	O
have	O
analbuminemia	SpecificDisease
in	O
the	O
neonatal	O
period,	O
is	O
reported	O
and	O
the	O
twelve	O
cases	O
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed.	O
Patients	O
lacking	O
this	O
serum	O
protein	O
are	O
essentially	O
asymptomatic,	O
apart	O
from	O
minimal	O
ankle	DiseaseClass
edema	DiseaseClass
and	O
ease	DiseaseClass
of	DiseaseClass
fatigue	DiseaseClass
.	O
Apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	O
albumin	O
is	O
low	O
include	O
prolonged	O
half-life	O
of	O
albumin	O
and	O
transferrin,	O
an	O
increase	O
in	O
serum	O
globulins,	O
beta	O
lipoprotein,	O
and	O
glycoproteins,	O
arterial	DiseaseClass
hypotension	DiseaseClass

Homozygous	O
presence	O
of	O
the	O
crossover	O
(fusion	O
gene)	O
mutation	O
identified	O
in	O
a	O
type	Modifier
II	Modifier
Gaucher	Modifier
disease	Modifier
fetus:	O
is	O
this	O
analogous	O
to	O
the	O
Gaucher	O
knock-out	O
mouse	O
model?	O
Gaucher	SpecificDisease
disease	SpecificDisease
(	O
GD	SpecificDisease
)	O
is	O
an	O
inherited	O
deficiency	SpecificDisease
of	SpecificDisease
beta-glucocerebrosidase	SpecificDisease
(EC	O
3.	O
1.	O
2.	O
45,	O
gene	O
symbol	O
GBA).	O
In	O
type	SpecificDisease
I	SpecificDisease
GD	SpecificDisease
,	O
the	O
CNS	O
is	O
not	O
involved	O
(nonneuronopathic),	O
whereas	O
in	O
type	SpecificDisease
II	SpecificDisease
GD	SpecificDisease
(acute	O
neuronopathic)	O
CNS	O
involvement	O
is	O
early	O
and	O
rapidly	O
progressive,	O
while	O
in	O
type	SpecificDisease
III	SpecificDisease
GD	SpecificDisease
(subacute	O
neuronopathic)	O
CNS	O
involvement	O
occurs	O
later	O
and	O
is	O
slowly	O
progressive.	O
The	O
T6433C	O
(L444P)	O
substitution	O
is	O
prevalent	O
in	O
type	SpecificDisease
GD	SpecificDisease
II	SpecificDisease
.	O
It	O
may	O
occur	O
alone	O
as	O
a	O
single	O
base-pair	O
mutation	O
but	O
often	O
is	O
found	O
as	O
part	O
of	O
a	O
complex	O
allele	O
containing	O
additional	O
GBA	O
nucleotide	O
substitutions,	O
G6468C	O
(A456P)	O
and	O
G6482C	O
(V460V),	O
without	O
(recNciI)	O
or	O
with	O
(recTL)	O
G5957C	O
(D409H).	O
This	O
complex	O
allele	O
is	O
presumed	O
to	O
have	O
formed	O
by	O
recombination	O
(crossover,	O
fusion)	O
of	O
the	O
structural	O
gene	O
with	O
the	O
pseudogene,	O
which	O
contains	O
the	O
mutated	O
sequences.	O
Two	O
complex	O
alleles	O
have	O
never	O
been	O
demonstrated	O
to	O
coexist	O
in	O
any	O
individual.	O
We	O
devised	O
a	O
selective	O
PCR	O
method	O
for	O
the	O
specific	O
amplification	O
of	O
the	O
normal	O
and/or	O
fusion	O
gene.	O
Using	O
this	O
procedure	O
we	O
demonstrated	O
the	O
fusion	O
gene	O
in	O
homozygous	O
form	O
for	O
the	O
first	O
time,	O
in	O
a	O
Macedonian/Ashkenazi	O
Jewish	O
GD	Modifier
type	Modifier
II	Modifier
fetus.	O
Both	O
parents	O
were	O
carriers	O
of	O
the	O
recombination.	O
This	O
was	O
confirmed	O
by	O
direct	O
sequence	O
analysis.	O
A	O
previous	O
conceptus	O
in	O
this	O
family	O
was	O
stillborn	DiseaseClass
at	O
36	O
weeks,	O
with	O
features	O
of	O
severe	O
type	SpecificDisease
II	SpecificDisease
GD	SpecificDisease

Decrease	O
in	O
GTP	O
cyclohydrolase	O
I	O
gene	O
expression	O
caused	O
by	O
inactivation	O
of	O
one	O
allele	O
in	O
hereditary	SpecificDisease
progressive	SpecificDisease
dystonia	SpecificDisease
with	O
marked	O
diurnal	O
fluctuation.	O
Hereditary	SpecificDisease
progressive	SpecificDisease
dystonia	SpecificDisease
with	O
marked	O
diurnal	O
fluctuation	O
(	O
HPD	SpecificDisease
;	O
dopa-responsive	SpecificDisease
dystonia	SpecificDisease
,	O
DRD	SpecificDisease
)	O
have	O
been	O
recently	O
found	O
to	O
be	O
caused	O
by	O
a	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
the	O
GTP	O
cyclohydrolase	O
I	O
(GCH1)	O
gene.	O
In	O
this	O
study,	O
we	O
quantified	O
the	O
mRNA	O
level	O
of	O
GCH1	O
in	O
phytohemagglutinin	O
(PHA)	O
-stimulated	O
mononuclear	O
blood	O
cells	O
from	O
one	O
Japanese	O
family	O
that	O
do	O
not	O
have	O
a	O
mutation	O
in	O
the	O
coding	O
region	O
or	O
splice	O
junctions	O
of	O
the	O
gene.	O
The	O
results	O
showed	O
that	O
the	O
amounts	O
of	O
the	O
GCH1	O
mRNA	O
were	O
decreased	O
to	O
about	O
40%	O
of	O
the	O
normal	O
level	O
in	O
both	O
patients	O
and	O
carriers.	O
In	O
addition,	O
we	O
found	O
that	O
the	O
GCH1	O
mRNA	O
was	O
transcribed	O
from	O
only	O
one	O
allele,	O
indicating	O
that	O
the	O
other	O
allele	O
was	O
in	O
an	O
inactive	O
state.	O
These	O
results	O
suggest	O
that	O
some	O
novel	O
mutations	O
should	O
exist	O
on	O
one	O
of	O
the	O
alleles	O
in	O
some	O
unknown	O
region	O
of	O
the	O
GCH1	O
gene,	O
and	O
may	O
decrease	O
the	O
GCH1	O
mRNA	O
causing	O
the	O
HPD	Modifier
/	O
DRD	Modifier

Novel	O
mutations	O
in	O
the	O
Wiskott-Aldrich	Modifier
syndrome	Modifier
protein	O
gene	O
and	O
their	O
effects	O
on	O
transcriptional,	O
translational,	O
and	O
clinical	O
phenotypes.	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
)	O
is	O
an	O
X-linked	DiseaseClass
recessive	DiseaseClass
immunodeficiency	DiseaseClass
characterized	O
by	O
thrombocytopenia	DiseaseClass
,	O
eczema	DiseaseClass
,	O
and	O
recurrent	O
infections,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	Modifier
protein	O
(WASP)	O
gene.	O
WASP	O
contains	O
several	O
functional	O
domains	O
through	O
which	O
it	O
interacts	O
with	O
proteins	O
involved	O
in	O
intracellular	O
signaling	O
and	O
regulation	O
of	O
the	O
actin	O
cytoskeleton.	O
In	O
this	O
report,	O
17	O
WASP	O
gene	O
mutations	O
were	O
identified,	O
12	O
of	O
which	O
are	O
novel.	O
DNA	O
of	O
affected	O
males	O
and	O
obligate	O
carriers	O
was	O
PCR	O
amplified	O
and	O
analyzed	O
by	O
SSCA,	O
heteroduplex	O
analysis,	O
and	O
direct	O
sequencing.	O
The	O
effects	O
of	O
the	O
mutations	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
were	O
ascertained	O
by	O
RT-PCR	O
and	O
Western	O
blot	O
analyses.	O
All	O
missense	O
mutations	O
were	O
located	O
in	O
exons	O
1-4.	O
Most	O
of	O
the	O
nonsense,	O
frameshift	O
and	O
splice	O
site	O
mutations	O
were	O
found	O
in	O
exons	O
6-11.	O
Mutations	O
that	O
alter	O
splice	O
sites	O
led	O
to	O
the	O
synthesis	O
of	O
several	O
types	O
of	O
mRNAs,	O
a	O
fraction	O
of	O
which	O
represented	O
the	O
normally	O
spliced	O
product.	O
The	O
presence	O
of	O
normally	O
spliced	O
transcripts	O
was	O
correlated	O
with	O
a	O
milder	O
phenotype.	O
When	O
one	O
such	O
case	O
was	O
studied	O
by	O
Western	O
blotting,	O
reduced	O
amounts	O
of	O
normal-size	O
WASP	O
were	O
present.	O
In	O
other	O
cases	O
as	O
well,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
amount	O
of	O
normal	O
or	O
mutant	O
WASP	O
present	O
and	O
the	O
phenotypes	O
of	O
the	O
affected	O
individuals.	O
No	O
protein	O
was	O
detected	O
in	O
two	O
individuals	O
with	O
severe	O
WAS	SpecificDisease
.	O
Reduced	O
levels	O
of	O
a	O
normal-size	O
WASP	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
XLT	SpecificDisease

Incidence	O
and	O
characteristics	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
variants	O
in	O
Japan.	O
A	O
total	O
of	O
3000	O
men	O
living	O
in	O
Yamaguchi	O
were	O
screened	O
for	O
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
using	O
Beutlers	O
spot	O
test	O
and	O
three	O
types	O
of	O
starch	O
gel	O
electrophoresis.	O
These	O
electrophoresis	O
used	O
a	O
phosphate	O
buffer	O
system	O
at	O
pH	O
7.	O
0,	O
a	O
TRIS-EDTA-borate	O
buffer	O
system	O
at	O
pH	O
8.	O
6,	O
and	O
a	O
TRIS-hydrochloride	O
buffer	O
system	O
at	O
pH	O
8..	O
Fifteen	O
G6PD-deficient	Modifier
variants	O
were	O
found	O
at	O
the	O
rate	O
of	O
0.	O
5%	O
and	O
classified	O
into	O
four	O
groups.	O
As	O
new	O
variants,	O
G6PD	O
Konan,	O
Kamiube,	O
and	O
Kiwa	O
were	O
identified.	O
These	O
three	O
variants	O
had	O
a	O
mild	O
to	O
moderate	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Difference	O
in	O
methylation	O
patterns	O
within	O
the	O
D15S9	O
region	O
of	O
chromosome	O
15q11-13	O
in	O
first	O
cousins	O
with	O
Angelman	SpecificDisease
syndrome	SpecificDisease
and	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
Abnormalities	O
of	O
chromosome	O
region	O
15q11-13	O
are	O
associated	O
with	O
Angelman	SpecificDisease
syndrome	SpecificDisease
(	O
AS	SpecificDisease
)	O
and	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
Differences	O
between	O
the	O
methylation	O
patterns	O
of	O
the	O
region	O
of	O
chromosome	O
15q11-13	O
which	O
hybridizes	O
to	O
the	O
highly	O
conserved	O
DNA,	O
DN34,	O
in	O
normal	O
individuals	O
and	O
in	O
patients	O
with	O
AS	SpecificDisease
and	O
PWS	SpecificDisease
have	O
been	O
described.	O
We	O
report	O
on	O
a	O
family	O
in	O
which	O
first	O
cousins	O
are	O
affected	O
by	O
AS	SpecificDisease
and	O
PWS	SpecificDisease

Mutations	O
in	O
the	O
candidate	O
gene	O
for	O
Norrie	SpecificDisease
disease	SpecificDisease
.	O
Recently,	O
we	O
and	O
others	O
have	O
isolated	O
a	O
candidate	O
gene	O
for	O
X	SpecificDisease
linked	SpecificDisease
Norrie	SpecificDisease
disease	SpecificDisease
(	O
ND	SpecificDisease
)	O
which	O
was	O
found	O
to	O
be	O
deleted	O
or	O
disrupted	O
in	O
several	O
patients.	O
As	O
a	O
prerequisite	O
for	O
the	O
identification	O
of	O
point	O
mutations	O
in	O
the	O
ND	Modifier
gene	O
we	O
have	O
established	O
the	O
exon-intron	O
structure	O
of	O
this	O
gene.	O
In	O
17	O
unrelated	O
patients	O
and	O
15	O
controls,	O
PCR	O
products	O
derived	O
from	O
the	O
promoter	O
region,	O
exons	O
1	O
and	O
2	O
as	O
well	O
as	O
the	O
coding	O
part	O
of	O
exon	O
3	O
were	O
analysed	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
technique.	O
In	O
12	O
patients	O
altered	O
PCR	O
fragments	O
were	O
detected	O
which	O
were	O
studied	O
in	O
detail	O
by	O
direct	O
sequencing.	O
Eleven	O
different	O
mutations	O
were	O
found,	O
and	O
all	O
but	O
one	O
are	O
likely	O
to	O
give	O
rise	O
to	O
significant	O
structural	O
changes	O
in	O
the	O
predicted	O
protein.	O
These	O
findings,	O
and	O
the	O
absence	O
of	O
functionally	O
relevant	O
base	O
changes	O
in	O
healthy	O
controls,	O
emphasize	O
the	O
causal	O
role	O
of	O
this	O
candidate	O
gene	O
in	O
Norrie	SpecificDisease
disease	SpecificDisease

A	O
single	O
amino	O
acid	O
substitution	O
(G103D)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
.	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
is	O
a	O
moderately	O
severe	O
chondrodysplasia	Modifier
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen,	O
COL2A1.	O
Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	SpecificDisease
trunk	SpecificDisease
and	SpecificDisease
extremities	SpecificDisease
,	O
mid-face	DiseaseClass
hypoplasia	DiseaseClass
,	O
cleft	SpecificDisease
palate	SpecificDisease
,	O
myopia	DiseaseClass
,	O
retinal	SpecificDisease
detachment	SpecificDisease
,	O
and	O
hearing	DiseaseClass
loss	DiseaseClass
.	O
Recently,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	Modifier
dysplasia	Modifier
phenotype.	O
We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	SpecificDisease
dysplasia	SpecificDisease
.	O
An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient.	O
DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate.	O
The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband.	O
Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage.	O
These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	SpecificDisease
dysplasia	SpecificDisease

Linkage	O
analysis	O
of	O
5	O
novel	O
van	Modifier
der	Modifier
Woude	Modifier
syndrome	Modifier
kindreds	O
to	O
1q32-q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait.	O
van	SpecificDisease
der	SpecificDisease
Woude	SpecificDisease
syndrome	SpecificDisease
(	O
vWS	SpecificDisease
,	O
MIM	O
119300)	O
is	O
a	O
rare	O
autosomal	DiseaseClass
dominant	DiseaseClass
clefting	DiseaseClass
condition	DiseaseClass
with	O
cardinal	O
features	O
of	O
mucous	SpecificDisease
cysts	SpecificDisease
(	O
lower-lip	SpecificDisease
pits	SpecificDisease
)	O
and	O
clefts	CompositeMention
to	CompositeMention
the	CompositeMention
lip	CompositeMention
and/or	CompositeMention
palate	CompositeMention
.	O
The	O
vWS	Modifier
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32-q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping.	O
We	O
have	O
investigated	O
5	O
novel	O
vWS	Modifier
families	O
through	O
probands	O
attended	O
for	O
cleft	Modifier
lip	Modifier
and/or	Modifier
palate	Modifier
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau,	O
Paris,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	Modifier
region	O
in	O
1q32-q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees.	O
Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
6	O
microsatellite	O
markers	O
(D1S249,	O
D1S425,	O
D1S491,	O
D1S205,	O
D1S414,	O
D1S425),	O
yielding	O
a	O
maximum	O
cumulative	O
LOD	O
score	O
of	O
Z	O
=	O
3.	O
27	O
at	O
theta	O
=	O
0.	O
00	O
for	O
D1S245.	O
The	O
innermost	O
four	O
markers	O
were	O
found	O
to	O
be	O
tightly	O
linked	O
to	O
one	O
another,	O
with	O
no	O
evidence	O
for	O
recombination.	O
Our	O
results	O
support	O
linkage	O
of	O
vWS	SpecificDisease

Hypopigmentation	DiseaseClass
in	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
Cutaneous	CompositeMention
and	CompositeMention
ocular	CompositeMention
pigmentation	CompositeMention
were	O
evaluated	O
in	O
29	O
individuals	O
with	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
Criteria	O
for	O
hypopigmentation	DiseaseClass
included	O
the	O
presence	O
of	O
type	O
I	O
or	O
II	O
skin,	O
the	O
lightest	O
skin	O
type	O
in	O
the	O
family	O
by	O
history,	O
and	O
iris	O
translucency	O
on	O
globe	O
transillumination.	O
On	O
the	O
basis	O
of	O
these	O
criteria,	O
48%	O
of	O
the	O
PWS	Modifier
individuals	O
were	O
hypopigmented	Modifier
.	O
The	O
presence	O
of	O
hypopigmentation	DiseaseClass
correlated	O
with	O
a	O
small	O
interstitial	O
deletion	O
on	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15;	O
however,	O
this	O
deletion	O
was	O
also	O
found	O
in	O
individuals	O
who	O
did	O
not	O
meet	O
the	O
full	O
criteria	O
for	O
hypopigmentation	DiseaseClass
.	O
Hairbulb	O
tyrosinase	O
activity	O
and	O
glutathione	O
content,	O
as	O
well	O
as	O
urine	O
cysteinyldopa	O
excretion,	O
were	O
low	O
in	O
PWS	Modifier
individuals	O
with	O
and	O
without	O
hypopigmentation	DiseaseClass
and	O
did	O
not	O
separate	O
these	O
two	O
groups.	O
We	O
conclude	O
that	O
hypopigmentation	DiseaseClass
is	O
found	O
in	O
a	O
significant	O
proportion	O
of	O
individuals	O
with	O
PWS	SpecificDisease
and	O
that	O
the	O
hypopigmentation	DiseaseClass
may	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
15.	O
The	O
mechanism	O
for	O
the	O
hypopigmentation	DiseaseClass

Deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
human	O
subjects.	O
Clinical,	O
genetic	O
and	O
immunologic	O
studies	O
in	O
a	O
large	O
kindred.	O
The	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C5)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
C5	O
in	O
human	O
subjects.	O
The	O
proband,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	SpecificDisease
infection	SpecificDisease
,	O
has	O
a	O
hemolytic	O
C5	O
level	O
of	O
approximately	O
0.	O
5	O
per	O
cent	O
of	O
normal.	O
No	O
C5	O
protein	O
was	O
detectable,	O
but	O
low	O
levels	O
of	O
functional	O
C5	O
activity	O
could	O
be	O
found	O
using	O
a	O
sensitive	O
bactericidal	O
assay.	O
The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	O
levels	O
of	O
hemolytic	O
C5	O
(approximately	O
0.	O
5	O
per	O
cent	O
normal),	O
but	O
both	O
these	O
subjects	O
have	O
been	O
healthy.	O
Hemolytic	O
complement	O
and	O
bacteriolytic	O
activity	O
could	O
be	O
restored	O
by	O
the	O
addition	O
of	O
purified	O
C5.	O
No	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5-deficient	Modifier
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors.	O
The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	O
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed.	O
Twenty-two	O
of	O
32	O
other	O
family	O
members	O
from	O
three	O
generations	O
had	O
depressed	O
whole	O
hemolytic	O
complement	O
levels.	O
In	O
19	O
of	O
30	O
family	O
members,	O
levels	O
of	O
hemolytic	O
C5	O
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal.	O
No	O
linkage	O
for	O
C5	SpecificDisease
deficiency	SpecificDisease
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found.	O
These	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
C5	SpecificDisease
deficiency	SpecificDisease
.	O
Deficiency	SpecificDisease
of	SpecificDisease
C5	SpecificDisease
is	O
compatible	O
with	O
good	O
health,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	SpecificDisease
infection	SpecificDisease

A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
variant,	O
G6PD	O
Orissa	O
(44	O
Ala-->Gly),	O
is	O
the	O
major	O
polymorphic	O
variant	O
in	O
tribal	O
populations	O
in	O
India.	O
Deficiency	SpecificDisease
of	SpecificDisease
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	O
is	O
usually	O
found	O
at	O
high	O
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	SpecificDisease
has	O
been	O
endemic.	O
The	O
frequency	O
and	O
genetic	O
basis	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
have	O
been	O
studied	O
in	O
Africa,	O
around	O
the	O
Mediterranean,	O
and	O
in	O
the	O
Far	O
East,	O
but	O
little	O
such	O
information	O
is	O
available	O
about	O
the	O
situation	O
in	O
India.	O
To	O
determine	O
the	O
extent	O
of	O
heterogeneity	O
of	O
G6PD,	O
we	O
have	O
studied	O
several	O
different	O
Indian	O
populations	O
by	O
screening	O
for	O
G6PD	SpecificDisease
deficiency	SpecificDisease
,	O
followed	O
by	O
molecular	O
analysis	O
of	O
deficient	O
alleles.	O
The	O
frequency	O
of	O
G6PD	SpecificDisease
deficiency	SpecificDisease
varies	O
between	O
3%	O
and	O
15%	O
in	O
different	O
tribal	O
and	O
urban	O
groups.	O
Remarkably,	O
a	O
previously	O
unreported	O
deficient	O
variant,	O
G6PD	O
Orissa	O
(44	O
Ala--	O
>	O
Gly),	O
is	O
responsible	O
for	O
most	O
of	O
the	O
G6PD	SpecificDisease
deficiency	SpecificDisease
in	O
tribal	O
Indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations,	O
where	O
most	O
of	O
the	O
G6PD	SpecificDisease
deficiency	SpecificDisease

Germline	O
mutations	O
in	O
the	O
Wilms'	Modifier
tumor	Modifier
suppressor	O
gene	O
are	O
associated	O
with	O
abnormal	O
urogenital	O
development	O
in	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
.	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
rare	O
human	O
condition	O
in	O
which	O
severe	O
urogenital	DiseaseClass
aberrations	DiseaseClass
result	O
in	O
renal	SpecificDisease
failure	SpecificDisease
,	O
pseudohermaphroditism	SpecificDisease
,	O
and	O
Wilms	SpecificDisease
tumor	SpecificDisease
(	O
nephroblastoma	SpecificDisease
).	O
To	O
investigate	O
its	O
possible	O
role,	O
we	O
have	O
analyzed	O
the	O
coding	O
exons	O
of	O
the	O
Wilms	Modifier
tumor	Modifier
suppressor	O
gene	O
(WT1)	O
for	O
germline	O
mutations.	O
In	O
ten	O
independent	O
cases	O
of	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
,	O
point	O
mutations	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
one	O
WT1	O
gene	O
copy	O
were	O
found.	O
Nine	O
of	O
these	O
mutations	O
are	O
found	O
within	O
exon	O
9	O
(zinc	O
finger	O
III);	O
the	O
remaining	O
mutation	O
is	O
in	O
exon	O
8	O
(zinc	O
finger	O
II).	O
These	O
mutations	O
directly	O
affect	O
DNA	O
sequence	O
recognition.	O
In	O
two	O
families	O
analyzed,	O
the	O
mutations	O
were	O
shown	O
to	O
arise	O
de	O
novo.	O
Wilms	SpecificDisease
tumors	SpecificDisease
from	O
three	O
individuals	O
and	O
one	O
juvenile	O
granulosa	O
cell	O
tumor	DiseaseClass
demonstrate	O
reduction	O
to	O
homozygosity	O
for	O
the	O
mutated	O
WT1	O
allele.	O
Our	O
results	O
provide	O
evidence	O
of	O
a	O
direct	O
role	O
for	O
WT1	O
in	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease

Molecular	O
basis	O
of	O
feline	O
beta-glucuronidase	SpecificDisease
deficiency	SpecificDisease
:	O
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	SpecificDisease
VII	SpecificDisease
.	O
A	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	O
abnormalities	O
consistent	O
with	O
mucopolysaccharidosis	SpecificDisease
VII	SpecificDisease
,	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
beta-glucuronidase	SpecificDisease
deficiency	SpecificDisease
.	O
beta-Glucuronidase	O
activity	O
was	O
undetectable	O
in	O
affected	O
cat	O
fibroblasts	O
and	O
restored	O
by	O
retroviral	O
gene	O
transfer	O
of	O
rat	O
beta-glucuronidase	O
cDNA.	O
beta-Glucuronidase	O
mRNA	O
was	O
normal	O
in	O
affected	O
cat	O
testis	O
by	O
Northern	O
blot	O
analysis.	O
Normal	O
feline	O
beta-glucuronidase	O
cDNA	O
was	O
cloned	O
and	O
characterized,	O
and	O
amplified	O
from	O
affected	O
cat	O
fibroblasts	O
by	O
reverse	O
transcription	O
coupled	O
polymerase	O
chain	O
reaction.	O
There	O
was	O
a	O
G-to-A	O
transition	O
in	O
the	O
affected	O
cat	O
cDNA	O
that	O
predicted	O
an	O
E351K	O
substitution,	O
destroyed	O
a	O
BssSI	O
site,	O
and	O
eliminated	O
GUSB	O
enzymatic	O
activity	O
in	O
expression	O
studies.	O
Multiple	O
species	O
comparison	O
and	O
the	O
crystal	O
structure	O
of	O
human	O
beta-glucuronidase	O
indicated	O
that	O
E351	O
is	O
a	O
highly	O
conserved	O
residue	O
most	O
likely	O
essential	O
in	O
maintenance	O
of	O
the	O
enzymes	O
conformation.	O
BssSI	O
digestion	O
of	O
polymerase	O
chain	O
reaction	O
products	O
amplified	O
from	O
genomic	O
DNA	O
indicated	O
that	O
affected	O
cats	O
were	O
homozygous	O
and	O
cats	O
with	O
half-normal	O
beta-glucuronidase	O
activity	O
were	O
heterozygous	O
for	O
the	O
missense	O
mutation.	O
Carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings,	O
and	O
a	O
feline	O
MPS	Modifier
VII	Modifier

Loss-of-function	O
mutations	O
in	O
the	O
cathepsin	O
C	O
gene	O
result	O
in	O
periodontal	SpecificDisease
disease	SpecificDisease
and	O
palmoplantar	DiseaseClass
keratosis	DiseaseClass
.	O
Papillon-Lefevre	SpecificDisease
syndrome	SpecificDisease
,	O
or	O
keratosis	DiseaseClass
palmoplantaris	DiseaseClass
with	O
periodontopathia	SpecificDisease
(	O
PLS	SpecificDisease
,	O
MIM	O
245000),	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	SpecificDisease
that	O
afflicts	O
patients.	O
Both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected,	O
resulting	O
in	O
premature	O
tooth	SpecificDisease
loss	SpecificDisease
.	O
Palmoplantar	DiseaseClass
keratosis	DiseaseClass
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	SpecificDisease
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life.	O
Keratosis	SpecificDisease
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees.	O
Most	O
PLS	Modifier
patients	O
display	O
both	O
periodontitis	SpecificDisease
and	O
hyperkeratosis	SpecificDisease
.	O
Some	O
patients	O
have	O
only	O
palmoplantar	DiseaseClass
keratosis	DiseaseClass
or	O
periodontitis	SpecificDisease
,	O
and	O
in	O
rare	O
individuals	O
the	O
periodontitis	SpecificDisease
is	O
mild	O
and	O
of	O
late	O
onset.	O
The	O
PLS	O
locus	O
has	O
been	O
mapped	O
to	O
chromosome	O
11q14-q21	O
(refs	O
7,	O
8,	O
9).	O
Using	O
homozygosity	O
mapping	O
in	O
eight	O
small	O
consanguineous	O
families,	O
we	O
have	O
narrowed	O
the	O
candidate	O
region	O
to	O
a	O
1.	O
2-cM	O
interval	O
between	O
D11S4082	O
and	O
D11S931.	O
The	O
gene	O
(CTSC)	O
encoding	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
(or	O
dipeptidyl	O
aminopeptidase	O
I)	O
lies	O
within	O
this	O
interval.	O
We	O
defined	O
the	O
genomic	O
structure	O
of	O
CTSC	O
and	O
found	O
mutations	O
in	O
all	O
eight	O
families.	O
In	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
C	O
activity	O
in	O
PLS	Modifier

Brca1	SpecificDisease
deficiency	SpecificDisease
results	O
in	O
early	O
embryonic	DiseaseClass
lethality	DiseaseClass
characterized	O
by	O
neuroepithelial	DiseaseClass
abnormalities	DiseaseClass
.	O
The	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
gene,	O
BRCA1,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc-finger	O
protein	O
of	O
unknown	O
function.	O
Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80%	O
of	O
families	O
with	O
both	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
,	O
as	O
well	O
as	O
some	O
non-familial	O
sporadic	O
ovarian	SpecificDisease
cancers	SpecificDisease
.	O
The	O
loss	O
of	O
wild-type	O
BRCA1	O
in	O
tumours	DiseaseClass
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	Modifier
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells.	O
To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	Modifier
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele.	O
Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(E10-E13).	O
Abnormalities	O
in	O
Brca1-deficient	Modifier
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube,	O
with	O
40%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	SpecificDisease
bifida	SpecificDisease
and	O
anencephaly	SpecificDisease
.	O
In	O
addition,	O
the	O
neuroepithelium	O
in	O
Brca1-deficient	Modifier

X	SpecificDisease
linked	SpecificDisease
recessive	SpecificDisease
thrombocytopenia	SpecificDisease
.	O
A	O
Saudi	O
Arab	O
boy	O
presented	O
in	O
early	O
childhood	O
with	O
thrombocytopenia	SpecificDisease
,	O
morphologically	O
large	O
and	O
normal	O
sized	O
platelets,	O
increased	O
mean	O
platelet	O
volume,	O
and	O
a	O
hypermegakaryocytic	O
bone	O
marrow.	O
There	O
was	O
no	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
any	O
significant	O
immunological	DiseaseClass
abnormalities	DiseaseClass
.	O
Similar	O
findings	O
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
X	SpecificDisease
linked	SpecificDisease
recessive	SpecificDisease
thrombocytopenic	SpecificDisease
disorder	SpecificDisease
.	O
Results	O
of	O
DNA	O
analysis	O
with	O
the	O
probe	O
M27	O
beta	O
are	O
consistent	O
with	O
X	O
linkage	O
and	O
indicate	O
also	O
that	O
the	O
locus	O
of	O
the	O
relevant	O
gene	O
lies	O
close	O
to	O
or	O
is	O
identical	O
to	O
the	O
locus	O
of	O
the	O
gene	O
for	O
the	O
Wiskott-Aldrich	SpecificDisease
syndrome	SpecificDisease
(	O
WAS	SpecificDisease
).	O
Because	O
of	O
various	O
features	O
which	O
include	O
the	O
presence	O
of	O
large	O
and	O
normal	O
sized	O
platelets	O
(rather	O
than	O
small	O
platelets)	O
and	O
freedom	O
from	O
significant	O
immune	DiseaseClass
deficiencies	DiseaseClass
,	O
it	O
is	O
likely	O
that	O
the	O
X	SpecificDisease
linked	SpecificDisease
recessive	SpecificDisease
thrombocytopenia	SpecificDisease
in	O
this	O
family	O
is	O
an	O
isolated	O
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
WAS	Modifier
phenotype.	O
However,	O
a	O
modified	O
expression	O
of	O
the	O
WAS	Modifier

Genetics	O
of	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
):	O
an	O
autosomal	O
recessive	O
trait	O
with	O
high	O
gene	O
frequency	O
in	O
Sephardim	O
of	O
Moroccan	O
origin.	O
We	O
described	O
6	O
patients	O
(from	O
3	O
families)	O
affected	O
with	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
).	O
All	O
are	O
Sephardic	O
Jews	O
of	O
Moroccan	O
extraction.	O
In	O
view	O
of	O
the	O
small	O
number	O
of	O
CTX	Modifier
patients	O
diagnosed	O
in	O
the	O
world	O
(a	O
total	O
of	O
50	O
including	O
our	O
6	O
patients),	O
we	O
are	O
probably	O
dealing	O
with	O
an	O
ethnic	O
subgroup	O
with	O
a	O
high	O
CTX	O
gene	O
frequency,	O
which	O
we	O
have	O
estimated	O
to	O
be	O
1/108.	O
Since	O
there	O
are	O
differences	O
in	O
expression	O
in	O
this	O
disease,	O
we	O
recommend	O
cholestanol	O
study	O
in	O
cases	O
of	O
undiagnosed	O
cataract	SpecificDisease
or	O
tendinous	SpecificDisease
xanthomas	SpecificDisease
in	O
childhood	O
or	O
early	O
adolescence.	O
The	O
diagnosis	O
in	O
CTX	SpecificDisease

A	O
missense	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
with	O
possible	O
dominant	O
effects	O
on	O
plasma	O
high	O
density	O
lipoproteins.	O
Plasma	O
HDL	O
are	O
a	O
negative	O
risk	O
factor	O
for	O
atherosclerosis	SpecificDisease
.	O
Cholesteryl	O
ester	O
transfer	O
protein	O
(CETP;	O
476	O
amino	O
acids)	O
transfers	O
cholesteryl	O
ester	O
from	O
HDL	O
to	O
other	O
lipoproteins.	O
Subjects	O
with	O
homozygous	O
CETP	SpecificDisease
deficiency	SpecificDisease

Huntington	SpecificDisease
disease	SpecificDisease
:	O
no	O
evidence	O
for	O
locus	O
heterogeneity.	O
A	O
total	O
of	O
63	O
families	O
with	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
were	O
examined	O
for	O
linkage	O
between	O
HD	SpecificDisease
and	O
G8	O
(D4S10).	O
The	O
families	O
included	O
57	O
Caucasian,	O
four	O
Black	O
American,	O
and	O
two	O
Japanese.	O
The	O
combined	O
maximum	O
lod	O
score	O
was	O
87.	O
69	O
at	O
theta	O
=	O
0.	O
04	O
(99%	O
confidence	O
interval	O
0.	O
018-0.	O
071).	O
The	O
maximum	O
frequency	O
of	O
recombination	O
was	O
0.	O
03	O
in	O
males	O
and	O
0.	O
05	O
in	O
females.	O
Fifty-seven	O
families	O
gave	O
positive	O
lod	O
scores;	O
five	O
small	O
families	O
gave	O
mildly	O
negative	O
lod	O
scores.	O
The	O
maximum	O
likelihood	O
estimate	O
of	O
alpha,	O
the	O
proportion	O
of	O
linked	O
loci,	O
was	O
1.	O
0	O
with	O
a	O
lower	O
99%	O
confidence	O
interval	O
of	O
0.	O
88.	O
These	O
data	O
suggest	O
that	O
there	O
is	O
only	O
one	O
HD	Modifier

Homozygous	O
and	O
heterozygous	O
deletions	O
of	O
the	O
von	Modifier
Willebrand	Modifier
factor	O
gene	O
in	O
patients	O
and	O
carriers	O
of	O
severe	SpecificDisease
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
.	O
Severe	SpecificDisease
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
is	O
characterized	O
by	O
undetectable	O
or	O
trace	O
quantities	O
of	O
von	Modifier
Willebrand	Modifier
factor	O
in	O
plasma	O
and	O
tissue	O
stores.	O
We	O
have	O
studied	O
the	O
genomic	O
DNA	O
of	O
10	O
affected	O
individuals	O
from	O
six	O
families	O
with	O
this	O
disorder	O
using	O
probes	O
from	O
the	O
5	O
and	O
3	O
ends	O
of	O
the	O
vWF	O
cDNA	O
and	O
with	O
a	O
probe	O
extending	O
from	O
the	O
5	O
end	O
into	O
the	O
central	O
region.	O
Southern	O
blots	O
of	O
restriction	O
endonuclease	O
digests	O
and	O
gene	O
dosage	O
analysis	O
measurements	O
carried	O
out	O
with	O
quantitative	O
slot	O
blots	O
of	O
undigested	O
genomic	O
DNA	O
separated	O
these	O
patients	O
into	O
three	O
groups.	O
The	O
first	O
group	O
consisted	O
of	O
a	O
family	O
with	O
complete	O
homozygous	O
deletions	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
four	O
probands.	O
Gene	O
dosage	O
analysis	O
was	O
consistent	O
with	O
heterozygous	O
deletions	O
in	O
both	O
of	O
the	O
asymptomatic	O
parents	O
and	O
four	O
asymptomatic	O
siblings	O
of	O
this	O
kindred	O
(P	O
less	O
than	O
0.	O
01).	O
The	O
second	O
group	O
was	O
comprised	O
of	O
a	O
family	O
in	O
which	O
there	O
was	O
a	O
complete	O
heterozygous	O
deletion	O
of	O
the	O
vWF	O
gene	O
in	O
the	O
proband	O
and	O
one	O
asymptomatic	O
parent,	O
suggesting	O
that	O
a	O
different	O
type	O
of	O
genetic	DiseaseClass
abnormality	DiseaseClass
was	O
inherited	O
from	O
the	O
other	O
parent.	O
Thus,	O
the	O
patient	O
appeared	O
to	O
be	O
doubly	O
heterozygous	O
for	O
interacting	O
genetic	DiseaseClass
abnormalities	DiseaseClass
affecting	O
vWF	O
expression.	O
In	O
the	O
third	O
group,	O
no	O
gene	O
deletions	O
could	O
be	O
detected.	O
Alloantibodies	O
developed	O
only	O
in	O
the	O
kindred	O
with	O
homozygous	O
deletions.	O
These	O
techniques	O
should	O
prove	O
useful	O
in	O
identifying	O
carriers	O
of	O
severe	SpecificDisease
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease

Spectrum	O
of	O
germline	O
mutations	O
in	O
the	O
RB1	O
gene:	O
a	O
study	O
of	O
232	O
patients	O
with	O
hereditary	CompositeMention
and	CompositeMention
non	CompositeMention
hereditary	CompositeMention
retinoblastoma	CompositeMention
.	O
Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
confer	O
hereditary	O
predisposition	O
to	O
retinoblastoma	SpecificDisease
.	O
We	O
have	O
performed	O
a	O
mutation	O
survey	O
of	O
the	O
RB1	O
gene	O
in	O
232	O
patients	O
with	O
hereditary	CompositeMention
or	CompositeMention
non	CompositeMention
hereditary	CompositeMention
retinoblastoma	CompositeMention
.	O
We	O
systematically	O
explored	O
all	O
27	O
exons	O
and	O
flanking	O
sequences	O
as	O
well	O
as	O
the	O
promotor.	O
All	O
types	O
of	O
point	O
mutations	O
are	O
represented	O
and	O
are	O
found	O
unequally	O
distributed	O
along	O
the	O
RB1	O
gene	O
sequence.	O
In	O
the	O
population	O
we	O
studied,	O
exons	O
3,	O
8,	O
18	O
and	O
19	O
are	O
preferentially	O
altered.	O
The	O
range	O
of	O
frequency	O
of	O
detection	O
of	O
germline	O
mutations	O
is	O
about	O
20%,	O
indicating	O
that	O
other	O
mechanisms	O
of	O
inactivation	O
of	O
RB1	O
should	O
be	O
involved.	O
The	O
spectrum	O
of	O
mutations	O
presented	O
here	O
should	O
help	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
retinoblastoma	SpecificDisease

Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
:	O
an	O
X-linked	DiseaseClass
neurologic	DiseaseClass
disorder	DiseaseClass
of	DiseaseClass
myelin	DiseaseClass
metabolism	DiseaseClass
with	O
a	O
novel	O
mutation	O
in	O
the	O
gene	O
encoding	O
proteolipid	O
protein.	O
The	O
nosology	O
of	O
the	O
inborn	DiseaseClass
errors	DiseaseClass
of	DiseaseClass
myelin	DiseaseClass
metabolism	DiseaseClass
has	O
been	O
stymied	O
by	O
the	O
lack	O
of	O
molecular	O
genetic	O
analysis.	O
Historically,	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
has	O
encompassed	O
a	O
host	O
of	O
neurologic	DiseaseClass
disorders	DiseaseClass
that	O
present	O
with	O
a	O
deficit	DiseaseClass
of	DiseaseClass
myelin	DiseaseClass
,	O
the	O
membrane	O
elaborated	O
by	O
glial	O
cells	O
that	O
encircles	O
and	O
successively	O
enwraps	O
axons.	O
We	O
describe	O
here	O
a	O
Pelizaeus-Merzbacher	Modifier
pedigree	O
of	O
the	O
classical	O
type,	O
with	O
X-linked	O
inheritance,	O
a	O
typical	O
clinical	O
progression,	O
and	O
a	O
pathologic	O
loss	O
of	O
myelinating	O
cells	O
and	O
myelin	O
in	O
the	O
central	O
nervous	O
system.	O
To	O
discriminate	O
variants	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
,	O
a	O
set	O
of	O
oligonucleotide	O
primers	O
was	O
constructed	O
to	O
polymerase-chain-reaction	O
(PCR)	O
amplify	O
and	O
sequence	O
the	O
gene	O
encoding	O
proteolipid	O
protein	O
(PLP),	O
a	O
structural	O
protein	O
that	O
comprises	O
half	O
of	O
the	O
protein	O
of	O
the	O
myelin	O
sheath.	O
The	O
PLP	O
gene	O
in	O
one	O
of	O
two	O
affected	O
males	O
and	O
the	O
carrier	O
mother	O
of	O
this	O
family	O
exhibited	O
a	O
single	O
base	O
difference	O
in	O
the	O
more	O
than	O
2	O
kb	O
of	O
the	O
PLP	O
gene	O
sequenced,	O
a	O
C----T	O
transition	O
that	O
would	O
create	O
a	O
serine	O
substitution	O
for	O
proline	O
at	O
the	O
carboxy	O
end	O
of	O
the	O
protein.	O
Our	O
results	O
delineate	O
the	O
clinical	O
features	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
,	O
define	O
the	O
possible	O
molecular	O
pathology	O
of	O
this	O
dysmyelinating	DiseaseClass
disorder	DiseaseClass
,	O
and	O
address	O
the	O
molecular	O
classification	O
of	O
inborn	DiseaseClass
errors	DiseaseClass
of	DiseaseClass
myelin	DiseaseClass
metabolism	DiseaseClass
.	O
Patients	O
with	O
the	O
classical	O
form	O
(type	O
I)	O
and	O
the	O
more	O
severely	O
affected,	O
connatal	O
variant	O
of	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
(type	SpecificDisease
II)	SpecificDisease
would	O
be	O
predicted	O
to	O
display	O
mutation	O
at	O
the	O
PLP	O
locus.	O
The	O
other	O
variants	O
(types	O
III-VI),	O
which	O
have	O
sometimes	O
been	O
categorized	O
as	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease

CAG	O
expansions	O
in	O
a	O
novel	O
gene	O
for	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
at	O
chromosome	O
14q32.1.	O
We	O
have	O
identified	O
a	O
novel	O
gene	O
containing	O
CAG	O
repeats	O
and	O
mapped	O
it	O
to	O
chromosome	O
14q32.	O
1,	O
the	O
genetic	O
locus	O
for	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
).	O
In	O
normal	O
individuals	O
the	O
gene	O
contains	O
between	O
13	O
and	O
36	O
CAG	O
repeats,	O
whereas	O
most	O
of	O
the	O
clinically	O
diagnosed	O
patients	O
and	O
all	O
of	O
the	O
affected	O
members	O
of	O
a	O
family	O
with	O
the	O
clinical	O
and	O
pathological	O
diagnosis	O
of	O
MJD	SpecificDisease
show	O
expansion	O
of	O
the	O
repeat-number	O
(from	O
68-79).	O
Southern	O
blot	O
analyses	O
and	O
genomic	O
cloning	O
demonstrates	O
the	O
existence	O
of	O
related	O
genes.	O
These	O
results	O
raise	O
the	O
possibility	O
that	O
similar	O
abnormalities	O
in	O
related	O
genes	O
may	O
give	O
rise	O
to	O
diseases	O
similar	O
to	O
MJD	SpecificDisease

Conservation	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
in	O
mice	O
and	O
humans.	O
A	O
portion	O
of	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
gene	O
transcript	O
from	O
human	O
fetal	O
skeletal	O
muscle	O
and	O
mouse	O
adult	O
heart	O
was	O
sequenced,	O
representing	O
approximately	O
25	O
percent	O
of	O
the	O
total,	O
14-kb	O
DMD	Modifier
transcript.	O
The	O
nucleic	O
acid	O
and	O
predicted	O
amino	O
acid	O
sequences	O
from	O
the	O
two	O
species	O
are	O
nearly	O
90	O
percent	O
homologous.	O
The	O
amino	O
acid	O
sequence	O
that	O
is	O
predicted	O
from	O
this	O
portion	O
of	O
the	O
DMD	Modifier
gene	O
indicates	O
that	O
the	O
protein	O
product	O
might	O
serve	O
a	O
structural	O
role	O
in	O
muscle,	O
but	O
the	O
abundance	O
and	O
tissue	O
distribution	O
of	O
the	O
messenger	O
RNA	O
suggests	O
that	O
the	O
DMD	Modifier

Deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
murine	SpecificDisease
fifth	SpecificDisease
complement	SpecificDisease
component	SpecificDisease
(C5)	SpecificDisease
.	O
A	O
2-base	O
pair	O
gene	O
deletion	O
in	O
a	O
5'-exon.	O
To	O
ascertain	O
the	O
molecular	O
mechanism	O
that	O
causes	O
murine	O
C5	SpecificDisease
deficiency	SpecificDisease
,	O
genomic	O
and	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
mouse	O
liver	O
DNA	O
and	O
mRNA	O
employing	O
the	O
congenic	O
strains	O
B10.	O
D2/nSnJ	O
and	O
B10.	O
D2/oSnJ	O
that	O
are	O
sufficient	O
and	O
deficient	SpecificDisease
for	SpecificDisease
C5	SpecificDisease
,	O
respectively.	O
Genomic	O
fragments	O
were	O
isolated	O
which	O
correspond	O
to	O
PvuII	O
and	O
HindIII	O
restriction	O
fragment	O
length	O
polymorphisms	O
associated	O
with	O
C5	SpecificDisease
deficiency	SpecificDisease
.	O
Sequence	O
analyses	O
demonstrated	O
that	O
each	O
of	O
these	O
polymorphisms	O
resulted	O
from	O
single	O
base	O
pair	O
substitutions	O
and	O
that	O
neither	O
substitution	O
would	O
probably	O
cause	O
or	O
contribute	O
to	O
the	O
C5	SpecificDisease
deficiency	SpecificDisease
.	O
Sequence	O
analyses	O
of	O
C5	O
sufficient	O
and	O
deficient	O
cDNAs	O
revealed	O
a	O
2	O
base-pair	O
deletion	O
in	O
the	O
deficient	O
cDNAs.	O
The	O
"	O
TA	O
"	O
deletion	O
was	O
located	O
near	O
the	O
5	O
end	O
of	O
the	O
cDNA.	O
This	O
deletion	O
shifts	O
the	O
reading	O
frame	O
of	O
the	O
C5	O
mRNA	O
so	O
that	O
the	O
termination	O
codon	O
UGA	O
is	O
present	O
4	O
base	O
pairs	O
downstream	O
from	O
the	O
deletion.	O
Genomic	O
DNA	O
was	O
amplified	O
and	O
sequenced	O
corresponding	O
to	O
the	O
area	O
surrounding	O
the	O
2-base	O
pair	O
deletion.	O
Six	O
C5-deficient	Modifier
strains,	O
A/HeJ,	O
AKR/J,	O
DBA/2J,	O
NZB/B1NJ,	O
SWR/J,	O
and	O
B10.	O
D2/oSnJ,	O
and	O
four	O
C5-sufficient	O
strains,	O
Balb/CJ,	O
C57Bl/6J,	O
DBA/1J,	O
and	O
B10.	O
D2/nSnJ,	O
were	O
analyzed.	O
The	O
sequencing	O
data	O
revealed	O
that	O
the	O
2	O
base	O
pairs	O
were	O
deleted	O
from	O
the	O
C5	O
gene	O
of	O
each	O
deficient	O
mouse	O
tested	O
but	O
not	O
from	O
the	O
C5	O
gene	O
of	O
any	O
sufficient	O
mouse.	O
These	O
data	O
demonstrate	O
that	O
	O
1)	O
there	O
is	O
an	O
identical	O
2-base	O
pair	O
deletion	O
in	O
an	O
exon	O
of	O
the	O
C5	O
gene	O
in	O
several	O
different	O
C5-deficient	Modifier
mouse	O
strains;	O
2)	O
the	O
mRNA	O
transcribed	O
from	O
the	O
C5D	O
gene	O
retains	O
this	O
deletion;	O
and	O
3)	O
this	O
mutation	O
should	O
result	O
in	O
C5	SpecificDisease
protein	SpecificDisease
deficiency	SpecificDisease

Recurrent	O
meningitis	SpecificDisease
in	O
a	O
patient	O
with	O
congenital	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
C9	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
.	O
First	O
case	O
of	O
C9	SpecificDisease
deficiency	SpecificDisease
in	O
Europe.	O
We	O
describe	O
the	O
first	O
cases,	O
to	O
our	O
knowledge,	O
of	O
C9	SpecificDisease
deficiency	SpecificDisease
in	O
Europe	O
that	O
were	O
detected	O
in	O
a	O
Swiss	O
family,	O
of	O
which	O
two	O
members--one	O
with	O
a	O
complete	O
deficiency	O
and	O
the	O
other	O
with	O
approximately	O
half-normal	O
C9	O
levels--experienced	O
bacterial	SpecificDisease
meningitis	SpecificDisease
.	O
The	O
index	O
patient,	O
a	O
56-year-old	O
white	O
man	O
with	O
a	O
history	O
of	O
purulent	SpecificDisease
meningitis	SpecificDisease
at	O
the	O
age	O
of	O
23	O
years,	O
presented	O
with	O
an	O
acute	SpecificDisease
meningococcal	SpecificDisease
meningitis	SpecificDisease
.	O
No	O
impairment	DiseaseClass
of	DiseaseClass
cellular	DiseaseClass
immunity	DiseaseClass
or	O
immunoglobulin	SpecificDisease
deficiency	SpecificDisease
could	O
be	O
found.	O
Complement	O
assays	O
showed	O
a	O
complete	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
C9	SpecificDisease
component	SpecificDisease
,	O
while	O
the	O
other	O
individual	O
component	O
levels	O
were	O
normal	O
and	O
the	O
hemolytic	O
activity	O
(measured	O
using	O
the	O
CH50	O
assay)	O
was	O
only	O
slightly	O
reduced.	O
A	O
family	O
study	O
revealed	O
complete	SpecificDisease
C9	SpecificDisease
deficiency	SpecificDisease
in	O
the	O
patients	O
healthy	O
brother	O
and	O
half-normal	O
C9	O
concentrations	O
in	O
his	O
sister,	O
his	O
son	O
(who	O
also	O
had	O
experienced	O
an	O
episode	O
of	O
bacterial	SpecificDisease
meningitis	SpecificDisease
),	O
and	O
his	O
niece,	O
consistent	O
with	O
an	O
inherited	O
C9	SpecificDisease
deficiency	SpecificDisease
.	O
This	O
first	O
case	O
of	O
recurrent	SpecificDisease
meningitis	SpecificDisease
in	O
a	O
white	O
patient	O
with	O
complete	SpecificDisease
C9	SpecificDisease
deficiency	SpecificDisease
suggests	O
that	O
this	O
complement	DiseaseClass
defect	DiseaseClass
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
bacterial,	DiseaseClass
especially	DiseaseClass
neisserial,	DiseaseClass
infections	DiseaseClass

Bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy	SpecificDisease
.	O
An	O
allogeneic	O
bone	O
marrow	O
transplant	O
(BMT)	O
from	O
a	O
normal	O
HLA	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13-year-old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
).	O
Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks,	O
but	O
neurologic	DiseaseClass
deterioration	DiseaseClass
continued.	O
The	O
patient	O
died	O
of	O
an	O
adenovirus	SpecificDisease
infection	SpecificDisease
141	O
days	O
after	O
BMT.	O
ALD	SpecificDisease

Increased	O
incidence	O
of	O
cataracts	SpecificDisease
in	O
male	O
subjects	O
deficient	SpecificDisease
in	SpecificDisease
glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
.	O
Glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	Modifier
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
Sardinian	O
origin.	O
The	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	SpecificDisease
.	O
In	O
the	O
G6PD-deficient	Modifier
group,	O
the	O
incidence	O
of	O
cortical	CompositeMention
and	CompositeMention
total	CompositeMention
cataracts	CompositeMention
was	O
also	O
increased.	O
It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	O
activity	O
in	O
the	O
lens,	O
which	O
accompanies	O
its	O
deficiency	O
in	O
the	O
erythrocyte,	O
might	O
play	O
a	O
role	O
in	O
the	O
cataracto-genesis	O
of	O
these	O
patients.	O
Moreover,	O
G6PD	SpecificDisease
deficiency	SpecificDisease
should	O
be	O
added	O
to	O
other	O
conditions,	O
such	O
as	O
the	O
galactosemic	Modifier
states	O
and	O
riboflavin	SpecificDisease
deficiency	SpecificDisease
,	O
where	O
cataracts	SpecificDisease
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	DiseaseClass
abnormalities	DiseaseClass

Von	SpecificDisease
Hippel-Lindau	SpecificDisease
disease	SpecificDisease
maps	O
to	O
the	O
region	O
of	O
chromosome	O
3	O
associated	O
with	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
.	O
Von	SpecificDisease
Hippel-Lindau	SpecificDisease
disease	SpecificDisease
(	O
VHL	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorder	DiseaseClass
with	O
inherited	O
susceptibility	O
to	O
various	O
forms	O
of	O
cancer	DiseaseClass
,	O
including	O
hemangioblastomas	SpecificDisease
of	O
the	O
central	O
nervous	O
system,	O
phaeochromocytomas	SpecificDisease
,	O
pancreatic	SpecificDisease
malignancies	SpecificDisease
,	O
and	O
renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
.	O
Renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
constitute	O
a	O
particularly	O
frequent	O
cause	O
of	O
death	O
in	O
this	O
disorder,	O
occurring	O
as	O
bilateral	CompositeMention
and	CompositeMention
multifocal	CompositeMention
tumours	CompositeMention
,	O
and	O
presenting	O
at	O
an	O
earlier	O
age	O
than	O
in	O
sporadic,	O
non-familial	O
cases	O
of	O
this	O
tumour	Modifier
type.	O
We	O
report	O
here	O
that	O
the	O
VHL	Modifier
gene	O
is	O
linked	O
to	O
the	O
locus	O
encoding	O
the	O
human	O
homologoue	O
of	O
the	O
RAF1	O
oncogene,	O
which	O
maps	O
to	O
chromosome	O
3p25	O
(ref.	O
4).	O
Crossovers	O
with	O
the	O
VHL	Modifier
locus	O
suggest	O
that	O
the	O
defect	O
responsible	O
for	O
the	O
VHL	Modifier
phenotype	O
is	O
not	O
a	O
mutation	O
in	O
the	O
RAF1	O
gene	O
itself.	O
An	O
alternative	O
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	Modifier
formation	O
may	O
be	O
the	O
inactivation	O
of	O
a	O
putative	O
tumour	Modifier
suppressor	O
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	CompositeMention
and	CompositeMention
sporadic	CompositeMention
forms	CompositeMention
of	CompositeMention
the	CompositeMention
cancer	CompositeMention
.	O
Sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
have	O
previously	O
been	O
associated	O
with	O
the	O
loss	O
of	O
regions	O
on	O
chromosome	O
3p	O
(refs	O
5,	O
6).	O
Consequently,	O
sporadic	O
and	O
VHL-associated	O
forms	O
of	O
renal	SpecificDisease
cell	SpecificDisease
carcinoma	SpecificDisease
might	O
both	O
result	O
from	O
alterations	O
causing	O
loss	O
of	O
function	O
of	O
the	O
same	O
tumour	Modifier

Tightly	O
linked	O
flanking	O
markers	O
for	O
the	O
Lowe	SpecificDisease
oculocerebrorenal	SpecificDisease
syndrome	SpecificDisease
,	O
with	O
application	O
to	O
carrier	O
assessment.	O
The	O
Lowe	SpecificDisease
oculocerebrorenal	SpecificDisease
syndrome	SpecificDisease
(	O
OCRL	SpecificDisease
)	O
is	O
characterized	O
by	O
congenital	O
cataract	SpecificDisease
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
and	O
defective	DiseaseClass
renal	DiseaseClass
tubular	DiseaseClass
function	DiseaseClass
.	O
A	O
map	O
assignment	O
of	O
OCRL	SpecificDisease
to	O
Xq24-q26	O
has	O
been	O
made	O
previously	O
by	O
linkage	O
analysis	O
with	O
DXS42	O
at	O
Xq24-q26	O
(theta	O
=	O
0,	O
z	O
=	O
5.	O
09)	O
and	O
with	O
DXS10	O
at	O
Xq26	O
(theta	O
=	O
0,	O
z	O
=	O
6.	O
45).	O
Two	O
additional	O
families	O
were	O
studied	O
and	O
three	O
additional	O
polymorphisms	O
were	O
identified	O
at	O
DXS42	O
by	O
using	O
a	O
35-kb	O
sequence	O
isolated	O
with	O
the	O
probe	O
detecting	O
the	O
original	O
polymorphism	O
at	O
DXS42.	O
With	O
additional	O
OCRL	Modifier
families	O
made	O
informative	O
for	O
DXS42,	O
theta	O
remained	O
0	O
with	O
z	O
=	O
6.	O
63;	O
and	O
for	O
DXS10	O
theta	O
=	O
0.	O
03	O
and	O
z	O
=	O
7.	O
07.	O
Evidence	O
for	O
placing	O
OCRL	O
at	O
Xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
Lowe	SpecificDisease
syndrome	SpecificDisease
and	O
an	O
X;	O
3	O
translocation.	O
We	O
have	O
used	O
the	O
Xq25	O
breakpoint	O
in	O
this	O
patient	O
to	O
determine	O
the	O
position	O
of	O
OCRL	O
relative	O
to	O
the	O
two	O
linked	O
markers.	O
Each	O
derivative	O
chromosome	O
was	O
isolated	O
away	O
from	O
its	O
normal	O
counterpart	O
in	O
somatic	O
cell	O
hybrids.	O
DXS42	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
X	O
containing	O
Xpterq25,	O
and	O
DXS10	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
3	O
containing	O
Xq25-qter.	O
The	O
markers	O
DXS10	O
and	O
DXS42	O
therefore	O
show	O
tight	O
linkage	O
with	O
OCRL	SpecificDisease
in	O
six	O
families	O
and	O
flank	O
the	O
Xq25	O
breakpoint	O
in	O
a	O
female	O
patient	O
with	O
an	O
X;	O
3	O
translocation.	O
Linkage	O
analysis	O
with	O
flanking	O
markers	O
was	O
used	O
to	O
assess	O
OCRL	Modifier

Abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
in	O
Atm	O
mutant	O
mice.	O
Motor	DiseaseClass
incoordination	DiseaseClass
,	O
immune	DiseaseClass
deficiencies	DiseaseClass
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	DiseaseClass
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	DiseaseClass
disease	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
),	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene.	O
Through	O
gene	O
targeting,	O
we	O
have	O
generated	O
a	O
line	O
of	O
Atm	O
mutant	O
mice,	O
Atm	O
(y/y)	O
mice.	O
In	O
contrast	O
to	O
other	O
Atm	O
mutant	O
mice,	O
Atm	O
(y/y)	O
mice	O
show	O
a	O
lower	O
incidence	O
of	O
thymic	SpecificDisease
lymphoma	SpecificDisease
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age.	O
Atm	O
(y/y)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	DiseaseClass
dysfunction	DiseaseClass
.	O
Even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	DiseaseClass
degeneration	DiseaseClass
in	O
older	O
Atm	O
(y/y)	O
animals,	O
ectopic	O
and	O
abnormally	O
differentiated	O
Purkinje	O
cells	O
were	O
apparent	O
in	O
mutant	O
mice	O
of	O
all	O
ages.	O
These	O
findings	O
establish	O
that	O
some	O
neuropathological	DiseaseClass
abnormalities	DiseaseClass
seen	O
in	O
A-T	Modifier
patients	O
also	O
are	O
present	O
in	O
Atm	O
mutant	O
mice.	O
In	O
addition,	O
we	O
report	O
a	O
previously	O
unrecognized	O
effect	O
of	O
Atm	SpecificDisease
deficiency	SpecificDisease
on	O
development	O
or	O
maintenance	O
of	O
CD4	O
(+)	O
8	O
(+)	O
thymocytes.	O
We	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
A-T	SpecificDisease

Both	O
mutations	O
in	O
G6PD	O
A-	O
are	O
necessary	O
to	O
produce	O
the	O
G6PD	Modifier
deficient	Modifier
phenotype.	O
The	O
high	O
prevalence	O
of	O
glucose	SpecificDisease
6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
in	O
African	O
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	O
variant	O
A-,	O
which	O
differs	O
from	O
the	O
wild-type	O
G6PD	O
B	O
by	O
two	O
amino	O
acid	O
replacements,	O
68	O
Val--	O
>	O
Met	O
and	O
126	O
Asn--	O
>	O
Asp.	O
The	O
non-deficient	O
polymorphic	O
variant	O
G6PD	O
A	O
contains	O
only	O
the	O
mutation	O
126	O
Asn--	O
>	O
Asp.	O
The	O
frequencies	O
of	O
the	O
G6PD	O
A	O
and	O
of	O
the	O
G6PD	O
A-	O
genes	O
in	O
parts	O
of	O
Africa	O
are	O
both	O
about	O
0.	O
2.	O
The	O
68	O
Val--	O
>	O
Met	O
mutation	O
has	O
not	O
been	O
found	O
in	O
a	O
B	O
background.	O
This	O
could	O
be	O
because	O
the	O
68	O
Val--	O
>	O
Met	O
mutation	O
happened	O
to	O
arise	O
in	O
an	O
A	O
gene	O
in	O
the	O
first	O
instance,	O
or	O
because	O
the	O
68	O
Val--	O
>	O
Met	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
G6PD	SpecificDisease
deficiency	SpecificDisease
.	O
We	O
have	O
approached	O
this	O
question	O
by	O
producing	O
G6PD	O
B,	O
A,	O
A-,	O
and	O
G6PD	O
68	O
Val--	O
>	O
Met	O
in	O
a	O
bacterial	O
expression	O
system	O
and	O
analysing	O
their	O
biochemical	O
properties.	O
With	O
each	O
single	O
mutation	O
we	O
found	O
a	O
slight	O
decrease	O
in	O
both	O
the	O
specific	O
activity	O
and	O
the	O
yield	O
of	O
enzyme	O
when	O
compared	O
to	O
G6PD	O
B.	O
When	O
both	O
mutations	O
were	O
introduced	O
together,	O
there	O
was	O
a	O
roughly	O
additive	O
effect	O
on	O
specific	O
activity,	O
but	O
a	O
much	O
more	O
drastic	O
effect	O
on	O
enzyme	O
yield	O
(4%	O
of	O
normal).	O
This	O
synergistic	O
effect	O
was	O
also	O
demonstrated	O
on	O
thermal	O
stability,	O
especially	O
at	O
low	O
NADP	O
concentrations.	O
Comparable	O
results	O
were	O
produced	O
when	O
the	O
replacement	O
119	O
Gln--	O
>	O
Glu	O
was	O
studied	O
instead	O
of	O
126	O
Asn--	O
>	O
Asp.	O
We	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	O
is	O
responsible	O
for	O
enzyme	SpecificDisease
deficiency	SpecificDisease
in	SpecificDisease
G6PD	SpecificDisease

Detection	O
of	O
98%	O
of	O
DMD	Modifier
/	O
BMD	Modifier
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction.	O
We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	O
promoter	O
of	O
the	O
dystrophin	O
gene	O
in	O
a	O
single	O
multiplex	O
polymerase	O
chain	O
reaction	O
(PCR).	O
When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98%	O
of	O
deletions	O
in	O
patients	O
with	O
Duchenne	CompositeMention
or	CompositeMention
Becker	CompositeMention
muscular	CompositeMention
dystrophy	CompositeMention
(	O
DMD	SpecificDisease
,	O
BMD	SpecificDisease
).	O
Furthermore,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	O
prone	O
"	O
hot	O
spot	O
"	O
region	O
around	O
exons	O
44	O
to	O
53,	O
allowing	O
determination	O
of	O
deletion	O
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	O
on	O
the	O
translational	O
reading	O
frame.	O
Thus,	O
use	O
of	O
these	O
PCR-based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
DMD	Modifier
/	O
BMD	Modifier

Recombination	O
events	O
that	O
locate	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
distal	O
to	O
APOC2	O
on	O
19q.	O
We	O
previously	O
reported	O
a	O
recombination	O
in	O
an	O
individual	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
which	O
placed	O
the	O
markers	O
D19S19	O
and	O
APOC2	O
on	O
the	O
same	O
side	O
of	O
the	O
DM	Modifier
locus.	O
Haplotyping	O
of	O
this	O
family	O
with	O
more	O
recently	O
characterized	O
probes	O
which	O
are	O
either	O
tightly	O
linked	O
to	O
DM	SpecificDisease
or	O
distal	O
to	O
the	O
linkage	O
group	O
at	O
q13.	O
2	O
shows	O
that	O
the	O
DM	Modifier
locus	O
is	O
distal	O
to	O
APOC2.	O
This	O
is	O
confirmed	O
by	O
other	O
recombinants	O
where	O
DM	SpecificDisease
segregates	O
with	O
distal	O
probes.	O
Additional	O
marker	O
to	O
marker	O
recombinations	O
in	O
unaffected	O
individuals	O
are	O
reported	O
and	O
support	O
the	O
order	O
and	O
orientation	O
of	O
the	O
DM	Modifier
linkage	O
group	O
as	O
pter-	O
(INSR,	O
LDLR,	O
S9)	O
-	O
(S19,	O
BCL3,	O
APOC2)	O
-	O
(CKMM,	O
DM)	O
-	O
(S22,	O
+	O
+	O
+	O
PRKCG)	O
-qter.	O
The	O
data	O
presented	O
here	O
cannot	O
determine	O
whether	O
DM	SpecificDisease
is	O
proximal	O
or	O
distal	O
to	O
CKMM.	O
The	O
consequences	O
of	O
this	O
probe	O
order	O
for	O
antenatal	O
diagnosis	O
and	O
future	O
research	O
aiming	O
to	O
isolate	O
the	O
gene	O
which	O
is	O
affected	O
in	O
DM	SpecificDisease

New	O
mutations,	O
polymorphisms,	O
and	O
rare	O
variants	O
in	O
the	O
ATM	O
gene	O
detected	O
by	O
a	O
novel	O
SSCP	O
strategy.	O
The	O
gene	O
for	O
ataxia-telangiectasia	SpecificDisease
,	O
ATM,	O
spans	O
about	O
150	O
kb	O
of	O
genomic	O
DNA.	O
ATM	O
mutations	O
are	O
found	O
along	O
the	O
entire	O
gene,	O
with	O
no	O
evidence	O
of	O
a	O
mutational	O
hot	O
spot.	O
Using	O
DNA	O
as	O
the	O
starting	O
material,	O
we	O
screened	O
the	O
ATM	O
gene	O
in	O
92	O
A-T	Modifier

Chromosome	O
breakage	O
in	O
the	O
Prader-Willi	CompositeMention
and	CompositeMention
Angelman	CompositeMention
syndromes	CompositeMention
involves	O
recombination	O
between	O
large,	O
transcribed	O
repeats	O
at	O
proximal	O
and	O
distal	O
breakpoints.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
and	O
Angelman	SpecificDisease
syndrome	SpecificDisease
(	O
AS	SpecificDisease
)	O
are	O
distinct	O
neurobehavioral	DiseaseClass
disorders	DiseaseClass
that	O
most	O
often	O
arise	O
from	O
a	O
4-Mb	O
deletion	O
of	O
chromosome	O
15q11-q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis,	O
respectively.	O
At	O
a	O
de	O
novo	O
frequency	O
of	O
approximately.	O
67-1/10,	O
000	O
births,	O
these	O
deletions	O
represent	O
a	O
common	O
structural	O
chromosome	O
change	O
in	O
the	O
human	O
genome.	O
To	O
elucidate	O
the	O
mechanism	O
underlying	O
these	O
events,	O
we	O
characterized	O
the	O
regions	O
that	O
contain	O
two	O
proximal	O
breakpoint	O
clusters	O
and	O
a	O
distal	O
cluster.	O
Novel	O
DNA	O
sequences	O
potentially	O
associated	O
with	O
the	O
breakpoints	O
were	O
positionally	O
cloned	O
from	O
YACs	O
within	O
or	O
near	O
these	O
regions.	O
Analyses	O
of	O
rodent-human	O
somatic-cell	O
hybrids,	O
YAC	O
contigs,	O
and	O
FISH	O
of	O
normal	O
or	O
rearranged	O
chromosomes	O
15	O
identified	O
duplicated	O
sequences	O
(the	O
END	O
repeats)	O
at	O
or	O
near	O
the	O
breakpoints.	O
The	O
END-repeat	O
units	O
are	O
derived	O
from	O
large	O
genomic	O
duplications	O
of	O
a	O
novel	O
gene	O
(HERC2),	O
many	O
copies	O
of	O
which	O
are	O
transcriptionally	O
active	O
in	O
germline	O
tissues.	O
One	O
of	O
five	O
PWS	Modifier
/	O
AS	Modifier

A	O
4-megabase	O
YAC	O
contig	O
that	O
spans	O
the	O
Langer-Giedion	Modifier
syndrome	Modifier
region	O
on	O
human	O
chromosome	O
8q24.1:	O
use	O
in	O
refining	O
the	O
location	O
of	O
the	O
trichorhinophalangeal	SpecificDisease
syndrome	SpecificDisease
and	O
multiple	O
exostoses	O
genes	O
(TRPS1	O
and	O
EXT1).	O
We	O
have	O
constructed	O
a	O
physical	O
map	O
covering	O
over	O
4	O
Mb	O
of	O
human	O
chromosome	O
8q24.	O
1	O
and	O
used	O
this	O
map	O
to	O
refine	O
the	O
locations	O
of	O
the	O
genes	O
responsible	O
for	O
Langer-Giedion	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
map	O
is	O
composed	O
of	O
overlapping	O
YAC	O
clones	O
that	O
were	O
identified	O
and	O
ordered	O
in	O
relation	O
to	O
sequence	O
tagged	O
sites	O
mapped	O
to	O
the	O
Langer-Giedion	O
chromosomal	O
region	O
on	O
somatic	O
cell	O
hybrids.	O
The	O
minimal	O
region	O
of	O
overlap	O
of	O
Langer-Giedion	Modifier
syndrome	Modifier
deletions,	O
previously	O
identified	O
by	O
analysis	O
of	O
15	O
patients,	O
was	O
placed	O
on	O
the	O
map	O
by	O
analysis	O
of	O
2	O
patients	O
whose	O
deletions	O
define	O
the	O
endpoints.	O
The	O
chromosome	O
8	O
breakpoint	O
of	O
a	O
balanced	O
t	O
(8;	O
9)	O
(q24.	O
11;	O
q33.	O
3)	O
translocation	O
from	O
a	O
patient	O
with	O
trichorhinophalangeal	SpecificDisease
syndrome	SpecificDisease
(	O
TRPS	SpecificDisease
I)	O
was	O
found	O
to	O
be	O
located	O
just	O
within	O
the	O
proximal	O
end	O
of	O
the	O
minimal	O
deletion	O
region.	O
A	O
deletion	O
of	O
8q24.	O
11-q24.	O
3	O
in	O
a	O
patient	O
with	O
multiple	O
exostoses	O
was	O
found	O
to	O
overlap	O
the	O
distal	O
end	O
of	O
the	O
LGS	Modifier
deletion	O
region,	O
indicating	O
that	O
the	O
EXT1	O
gene	O
is	O
distal	O
to	O
the	O
TRPS1	O
gene	O
and	O
supporting	O
the	O
hypothesis	O
that	O
Langer-Giedion	SpecificDisease
syndrome	SpecificDisease

Genetic	O
mapping	O
of	O
the	O
breast-ovarian	DiseaseClass
cancer	DiseaseClass
syndrome	DiseaseClass
to	O
a	O
small	O
interval	O
on	O
chromosome	O
17q12-21:	O
exclusion	O
of	O
candidate	O
genes	O
EDH17B2	O
and	O
RARA.	O
A	O
susceptibility	O
gene	O
for	O
hereditary	DiseaseClass
breast-ovarian	DiseaseClass
cancer	DiseaseClass
,	O
BRCA1,	O
has	O
been	O
assigned	O
by	O
linkage	O
analysis	O
to	O
chromosome	O
17q21.	O
Candidate	O
genes	O
in	O
this	O
region	O
include	O
EDH17B2,	O
which	O
encodes	O
estradiol	O
17	O
beta-hydroxysteroid	O
dehydrogenase	O
II	O
(17	O
beta-HSD	O
II),	O
and	O
RARA,	O
the	O
gene	O
for	O
retinoic	O
acid	O
receptor	O
alpha.	O
We	O
have	O
typed	O
22	O
breast	Modifier
and	Modifier
breast-ovarian	Modifier
cancer	Modifier
families	O
with	O
eight	O
polymorphisms	O
from	O
the	O
chromosome	O
17q12-21	O
region,	O
including	O
two	O
in	O
the	O
EDH17B2	O
gene.	O
Genetic	O
recombination	O
with	O
the	O
breast	Modifier
cancer	Modifier
trait	O
excludes	O
RARA	O
from	O
further	O
consideration	O
as	O
a	O
candidate	O
gene	O
for	O
BRCA1.	O
Both	O
BRCA1	O
and	O
EDH17B2	O
map	O
to	O
a	O
6	O
cM	O
interval	O
(between	O
THRA1	O
and	O
D17S579)	O
and	O
no	O
recombination	O
was	O
observed	O
between	O
the	O
two	O
genes.	O
However,	O
direct	O
sequencing	O
of	O
overlapping	O
PCR	O
products	O
containing	O
the	O
entire	O
EDH17B2	O
gene	O
in	O
four	O
unrelated	O
affected	O
women	O
did	O
not	O
uncover	O
any	O
sequence	O
variation,	O
other	O
than	O
previously	O
described	O
polymorphisms.	O
Mutations	O
in	O
the	O
EDH17B2	O
gene,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
hereditary	DiseaseClass
breast-ovarian	DiseaseClass
cancer	DiseaseClass
syndrome	DiseaseClass

Hereditary	SpecificDisease
C2	SpecificDisease
deficiency	SpecificDisease
associated	O
with	O
common	O
variable	O
immunodeficiency	DiseaseClass
.	O
Homozygous	O
C2	SpecificDisease
deficiency	SpecificDisease
in	O
a	O
19-year-old	O
boy	O
was	O
associated	O
with	O
variable	O
immunodeficiency	DiseaseClass
manifested	O
by	O
marked	O
hypoimmunoglobulinemia	DiseaseClass
and	O
impaired	O
antibody	O
responses,	O
normal	O
circulating	O
B	O
lymphocytes,	O
and	O
subnormal	O
T-cell	O
functions.	O
Neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	DiseaseClass
abnormalities	DiseaseClass
were	O
found.	O
Serum	O
immunoglobulin	O
levels	O
were	O
within	O
normal	O
limits	O
in	O
his	O
parents	O
and	O
brother	O
who	O
were	O
heterozygous	O
for	O
C2	SpecificDisease
deficiency	SpecificDisease

Isolation	O
of	O
molecular	O
probes	O
associated	O
with	O
the	O
chromosome	O
15	O
instability	O
in	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
.	O
Flow	O
cytometry	O
and	O
recombinant	O
DNA	O
techniques	O
have	O
been	O
used	O
to	O
obtain	O
reagents	O
for	O
a	O
molecular	O
analysis	O
of	O
the	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
HindIII	O
total-digest	O
libraries	O
were	O
prepared	O
in	O
lambda	O
phage	O
Charon	O
21A	O
from	O
flow-sorted	O
inverted	O
duplicated	O
no.	O
15	O
human	O
chromosomes	O
and	O
propagated	O
on	O
recombination-proficient	O
(LE392)	O
and	O
recBC-,	O
sbcB-	O
(DB1257)	O
bacteria.	O
Twelve	O
distinct	O
chromosome	O
15-specific	O
probes	O
have	O
been	O
isolated.	O
Eight	O
localized	O
to	O
the	O
region	O
15q11----13.	O
Four	O
of	O
these	O
eight	O
sublocalized	O
to	O
band	O
15q11.	O
2	O
and	O
are	O
shown	O
to	O
be	O
deleted	O
in	O
DNA	O
of	O
one	O
of	O
two	O
patients	O
examined	O
with	O
the	O
PWS	SpecificDisease
.	O
Heteroduplex	O
analysis	O
of	O
two	O
of	O
these	O
clones,	O
which	O
grew	O
on	O
DB1257	O
but	O
not	O
on	O
LE392,	O
revealed	O
stem-loop	O
structures	O
in	O
the	O
inserts,	O
indicative	O
of	O
inverted,	O
repeated	O
DNA	O
elements.	O
Such	O
DNA	O
repeats	O
might	O
account	O
for	O
some	O
of	O
the	O
cloning	O
instability	O
of	O
DNA	O
segments	O
from	O
proximal	O
15q.	O
Analysis	O
of	O
the	O
genetic	O
and	O
physical	O
instability	O
associated	O
with	O
the	O
repeated	O
sequences	O
we	O
have	O
isolated	O
from	O
band	O
15q11.	O
2	O
may	O
elucidate	O
the	O
molecular	O
basis	O
for	O
the	O
instability	O
of	O
this	O
chromosomal	O
region	O
in	O
patients	O
with	O
the	O
PWS	SpecificDisease
or	O
other	O
diseases	O
associated	O
with	O
chromosomal	DiseaseClass
abnormalities	DiseaseClass

Myotonic	SpecificDisease
dystrophy	SpecificDisease
:	O
evidence	O
for	O
a	O
possible	O
dominant-negative	O
RNA	O
mutation.	O
The	O
trinucleotide	O
expansion	O
mutation	O
causing	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
is	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
gene.	O
The	O
molecular	O
mechanisms	O
by	O
which	O
the	O
expanded	O
repeat	O
causes	O
the	O
clinically	O
variable	O
and	O
multisystemic	DiseaseClass
disease	DiseaseClass
,	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
,	O
are	O
not	O
understood.	O
It	O
has	O
been	O
particularly	O
difficult	O
to	O
rationalize	O
the	O
dominant	O
inheritance	O
with	O
the	O
fact	O
that	O
the	O
expansion	O
mutation	O
lies	O
outside	O
of	O
the	O
protein-encoding	O
gene	O
elements,	O
and	O
should	O
not	O
be	O
translated	O
into	O
protein.	O
Here	O
we	O
use	O
muscle	O
biopsies	O
from	O
classical	O
adult-onset	O
myotonic	Modifier
dystrophy	Modifier
patients	O
to	O
study	O
the	O
accumulation	O
of	O
transcripts	O
from	O
both	O
the	O
normal	O
and	O
expanded	O
DM	Modifier
kinase	O
genes	O
in	O
patient	O
muscle,	O
and	O
compare	O
the	O
results	O
to	O
normal	O
and	O
myopathic	Modifier
controls.	O
We	O
found	O
relatively	O
small	O
decreases	O
of	O
DM	Modifier
kinase	O
RNA	O
in	O
the	O
total	O
RNA	O
pool	O
from	O
muscle;	O
however,	O
these	O
reductions	O
were	O
not	O
disease	O
specific.	O
Analysis	O
of	O
poly	O
(A)	O
+	O
RNA	O
showed	O
dramatic	O
decreases	O
of	O
both	O
the	O
mutant	O
and	O
normal	O
DM	Modifier
kinase	O
RNAs,	O
and	O
these	O
changes	O
were	O
disease-specific.	O
Our	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
molecular	O
pathogenetic	O
mechanism	O
for	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
both	O
the	O
normal	O
and	O
expanded	O
DM	Modifier
kinase	O
genes	O
are	O
transcribed	O
in	O
patient	O
muscle,	O
but	O
the	O
abnormal	O
expansion-containing	O
RNA	O
has	O
a	O
dominant	O
effect	O
on	O
RNA	O
metabolism	O
by	O
preventing	O
the	O
accumulation	O
of	O
poly	O
(A)	O
+	O
RNA.	O
The	O
ability	O
of	O
the	O
expansion	O
mutation	O
to	O
alter	O
accumulation	O
of	O
poly	O
(A)	O
+	O
RNA	O
in	O
trans	O
suggests	O
that	O
myotonic	SpecificDisease
dystrophy	SpecificDisease

Isolation	O
of	O
the	O
gene	O
for	O
McLeod	SpecificDisease
syndrome	SpecificDisease
that	O
encodes	O
a	O
novel	O
membrane	O
transport	O
protein.	O
McLeod	SpecificDisease
syndrome	SpecificDisease
is	O
an	O
X-linked	DiseaseClass
multisystem	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
abnormalities	O
in	O
the	O
neuromuscular	O
and	O
hematopoietic	O
systems.	O
We	O
have	O
assembled	O
a	O
cosmid	O
contig	O
of	O
360	O
kb	O
that	O
encompasses	O
the	O
McLeod	Modifier
gene	O
locus.	O
A	O
50	O
kb	O
deletion	O
was	O
detected	O
by	O
screening	O
DNA	O
from	O
patients	O
with	O
radiolabeled	O
whole	O
cosmids,	O
and	O
two	O
transcription	O
units	O
were	O
identified	O
within	O
this	O
deletion.	O
The	O
mRNA	O
expression	O
pattern	O
of	O
one	O
of	O
them,	O
designated	O
as	O
XK,	O
correlates	O
closely	O
to	O
the	O
McLeod	Modifier
phenotype.	O
XK	O
encodes	O
a	O
novel	O
protein	O
with	O
structural	O
characteristics	O
of	O
prokaryotic	O
and	O
eukaryotic	O
membrane	O
transport	O
proteins.	O
Nucleotide	O
sequence	O
analysis	O
of	O
XK	O
from	O
two	O
unrelated	O
McLeod	Modifier
patients	O
has	O
identified	O
point	O
mutations	O
at	O
conserved	O
splice	O
donor	O
and	O
acceptor	O
sites.	O
These	O
findings	O
provide	O
direct	O
evidence	O
that	O
XK	O
is	O
responsible	O
for	O
McLeod	SpecificDisease
syndrome	SpecificDisease

Molecular	O
basis	O
of	O
very	SpecificDisease
long	SpecificDisease
chain	SpecificDisease
acyl-CoA	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
in	O
three	O
Israeli	O
patients:	O
identification	O
of	O
a	O
complex	O
mutant	O
allele	O
with	O
P65L	O
and	O
K247Q	O
mutations,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	O
causing	O
exon	O
3	O
skipping.	O
Very	SpecificDisease
long	SpecificDisease
chain	SpecificDisease
acyl-CoA	SpecificDisease
dehydrogenase	SpecificDisease
(VLCAD)	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
life-threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta-oxidation.	O
We	O
identified	O
four	O
novel	O
mutations	O
in	O
three	O
unrelated	O
patients.	O
All	O
patients	O
had	O
the	O
severe	O
childhood	O
form	O
of	O
VLCAD	SpecificDisease
deficiency	SpecificDisease

Amino-terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
show	O
selective	O
accumulation	O
in	O
striatal	O
neurons	O
and	O
synaptic	O
toxicity.	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
is	O
caused	O
by	O
expansion	O
of	O
a	O
glutamine	O
repeat	O
in	O
the	O
amino-terminal	O
region	O
of	O
huntingtin.	O
Despite	O
its	O
widespread	O
expression,	O
mutant	O
huntingtin	O
induces	O
selective	O
neuronal	O
loss	O
in	O
striatal	O
neurons.	O
Here	O
we	O
report	O
that,	O
in	O
mutant	O
mice	O
expressing	O
HD	Modifier
repeats,	O
the	O
production	O
and	O
aggregation	O
of	O
N-terminal	O
huntingtin	O
fragments	O
preferentially	O
occur	O
in	O
HD	Modifier
-affected	O
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals.	O
N-terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
form	O
aggregates	O
and	O
induce	O
neuritic	DiseaseClass
degeneration	DiseaseClass
in	O
cultured	O
striatal	O
neurons.	O
N-terminal	O
mutant	O
huntingtin	O
also	O
binds	O
to	O
synaptic	O
vesicles	O
and	O
inhibits	O
their	O
glutamate	O
uptake	O
in	O
vitro.	O
The	O
specific	O
processing	O
and	O
accumulation	O
of	O
toxic	O
fragments	O
of	O
N-terminal	O
huntingtin	O
in	O
HD	Modifier
-affected	O
striatal	O
neurons,	O
especially	O
in	O
their	O
neuronal	O
processes	O
and	O
axonal	O
terminals,	O
may	O
contribute	O
to	O
the	O
selective	O
neuropathology	O
of	O
HD	SpecificDisease

Phenotypic	O
variation	O
including	O
retinitis	SpecificDisease
pigmentosa	SpecificDisease
,	O
pattern	SpecificDisease
dystrophy	SpecificDisease
,	O
and	O
fundus	SpecificDisease
flavimaculatus	SpecificDisease
in	O
a	O
single	O
family	O
with	O
a	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin/RDS	O
gene.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
	O
Mutations	O
of	O
the	O
peripherin/RDS	O
gene	O
have	O
been	O
reported	O
in	O
autosomal	SpecificDisease
dominant	SpecificDisease
retinitis	SpecificDisease
pigmentosa	SpecificDisease
,	O
pattern	O
macular	SpecificDisease
dystrophy	SpecificDisease
,	O
and	O
retinitis	SpecificDisease
punctata	SpecificDisease
albescens	SpecificDisease
.	O
We	O
report	O
herein	O
the	O
occurrence	O
of	O
three	O
separate	O
phenotypes	O
within	O
a	O
single	O
family	O
with	O
a	O
novel	O
3-base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin/RDS	O
gene.	O
DESIGN	O
	O
Case	O
reports	O
with	O
clinical	O
features,	O
fluorescein	O
angiography,	O
kinetic	O
perimetry,	O
electrophysiological	O
studies,	O
and	O
molecular	O
genetics.	O
SETTING	O
	O
University	O
medical	O
centers.	O
PATIENTS	O
	O
A	O
75-year-old	O
woman,	O
her	O
two	O
daughters	O
(aged	O
44	O
and	O
50	O
years),	O
and	O
her	O
49-year-old	O
son	O
were	O
screened	O
for	O
peripherin/RDS	O
mutations	O
because	O
of	O
the	O
presence	O
of	O
multiple	O
phenotypes	O
within	O
the	O
same	O
family.	O
RESULTS	O
	O
The	O
mother	O
presented	O
at	O
age	O
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(ERG)	O
and	O
adult-onset	O
retinitis	SpecificDisease
pigmentosa	SpecificDisease
that	O
progressed	O
dramatically	O
over	O
12	O
years,	O
with	O
marked	O
loss	O
of	O
peripheral	O
visual	O
field.	O
One	O
daughter	O
developed	O
pattern	SpecificDisease
macular	SpecificDisease
dystrophy	SpecificDisease
at	O
age	O
31	O
years.	O
At	O
age	O
44	O
years,	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
but	O
her	O
clinical	O
disease	O
was	O
limited	O
to	O
the	O
macula.	O
Another	O
daughter	O
presented	O
at	O
age	O
42	O
years	O
with	O
macular	SpecificDisease
degeneration	SpecificDisease
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	O
picture	O
of	O
fundus	SpecificDisease
flavimaculatus	SpecificDisease
.	O
Her	O
peripheral	O
visual	O
field	O
was	O
preserved	O
but	O
her	O
ERG	O
was	O
moderately	O
abnormal.	O
The	O
son	O
had	O
onset	O
of	O
macular	SpecificDisease
degeneration	SpecificDisease
at	O
age	O
44	O
years.	O
Pericentral	SpecificDisease
scotomas	SpecificDisease

Missense	O
mutation	O
in	O
the	O
alternative	O
splice	O
region	O
of	O
the	O
PAX6	O
gene	O
in	O
eye	DiseaseClass
anomalies	DiseaseClass
.	O
The	O
PAX6	O
gene	O
is	O
involved	O
in	O
ocular	O
morphogenesis,	O
and	O
PAX6	O
mutations	O
have	O
been	O
detected	O
in	O
various	O
types	O
of	O
ocular	DiseaseClass
anomalies	DiseaseClass
,	O
including	O
aniridia	SpecificDisease
,	O
Peters	SpecificDisease
anomaly	SpecificDisease
,	O
corneal	SpecificDisease
dystrophy	SpecificDisease
,	O
congenital	SpecificDisease
cataract	SpecificDisease
,	O
and	O
foveal	SpecificDisease
hypoplasia	SpecificDisease
.	O
The	O
gene	O
encodes	O
a	O
transcriptional	O
regulator	O
that	O
recognizes	O
target	O
genes	O
through	O
its	O
paired-type	O
DNA-binding	O
domain.	O
The	O
paired	O
domain	O
is	O
composed	O
of	O
two	O
distinct	O
DNA-binding	O
subdomains,	O
the	O
N-terminal	O
subdomain	O
(NTS)	O
and	O
the	O
C-terminal	O
subdomain	O
(CTS),	O
which	O
bind	O
respective	O
consensus	O
DNA	O
sequences.	O
The	O
human	O
PAX6	O
gene	O
produces	O
two	O
alternative	O
splice	O
isoforms	O
that	O
have	O
the	O
distinct	O
structure	O
of	O
the	O
paired	O
domain.	O
The	O
insertion,	O
into	O
the	O
NTS,	O
of	O
14	O
additional	O
amino	O
acids	O
encoded	O
by	O
exon	O
5a	O
abolishes	O
the	O
DNA-binding	O
activity	O
of	O
the	O
NTS	O
and	O
unmasks	O
the	O
DNA-binding	O
ability	O
of	O
the	O
CTS.	O
Thus,	O
exon	O
5a	O
appears	O
to	O
function	O
as	O
a	O
molecular	O
switch	O
that	O
specifies	O
target	O
genes.	O
We	O
ascertained	O
a	O
novel	O
missense	O
mutation	O
in	O
four	O
pedigrees	O
with	O
Peters	SpecificDisease
anomaly	SpecificDisease
,	O
congenital	SpecificDisease
cataract	SpecificDisease
,	O
Axenfeldt	SpecificDisease
anomaly	SpecificDisease
,	O
and/or	O
foveal	SpecificDisease
hypoplasia	SpecificDisease

A	O
detailed	O
multipoint	O
map	O
of	O
human	O
chromosome	O
4	O
provides	O
evidence	O
for	O
linkage	O
heterogeneity	O
and	O
position-specific	O
recombination	O
rates.	O
Utilizing	O
the	O
CEPH	O
reference	O
panel	O
and	O
genotypic	O
data	O
for	O
53	O
markers,	O
we	O
have	O
constructed	O
a	O
20-locus	O
multipoint	O
genetic	O
map	O
of	O
human	O
chromosome	O
4.	O
New	O
RFLPs	O
are	O
reported	O
for	O
four	O
loci.	O
The	O
map	O
integrates	O
a	O
high-resolution	O
genetic	O
map	O
of	O
4p16	O
into	O
a	O
continuous	O
map	O
extending	O
to	O
4q31	O
and	O
an	O
unlinked	O
cluster	O
of	O
three	O
loci	O
at	O
4q35.	O
The	O
20	O
linked	O
markers	O
form	O
a	O
continuous	O
linkage	O
group	O
of	O
152	O
cM	O
in	O
males	O
and	O
202	O
cM	O
in	O
females.	O
Likely	O
genetic	O
locations	O
are	O
provided	O
for	O
25	O
polymorphic	O
anonymous	O
sequences	O
and	O
28	O
gene-specific	O
RFLPs.	O
The	O
map	O
was	O
constructed	O
employing	O
the	O
LINKAGE	O
and	O
CRIMAP	O
computational	O
methodologies	O
to	O
build	O
the	O
multipoint	O
map	O
via	O
a	O
stepwise	O
algorithm.	O
A	O
detailed	O
10-point	O
map	O
of	O
the	O
4p16	O
region	O
constructed	O
from	O
the	O
CEPH	O
panel	O
provides	O
evidence	O
for	O
heterogeneity	O
in	O
the	O
linkage	O
maps	O
constructed	O
from	O
families	O
segregating	O
for	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease

The	O
murine	O
homolog	O
of	O
the	O
human	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
gene	O
Brca1	O
maps	O
to	O
mouse	O
chromosome	O
11D.	O
The	O
recently	O
cloned	O
human	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier

High	O
residual	O
arylsulfatase	O
A	O
(ARSA)	O
activity	O
in	O
a	O
patient	O
with	O
late-infantile	SpecificDisease
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
.	O
We	O
identified	O
a	O
patient	O
suffering	O
from	O
late-infantile	SpecificDisease
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
)	O
who	O
has	O
a	O
residual	O
arylsulfatase	O
A	O
(ARSA)	O
activity	O
of	O
about	O
10%.	O
Fibroblasts	O
of	O
the	O
patient	O
show	O
significant	O
sulfatide	O
degradation	O
activity	O
exceeding	O
that	O
of	O
adult	Modifier
MLD	Modifier
patients.	O
Analysis	O
of	O
the	O
ARSA	O
gene	O
in	O
this	O
patient	O
revealed	O
heterozygosity	O
for	O
two	O
new	O
mutant	O
alleles	O
	O
in	O
one	O
allele,	O
deletion	O
of	O
C	O
447	O
in	O
exon	O
2	O
leads	O
to	O
a	O
frameshift	O
and	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
position	O
105;	O
in	O
the	O
second	O
allele,	O
a	O
G--	O
>	O
A	O
transition	O
in	O
exon	O
5	O
causes	O
a	O
Gly309--	O
>	O
Ser	O
substitution.	O
Transient	O
expression	O
of	O
the	O
mutant	O
Ser309-ARSA	O
resulted	O
in	O
only	O
13%	O
enzyme	O
activity	O
of	O
that	O
observed	O
in	O
cells	O
expressing	O
normal	O
ARSA.	O
The	O
mutant	O
ARSA	O
is	O
correctly	O
targeted	O
to	O
the	O
lysosomes	O
but	O
is	O
unstable.	O
These	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
results	O
showing	O
that	O
the	O
late-infantile	SpecificDisease
type	SpecificDisease
of	SpecificDisease
MLD	SpecificDisease

De	O
novo	O
deletions	O
of	O
SNRPN	O
exon	O
1	O
in	O
early	O
human	O
and	O
mouse	O
embryos	O
result	O
in	O
a	O
paternal	O
to	O
maternal	O
imprint	O
switch.	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
)	O
is	O
a	O
neurogenetic	DiseaseClass
disease	DiseaseClass
characterized	O
by	O
infantile	SpecificDisease
hypotonia	SpecificDisease
,	O
gonadal	SpecificDisease
hypoplasia	SpecificDisease
,	O
obsessive	O
behaviour	O
and	O
neonatal	O
feeding	O
difficulties	O
followed	O
by	O
hyperphagia	SpecificDisease
,	O
leading	O
to	O
profound	O
obesity	SpecificDisease
.	O
PWS	SpecificDisease
is	O
due	O
to	O
a	O
lack	O
of	O
paternal	O
genetic	O
information	O
at	O
15q11-q13	O
(ref.	O
2).	O
Five	O
imprinted,	O
paternally	O
expressed	O
genes	O
map	O
to	O
the	O
PWS	Modifier
region,	O
MKRN3	O
(ref.	O
3),	O
NDN	O
(ref.	O
4),	O
NDNL1	O
(ref.	O
5),	O
SNRPN	O
(refs	O
6-8)	O
and	O
IPW	O
(ref.	O
9),	O
as	O
well	O
as	O
two	O
poorly	O
characterized	O
framents	O
designated	O
PAR-1	O
and	O
PAR-5	O
(ref.	O
10).	O
Imprinting	O
of	O
this	O
region	O
involves	O
a	O
bipartite	O
imprinting	O
centre	O
(IC),	O
which	O
overlaps	O
SNRPN	O
(refs	O
10,	O
11).	O
Deletion	O
of	O
the	O
SNRPN	O
promoter/exon	O
1	O
region	O
(the	O
PWS	Modifier
IC	O
element)	O
appears	O
to	O
impair	O
the	O
establishment	O
of	O
the	O
paternal	O
imprint	O
in	O
the	O
male	O
germ	O
line	O
and	O
leads	O
to	O
PWS	SpecificDisease
.	O
Here	O
we	O
report	O
a	O
PWS	Modifier
family	O
in	O
which	O
the	O
father	O
is	O
mosaic	O
for	O
an	O
IC	O
deletion	O
on	O
his	O
paternal	O
chromosome.	O
The	O
deletion	O
chromosome	O
has	O
acquired	O
a	O
maternal	O
methylation	O
imprint	O
in	O
his	O
somatic	O
cells.	O
We	O
have	O
made	O
identical	O
findings	O
in	O
chimaeric	O
mice	O
generated	O
from	O
two	O
independent	O
embryonic	O
stem	O
(ES)	O
cell	O
lines	O
harbouring	O
a	O
similar	O
deletion.	O
Our	O
studies	O
demonstrate	O
that	O
the	O
PWS	Modifier

Molecular	O
characterization	O
of	O
two	O
galactosemia	Modifier
mutations:	O
correlation	O
of	O
mutations	O
with	O
highly	O
conserved	O
domains	O
in	O
galactose-1-phosphate	O
uridyl	O
transferase.	O
Galactosemia	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
of	DiseaseClass
human	DiseaseClass
galactose	DiseaseClass
metabolism	DiseaseClass
caused	O
by	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
enzyme	SpecificDisease
galactose-1-phosphate	SpecificDisease
uridyl	SpecificDisease
transferase	SpecificDisease
(GALT).	O
The	O
molecular	O
basis	O
of	O
this	O
disorder	O
is	O
at	O
present	O
not	O
well	O
understood.	O
We	O
report	O
here	O
two	O
missense	O
mutations	O
which	O
result	O
in	O
low	O
or	O
undetectable	O
enzymatic	O
activity.	O
First,	O
we	O
identified	O
at	O
nucleotide	O
591	O
a	O
transition	O
which	O
substitutes	O
glutamine	O
188	O
by	O
arginine.	O
The	O
mutated	O
glutamine	O
is	O
not	O
only	O
highly	O
conserved	O
in	O
evolution	O
(conserved	O
also	O
in	O
Escherichia	O
coli	O
and	O
Saccharomyces	O
cerevisiae),	O
but	O
is	O
also	O
two	O
amino	O
acid	O
residues	O
downstream	O
from	O
the	O
active	O
site	O
histidine-proline-histidine	O
triad	O
and	O
results	O
in	O
about	O
10%	O
of	O
normal	O
enzymatic	O
activity.	O
The	O
arginine	O
188	O
mutation	O
is	O
the	O
most	O
common	O
galactosemia	Modifier
mutation	O
characterized	O
to	O
date.	O
It	O
accounts	O
for	O
one-fourth	O
of	O
the	O
galactosemia	Modifier
alleles	O
studied.	O
Second,	O
we	O
report	O
the	O
substitution	O
of	O
arginine	O
333	O
by	O
tryptophan,	O
caused	O
by	O
a	O
transition	O
at	O
nucleotide	O
1025.	O
The	O
area	O
surrounding	O
this	O
missense	O
mutation	O
is	O
the	O
most	O
highly	O
conserved	O
domain	O
in	O
the	O
homologous	O
enzymes	O
from	O
E.	O
coli,	O
yeast,	O
and	O
humans,	O
and	O
this	O
mutation	O
results	O
in	O
undetectable	O
enzymatic	O
activity,	O
suggesting	O
that	O
this	O
is	O
a	O
severe	O
mutation.	O
This	O
second	O
mutation	O
appears	O
to	O
be	O
rare,	O
since	O
it	O
was	O
found	O
only	O
in	O
the	O
patient	O
we	O
sequenced.	O
Our	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
heterogeneity	O
of	O
galactosemia	SpecificDisease

Neurophysiologic	O
follow-up	O
of	O
long-term	O
dietary	O
treatment	O
in	O
adult-onset	O
adrenoleukodystrophy	SpecificDisease
.	O
OBJECTIVE	O
	O
To	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult-onset	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(SEPs)	O
and	O
motor	O
evoked	O
potentials	O
(MEPs).	O
BACKGROUND	O
	O
SEPs	O
and	O
MEPs	O
have	O
proved	O
useful	O
in	O
revealing	O
signs	O
of	O
progressively	O
severe,	O
central	O
dying-back	SpecificDisease
axonopathy	SpecificDisease
in	O
early	O
stages	O
of	O
adult-onset	O
ALD	SpecificDisease
.	O
METHODS	O
	O
Eight	O
patients	O
with	O
adult-onset	O
ALD	SpecificDisease
underwent	O
clinical	O
examination,	O
brain	O
and	O
spine	O
MRI,	O
and	O
SEP	O
and	O
MEP	O
studies	O
before	O
and	O
after	O
3	O
years	O
of	O
Lorenzos	O
oil	O
dietary	O
therapy.	O
RESULTS	O
	O
Before	O
treatment,	O
brain	O
MRI	O
was	O
normal	O
in	O
five	O
patients.	O
Three	O
of	O
these	O
patients	O
had	O
pure	O
spinal	DiseaseClass
SEP	DiseaseClass
abnormalities	DiseaseClass
and	O
in	O
the	O
remaining	O
two	O
patients	O
SEPs	O
showed	O
signs	O
of	O
involvement	O
of	O
both	O
the	O
spinal	O
and	O
cerebral	O
somatosensory	O
tracts.	O
After	O
treatment,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	DiseaseClass
abnormalities	DiseaseClass
showed	O
clinical	O
and	O
neurophysiologic	O
worsening,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(exhibited	O
by	O
SEPs)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features.	O
The	O
patients	O
with	O
abnormal	O
brain	O
MRI	O
at	O
the	O
onset	O
of	O
treatment	O
showed	O
clinical	O
and	O
neurophysiologic	O
worsening.	O
CONCLUSIONS	O
	O
Lorenzos	O
oil	O
therapy	O
had	O
no	O
effect	O
on	O
patients	O
with	O
evidence	O
of	O
inflammatory	DiseaseClass
brain	DiseaseClass
lesions	DiseaseClass

The	O
molecular	O
basis	O
of	O
Sjogren-Larsson	SpecificDisease
syndrome	SpecificDisease
:	O
mutation	O
analysis	O
of	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene.	O
Sjogren-Larsson	SpecificDisease
syndrome	SpecificDisease
(	O
SLS	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
ichthyosis	DiseaseClass
,	O
mental	DiseaseClass
retardation	DiseaseClass
,	O
spasticity	DiseaseClass
,	O
and	O
deficient	SpecificDisease
activity	SpecificDisease
of	SpecificDisease
fatty	SpecificDisease
aldehyde	SpecificDisease
dehydrogenase	SpecificDisease
(FALDH).	O
To	O
define	O
the	O
molecular	O
defects	O
causing	O
SLS	SpecificDisease
,	O
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
FALDH	O
gene	O
in	O
probands	O
from	O
63	O
kindreds	O
with	O
SLS	SpecificDisease
.	O
Among	O
these	O
patients,	O
49	O
different	O
mutations-including	O
10	O
deletions,	O
2	O
insertions,	O
22	O
amino	O
acid	O
substitutions,	O
3	O
nonsense	O
mutations,	O
9	O
splice-site	O
defects,	O
and	O
3	O
complex	O
mutations-were	O
found.	O
All	O
of	O
the	O
patients	O
with	O
SLS	SpecificDisease
were	O
found	O
to	O
carry	O
mutations.	O
Nineteen	O
of	O
the	O
missense	O
mutations	O
resulted	O
in	O
a	O
severe	O
reduction	O
of	O
FALDH	O
enzyme	O
catalytic	O
activity	O
when	O
expressed	O
in	O
mammalian	O
cells,	O
but	O
one	O
mutation	O
(798G--	O
>	O
C	O
[K266N])	O
seemed	O
to	O
have	O
a	O
greater	O
effect	O
on	O
mRNA	O
stability.	O
The	O
splice-site	O
mutations	O
led	O
to	O
exon	O
skipping	O
or	O
utilization	O
of	O
cryptic	O
acceptor-splice	O
sites.	O
Thirty-seven	O
mutations	O
were	O
private,	O
and	O
12	O
mutations	O
were	O
seen	O
in	O
two	O
or	O
more	O
probands	O
of	O
European	O
or	O
Middle	O
Eastern	O
descent.	O
Four	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
found	O
in	O
the	O
FALDH	O
gene.	O
At	O
least	O
four	O
of	O
the	O
common	O
mutations	O
(551C--	O
>	O
T,	O
682C--	O
>	O
T,	O
733G--	O
>	O
A,	O
and	O
798	O
+	O
1delG)	O
were	O
associated	O
with	O
multiple	O
SNP	O
haplotypes,	O
suggesting	O
that	O
these	O
mutations	O
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
SLS	Modifier
genes	O
that	O
had	O
undergone	O
intragenic	O
recombination.	O
Our	O
results	O
demonstrate	O
that	O
SLS	SpecificDisease
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
FALDH	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
SLS	SpecificDisease

Severe-glucose-6-phosphate	SpecificDisease
dehydrogenase	SpecificDisease
(G6PD)	SpecificDisease
deficiency	SpecificDisease
associated	O
with	O
chronic	O
hemolytic	SpecificDisease
anemia	SpecificDisease
,	O
granulocyte	DiseaseClass
dysfunction	DiseaseClass
,	O
and	O
increased	O
susceptibility	O
to	O
infections:	O
description	O
of	O
a	O
new	O
molecular	O
variant	O
(G6PD	O
Barcelona).	O
Molecular,	O
kinetic,	O
and	O
functional	O
studies	O
were	O
carried	O
out	O
on	O
erythrocytes	O
and	O
leukocytes	O
in	O
a	O
Spanish	O
male	O
with	O
G6PD	SpecificDisease
deficiency	SpecificDisease
,	O
congenital	SpecificDisease
nonspherocytic	SpecificDisease
hemolytic	SpecificDisease
anemia	SpecificDisease
(	O
CNSHA	SpecificDisease
),	O
and	O
increased	O
susceptibility	O
to	O
infections.	O
G6PD	O
activity	O
was	O
absent	O
in	O
patients	O
red	O
cells	O
and	O
was	O
about	O
2%	O
of	O
normal	O
in	O
leukocytes.	O
Molecular	O
studies	O
using	O
standard	O
methods	O
(WHO,	O
1967)	O
showed	O
G6PD	O
in	O
the	O
patient	O
to	O
have	O
a	O
slightly	O
fast	O
electrophoretic	O
mobility	O
at	O
pH	O
8.	O
0	O
with	O
otherwise	O
normal	O
properties	O
(heat	O
stability	O
at	O
46	O
degrees	O
C,	O
apparent	O
affinity	O
for	O
substrates,	O
optimum	O
pH,	O
and	O
utilization	O
of	O
substrate	O
analogues).	O
Other	O
tests	O
showed	O
the	O
patients	O
granulocytes	O
to	O
engulf	O
latex	O
particles	O
normally,	O
but	O
to	O
have	O
impaired	O
reduction	O
of	O
nitroblue	O
tetrazolium	O
and	O
ferricytochrome-c	O
as	O
well	O
as	O
reduced	O
iodination.	O
Chemotaxis	O
and	O
random	O
migration	O
of	O
the	O
patients	O
granulocytes	O
were	O
normal	O
as	O
were	O
myeloperoxidase,	O
leukocyte	O
alkaline	O
phosphatase	O
(LAP),	O
and	O
ultrastructural	O
features.	O
The	O
molecular	O
characteristics	O
of	O
G6PD	O
in	O
the	O
patient	O
differed	O
from	O
those	O
of	O
all	O
previously	O
reported	O
variants	O
associated	O
with	O
CNSHA	SpecificDisease
,	O
so	O
the	O
present	O
variant	O
was	O
provisionally	O
called	O
G6PD	O
Barcelona	O
to	O
distinguish	O
it	O
from	O
other	O
G6PD	O
variants	O
previously	O
described.	O
Possible	O
mechanisms	O
for	O
the	O
severe	O
deficiency	SpecificDisease
of	SpecificDisease
G6PD	SpecificDisease

Mutations	O
at	O
the	O
PAX6	O
locus	O
are	O
found	O
in	O
heterogeneous	O
anterior	DiseaseClass
segment	DiseaseClass
malformations	DiseaseClass
including	O
Peters'	SpecificDisease
anomaly	SpecificDisease
.	O
Mutation	O
or	O
deletion	O
of	O
the	O
PAX6	O
gene	O
underlies	O
many	O
cases	O
of	O
aniridia	SpecificDisease
.	O
Three	O
lines	O
of	O
evidence	O
now	O
converge	O
to	O
implicate	O
PAX6	O
more	O
widely	O
in	O
anterior	DiseaseClass
segment	DiseaseClass
malformations	DiseaseClass
including	O
Peters	SpecificDisease
anomaly	SpecificDisease
.	O
First,	O
a	O
child	O
with	O
Peters	SpecificDisease
anomaly	SpecificDisease
is	O
deleted	O
for	O
one	O
copy	O
of	O
PAX6.	O
Second,	O
affected	O
members	O
of	O
a	O
family	O
with	O
dominantly	O
inherited	O
anterior	DiseaseClass
segment	DiseaseClass
malformations	DiseaseClass
,	O
including	O
Peters	SpecificDisease
anomaly	SpecificDisease
are	O
heterozygous	O
for	O
an	O
R26G	O
mutation	O
in	O
the	O
PAX6	O
paired	O
box.	O
Third,	O
a	O
proportion	O
of	O
Sey/+	O
Smalleye	O
mice,	O
heterozygous	O
for	O
a	O
nonsense	O
mutation	O
in	O
murine	O
Pax-6,	O
have	O
an	O
ocular	O
phenotype	O
resembling	O
Peters	SpecificDisease
anomaly	SpecificDisease
.	O
We	O
therefore	O
propose	O
that	O
a	O
variety	O
of	O
anterior	DiseaseClass
segment	DiseaseClass
anomalies	DiseaseClass

In	O
Swedish	O
families	O
with	O
hereditary	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
,	O
linkage	O
to	O
the	O
HPC1	O
locus	O
on	O
chromosome	O
1q24-25	O
is	O
restricted	O
to	O
families	O
with	O
early-onset	O
prostate	SpecificDisease
cancer	SpecificDisease
.	O
Prostate	SpecificDisease
cancer	SpecificDisease
clusters	O
in	O
some	O
families,	O
and	O
an	O
estimated	O
5%	O
-10%	O
of	O
all	O
cases	O
are	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
prostate	O
cancer-susceptibility	O
genes.	O
We	O
previously	O
reported	O
evidence	O
of	O
linkage	O
to	O
the	O
1q24-25	O
region	O
(HPC1)	O
in	O
91	O
North	O
American	O
and	O
Swedish	O
families	O
each	O
with	O
multiple	O
cases	O
of	O
prostate	SpecificDisease
cancer	SpecificDisease
(Smith	O
et	O
al.	O
1996).	O
In	O
the	O
present	O
report	O
we	O
analyze	O
40	O
(12	O
original	O
and	O
28	O
newly	O
identified)	O
Swedish	O
families	O
with	O
hereditary	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
(	O
HPC	SpecificDisease
)	O
that,	O
on	O
the	O
basis	O
of	O
40	O
markers	O
spanning	O
a	O
25-cM	O
interval	O
within	O
1q24-25,	O
have	O
evidence	O
of	O
linkage.	O
In	O
the	O
complete	O
set	O
of	O
families,	O
a	O
maximum	O
two-point	O
LOD	O
score	O
of	O
1.	O
10	O
was	O
observed	O
at	O
D1S413	O
(at	O
a	O
recombination	O
fraction	O
[theta]	O
of.	O
1),	O
with	O
a	O
maximum	O
NPL	O
(nonparametric	O
linkage)	O
Z	O
score	O
of	O
1.	O
64	O
at	O
D1S202	O
(P	O
=.	O
05).	O
The	O
evidence	O
of	O
linkage	O
to	O
this	O
region	O
originated	O
almost	O
exclusively	O
from	O
the	O
subset	O
of	O
12	O
early-onset	O
(age	O
<	O
65	O
years)	O
families,	O
which	O
yielded	O
a	O
maximum	O
LOD	O
score	O
of	O
2.	O
38	O
at	O
D1S413	O
(straight	O
theta	O
=	O
0)	O
and	O
an	O
NPL	O
Z	O
score	O
of	O
1.	O
95	O
at	O
D1S422	O
(P	O
=.	O
03).	O
Estimates	O
from	O
heterogeneity	O
tests	O
suggest	O
that,	O
within	O
Sweden,	O
as	O
many	O
as	O
50%	O
of	O
early-onset	O
families	O
had	O
evidence	O
of	O
linkage	O
to	O
the	O
HPC1	O
region.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
of	O
linkage	O
to	O
HPC1	O
in	O
a	O
subset	O
of	O
families	O
with	O
prostate	SpecificDisease
cancer	SpecificDisease

Localisation	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
locus	O
to	O
19q13.2-19q13.3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q.	O
The	O
order	O
of	O
fourteen	O
polymorphic	O
markers	O
localised	O
to	O
the	O
long	O
arm	O
of	O
human	O
chromosome	O
19	O
has	O
been	O
established	O
by	O
multipoint	O
mapping	O
in	O
a	O
set	O
of	O
40	O
CEPH	O
(Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain,	O
Paris)	O
reference	O
families.	O
We	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
DM	SpecificDisease
.	O
The	O
resulting	O
genetic	O
map	O
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	O
markers	O
in	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids.	O
Ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
DM	Modifier
gene	O
and	O
two,	O
PRKCG	O
and	O
D19S22,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	O
and	O
15	O
cM,	O
respectively.	O
The	O
closest	O
proximal	O
markers	O
are	O
APOC2	O
(apolipoprotein	O
C-II)	O
and	O
CKM	O
(creatine	O
kinase,	O
muscle)	O
approximately	O
3	O
cM	O
and	O
2	O
cM	O
from	O
the	O
DM	Modifier
gene	O
respectively,	O
in	O
the	O
order	O
APOC2-CKM-DM.	O
The	O
distance	O
between	O
APOC2,	O
CKM	O
and	O
DM	SpecificDisease
(of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping.	O
The	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
APOC2/CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	Modifier

A	O
recurrent	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
causes	O
Huntington	SpecificDisease
disease	SpecificDisease
in	O
two	O
sisters.	O
Large	O
intergenerational	O
repeat	O
expansions	O
of	O
the	O
CAG	O
trinucleotide	O
repeat	O
in	O
the	O
HD	Modifier
gene	O
have	O
been	O
well	O
documented	O
for	O
the	O
male	O
germline.	O
We	O
describe	O
a	O
recurrent	O
large	O
expansion	O
of	O
a	O
maternal	O
allele	O
with	O
36	O
CAG	O
repeats	O
(to	O
66	O
and	O
57	O
repeats,	O
respectively,	O
in	O
two	O
daughters)	O
associated	O
with	O
onset	O
of	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
in	O
the	O
second	O
and	O
third	O
decade	O
in	O
a	O
family	O
without	O
history	O
of	O
HD	SpecificDisease

Germline	O
E-cadherin	O
gene	O
(CDH1)	O
mutations	O
predispose	O
to	O
familial	SpecificDisease
gastric	SpecificDisease
cancer	SpecificDisease
and	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
Inherited	O
mutations	O
in	O
the	O
E-cadherin	O
gene	O
(CDH1)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	SpecificDisease
gastric	SpecificDisease
cancer	SpecificDisease
.	O
Familial	SpecificDisease
gastric	SpecificDisease
cancer	SpecificDisease
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	Modifier
cancer	Modifier
susceptibility	O
in	O
non-Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations.	O
Therefore,	O
we	O
screened	O
eight	O
familial	Modifier
gastric	Modifier
cancer	Modifier
kindreds	O
of	O
British	O
and	O
Irish	O
origin	O
for	O
germline	O
CDH1	O
mutations,	O
by	O
SSCP	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences.	O
Each	O
family	O
contained	O
	O
(i)	O
two	O
cases	O
of	O
gastric	SpecificDisease
cancer	SpecificDisease
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years;	O
or	O
(ii)	O
three	O
or	O
more	O
cases	O
of	O
gastric	SpecificDisease
cancer	SpecificDisease
.	O
Novel	O
germline	O
CDH1	O
mutations	O
(a	O
nonsense	O
and	O
a	O
splice	O
site)	O
were	O
detected	O
in	O
two	O
families	O
(25%).	O
Both	O
mutations	O
were	O
predicted	O
to	O
truncate	O
the	O
E-cadherin	O
protein	O
in	O
the	O
signal	O
peptide	O
domain.	O
In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non-penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	CompositeMention
and	CompositeMention
colorectal	CompositeMention
cancer	CompositeMention
;	O
thus,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	SpecificDisease
cancer	SpecificDisease
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	SpecificDisease
cancer	SpecificDisease
at	O
age	O
30	O
years.	O
We	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
CDH1	O
gene	O
cause	O
familial	SpecificDisease
gastric	SpecificDisease
cancer	SpecificDisease
in	O
non-Maori	O
populations.	O
However,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	SpecificDisease
cancers	SpecificDisease
can	O
be	O
accounted	O
for	O
by	O
CDH1	O
mutations.	O
Loss	O
of	O
E-cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	DiseaseClass
and	DiseaseClass
other	DiseaseClass
cancers	DiseaseClass
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
Thus,	O
CDH1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	CompositeMention
and	CompositeMention
colorectal	CompositeMention
cancers	CompositeMention

Germinal	O
mosaicism	O
in	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
We	O
have	O
identified	O
a	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(	O
DMD	Modifier
)	O
pedigree	O
where	O
the	O
disease	O
is	O
associated	O
with	O
a	O
molecular	O
deletion	O
within	O
the	O
DMD	Modifier

Expression	O
of	O
the	O
murine	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene	O
in	O
muscle	O
and	O
brain.	O
Complementary	O
DNA	O
clones	O
were	O
isolated	O
that	O
represent	O
the	O
5	O
terminal	O
2.	O
5	O
kilobases	O
of	O
the	O
murine	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
(Dmd)	O
messenger	O
RNA	O
(mRNA).	O
Mouse	O
Dmd	O
mRNA	O
was	O
detectable	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
and	O
at	O
a	O
level	O
approximately	O
90	O
percent	O
lower	O
in	O
brain.	O
Dmd	O
mRNA	O
is	O
also	O
present,	O
but	O
at	O
much	O
lower	O
than	O
normal	O
levels,	O
in	O
both	O
the	O
muscle	O
and	O
brain	O
of	O
three	O
different	O
strains	O
of	O
dystrophic	Modifier
mdx	O
mice.	O
The	O
identification	O
of	O
Dmd	O
mRNA	O
in	O
brain	O
raises	O
the	O
possibility	O
of	O
a	O
relation	O
between	O
human	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
gene	O
expression	O
and	O
the	O
mental	DiseaseClass
retardation	DiseaseClass
found	O
in	O
some	O
DMD	Modifier

Human	O
peroxisomal	O
targeting	O
signal-1	O
receptor	O
restores	O
peroxisomal	O
protein	O
import	O
in	O
cells	O
from	O
patients	O
with	O
fatal	O
peroxisomal	DiseaseClass
disorders	DiseaseClass
.	O
Two	O
peroxisomal	O
targeting	O
signals,	O
PTS1	O
and	O
PTS2,	O
are	O
involved	O
in	O
the	O
import	O
of	O
proteins	O
into	O
the	O
peroxisome	O
matrix.	O
Human	O
patients	O
with	O
fatal	O
generalized	O
peroxisomal	DiseaseClass
deficiency	DiseaseClass
disorders	DiseaseClass
fall	O
into	O
at	O
least	O
nine	O
genetic	O
complementation	O
groups.	O
Cells	O
from	O
many	O
of	O
these	O
patients	O
are	O
deficient	O
in	O
the	O
import	O
of	O
PTS1-containing	O
proteins,	O
but	O
the	O
causes	O
of	O
the	O
protein-import	O
defect	O
in	O
these	O
patients	O
are	O
unknown.	O
We	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	O
cDNA	O
homologue	O
(PTS1R)	O
of	O
the	O
Pichia	O
pastoris	O
PAS8	O
gene,	O
the	O
PTS1	O
receptor	O
(McCollum,	O
D.,	O
E.	O
Monosov,	O
and	O
S.	O
Subramani.	O
1993.	O
J.	O
Cell	O
Biol.	O
121	O
	O
761-774).	O
The	O
PTS1R	O
mRNA	O
is	O
expressed	O
in	O
all	O
human	O
tissues	O
examined.	O
Antibodies	O
to	O
the	O
human	O
PTS1R	O
recognize	O
this	O
protein	O
in	O
human,	O
monkey,	O
rat,	O
and	O
hamster	O
cells.	O
The	O
protein	O
is	O
localized	O
mainly	O
in	O
the	O
cytosol	O
but	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
peroxisomes.	O
Part	O
of	O
the	O
peroxisomal	O
PTS1R	O
protein	O
is	O
tightly	O
bound	O
to	O
the	O
peroxisomal	O
membrane.	O
Antibodies	O
to	O
PTS1R	O
inhibit	O
peroxisomal	O
protein-import	O
of	O
PTS1-containing	O
proteins	O
in	O
a	O
permeabilized	O
CHO	O
cell	O
system.	O
In	O
vitro-translated	O
PTS1R	O
protein	O
specifically	O
binds	O
a	O
serine-lysine-leucine-peptide.	O
A	O
PAS8-PTS1R	O
fusion	O
protein	O
complements	O
the	O
P.	O
pastoris	O
pas8	O
mutant.	O
The	O
PTS1R	O
cDNA	O
also	O
complements	O
the	O
PTS1	SpecificDisease
protein-import	SpecificDisease
defect	SpecificDisease
in	O
skin	O
fibroblasts	O
from	O
patients--belonging	O
to	O
complementation	O
group	O
two--diagnosed	O
as	O
having	O
neonatal	SpecificDisease
adrenoleukodystrophy	SpecificDisease
or	O
Zellweger	SpecificDisease
syndrome	SpecificDisease
.	O
The	O
PTS1R	O
gene	O
has	O
been	O
localized	O
to	O
a	O
chromosomal	O
location	O
where	O
no	O
other	O
peroxisomal	Modifier
disorder	Modifier
genes	O
are	O
known	O
to	O
map.	O
Our	O
findings	O
represent	O
the	O
only	O
case	O
in	O
which	O
the	O
molecular	O
basis	O
of	O
the	O
protein-import	DiseaseClass
deficiency	DiseaseClass
in	O
human	O
peroxisomal	DiseaseClass
disorders	DiseaseClass

X-linked	SpecificDisease
spastic	SpecificDisease
paraplegia	SpecificDisease
and	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
are	O
allelic	DiseaseClass
disorders	DiseaseClass
at	O
the	O
proteolipid	O
protein	O
locus.	O
Three	O
forms	O
of	O
X-linked	SpecificDisease
spastic	SpecificDisease
paraplegia	SpecificDisease
(	O
SPG	SpecificDisease
)	O
have	O
been	O
defined.	O
One	O
locus	O
(SPG	O
1)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(SPG2).	O
A	O
rare	O
X-linked	DiseaseClass
dysmyelinating	DiseaseClass
disorder	DiseaseClass
of	O
the	O
central	O
nervous	O
system,	O
Pelizaeus-Merzbacher	SpecificDisease
disease	SpecificDisease
(	O
PMD	SpecificDisease
),	O
has	O
also	O
been	O
mapped	O
to	O
Xq21-q22,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(PLP)	O
which	O
encodes	O
two	O
myelin	O
proteins,	O
PLP	O
and	O
DM20.	O
While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene.	O
We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(His139Tyr)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20,	O
and	O
segregates	O
with	O
the	O
disease	O
(Zmax	O
=	O
6.	O
63,	O
theta	O
=	O
0.	O
00).	O
It	O
appears,	O
therefore,	O
that	O
SPG2	O
and	O
PMD	SpecificDisease
are	O
allelic	DiseaseClass
disorders	DiseaseClass

